<SEC-DOCUMENT>0001193125-15-279400.txt : 20150806
<SEC-HEADER>0001193125-15-279400.hdr.sgml : 20150806
<ACCEPTANCE-DATETIME>20150805213454
ACCESSION NUMBER:		0001193125-15-279400
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20150630
FILED AS OF DATE:		20150806
DATE AS OF CHANGE:		20150805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEKTAR THERAPEUTICS
		CENTRAL INDEX KEY:			0000906709
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943134940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24006
		FILM NUMBER:		151030833

	BUSINESS ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		4154825300

	MAIL ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS INC
		DATE OF NAME CHANGE:	19980723

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS
		DATE OF NAME CHANGE:	19940303
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d86512d10q.htm
<DESCRIPTION>10-Q
<TEXT>
<HTML><HEAD>
<TITLE>10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 10-Q
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the quarterly period ended June&nbsp;30, 2015 </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>or </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period
from&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: 0-24006 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>NEKTAR
THERAPEUTICS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>94-3134940</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>455 Mission Bay Boulevard South </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San Francisco, California 94158 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>415-482-5300 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name, former address and former fiscal year, if changed since last report) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90
days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange
Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of outstanding shares of the registrant&#146;s Common Stock, $0.0001 par value, was 132,371,000 on July&nbsp;30, 2015. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NEKTAR THERAPEUTICS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><A HREF="#tx86512_1">PART I: FINANCIAL INFORMATION </A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx86512_2">Condensed Consolidated Financial Statements &#151; Unaudited:</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx86512_3">Condensed Consolidated Balance Sheets &#151; June&nbsp;30, 2015 and December&nbsp;31, 2014</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx86512_4">Condensed Consolidated Statements of Operations for the three and six months ended June&nbsp;30, 2015 and 2014</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx86512_5">Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June&nbsp;
30, 2015 and 2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx86512_6">Condensed Consolidated Statements of Cash Flows for the six months ended June&nbsp;30, 2015 and 2014</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx86512_7">Notes to Condensed Consolidated Financial Statements</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx86512_8">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx86512_9">Quantitative and Qualitative Disclosures About Market Risk</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx86512_10">Controls and Procedures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B><A HREF="#tx86512_11">PART II: OTHER INFORMATION </A></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx86512_12">Legal Proceedings</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx86512_13">Risk Factors</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx86512_14">Unregistered Sales of Equity Securities and Use of Proceeds</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx86512_15">Defaults Upon Senior Securities</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx86512_16">Mine Safety Disclosures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx86512_17">Other Information</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx86512_18">Exhibits</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><A HREF="#tx86512_19">Signatures </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This report includes &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended
(Securities Act), and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (Exchange Act). All statements other than statements of historical fact are &#147;forward-looking statements&#148; for purposes of this quarterly report on
Form 10-Q, including any projections of earnings, revenue, milestone payments, royalties, sales or other financial items, any statements of the plans and objectives of management for future operations (including, but not limited to, preclinical
development, clinical trials and manufacturing), any statements related to our financial condition and future working capital needs, any statements regarding potential future financing alternatives, any statements concerning proposed drug
candidates, any statements regarding the timing for the start or end of clinical trials or submission of regulatory approval filings, any statements regarding future economic conditions or performance, any statements regarding the success of our
collaboration arrangements, timing of commercial launches and product sales levels by our collaboration partners and future payments that may come due to us under these arrangements, any statements regarding our plans and objectives to initiate or
continue clinical trials, and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by the use of terminology such as &#147;may,&#148; &#147;will,&#148; &#147;expects,&#148;
&#147;plans,&#148; &#147;anticipates,&#148; &#147;estimates,&#148; &#147;potential&#148; or &#147;continue,&#148; or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking
statements contained herein are reasonable, such expectations or any of the forward-looking statements may prove to be incorrect and actual results could differ materially from those projected or assumed in the forward-looking statements. Our future
financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including, but not limited to, the risk factors set forth in Part II, Item&nbsp;1A &#147;Risk Factors&#148;
below and for the reasons described elsewhere in this quarterly report on Form 10-Q. All forward-looking statements and reasons why results may differ included in this report are made as of the date hereof and we do not intend to update any
forward-looking statements except as required by law or applicable regulations. Except where the context otherwise requires, in this quarterly report on Form 10-Q, the &#147;Company,&#148; &#147;Nektar,&#148; &#147;we,&#148; &#147;us,&#148; and
&#147;our&#148; refer to Nektar Therapeutics, a Delaware corporation, and, where appropriate, its subsidiaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Trademarks </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nektar brand and product names, including but not limited to Nektar<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, contained in
this document are trademarks and registered trademarks of Nektar Therapeutics in the United States (U.S.) and certain other countries. This document also contains references to trademarks and service marks of other companies that are the property of
their respective owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx86512_1"></A>PART I: FINANCIAL INFORMATION </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="tx86512_2"></A>Condensed Consolidated Financial Statements&#151;Unaudited: </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NEKTAR THERAPEUTICS </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx86512_3"></A>CONDENSED CONSOLIDATED BALANCE SHEETS </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except par value) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B><br><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December 31,<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>ASSETS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">302,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">288,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">456,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">441,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued clinical trial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital lease obligations, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior secured notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital lease obligations, less current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liability related to sale of future royalties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, less current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">421,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value, 10,000 shares authorized, no shares designated, issued or outstanding at June&nbsp;30, 2015 or
December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value, 300,000 authorized; 132,185 shares and 131,216 shares issued and outstanding at June&nbsp;30, 2015 and
December&nbsp;31, 2014, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital in excess of par value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,841,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,824,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,498</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,805,146</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,786,309</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">456,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">441,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NEKTAR THERAPEUTICS </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx86512_4"></A>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except per share information) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product sales and royalty revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash royalty revenue related to sale of future royalties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License, collaboration and other revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,469</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(426</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-operating income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,488</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash interest expense on liability related to sale of future royalties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,134</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,521</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income and other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total non-operating expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,526</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,034</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,134</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,657</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,637</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,837</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(78,838</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding used in computing basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

 <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx86512_5"></A>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three months ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(78,544</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NEKTAR THERAPEUTICS </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx86512_6"></A>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended</B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,837</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(78,838</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash royalty revenue related to sale of future royalties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,702</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,610</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash interest expense on liability related to sale of future royalties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other non-cash transactions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(621</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(818</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(659</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,818</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued clinical trial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,697</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(314</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,434</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,557</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71,375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maturities of investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124,468</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sale of investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,192</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,911</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of capital lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,484</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of proceeds from sale of future royalties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from shares issued under equity compensation plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rates on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
</P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NEKTAR THERAPEUTICS </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx86512_7"></A>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>June&nbsp;30, 2015 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1 &#151; Organization and Summary of Significant Accounting Policies </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Organization </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are a biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our PEGylation and advanced polymer conjugate technology platforms with the
objective to improve the benefits of drugs for patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development activities have required significant ongoing
investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily
through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. At June&nbsp;30, 2015, we had approximately $279.7 million in cash and investments in marketable securities.&nbsp;Also, as of June&nbsp;30,
2015, we had $133.5 million in long-term debt, including $125.0 million of senior secured notes and $8.5 million of capital lease obligations, of which $5.6 million is current. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation and Principles of Consolidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries:
Nektar Therapeutics (India) Private Limited (Nektar India) and Nektar Therapeutics UK Limited. All intercompany accounts and transactions have been eliminated in consolidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for
interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods can be condensed or omitted. In the opinion of
management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable
foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#146;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. Translation gains and losses are included in
accumulated other comprehensive loss in the stockholders&#146; equity section of the Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and
losses on available-for-sale securities, neither of which were significant during the three and six months ended June&nbsp;30, 2015 and 2014. In addition, there were no significant reclassifications out of accumulated other comprehensive loss to the
statements of operations during the three and six months ended June&nbsp;30, 2015 and 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying Condensed Consolidated
Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&nbsp;31, 2014 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&nbsp;10-K for the year
ended December&nbsp;31, 2014 filed with the SEC on February&nbsp;26, 2015. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those
financial statements included in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue, expenses, assets, and
liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other periods. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation
of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the
consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and
assumptions. Our estimates include those related to estimated selling prices of deliverables in collaboration agreements, estimated periods of performance, the net realizable value of inventory, the impairment of investments, the impairment of
goodwill and long-lived assets, contingencies, accrued clinical trial expenses, estimated interest expense from our liability related to our sale of future royalties, stock-based compensation, and ongoing litigation, among other estimates. We base
our estimates on historical experience and on other assumptions that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not
readily apparent from other sources. As appropriate, estimates are assessed each period and updated to reflect current information and any changes in estimates will generally be reflected in the period first identified. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reclassifications </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain items
previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets,
liabilities or stockholders&#146; equity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We operate in one business segment which focuses on applying our technology platforms to improve the performance of established and novel drug
candidates. We operate in one segment because our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment.
We are comprehensively managed as one business segment by our Chief Executive Officer and his management team. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant Concentrations
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&nbsp;and Europe. Our accounts
receivable balance contains billed and unbilled trade receivables from product sales and royalties, as well as milestones and time and materials based billings from collaborative research and development agreements. When appropriate, we provide for
an allowance for doubtful accounts by reserving for specifically identified doubtful accounts. We generally do not require collateral from our customers. We perform a regular review of our customers&#146; payment histories and associated credit
risk. We have not experienced significant credit losses from our accounts receivable and our allowance for doubtful accounts was not significant at either June&nbsp;30, 2015 or December&nbsp;31, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are dependent on our suppliers and contract manufacturers to provide raw materials, drugs and devices of appropriate quality and
reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our
ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue
is derived from our arrangements with pharmaceutical and biotechnology collaboration partners and may result from one or more of the following: upfront and license fees, payments for contract research and development, milestone payments,
manufacturing and supply payments, and royalties. Our performance obligations under our collaborations may include licensing our intellectual property, manufacturing and supply obligations, and research and development obligations. In order to
account for the multiple-element arrangements, we identify the deliverables included within the arrangement and evaluate which deliverables represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use
of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. Revenue is recognized separately for each identified unit of accounting when the basic revenue
recognition criteria are met: there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the inception of each new multiple-element arrangement or the material modification of an existing multiple-element arrangement, we
allocate all consideration received under multiple-element arrangements to all units of accounting based on the relative selling price method, generally based on our best estimate of selling price (ESP). The objective of ESP is to determine the
price at which we would transact a sale if the product or service was sold on a stand-alone basis. We determine ESP for the elements in our collaboration arrangements by considering multiple factors including, but not limited to, technical
complexity of the performance obligation and similarity of elements to those performed under previous arrangements. Since we apply significant judgment in arriving at the ESPs, any material change in our estimates would significantly affect the
allocation of the total consideration to the different elements of a multiple element arrangement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Product sales </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Product sales are primarily derived from fixed price and cost-plus manufacturing and supply agreements with our collaboration partners. We have
not experienced any significant returns from our customers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Royalty revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, we are entitled to royalties from our collaboration partners based on the net sales of their approved drugs that are marketed and
sold in one or more countries where we hold royalty rights. We recognize royalty revenue when the cash is received or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
when the royalty amount to be received is estimable and collection is reasonably assured. With respect to the non-cash royalties related to sale of future royalties described at Note 4, revenue
is recognized when estimable, otherwise, revenue is recognized during the period in which the related royalty report is received, which generally occurs in the quarter after the applicable product sales are made. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>License, collaboration and other revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount of upfront fees and other payments received by us in license and collaboration arrangements that are allocated to continuing
performance obligations, such as manufacturing and supply obligations, are deferred and generally recognized ratably over our expected performance period under each respective arrangement. We make our best estimate of the period over which we expect
to fulfill our performance obligations, which may include technology transfer assistance, research activities, clinical development activities, and manufacturing activities from development through the commercialization of the product. Given the
uncertainties of these collaboration arrangements, significant judgment is required to determine the duration of the performance period and this estimate is periodically re-evaluated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Contingent consideration received from the achievement of a substantive milestone is recognized in its entirety in the period in which the
milestone is achieved, which we believe is consistent with the substance of our performance under our various license and collaboration agreements. A milestone is defined as an event (i)&nbsp;that can only be achieved based in whole or in part
either on the entity&#146;s performance or on the occurrence of a specific outcome resulting from the entity&#146;s performance, (ii)&nbsp;for which there is substantive uncertainty at the date the arrangement is entered into that the event will be
achieved, and (iii)&nbsp;that would result in additional payments being due to the entity. A milestone is substantive if the consideration earned from the achievement of the milestone is consistent with our performance required to achieve the
milestone or the increase in value to the collaboration resulting from our performance, relates solely to our past performance, and is reasonable relative to all of the other deliverables and payments within the arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our license and collaboration agreements with our partners provide for payments to us upon the achievement of development milestones, such as
the completion of clinical trials or regulatory submissions, approvals by regulatory authorities, and commercial launches of drugs. Given the challenges inherent in developing and obtaining regulatory approval for drug products and in achieving
commercial launches, there was substantial uncertainty whether any such milestones would be achieved at the time of execution of these licensing and collaboration agreements. In addition, we evaluated whether the development milestones meet the
remaining criteria to be considered substantive. As a result of our analysis, we consider our remaining development milestones under all of our license and collaboration agreements to be substantive and, accordingly, we expect to recognize as
revenue future payments received from such milestones only if and as each milestone is achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our license and collaboration agreements
with certain partners also provide for contingent payments to us based solely upon the performance of the respective partner. For such contingent amounts we expect to recognize the payments as revenue when earned under the applicable contract, which
is generally upon completion of performance by the respective partner, provided that collection is reasonably assured. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our license and
collaboration agreements with our partners also provide for payments to us upon the achievement of specified sales volumes of approved drugs. We consider these payments to be similar to royalty payments and we will recognize such sales-based
payments upon achievement of such sales volumes, provided that collection is reasonably assured. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services,
supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our
internal technology development programs, we invest our own funds without reimbursement from a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We record accruals for the
estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the
contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the
clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the total estimated cost of the treatment phase on a per patient
basis and we expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a
methodology that we consider to be more reflective of the timing of costs incurred. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and
recognized as expense as the related goods are delivered or the related services are performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to
make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in
cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We assess the impairment of long-lived assets, primarily property, plant and equipment and goodwill included in other non-current assets,
whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. When such events occur, we determine whether there has been an impairment in value by comparing the asset&#146;s
carrying value with its fair value, as measured by the anticipated undiscounted net cash flows of the asset. In the case of goodwill impairment, market capitalization is generally used as the measure of fair value. If an impairment in value exists,
the asset is written down to its estimated fair value. In March 2015, we announced that the primary endpoint for our BEACON Phase 3 clinical study for NKTR-102 as a single-agent therapy for women with advanced metastatic breast cancer did not
achieve statistical significance. As a result, we performed an impairment analysis for our long-lived assets, including goodwill, as well as our primary long-lived asset group which is dedicated to NKTR-102. Based on this analysis, we concluded that
there is no impairment at March&nbsp;31, 2015 or June&nbsp;30, 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three and six months ended June&nbsp;30, 2015 and 2014, we recorded an income tax provision for our Nektar India operations at an
effective tax rate of approximately 34%. The U.S. federal deferred tax assets generated from our net operating losses have been fully reserved, as we believe it is not more likely than not that the benefit will be realized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2014, the Financial Accounting Standards Board (FASB) issued guidance codified in Accounting Standards Codification (ASC) 606,
<I>Revenue Recognition &#151; Revenue from Contracts with Customers</I>, which amends the guidance in former ASC 605, <I>Revenue Recognition, </I>and is effective for public companies for fiscal years beginning after December&nbsp;15, 2017. Entities
have the option of using either a full retrospective or a modified retrospective approach to adopt this new guidance. We are currently evaluating the impact of the provisions of ASC 606. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2015, the FASB issued guidance to simplify the presentation of debt issuance costs by requiring debt issuance costs to be presented
as a deduction from the corresponding debt liability. This guidance is effective for our interim and annual periods beginning January&nbsp;1, 2016. Upon adoption, the new guidance must be applied retrospectively to all periods presented. We do not
believe the adoption of this guidance will have a material impact on our consolidated financial statements. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2 </B>&#151;<B> Cash and Investments in Marketable Securities </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash and investments in marketable securities, including cash equivalents and restricted cash, are as follows (in
thousands). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated Fair Value at</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June 30,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash and investments in marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">279,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">262,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest
rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. As of June&nbsp;30, 2015 and December&nbsp;31,
2014, all of our investments had maturities of one year or less. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gross unrealized gains and losses were not significant at either
June&nbsp;30, 2015 or December&nbsp;31, 2014. During the three months ended June&nbsp;30, 2015 and the three and six months ended June&nbsp;30, 2014, we did not sell any of our available-for-sale securities. During the six months ended June&nbsp;30,
2015, we sold available-for-sale securities totaling $5.2 million, and gross realized gains and losses on those sales were not significant. The cost of securities sold is based on the specific identification method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted cash of $25.0 million was required to be maintained in a separate account until July&nbsp;1, 2015 under the terms of our 12% senior
secured notes due July 2017. This restriction expired on July&nbsp;1, 2015 and the restricted funds were returned to us. We are currently required by a covenant under the senior secured notes to maintain the aggregate balance of our unrestricted
cash and cash equivalents of not less than $25.0 million at the end of any two consecutive fiscal quarters, subject to certain conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our portfolio of cash and investments in marketable securities includes (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value</B><br><B>Hierarchy</B><br><B>Level</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated Fair Value at</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate notes and bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">185,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">182,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Available-for-sale investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificate of deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, including restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash and investments in marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">279,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">262,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Level&nbsp;1&nbsp;&#151;</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Quoted prices in active markets for identical assets or liabilities.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Level&nbsp;2&nbsp;&#151;</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Inputs other than Level&nbsp;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can
be corroborated by observable market data for substantially the full term of the assets or liabilities.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Level&nbsp;3&nbsp;&#151;</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our investments are categorized as Level 1 or Level 2, as explained in the table above. We use a market
approach to value our Level 2 investments. The disclosed fair value related to our investments is based primarily on the reported fair values in our period-end brokerage statements, which are based on market prices from a variety of industry
standard data providers and generally represent quoted prices for similar assets in active markets or have been derived from observable market data. We independently validate these fair values using available market quotes and other information.
During the three and six months ended June&nbsp;30, 2015 and 2014, there were no transfers between Level 1 and Level 2 of the fair value hierarchy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, as of June&nbsp;30, 2015, based on a discounted cash flow analysis using Level 3 inputs including financial discount rates, we
believe the $125.0 million carrying amount of our 12% Senior Secured Notes due July 2017 is consistent with its fair value. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3 &#151; Inventory </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventory consists of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Raw materials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Work-in-process</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finished goods</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventory is generally manufactured upon receipt of firm purchase orders from our collaboration partners.
Inventory includes direct materials, direct labor, and manufacturing overhead and cost is determined on a first-in, first-out basis. Inventory is valued at the lower of cost or market and defective or excess inventory is written down to net
realizable value based on historical experience or projected usage. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4 &#151; Liability Related to Sale of Future Royalties </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;24, 2012, we entered into a Purchase and Sale Agreement (the Purchase and Sale Agreement) with RPI Finance
Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the Royalty Entitlement) arising from the worldwide net sales, from and after January&nbsp;1, 2012, of (a)&nbsp;CIMZIA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&nbsp;MIRCERA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, under our license, manufacturing and
supply agreement with F. Hoffmann-La&nbsp;Roche Ltd and Hoffmann-La&nbsp;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of $124.0 million for the Royalty Entitlement.&nbsp;Although we sold all of our rights to
receive royalties from the CIMZIA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and MIRCERA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> products, as a result of our ongoing manufacturing and supply obligations related to
the generation of these royalties, we will continue to account for these royalties as revenue. We recorded the $124.0 million in proceeds from this transaction as a liability (Royalty Obligation) that will be amortized using the interest method over
the estimated life of the Purchase and Sale Agreement as royalties from the CIMZIA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and MIRCERA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> products are remitted directly to RPI.
During the six months ended June&nbsp;30, 2015 and 2014, we recognized $8.7 million and $10.6 million, respectively, in aggregate royalties from net sales of CIMZIA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and MIRCERA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its inception, our estimate of the total interest expense on the Royalty Obligation
resulted in an effective annual interest rate of approximately 17%. We periodically assess the estimated royalty payments to RPI from UCB and Roche and to the extent such payments are greater or less than our initial estimates, or the timing of such
payments is materially different than our original estimates, we will prospectively adjust the amortization of the Royalty Obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Purchase and Sale Agreement, in March 2014 and March 2013, we were required to pay RPI $7.0 million and $3.0 million,
respectively, as a result of worldwide net sales of MIRCERA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for the 12 month periods ended December&nbsp;31, 2013 and 2012 not reaching certain minimum thresholds. The Purchase and Sale
Agreement does not include any other potential payments related to minimum net sales thresholds and, therefore, we do not expect to make any further payments to RPI related to this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Purchase and Sale Agreement grants RPI the right to receive certain reports and other information relating to the Royalty
Entitlement and contains other representations and warranties, covenants and indemnification obligations that are customary for a transaction of this nature. To our knowledge, we are currently in compliance with these provisions of the Purchase and
Sale Agreement, however, if we were to breach our obligations, we could be required to pay damages to RPI that are not limited to the purchase price we received in the sale transaction. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5 &#151; Commitments and Contingencies </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property,
commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such
provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is
inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations of that period and on our cash flows and liquidity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnifications in Connection with Commercial Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs based on our
proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities)
and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual any time after execution of the agreement. There
is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required
to make representations and warranties and undertake to perform or comply with certain covenants. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements, we could
incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not
incurred costs to defend lawsuits or settle claims related to these indemnification obligations. Because the aggregate amount of any potential indemnification obligation is not a stated amount, the overall maximum amount of any such obligations
cannot be reasonably estimated. No liabilities have been recorded for these obligations in our Condensed Consolidated Balance Sheets at either June&nbsp;30, 2015 or December&nbsp;31, 2014. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6 &#151; License and Collaboration Agreements </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into various collaboration agreements including license agreements and collaborative research,
manufacturing, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration agreements, we are entitled to receive license fees, upfront payments, milestone payments, royalties,
sales milestones, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. All of our collaboration agreements are generally cancelable by our partners without
significant financial penalty. Our costs of performing these services are generally included in research and development expense, except that costs for product sales to our collaboration partners are included in cost of goods sold. In accordance
with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands): </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months&nbsp;ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:26.65pt; font-size:8pt; font-family:Times New Roman"><B>Partner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Drug or Drug Candidate</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AstraZeneca AB</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> (NKTR-118) and MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> fixed-dose combination program (NKTR-119)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roche</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">PEGASYS<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and MIRCERA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amgen, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Neulasta<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bayer Healthcare LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">BAY41-6551 (Amikacin Inhale)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baxalta</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">BAX 855 (Hemophilia)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License, collaboration, and other revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2015, our collaboration agreements with partners included potential future payments for
development milestones totaling approximately $128.3 million, including amounts from our agreements with Baxalta, Bayer, and Ophthotech described below. In addition, we are entitled to receive the contingent payments described below related to the
MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> and MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> fixed-dose combination drug development programs, respectively, based on development and regulatory events to be
pursued and completed solely by AstraZeneca. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been no material changes to our collaboration agreements in the six months ended
June&nbsp;30, 2015, except as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>AstraZeneca AB</I></B><I>: MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>
(naloxegol oxalate), previously referred to as naloxegol and NKTR-118, and MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> fixed-dose combination program, previously referred to as NKTR-119 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to an agreement with AstraZeneca AB (AstraZeneca) under which we granted AstraZeneca a worldwide, exclusive license under our
patents and other intellectual property to develop, market, and sell MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> and MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> fixed-dose combination program. AstraZeneca is
responsible for all research, development and commercialization and is responsible for all drug development and commercialization decisions for MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM </SUP>and the MOVANTIK<SUP
STYLE="font-size:85%; vertical-align:top">TM </SUP>fixed-dose combination program. AstraZeneca paid us an upfront payment of $125.0&nbsp;million, which we received in the fourth quarter of 2009 and which was fully recognized as of December&nbsp;31,
2010. We will be entitled to up to an additional $40.0 million of contingent payments upon the first commercial sale of MOVENTIG<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (the naloxegol brand name in the European Union or EU) in one
major European Union country. We are also entitled to receive up to $75.0 million of commercial launch contingent payments related to the MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> fixed-dose combination program, based on
development events to be pursued and completed solely by AstraZeneca. In addition, we are entitled to significant and escalating double-digit royalty payments and sales milestone payments based on annual worldwide net sales of MOVANTIK<SUP
STYLE="font-size:85%; vertical-align:top">TM </SUP>and MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM </SUP>fixed-dose combination products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;16, 2014, the United States Food and Drug Administration (FDA) approved
MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain. On December&nbsp;9, 2014, AstraZeneca announced that MOVENTIG<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> has been granted Marketing Authorisation by the European Commission (EC) for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to
laxative(s). As a result of the FDA&#146;s approval, on September&nbsp;16, 2014, we were entitled to a $35.0 million non-refundable payment from AstraZeneca, which was fully recognized as revenue in September 2014 and was received in October 2014.
In addition, the FDA&#146;s approval of MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> extinguished our contingent obligation to repay the $70.0 million payment made to us by AstraZeneca in November 2013 after the MOVANTIK<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> New Drug Application was accepted for review by the FDA. As a result, in September 2014, we fully recognized as revenue this $70.0 million payment. On March&nbsp;31, 2015, AstraZeneca announced that
MOVANTIK&#153; launched in the United States which resulted in our receipt of a $100.0 million non-refundable commercial launch milestone payment on March&nbsp;31, 2015, which was recognized as revenue in March 2015. In addition, in March 2015, we
agreed to pay AstraZeneca a total of $10.0 million to fund U.S. television advertising in consideration for certain additional commercial information rights. We recorded this $10.0 million obligation as a liability, with $5.0 million included in
other current liabilities and $5.0 million included in other long-term liabilities in our Condensed Consolidated Balance Sheet at June&nbsp;30, 2015. We made the initial $5.0 million payment to AstraZeneca in July 2015 and will pay the remaining
$5.0 million in July 2016. We determined that this $10.0 million obligation should be recorded as a reduction of revenue, which we recorded in the three months ended March&nbsp;31, 2015. As of June&nbsp;30, 2015, we do not have deferred revenue
related to this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, other than as described above and in this paragraph, AstraZeneca has full responsibility for all
research, development and commercialization costs under our license agreement. As part of its approval of MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, the FDA required AstraZeneca to perform a post-marketing, observational
epidemiological study comparing MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> to other treatments of OIC in patients with chronic, non-cancer pain. As a result, the royalty rate payable to us from net sales of MOVANTIK<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> in the U.S. by AstraZeneca will be reduced by up to two percentage points to fund 33% of the external costs incurred by AstraZeneca to fund such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
post approval study subject to a $35.0 million aggregate cap. Any costs incurred by AstraZeneca can only be recovered by the reduction of the royalty paid to us. In no case can amounts be
recovered by the reduction of a contingent payment due from AstraZeneca to us or through a payment from us to AstraZeneca. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Roche</I></B><I>:
PEGASYS<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and MIRCERA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 1997, we entered into a license, manufacturing and supply agreement with Roche, under which we granted Roche a worldwide, exclusive
license to certain intellectual property related to our proprietary PEGylation materials used in the manufacture and commercialization of PEGASYS<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. As of June&nbsp;30, 2015, we have deferred
revenue of approximately $2.6 million related to this agreement, which we expect to recognize through December 2015, the period through which we are required to provide back-up manufacturing and supply services related to PEGASYS<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2012, we entered into a toll-manufacturing agreement with Roche under
which we will manufacture the proprietary PEGylation material used by Roche to produce MIRCERA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. Roche entered into the toll-manufacturing agreement with the objective of establishing us as a
secondary back-up supply source on a non-exclusive basis. Under the terms of our toll-manufacturing agreement, Roche paid us an upfront payment of $5.0 million and an additional $22.0 million in performance-based milestone payments upon our
achievement of certain manufacturing readiness, validation and production milestones, including the delivery of specified quantities of PEGylation materials, all of which were completed as of January 2013. Roche will also pay us additional
consideration for any future orders of the PEGylation materials for MIRCERA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> beyond the initial quantities manufactured through January 2013.&nbsp;Roche has the right to terminate the
toll-manufacturing agreement due to an uncured material default by us. As of June&nbsp;30, 2015, we have deferred revenue of approximately $8.1&nbsp;million, which we expect to recognize through December 2016, the estimated end of our obligations
under this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2013, we agreed to deliver additional quantities of PEGylation materials used by Roche to produce PEGASYS<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and MIRCERA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, all of which were delivered in the last quarter of 2013, for total consideration of $18.6 million. We determined that these
incremental activities should be considered a material modification of the existing PEGASYS<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and MIRCERA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> -related arrangements
described above. As a result, we allocated the $18.6 million consideration to each of these arrangements and determined the amounts to be recognized or deferred based on the estimated selling prices of the undelivered obligations. As of
June&nbsp;30, 2015, we have deferred revenue of approximately $3.4&nbsp;million related to these activities, which we expect to recognize through December 2016, the estimated end of our obligations under the modified arrangements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amgen, Inc.</I></B><I>: Neulasta</I><B><I></I></B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> <B><I> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2010, we amended and restated an existing supply and license agreement by entering into a supply, dedicated suite and manufacturing
guarantee agreement (the amended and restated agreement) and a license agreement with Amgen Inc. and Amgen Manufacturing, Limited (together referred to as Amgen). Under the terms of the amended and restated agreement, we received a $50.0 million
payment in the fourth quarter of 2010 in return for our guaranteeing the supply of certain quantities of our proprietary PEGylation materials to Amgen. As of June&nbsp;30, 2015, we have deferred revenue of approximately $26.7&nbsp;million related to
this agreement, which we expect to recognize through October 2020, the estimated end of our obligations under this agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bayer Healthcare
LLC</I></B><I>: BAY41-6551 (Amikacin Inhale) </I><B><I> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2007, we entered into a co-development, license and co-promotion
agreement with Bayer Healthcare LLC (Bayer) to develop a specially-formulated inhaled Amikacin. We are responsible for development and manufacturing and supply of the nebulizer device included in the Amikacin product. In April 2013, Bayer initiated
a Phase 3 clinical trial in the treatment of intubated and mechanically ventilated patients with Gram-negative pneumonia. As of June&nbsp;30, 2015, we have received an upfront payment of $40.0&nbsp;million (which was paid to us in 2007) and
milestone payments totaling $30.0&nbsp;million. In addition, in June 2013, we made a $10.0 million payment to Bayer for the reimbursement of some of its costs of the Phase 3 clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are entitled to receive a total of up to $50.0 million for development milestones upon achievement of certain development
objectives, as well as sales milestones upon achievement of annual sales targets and royalties based on annual worldwide net sales of Amikacin Inhale. As of June&nbsp;30, 2015, we have deferred revenue of approximately $20.0 million related to this
agreement, which we expect to recognize through February 2028, the estimated end of our obligations under this agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Baxalta</I></B><I>:
Hemophilia </I><B><I> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to an exclusive research, development, license and manufacturing and supply agreement with
Baxalta Incorporated (Baxalta) executed in September 2005 to develop products designed to improve therapies for Hemophilia A patients using our PEGylation technology. This Hemophilia A program includes BAX 855, which will be marketed in the U.S.
under the brand name ADYNOVATE upon approval. Under the terms of this agreement, as of June&nbsp;30, 2015, we are entitled to up to $20.0 million of development milestones upon achievement of certain development objectives, including $10.0 million
due upon marketing authorization in the U.S., as well as sales milestones upon achievement of annual sales targets and royalties based on annual worldwide net sales of products resulting from this agreement. In August 2014, Baxalta announced
positive top-line results from its Phase 3 pivotal clinical trial of BAX 855 which met the primary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
endpoint for the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. As a result of this Phase 3 clinical trial meeting
its primary endpoint, we earned development milestones totaling $8.0 million in September 2014. In December 2014, Baxalta announced that it filed a biologic license application with the FDA for BAX 855. As of June&nbsp;30, 2015, we do not have
significant deferred revenue related to this agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ophthotech Corporation</I></B><I>: Fovista</I><B><I></I></B><SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> <B><I> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to an agreement with Ophthotech Corporation
(Ophthotech), dated September&nbsp;30, 2006, under which Ophthotech received a worldwide, exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and sell
Fovista<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. Under the terms of our agreement, we are the exclusive supplier of all of Ophthotech&#146;s clinical and commercial requirements for our proprietary PEGylation reagent used in
Fovista<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, which is currently in a Phase 3 clinical program. On May&nbsp;19, 2014, Ophthotech entered into a Licensing and Commercialization Agreement with Novartis Pharma AG for Fovista<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. Under our agreement with Ophthotech, we received a $19.75 million payment in connection with this licensing agreement in June 2014. As of June&nbsp;30, 2015, we have deferred revenue of
approximately $18.2 million related to this agreement, which we expect to recognize through March 2029, the estimated end of our obligations under our agreement with Ophthotech. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are entitled to up to $9.5 million in additional payments based upon Ophthotech&#146;s potential achievement of certain
regulatory and sales milestones. We are also entitled to royalties on net sales of Fovista<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> that vary based on sales levels. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as of
June&nbsp;30, 2015, we have a number of collaboration agreements, including with our collaboration partner UCB, under which we are entitled to up to a total of $51.8 million of development milestones upon achievement of certain development
objectives, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential products under these collaboration
agreements, we cannot estimate the probability or timing of achieving these milestones. As of June&nbsp;30, 2015, we have deferred revenue of approximately $18.0 million related to these other collaboration agreements, which we expect to recognize
through 2020, the estimated end of our obligations under those agreements. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7 &#151; Stock-Based Compensation </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense was recognized in our Condensed Consolidated Statements of Operations as follows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months&nbsp;ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the three months ended June&nbsp;30, 2015 and 2014, we granted 68,200 and 642,860 stock options,
respectively, at a weighted average grant-date fair value of $4.81 per share and $5.24 per share, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the six months
ended June&nbsp;30, 2015 and 2014, we granted 479,010 and 3,776,040 stock options, respectively, at a weighted average grant-date fair value of $6.31 per share and $5.84 per share, respectively. The number of stock options granted during the six
months ended June&nbsp;30, 2014 was significantly higher than the stock options granted during the six months ended June&nbsp;30, 2015 because we made our annual employee stock option grant for the 2013 performance period in February 2014 and our
annual employee stock option grant for the 2014 performance period in December 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of stock issuances under our equity
compensation plans, during the three months ended June&nbsp;30, 2015 and 2014, we issued 733,952 and 350,513 common shares, respectively, and during the six months ended June&nbsp;30, 2015 and 2014, we issued 969,250 and 1,017,887 common shares,
respectively. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8 &#151; Net Loss Per Share </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic net loss per share is calculated based on the weighted-average number of common shares
outstanding during the periods presented. For all periods presented in the accompanying Condensed Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. Basic and diluted net loss per
share are the same due to our historical net losses and the requirement to exclude potentially dilutive securities which would have an anti-dilutive effect on net loss per share. During the three and six month periods ended June&nbsp;30, 2015 and
2014, potentially dilutive securities consisted of common shares underlying outstanding stock options. During the three months ended June&nbsp;30, 2015 and 2014, there were weighted average outstanding stock options of 21.6&nbsp;million and
22.5&nbsp;million, respectively, and during the six months ended June&nbsp;30, 2015 and 2014, there were weighted average outstanding stock options of 21.7&nbsp;million and 21.9&nbsp;million, respectively. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="tx86512_8"></A>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially
from those discussed here. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this section as well as factors described in &#147;Part II, Item&nbsp;1A-Risk Factors.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Strategic
Direction of Our Business </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company developing a pipeline of drug candidates that utilize our PEGylation
and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our current proprietary pipeline is comprised of drug candidates across a number of
therapeutic areas including oncology, pain, anti-infectives, and immunology. Our research and development activities involve small molecule drugs, peptides and other biologic drug candidates. We create innovative drug candidates by using our
proprietary advanced polymer conjugate technologies and expertise to modify the chemical structure of pharmacophores to create new molecular entities. Polymer chemistry is a science focused on the synthesis or bonding of polymer architectures with
drug molecules to alter the properties of a molecule. Additionally, we may utilize established pharmacologic targets to engineer a new drug candidate relying on a combination of the known properties of these targets and our proprietary polymer
chemistry technology and expertise. Our drug candidates are designed to improve the overall benefits and use of a drug for patients by improving the metabolism, distribution, pharmacokinetics, pharmacodynamics, half-life and/or bioavailability of
drugs. Our objective is to apply our advanced polymer conjugate technology platform to create new drug candidates in multiple therapeutic areas that address large potential markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2014, we achieved the first approval of one of our proprietary drug candidates, MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM
</SUP>(previously referred to as naloxegol and NKTR-118), under a global license agreement with AstraZeneca. MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> is an oral peripherally-acting opioid antagonist, for the treatment of
opioid-induced constipation, or OIC, a side effect caused by chronic administration of prescription opioid pain medicines. MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> was developed using our oral small molecule polymer conjugate
technology and we advanced this drug through the completion of Phase 2 clinical studies prior to licensing it to AstraZeneca. On September&nbsp;16, 2014, the United States Food and Drug Administration, or FDA, approved MOVANTIK<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer
pain. On December&nbsp;9, 2014, the European Commission, or EC, granted Marketing Authorisation to MOVENTIG<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (the naloxegol brand name in the European Union, or EU) as the first once-daily
oral PAMORA approved in the European Union (EU) for the treatment of OIC in adult patients who have had an inadequate response to laxative(s). The EC&#146;s approval applies to all 28 European Union member countries plus Iceland and Norway. On
March&nbsp;31, 2015, AstraZeneca announced that it has launched MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> in the United States, as a result of which we received a $100 million commercial launch milestone on March&nbsp;31, 2015.
AstraZeneca plans to launch MOVENTIG<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in the European Union in the second half of 2015. Given the significant milestone and royalty opportunity for us associated with MOVANTIK<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> under our AstraZeneca license agreement, the level of sales achieved by AstraZeneca for MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> will have a significant impact on our
operating results and financial condition over the coming years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Etirinotecan pegol (also known as NKTR-102), is our next-generation
topoisomerase I inhibitor proprietary drug candidate. On March&nbsp;17, 2015, we announced topline data from the BEACON Phase 3 clinical study for NKTR-102 as a single-agent therapy for women with advanced metastatic breast cancer. The BEACON study
compared NKTR-102 to an active control arm comprised of a single chemotherapy agent of physician&#146;s choice (TPC) in patients who were heavily pre-treated with a median of three prior therapies for metastatic disease. In a topline analysis of 852
patients from the trial, NKTR-102 provided a 2.1 month improvement in median overall survival (OS) over TPC (12.4 months for patients receiving NKTR-102 compared to 10.3 months for patients receiving TPC). Based on a stratified log-rank analysis,
the primary endpoint measuring the Hazard Ratio (HR) for survival in the NKTR-102 group compared to the active control arm was 0.87 with a p-value of 0.08, which did not achieve statistical significance. Secondary endpoints in the BEACON study
included objective response rate and progression-free survival, which did not achieve statistical significance in the study. We also announced that we observed a significant overall survival benefit in two pre-specified subgroups&#151;patients with
a history of brain metastases and patients with baseline liver metastases at study entry. We are currently exploring various future regulatory paths forward for NKTR-102 with EU and U.S. regulatory authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NKTR-181 is a novel mu-opioid analgesic drug candidate for chronic pain conditions. NKTR-181 has been designed to have a slow rate of entry
into the brain, which is expected to reduce the attractiveness of the molecule as a target of abuse and reduce other serious central nervous system-related side effects, such as sedation and respiratory depression, which are commonly associated with
standard opioid therapies. The potential differentiating properties of NKTR-181 are inherent to its molecular design and, as a new molecular structure, NKTR-181&#146;s potential abuse deterrent properties do not rely on a formulation approach, a
common method used </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with opioid drugs to reduce their ease of conversion into abusable forms of an opioid. In May 2012, the FDA designated NKTR-181 as a Fast Track development program for the treatment of moderate
to severe chronic pain. In June 2013, we announced results from a human abuse liability study that demonstrated that NKTR-181 had highly statistically significant lower &#147;drug liking&#148; scores and reduced &#147;feeling high&#148; scores as
compared to oxycodone at all doses tested (p&lt;0.0001). In September 2013, we announced topline results from a Phase 2 clinical study of NKTR-181 in patients with moderate to severe chronic pain from osteoarthritis of the knee. In this study,
NKTR-181 performed as expected as an opioid analgesic throughout the study. However, patients who were randomized to the placebo arm following a drug titration phase did not show the expected increase in pain scores observed in similar enriched
enrollment, randomized withdrawal studies. This lack of a placebo rebound in the maintenance phase of the trial caused the Phase 2 study to miss the primary endpoint. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2014, we had an end-of-Phase 2 meeting for NKTR-181 with the FDA, which included discussions of certain considerations for the
Phase 3 clinical study program. In this Phase 3 program for NKTR-181, we plan to include two separate efficacy studies in patients with chronic lower back pain, a long-term safety study, and a human abuse liability study. We enrolled the first
patient in the first Phase 3 efficacy study on February&nbsp;24, 2015. In this first efficacy study, we plan to randomize approximately 416 patients in an enriched enrollment randomized withdrawal design which will include a qualifying screening
period, an open-label titration period where NKTR-181 is given to all patients, followed by a 12 week double-blind randomized period where subjects will be randomized on a 1:1 basis to receive either NKTR-181 or placebo. The study design also
includes a single interim analysis for sample size reassessment which will be conducted by an independent data monitoring committee. The primary endpoint will be change in weekly pain score in the double-blind randomized period relative to the
baseline pain score and the key secondary endpoints will include percentage of responders (&gt;30% reduction in pain score) and patient impression of change. We plan to have further interactions with the FDA to finalize the study design for the
other clinical studies planned for the Phase 3 program. Over the next two to three years, the NKTR-181 clinical development program will require a substantial investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a collaboration with Baxalta Incorporated (Baxalta), to identify and develop PEGylated drug candidates with the objective of providing
new long-acting therapies for hemophilia patients. Under the terms of this collaboration, we are providing our PEGylation technology and expertise and Baxalta is responsible for all clinical development. The first drug candidate in this
collaboration is BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)]. BAX 855 will be marketed in the U.S. under the brand name ADYNOVATE
upon approval. In December 2014, Baxalta announced that it filed a biologic license application with the FDA for BAX 855. On April&nbsp;16, 2015, Baxalta announced that it had submitted a new drug application to Japan&#146;s Ministry of Health,
Labour and Welfare for the approval of BAX 855. This regulatory submission was based on positive results from a prospective, global, multi-center, open-label, two-arm Phase 3 study of BAX 855 in 137 previously treated patients. Baxalta reported that
the results demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding episodes and routine prophylaxis for patients who were 12 years or older. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have two significant drug development programs with Bayer. The first is a collaboration to develop BAY41-6551 (Amikacin Inhale,
formerly known as NKTR-061), which is an inhaled solution of amikacin, an aminoglycoside antibiotic. We originally developed the liquid aerosol inhalation platform and the NKTR-061 drug candidate and entered into a collaboration agreement with Bayer
to further advance the drug candidate&#146;s development and potential commercialization. Bayer is currently enrolling patients in a Phase 3 clinical study for Amikacin Inhale. Bayer is conducting this study under a Special Protocol Assessment
process agreed to with the FDA. The second is our significant royalty rights in the Cipro DPI (Cipro Dry Powder Inhaler, previously called Cipro Inhale) program with Bayer that we transferred to Novartis as part of the 2008 pulmonary asset
divestiture transaction. In August 2012, Bayer initiated a global Phase 3 program called RESPIRE for the Cipro DPI product candidate in patients with non-cystic fibrosis bronchiectasis. These programs represent a significant future economic
opportunity for us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the approved drugs and clinical development programs described above are key elements of the future success of
our company, we believe it is critically important that we continue to make substantial investments in our earlier-stage drug candidate pipeline. We have several drug candidates in earlier stage clinical development or being explored in research
that we are preparing to advance into the clinic in future years. We also have additional proprietary preclinical and clinical drug candidates in research and development. We have an ongoing Phase 1 clinical development program for NKTR-171, a new
sodium channel blocker being developed as a potential oral therapy for the treatment of peripheral neuropathic pain. On June&nbsp;2, 2015, we and the University of Texas MD Anderson Cancer Center announced a research collaboration that includes a
Phase 1/2 clinical study to evaluate NKTR-214 in a variety of tumor types as a monotherapy and in combination with other therapies, including PD-1 pathway inhibitors. NKTR-214 is an engineered immunostimulatory cytokine being developed to
selectively activate IL-2 receptors on cytotoxic T cells that kill tumor cells, with relatively low affinity for IL-2 receptors on regulatory T cells that dampen the immune response to tumors. We are also advancing numerous other drug candidates in
preclinical development in the areas of cancer immunotherapy, pain and other therapeutic indications. While we believe that our substantial investment in research and development has the potential to create significant value if one or more of our
drug candidates demonstrate positive clinical results, receive regulatory approval in one or more major markets and achieve commercialization success, drug research and development is an inherently uncertain process and there is a high risk of
failure at every stage prior to approval and the timing and outcome of clinical trial results are extremely difficult to predict. Clinical development successes and failures can have a disproportionate positive or negative impact on our scientific
and medical prospects, financial condition and prospects, results of operations and market value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, we have entered into a number of license and supply contracts under which we
manufactured and supplied our proprietary PEGylation reagents on a cost-plus or fixed price basis. Our current strategy is to manufacture and supply PEGylation reagents to support our proprietary drug candidates or our third-party collaborators
where we have a strategic development and commercialization relationship or where we derive substantial economic benefit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Key Developments and
Trends in Liquidity and Capital Resources </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2015, we estimated that we had at least twelve months of working
capital to fund our current business plans. At June&nbsp;30, 2015, we had approximately $279.7 million in cash and investments in marketable securities.&nbsp;Also, as of June&nbsp;30, 2015, we had $133.5 million in long-term debt, including $125.0
million of senior secured notes and $8.5 million of capital lease obligations, of which $5.6 million is current. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Results of Operations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Three and Six Months Ended June&nbsp;30, 2015 and 2014 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue (in thousands, except percentages) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months<BR>ended<BR>June&nbsp;30, 2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months<BR>ended<BR>June&nbsp;30,&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase /<BR>(Decrease)<BR>2015&nbsp;vs.&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>Increase /<BR>(Decrease)<BR>2015&nbsp;vs.&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product sales and royalty revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash royalty revenue related to sale of future royalties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License, collaboration and other revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,577</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,852</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months<BR>ended<BR>June&nbsp;30,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months<BR>ended<BR>June&nbsp;30,&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase /<BR>(Decrease)<BR>2015 vs. 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>Increase /<BR>(Decrease)<BR>2015 vs. 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product sales and royalty revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash royalty revenue related to sale of future royalties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,908</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License, collaboration and other revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&gt;100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">131,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&gt;100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue is derived from our collaboration agreements, under which we may receive product sales revenue,
royalties, license fees, milestone payments and/or contract research payments. Revenue is recognized when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is
reasonably assured. The amount of upfront fees received under our license and collaboration agreements allocated to continuing obligations, such as manufacturing and supply commitments, are recognized ratably over our expected performance period
under the arrangement. As a result, there may be significant variations in the timing of cash receipts and our recognition of revenue. We make our best estimate of the period over which we expect to fulfill our performance obligations. Given the
uncertainties in research and development collaborations, significant judgment is required by us to determine the performance periods. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product
sales and royalty revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Product sales include fixed price and cost-plus manufacturing and supply agreements with our
collaboration partners and result from the receipt of firm purchase orders from those partners. The timing of shipments is based solely on the demand and requirements of our collaboration partners and is not ratable throughout the year. We also
receive royalty revenue from certain of our collaboration partners based on their net sales of commercial products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Product sales and
royalty revenue increased for the three and six months ended June&nbsp;30, 2015 compared to the three and six months ended June&nbsp;30, 2014 primarily due to increased product sales as a result of increased product demand from a number of our
collaboration partners. We currently expect product sales to increase in 2015 as compared to 2014 due to increased product demand from our collaboration partners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AstraZeneca launched MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> in the U.S.
in March 2015 and plans to launch MOVENTIG<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in the EU in the second half of 2015. We expect royalty revenue will increase in 2015 as compared to 2014 due to royalties we expect to receive from
net sales of this product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Non-cash royalty revenue related to sale of future royalties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2012, we sold all of our rights to receive future royalty payments on
CIMZIA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and MIRCERA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. As described in Note 4 to our Condensed Consolidated Financial Statements, this royalty sale transaction has been
recorded as a liability that amortizes over the estimated royalty payment period. As a result of this liability accounting, even though the royalties from UCB and Roche are remitted directly to the purchaser of these royalty interests, we will
continue to record revenue for these royalties. We expect non-cash royalties from net sales of CIMZIA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and MIRCERA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> will decrease in
2015 as compared to 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License, Collaboration and Other Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">License, collaboration and other revenue includes the recognition of upfront payments and milestone payments received in connection with our
license and collaboration agreements and reimbursed research and development expenses. The level of license, collaboration and other revenue depends in part upon the estimated amortization period of the upfront payments, the achievement of
milestones, the continuation of existing collaborations, the amount of reimbursed research and development work, and entering into new collaboration agreements, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">License, collaboration and other revenue decreased for the three months ended June&nbsp;30, 2015 compared to the three months ended
June&nbsp;30, 2014 primarily as a result of the recognition in the three months ended June&nbsp;30, 2014 of $9.0 million of milestone payments resulting from the transfer of our manufacturing technology to two of our collaboration partners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">License, collaboration and other revenue increased for the six months ended June&nbsp;30, 2015 compared to the six months ended June&nbsp;30,
2014 primarily as a result of the recognition of the $100.0 million milestone payment received in March 2015 from AstraZeneca as a result of the U.S. commercial launch of MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> in March 2015.
In addition, in March 2015, we agreed to pay AstraZeneca a total of $10.0 million, including $5.0 million paid in July 2015 and $5.0 million to be paid in July 2016, to fund U.S. television advertising in consideration for certain additional
commercial information rights. We have determined that this $10.0 million obligation should be recorded as a reduction of revenue, which we also recorded in the three months ended March&nbsp;31, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect license, collaboration and other revenue in 2015 will be significantly impacted by the outcome and timing of AstraZeneca&#146;s E.U.
launch of MOVENTIG<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> as we will be entitled to a $40.0 million development milestone payment due upon the commercial launch of MOVENTIG<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
in the E.U. under our collaboration agreement with AstraZeneca. If this activity occurs in the second half of 2015 as expected, our license, collaboration and other revenue in 2015 will increase significantly from 2014. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost of Goods Sold and Product Gross Margin (in thousands, except percentages) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months<BR>ended<BR>June&nbsp;30,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months<BR>ended<BR>June&nbsp;30,&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase /<BR>(Decrease)<BR>2015&nbsp;vs.&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>Increase /<BR>(Decrease)<BR>2015&nbsp;vs.&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&gt;100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product gross profit (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months<BR>ended<BR>June&nbsp;30,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months<BR>ended<BR>June&nbsp;30, 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase /<BR>(Decrease)<BR>2015 vs. 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>Increase /<BR>(Decrease)<BR>2015&nbsp;vs.&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product gross profit (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,207</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&gt;100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of goods sold increased during the three and six months ended June&nbsp;30, 2015 compared to the three
and six months ended June&nbsp;30, 2014 primarily due to the increases in product sales in the three and six months ended June&nbsp;30, 2015 compared to the three and six months ended June&nbsp;30, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The improvement in product gross profit (loss) during the three and six months ended June&nbsp;30, 2015 compared to the three and six months
ended June&nbsp;30, 2014 is primarily due to a more favorable product mix in 2015 compared to 2014. In particular, the manufacturing arrangement with one of our collaboration partners includes a fixed price for proprietary PEGylation reagent sales,
which is less than the fully burdened manufacturing cost for the reagent in 2014 and 2015 and we expect this situation to continue in future years. There were fewer shipments to this partner in total and relative to shipments to other customers
during the three and six </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
months ended June&nbsp;30, 2015 compared to the three and six months ended June&nbsp;30, 2014. In addition to product sales from reagent shipments to this partner, we also receive royalty
revenues from this collaboration. In the three and six months ended June&nbsp;30, 2015 and 2014, the royalty revenue from the collaboration exceeded the related negative gross profit.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect product gross margin to continue to fluctuate in future periods depending on the level and mix of manufacturing orders from our
customers due to the predominantly fixed cost base associated with our manufacturing activities. We currently expect product gross margin to increase in 2015 as compared to 2014 as a result of the anticipated increase in product sales, as well as
based on the anticipated product mix. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense (in thousands, except percentages) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months<BR>ended<BR>June&nbsp;30,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months<BR>ended<BR>June&nbsp;30,&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase /<BR>(Decrease)<BR>2015&nbsp;vs.&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>Increase /<BR>(Decrease)<BR>2015&nbsp;vs.&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months<BR>ended<BR>June&nbsp;30, 2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months<BR>ended<BR>June&nbsp;30, 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase /<BR>(Decrease)<BR>2015 vs. 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>Increase /<BR>(Decrease)<BR>2015 vs. 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expense consists primarily of clinical study costs, direct costs of outside research,
materials, supplies, licenses and fees as well as personnel costs (including salaries, benefits, and stock-based compensation). Research and development expense also includes certain overhead allocations consisting of support and facilities-related
costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expense increased during the three and six months ended June&nbsp;30, 2015 compared to the three and six
months ended June&nbsp;30, 2014 primarily due to the initiation of Phase 3 clinical studies for NKTR-181 in the first quarter of 2015. Research and development expense is not expected to be ratable over the four quarters of the year. Overall, we
expect research and development expense to increase significantly in the full year of 2015 as compared to 2014 primarily due to costs incurred in connection with the Phase 3 clinical studies for NKTR-181. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than as described in the Overview section above, there have been no material changes to the status of clinical programs in the six
months ended June&nbsp;30, 2015 from the activities discussed in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2014 on file with the Securities and Exchange Commission. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expense (in thousands, except percentages) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months<BR>ended<BR>June&nbsp;30,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months<BR>ended<BR>June&nbsp;30,&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase /<BR>(Decrease)<BR>2015&nbsp;vs.&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>Increase /<BR>(Decrease)<BR>2015&nbsp;vs.&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months<BR>ended<BR>June&nbsp;30, 2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months<BR>ended<BR>June&nbsp;30, 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase /<BR>(Decrease)<BR>2015 vs. 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>Increase /<BR>(Decrease)<BR>2015 vs. 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expense includes the cost of administrative staffing, business development,
marketing, finance, and legal activities. General and administrative expense during the three and six months ended June&nbsp;30, 2015 increased slightly compared to the three and six months ended June&nbsp;30, 2014. In 2015, we expect general and
administrative expenses to increase slightly compared to 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense (in thousands, except percentages) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months<BR>ended<BR>June&nbsp;30,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months<BR>ended<BR>June&nbsp;30,&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase /<BR>(Decrease)<BR>2015&nbsp;vs.&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>Increase /<BR>(Decrease)<BR>2015&nbsp;vs.&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(370</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash interest expense on liability related to sale of future royalties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&lt;1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months<BR>ended<BR>June&nbsp;30, 2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months<BR>ended<BR>June&nbsp;30, 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase /<BR>(Decrease)<BR>2015 vs. 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>Increase /<BR>(Decrease)<BR>2015 vs. 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-cash interest expense on liability related to sale of future royalties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(319</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2012, we issued $125.0 million of 12% senior secured notes due July&nbsp;15, 2017. Interest expense
for the three and six months ended June&nbsp;30, 2015 decreased compared to the three and six months ended June&nbsp;30, 2014 due to decreased interest from capital leases and other obligations. We expect interest expense to decrease slightly during
the full year of 2015 compared to 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Non-cash interest expense on the liability related to sale of future royalties for the three and
six months ended June&nbsp;30, 2015 was consistent with the three and six months ended June&nbsp;30, 2014. In February 2012, we sold all of our rights to receive future royalty payments on
CIMZIA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and MIRCERA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in exchange for $124.0 million. As described in Note 4 to our Condensed Consolidated Financial Statements, this
royalty sale transaction has been recorded as a liability that amortizes over the estimated royalty payment period as CIMZIA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and
MIRCERA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> royalties are remitted directly to the purchaser. We impute interest on the transaction and record interest expense at the effective interest rate, which we currently estimate to be
approximately 17%. There are a number of factors that could materially affect the estimated interest rate, in particular, the amount and timing of royalty payments from future net sales of
CIMZIA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and MIRCERA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, and we will assess this estimate on a periodic basis. As a result, future interest rates could differ
significantly and any such change in interest rate will be adjusted prospectively. Unless we adjust our estimated interest rate, we expect non-cash interest expense on the liability related to sale of future royalties during the full year of 2015 to
be consistent with 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity and Capital Resources </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have financed our operations primarily through revenue from product sales, royalties and research and development contracts, as well as
public offerings and private placements of debt and equity securities. At June&nbsp;30, 2015, we had approximately $279.7 million in cash and investments in marketable securities.&nbsp;Also, as of June&nbsp;30, 2015, we had $133.5 million in
long-term debt, including $125.0 million of senior secured notes and $8.5 million of capital lease obligations, of which $5.6 million is current. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2015, we estimated that we had at least twelve months of working capital to fund our current business plans. We expect the
clinical development of our proprietary drug candidates, including NKTR-102, Amikacin Inhale, NKTR-181, NKTR-171 and NKTR-214, will require significant investment in order to continue to advance in clinical development with the objective of entering
into a collaboration partnership or obtaining regulatory approval. However, we have no credit facility or any other sources of committed capital. In the past we have received a number of significant payments from collaboration agreements and other
significant transactions.&nbsp;In the future we expect to receive royalties from commercial sales of products such as MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>&nbsp;and BAX 855 (if approved) and potential substantial payments
from future collaboration transactions if drug candidates in our pipeline achieve positive clinical or regulatory outcomes. Our current business plan is also subject to significant uncertainties and risks as a result of, among other factors, the
sales levels of products for which we are entitled to royalties such as MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, clinical program outcomes, whether, when and on what terms we are able to enter into new collaboration
transactions, expenses being higher than anticipated, unplanned expenses, cash receipts being lower than anticipated, and the need to satisfy contingent liabilities, including litigation matters and indemnification obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The availability and terms of various financing alternatives substantially depend on many factors including the success or failure of drug
development programs in our pipeline, including NKTR-102, BAX 855, Amikacin Inhale, NKTR-181, NKTR-171, NKTR-214, as well as other early stage development programs. The availability and terms of financing alternatives and any future significant
payments from existing or new collaborations depend on the positive outcome of ongoing or planned clinical studies, whether we or our partners are successful in obtaining regulatory authority approvals in major markets, and if approved, the
commercial success of these drugs, as well as general capital market conditions.&nbsp;We will pursue various financing alternatives, including equity and debt, as needed to continue to fund our research and development activities and to fund the
expansion of our business as appropriate.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the potential for adverse developments in the credit markets in 2015 and thereafter, we
may experience reduced liquidity with respect to some of our investments in marketable securities. These investments are generally held to maturity, which, in accordance with our investment policy, is less than two years. However, if the need arises
to liquidate such securities before maturity, we may experience losses on liquidation. At June&nbsp;30, 2015, the average time to maturity of the investments held in our portfolio was approximately five months and the maturity of any single
investment did not exceed one year. To date we have not experienced any liquidity issues with respect to these securities, but if such issues arise, we may be required to hold some, or all, of these securities until maturity. We believe that, even
allowing for potential liquidity issues with respect to these securities, our remaining cash and investments in marketable securities will be sufficient to meet our anticipated cash needs for at least the next twelve months. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash flows from operating activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash flows provided by operating activities for the six months ended June&nbsp;30, 2015 totaled $16.1 million, which includes the receipt of
$102.0 million for milestones from collaboration agreements, including the $100.0 million payment received as a result of the US launch of MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, partially offset by $78.4 million of net
operating cash uses as well as $7.5 million for interest payments on our senior secured notes. Because of the nature and timing of certain cash receipts and payments, net cash utilization is not expected to be ratable over the four quarters of the
year. We expect cash flows used in operating activities, excluding upfront and milestone payments received, if any, will decrease for the full year of 2015 as compared to 2014. While we expect increased spending on our proprietary research and
development programs due primarily to the initiation of the NKTR-181 Phase 3 clinical program, we expect these increases will be offset by decreased payments for other operating activities in 2015 as compared to 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash flows used in operating activities for the six months ended June&nbsp;30, 2014 totaled $71.4 million, which includes $92.7 million of net
operating cash uses as well as $7.5 million for interest payments on our senior secured notes, partially offset by the receipt of $28.8 million for milestones from collaboration agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash flows from investing activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
paid $4.6 million and $5.2 million to purchase property, plant and equipment in the six months ended June&nbsp;30, 2015 and 2014, respectively. We expect our capital expenditures in 2015, which include costs to build commercial manufacturing
capacity for Amikacin Inhale devices and other capital projects, to increase as compared to 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash flows from financing activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;28, 2014, we completed the issuance and sale of 9,775,000 shares of our common stock in a public offering with total proceeds
of approximately $117.2 million after deducting the underwriting commissions and discounts of approximately $7.5 million. In addition, we incurred approximately $0.6 million in legal and accounting fees, filing fees, and other offering expenses in
connection with this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2012, we sold all of our rights to receive future royalty payments on CIMZIA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and MIRCERA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in exchange for a cash payment of $124.0 million. During the six months ended June&nbsp;30, 2014, we made a payment of $7.0
million to the purchaser of these royalties because the minimum 2013 MIRCERA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> net sales threshold was not met. As of June&nbsp;30, 2015, we are not required to make any further payments to the
purchaser of these royalties. The remaining $122.0 million liability related to sale of future royalties at June&nbsp;30, 2015 will not be settled in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We received $7.8 million and $8.0 million from issuances of common stock to employees under our equity compensation plans during the six
months ended June&nbsp;30, 2015 and 2014, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contractual Obligations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no material changes during the six months ended June&nbsp;30, 2015 to the summary of contractual obligations included in our Annual
Report on Form 10-K for the year ended December&nbsp;31, 2014 on file with the Securities and Exchange Commission. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Off-Balance Sheet Arrangements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not utilize off-balance sheet financing arrangements as a source of liquidity or financing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting
period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the
circumstances, the results of which form our basis for making judgments about the carrying value of assets and liabilities that are not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
readily apparent from other sources. We evaluate our estimates on an ongoing basis. Actual results may differ from those estimates under different assumptions or conditions. There have been no
material changes to our critical accounting policies and estimates discussed in our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2014. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="tx86512_9"></A>Quantitative and Qualitative Disclosures about Market Risk </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
market risks at June&nbsp;30, 2015 have not changed significantly from those discussed in Item&nbsp;7A of our Annual Report on Form 10-K for the year ended December&nbsp;31, 2014 on file with the Securities and Exchange Commission. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="tx86512_10"></A>Controls and Procedures </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disclosure Controls and Procedures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange
Act of 1934 (Exchange Act) reports is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to
management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our
management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon, and as of the date of, this
evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes
in Internal Control Over Financial Reporting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We continuously seek to improve the efficiency and effectiveness of our internal
controls. This results in refinements to processes throughout the Company. However, there was no change in our internal control over financial reporting that occurred in the three months ended June&nbsp;30, 2015 that has materially affected, or is
reasonably likely to materially affect, our internal control over financial reporting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitations on the Effectiveness of Controls </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures
or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are
met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations
include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more
people or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its
stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a
cost-effective control system, misstatements due to error or fraud may occur and not be detected. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx86512_11"></A>PART II:
OTHER INFORMATION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="tx86512_12"></A>Legal Proceedings </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is hereby made to our disclosures
in &#147;Legal Matters&#148; under Note 5 to our Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q and the information under the heading &#147;Legal Matters&#148; is incorporated by reference herein. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="tx86512_13"></A>Risk Factors </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investors in
Nektar Therapeutics should carefully consider the risks described below before making an investment decision. The risks described below may not be the only ones relating to our company. This description includes any material changes to and
supersedes the description of the risk factors associated with our business previously disclosed in Item&nbsp;1A of our Annual Report on Form 10-K for the year ended December&nbsp;31, 2014. Additional risks that we currently believe are immaterial
may also impair our business operations. Our business, results of operations, financial condition, cash flows and future prospects and the trading price of our common stock and our abilities to repay our senior secured notes could be harmed as a
result of any of these risks, and investors may lose all or part of their investment. In assessing these risks, investors should also refer to the other information contained or incorporated by reference in this Quarterly Report on Form 10-Q and our
Annual Report on Form 10-K for the year ended December&nbsp;31, 2014, including our consolidated financial statements and related notes, and our other filings made from time to time with the Securities and Exchange Commission (SEC). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Drug development is a long and inherently uncertain process with a high risk of failure at
every stage of development. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a number of proprietary drug candidates and partnered drug candidates in research and
development ranging from the early discovery research phase through preclinical testing and clinical trials. Preclinical testing and clinical studies are long, expensive and highly uncertain processes. It will take us, or our collaborative partners,
several years to complete clinical studies. The start or end of a clinical study is often delayed or halted due to changing regulatory requirements, manufacturing challenges, required clinical trial administrative actions, slower than anticipated
patient enrollment, changing standards of care, availability or prevalence of use of a comparator drug or required prior therapy, clinical outcomes, or our and our partners&#146; financial constraints. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drug development is a highly uncertain scientific and medical endeavor, and failure can unexpectedly occur at any stage of preclinical and
clinical development. Typically, there is a high rate of attrition for drug candidates in preclinical and clinical trials due to scientific feasibility, safety, efficacy, changing standards of medical care and other variables. The risk of failure
increases for our drug candidates that are based on new technologies, such as the application of our advanced polymer conjugate technology to NKTR-102, NKTR-181, NKTR-171, NKTR-214 and other drug candidates currently in discovery research or
preclinical development. For example, while we recently started a Phase 3 clinical program for NKTR-181 which we believe employs the most appropriate clinical trial design, we were unable to identify a single cause for the Phase 2 study for NKTR-181
not meeting its primary efficacy endpoint, and therefore there is increased risk in effectively designing a Phase 3 clinical program for NKTR-181. The failure of one or more of our drug candidates could have a material adverse effect on our
business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Even with success in previously completed clinical trials, the risk of
clinical failure for any drug candidate remains high prior to regulatory approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A number of companies have suffered significant
unforeseen failures in late stage (i.e. Phase 3) clinical studies due to factors such as inconclusive efficacy or safety, even after achieving positive results in earlier clinical studies that were satisfactory both to them and to reviewing
regulatory authorities. Phase 3 clinical study outcomes remain very unpredictable and it is possible that one or more of these Phase 3 clinical studies could fail at any time due to efficacy, safety or other important clinical findings or regulatory
requirements. If one or more of these drug candidates fail in Phase&nbsp;3 clinical studies, it would have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our results of operations and financial condition depend significantly on the ability of our collaboration partners to successfully
develop and market drugs and they may fail to do so. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we sign a collaborative development agreement or license agreement to
develop a drug candidate with a pharmaceutical or biotechnology company, the pharmaceutical or biotechnology company is generally expected to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">design and conduct large scale clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prepare and file documents necessary to obtain government approvals to sell a given drug candidate; and/or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market and sell the drugs when and if they are approved. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reliance on collaboration
partners poses a number of significant risks to our business, including risks that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we have very little control over the timing and level of resources that our collaboration partners dedicate to commercial marketing efforts such as the amount of investment in sales and marketing personnel, general
marketing campaigns, direct-to-consumer advertising (where appropriate), product sampling, pricing agreements and rebate strategies with government and private payers, manufacturing and supply of drug product, and other marketing and selling
activities that need to be undertaken and well executed for a drug to have the potential to achieve commercial success; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaboration partners with commercial rights may choose to devote fewer resources to the marketing of our partnered drugs than they devote to their own drugs or other drugs that they have in-licensed;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we have very little control over the timing and amount of resources our partners devote to development programs in one or more major markets; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disagreements with partners could lead to delays in, or termination of, the research, development or commercialization of product candidates or to litigation or arbitration proceedings; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disputes may arise or escalate in the future with respect to the ownership of rights to technology or intellectual property developed with partners; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we do not have the ability to unilaterally terminate agreements (or partners may have extension or renewal rights) that we believe are not on commercially reasonable terms or consistent with our current business
strategy; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partners may be unable to pay us as expected; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partners may terminate their agreements with us unilaterally for any or no reason, in some cases with the payment of a termination fee penalty and in other cases with no termination fee penalty. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given these risks, the success of our current and future collaboration partnerships is highly unpredictable and can have a substantial
negative or positive impact on our business&#151;in particular, we expect the commercial outcomes of MOVANTIK&#153;, and if approved, BAX 855, to have a particularly significant impact on our near to mid- term financial results and financial
condition. If our collaboration arrangements underperform or fail, our drug development efforts for our proprietary drug candidate pipeline could be delayed or reduced unless we can secure capital funding from other sources. If we are unable to
obtain sufficient capital resources to advance our drug candidate pipeline, it would negatively impact the value of our business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The commercial potential of a drug candidate in development is difficult to predict. If the market size for a new drug is significantly
smaller than we anticipate, it could significantly and negatively impact our revenue, results of operations and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is very difficult to estimate the commercial potential of product candidates due to important factors such as safety and efficacy compared
to other available treatments, including potential generic drug alternatives with similar efficacy profiles, changing standards of care, third party payer reimbursement standards, patient and physician preferences, drug scheduling status, the
availability of competitive alternatives that may emerge either during the long drug development process or after commercial introduction, and the availability of generic versions of our product candidates following approval by regulatory
authorities based on the expiration of regulatory exclusivity or our inability to prevent generic versions from coming to market by asserting our patents. If due to one or more of these risks the market potential for a drug candidate is lower than
we anticipated, it could significantly and negatively impact the commercial terms of any collaboration partnership potential for such drug candidate or, if we have already entered into a collaboration for such drug candidate, the revenue potential
from royalty and milestone payments could be significantly diminished and this would negatively impact our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could
result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently derive, and expect to derive in the foreseeable future, all of our revenue from collaboration agreements with biotechnology and
pharmaceutical companies. These collaboration agreements contain complex commercial terms, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical development and commercialization obligations that are based on certain commercial reasonableness performance standards that can often be difficult to enforce if disputes arise as to adequacy of our
partner&#146;s performance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">research and development performance and reimbursement obligations for our personnel and other resources allocated to partnered drug candidate development programs; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical and commercial manufacturing agreements, some of which are priced on an actual cost basis for products supplied by us to our partners with complicated cost allocation formulas and methodologies;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">intellectual property ownership allocation between us and our partners for improvements and new inventions developed during the course of the collaboration; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">royalties on drug sales based on a number of complex variables, including net sales calculations, geography, scope of patent claim coverage, patent life, generic competitors, bundled pricing and other factors; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">indemnity obligations for intellectual property infringement, product liability and certain other claims. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to certain significant agreements, including an asset purchase agreement with Novartis pursuant to which we sold a significant
portion of our pulmonary business at the end of 2008, the worldwide exclusive license agreement with AstraZeneca related to the further development and commercialization of MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, and the
purchase and sale agreement with RPI Finance Trust (RPI) related to the sale of our royalty interests in UCB&#146;s CIMZIA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Roche&#146;s
MIRCERA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> that we completed in February 2012. Each of these agreements contains complex representations and warranties, covenants and indemnification obligations. If we breach any of our
agreements with Novartis, AstraZeneca, RPI or any other third party agreements, it could subject us to substantial liabilities and harm our financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we have informal dispute resolution discussions with third parties regarding the appropriate interpretation of the complex
commercial terms contained in our agreements. For example, on January&nbsp;23, 2015, we filed a lawsuit against Allergan and MAP seeking economic damages related to a dispute over the economic sharing provisions of our license agreement with MAP.
One or more disputes may arise or escalate in the future regarding our collaboration agreements, transaction documents, or third-party license agreements that may ultimately result in costly litigation and unfavorable interpretation of contract
terms, which would have a material adverse effect on our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we or our partners do not obtain regulatory approval for our drug candidates on a timely
basis, or at all, or if the terms of any approval impose significant restrictions or limitations on use, our business, results of operations and financial condition will be negatively affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or our partners may not obtain regulatory approval for drug candidates on a timely basis, or at all, or the terms of any approval (which in
some countries includes pricing approval) may impose significant restrictions or limitations on use. Drug candidates must undergo rigorous animal and human testing and an extensive review process for safety and efficacy by the FDA and equivalent
foreign regulatory authorities. The time required for obtaining regulatory decisions is uncertain and difficult to predict. The FDA and other U.S. and foreign regulatory authorities have substantial discretion, at any phase of development, to
terminate clinical studies, require additional clinical development or other testing, delay or withhold registration and marketing approval and mandate product withdrawals, including recalls. For example, while data from certain pre-specified
subgroups in the BEACON study was positive, the study did not achieve statistical significance for its primary endpoint and the FDA and European Medicines Agency rarely approve drugs on the basis of studies that do not achieve statistical
significance on the primary endpoint. Further, regulatory authorities have the discretion to analyze data using their own methodologies that may differ from those used by us or our partners which could lead such authorities to arrive at different
conclusions regarding the safety or efficacy of a drug candidate. In addition, undesirable side effects caused by our drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more
restricted label or the delay or denial of regulatory approval by regulatory authorities. For example, AstraZeneca will be conducting a post-marketing, observational epidemiological study comparing MOVANTIK<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> to other treatments of OIC in patients with chronic, non-cancer pain and the results of this study could at some point in the future negatively impact the labeling, regulatory status, and commercial
potential of MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we or our partners receive regulatory approval of a
product, the approval may limit the indicated uses for which the drug may be marketed. Our partnered drugs that have obtained regulatory approval, and the manufacturing processes for these products, are subject to continued review and periodic
inspections by the FDA and other regulatory authorities. Discovery from such review and inspection of previously unknown problems may result in restrictions on marketed products or on us, including withdrawal or recall of such products from the
market, suspension of related manufacturing operations or a more restricted label. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations or a product withdrawal would negatively impact our
business, results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have substantial future capital requirements and there is a risk we may
not have access to sufficient capital to meet our current business plan. If we do not receive substantial milestone or royalty payments from our existing collaboration agreements, execute new high value collaborations or other arrangements, or are
unable to raise additional capital in one or more financing transactions, we would be unable to continue our current level of investment in research and development. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2015, we had cash and investments in marketable securities valued at approximately $279.7 million.&nbsp;Also, as of
June&nbsp;30, 2015, we had $133.5 million in long-term debt, including $125.0 million of senior secured notes and $8.5 million of capital lease obligations, of which $5.6 million is current. While we believe that our cash position will be sufficient
to meet our liquidity requirements through at least the next 12 months, our future capital requirements will depend upon numerous unpredictable factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost, timing and outcomes of clinical studies and regulatory reviews of our proprietary drug candidates that we have licensed to our collaboration partners &#151;important examples include Amikacin Inhale and CIPRO
Inhale licensed to Bayer, and BAX 855 that is being developed by Baxalta; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the commercial launch and sales levels of products marketed by our collaboration partners for which we are entitled to royalties and sales milestones&#151;importantly, AstraZeneca&#146;s level of success in marketing
and selling MOVANTIK&#153; (or MOVENTIG<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, the naloxegol brand name in the EU); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if and when we receive potential milestone payments and royalties from our existing collaborations if the drug candidates subject to those collaborations achieve clinical, regulatory or commercial success;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the progress, timing, cost and results of our clinical development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success, progress, timing and costs of our efforts to implement new collaborations, licenses and other transactions that increase our current net cash, such as the sale of additional royalty interests held by us,
term loan or other debt arrangements, and the issuance of securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of patients, enrollment criteria, primary and secondary endpoints, and the number of clinical studies required by the regulatory authorities in order to consider for approval our drug candidates and those of
our collaboration partners; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our general and administrative expenses, capital expenditures and other uses of cash; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disputes concerning patents, proprietary rights, or license and collaboration agreements that negatively impact our receipt of milestone payments or royalties or require us to make significant payments arising from
licenses, settlements, adverse judgments or ongoing royalties. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A significant multi-year capital commitment is required to advance our drug candidates through
the various stages of research and development in order to generate sufficient data to enable high value collaboration partnerships with significant upfront payments or to successfully achieve regulatory approval. In the event we do not enter into
any new collaboration partnerships with significant upfront payments and we choose to continue our later stage research and development programs, we may need to pursue financing alternatives, including dilutive equity-based financings, such as an
offering of convertible debt or common stock, which would dilute the percentage ownership of our current common stockholders and could significantly lower the market value of our common stock. If sufficient capital is not available to us or is not
available on commercially reasonable terms, it could require us to delay or reduce one or more of our research and development programs. If we are unable to sufficiently advance our research and development programs, it could substantially impair
the value of such programs and result in a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>While we have conducted numerous experiments using laboratory and home-based chemistry techniques that have not been able to convert
NKTR-181 into a rapid-acting and more abusable opioid, there is a risk that a technique could be discovered in the future to convert NKTR-181 into a rapid-acting and more abusable opioid, which would significantly diminish the value of this drug
candidate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An important objective of our NKTR-181 drug development program is to create a unique opioid molecule that does not
rapidly enter a patient&#146;s central nervous system and therefore has the potential to be less susceptible to abuse than alternative opioid therapies. To date, we have conducted numerous experiments using laboratory and home-based chemistry
techniques that have been unable to convert NKTR-181 into a rapidly-acting, more abusable form of opioid. In the future, an alternative chemistry technique, process or method of administration, or combination thereof, may be discovered to enable the
conversion of NKTR-181 into a more abusable opioid, which could significantly and negatively impact the commercial potential or diminish the value of NKTR-181. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to establish and maintain collaboration partnerships on attractive commercial terms, our business, results of
operations and financial condition could suffer. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to continue to seek partnerships with pharmaceutical and biotechnology
partners to fund a portion of our research and development capital requirements. The timing of new collaboration partnerships is difficult to predict due to availability of clinical data, the outcomes from our clinical studies, the number of
potential partners that need to complete due diligence and approval processes, the definitive agreement negotiation process and numerous other unpredictable factors that can delay, impede or prevent significant transactions. If we are unable to find
suitable partners or negotiate collaboration arrangements with favorable commercial terms with respect to our existing and future drug candidates or the licensing of our intellectual property, or if any arrangements we negotiate, or have negotiated,
are terminated, it could have a material adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preliminary
and interim data from our clinical studies that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we publish preliminary or interim data from our clinical studies. Preliminary data remain subject to audit
confirmation and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Interim data are also subject to the risk that one or more of the clinical outcomes may
materially change as patient enrollment continues and more patient data become available. As a result, preliminary and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data could
significantly harm our business prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Delays in clinical studies are common and have many causes, and any significant delay in
clinical studies being conducted by us or our partners could result in delay in regulatory approvals and jeopardize the ability to proceed to commercialization. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or our partners may experience delays in clinical trials of drug candidates. We currently have ongoing clinical studies for NKTR-181 in
patients with chronic lower back pain and NKTR-171 in healthy volunteers to determine dosing ranges. In addition, our collaboration partners have several ongoing Phase 3 clinical programs including Baxalta for BAX 855, Bayer for Amikacin Inhale and
CIPRO Inhale, and Ophthotech for Fovista<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. These and other clinical studies may not begin on time, enroll a sufficient number of patients or be completed on schedule, if at all. Clinical
trials for any of our product candidates could be delayed for a variety of reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in obtaining regulatory approval to commence a clinical study; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in reaching agreement with applicable regulatory authorities on a clinical study design; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">imposition of a clinical hold following an inspection of clinical trial operations or trial sites by the FDA or other health authorities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension or termination of a clinical study by us, our partners, the FDA or foreign regulatory authorities due to adverse side effects of a drug on subjects in the trial; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in recruiting suitable patients to participate in a trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in having patients complete participation in a trial or return for post-treatment follow-up; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical sites dropping out of a trial to the detriment of enrollment rates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in manufacturing and delivery of sufficient supply of clinical trial materials; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in regulatory authorities policies or guidance applicable to our drug candidates. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
the initiation or completion of any of the planned clinical studies for our drug candidates is delayed for any of the above or other reasons, the regulatory approval process would be delayed and the ability to commercialize and commence sales of
these drug candidates could be materially harmed, which could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commercially
reasonable basis, if at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous pending and issued U.S. and foreign patent rights and other proprietary rights owned by
third parties relate to pharmaceutical compositions, methods of preparation and manufacturing, and methods of use and administration. We cannot predict with any certainty which, if any, patent references will be considered relevant to our or our
collaboration partners&#146; technology or drug candidates by authorities in the various jurisdictions where such rights exist, nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties. In
certain cases, we have existing licenses or cross-licenses with third parties; however, the scope and adequacy of these licenses is very uncertain and can change substantially during long development and commercialization cycles for biotechnology
and pharmaceutical products. There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable terms, if at all, or that we could develop or otherwise obtain alternate technology. If we are required to
enter into a license with a third party, our potential economic benefit for the products subject to the license will be diminished. If a license is not available on commercially reasonable terms or at all, we may be prevented from developing and
commercializing the drug, which could significantly harm our business, results of operations, and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If any of
our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve complex legal and factual issues.
We own more than 215 U.S. and 750 foreign patents and a number of pending patent applications that cover various aspects of our technologies. There can be no assurance that patents that have issued will be held valid and enforceable in a court of
law. Even for patents that are held valid and enforceable, the legal process associated with obtaining such a judgment is time consuming and costly.&nbsp;Additionally, issued patents can be subject to opposition or other proceedings that can result
in the revocation of the patent or maintenance of the patent in amended form (and potentially in a form that renders the patent without commercially relevant and/or broad coverage).&nbsp;Further, our competitors may be able to circumvent and
otherwise design around our patents. Even if a patent is issued and enforceable, because development and commercialization of pharmaceutical products can be subject to substantial delays, patents may expire early and provide only a short period of
protection, if any, following the commercialization of products encompassed by our patents.&nbsp;We may have to participate in interference proceedings declared by the U.S. Patent and Trademark Office, which could result in a loss of the patent
and/or substantial cost to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed patent applications, and plan to file additional patent applications, covering various
aspects of our PEGylation and advanced polymer conjugate technologies and our proprietary product candidates.&nbsp;There can be no assurance that the patent applications for which we apply would actually issue as patents, or do so with commercially
relevant and/or broad coverage. The coverage claimed in a patent application can be significantly reduced before the patent is issued.&nbsp;The scope of our claim coverage can be critical to our ability to enter into licensing transactions with
third parties and our right to receive royalties from our collaboration partnerships. Since publication of discoveries in scientific or patent literature often lags behind the date of such discoveries, we cannot be certain that we were the first
inventor of inventions covered by our patents or patent applications.&nbsp;In addition, there is no guarantee that we will be the first to file a patent application directed to an invention. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An adverse outcome in any judicial proceeding involving intellectual property, including patents, could subject us to significant liabilities
to third parties, require disputed rights to be licensed from or to third parties or require us to cease using the technology in dispute.&nbsp;In those instances where we seek an intellectual property license from another, we may not be able to
obtain the license on a commercially reasonable basis, if at all, thereby raising concerns on our ability to freely commercialize our technologies or products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are involved in legal proceedings and may incur substantial litigation costs and liabilities that will adversely affect our business,
financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, third parties have asserted, and may in the future assert, that
we or our partners infringe their proprietary rights, such as patents and trade secrets, or have otherwise breached our obligations to them. The third party often bases its assertions on a claim that its patents cover our technology platform or drug
candidates or that we have misappropriated its confidential or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proprietary information. Similar assertions of infringement could be based on future patents that may issue to third parties. In certain of our agreements with our partners, we are obligated to
indemnify and hold harmless our collaboration partners from intellectual property infringement, product liability and certain other claims, which could cause us to incur substantial costs and liability if we are called upon to defend ourselves and
our partners against any claims. If a third party obtains injunctive or other equitable relief against us or our partners, they could effectively prevent us, or our partners, from developing or commercializing, or deriving revenue from, certain
drugs or drug candidates in the U.S. and abroad. Costs associated with litigation, substantial damage claims, indemnification claims or royalties paid for licenses from third parties could have a material adverse effect on our business, financial
condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party claims involving proprietary rights or other matters could also result in substantial
settlement payments or substantial damages to be paid by us. For instance, a settlement might require us to enter a license agreement under which we would pay substantial royalties or other compensation to a third party, diminishing our future
economic returns from the related drug. In December 2013, we entered into a litigation settlement with the Research Foundation of the State University of New York (SUNY) pursuant to which we agreed to pay $12.0 million and certain other terms and
conditions in exchange for the full release of certain breach of contract claims by SUNY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, from time to time, we are involved
in legal proceedings where we or other third parties are enforcing or seeking intellectual property rights, invalidating or limiting patent rights that have already been allowed or issued, or otherwise asserting proprietary rights through one or
more potential legal remedies. For example, we are currently involved in a German litigation proceeding whereby Bayer is seeking co-ownership rights in certain of our patent filings pending at the European Patent Office covering (among other things)
PEGylated Factor VIII which we have exclusively licensed to Baxalta. The subject matter of our patent filings in this proceeding relates to Bayer&#146;s investigational PEGylated recombinant Factor VIII compound. We believe that Bayer&#146;s claim
to an ownership interest in these patent filings is without merit and are vigorously defending sole and exclusive ownership rights to this intellectual property. We are also regularly involved in opposition proceedings at the European Patent Office
where third parties seek to invalidate or limit the scope of our allowed European patent applications covering (among other things) our drugs and platform technologies. The cost to us in initiating or defending any litigation or other proceeding,
even if resolved in our favor, could be substantial, and litigation would divert our management&#146;s attention. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and
development efforts or result in financial implications either in terms of seeking license arrangements or payment of damages or royalties.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our manufacturing operations and those of our contract manufacturers are subject to laws and other governmental regulatory requirements,
which, if not met, would have a material adverse effect on our business, results of operations and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our
contract manufacturers are required in certain cases to maintain compliance with current good manufacturing practices (cGMP), including cGMP guidelines applicable to active pharmaceutical ingredients, and with laws and regulations governing
manufacture and distribution of controlled substances, and are subject to inspections by the FDA, the Drug Enforcement Administration or comparable agencies in other jurisdictions administering such compliance. We anticipate periodic regulatory
inspections of our drug manufacturing facilities and the manufacturing facilities of our contract manufacturers for compliance with applicable regulatory requirements. Any failure to follow and document our or our contract manufacturers&#146;
adherence to such cGMP and other laws and governmental regulations or satisfy other manufacturing and product release regulatory requirements may disrupt our ability to meet our manufacturing obligations to our customers, lead to significant delays
in the availability of products for commercial use or clinical study, result in the termination or hold on a clinical study or delay or prevent filing or approval of marketing applications for our products. Failure to comply with applicable laws and
regulations may also result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delays, suspension or withdrawal of approvals, license
revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could harm our business. Regulatory inspections could result in costly manufacturing changes or facility or capital equipment upgrades to
satisfy the FDA that our manufacturing and quality control procedures are in substantial compliance with cGMP. Manufacturing delays, for us or our contract manufacturers, pending resolution of regulatory deficiencies or suspensions could have a
material adverse effect on our business, results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we or our contract manufacturers are not
able to manufacture drugs or drug substances in sufficient quantities that meet applicable quality standards, it could delay clinical studies, result in reduced sales or constitute a breach of our contractual obligations, any of which could
significantly harm our business, financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or our contract manufacturers are not able
to manufacture and supply sufficient drug quantities meeting applicable quality standards required to support large clinical studies or commercial manufacturing in a timely manner, it could delay our or our collaboration partners&#146; clinical
studies or result in a breach of our contractual obligations, which could in turn reduce the potential commercial sales of our or our collaboration partners&#146; products. As a result, we could incur substantial costs and damages and any product
sales or royalty revenue that we would otherwise be entitled to receive could be reduced, delayed or eliminated. In some cases, we rely on contract manufacturing organizations to manufacture and supply drug product for our clinical studies and those
of our collaboration partners. Pharmaceutical manufacturing of drugs and devices involves significant risks and uncertainties related to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the demonstration of adequate stability, sufficient purification of the drug substance and drug product, the identification and elimination of impurities, optimal formulations, process and
analytical methods validations, device performance and challenges in controlling for all of these variables. We have faced and may in the future face significant difficulties, delays and unexpected expenses as we validate third party contract
manufacturers required for drug and device supply to support our clinical studies and the clinical studies and products of our collaboration partners. Failure by us or our contract manufacturers to supply drug product or devices in sufficient
quantities that meet all applicable quality requirements could result in supply shortages for our clinical studies or the clinical studies and commercial activities of our collaboration partners. Such failures could significantly and materially
delay clinical trials and regulatory submissions or result in reduced sales, any of which could significantly harm our business prospects, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Building and validating large scale clinical or commercial-scale manufacturing facilities and processes, recruiting and training qualified
personnel and obtaining necessary regulatory approvals is complex, expensive and time consuming. In the past we have encountered challenges in scaling up manufacturing to meet the requirements of large scale clinical trials without making
modifications to the drug formulation, which may cause significant delays in clinical development. We experienced repeated significant delays in starting the Phase 3 clinical development program for Amikacin Inhale as we sought to finalize and
validate the device design with a demonstrated capability to be manufactured at commercial scale. Drug/device combination products are particularly complex, expensive and time-consuming to develop due to the number of variables involved in the final
product design, including ease of patient and doctor use, maintenance of clinical efficacy, reliability and cost of manufacturing, regulatory approval requirements and standards and other important factors. There continues to be substantial and
unpredictable risk and uncertainty related to manufacturing and supply until such time as the commercial supply chain is validated and proven. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our revenue is exclusively derived from our collaboration agreements, which can result in significant fluctuation in our revenue from
period to period, and our past revenue is therefore not necessarily indicative of our future revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue is exclusively
derived from our collaboration agreements, from which we receive contract research payments, milestone payments based on clinical progress, regulatory progress or net sales achievements, royalties and manufacturing revenue. Significant variations in
the timing of receipt of cash payments and our recognition of revenue can result from significant milestone payments based on the execution of new collaboration agreements, the timing of clinical outcomes, regulatory approval, commercial launch or
the achievement of certain annual sales thresholds. The amount of our revenue derived from collaboration agreements in any given period will depend on a number of unpredictable factors, including our ability to find and maintain suitable
collaboration partners, the timing of the negotiation and conclusion of collaboration agreements with such partners, whether and when we or our collaboration partners achieve clinical, regulatory and sales milestones, the timing of regulatory
approvals in one or more major markets, reimbursement levels by private and government payers, and the market introduction of new drugs or generic versions of the approved drug, as well as other factors. Our past revenue generated from collaboration
agreements is not necessarily indicative of our future revenue. If any of our existing or future collaboration partners fails to develop, obtain regulatory approval for, manufacture or ultimately commercialize any product candidate under our
collaboration agreement, our business, financial condition, and results of operations could be materially and adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable either to create sales, marketing and distribution capabilities or to enter into agreements with third parties to
perform these functions, we will be unable to commercialize our product candidates successfully. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no sales,
marketing or distribution capabilities. To commercialize any of our drugs that receive regulatory approval for commercialization, we must either develop internal sales, marketing and distribution capabilities, which would be expensive and time
consuming, or enter into collaboration arrangements with third parties to perform these services. If we decide to market our products directly, we must commit significant financial and managerial resources to develop a marketing and sales force with
technical expertise and with supporting distribution, administration and compliance capabilities. Factors that may inhibit our efforts to commercialize our products directly or indirectly with our partners include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability of sales personnel to obtain access to or persuade adequate numbers of physicians to use or prescribe our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the lack of complementary products or multiple product pricing arrangements may put us at a competitive disadvantage relative to companies with more extensive product lines; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen costs and expenses associated with creating and sustaining an independent sales and marketing organization. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we, or our partners through our collaborations, are not successful in recruiting sales and marketing personnel or in building a sales
and marketing infrastructure, we will have difficulty commercializing our products, which would adversely affect our business, results of operations and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent we rely on other pharmaceutical or biotechnology companies with established sales, marketing and distribution systems to market
our products, we will need to establish and maintain partnership arrangements, and we may not be able to enter into these arrangements on acceptable terms or at all. To the extent that we enter into co-promotion or other arrangements, any revenue we
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
receive will depend upon the efforts of third parties, which may not be successful and are only partially in our control&#151;important examples of this risk include MOVANTIK&#153; partnered with
AstraZeneca and BAX 855 partnered with Baxalta. In the event that we market our products without a partner, we would be required to build a sales and marketing organization and infrastructure, which would require a significant investment and we may
not be successful in building this organization and infrastructure in a timely or efficient manner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We purchase some of the
starting material for drugs and drug candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause production delays, clinical trial delays, substantial loss of revenue and
contract liability to third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We often face very limited supply of a critical raw material that can only be obtained from a
single, or a limited number of, suppliers, which could cause production delays, clinical trial delays, substantial lost revenue opportunities or contract liabilities to third parties. For example, there are only a limited number of qualified
suppliers, and in some cases single source suppliers, for the raw materials included in our PEGylation and advanced polymer conjugate drug formulations. Any interruption in supply or failure to procure such raw materials on commercially feasible
terms could harm our business by delaying our clinical trials, impeding commercialization of approved drugs or increasing our costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such
rights could harm our business, results of operations and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on trade secret protection for our
confidential and proprietary information. No assurance can be given that others will not independently develop substantially equivalent confidential and proprietary information or otherwise gain access to our trade secrets or disclose such
technology, or that we can meaningfully protect our trade secrets. In addition, unpatented proprietary rights, including trade secrets and know-how, can be difficult to protect and may lose their value if they are independently developed by a third
party or if their secrecy is lost. Any loss of trade secret protection or other unpatented proprietary rights could harm our business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We expect to continue to incur substantial losses and negative cash flow from operations and may not achieve or sustain profitability in
the future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the six months ended June&nbsp;30, 2015, we reported a net loss of $18.8 million. If and when we achieve
profitability depends upon a number of factors, including the timing and recognition of milestone payments and royalties received, the timing of revenue under our collaboration agreements, the amount of investments we make in our proprietary product
candidates and the regulatory approval and market success of our product candidates. We may not be able to achieve and sustain profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other factors that will affect whether we achieve and sustain profitability include our ability, alone or together with our partners, to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">develop drugs utilizing our technologies, either independently or in collaboration with other pharmaceutical or biotech companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effectively estimate and manage clinical development costs, particularly the cost of the clinical studies for NKTR-181, NKTR-171, and NKTR-214; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receive necessary regulatory and marketing approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain or expand manufacturing at necessary levels; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">achieve market acceptance of our partnered products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receive royalties on products that have been approved, marketed or submitted for marketing approval with regulatory authorities; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain sufficient funds to finance our activities. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If government and private
insurance programs do not provide payment or reimbursement for our partnered products or proprietary products, those products will not be widely accepted, which would have a negative impact on our business, results of operations and financial
condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In both domestic and foreign markets, sales of our partnered and proprietary products
that have received regulatory approval will depend in part on market acceptance among physicians and patients, pricing approvals by government authorities and the availability of payment or reimbursement from third-party payers, such as government
health administration authorities, managed care providers, private health insurers and other organizations. Such third-party payers are increasingly challenging the price and cost effectiveness of medical products and services. Therefore,
significant uncertainty exists as to the pricing approvals for, and the payment or reimbursement status of, newly approved healthcare products. Moreover, legislation and regulations affecting the pricing of pharmaceuticals may change before
regulatory agencies approve our proposed products for marketing and could further limit pricing approvals for, and reimbursement of, our products from government authorities and third-party payers. A government or third- party payer decision not to
approve pricing for, or provide adequate coverage and reimbursements of, our products would limit market acceptance of such products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We depend on third parties to conduct the clinical trials for our proprietary product
candidates and any failure of those parties to fulfill their obligations could harm our development and commercialization plans. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We depend on independent clinical investigators, contract research organizations and other third-party service providers to conduct clinical
trials for our proprietary product candidates. We rely heavily on these parties for successful execution of our clinical trials. Though we are ultimately responsible for the results of their activities, many aspects of their activities are beyond
our control. For example, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trials, but the independent clinical investigators may prioritize other
projects over ours or communicate issues regarding our products to us in an untimely manner. Third parties may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or our stated
protocols. The early termination of any of our clinical trial arrangements, the failure of third parties to comply with the regulations and requirements governing clinical trials or the failure of third parties to properly conduct our clinical
trials, approval and commercialization of our product candidates and would adversely affect our business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Significant competition for our polymer conjugate chemistry technology platforms and our partnered and proprietary products and product
candidates could make our technologies, products or product candidates obsolete or uncompetitive, which would negatively impact our business, results of operations and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our PEGylation and advanced polymer conjugate chemistry platforms and our partnered and proprietary products and product candidates compete
with various pharmaceutical and biotechnology companies. Competitors of our PEGylation and polymer conjugate chemistry technologies include Biogen Idec Inc., Savient Pharmaceuticals, Inc., Dr.&nbsp;Reddy&#146;s Laboratories Ltd., Enzon
Pharmaceuticals, Inc., SunBio Corporation, Mountain View Pharmaceuticals, Inc., Novo Nordisk A/S (formerly assets held by Neose Technologies, Inc.), and NOF Corporation. Several other chemical, biotechnology and pharmaceutical companies may also be
developing PEGylation technologies or technologies that have similar impact on target drug molecules. Some of these companies license or provide the technology to other companies, while others are developing the technology for internal use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are several competitors for our proprietary product candidates currently in development. For Amikacin Inhale, the current standard of
care includes several approved intravenous antibiotics for the treatment of either hospital-acquired pneumonia or ventilator-associated pneumonia in patients on mechanical ventilators. For
MOVANTIK<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, there are currently several alternative therapies used to address opioid-induced constipation (OIC) and opioid-induced bowel dysfunction (OBD), including Relistor<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (methylnaltrexone bromide) Subcutaneous Injection, oral Amitizia (lubiprostone), and oral and rectal over-the-counter laxatives and stool softeners such as docusate sodium, senna and milk of
magnesia. In addition, there are a number of companies developing potential products which are in various stages of clinical development and are being evaluated for the treatment of OIC and OBD in different patient populations, including Cubist
Pharmaceuticals, Inc., Progenics Pharmaceuticals, Inc. in collaboration with Salix Pharmaceuticals, Ltd., Mundipharma Int. Limited, Sucampo Pharmaceuticals, Inc., Develco Pharma GmbH, Alkermes, Inc., GlaxoSmithKline plc, Theravance, Inc., and Takeda
Pharmaceutical Company Limited. For etirinotecan pegol, there are a number of chemotherapies and cancer therapies approved today and in various stages of clinical development for breast and ovarian cancers, including, but not limited to: Abraxane<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (paclitaxel protein-bound particles for injectable suspension (albumin bound)), Xeloda<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (capecitabine), Afinitor<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (everolimus), Doxil<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (doxorubicin HCl), Ellence<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (epirubicin), Gemzar<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (gemcitabine), Halaven<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (eribulin), Herceptin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (trastuzumab), Hycamtin<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (topotecan), Ibrance<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (palbociclib), Ixempra<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (ixabepilone), Navelbine<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (vinolrebine), Iniparib, Paraplatin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (carboplatin), Taxol<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (paclitaxel) and
Taxotere<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (docetaxel). Major pharmaceutical or biotechnology companies with approved drugs or drugs in development for these cancers include, but are not limited to, Bristol-Meyers Squibb
Company, Eli Lilly&nbsp;&amp; Co., Roche, GlaxoSmithKline plc, Johnson and Johnson, Pfizer, Inc. Eisai, Inc., and Sanofi Aventis S.A. There are approved therapies for the treatment of colorectal cancer, including Eloxatin<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (oxaliplatin), Camptosar<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (irinotecan), Avastin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (bevacizumab), Zaltrap<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (Ziv-afilbercept), Stivarga<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (regorafenib), Erbitux<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (cetuximab), Vectibix<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (panitumumab), Xeloda<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (capecitabine), Adrucil<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (fluorouracil) and Wellcovorin<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (leucovorin). In addition, there are a number of drugs in various stages of preclinical and clinical development from companies exploring cancer therapies or improved chemotherapeutic agents to
potentially treat colorectal cancer, including, but not limited to, products in development from Bristol-Myers Squibb Company, Pfizer, Inc., GlaxoSmithKline plc, Antigenics, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Cell Therapeutics, Inc.,
Neopharm Inc. (acquired by Insys Therapeutics, Inc.), Meditech Research Ltd, Alchemia Limited, and Enzon Pharmaceuticals, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can
be no assurance that we or our partners will successfully develop, obtain regulatory approvals for and commercialize next-generation or new products that will successfully compete with those of our competitors. Many of our competitors have greater
financial, research and development, marketing and sales, manufacturing and managerial capabilities. We face competition from these companies not just in product development but also in areas such as recruiting employees, acquiring technologies that
might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical
companies. As a result, our competitors may succeed in developing competing technologies, obtaining regulatory approval or gaining market acceptance for products before we do. These developments could make our products or technologies uncompetitive
or obsolete. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If product liability lawsuits are brought against us, we may incur substantial liabilities.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacture, clinical testing, marketing and sale of medical products involve inherent product liability risks. If product
liability costs exceed our product liability insurance coverage, we may incur substantial liabilities that could have a severe negative impact on our financial position. Whether or not we are ultimately successful in any product liability
litigation, such litigation would consume substantial amounts of our financial and managerial resources and might result in adverse publicity, all of which would impair our business. Additionally, we may not be able to maintain our clinical trial
insurance or product liability insurance at an acceptable cost, if at all, and this insurance may not provide adequate coverage against potential claims or losses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our future depends on the proper management of our current and future business operations and their associated expenses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business strategy requires us to manage our business to provide for the continued development and potential commercialization of our
proprietary and partnered drug candidates. Our strategy also calls for us to undertake increased research and development activities and to manage an increasing number of relationships with partners and other third parties, while simultaneously
managing the capital necessary to support this strategy. Our decision to bear a majority or all of the clinical development costs of etirinotecan pegol substantially increases our future capital requirements. If we are unable to manage effectively
our current operations and any growth we may experience, our business, financial condition and results of operations may be adversely affected. If we are unable to effectively manage our expenses, we may find it necessary to reduce our
personnel-related costs through reductions in our workforce, which could harm our operations, employee morale and impair our ability to retain and recruit talent. Furthermore, if adequate funds are not available, we may be required to obtain funds
through arrangements with partners or other sources that may require us to relinquish rights to certain of our technologies, products or future economic rights that we would not otherwise relinquish or require us to enter into other financing
arrangements on unfavorable terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are dependent on our management team and key technical personnel, and the loss of any key
manager or employee may impair our ability to develop our products effectively and may harm our business, operating results and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success largely depends on the continued services of our executive officers and other key personnel. The loss of one or more members of our
management team or other key employees could seriously harm our business, operating results and financial condition. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued
employment with us. We are also dependent on the continued services of our technical personnel because of the highly technical nature of our products and the regulatory approval process. Because our executive officers and key employees are not
obligated to provide us with continued services, they could terminate their employment with us at any time without penalty. We do not have any post-employment noncompetition agreements with any of our employees and do not maintain key person life
insurance policies on any of our executive officers or key employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Because competition for highly qualified technical personnel
is intense, we may not be able to attract and retain the personnel we need to support our operations and growth. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must attract
and retain experts in the areas of clinical testing, manufacturing, research, regulatory and finance, and may need to attract and retain marketing and distribution experts and develop additional expertise in our existing personnel. We face intense
competition from other biopharmaceutical companies, research and academic institutions and other organizations for qualified personnel. Many of the organizations with which we compete for qualified personnel have greater resources than we have.
Because competition for skilled personnel in our industry is intense, companies such as ours sometimes experience high attrition rates with regard to their skilled employees. Further, in making employment decisions, job candidates often consider the
value of the stock options they are to receive in connection with their employment. Our equity incentive plan and employee benefit plans may not be effective in motivating or retaining our employees or attracting new employees, and significant
volatility in the price of our stock may adversely affect our ability to attract or retain qualified personnel. If we fail to attract new personnel or to retain and motivate our current personnel, our business and future growth prospects could be
severely harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If earthquakes or other catastrophic events strike, our business may be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our corporate headquarters, including a substantial portion of our research and development operations, are
located in the San Francisco Bay Area, a region known for seismic activity and a potential terrorist target. In addition, we own facilities for the manufacture of products using our PEGylation and advanced polymer conjugate technologies in
Huntsville, Alabama and own and lease offices in Hyderabad, India. There are no backup facilities for our manufacturing operations located in Huntsville, Alabama. In the event of an earthquake or other natural disaster, political instability, or
terrorist event in any of these locations, our ability to manufacture and supply materials for drug candidates in development and our ability to meet our manufacturing obligations to our customers would be significantly disrupted and our business,
results of operations and financial condition would be harmed. Our collaborative partners may also be subject to catastrophic events, such as earthquakes, floods, hurricanes and tornadoes, any of which could harm our business, results of operations
and financial condition. We have not undertaken a systematic analysis of the potential consequences to our business, results of operations and financial condition from a major earthquake or other catastrophic event, such as a fire, sustained loss of
power, terrorist activity or other disaster, and do not have a recovery plan for such disasters. In addition, our insurance coverage may not be sufficient to compensate us for actual losses from any interruption of our business that may occur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have implemented certain anti-takeover measures, which make it more difficult to acquire
us, even though such acquisitions may be beneficial to our stockholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions of our certificate of incorporation and
bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even though such acquisitions may be beneficial to our stockholders. These anti-takeover provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishment of a classified board of directors such that not all members of the board may be elected at one time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of a provision for cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability of our board to authorize the issuance of &#147;blank check&#148; preferred stock to increase the number of outstanding shares and thwart a takeover attempt; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prohibition on stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of stockholders; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishment of advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon by stockholders at stockholder meetings; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations on who may call a special meeting of stockholders. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, provisions of
Delaware law relating to business combinations with interested stockholders may discourage, delay or prevent a third party from acquiring us. These provisions may also discourage, delay or prevent a third party from acquiring a large portion of our
securities or initiating a tender offer or proxy contest, even if our stockholders might receive a premium for their shares in the acquisition over the then-current market prices. We also have a change of control severance benefit plan, which
provides for certain cash severance, stock award acceleration and other benefits in the event our employees are terminated (or, in some cases, resign for specified reasons) following an acquisition. This severance plan could discourage a third party
from acquiring us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The price of our common stock is expected to remain volatile. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our stock price is volatile. During the three months ended June&nbsp;30, 2015, based on closing prices on The NASDAQ Global Select Market, the
closing price of our common stock ranged from $9.52 to $13.84 per share. We expect our stock price to remain volatile. A variety of factors may have a significant effect on the market price of our common stock, including the risks described in this
section titled &#147;Risk Factors&#148; and the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of data from, or material developments in, our clinical studies and those of our collaboration partners, including data regarding efficacy and safety, delays in clinical development, regulatory approval or
commercial launch; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by collaboration partners as to their plans or expectations related to drug candidates and approved drugs in which we have a substantial economic interest; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the level of commercial sales achieved by our collaboration partners, particularly AstraZeneca&#146;s sales of MOVANTIK&#153;; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements regarding terminations or disputes under our collaboration agreements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fluctuations in our results of operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments in patent or other proprietary rights, including intellectual property litigation or entering into intellectual property license agreements and the costs associated with those arrangements;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of technological innovations or new therapeutic products that may compete with our approved products or products under development; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of changes in governmental regulation affecting us or our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">litigation brought against us or third parties to whom we have indemnification obligations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">public concern as to the safety of drug formulations developed by us or others; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our financing needs and activities; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general market conditions. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At times, our stock price has been volatile even in the absence of significant news or
developments. The stock prices of biotechnology companies and securities markets generally have been subject to dramatic price swings in recent years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The indenture governing the senior secured notes imposes significant operating and financial restrictions on us and our subsidiaries
that may prevent us from pursuing certain business opportunities and restrict our ability to operate our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture
governing the senior secured notes contains covenants that restrict our and our subsidiaries&#146; ability to take various actions, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">incur or guarantee additional indebtedness or issue disqualified capital stock or cause certain of our subsidiaries to issue preferred stock; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pay dividends or distributions, redeem equity interests or subordinated indebtedness or make certain types of investments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">create or incur liens; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfer, sell, lease or otherwise dispose of assets and issue or sell equity interests in certain of our subsidiaries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">incur restrictions on certain of our subsidiaries&#146; ability to pay dividends or other distributions to the Company or to make intercompany loans or asset transfers; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enter into transactions with affiliates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">engage in any business other than businesses which are the same, similar, ancillary or reasonably related to our business as of July&nbsp;11, 2012; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">consummate a merger, consolidation, reorganization or business combination, or sell, assign, transfer, lease or otherwise dispose of all or substantially all of our assets. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This indenture also requires us not to permit, from July&nbsp;1, 2015 through the quarter ending June&nbsp;30, 2017, the aggregate balance of
our unrestricted cash and cash equivalents at the end of any two consecutive fiscal quarters to be less than $25.0 million, subject to certain conditions. Our ability to comply with these covenants will likely be affected by many factors, including
events beyond our control, and we may not satisfy those requirements. Our failure to comply with our debt-related obligations could result in an event of default under our other indebtedness and the acceleration of our other indebtedness, in whole
or in part, could result in an event of default under the indenture governing the senior secured notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions contained in the
indenture governing the senior secured notes could also limit our ability to plan for or react to market conditions, meet capital needs or otherwise restrict our activities or business plans and adversely affect our ability to finance our
operations, enter into acquisitions or to engage in other business activities that would be in our interest. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="tx86512_14"></A>Unregistered Sales of Equity Securities and Use of Proceeds </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None, including no purchases of any class of our equity securities by us or any affiliate pursuant to any publicly announced repurchase plan in
the three months ended June&nbsp;30, 2015. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="tx86512_15"></A>Defaults Upon Senior Securities </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="tx86512_16"></A>Mine Safety Disclosures </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="tx86512_17"></A>Other Information </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><A NAME="tx86512_18"></A>Exhibits </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as so indicated in Exhibits 32.1 and 101, the
following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:88.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Documents</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2012 Performance Incentive Plan, as amended and restated</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>31.1(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Certification of Nektar Therapeutics&#146; principal executive officer required by Rule 13a-14(a) or Rule 15d-14(a).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>31.2(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Certification of Nektar Therapeutics&#146; principal financial officer required by Rule 13a-14(a) or Rule 15d-14(a).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>32.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Section 1350 Certifications.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The following materials from Nektar Therapeutics&#146; Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, formatted in XBRL (Extensible Business Reporting Language): (i) the unaudited Condensed Consolidated Balance
Sheets, (ii) the unaudited Condensed Consolidated Statements of Operations, (iii) the unaudited Condensed Consolidated Statements of Comprehensive Loss, (iv) the unaudited Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed
Consolidated Financial Statements.</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form 8-K, filed on June&nbsp;17, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Filed herewith. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Exhibit 32.1 is being furnished and shall not be deemed to be &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section,
nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as otherwise stated in such filing.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">XBRL information is filed herewith. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx86512_19"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ J<SMALL>OHN</SMALL> N<SMALL>ICHOLSON</SMALL></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>John Nicholson</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Senior&nbsp;Vice&nbsp;President&nbsp;and&nbsp;Chief&nbsp;Financial&nbsp;Officer</B></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Date: August&nbsp;5, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ J<SMALL>ILLIAN</SMALL> B. T<SMALL>HOMSEN</SMALL></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Jillian B. Thomsen</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Senior&nbsp;Vice&nbsp;President,&nbsp;Finance&nbsp;and&nbsp;Chief&nbsp;Accounting&nbsp;Officer</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Date: August&nbsp;5, 2015</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as so indicated in Exhibits 32.1 and 101, the following exhibits are filed as part of, or incorporated by reference in, this Quarterly
Report on Form 10-Q. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:88.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Documents</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2012 Performance Incentive Plan, as amended and restated</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>31.1(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Certification of Nektar Therapeutics&#146; principal executive officer required by Rule 13a-14(a) or Rule 15d-14(a).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>31.2(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Certification of Nektar Therapeutics&#146; principal financial officer required by Rule 13a-14(a) or Rule 15d-14(a).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>32.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Section 1350 Certifications.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The following materials from Nektar Therapeutics&#146; Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, formatted in XBRL (Extensible Business Reporting Language): (i) the unaudited Condensed Consolidated Balance
Sheets, (ii) the unaudited Condensed Consolidated Statements of Operations, (iii) the unaudited Condensed Consolidated Statements of Comprehensive Loss, (iv) the unaudited Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed
Consolidated Financial Statements.</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Incorporated by reference to the indicated exhibit in Nektar Therapeutics&#146; Current Report on Form 8-K, filed on June&nbsp;17, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Filed herewith. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Exhibit 32.1 is being furnished and shall not be deemed to be &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section,
nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as otherwise stated in such filing.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">XBRL information is filed herewith. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d86512dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Howard W. Robin,
certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this Quarterly Report on Form 10-Q of Nektar Therapeutics; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August&nbsp;5, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ H<SMALL>OWARD</SMALL> W. R<SMALL>OBIN</SMALL></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:10pt"><B>Howard W. Robin</B></FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Chief Executive Officer, President and Director</B></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d86512dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, John Nicholson,
certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this Quarterly Report on Form 10-Q of Nektar Therapeutics; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August&nbsp;5, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ J<SMALL>OHN</SMALL> N<SMALL>ICHOLSON</SMALL></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:10pt"><B>John Nicholson</B></FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Senior Vice President and Chief Financial Officer</B></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>d86512dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 1350 CERTIFICATIONS* </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to
the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;) and Section&nbsp;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Howard W. Robin, Chief
Executive Officer, President and Director of Nektar Therapeutics (the &#147;Company&#148;), and John Nicholson, Senior Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s Quarterly Report on Form 10-Q for the three and six months ended June&nbsp;30, 2015, to which this Certification is attached as Exhibit 32.1 (the &#147;Periodic Report&#148;), fully complies with the
requirements of Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: August&nbsp;5, 2015 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="54%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ H<SMALL>OWARD</SMALL> W. R<SMALL>OBIN</SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ J<SMALL>OHN</SMALL> N<SMALL>ICHOLSON</SMALL></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Howard W. Robin</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>John Nicholson</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Chief Executive Officer, President and Director</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Senior Vice President and Chief Financial Officer</B></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the
Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>nktr-20150630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="yes" ?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.22.4 -->
<!-- Round: 4 -->
<!-- Creation date: 2015-08-05T06:53:07Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2015-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:nktr="http://www.nektar.com/20150630" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <xbrll:schemaRef xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="nktr-20150630.xsd" xlink:type="simple" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  <nktr:LiabilitiesToPartnersForDirectConsumerAdvertisingPayments contextRef="eol_PE10737---1510-Q0005_STD_0_20150731_0_1633579x1814659_1640593x1641344_1641811x1641076" decimals="-5" id="id_6185658_406B6926-D885-4428-B16A-22DE79358D2C_4004_1" unitRef="iso4217_USD">5000000</nktr:LiabilitiesToPartnersForDirectConsumerAdvertisingPayments>
  <nktr:LiabilitiesToPartnersForDirectConsumerAdvertisingPayments contextRef="eol_PE10737---1510-Q0005_STD_0_20160731_0_1633579x1814659_1640593x1641344_1641811x1641076" decimals="-5" id="id_6185658_406B6926-D885-4428-B16A-22DE79358D2C_4005_1" unitRef="iso4217_USD">5000000</nktr:LiabilitiesToPartnersForDirectConsumerAdvertisingPayments>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE10737---1510-Q0005_STD_0_20150730_0" decimals="INF" id="id_6185658_62CFB107-DB68-4750-A7EE-232FC7A8641E_2_5" unitRef="shares">132371000</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount contextRef="eol_PE10737---1510-Q0005_STD_0_20140630_0" decimals="INF" id="id_6185658_97BF0196-F7C8-41DC-A600-BC495CE87FC5_1003_0" unitRef="iso4217_USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount contextRef="eol_PE10737---1510-Q0005_STD_0_20140630_0" decimals="INF" id="id_6185658_97BF0196-F7C8-41DC-A600-BC495CE87FC5_1003_1" unitRef="iso4217_USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE10737---1510-Q0005_STD_0_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1002_35" unitRef="iso4217_USD">30699000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <nktr:PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies contextRef="eol_PE10737---1510-Q0005_STD_0_20140916_0_1633579x1814659_1634968x1689625" decimals="-5" id="id_6185658_DBC1A9FB-93DF-4066-AF0A-8395FEDBC287_3001_2" unitRef="iso4217_USD">35000000</nktr:PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies>
  <nktr:LiabilitiesToPartnersForDirectConsumerAdvertisingPayments contextRef="eol_PE10737---1510-Q0005_STD_0_20150331_0_1633579x1814659_1641811x1641076" decimals="-5" id="id_6185658_406B6926-D885-4428-B16A-22DE79358D2C_4001_1" unitRef="iso4217_USD">10000000</nktr:LiabilitiesToPartnersForDirectConsumerAdvertisingPayments>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="INF" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_41" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_38" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_43" unitRef="shares">132185000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="INF" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_40" unitRef="iso4217_USD_per_shares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="INF" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_35" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_37" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_42" unitRef="shares">132185000</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="INF" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_34" unitRef="iso4217_USD_per_shares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_44" unitRef="iso4217_USD">1841730000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_19" unitRef="iso4217_USD">9713000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_25" unitRef="iso4217_USD">125000000</us-gaap:SeniorLongTermNotes>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_16" unitRef="iso4217_USD">10824000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_47" unitRef="iso4217_USD">35099000</us-gaap:StockholdersEquity>
  <us-gaap:CapitalLeaseObligations contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-5" id="id_6185658_974DB831-F1F6-4DF1-B2E4-DF6883FD1557_1_3" unitRef="iso4217_USD">8500000</us-gaap:CapitalLeaseObligations>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_29" unitRef="iso4217_USD">16668000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="INF" id="id_6185658_97BF0196-F7C8-41DC-A600-BC495CE87FC5_1001_0" unitRef="iso4217_USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="INF" id="id_6185658_97BF0196-F7C8-41DC-A600-BC495CE87FC5_1001_1" unitRef="iso4217_USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:LongTermDebt contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-5" id="id_6185658_974DB831-F1F6-4DF1-B2E4-DF6883FD1557_1_2" unitRef="iso4217_USD">133500000</us-gaap:LongTermDebt>
  <us-gaap:OtherLiabilitiesCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_23" unitRef="iso4217_USD">13214000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_22" unitRef="iso4217_USD">22987000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_15" unitRef="iso4217_USD">2833000</us-gaap:AccountsPayableCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_46" unitRef="iso4217_USD">-1805146000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:Liabilities contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_30" unitRef="iso4217_USD">421568000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_48" unitRef="iso4217_USD">456667000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_28" unitRef="iso4217_USD">73963000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_39" unitRef="iso4217_USD">13000</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_31" unitRef="iso4217_USD" xsi:nil="true"/>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_24" unitRef="iso4217_USD">81077000</us-gaap:LiabilitiesCurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_33" unitRef="iso4217_USD">0</us-gaap:PreferredStockValue>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_45" unitRef="iso4217_USD">-1498000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_20" unitRef="iso4217_USD">6917000</us-gaap:InterestPayableCurrent>
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_21" unitRef="iso4217_USD">5643000</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_26" unitRef="iso4217_USD">2889000</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_C614D649-633E-47DE-AC8E-796B34B0E3EE_1_1" unitRef="iso4217_USD">6117000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_36AFD7AA-7B1C-4E9D-B71A-D5DFEAB292AE_1_2" unitRef="iso4217_USD">230856000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_11" unitRef="iso4217_USD">5762000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_12" unitRef="iso4217_USD">456667000</us-gaap:Assets>
  <us-gaap:InventoryNet contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_6" unitRef="iso4217_USD">10124000</us-gaap:InventoryNet>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_5" unitRef="iso4217_USD">3680000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_9" unitRef="iso4217_USD">72158000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:AvailableForSaleSecuritiesCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_4" unitRef="iso4217_USD">233785000</us-gaap:AvailableForSaleSecuritiesCurrent>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_C614D649-633E-47DE-AC8E-796B34B0E3EE_1_2" unitRef="iso4217_USD">1615000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:AssetsCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_8" unitRef="iso4217_USD">302246000</us-gaap:AssetsCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_7" unitRef="iso4217_USD">8782000</us-gaap:OtherAssetsCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_3" unitRef="iso4217_USD">25000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:Goodwill contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_10" unitRef="iso4217_USD">76501000</us-gaap:Goodwill>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_2" unitRef="iso4217_USD">20875000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_C614D649-633E-47DE-AC8E-796B34B0E3EE_1_0" unitRef="iso4217_USD">2392000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_27" unitRef="iso4217_USD">121971000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
  <nktr:AccruedClinicalTrialExpenses contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_18" unitRef="iso4217_USD">8946000</nktr:AccruedClinicalTrialExpenses>
  <nktr:CashAndRestrictedCash contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_36AFD7AA-7B1C-4E9D-B71A-D5DFEAB292AE_1_5" unitRef="iso4217_USD">29363000</nktr:CashAndRestrictedCash>
  <nktr:PreferredStockShareDesignated contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_1_36" unitRef="shares">0</nktr:PreferredStockShareDesignated>
  <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0" decimals="-3" id="id_6185658_974DB831-F1F6-4DF1-B2E4-DF6883FD1557_1_0" unitRef="iso4217_USD">279660000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
  <us-gaap:DeferredRevenue contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1664673_1634968x1849413" decimals="-5" id="id_6185658_997EF810-0A7B-4F9A-82B0-436D139B4A24_2001_1" unitRef="iso4217_USD">3400000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1664673_1634968x1905729" decimals="-5" id="id_6185658_EE33268A-EDD1-4E5F-843A-C4C98CEF44F6_1001_0" unitRef="iso4217_USD">2600000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1664673_1634968x1950545" decimals="-5" id="id_6185658_AD9F89B8-E880-43D0-B847-6366B535828F_1001_0" unitRef="iso4217_USD">8100000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1738293_1634968x1656106" decimals="-5" id="id_6185658_11693B84-EBCC-44BD-9B4D-B6A1C287090A_1002_1" unitRef="iso4217_USD">18200000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1760274" decimals="-5" id="id_6185658_2E3CD8D8-83B7-4970-8A76-AB8FA190770C_1001_0" unitRef="iso4217_USD">26700000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1814659_1634968x1689625" decimals="INF" id="id_6185658_406B6926-D885-4428-B16A-22DE79358D2C_3006_3" unitRef="iso4217_USD">0</us-gaap:DeferredRevenue>
  <nktr:ContingentPaymentsReceivableBasedOnDevelopmentEvents contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1814659_1634968x1689625_1641811x1632305" decimals="-5" id="id_6185658_6C0A5DF8-7FF0-43AE-838C-33E09DBC6195_2002_1" unitRef="iso4217_USD">40000000</nktr:ContingentPaymentsReceivableBasedOnDevelopmentEvents>
  <nktr:ContingentPaymentsReceivableBasedOnDevelopmentEvents contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1814659_1634968x1722353" decimals="-5" id="id_6185658_6C0A5DF8-7FF0-43AE-838C-33E09DBC6195_3002_2" unitRef="iso4217_USD">75000000</nktr:ContingentPaymentsReceivableBasedOnDevelopmentEvents>
  <nktr:LiabilitiesToPartnersForDirectConsumerAdvertisingPayments contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1814659_1638287x1635282_1641811x1641076" decimals="-5" id="id_6185658_406B6926-D885-4428-B16A-22DE79358D2C_2003_1" unitRef="iso4217_USD">5000000</nktr:LiabilitiesToPartnersForDirectConsumerAdvertisingPayments>
  <nktr:LiabilitiesToPartnersForDirectConsumerAdvertisingPayments contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1814659_1638287x1638889_1641811x1641076" decimals="-5" id="id_6185658_406B6926-D885-4428-B16A-22DE79358D2C_2002_1" unitRef="iso4217_USD">5000000</nktr:LiabilitiesToPartnersForDirectConsumerAdvertisingPayments>
  <us-gaap:DeferredRevenue contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1834994" decimals="-5" id="id_6185658_2E27A7D3-4557-4946-AAE5-B6000EB2E384_2001_1" unitRef="iso4217_USD">20000000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1888068" decimals="-5" id="id_6185658_ACBCC183-FDED-4A63-95DB-93447769119E_1001_0" unitRef="iso4217_USD">18000000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenue contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1977273_1634968x1715959" decimals="INF" id="id_6185658_0A1A16BE-64FB-4D6E-A227-E82A62E26ECF_1002_1" unitRef="iso4217_USD">0</us-gaap:DeferredRevenue>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1634760x1634767_1643325x1636521" decimals="INF" id="id_6185658_FA739A31-B3AC-421F-BAAF-981A4A49D5DA_1001_0" unitRef="pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1634760x1634767_1643325x1636521" decimals="-5" id="id_6185658_FA739A31-B3AC-421F-BAAF-981A4A49D5DA_1001_2" unitRef="iso4217_USD">125000000</us-gaap:SeniorLongTermNotes>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1634760x1637150_1643713x1633464" decimals="-3" id="id_6185658_36AFD7AA-7B1C-4E9D-B71A-D5DFEAB292AE_1001_0" unitRef="iso4217_USD">185917000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1634760x1637150_1643713x1671183" decimals="-3" id="id_6185658_36AFD7AA-7B1C-4E9D-B71A-D5DFEAB292AE_2001_1" unitRef="iso4217_USD">44939000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:InvestmentsFairValueDisclosure contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1634760x1643241_1643713x1637231" decimals="-3" id="id_6185658_36AFD7AA-7B1C-4E9D-B71A-D5DFEAB292AE_3001_3" unitRef="iso4217_USD">16512000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1640416x1634809" decimals="INF" id="id_6185658_548A9937-F414-4CCA-A87C-5ED8A173BC6F_1001_0" unitRef="iso4217_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1643325x1636521" decimals="INF" id="id_6185658_70E551C0-5054-4FDF-9817-D69A0FE27589_1001_1" unitRef="pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1643325x1636521" decimals="-5" id="id_6185658_70E551C0-5054-4FDF-9817-D69A0FE27589_1001_0" unitRef="iso4217_USD">25000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:InvestmentsFairValueDisclosure contextRef="eol_PE10737---1510-Q0005_STD_0_20150630_0_1643713x1640681" decimals="-3" id="id_6185658_36AFD7AA-7B1C-4E9D-B71A-D5DFEAB292AE_4001_4" unitRef="iso4217_USD">2929000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE10737---1510-Q0005_STD_0_20131231_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2001_34" unitRef="iso4217_USD">39067000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="INF" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_41" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_38" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_43" unitRef="shares">131216000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="INF" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_40" unitRef="iso4217_USD_per_shares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="INF" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_35" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_37" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_42" unitRef="shares">131216000</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="INF" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_34" unitRef="iso4217_USD_per_shares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_44" unitRef="iso4217_USD">1824195000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_19" unitRef="iso4217_USD">6418000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:SeniorLongTermNotes contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_25" unitRef="iso4217_USD">125000000</us-gaap:SeniorLongTermNotes>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_16" unitRef="iso4217_USD">5749000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_47" unitRef="iso4217_USD">36332000</us-gaap:StockholdersEquity>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_29" unitRef="iso4217_USD">14721000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_23" unitRef="iso4217_USD">5567000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_22" unitRef="iso4217_USD">24473000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_15" unitRef="iso4217_USD">2703000</us-gaap:AccountsPayableCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_46" unitRef="iso4217_USD">-1786309000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:Liabilities contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_30" unitRef="iso4217_USD">405289000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_48" unitRef="iso4217_USD">441621000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_28" unitRef="iso4217_USD">76911000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_39" unitRef="iso4217_USD">13000</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_31" unitRef="iso4217_USD" xsi:nil="true"/>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_24" unitRef="iso4217_USD">64047000</us-gaap:LiabilitiesCurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_33" unitRef="iso4217_USD">0</us-gaap:PreferredStockValue>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_45" unitRef="iso4217_USD">-1567000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:InterestPayableCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_20" unitRef="iso4217_USD">6917000</us-gaap:InterestPayableCurrent>
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_21" unitRef="iso4217_USD">4512000</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_26" unitRef="iso4217_USD">4139000</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_C614D649-633E-47DE-AC8E-796B34B0E3EE_2_1" unitRef="iso4217_USD">5187000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_36AFD7AA-7B1C-4E9D-B71A-D5DFEAB292AE_2_2" unitRef="iso4217_USD">225459000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_11" unitRef="iso4217_USD">6552000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_12" unitRef="iso4217_USD">441621000</us-gaap:Assets>
  <us-gaap:InventoryNet contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_6" unitRef="iso4217_USD">12952000</us-gaap:InventoryNet>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_5" unitRef="iso4217_USD">3607000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_9" unitRef="iso4217_USD">70368000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:AvailableForSaleSecuritiesCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_4" unitRef="iso4217_USD">225459000</us-gaap:AvailableForSaleSecuritiesCurrent>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_C614D649-633E-47DE-AC8E-796B34B0E3EE_2_2" unitRef="iso4217_USD">5565000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:AssetsCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_8" unitRef="iso4217_USD">288200000</us-gaap:AssetsCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_7" unitRef="iso4217_USD">8817000</us-gaap:OtherAssetsCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_3" unitRef="iso4217_USD">25000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:Goodwill contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_10" unitRef="iso4217_USD">76501000</us-gaap:Goodwill>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_2" unitRef="iso4217_USD">12365000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_C614D649-633E-47DE-AC8E-796B34B0E3EE_2_0" unitRef="iso4217_USD">2200000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_27" unitRef="iso4217_USD">120471000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent>
  <nktr:AccruedClinicalTrialExpenses contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_18" unitRef="iso4217_USD">7708000</nktr:AccruedClinicalTrialExpenses>
  <nktr:CashAndRestrictedCash contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_36AFD7AA-7B1C-4E9D-B71A-D5DFEAB292AE_2_5" unitRef="iso4217_USD">26136000</nktr:CashAndRestrictedCash>
  <nktr:PreferredStockShareDesignated contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_814553F8-E99F-4F78-BB4B-34FEC2FEE4FC_2_36" unitRef="shares">0</nktr:PreferredStockShareDesignated>
  <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0" decimals="-3" id="id_6185658_52AC3058-B620-4098-982F-C0C9DBE90C6C_2_3" unitRef="iso4217_USD">262824000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0_1634760x1637150_1643713x1633464" decimals="-3" id="id_6185658_36AFD7AA-7B1C-4E9D-B71A-D5DFEAB292AE_1002_0" unitRef="iso4217_USD">182544000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0_1634760x1637150_1643713x1671183" decimals="-3" id="id_6185658_36AFD7AA-7B1C-4E9D-B71A-D5DFEAB292AE_2002_1" unitRef="iso4217_USD">42915000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:InvestmentsFairValueDisclosure contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0_1634760x1643241_1643713x1637231" decimals="-3" id="id_6185658_36AFD7AA-7B1C-4E9D-B71A-D5DFEAB292AE_3002_3" unitRef="iso4217_USD">11229000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0_1640416x1634809" decimals="INF" id="id_6185658_548A9937-F414-4CCA-A87C-5ED8A173BC6F_1002_0" unitRef="iso4217_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
  <us-gaap:InvestmentsFairValueDisclosure contextRef="eol_PE10737---1510-Q0005_STD_0_20141231_0_1643713x1640681" decimals="-3" id="id_6185658_36AFD7AA-7B1C-4E9D-B71A-D5DFEAB292AE_4002_4" unitRef="iso4217_USD">0</us-gaap:InvestmentsFairValueDisclosure>
  <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross contextRef="eol_PE10737---1510-Q0005_STD_1_20120224_0_1634968x1754234" decimals="-5" id="id_6185658_448E20EC-7725-49AB-A6AE-B73DE1B64FD6_1001_0" unitRef="iso4217_USD">124000000</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
  <nktr:PercentageOfPostApprovalStudyCostsToRepay contextRef="eol_PE10737---1510-Q0005_STD_1_20140916_0_1633579x1814659_1634968x1689625" decimals="2" id="id_6185658_DBC1A9FB-93DF-4066-AF0A-8395FEDBC287_1001_1" unitRef="pure">0.33</nktr:PercentageOfPostApprovalStudyCostsToRepay>
  <nktr:PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired contextRef="eol_PE10737---1510-Q0005_STD_1_20140916_0_1633579x1814659_1634968x1689625_1641811x1641076" decimals="2" id="id_6185658_DBC1A9FB-93DF-4066-AF0A-8395FEDBC287_2001_0" unitRef="pure">0.02</nktr:PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_19" unitRef="iso4217_USD">-71375000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="2" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_4_19" unitRef="iso4217_USD_per_shares">-0.63</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="INF" id="id_6185658_BC717D5A-EA21-4654-9D8C-09D8C809E792_4_0" unitRef="shares">1017887</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_4_20" unitRef="shares">125301000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="2" id="id_6185658_4164079B-BDC2-44E2-AD5A-F7A65154323C_4_0" unitRef="pure">0.34</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_27" unitRef="iso4217_USD">1650000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_24" unitRef="iso4217_USD">5192000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetIncomeLoss contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_4_18" unitRef="iso4217_USD">-78838000</us-gaap:NetIncomeLoss>
  <us-gaap:Revenues contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_4_4" unitRef="iso4217_USD">48284000</us-gaap:Revenues>
  <us-gaap:InterestPaid contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_37" unitRef="iso4217_USD">8622000</us-gaap:InterestPaid>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_4_10" unitRef="iso4217_USD">-59318000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_10" unitRef="iso4217_USD">659000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_11" unitRef="iso4217_USD">-738000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_4_14" unitRef="iso4217_USD">408000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_4_15" unitRef="iso4217_USD">-19134000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_9" unitRef="iso4217_USD">818000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_1334E699-D194-4475-B92C-4A615F56AA32_4_0" unitRef="iso4217_USD">-78544000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_4_16" unitRef="iso4217_USD">-78452000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="INF" id="id_6185658_31BCBE64-8308-4115-8B20-01649355D37E_4_700000" unitRef="iso4217_USD">0.0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_22" unitRef="iso4217_USD">166496000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_7" unitRef="iso4217_USD">-865000</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_4_17" unitRef="iso4217_USD">386000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_23" unitRef="iso4217_USD">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_164D7284-8416-45B8-A4B9-D24ACA7C275E_4_3" unitRef="iso4217_USD">8525000</us-gaap:ShareBasedCompensation>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_30" unitRef="iso4217_USD">7961000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_17" unitRef="iso4217_USD">7636000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_16" unitRef="iso4217_USD">-314000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_33" unitRef="iso4217_USD">-8368000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:InterestExpense contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_4_12" unitRef="iso4217_USD">9021000</us-gaap:InterestExpense>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_25" unitRef="iso4217_USD">-52911000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:CostsAndExpenses contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_4_9" unitRef="iso4217_USD">107602000</us-gaap:CostsAndExpenses>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_31" unitRef="iso4217_USD">115912000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_4_7" unitRef="iso4217_USD">75040000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_13" unitRef="iso4217_USD">-2868000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_18" unitRef="iso4217_USD">-6557000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_5" unitRef="iso4217_USD">8525000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_4_8" unitRef="iso4217_USD">19547000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_32" unitRef="iso4217_USD">6000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_4_6" unitRef="iso4217_USD">13015000</us-gaap:CostOfGoodsSold>
  <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_21" unitRef="iso4217_USD">118777000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_12" unitRef="iso4217_USD">-1818000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_6" unitRef="iso4217_USD">6519000</us-gaap:DepreciationAndAmortization>
  <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_4_13" unitRef="iso4217_USD">10521000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
  <nktr:IncreaseDecreaseInAccruedClinicalTrialExpenses contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_15" unitRef="iso4217_USD">-3697000</nktr:IncreaseDecreaseInAccruedClinicalTrialExpenses>
  <nktr:RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_28" unitRef="iso4217_USD">-7000000</nktr:RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts>
  <nktr:ProductSalesAndRoyalties contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_4_1" unitRef="iso4217_USD">11808000</nktr:ProductSalesAndRoyalties>
  <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_4_2" unitRef="iso4217_USD">10610000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_4_3" unitRef="iso4217_USD">25866000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_2_29" unitRef="iso4217_USD">116601000</nktr:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0_1633579x1664673_1634968x1849413" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_1004_1" unitRef="iso4217_USD">6415000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0_1633579x1760274_1634968x1746553" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_2004_2" unitRef="iso4217_USD">2500000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0_1633579x1814659_1634968x1710542" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_3004_0" unitRef="iso4217_USD">0</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0_1633579x1834994_1634968x1774465" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_4004_3" unitRef="iso4217_USD">3146000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0_1633579x1888068" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_5004_5" unitRef="iso4217_USD">12799000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0_1633579x1977273_1634968x1715959" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_6004_4" unitRef="iso4217_USD">1006000</nktr:LicenseCollaborationOtherRevenue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0_1634394x1638321" decimals="-3" id="id_6185658_164D7284-8416-45B8-A4B9-D24ACA7C275E_1004_0" unitRef="iso4217_USD">599000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0_1634394x1639948" decimals="-3" id="id_6185658_164D7284-8416-45B8-A4B9-D24ACA7C275E_2004_2" unitRef="iso4217_USD">4121000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0_1634394x1642216" decimals="-3" id="id_6185658_164D7284-8416-45B8-A4B9-D24ACA7C275E_3004_1" unitRef="iso4217_USD">3805000</us-gaap:ShareBasedCompensation>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0_1642755x1633925" decimals="-5" id="id_6185658_26C0D0B2-313B-430F-8156-4B18C808178A_1004_0" unitRef="shares">21900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0_1642755x1633925" decimals="2" id="id_6185658_6F6628C2-A395-46FC-9948-9A33661E2D29_1002_1" unitRef="iso4217_USD_per_shares">5.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE10737---1510-Q0005_STD_181_20140630_0_1642755x1633925" decimals="INF" id="id_6185658_6F6628C2-A395-46FC-9948-9A33661E2D29_1002_0" unitRef="shares">3776040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_CD3A63EC-6D9C-48AD-9308-77BCFEE81A88_1_4">Q2</dei:DocumentFiscalPeriodFocus>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_19" unitRef="iso4217_USD">16057000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_5317FB6F-D69C-452A-8302-FBF724397AA7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Our portfolio of cash and investments in marketable securities
 includes (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" rowspan="2" align="center"&gt;&lt;b&gt;Fair&amp;#xA0;Value&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Hierarchy&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Level&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Estimated Fair Value at&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Corporate notes and bonds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;2&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;185,917&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;182,544&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Corporate commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;2&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,939&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42,915&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Available-for-sale investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;230,856&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;225,459&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,512&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,229&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Certificate of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;N/A&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,929&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash, including restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;N/A&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,363&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,136&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total cash and investments in marketable securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;279,660&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;262,824&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
  <us-gaap:NumberOfOperatingSegments contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="INF" id="id_6185658_E35ED65D-FC9B-4BCF-808D-4004903DF47B_1_0" unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_CD3A63EC-6D9C-48AD-9308-77BCFEE81A88_1_3">2015</dei:DocumentFiscalYearFocus>
  <dei:AmendmentFlag contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_CD3A63EC-6D9C-48AD-9308-77BCFEE81A88_1_1">false</dei:AmendmentFlag>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_6FBFCD61-CE48-41C8-865C-4CA48AE8233D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Our revenue is derived from our arrangements with pharmaceutical
 and biotechnology collaboration partners and may result from one or
 more of the following: upfront and license fees, payments for
 contract research and development, milestone payments,
 manufacturing and supply payments, and royalties. Our performance
 obligations under our collaborations may include licensing our
 intellectual property, manufacturing and supply obligations, and
 research and development obligations. In order to account for the
 multiple-element arrangements, we identify the deliverables
 included within the arrangement and evaluate which deliverables
 represent separate units of accounting. Analyzing the arrangement
 to identify deliverables requires the use of judgment, and each
 deliverable may be an obligation to deliver services, a right or
 license to use an asset, or another performance obligation. Revenue
 is recognized separately for each identified unit of accounting
 when the basic revenue recognition criteria are met: there is
 persuasive evidence that an arrangement exists, delivery has
 occurred, the price is fixed or determinable, and collection is
 reasonably assured.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 At the inception of each new multiple-element arrangement or the
 material modification of an existing multiple-element arrangement,
 we allocate all consideration received under multiple-element
 arrangements to all units of accounting based on the relative
 selling price method, generally based on our best estimate of
 selling price (ESP). The objective of ESP is to determine the price
 at which we would transact a sale if the product or service was
 sold on a stand-alone basis. We determine ESP for the elements in
 our collaboration arrangements by considering multiple factors
 including, but not limited to, technical complexity of the
 performance obligation and similarity of elements to those
 performed under previous arrangements. Since we apply significant
 judgment in arriving at the ESPs, any material change in our
 estimates would significantly affect the allocation of the total
 consideration to the different elements of a multiple element
 arrangement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Product sales&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Product sales are primarily derived from fixed price and cost-plus
 manufacturing and supply agreements with our collaboration
 partners. We have not experienced any significant returns from our
 customers.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Royalty revenue&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Generally, we are entitled to royalties from our collaboration
 partners based on the net sales of their approved drugs that are
 marketed and sold in one or more countries where we hold royalty
 rights. We recognize royalty revenue when the cash is received or
 when the royalty amount to be received is estimable and collection
 is reasonably assured. With respect to the non-cash royalties
 related to sale of future royalties described at Note 4, revenue is
 recognized when estimable, otherwise, revenue is recognized during
 the period in which the related royalty report is received, which
 generally occurs in the quarter after the applicable product sales
 are made.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;License, collaboration and other revenue&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The amount of upfront fees and other payments received by us in
 license and collaboration arrangements that are allocated to
 continuing performance obligations, such as manufacturing and
 supply obligations, are deferred and generally recognized ratably
 over our expected performance period under each respective
 arrangement. We make our best estimate of the period over which we
 expect to fulfill our performance obligations, which may include
 technology transfer assistance, research activities, clinical
 development activities, and manufacturing activities from
 development through the commercialization of the product. Given the
 uncertainties of these collaboration arrangements, significant
 judgment is required to determine the duration of the performance
 period and this estimate is periodically re-evaluated.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Contingent consideration received from the achievement of a
 substantive milestone is recognized in its entirety in the period
 in which the milestone is achieved, which we believe is consistent
 with the substance of our performance under our various license and
 collaboration agreements. A milestone is defined as an event
 (i)&amp;#xA0;that can only be achieved based in whole or in part either
 on the entity&amp;#x2019;s performance or on the occurrence of a
 specific outcome resulting from the entity&amp;#x2019;s performance,
 (ii)&amp;#xA0;for which there is substantive uncertainty at the date
 the arrangement is entered into that the event will be achieved,
 and (iii)&amp;#xA0;that would result in additional payments being due
 to the entity. A milestone is substantive if the consideration
 earned from the achievement of the milestone is consistent with our
 performance required to achieve the milestone or the increase in
 value to the collaboration resulting from our performance, relates
 solely to our past performance, and is reasonable relative to all
 of the other deliverables and payments within the arrangement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Our license and collaboration agreements with our partners provide
 for payments to us upon the achievement of development milestones,
 such as the completion of clinical trials or regulatory
 submissions, approvals by regulatory authorities, and commercial
 launches of drugs. Given the challenges inherent in developing and
 obtaining regulatory approval for drug products and in achieving
 commercial launches, there was substantial uncertainty whether any
 such milestones would be achieved at the time of execution of these
 licensing and collaboration agreements. In addition, we evaluated
 whether the development milestones meet the remaining criteria to
 be considered substantive. As a result of our analysis, we consider
 our remaining development milestones under all of our license and
 collaboration agreements to be substantive and, accordingly, we
 expect to recognize as revenue future payments received from such
 milestones only if and as each milestone is achieved.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Our license and collaboration agreements with certain partners also
 provide for contingent payments to us based solely upon the
 performance of the respective partner. For such contingent amounts
 we expect to recognize the payments as revenue when earned under
 the applicable contract, which is generally upon completion of
 performance by the respective partner, provided that collection is
 reasonably assured.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Our license and collaboration agreements with our partners also
 provide for payments to us upon the achievement of specified sales
 volumes of approved drugs. We consider these payments to be similar
 to royalty payments and we will recognize such sales-based payments
 upon achievement of such sales volumes, provided that collection is
 reasonably assured.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_2B0111C4-07B0-45A5-997A-11CCBF186538_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 We operate in one business segment which focuses on applying our
 technology platforms to improve the performance of established and
 novel drug candidates. We operate in one segment because our
 business offerings have similar economics and other
 characteristics, including the nature of products and manufacturing
 processes, types of customers, distribution methods and regulatory
 environment. We are comprehensively managed as one business segment
 by our Chief Executive Officer and his management team.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="2" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_3_19" unitRef="iso4217_USD_per_shares">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_41600D66-82FF-4328-8701-526482D902C1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 We assess the impairment of long-lived assets, primarily property,
 plant and equipment and goodwill included in other non-current
 assets, whenever events or changes in business circumstances
 indicate that the carrying amounts of the assets may not be fully
 recoverable. When such events occur, we determine whether there has
 been an impairment in value by comparing the asset&amp;#x2019;s carrying
 value with its fair value, as measured by the anticipated
 undiscounted net cash flows of the asset. In the case of goodwill
 impairment, market capitalization is generally used as the measure
 of fair value. If an impairment in value exists, the asset is
 written down to its estimated fair value. In March 2015, we
 announced that the primary endpoint for our BEACON Phase 3 clinical
 study for NKTR-102 as a single-agent therapy for women with
 advanced metastatic breast cancer did not achieve statistical
 significance. As a result, we performed an impairment analysis for
 our long-lived assets, including goodwill, as well as our primary
 long-lived asset group which is dedicated to NKTR-102. Based on
 this analysis, we concluded that there is no impairment at
 March&amp;#xA0;31, 2015 or June&amp;#xA0;30, 2015.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <dei:DocumentType contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_CD3A63EC-6D9C-48AD-9308-77BCFEE81A88_1_0">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_62CFB107-DB68-4750-A7EE-232FC7A8641E_1_2">0000906709</dei:EntityCentralIndexKey>
  <dei:EntityFilerCategory contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_62CFB107-DB68-4750-A7EE-232FC7A8641E_1_4">Large Accelerated Filer</dei:EntityFilerCategory>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_A471DEE9-B0D2-48F8-9D29-2DD9CFC31406_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development Expense&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Research and development costs are expensed as incurred and include
 salaries, benefits and other operating costs such as outside
 services, supplies and allocated overhead costs. We perform
 research and development for our proprietary drug candidates and
 technology development and for certain third parties under
 collaboration agreements. For our proprietary drug candidates and
 our internal technology development programs, we invest our own
 funds without reimbursement from a third party.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 We record accruals for the estimated costs of our clinical trial
 activities performed by third parties. The financial terms of these
 agreements are subject to negotiation, vary from contract to
 contract and may result in uneven payment flows to our vendors.
 Payments under the contracts depend on factors such as the
 achievement of certain events, successful enrollment of patients,
 and completion of certain clinical trial activities. We generally
 accrue costs associated with the start-up and reporting phases of
 the clinical trials ratably over the estimated duration of the
 start-up and reporting phases. We generally accrue costs associated
 with the treatment phase of clinical trials based on the total
 estimated cost of the treatment phase on a per patient basis and we
 expense the per patient cost ratably over the estimated patient
 treatment period based on patient enrollment in the trials. In
 specific circumstances, such as for certain time-based costs, we
 recognize clinical trial expenses using a methodology that we
 consider to be more reflective of the timing of costs incurred.
 Advance payments for goods or services that will be used or
 rendered for future research and development activities are
 capitalized as prepaid expenses and recognized as expense as the
 related goods are delivered or the related services are performed.
 We base our estimates on the best information available at the
 time. However, additional information may become available to us
 which may allow us to make a more accurate estimate in future
 periods. In this event, we may be required to record adjustments to
 research and development expenses in future periods when the actual
 level of activity becomes more certain. Such increases or decreases
 in cost are generally considered to be changes in estimates and
 will be reflected in research and development expenses in the
 period identified.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_8CD42A7F-069F-433E-9246-9149903CDB19_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Cash and investments in marketable securities, including cash
 equivalents and restricted cash, are as follows (in thousands).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Estimated Fair Value at&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,875&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,365&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Short-term investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;233,785&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;225,459&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total cash and investments in marketable securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;279,660&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;262,824&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_61F89D55-3E72-492C-BE5D-B1CADDC1D32D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Note 6 &amp;#x2014; License and Collaboration Agreements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 We have entered into various collaboration agreements including
 license agreements and collaborative research, manufacturing,
 development and commercialization agreements with various
 pharmaceutical and biotechnology companies. Under these
 collaboration agreements, we are entitled to receive license fees,
 upfront payments, milestone payments, royalties, sales milestones,
 and payments for the manufacture and supply of our proprietary
 PEGylation materials and/or reimbursement for research and
 development activities. All of our collaboration agreements are
 generally cancelable by our partners without significant financial
 penalty. Our costs of performing these services are generally
 included in research and development expense, except that costs for
 product sales to our collaboration partners are included in cost of
 goods sold. In accordance with our collaboration agreements, we
 recognized license, collaboration and other revenue as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="39%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td width="36%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Six months ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 26.65pt"&gt;
 &lt;b&gt;Partner&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;Drug or Drug Candidate&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 AstraZeneca AB&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;MOVANTIK&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;TM&lt;/sup&gt;&amp;#xA0;(NKTR-118) and
 MOVANTIK&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;TM&lt;/sup&gt;&amp;#xA0;fixed-dose combination program
 (NKTR-119)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Roche&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;PEGASYS&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;and MIRCERA&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,219&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,408&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,415&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amgen, Inc.&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;Neulasta&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,250&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,250&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Bayer Healthcare LLC&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;BAY41-6551 (Amikacin Inhale)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;395&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,393&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,205&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Baxalta&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;BAX 855 (Hemophilia)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;88&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;669&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,006&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,278&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,254&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,799&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 License, collaboration, and other revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,208&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,785&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;102,948&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,866&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 As of June&amp;#xA0;30, 2015, our collaboration agreements with
 partners included potential future payments for development
 milestones totaling approximately $128.3 million, including amounts
 from our agreements with Baxalta, Bayer, and Ophthotech described
 below. In addition, we are entitled to receive the contingent
 payments described below related to the MOVANTIK&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;TM&lt;/sup&gt;&amp;#xA0;and MOVANTIK&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;TM&lt;/sup&gt;&amp;#xA0;fixed-dose combination drug
 development programs, respectively, based on development and
 regulatory events to be pursued and completed solely by
 AstraZeneca.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 There have been no material changes to our collaboration agreements
 in the six months ended June&amp;#xA0;30, 2015, except as described
 below.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;AstraZeneca AB&lt;/i&gt;&lt;/b&gt;&lt;i&gt;: MOVANTIK&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;TM&lt;/sup&gt;&amp;#xA0;(naloxegol oxalate),
 previously referred to as naloxegol and NKTR-118, and
 MOVANTIK&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;TM&lt;/sup&gt;&amp;#xA0;fixed-dose combination
 program, previously referred to as NKTR-119&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 We are a party to an agreement with AstraZeneca AB (AstraZeneca)
 under which we granted AstraZeneca a worldwide, exclusive license
 under our patents and other intellectual property to develop,
 market, and sell MOVANTIK&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;TM&lt;/sup&gt;&amp;#xA0;and MOVANTIK&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;TM&lt;/sup&gt;&amp;#xA0;fixed-dose combination
 program. AstraZeneca is responsible for all research, development
 and commercialization and is responsible for all drug development
 and commercialization decisions for MOVANTIK&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;TM&amp;#xA0;&lt;/sup&gt;and the
 MOVANTIK&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;TM&amp;#xA0;&lt;/sup&gt;fixed-dose combination
 program. AstraZeneca paid us an upfront payment of
 $125.0&amp;#xA0;million, which we received in the fourth quarter of
 2009 and which was fully recognized as of December&amp;#xA0;31, 2010.
 We will be entitled to up to an additional $40.0 million of
 contingent payments upon the first commercial sale of
 MOVENTIG&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;(the naloxegol brand name in
 the European Union or EU) in one major European Union country. We
 are also entitled to receive up to $75.0 million of commercial
 launch contingent payments related to the MOVANTIK&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;TM&lt;/sup&gt;&amp;#xA0;fixed-dose combination
 program, based on development events to be pursued and completed
 solely by AstraZeneca. In addition, we are entitled to significant
 and escalating double-digit royalty payments and sales milestone
 payments based on annual worldwide net sales of MOVANTIK&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;TM&amp;#xA0;&lt;/sup&gt;and MOVANTIK&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;TM&amp;#xA0;&lt;/sup&gt;fixed-dose combination
 products.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 On September&amp;#xA0;16, 2014, the United States Food and Drug
 Administration (FDA) approved MOVANTIK&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;TM&lt;/sup&gt;&amp;#xA0;for the treatment of
 opioid-induced constipation (OIC) in adult patients with chronic,
 non-cancer pain. On December&amp;#xA0;9, 2014, AstraZeneca announced
 that MOVENTIG&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;has been granted Marketing
 Authorisation by the European Commission (EC) for the treatment of
 opioid-induced constipation (OIC) in adult patients who have had an
 inadequate response to laxative(s). As a result of the FDA&amp;#x2019;s
 approval, on September&amp;#xA0;16, 2014, we were entitled to a $35.0
 million non-refundable payment from AstraZeneca, which was fully
 recognized as revenue in September 2014 and was received in October
 2014. In addition, the FDA&amp;#x2019;s approval of MOVANTIK&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;TM&lt;/sup&gt;&amp;#xA0;extinguished our contingent
 obligation to repay the $70.0 million payment made to us by
 AstraZeneca in November 2013 after the MOVANTIK&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;TM&lt;/sup&gt;&amp;#xA0;New Drug Application was
 accepted for review by the FDA. As a result, in September 2014, we
 fully recognized as revenue this $70.0 million payment. On
 March&amp;#xA0;31, 2015, AstraZeneca announced that MOVANTIK&amp;#x2122;
 launched in the United States which resulted in our receipt of a
 $100.0 million non-refundable commercial launch milestone payment
 on March&amp;#xA0;31, 2015, which was recognized as revenue in March
 2015. In addition, in March 2015, we agreed to pay AstraZeneca a
 total of $10.0 million to fund U.S. television advertising in
 consideration for certain additional commercial information rights.
 We recorded this $10.0 million obligation as a liability, with $5.0
 million included in other current liabilities and $5.0 million
 included in other long-term liabilities in our Condensed
 Consolidated Balance Sheet at June&amp;#xA0;30, 2015. We made the
 initial $5.0 million payment to AstraZeneca in July 2015 and will
 pay the remaining $5.0 million in July 2016. We determined that
 this $10.0 million obligation should be recorded as a reduction of
 revenue, which we recorded in the three months ended March&amp;#xA0;31,
 2015. As of June&amp;#xA0;30, 2015, we do not have deferred revenue
 related to this agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In general, other than as described above and in this paragraph,
 AstraZeneca has full responsibility for all research, development
 and commercialization costs under our license agreement. As part of
 its approval of MOVANTIK&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;TM&lt;/sup&gt;, the FDA required
 AstraZeneca to perform a post-marketing, observational
 epidemiological study comparing MOVANTIK&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;TM&lt;/sup&gt;&amp;#xA0;to other treatments of OIC in
 patients with chronic, non-cancer pain. As a result, the royalty
 rate payable to us from net sales of MOVANTIK&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;TM&lt;/sup&gt;&amp;#xA0;in the U.S. by AstraZeneca
 will be reduced by up to two percentage points to fund 33% of the
 external costs incurred by AstraZeneca to fund such post approval
 study subject to a $35.0 million aggregate cap. Any costs incurred
 by AstraZeneca can only be recovered by the reduction of the
 royalty paid to us. In no case can amounts be recovered by the
 reduction of a contingent payment due from AstraZeneca to us or
 through a payment from us to AstraZeneca.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Roche&lt;/i&gt;&lt;/b&gt;&lt;i&gt;: PEGASYS&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;and MIRCERA&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In February 1997, we entered into a license, manufacturing and
 supply agreement with Roche, under which we granted Roche a
 worldwide, exclusive license to certain intellectual property
 related to our proprietary PEGylation materials used in the
 manufacture and commercialization of PEGASYS&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;. As of
 June&amp;#xA0;30, 2015, we have deferred revenue of approximately $2.6
 million related to this agreement, which we expect to recognize
 through December 2015, the period through which we are required to
 provide back-up manufacturing and supply services related to
 PEGASYS&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In February 2012, we entered into a toll-manufacturing agreement
 with Roche under which we will manufacture the proprietary
 PEGylation material used by Roche to produce MIRCERA&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;. Roche entered
 into the toll-manufacturing agreement with the objective of
 establishing us as a secondary back-up supply source on a
 non-exclusive basis. Under the terms of our toll-manufacturing
 agreement, Roche paid us an upfront payment of $5.0 million and an
 additional $22.0 million in performance-based milestone payments
 upon our achievement of certain manufacturing readiness, validation
 and production milestones, including the delivery of specified
 quantities of PEGylation materials, all of which were completed as
 of January 2013. Roche will also pay us additional consideration
 for any future orders of the PEGylation materials for
 MIRCERA&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;beyond the initial quantities
 manufactured through January 2013.&amp;#xA0;Roche has the right to
 terminate the toll-manufacturing agreement due to an uncured
 material default by us. As of June&amp;#xA0;30, 2015, we have deferred
 revenue of approximately $8.1&amp;#xA0;million, which we expect to
 recognize through December 2016, the estimated end of our
 obligations under this agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In August 2013, we agreed to deliver additional quantities of
 PEGylation materials used by Roche to produce PEGASYS&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;and MIRCERA&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;, all of which
 were delivered in the last quarter of 2013, for total consideration
 of $18.6 million. We determined that these incremental activities
 should be considered a material modification of the existing
 PEGASYS&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;and MIRCERA&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;-related arrangements
 described above. As a result, we allocated the $18.6 million
 consideration to each of these arrangements and determined the
 amounts to be recognized or deferred based on the estimated selling
 prices of the undelivered obligations. As of June&amp;#xA0;30, 2015, we
 have deferred revenue of approximately $3.4&amp;#xA0;million related to
 these activities, which we expect to recognize through December
 2016, the estimated end of our obligations under the modified
 arrangements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Amgen, Inc.&lt;/i&gt;&lt;/b&gt;&lt;i&gt;: Neulasta&lt;/i&gt;&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In October 2010, we amended and restated an existing supply and
 license agreement by entering into a supply, dedicated suite and
 manufacturing guarantee agreement (the amended and restated
 agreement) and a license agreement with Amgen Inc. and Amgen
 Manufacturing, Limited (together referred to as Amgen). Under the
 terms of the amended and restated agreement, we received a $50.0
 million payment in the fourth quarter of 2010 in return for our
 guaranteeing the supply of certain quantities of our proprietary
 PEGylation materials to Amgen. As of June&amp;#xA0;30, 2015, we have
 deferred revenue of approximately $26.7&amp;#xA0;million related to
 this agreement, which we expect to recognize through October 2020,
 the estimated end of our obligations under this agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Bayer Healthcare LLC&lt;/i&gt;&lt;/b&gt;&lt;i&gt;: BAY41-6551 (Amikacin
 Inhale)&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In August 2007, we entered into a co-development, license and
 co-promotion agreement with Bayer Healthcare LLC (Bayer) to develop
 a specially-formulated inhaled Amikacin. We are responsible for
 development and manufacturing and supply of the nebulizer device
 included in the Amikacin product. In April 2013, Bayer initiated a
 Phase 3 clinical trial in the treatment of intubated and
 mechanically ventilated patients with Gram-negative pneumonia. As
 of June&amp;#xA0;30, 2015, we have received an upfront payment of
 $40.0&amp;#xA0;million (which was paid to us in 2007) and milestone
 payments totaling $30.0&amp;#xA0;million. In addition, in June 2013, we
 made a $10.0 million payment to Bayer for the reimbursement of some
 of its costs of the Phase 3 clinical trial.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In addition, we are entitled to receive a total of up to $50.0
 million for development milestones upon achievement of certain
 development objectives, as well as sales milestones upon
 achievement of annual sales targets and royalties based on annual
 worldwide net sales of Amikacin Inhale. As of June&amp;#xA0;30, 2015,
 we have deferred revenue of approximately $20.0 million related to
 this agreement, which we expect to recognize through February 2028,
 the estimated end of our obligations under this agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Baxalta&lt;/i&gt;&lt;/b&gt;&lt;i&gt;: Hemophilia&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 We are a party to an exclusive research, development, license and
 manufacturing and supply agreement with Baxalta Incorporated
 (Baxalta) executed in September 2005 to develop products designed
 to improve therapies for Hemophilia A patients using our PEGylation
 technology. This Hemophilia A program includes BAX 855, which will
 be marketed in the U.S. under the brand name ADYNOVATE upon
 approval. Under the terms of this agreement, as of June&amp;#xA0;30,
 2015, we are entitled to up to $20.0 million of development
 milestones upon achievement of certain development objectives,
 including $10.0 million due upon marketing authorization in the
 U.S., as well as sales milestones upon achievement of annual sales
 targets and royalties based on annual worldwide net sales of
 products resulting from this agreement. In August 2014, Baxalta
 announced positive top-line results from its Phase 3 pivotal
 clinical trial of BAX 855 which met the primary endpoint for the
 control and prevention of bleeding, routine prophylaxis and
 perioperative management for patients who were 12 years or older.
 As a result of this Phase 3 clinical trial meeting its primary
 endpoint, we earned development milestones totaling $8.0 million in
 September 2014. In December 2014, Baxalta announced that it filed a
 biologic license application with the FDA for BAX 855. As of
 June&amp;#xA0;30, 2015, we do not have significant deferred revenue
 related to this agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Ophthotech Corporation&lt;/i&gt;&lt;/b&gt;&lt;i&gt;: Fovista&lt;/i&gt;&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 We are a party to an agreement with Ophthotech Corporation
 (Ophthotech), dated September&amp;#xA0;30, 2006, under which Ophthotech
 received a worldwide, exclusive license to certain of our
 proprietary PEGylation technology to develop, manufacture and sell
 Fovista&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;. Under the
 terms of our agreement, we are the exclusive supplier of all of
 Ophthotech&amp;#x2019;s clinical and commercial requirements for our
 proprietary PEGylation reagent used in Fovista&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;, which is
 currently in a Phase 3 clinical program. On May&amp;#xA0;19, 2014,
 Ophthotech entered into a Licensing and Commercialization Agreement
 with Novartis Pharma AG for Fovista&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;. Under our
 agreement with Ophthotech, we received a $19.75 million payment in
 connection with this licensing agreement in June 2014. As of
 June&amp;#xA0;30, 2015, we have deferred revenue of approximately $18.2
 million related to this agreement, which we expect to recognize
 through March 2029, the estimated end of our obligations under our
 agreement with Ophthotech.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In addition, we are entitled to up to $9.5 million in additional
 payments based upon Ophthotech&amp;#x2019;s potential achievement of
 certain regulatory and sales milestones. We are also entitled to
 royalties on net sales of Fovista&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;that vary based on sales
 levels.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Other&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In addition, as of June&amp;#xA0;30, 2015, we have a number of
 collaboration agreements, including with our collaboration partner
 UCB, under which we are entitled to up to a total of $51.8 million
 of development milestones upon achievement of certain development
 objectives, as well as sales milestones upon achievement of annual
 sales targets and royalties based on net sales of commercialized
 products, if any. However, given the current phase of development
 of the potential products under these collaboration agreements, we
 cannot estimate the probability or timing of achieving these
 milestones. As of June&amp;#xA0;30, 2015, we have deferred revenue of
 approximately $18.0 million related to these other collaboration
 agreements, which we expect to recognize through 2020, the
 estimated end of our obligations under those agreements.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_C4DE7146-83C9-42F0-89FC-1A3634AFA39E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Note 2&amp;#xA0;&lt;/b&gt;&amp;#x2014;&lt;b&gt;&amp;#xA0;Cash and Investments in
 Marketable Securities&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Cash and investments in marketable securities, including cash
 equivalents and restricted cash, are as follows (in thousands).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Estimated Fair Value at&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June 30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,875&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,365&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Short-term investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;233,785&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;225,459&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total cash and investments in marketable securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;279,660&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;262,824&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 We invest in liquid, high quality debt securities. Our investments
 in debt securities are subject to interest rate risk. To minimize
 the exposure due to an adverse shift in interest rates, we invest
 in securities with maturities of two years or less and maintain a
 weighted average maturity of one year or less. As of June&amp;#xA0;30,
 2015 and December&amp;#xA0;31, 2014, all of our investments had
 maturities of one year or less.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Gross unrealized gains and losses were not significant at either
 June&amp;#xA0;30, 2015 or December&amp;#xA0;31, 2014. During the three
 months ended June&amp;#xA0;30, 2015 and the three and six months ended
 June&amp;#xA0;30, 2014, we did not sell any of our available-for-sale
 securities. During the six months ended June&amp;#xA0;30, 2015, we sold
 available-for-sale securities totaling $5.2 million, and gross
 realized gains and losses on those sales were not significant. The
 cost of securities sold is based on the specific identification
 method.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Restricted cash of $25.0 million was required to be maintained in a
 separate account until July&amp;#xA0;1, 2015 under the terms of our 12%
 senior secured notes due July 2017. This restriction expired on
 July&amp;#xA0;1, 2015 and the restricted funds were returned to us. We
 are currently required by a covenant under the senior secured notes
 to maintain the aggregate balance of our unrestricted cash and cash
 equivalents of not less than $25.0 million at the end of any two
 consecutive fiscal quarters, subject to certain conditions.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Our portfolio of cash and investments in marketable securities
 includes (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" rowspan="2" align="center"&gt;&lt;b&gt;Fair&amp;#xA0;Value&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Hierarchy&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Level&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Estimated Fair Value at&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Corporate notes and bonds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;2&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;185,917&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;182,544&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Corporate commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;2&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,939&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42,915&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Available-for-sale investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;230,856&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;225,459&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,512&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,229&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Certificate of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;N/A&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,929&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash, including restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;N/A&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,363&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,136&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total cash and investments in marketable securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;279,660&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;262,824&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 2pt; WHITE-SPACE: normal; BORDER-BOTTOM: rgb(0,0,0) 1px solid; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium/8pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; WIDTH: 156px; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="7%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td width="92%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;i&gt;Level&amp;#xA0;1&amp;#xA0;&amp;#x2014;&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;Quoted prices in active markets for identical
 assets or liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;i&gt;Level&amp;#xA0;2&amp;#xA0;&amp;#x2014;&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;Inputs other than Level&amp;#xA0;1 that are
 observable, either directly or indirectly, such as quoted prices
 for similar assets or liabilities; quoted prices in markets that
 are not active; or other inputs that are observable or can be
 corroborated by observable market data for substantially the full
 term of the assets or liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;i&gt;Level&amp;#xA0;3&amp;#xA0;&amp;#x2014;&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;Unobservable inputs that are supported by
 little or no market activity and that are significant to the fair
 value of the assets or liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 All of our investments are categorized as Level 1 or Level 2, as
 explained in the table above. We use a market approach to value our
 Level 2 investments. The disclosed fair value related to our
 investments is based primarily on the reported fair values in our
 period-end brokerage statements, which are based on market prices
 from a variety of industry standard data providers and generally
 represent quoted prices for similar assets in active markets or
 have been derived from observable market data. We independently
 validate these fair values using available market quotes and other
 information. During the three and six months ended June&amp;#xA0;30,
 2015 and 2014, there were no transfers between Level 1 and Level 2
 of the fair value hierarchy.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Additionally, as of June&amp;#xA0;30, 2015, based on a discounted cash
 flow analysis using Level 3 inputs including financial discount
 rates, we believe the $125.0 million carrying amount of our 12%
 Senior Secured Notes due July 2017 is consistent with its fair
 value.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_3F2A6FE8-10DB-428A-834F-24EA777698DB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In accordance with our collaboration agreements, we recognized
 license, collaboration and other revenue as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;br class="Apple-interchange-newline" /&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="39%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td width="36%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Six months ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 26.65pt"&gt;
 &lt;b&gt;Partner&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;Drug or Drug Candidate&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 AstraZeneca AB&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;MOVANTIK&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;TM&lt;/sup&gt;&amp;#xA0;(NKTR-118) and
 MOVANTIK&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;TM&lt;/sup&gt;&amp;#xA0;fixed-dose combination program
 (NKTR-119)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Roche&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;PEGASYS&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;and MIRCERA&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,219&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,408&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,415&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amgen, Inc.&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;Neulasta&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,250&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,250&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Bayer Healthcare LLC&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;BAY41-6551 (Amikacin Inhale)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;395&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,393&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,205&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Baxalta&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;BAX 855 (Hemophilia)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;88&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;669&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,006&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,278&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,254&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,799&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 License, collaboration, and other revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,208&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,785&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;102,948&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,866&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"&gt;&lt;/td&gt;
 &lt;td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"&gt;&lt;/td&gt;
 &lt;td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/td&gt;
 &lt;td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/td&gt;
 &lt;td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/td&gt;
 &lt;td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_575B4D61-AF92-4A01-9FD8-815E3B34E902_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation and Principles of
 Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Our consolidated financial statements include the financial
 position, results of operations and cash flows of our wholly-owned
 subsidiaries: Nektar Therapeutics (India) Private Limited (Nektar
 India) and Nektar Therapeutics UK Limited. All intercompany
 accounts and transactions have been eliminated in
 consolidation.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 We prepared our Condensed Consolidated Financial Statements
 following the requirements of the Securities and Exchange
 Commission (SEC) for interim reporting. As permitted under those
 rules, certain footnotes or other financial information that are
 normally required by U.S. generally accepted accounting principles
 (GAAP) for annual periods can be condensed or omitted. In the
 opinion of management, these financial statements include all
 normal and recurring adjustments that we consider necessary for the
 fair presentation of our financial position and operating
 results.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Our Condensed Consolidated Financial Statements are denominated in
 U.S. dollars. Accordingly, changes in exchange rates between the
 applicable foreign currency and the U.S. dollar will affect the
 translation of each foreign subsidiary&amp;#x2019;s financial results
 into U.S. dollars for purposes of reporting our consolidated
 financial results. Translation gains and losses are included in
 accumulated other comprehensive loss in the stockholders&amp;#x2019;
 equity section of the Condensed Consolidated Balance Sheets. To
 date, such cumulative currency translation adjustments have not
 been significant to our consolidated financial position.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Our comprehensive loss consists of our net loss plus our foreign
 currency translation gains and losses and unrealized holding gains
 and losses on available-for-sale securities, neither of which were
 significant during the three and six months ended June&amp;#xA0;30,
 2015 and 2014. In addition, there were no significant
 reclassifications out of accumulated other comprehensive loss to
 the statements of operations during the three and six months ended
 June&amp;#xA0;30, 2015 and 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The accompanying Condensed Consolidated Financial Statements are
 unaudited. The Condensed Consolidated Balance Sheet data as of
 December&amp;#xA0;31, 2014 was derived from the audited consolidated
 financial statements which are included in our Annual Report on
 Form&amp;#xA0;10-K for the year ended December&amp;#xA0;31, 2014 filed with
 the SEC on February&amp;#xA0;26, 2015. The information included in this
 Quarterly Report on Form 10-Q should be read in conjunction with
 the consolidated financial statements and the accompanying notes to
 those financial statements included in our Annual Report on Form
 10-K for the year ended December&amp;#xA0;31, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Revenue, expenses, assets, and liabilities can vary during each
 quarter of the year. The results and trends in these interim
 Condensed Consolidated Financial Statements are not necessarily
 indicative of the results to be expected for the full year or any
 other periods.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_03B8DEAD-EAD5-44A0-83B3-B65EF18E6F3E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Total stock-based compensation expense was recognized in our
 Condensed Consolidated Statements of Operations as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Six months ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cost of goods sold&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;239&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;280&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;563&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;599&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,125&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,832&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,547&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,805&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,196&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,052&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,627&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,121&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total stock-based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,560&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,164&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,737&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,525&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_81B05BC5-445C-4898-BC1E-E7B81DFFAAD3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Inventory consists of the following (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Raw materials&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,392&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Work-in-process&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,117&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,187&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Finished goods&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,615&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,565&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total inventory&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,124&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_62CFB107-DB68-4750-A7EE-232FC7A8641E_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityRegistrantName contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_62CFB107-DB68-4750-A7EE-232FC7A8641E_1_1">NEKTAR THERAPEUTICS</dei:EntityRegistrantName>
  <us-gaap:InventoryDisclosureTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_9D83CCF8-5EB0-4F34-8172-1ABDC702E28B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Note 3 &amp;#x2014; Inventory&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Inventory consists of the following (in thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Raw materials&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,392&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Work-in-process&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,117&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,187&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Finished goods&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,615&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,565&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 0pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total inventory&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,124&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Inventory is generally manufactured upon receipt of firm purchase
 orders from our collaboration partners. Inventory includes direct
 materials, direct labor, and manufacturing overhead and cost is
 determined on a first-in, first-out basis. Inventory is valued at
 the lower of cost or market and defective or excess inventory is
 written down to net realizable value based on historical experience
 or projected usage.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_BA052DB2-65EA-4558-856C-C9EDCD00A1B1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Note 1 &amp;#x2014; Organization and Summary of Significant
 Accounting Policies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Organization&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 We are a biopharmaceutical company headquartered in San Francisco,
 California and incorporated in Delaware. We are developing a
 pipeline of drug candidates that utilize our PEGylation and
 advanced polymer conjugate technology platforms with the objective
 to improve the benefits of drugs for patients.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Our research and development activities have required significant
 ongoing investment to date and are expected to continue to require
 significant investment. As a result, we expect to continue to incur
 substantial losses and negative cash flows from operations in the
 future. We have financed our operations primarily through cash
 generated from licensing, collaboration and manufacturing
 agreements and financing transactions. At June&amp;#xA0;30, 2015, we
 had approximately $279.7 million in cash and investments in
 marketable securities.&amp;#xA0;Also, as of June&amp;#xA0;30, 2015, we had
 $133.5 million in long-term debt, including $125.0 million of
 senior secured notes and $8.5 million of capital lease obligations,
 of which $5.6 million is current.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation and Principles of
 Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Our consolidated financial statements include the financial
 position, results of operations and cash flows of our wholly-owned
 subsidiaries: Nektar Therapeutics (India) Private Limited (Nektar
 India) and Nektar Therapeutics UK Limited. All intercompany
 accounts and transactions have been eliminated in
 consolidation.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 We prepared our Condensed Consolidated Financial Statements
 following the requirements of the Securities and Exchange
 Commission (SEC) for interim reporting. As permitted under those
 rules, certain footnotes or other financial information that are
 normally required by U.S. generally accepted accounting principles
 (GAAP) for annual periods can be condensed or omitted. In the
 opinion of management, these financial statements include all
 normal and recurring adjustments that we consider necessary for the
 fair presentation of our financial position and operating
 results.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Our Condensed Consolidated Financial Statements are denominated in
 U.S. dollars. Accordingly, changes in exchange rates between the
 applicable foreign currency and the U.S. dollar will affect the
 translation of each foreign subsidiary&amp;#x2019;s financial results
 into U.S. dollars for purposes of reporting our consolidated
 financial results. Translation gains and losses are included in
 accumulated other comprehensive loss in the stockholders&amp;#x2019;
 equity section of the Condensed Consolidated Balance Sheets. To
 date, such cumulative currency translation adjustments have not
 been significant to our consolidated financial position.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Our comprehensive loss consists of our net loss plus our foreign
 currency translation gains and losses and unrealized holding gains
 and losses on available-for-sale securities, neither of which were
 significant during the three and six months ended June&amp;#xA0;30,
 2015 and 2014. In addition, there were no significant
 reclassifications out of accumulated other comprehensive loss to
 the statements of operations during the three and six months ended
 June&amp;#xA0;30, 2015 and 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The accompanying Condensed Consolidated Financial Statements are
 unaudited. The Condensed Consolidated Balance Sheet data as of
 December&amp;#xA0;31, 2014 was derived from the audited consolidated
 financial statements which are included in our Annual Report on
 Form&amp;#xA0;10-K for the year ended December&amp;#xA0;31, 2014 filed with
 the SEC on February&amp;#xA0;26, 2015. The information included in this
 Quarterly Report on Form 10-Q should be read in conjunction with
 the consolidated financial statements and the accompanying notes to
 those financial statements included in our Annual Report on Form
 10-K for the year ended December&amp;#xA0;31, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Revenue, expenses, assets, and liabilities can vary during each
 quarter of the year. The results and trends in these interim
 Condensed Consolidated Financial Statements are not necessarily
 indicative of the results to be expected for the full year or any
 other periods.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The preparation of consolidated financial statements in conformity
 with GAAP requires management to make estimates and assumptions
 that affect the reported amounts of assets and liabilities and
 disclosure of contingent assets and liabilities at the date of the
 consolidated financial statements and the reported amounts of
 revenue and expenses during the reporting period. Accounting
 estimates and assumptions are inherently uncertain. Actual results
 could differ materially from those estimates and assumptions. Our
 estimates include those related to estimated selling prices of
 deliverables in collaboration agreements, estimated periods of
 performance, the net realizable value of inventory, the impairment
 of investments, the impairment of goodwill and long-lived assets,
 contingencies, accrued clinical trial expenses, estimated interest
 expense from our liability related to our sale of future royalties,
 stock-based compensation, and ongoing litigation, among other
 estimates. We base our estimates on historical experience and on
 other assumptions that management believes are reasonable under the
 circumstances. These estimates form the basis for making judgments
 about the carrying values of assets and liabilities when these
 values are not readily apparent from other sources. As appropriate,
 estimates are assessed each period and updated to reflect current
 information and any changes in estimates will generally be
 reflected in the period first identified.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Certain items previously reported in specific financial statement
 captions have been reclassified to conform to the current period
 presentation. Such reclassifications do not materially impact
 previously reported revenue, operating loss, net loss, total
 assets, liabilities or stockholders&amp;#x2019; equity.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 We operate in one business segment which focuses on applying our
 technology platforms to improve the performance of established and
 novel drug candidates. We operate in one segment because our
 business offerings have similar economics and other
 characteristics, including the nature of products and manufacturing
 processes, types of customers, distribution methods and regulatory
 environment. We are comprehensively managed as one business segment
 by our Chief Executive Officer and his management team.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Significant Concentrations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Our customers are primarily pharmaceutical and biotechnology
 companies that are located in the U.S.&amp;#xA0;and Europe. Our
 accounts receivable balance contains billed and unbilled trade
 receivables from product sales and royalties, as well as milestones
 and time and materials based billings from collaborative research
 and development agreements. When appropriate, we provide for an
 allowance for doubtful accounts by reserving for specifically
 identified doubtful accounts. We generally do not require
 collateral from our customers. We perform a regular review of our
 customers&amp;#x2019; payment histories and associated credit risk. We
 have not experienced significant credit losses from our accounts
 receivable and our allowance for doubtful accounts was not
 significant at either June&amp;#xA0;30, 2015 or December&amp;#xA0;31,
 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 We are dependent on our suppliers and contract manufacturers to
 provide raw materials, drugs and devices of appropriate quality and
 reliability and to meet applicable contract and regulatory
 requirements. In certain cases, we rely on single sources of supply
 of one or more critical materials. Consequently, in the event that
 supplies are delayed or interrupted for any reason, our ability to
 develop and produce our drug candidates or our ability to meet our
 supply obligations could be significantly impaired, which could
 have a material adverse effect on our business, financial condition
 and results of operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Our revenue is derived from our arrangements with pharmaceutical
 and biotechnology collaboration partners and may result from one or
 more of the following: upfront and license fees, payments for
 contract research and development, milestone payments,
 manufacturing and supply payments, and royalties. Our performance
 obligations under our collaborations may include licensing our
 intellectual property, manufacturing and supply obligations, and
 research and development obligations. In order to account for the
 multiple-element arrangements, we identify the deliverables
 included within the arrangement and evaluate which deliverables
 represent separate units of accounting. Analyzing the arrangement
 to identify deliverables requires the use of judgment, and each
 deliverable may be an obligation to deliver services, a right or
 license to use an asset, or another performance obligation. Revenue
 is recognized separately for each identified unit of accounting
 when the basic revenue recognition criteria are met: there is
 persuasive evidence that an arrangement exists, delivery has
 occurred, the price is fixed or determinable, and collection is
 reasonably assured.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 At the inception of each new multiple-element arrangement or the
 material modification of an existing multiple-element arrangement,
 we allocate all consideration received under multiple-element
 arrangements to all units of accounting based on the relative
 selling price method, generally based on our best estimate of
 selling price (ESP). The objective of ESP is to determine the price
 at which we would transact a sale if the product or service was
 sold on a stand-alone basis. We determine ESP for the elements in
 our collaboration arrangements by considering multiple factors
 including, but not limited to, technical complexity of the
 performance obligation and similarity of elements to those
 performed under previous arrangements. Since we apply significant
 judgment in arriving at the ESPs, any material change in our
 estimates would significantly affect the allocation of the total
 consideration to the different elements of a multiple element
 arrangement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Product sales&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Product sales are primarily derived from fixed price and cost-plus
 manufacturing and supply agreements with our collaboration
 partners. We have not experienced any significant returns from our
 customers.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Royalty revenue&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Generally, we are entitled to royalties from our collaboration
 partners based on the net sales of their approved drugs that are
 marketed and sold in one or more countries where we hold royalty
 rights. We recognize royalty revenue when the cash is received or
 when the royalty amount to be received is estimable and collection
 is reasonably assured. With respect to the non-cash royalties
 related to sale of future royalties described at Note 4, revenue is
 recognized when estimable, otherwise, revenue is recognized during
 the period in which the related royalty report is received, which
 generally occurs in the quarter after the applicable product sales
 are made.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;License, collaboration and other revenue&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The amount of upfront fees and other payments received by us in
 license and collaboration arrangements that are allocated to
 continuing performance obligations, such as manufacturing and
 supply obligations, are deferred and generally recognized ratably
 over our expected performance period under each respective
 arrangement. We make our best estimate of the period over which we
 expect to fulfill our performance obligations, which may include
 technology transfer assistance, research activities, clinical
 development activities, and manufacturing activities from
 development through the commercialization of the product. Given the
 uncertainties of these collaboration arrangements, significant
 judgment is required to determine the duration of the performance
 period and this estimate is periodically re-evaluated.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Contingent consideration received from the achievement of a
 substantive milestone is recognized in its entirety in the period
 in which the milestone is achieved, which we believe is consistent
 with the substance of our performance under our various license and
 collaboration agreements. A milestone is defined as an event
 (i)&amp;#xA0;that can only be achieved based in whole or in part either
 on the entity&amp;#x2019;s performance or on the occurrence of a
 specific outcome resulting from the entity&amp;#x2019;s performance,
 (ii)&amp;#xA0;for which there is substantive uncertainty at the date
 the arrangement is entered into that the event will be achieved,
 and (iii)&amp;#xA0;that would result in additional payments being due
 to the entity. A milestone is substantive if the consideration
 earned from the achievement of the milestone is consistent with our
 performance required to achieve the milestone or the increase in
 value to the collaboration resulting from our performance, relates
 solely to our past performance, and is reasonable relative to all
 of the other deliverables and payments within the arrangement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Our license and collaboration agreements with our partners provide
 for payments to us upon the achievement of development milestones,
 such as the completion of clinical trials or regulatory
 submissions, approvals by regulatory authorities, and commercial
 launches of drugs. Given the challenges inherent in developing and
 obtaining regulatory approval for drug products and in achieving
 commercial launches, there was substantial uncertainty whether any
 such milestones would be achieved at the time of execution of these
 licensing and collaboration agreements. In addition, we evaluated
 whether the development milestones meet the remaining criteria to
 be considered substantive. As a result of our analysis, we consider
 our remaining development milestones under all of our license and
 collaboration agreements to be substantive and, accordingly, we
 expect to recognize as revenue future payments received from such
 milestones only if and as each milestone is achieved.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Our license and collaboration agreements with certain partners also
 provide for contingent payments to us based solely upon the
 performance of the respective partner. For such contingent amounts
 we expect to recognize the payments as revenue when earned under
 the applicable contract, which is generally upon completion of
 performance by the respective partner, provided that collection is
 reasonably assured.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Our license and collaboration agreements with our partners also
 provide for payments to us upon the achievement of specified sales
 volumes of approved drugs. We consider these payments to be similar
 to royalty payments and we will recognize such sales-based payments
 upon achievement of such sales volumes, provided that collection is
 reasonably assured.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development Expense&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Research and development costs are expensed as incurred and include
 salaries, benefits and other operating costs such as outside
 services, supplies and allocated overhead costs. We perform
 research and development for our proprietary drug candidates and
 technology development and for certain third parties under
 collaboration agreements. For our proprietary drug candidates and
 our internal technology development programs, we invest our own
 funds without reimbursement from a third party.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 We record accruals for the estimated costs of our clinical trial
 activities performed by third parties. The financial terms of these
 agreements are subject to negotiation, vary from contract to
 contract and may result in uneven payment flows to our vendors.
 Payments under the contracts depend on factors such as the
 achievement of certain events, successful enrollment of patients,
 and completion of certain clinical trial activities. We generally
 accrue costs associated with the start-up and reporting phases of
 the clinical trials ratably over the estimated duration of the
 start-up and reporting phases. We generally accrue costs associated
 with the treatment phase of clinical trials based on the total
 estimated cost of the treatment phase on a per patient basis and we
 expense the per patient cost ratably over the estimated patient
 treatment period based on patient enrollment in the trials. In
 specific circumstances, such as for certain time-based costs, we
 recognize clinical trial expenses using a methodology that we
 consider to be more reflective of the timing of costs incurred.
 Advance payments for goods or services that will be used or
 rendered for future research and development activities are
 capitalized as prepaid expenses and recognized as expense as the
 related goods are delivered or the related services are performed.
 We base our estimates on the best information available at the
 time. However, additional information may become available to us
 which may allow us to make a more accurate estimate in future
 periods. In this event, we may be required to record adjustments to
 research and development expenses in future periods when the actual
 level of activity becomes more certain. Such increases or decreases
 in cost are generally considered to be changes in estimates and
 will be reflected in research and development expenses in the
 period identified.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 We assess the impairment of long-lived assets, primarily property,
 plant and equipment and goodwill included in other non-current
 assets, whenever events or changes in business circumstances
 indicate that the carrying amounts of the assets may not be fully
 recoverable. When such events occur, we determine whether there has
 been an impairment in value by comparing the asset&amp;#x2019;s carrying
 value with its fair value, as measured by the anticipated
 undiscounted net cash flows of the asset. In the case of goodwill
 impairment, market capitalization is generally used as the measure
 of fair value. If an impairment in value exists, the asset is
 written down to its estimated fair value. In March 2015, we
 announced that the primary endpoint for our BEACON Phase 3 clinical
 study for NKTR-102 as a single-agent therapy for women with
 advanced metastatic breast cancer did not achieve statistical
 significance. As a result, we performed an impairment analysis for
 our long-lived assets, including goodwill, as well as our primary
 long-lived asset group which is dedicated to NKTR-102. Based on
 this analysis, we concluded that there is no impairment at
 March&amp;#xA0;31, 2015 or June&amp;#xA0;30, 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 For the three and six months ended June&amp;#xA0;30, 2015 and 2014, we
 recorded an income tax provision for our Nektar India operations at
 an effective tax rate of approximately 34%. The U.S. federal
 deferred tax assets generated from our net operating losses have
 been fully reserved, as we believe it is not more likely than not
 that the benefit will be realized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In May 2014, the Financial Accounting Standards Board (FASB) issued
 guidance codified in Accounting Standards Codification (ASC)
 606,&amp;#xA0;&lt;i&gt;Revenue
 Recognition &amp;#x2014; Revenue from Contracts with Customers&lt;/i&gt;,
 which amends the guidance in former ASC 605,&amp;#xA0;&lt;i&gt;Revenue
 Recognition,&amp;#xA0;&lt;/i&gt;and is effective for
 public companies for fiscal years beginning after December&amp;#xA0;15,
 2017. Entities have the option of using either a full retrospective
 or a modified retrospective approach to adopt this new guidance. We
 are currently evaluating the impact of the provisions of ASC
 606.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In April 2015, the FASB issued guidance to simplify the
 presentation of debt issuance costs by requiring debt issuance
 costs to be presented as a deduction from the corresponding debt
 liability. This guidance is effective for our interim and annual
 periods beginning January&amp;#xA0;1, 2016. Upon adoption, the new
 guidance must be applied retrospectively to all periods presented.
 We do not believe the adoption of this guidance will have a
 material impact on our consolidated financial statements.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="INF" id="id_6185658_BC717D5A-EA21-4654-9D8C-09D8C809E792_3_0" unitRef="shares">969250</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_A295526A-4986-426A-BB8B-02DA0BE84541_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Note 5 &amp;#x2014; Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Legal Matters&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 From time to time, we are involved in lawsuits, arbitrations,
 claims, investigations and proceedings, consisting of intellectual
 property, commercial, employment and other matters, which arise in
 the ordinary course of business. We make provisions for liabilities
 when it is both probable that a liability has been incurred and the
 amount of the loss can be reasonably estimated. Such provisions are
 reviewed at least quarterly and adjusted to reflect the impact of
 settlement negotiations, judicial and administrative rulings,
 advice of legal counsel, and other information and events
 pertaining to a particular case. Litigation is inherently
 unpredictable. If any unfavorable ruling were to occur in any
 specific period, there exists the possibility of a material adverse
 impact on the results of our operations of that period and on our
 cash flows and liquidity.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;&lt;i&gt;Indemnifications in Connection with Commercial
 Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 As part of our collaboration agreements with our partners related
 to the license, development, manufacture and supply of drugs based
 on our proprietary technologies and drug candidates, we generally
 agree to defend, indemnify and hold harmless our partners from and
 against third party liabilities arising out of the agreement,
 including product liability (with respect to our activities) and
 infringement of intellectual property to the extent the
 intellectual property is developed by us and licensed to our
 partners. The term of these indemnification obligations is
 generally perpetual any time after execution of the agreement.
 There is generally no limitation on the potential amount of future
 payments we could be required to make under these indemnification
 obligations.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 From time to time we enter into other strategic agreements such as
 divestitures and financing transactions pursuant to which we are
 required to make representations and warranties and undertake to
 perform or comply with certain covenants. In the event it is
 determined that we breached certain of the representations and
 warranties or covenants made by us in any such agreements, we could
 incur substantial indemnification liabilities depending on the
 timing, nature, and amount of any such claims.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 To date, we have not incurred costs to defend lawsuits or settle
 claims related to these indemnification obligations. Because the
 aggregate amount of any potential indemnification obligation is not
 a stated amount, the overall maximum amount of any such obligations
 cannot be reasonably estimated. No liabilities have been recorded
 for these obligations in our Condensed Consolidated Balance Sheets
 at either June&amp;#xA0;30, 2015 or December&amp;#xA0;31, 2014.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_160C6457-CCE2-4ADA-BB54-517E115E1189_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Certain items previously reported in specific financial statement
 captions have been reclassified to conform to the current period
 presentation. Such reclassifications do not materially impact
 previously reported revenue, operating loss, net loss, total
 assets, liabilities or stockholders&amp;#x2019; equity.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <dei:DocumentPeriodEndDate contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_CD3A63EC-6D9C-48AD-9308-77BCFEE81A88_1_2">2015-06-30</dei:DocumentPeriodEndDate>
  <us-gaap:UseOfEstimates contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_54DCE66E-5B99-4A78-8FFC-F5F78C487641_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 The preparation of consolidated financial statements in conformity
 with GAAP requires management to make estimates and assumptions
 that affect the reported amounts of assets and liabilities and
 disclosure of contingent assets and liabilities at the date of the
 consolidated financial statements and the reported amounts of
 revenue and expenses during the reporting period. Accounting
 estimates and assumptions are inherently uncertain. Actual results
 could differ materially from those estimates and assumptions. Our
 estimates include those related to estimated selling prices of
 deliverables in collaboration agreements, estimated periods of
 performance, the net realizable value of inventory, the impairment
 of investments, the impairment of goodwill and long-lived assets,
 contingencies, accrued clinical trial expenses, estimated interest
 expense from our liability related to our sale of future royalties,
 stock-based compensation, and ongoing litigation, among other
 estimates. We base our estimates on historical experience and on
 other assumptions that management believes are reasonable under the
 circumstances. These estimates form the basis for making judgments
 about the carrying values of assets and liabilities when these
 values are not readily apparent from other sources. As appropriate,
 estimates are assessed each period and updated to reflect current
 information and any changes in estimates will generally be
 reflected in the period first identified.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_FD2DAF20-7D0C-4D86-A893-9645D4736F6A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Note 7 &amp;#x2014; Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Total stock-based compensation expense was recognized in our
 Condensed Consolidated Statements of Operations as follows (in
 thousands):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Six months ended&lt;br /&gt;
 June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cost of goods sold&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;239&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;280&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;563&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;599&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,125&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,832&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,547&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,805&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,196&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,052&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,627&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,121&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total stock-based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,560&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,164&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,737&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,525&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 4pt"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 During the three months ended June&amp;#xA0;30, 2015 and 2014, we
 granted 68,200 and 642,860 stock options, respectively, at a
 weighted average grant-date fair value of $4.81 per share and $5.24
 per share, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 During the six months ended June&amp;#xA0;30, 2015 and 2014, we granted
 479,010 and 3,776,040 stock options, respectively, at a weighted
 average grant-date fair value of $6.31 per share and $5.84 per
 share, respectively. The number of stock options granted during the
 six months ended June&amp;#xA0;30, 2014 was significantly higher than
 the stock options granted during the six months ended June&amp;#xA0;30,
 2015 because we made our annual employee stock option grant for the
 2013 performance period in February 2014 and our annual employee
 stock option grant for the 2014 performance period in December
 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 As a result of stock issuances under our equity compensation plans,
 during the three months ended June&amp;#xA0;30, 2015 and 2014, we
 issued 733,952 and 350,513 common shares, respectively, and during
 the six months ended June&amp;#xA0;30, 2015 and 2014, we issued 969,250
 and 1,017,887 common shares, respectively.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_6405DB56-264F-4E6A-9369-AE76D6823DA6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In May 2014, the Financial Accounting Standards Board (FASB) issued
 guidance codified in Accounting Standards Codification (ASC)
 606,&amp;#xA0;&lt;i&gt;Revenue
 Recognition &amp;#x2014; Revenue from Contracts with Customers&lt;/i&gt;,
 which amends the guidance in former ASC 605,&amp;#xA0;&lt;i&gt;Revenue
 Recognition,&amp;#xA0;&lt;/i&gt;and is effective for
 public companies for fiscal years beginning after December&amp;#xA0;15,
 2017. Entities have the option of using either a full retrospective
 or a modified retrospective approach to adopt this new guidance. We
 are currently evaluating the impact of the provisions of ASC
 606.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In April 2015, the FASB issued guidance to simplify the
 presentation of debt issuance costs by requiring debt issuance
 costs to be presented as a deduction from the corresponding debt
 liability. This guidance is effective for our interim and annual
 periods beginning January&amp;#xA0;1, 2016. Upon adoption, the new
 guidance must be applied retrospectively to all periods presented.
 We do not believe the adoption of this guidance will have a
 material impact on our consolidated financial statement&lt;/p&gt;


 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <dei:TradingSymbol contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_62CFB107-DB68-4750-A7EE-232FC7A8641E_1_0">NKTR</dei:TradingSymbol>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_3_20" unitRef="shares">131502000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_569A5248-1971-4917-8D6E-BE202A0B1798_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Note 8 &amp;#x2014; Net Loss Per Share&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Basic net loss per share is calculated based on the
 weighted-average number of common shares outstanding during the
 periods presented. For all periods presented in the accompanying
 Condensed Consolidated Statements of Operations, the net loss
 available to common stockholders is equal to the reported net loss.
 Basic and diluted net loss per share are the same due to our
 historical net losses and the requirement to exclude potentially
 dilutive securities which would have an anti-dilutive effect on net
 loss per share. During the three and six month periods ended
 June&amp;#xA0;30, 2015 and 2014, potentially dilutive securities
 consisted of common shares underlying outstanding stock options.
 During the three months ended June&amp;#xA0;30, 2015 and 2014, there
 were weighted average outstanding stock options of
 21.6&amp;#xA0;million and 22.5&amp;#xA0;million, respectively, and during
 the six months ended June&amp;#xA0;30, 2015 and 2014, there were
 weighted average outstanding stock options of 21.7&amp;#xA0;million and
 21.9&amp;#xA0;million, respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="2" id="id_6185658_4164079B-BDC2-44E2-AD5A-F7A65154323C_3_0" unitRef="pure">0.34</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_CDCE0E46-5281-4279-9D12-0A4CFB13B5B6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 For the three and six months ended June&amp;#xA0;30, 2015 and 2014, we
 recorded an income tax provision for our Nektar India operations at
 an effective tax rate of approximately 34%. The U.S. federal
 deferred tax assets generated from our net operating losses have
 been fully reserved, as we believe it is not more likely than not
 that the benefit will be realized.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_27" unitRef="iso4217_USD">2484000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_24" unitRef="iso4217_USD">4584000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetIncomeLoss contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_3_18" unitRef="iso4217_USD">-18837000</us-gaap:NetIncomeLoss>
  <us-gaap:Revenues contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_3_4" unitRef="iso4217_USD">131462000</us-gaap:Revenues>
  <us-gaap:InterestPaid contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_37" unitRef="iso4217_USD">8320000</us-gaap:InterestPaid>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_3_10" unitRef="iso4217_USD">-426000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_10" unitRef="iso4217_USD">-2828000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_11" unitRef="iso4217_USD">-190000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_3_14" unitRef="iso4217_USD">457000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_3_15" unitRef="iso4217_USD">-18034000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_9" unitRef="iso4217_USD">73000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_1334E699-D194-4475-B92C-4A615F56AA32_3_0" unitRef="iso4217_USD">-18768000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_3_16" unitRef="iso4217_USD">-18460000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-5" id="id_6185658_31BCBE64-8308-4115-8B20-01649355D37E_2_500000" unitRef="iso4217_USD">5200000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_22" unitRef="iso4217_USD">124468000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_7" unitRef="iso4217_USD">621000</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_3_17" unitRef="iso4217_USD">377000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_23" unitRef="iso4217_USD">5215000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_164D7284-8416-45B8-A4B9-D24ACA7C275E_3_3" unitRef="iso4217_USD">9737000</us-gaap:ShareBasedCompensation>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_30" unitRef="iso4217_USD">7798000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_17" unitRef="iso4217_USD">-4434000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_16" unitRef="iso4217_USD">1859000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_33" unitRef="iso4217_USD">8510000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:InterestExpense contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_3_12" unitRef="iso4217_USD">8289000</us-gaap:InterestExpense>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_25" unitRef="iso4217_USD">-12836000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:CostsAndExpenses contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_3_9" unitRef="iso4217_USD">131888000</us-gaap:CostsAndExpenses>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_31" unitRef="iso4217_USD">5314000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_3_7" unitRef="iso4217_USD">92423000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_13" unitRef="iso4217_USD">5075000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_18" unitRef="iso4217_USD">11772000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_5" unitRef="iso4217_USD">9737000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_3_8" unitRef="iso4217_USD">20487000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_32" unitRef="iso4217_USD">-25000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_3_6" unitRef="iso4217_USD">18978000</us-gaap:CostOfGoodsSold>
  <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_21" unitRef="iso4217_USD">111001000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_12" unitRef="iso4217_USD">-10000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:AssetImpairmentCharges contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="INF" id="id_6185658_8D80DBD2-0BB2-4053-814A-F73FD7B8BC82_1_0" unitRef="iso4217_USD">0</us-gaap:AssetImpairmentCharges>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_6" unitRef="iso4217_USD">5833000</us-gaap:DepreciationAndAmortization>
  <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_3_13" unitRef="iso4217_USD">10202000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
  <nktr:IncreaseDecreaseInAccruedClinicalTrialExpenses contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_15" unitRef="iso4217_USD">1238000</nktr:IncreaseDecreaseInAccruedClinicalTrialExpenses>
  <nktr:RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_28" unitRef="iso4217_USD">0</nktr:RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts>
  <nktr:ProductSalesAndRoyalties contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_3_1" unitRef="iso4217_USD">19812000</nktr:ProductSalesAndRoyalties>
  <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_40FC287F-F329-4B75-97A7-401186133553_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Note 4 &amp;#x2014; Liability Related to Sale of Future
 Royalties&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 On February&amp;#xA0;24, 2012, we entered into a Purchase and Sale
 Agreement (the Purchase and Sale Agreement) with RPI Finance Trust
 (RPI), an affiliate of Royalty Pharma, pursuant to which we sold,
 and RPI purchased, our right to receive royalty payments (the
 Royalty Entitlement) arising from the worldwide net sales, from and
 after January&amp;#xA0;1, 2012, of (a)&amp;#xA0;CIMZIA&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;, under our
 license, manufacturing and supply agreement with UCB Pharma (UCB),
 and (b)&amp;#xA0;MIRCERA&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;, under our
 license, manufacturing and supply agreement with F.
 Hoffmann-La&amp;#xA0;Roche Ltd and Hoffmann-La&amp;#xA0;Roche Inc.
 (together referred to as Roche). We received aggregate cash
 proceeds of $124.0 million for the Royalty
 Entitlement.&amp;#xA0;Although we sold all of our rights to receive
 royalties from the CIMZIA&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;and MIRCERA&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;products, as a result of our
 ongoing manufacturing and supply obligations related to the
 generation of these royalties, we will continue to account for
 these royalties as revenue. We recorded the $124.0 million in
 proceeds from this transaction as a liability (Royalty Obligation)
 that will be amortized using the interest method over the estimated
 life of the Purchase and Sale Agreement as royalties from the
 CIMZIA&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;and MIRCERA&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;products are remitted directly
 to RPI. During the six months ended June&amp;#xA0;30, 2015 and 2014, we
 recognized $8.7 million and $10.6 million, respectively, in
 aggregate royalties from net sales of CIMZIA&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;and MIRCERA&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Since its inception, our estimate of the total interest expense on
 the Royalty Obligation resulted in an effective annual interest
 rate of approximately 17%. We periodically assess the estimated
 royalty payments to RPI from UCB and Roche and to the extent such
 payments are greater or less than our initial estimates, or the
 timing of such payments is materially different than our original
 estimates, we will prospectively adjust the amortization of the
 Royalty Obligation.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 Pursuant to the Purchase and Sale Agreement, in March 2014 and
 March 2013, we were required to pay RPI $7.0 million and $3.0
 million, respectively, as a result of worldwide net sales of
 MIRCERA&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;for the 12 month periods ended
 December&amp;#xA0;31, 2013 and 2012 not reaching certain minimum
 thresholds. The Purchase and Sale Agreement does not include any
 other potential payments related to minimum net sales thresholds
 and, therefore, we do not expect to make any further payments to
 RPI related to this agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"&gt;
 In addition, the Purchase and Sale Agreement grants RPI the right
 to receive certain reports and other information relating to the
 Royalty Entitlement and contains other representations and
 warranties, covenants and indemnification obligations that are
 customary for a transaction of this nature. To our knowledge, we
 are currently in compliance with these provisions of the Purchase
 and Sale Agreement, however, if we were to breach our obligations,
 we could be required to pay damages to RPI that are not limited to
 the purchase price we received in the sale transaction.&lt;/p&gt;
 &lt;/div&gt;</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock>
  <nktr:OrganizationPolicyTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_737A9C64-8EBF-4B08-BA59-72DE5ED761F9_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Organization&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 We are a biopharmaceutical company headquartered in San Francisco,
 California and incorporated in Delaware. We are developing a
 pipeline of drug candidates that utilize our PEGylation and
 advanced polymer conjugate technology platforms with the objective
 to improve the benefits of drugs for patients.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Our research and development activities have required significant
 ongoing investment to date and are expected to continue to require
 significant investment. As a result, we expect to continue to incur
 substantial losses and negative cash flows from operations in the
 future. We have financed our operations primarily through cash
 generated from licensing, collaboration and manufacturing
 agreements and financing transactions. At June&amp;#xA0;30, 2015, we
 had approximately $279.7 million in cash and investments in
 marketable securities.&amp;#xA0;Also, as of June&amp;#xA0;30, 2015, we had
 $133.5 million in long-term debt, including $125.0 million of
 senior secured notes and $8.5 million of capital lease obligations,
 of which $5.6 million is current.&lt;/p&gt;
 &lt;/div&gt;</nktr:OrganizationPolicyTextBlock>
  <nktr:DebtInvestmentMaturityDateDescription contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_9E10E39D-FEBC-4D34-9C12-4F21AF108E36_1_1">One year or less</nktr:DebtInvestmentMaturityDateDescription>
  <nktr:EstimatedAnnualInterestRateOnRoyaltyLiability contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="2" id="id_6185658_D5093E9E-8ECD-446B-9A5C-2019A023F3B5_1_0" unitRef="pure">0.17</nktr:EstimatedAnnualInterestRateOnRoyaltyLiability>
  <nktr:SignificantConcentrationsPolicyTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_A687FB67-D12B-4A08-AFD9-8AEC8DF57FCF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Significant Concentrations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Our customers are primarily pharmaceutical and biotechnology
 companies that are located in the U.S.&amp;#xA0;and Europe. Our
 accounts receivable balance contains billed and unbilled trade
 receivables from product sales and royalties, as well as milestones
 and time and materials based billings from collaborative research
 and development agreements. When appropriate, we provide for an
 allowance for doubtful accounts by reserving for specifically
 identified doubtful accounts. We generally do not require
 collateral from our customers. We perform a regular review of our
 customers&amp;#x2019; payment histories and associated credit risk. We
 have not experienced significant credit losses from our accounts
 receivable and our allowance for doubtful accounts was not
 significant at either June&amp;#xA0;30, 2015 or December&amp;#xA0;31,
 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 We are dependent on our suppliers and contract manufacturers to
 provide raw materials, drugs and devices of appropriate quality and
 reliability and to meet applicable contract and regulatory
 requirements. In certain cases, we rely on single sources of supply
 of one or more critical materials. Consequently, in the event that
 supplies are delayed or interrupted for any reason, our ability to
 develop and produce our drug candidates or our ability to meet our
 supply obligations could be significantly impaired, which could
 have a material adverse effect on our business, financial condition
 and results of operations.&lt;/p&gt;
 &lt;/div&gt;</nktr:SignificantConcentrationsPolicyTextBlock>
  <nktr:DebtInvestmentMaximumMaturityPeriod contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_9E10E39D-FEBC-4D34-9C12-4F21AF108E36_1_0">Two years or less</nktr:DebtInvestmentMaximumMaturityPeriod>
  <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_3_2" unitRef="iso4217_USD">8702000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
  <nktr:PotentialDevelopmentMilestones contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-5" id="id_6185658_91FD0650-F20B-4907-A463-008B8F90445A_1_0" unitRef="iso4217_USD">128300000</nktr:PotentialDevelopmentMilestones>
  <nktr:RoyaltyAgreementContingentPaymentDescription contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_1C60B221-38A3-4B5E-B725-599C23E2386A_1_2">As a result of worldwide net sales of MIRCERA&#xAe; for the 12 month periods ended December 31, 2013 and 2012 not reaching certain minimum thresholds.</nktr:RoyaltyAgreementContingentPaymentDescription>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_3_3" unitRef="iso4217_USD">102948000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" decimals="-3" id="id_6185658_C8B2FEE8-1727-4343-AEC4-FB304C55BBE9_1_29" unitRef="iso4217_USD">0</nktr:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
  <nktr:LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0" id="id_6185658_1B8F782A-8DEE-4E84-88E8-6540871BF2BB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 We periodically assess the estimated royalty payments to RPI from
 UCB and Roche and to the extent such payments are greater or less
 than our initial estimates, or the timing of such payments is
 materially different than our original estimates, we will
 prospectively adjust the amortization of the Royalty
 Obligation.&lt;/p&gt;
 &lt;/div&gt;</nktr:LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock>
  <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0_1632061x1836928_1633579x1834994" decimals="-5" id="id_6185658_23DBE378-3624-400D-884F-6662AB77C407_1001_1" unitRef="iso4217_USD">30000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0_1633579x1664673_1634968x1849413" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_1003_1" unitRef="iso4217_USD">6408000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:PotentialDevelopmentMilestones contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0_1633579x1738293_1634968x1656106" decimals="-5" id="id_6185658_80472779-22BF-4ED0-9C50-B88662621FC9_1001_0" unitRef="iso4217_USD">9500000</nktr:PotentialDevelopmentMilestones>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0_1633579x1760274_1634968x1746553" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_2003_2" unitRef="iso4217_USD">2500000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0_1633579x1814659_1634968x1710542" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_3003_0" unitRef="iso4217_USD">90000000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:PotentialDevelopmentMilestones contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0_1633579x1834994" decimals="-5" id="id_6185658_2E27A7D3-4557-4946-AAE5-B6000EB2E384_1001_0" unitRef="iso4217_USD">50000000</nktr:PotentialDevelopmentMilestones>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0_1633579x1834994_1634968x1774465" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_4003_3" unitRef="iso4217_USD">1205000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:PotentialDevelopmentMilestones contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0_1633579x1888068" decimals="-5" id="id_6185658_1F92E227-35A5-4436-A6E0-917C7801E05E_1001_0" unitRef="iso4217_USD">51800000</nktr:PotentialDevelopmentMilestones>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0_1633579x1888068" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_5003_5" unitRef="iso4217_USD">2638000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:PotentialDevelopmentMilestones contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0_1633579x1977273_1634968x1715959" decimals="-5" id="id_6185658_769F7A06-BA44-4852-AF15-A560B9B98450_1001_0" unitRef="iso4217_USD">20000000</nktr:PotentialDevelopmentMilestones>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0_1633579x1977273_1634968x1715959" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_6003_4" unitRef="iso4217_USD">197000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:PotentialDevelopmentMilestones contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0_1633579x1977273_1634968x1715959_1641811x1641076" decimals="-5" id="id_6185658_769F7A06-BA44-4852-AF15-A560B9B98450_2001_1" unitRef="iso4217_USD">10000000</nktr:PotentialDevelopmentMilestones>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0_1634394x1638321" decimals="-3" id="id_6185658_164D7284-8416-45B8-A4B9-D24ACA7C275E_1003_0" unitRef="iso4217_USD">563000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0_1634394x1639948" decimals="-3" id="id_6185658_164D7284-8416-45B8-A4B9-D24ACA7C275E_2003_2" unitRef="iso4217_USD">4627000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0_1634394x1642216" decimals="-3" id="id_6185658_164D7284-8416-45B8-A4B9-D24ACA7C275E_3003_1" unitRef="iso4217_USD">4547000</us-gaap:ShareBasedCompensation>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0_1634760x1634767_1643325x1636521" id="id_6185658_FA739A31-B3AC-421F-BAAF-981A4A49D5DA_1002_1">2017-07-15</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0_1642755x1633925" decimals="-5" id="id_6185658_26C0D0B2-313B-430F-8156-4B18C808178A_1003_0" unitRef="shares">21700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0_1642755x1633925" decimals="2" id="id_6185658_6F6628C2-A395-46FC-9948-9A33661E2D29_1001_1" unitRef="iso4217_USD_per_shares">6.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0_1642755x1633925" decimals="INF" id="id_6185658_6F6628C2-A395-46FC-9948-9A33661E2D29_1001_0" unitRef="shares">479010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE10737---1510-Q0005_STD_181_20150630_0_1643325x1636521" id="id_6185658_70E551C0-5054-4FDF-9817-D69A0FE27589_1002_2">2017-07-15</us-gaap:DebtInstrumentMaturityDate>
  <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="eol_PE10737---1510-Q0005_STD_29_20120229_0_1632061x1836928_1633579x1664673_1634968x1950545" decimals="-5" id="id_6185658_72AF513E-9663-434C-9413-EA42B3DD33A7_1001_1" unitRef="iso4217_USD">22000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
  <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="eol_PE10737---1510-Q0005_STD_29_20120229_0_1633579x1664673_1634968x1950545_1643986x1643540" decimals="-5" id="id_6185658_72AF513E-9663-434C-9413-EA42B3DD33A7_2001_0" unitRef="iso4217_USD">5000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
  <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="eol_PE10737---1510-Q0005_STD_30_20131130_0_1633579x1814659_1634968x1689625" decimals="-5" id="id_6185658_00988BA7-AC37-4AC0-8E41-66699E39F8E9_1002_1" unitRef="iso4217_USD">70000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
  <nktr:PaymentForReimbursementOfCosts contextRef="eol_PE10737---1510-Q0005_STD_30_20130630_0_1633579x1834994" decimals="-5" id="id_6185658_23DBE378-3624-400D-884F-6662AB77C407_2002_2" unitRef="iso4217_USD">10000000</nktr:PaymentForReimbursementOfCosts>
  <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="eol_PE10737---1510-Q0005_STD_30_20140630_0_1633579x1738293_1634968x1656106" decimals="-4" id="id_6185658_11693B84-EBCC-44BD-9B4D-B6A1C287090A_1001_0" unitRef="iso4217_USD">19750000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE10737---1510-Q0005_STD_30_20140930_0_1633579x1977273_1634968x1715959" decimals="-5" id="id_6185658_0A1A16BE-64FB-4D6E-A227-E82A62E26ECF_1001_0" unitRef="iso4217_USD">8000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="eol_PE10737---1510-Q0005_STD_31_20141031_0_1633579x1814659_1634968x1689625" decimals="-5" id="id_6185658_00988BA7-AC37-4AC0-8E41-66699E39F8E9_1001_0" unitRef="iso4217_USD">35000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
  <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="eol_PE10737---1510-Q0005_STD_365_20071231_0_1633579x1834994_1643986x1643540" decimals="-5" id="id_6185658_23DBE378-3624-400D-884F-6662AB77C407_3003_0" unitRef="iso4217_USD">40000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
  <nktr:PaymentMadeForMilestoneNotAchievedYearOne contextRef="eol_PE10737---1510-Q0005_STD_37_20130331_0_1636295x1787206" decimals="-5" id="id_6185658_1C60B221-38A3-4B5E-B725-599C23E2386A_2003_0" unitRef="iso4217_USD">3000000</nktr:PaymentMadeForMilestoneNotAchievedYearOne>
  <nktr:PaymentMadeForMilestoneNotAchievedYearTwo contextRef="eol_PE10737---1510-Q0005_STD_39_20140331_0_1636295x1698241" decimals="-5" id="id_6185658_1C60B221-38A3-4B5E-B725-599C23E2386A_1002_1" unitRef="iso4217_USD">7000000</nktr:PaymentMadeForMilestoneNotAchievedYearTwo>
  <us-gaap:AssetImpairmentCharges contextRef="eol_PE10737---1510-Q0005_STD_90_20150331_0" decimals="INF" id="id_6185658_8D80DBD2-0BB2-4053-814A-F73FD7B8BC82_2_0" unitRef="iso4217_USD">0</us-gaap:AssetImpairmentCharges>
  <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="eol_PE10737---1510-Q0005_STD_90_20150331_0_1633579x1814659_1634968x1689625" decimals="-5" id="id_6185658_406B6926-D885-4428-B16A-22DE79358D2C_1001_0" unitRef="iso4217_USD">100000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
  <nktr:IncreaseDecreaseInRevenue contextRef="eol_PE10737---1510-Q0005_STD_90_20150331_0_1633579x1814659_1641811x1641076" decimals="-5" id="id_6185658_406B6926-D885-4428-B16A-22DE79358D2C_2001_2" unitRef="iso4217_USD">-10000000</nktr:IncreaseDecreaseInRevenue>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="2" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_2_19" unitRef="iso4217_USD_per_shares">-0.26</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="INF" id="id_6185658_BC717D5A-EA21-4654-9D8C-09D8C809E792_2_0" unitRef="shares">350513</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_2_20" unitRef="shares">127040000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="2" id="id_6185658_4164079B-BDC2-44E2-AD5A-F7A65154323C_2_0" unitRef="pure">0.34</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:NetIncomeLoss contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_2_18" unitRef="iso4217_USD">-32637000</us-gaap:NetIncomeLoss>
  <us-gaap:Revenues contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_2_4" unitRef="iso4217_USD">28513000</us-gaap:Revenues>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_2_10" unitRef="iso4217_USD">-22916000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_2_14" unitRef="iso4217_USD">96000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_2_15" unitRef="iso4217_USD">-9526000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="-3" id="id_6185658_1334E699-D194-4475-B92C-4A615F56AA32_2_0" unitRef="iso4217_USD">-32584000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_2_16" unitRef="iso4217_USD">-32442000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="INF" id="id_6185658_31BCBE64-8308-4115-8B20-01649355D37E_3_600000" unitRef="iso4217_USD">0.0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_2_17" unitRef="iso4217_USD">195000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="-3" id="id_6185658_164D7284-8416-45B8-A4B9-D24ACA7C275E_2_3" unitRef="iso4217_USD">4164000</us-gaap:ShareBasedCompensation>
  <us-gaap:InterestExpense contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_2_12" unitRef="iso4217_USD">4488000</us-gaap:InterestExpense>
  <us-gaap:CostsAndExpenses contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_2_9" unitRef="iso4217_USD">51429000</us-gaap:CostsAndExpenses>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_2_7" unitRef="iso4217_USD">36702000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_2_8" unitRef="iso4217_USD">9619000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_2_6" unitRef="iso4217_USD">5108000</us-gaap:CostOfGoodsSold>
  <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_2_13" unitRef="iso4217_USD">5134000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
  <nktr:ProductSalesAndRoyalties contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_2_1" unitRef="iso4217_USD">5891000</nktr:ProductSalesAndRoyalties>
  <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_2_2" unitRef="iso4217_USD">4837000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_2_3" unitRef="iso4217_USD">17785000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0_1633579x1664673_1634968x1849413" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_1002_1" unitRef="iso4217_USD">3219000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0_1633579x1760274_1634968x1746553" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_2002_2" unitRef="iso4217_USD">1250000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0_1633579x1814659_1634968x1710542" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_3002_0" unitRef="iso4217_USD">0</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0_1633579x1834994_1634968x1774465" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_4002_3" unitRef="iso4217_USD">2393000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0_1633579x1888068" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_5002_5" unitRef="iso4217_USD">10254000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0_1633579x1977273_1634968x1715959" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_6002_4" unitRef="iso4217_USD">669000</nktr:LicenseCollaborationOtherRevenue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0_1634394x1638321" decimals="-3" id="id_6185658_164D7284-8416-45B8-A4B9-D24ACA7C275E_1002_0" unitRef="iso4217_USD">280000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0_1634394x1639948" decimals="-3" id="id_6185658_164D7284-8416-45B8-A4B9-D24ACA7C275E_2002_2" unitRef="iso4217_USD">2052000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0_1634394x1642216" decimals="-3" id="id_6185658_164D7284-8416-45B8-A4B9-D24ACA7C275E_3002_1" unitRef="iso4217_USD">1832000</us-gaap:ShareBasedCompensation>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0_1642755x1633925" decimals="-5" id="id_6185658_26C0D0B2-313B-430F-8156-4B18C808178A_1002_0" unitRef="shares">22500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0_1642755x1633925" decimals="2" id="id_6185658_EFB7BB7F-56F3-444A-812B-8D3B568406A4_1002_1" unitRef="iso4217_USD_per_shares">5.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE10737---1510-Q0005_STD_91_20140630_0_1642755x1633925" decimals="INF" id="id_6185658_EFB7BB7F-56F3-444A-812B-8D3B568406A4_1002_0" unitRef="shares">642860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="2" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_1_19" unitRef="iso4217_USD_per_shares">-0.40</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="INF" id="id_6185658_BC717D5A-EA21-4654-9D8C-09D8C809E792_1_0" unitRef="shares">733952</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_1_20" unitRef="shares">131643000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="2" id="id_6185658_4164079B-BDC2-44E2-AD5A-F7A65154323C_1_0" unitRef="pure">0.34</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:NetIncomeLoss contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_1_18" unitRef="iso4217_USD">-52657000</us-gaap:NetIncomeLoss>
  <us-gaap:Revenues contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_1_4" unitRef="iso4217_USD">22661000</us-gaap:Revenues>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_1_10" unitRef="iso4217_USD">-43469000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_1_14" unitRef="iso4217_USD">246000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_1_15" unitRef="iso4217_USD">-9024000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="-3" id="id_6185658_1334E699-D194-4475-B92C-4A615F56AA32_1_0" unitRef="iso4217_USD">-52879000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_1_16" unitRef="iso4217_USD">-52493000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="INF" id="id_6185658_31BCBE64-8308-4115-8B20-01649355D37E_1_400000" unitRef="iso4217_USD">0.0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_1_17" unitRef="iso4217_USD">164000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="-3" id="id_6185658_164D7284-8416-45B8-A4B9-D24ACA7C275E_1_3" unitRef="iso4217_USD">4560000</us-gaap:ShareBasedCompensation>
  <us-gaap:InterestExpense contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_1_12" unitRef="iso4217_USD">4118000</us-gaap:InterestExpense>
  <us-gaap:CostsAndExpenses contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_1_9" unitRef="iso4217_USD">66130000</us-gaap:CostsAndExpenses>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_1_7" unitRef="iso4217_USD">45412000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_1_8" unitRef="iso4217_USD">10184000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_1_6" unitRef="iso4217_USD">10534000</us-gaap:CostOfGoodsSold>
  <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_1_13" unitRef="iso4217_USD">5152000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
  <nktr:ProductSalesAndRoyalties contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_1_1" unitRef="iso4217_USD">11713000</nktr:ProductSalesAndRoyalties>
  <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_1_2" unitRef="iso4217_USD">4740000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0" decimals="-3" id="id_6185658_C8A48600-D313-42C6-A5B6-36B09280B988_1_3" unitRef="iso4217_USD">6208000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0_1633579x1664673_1634968x1849413" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_1001_1" unitRef="iso4217_USD">3197000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0_1633579x1760274_1634968x1746553" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_2001_2" unitRef="iso4217_USD">1250000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0_1633579x1814659_1634968x1710542" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_3001_0" unitRef="iso4217_USD">0</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0_1633579x1834994_1634968x1774465" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_4001_3" unitRef="iso4217_USD">395000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0_1633579x1888068" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_5001_5" unitRef="iso4217_USD">1278000</nktr:LicenseCollaborationOtherRevenue>
  <nktr:LicenseCollaborationOtherRevenue contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0_1633579x1977273_1634968x1715959" decimals="-3" id="id_6185658_1889C24E-FEC5-48F7-9C22-7E0BCF9F476C_6001_4" unitRef="iso4217_USD">88000</nktr:LicenseCollaborationOtherRevenue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0_1634394x1638321" decimals="-3" id="id_6185658_164D7284-8416-45B8-A4B9-D24ACA7C275E_1001_0" unitRef="iso4217_USD">239000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0_1634394x1639948" decimals="-3" id="id_6185658_164D7284-8416-45B8-A4B9-D24ACA7C275E_2001_2" unitRef="iso4217_USD">2196000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0_1634394x1642216" decimals="-3" id="id_6185658_164D7284-8416-45B8-A4B9-D24ACA7C275E_3001_1" unitRef="iso4217_USD">2125000</us-gaap:ShareBasedCompensation>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0_1642755x1633925" decimals="-5" id="id_6185658_26C0D0B2-313B-430F-8156-4B18C808178A_1001_0" unitRef="shares">21600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0_1642755x1633925" decimals="2" id="id_6185658_EFB7BB7F-56F3-444A-812B-8D3B568406A4_1001_1" unitRef="iso4217_USD_per_shares">4.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE10737---1510-Q0005_STD_91_20150630_0_1642755x1633925" decimals="INF" id="id_6185658_EFB7BB7F-56F3-444A-812B-8D3B568406A4_1001_0" unitRef="shares">68200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="eol_PE10737---1510-Q0005_STD_92_20091231_0_1633579x1814659_1634968x1710542_1643986x1643540" decimals="-5" id="id_6185658_6C0A5DF8-7FF0-43AE-838C-33E09DBC6195_1001_0" unitRef="iso4217_USD">125000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
  <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="eol_PE10737---1510-Q0005_STD_92_20101231_0_1633579x1760274" decimals="-5" id="id_6185658_AE897B31-F3CD-417A-8CBB-14076E5F1F00_1001_0" unitRef="iso4217_USD">50000000</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
  <nktr:ConsiderationReceivedForProductDelivered contextRef="eol_PE10737---1510-Q0005_STD_92_20131231_0_1633579x1664673_1634968x1950545" decimals="-5" id="id_6185658_997EF810-0A7B-4F9A-82B0-436D139B4A24_1002_0" unitRef="iso4217_USD">18600000</nktr:ConsiderationReceivedForProductDelivered>
  <context id="eol_PE10737---1510-Q0005_STD_92_20131231_0_1633579x1664673_1634968x1950545">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:RocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MirceraMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_92_20101231_0_1633579x1760274">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-10-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_92_20091231_0_1633579x1814659_1634968x1710542_1643986x1643540">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikAndMovantikFixedDoseCombinationProgramMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20150630_0_1642755x1633925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20150630_0_1634394x1642216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20150630_0_1634394x1639948">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20150630_0_1634394x1638321">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20150630_0_1633579x1977273_1634968x1715959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20150630_0_1633579x1888068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20150630_0_1633579x1834994_1634968x1774465">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BayerHealthcareLlcMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BayFourOneSixFiveFiveOneAmikacinInhaleMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20150630_0_1633579x1814659_1634968x1710542">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikAndMovantikFixedDoseCombinationProgramMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20150630_0_1633579x1760274_1634968x1746553">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20150630_0_1633579x1664673_1634968x1849413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:RocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PegasysAndMirceraMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20140630_0_1642755x1633925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20140630_0_1634394x1642216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20140630_0_1634394x1639948">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20140630_0_1634394x1638321">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20140630_0_1633579x1977273_1634968x1715959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20140630_0_1633579x1888068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20140630_0_1633579x1834994_1634968x1774465">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BayerHealthcareLlcMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BayFourOneSixFiveFiveOneAmikacinInhaleMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20140630_0_1633579x1814659_1634968x1710542">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikAndMovantikFixedDoseCombinationProgramMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20140630_0_1633579x1760274_1634968x1746553">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20140630_0_1633579x1664673_1634968x1849413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:RocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PegasysAndMirceraMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_91_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <startDate>2014-04-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_90_20150331_0_1633579x1814659_1641811x1641076">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_90_20150331_0_1633579x1814659_1634968x1689625">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_90_20150331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_39_20140331_0_1636295x1698241">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nktr:MilestoneScenarioTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-02-21</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_37_20130331_0_1636295x1787206">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">nktr:MilestoneScenarioOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-02-23</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_365_20071231_0_1633579x1834994_1643986x1643540">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BayerHealthcareLlcMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_31_20141031_0_1633579x1814659_1634968x1689625">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-10-01</startDate>
      <endDate>2014-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_30_20140930_0_1633579x1977273_1634968x1715959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-09-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_30_20140630_0_1633579x1738293_1634968x1656106">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OphthotechCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:FovistaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-06-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_30_20130630_0_1633579x1834994">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BayerHealthcareLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-06-01</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_30_20131130_0_1633579x1814659_1634968x1689625">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-11-01</startDate>
      <endDate>2013-11-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_29_20120229_0_1633579x1664673_1634968x1950545_1643986x1643540">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:RocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MirceraMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-02-01</startDate>
      <endDate>2012-02-29</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_29_20120229_0_1632061x1836928_1633579x1664673_1634968x1950545">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:RocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis">nktr:PerformanceMilestonePaymentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MirceraMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-02-01</startDate>
      <endDate>2012-02-29</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20150630_0_1643325x1636521">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20150630_0_1642755x1633925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20150630_0_1634760x1634767_1643325x1636521">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20150630_0_1634394x1642216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20150630_0_1634394x1639948">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20150630_0_1634394x1638321">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20150630_0_1633579x1977273_1634968x1715959_1641811x1641076">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20150630_0_1633579x1977273_1634968x1715959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20150630_0_1633579x1888068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20150630_0_1633579x1834994_1634968x1774465">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BayerHealthcareLlcMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BayFourOneSixFiveFiveOneAmikacinInhaleMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20150630_0_1633579x1834994">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BayerHealthcareLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20150630_0_1633579x1814659_1634968x1710542">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikAndMovantikFixedDoseCombinationProgramMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20150630_0_1633579x1760274_1634968x1746553">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20150630_0_1633579x1738293_1634968x1656106">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OphthotechCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:FovistaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20150630_0_1633579x1664673_1634968x1849413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:RocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PegasysAndMirceraMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20150630_0_1632061x1836928_1633579x1834994">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BayerHealthcareLlcMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis">nktr:PerformanceMilestonePaymentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20140630_0_1642755x1633925">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20140630_0_1634394x1642216">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20140630_0_1634394x1639948">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20140630_0_1634394x1638321">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20140630_0_1633579x1977273_1634968x1715959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20140630_0_1633579x1888068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20140630_0_1633579x1834994_1634968x1774465">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BayerHealthcareLlcMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BayFourOneSixFiveFiveOneAmikacinInhaleMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20140630_0_1633579x1814659_1634968x1710542">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikAndMovantikFixedDoseCombinationProgramMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20140630_0_1633579x1760274_1634968x1746553">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20140630_0_1633579x1664673_1634968x1849413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:RocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PegasysAndMirceraMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_181_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_1_20140916_0_1633579x1814659_1634968x1689625_1641811x1641076">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-09-16</startDate>
      <endDate>2014-09-16</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_1_20140916_0_1633579x1814659_1634968x1689625">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-09-16</startDate>
      <endDate>2014-09-16</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_1_20120224_0_1634968x1754234">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-02-24</startDate>
      <endDate>2012-02-24</endDate>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20141231_0_1643713x1640681">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20141231_0_1640416x1634809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20141231_0_1634760x1643241_1643713x1637231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20141231_0_1634760x1637150_1643713x1671183">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nktr:CorporateCommercialPaperMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20141231_0_1634760x1637150_1643713x1633464">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150630_0_1643713x1640681">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150630_0_1643325x1636521">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150630_0_1640416x1634809">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150630_0_1634760x1643241_1643713x1637231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150630_0_1634760x1637150_1643713x1671183">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nktr:CorporateCommercialPaperMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150630_0_1634760x1637150_1643713x1633464">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150630_0_1634760x1634767_1643325x1636521">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1977273_1634968x1715959">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1888068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1834994">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BayerHealthcareLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1814659_1638287x1638889_1641811x1641076">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1814659_1638287x1635282_1641811x1641076">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1814659_1634968x1722353">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikFixedDoseCombinationProgramMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1814659_1634968x1689625_1641811x1632305">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1814659_1634968x1689625">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1760274">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1738293_1634968x1656106">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OphthotechCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:FovistaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1664673_1634968x1950545">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:RocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MirceraMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1664673_1634968x1905729">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:RocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PegasysMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150630_0_1633579x1664673_1634968x1849413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:RocheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PegasysAndMirceraMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <instant>2015-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150331_0_1633579x1814659_1641811x1641076">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20140916_0_1633579x1814659_1634968x1689625">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MovantikMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-09-16</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20140630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <instant>2014-06-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150730_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
    </entity>
    <period>
      <instant>2015-07-30</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20160731_0_1633579x1814659_1640593x1641344_1641811x1641076">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-07-31</instant>
    </period>
  </context>
  <context id="eol_PE10737---1510-Q0005_STD_0_20150731_0_1633579x1814659_1640593x1641344_1641811x1641076">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-07-31</instant>
    </period>
  </context>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="Segment">
    <measure>nktr:Segment</measure>
  </unit>

</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>nktr-20150630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 4 -->
<!-- Creation date: 2015-08-05T06:53:07Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31"
  xmlns:us-types="http://fasb.org/us-types/2015-01-31"
  xmlns:nktr="http://www.nektar.com/20150630"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2015-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
  targetNamespace="http://www.nektar.com/20150630"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/StatementOfIncomeAlternative" id="Role_StatementOfIncomeAlternative">
        <link:definition>105 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/StatementOfPartnersCapital" id="Role_StatementOfPartnersCapital">
        <link:definition>106 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>107 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
        <link:definition>108 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock" id="Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock">
        <link:definition>109 - Disclosure - Cash and Investments in Marketable Securities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock" id="Role_NotesToFinancialStatementsInventoryDisclosureTextBlock">
        <link:definition>110 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" id="Role_NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock">
        <link:definition>111 - Disclosure - Liability Related to Sale of Future Royalties</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
        <link:definition>112 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" id="Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
        <link:definition>113 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <link:definition>114 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock" id="Role_NotesToFinancialStatementsEarningsPerShareTextBlock">
        <link:definition>115 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies">
        <link:definition>116 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" id="Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
        <link:definition>117 - Disclosure - Cash and Investments in Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsInventoryDisclosureTextBlockTables">
        <link:definition>118 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
        <link:definition>119 - Disclosure - License and Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
        <link:definition>120 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
        <link:definition>121 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash" id="DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash">
        <link:definition>122 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents and Restricted Cash (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation" id="DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation">
        <link:definition>123 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities" id="DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities">
        <link:definition>124 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureInventoryInventory" id="DisclosureInventoryInventory">
        <link:definition>125 - Disclosure - Inventory - Inventory (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation" id="DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation">
        <link:definition>126 - Disclosure - Liability Related to Sale of Future Royalties - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation" id="DisclosureCommitmentsAndContingenciesAdditionalInformation">
        <link:definition>127 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue" id="DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue">
        <link:definition>128 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformation" id="DisclosureLicenseAndCollaborationAgreementsAdditionalInformation">
        <link:definition>129 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense" id="DisclosureStockBasedCompensationStockBasedCompensationExpense">
        <link:definition>130 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation" id="DisclosureStockBasedCompensationAdditionalInformation">
        <link:definition>131 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nektar.com/taxonomy/role/DisclosureNetLossPerShareAdditionalInformation" id="DisclosureNetLossPerShareAdditionalInformation">
        <link:definition>132 - Disclosure - Net Loss Per Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="nktr-20150630_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="nktr-20150630_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="nktr-20150630_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="nktr-20150630_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://fasb.org/us-types/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-types-2015-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2015-01-31" schemaLocation="http://xbrl.sec.gov/exch/2015/exch-2015-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <element name="AccruedClinicalTrialExpenses" id="nktr_AccruedClinicalTrialExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmgenIncMember" id="nktr_AmgenIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AstraZenecaAbMember" id="nktr_AstraZenecaAbMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BaxaltaMember" id="nktr_BaxaltaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BayerHealthcareLlcMember" id="nktr_BayerHealthcareLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BayFourOneSixFiveFiveOneAmikacinInhaleMember" id="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashAndInvestmentsInMarketableSecuritiesLineItems" id="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashAndInvestmentsInMarketableSecuritiesTable" id="nktr_CashAndInvestmentsInMarketableSecuritiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="CashAndRestrictedCash" id="nktr_CashAndRestrictedCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" id="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConsiderationReceivedForProductDelivered" id="nktr_ConsiderationReceivedForProductDelivered" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ContingentPaymentsReceivableBasedOnDevelopmentEvents" id="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CorporateCommercialPaperMember" id="nktr_CorporateCommercialPaperMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInvestmentMaturityDateDescription" id="nktr_DebtInvestmentMaturityDateDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInvestmentMaximumMaturityPeriod" id="nktr_DebtInvestmentMaximumMaturityPeriod" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="nktr_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EstimatedAnnualInterestRateOnRoyaltyLiability" id="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FovistaMember" id="nktr_FovistaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="HemophiliaMember" id="nktr_HemophiliaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInAccruedClinicalTrialExpenses" id="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInRevenue" id="nktr_IncreaseDecreaseInRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LiabilitiesToPartnersForDirectConsumerAdvertisingPayments" id="nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LiabilityRelatedToSaleOfFutureRoyaltiesTable" id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAndCollaborationAgreementsAbstract" id="nktr_LicenseAndCollaborationAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAndCollaborationAgreementsLineItems" id="nktr_LicenseAndCollaborationAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAndCollaborationAgreementsTable" id="nktr_LicenseAndCollaborationAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="LicenseCollaborationOtherRevenue" id="nktr_LicenseCollaborationOtherRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestoneScenarioOneMember" id="nktr_MilestoneScenarioOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestoneScenarioTwoMember" id="nktr_MilestoneScenarioTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MirceraMember" id="nktr_MirceraMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MovantikAndMovantikFixedDoseCombinationProgramMember" id="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MovantikFixedDoseCombinationProgramMember" id="nktr_MovantikFixedDoseCombinationProgramMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MovantikMember" id="nktr_MovantikMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NeulastaMember" id="nktr_NeulastaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonCashInterestExpenseRelatedToSaleOfRoyalties" id="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OphthotechCorporationMember" id="nktr_OphthotechCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrganizationPolicyTextBlock" id="nktr_OrganizationPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OtherPartnerMember" id="nktr_OtherPartnerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PaymentForReimbursementOfCosts" id="nktr_PaymentForReimbursementOfCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PaymentMadeForMilestoneNotAchievedYearOne" id="nktr_PaymentMadeForMilestoneNotAchievedYearOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PaymentMadeForMilestoneNotAchievedYearTwo" id="nktr_PaymentMadeForMilestoneNotAchievedYearTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PegasysAndMirceraMember" id="nktr_PegasysAndMirceraMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PegasysMember" id="nktr_PegasysMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfPostApprovalStudyCostsToRepay" id="nktr_PercentageOfPostApprovalStudyCostsToRepay" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PerformanceMilestonePaymentsMember" id="nktr_PerformanceMilestonePaymentsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PotentialDevelopmentMilestones" id="nktr_PotentialDevelopmentMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies" id="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired" id="nktr_PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PreferredStockShareDesignated" id="nktr_PreferredStockShareDesignated" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" id="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromSaleOfPotentialFutureRoyaltiesGross" id="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProductSalesAndRoyalties" id="nktr_ProductSalesAndRoyalties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PurchaseAndSaleAgreementMember" id="nktr_PurchaseAndSaleAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts" id="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RocheMember" id="nktr_RocheMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RoyaltyAgreementContingentPaymentDescription" id="nktr_RoyaltyAgreementContingentPaymentDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SignificantConcentrationsPolicyTextBlock" id="nktr_SignificantConcentrationsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" id="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>nktr-20150630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 4 -->
<!-- Creation date: 2015-08-05T06:53:07Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DocumentandEntityInformation" roleURI="http://www.nektar.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.nektar.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_StatementOfPartnersCapital" roleURI="http://www.nektar.com/taxonomy/role/StatementOfPartnersCapital"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureInventoryInventory" roleURI="http://www.nektar.com/taxonomy/role/DisclosureInventoryInventory"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureLicenseAndCollaborationAgreementsAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpense" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureNetLossPerShareAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureNetLossPerShareAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_AccruedClinicalTrialExpenses" xlink:label="nktr_AccruedClinicalTrialExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_SeniorLongTermNotes" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.3100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="nktr_AccruedClinicalTrialExpenses" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1.2600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.2700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.2800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.2900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.3000" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LicenseCollaborationOtherRevenue" xlink:label="nktr_LicenseCollaborationOtherRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:label="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_ProductSalesAndRoyalties" xlink:label="nktr_ProductSalesAndRoyalties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsSold" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1.1000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" order="1.1100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="nktr_ProductSalesAndRoyalties" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="nktr_LicenseCollaborationOtherRevenue" order="1.0300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfPartnersCapital">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses" xlink:label="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:label="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts" xlink:label="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.2600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="1.2700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1.2200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" order="1.1800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.2000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" order="1.0200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationAndAmortization" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="1.1500" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_CashAndRestrictedCash" xlink:label="nktr_CashAndRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="us-gaap_AvailableForSaleSecurities" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="nktr_CashAndRestrictedCash" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1.0400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureInventoryInventory">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="1.0300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureNetLossPerShareAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>nktr-20150630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 4 -->
<!-- Creation date: 2015-08-05T06:53:07Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DocumentandEntityInformation" roleURI="http://www.nektar.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.nektar.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_StatementOfPartnersCapital" roleURI="http://www.nektar.com/taxonomy/role/StatementOfPartnersCapital"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureInventoryInventory" roleURI="http://www.nektar.com/taxonomy/role/DisclosureInventoryInventory"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureLicenseAndCollaborationAgreementsAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpense" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureNetLossPerShareAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureNetLossPerShareAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DocumentandEntityInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassified">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfIncomeAlternative">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfPartnersCapital">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirect">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_DebtInvestmentMaturityDateDescription" xlink:label="nktr_DebtInvestmentMaturityDateDescription"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_DebtInvestmentMaximumMaturityPeriod" xlink:label="nktr_DebtInvestmentMaximumMaturityPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="nktr_CashAndInvestmentsInMarketableSecuritiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="nktr_DebtInvestmentMaximumMaturityPeriod" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="nktr_DebtInvestmentMaturityDateDescription" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_SeniorLongTermNotes" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SeniorNotesMember" order="1.1000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_CashAndRestrictedCash" xlink:label="nktr_CashAndRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_CorporateCommercialPaperMember" xlink:label="nktr_CorporateCommercialPaperMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="nktr_CashAndRestrictedCash" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="nktr_CorporateCommercialPaperMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="1.1000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureInventoryInventory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_EstimatedAnnualInterestRateOnRoyaltyLiability" xlink:label="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_MilestoneScenarioOneMember" xlink:label="nktr_MilestoneScenarioOneMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_MilestoneScenarioTwoMember" xlink:label="nktr_MilestoneScenarioTwoMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearOne"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearTwo"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:label="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PurchaseAndSaleAgreementMember" xlink:label="nktr_PurchaseAndSaleAgreementMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_RoyaltyAgreementContingentPaymentDescription" xlink:label="nktr_RoyaltyAgreementContingentPaymentDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_PurchaseAndSaleAgreementMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nktr_MilestoneScenarioOneMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nktr_MilestoneScenarioTwoMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_PaymentMadeForMilestoneNotAchievedYearOne" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_PaymentMadeForMilestoneNotAchievedYearTwo" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_RoyaltyAgreementContingentPaymentDescription" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="us-gaap_IndemnificationGuaranteeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_IndemnificationGuaranteeMember" order="1.0200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue">
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_AmgenIncMember" xlink:label="nktr_AmgenIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_AstraZenecaAbMember" xlink:label="nktr_AstraZenecaAbMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_BaxaltaMember" xlink:label="nktr_BaxaltaMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_BayerHealthcareLlcMember" xlink:label="nktr_BayerHealthcareLlcMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember" xlink:label="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_HemophiliaMember" xlink:label="nktr_HemophiliaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LicenseAndCollaborationAgreementsLineItems" xlink:label="nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LicenseAndCollaborationAgreementsTable" xlink:label="nktr_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LicenseCollaborationOtherRevenue" xlink:label="nktr_LicenseCollaborationOtherRevenue"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" xlink:label="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_NeulastaMember" xlink:label="nktr_NeulastaMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_OtherPartnerMember" xlink:label="nktr_OtherPartnerMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PegasysAndMirceraMember" xlink:label="nktr_PegasysAndMirceraMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_RocheMember" xlink:label="nktr_RocheMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_PegasysAndMirceraMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_NeulastaMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_HemophiliaMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_AstraZenecaAbMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_RocheMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_AmgenIncMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_BayerHealthcareLlcMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_BaxaltaMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_OtherPartnerMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nktr_LicenseAndCollaborationAgreementsLineItems" xlink:to="nktr_LicenseAndCollaborationAgreementsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nktr_LicenseAndCollaborationAgreementsLineItems" xlink:to="nktr_LicenseCollaborationOtherRevenue" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktr_LicenseAndCollaborationAgreementsTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nktr_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_AmgenIncMember" xlink:label="nktr_AmgenIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_AstraZenecaAbMember" xlink:label="nktr_AstraZenecaAbMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_BaxaltaMember" xlink:label="nktr_BaxaltaMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_BayerHealthcareLlcMember" xlink:label="nktr_BayerHealthcareLlcMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_ConsiderationReceivedForProductDelivered" xlink:label="nktr_ConsiderationReceivedForProductDelivered"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents" xlink:label="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="us-gaap_DeferredRevenueArrangementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="us-gaap_EuropeanUnionMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_FovistaMember" xlink:label="nktr_FovistaMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_HemophiliaMember" xlink:label="nktr_HemophiliaMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_IncreaseDecreaseInRevenue" xlink:label="nktr_IncreaseDecreaseInRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments" xlink:label="nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_MirceraMember" xlink:label="nktr_MirceraMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" xlink:label="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_MovantikFixedDoseCombinationProgramMember" xlink:label="nktr_MovantikFixedDoseCombinationProgramMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_MovantikMember" xlink:label="nktr_MovantikMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfReportingCategoryDomain" xlink:label="us-gaap_NameOfReportingCategoryDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfReportingCategoryDomain" xlink:label="us-gaap_NameOfReportingCategoryDomain_2"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_OphthotechCorporationMember" xlink:label="nktr_OphthotechCorporationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_OtherPartnerMember" xlink:label="nktr_OtherPartnerMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PaymentForReimbursementOfCosts" xlink:label="nktr_PaymentForReimbursementOfCosts"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PegasysAndMirceraMember" xlink:label="nktr_PegasysAndMirceraMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PegasysMember" xlink:label="nktr_PegasysMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PercentageOfPostApprovalStudyCostsToRepay" xlink:label="nktr_PercentageOfPostApprovalStudyCostsToRepay"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PerformanceMilestonePaymentsMember" xlink:label="nktr_PerformanceMilestonePaymentsMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PotentialDevelopmentMilestones" xlink:label="nktr_PotentialDevelopmentMilestones"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies" xlink:label="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired" xlink:label="nktr_PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis" xlink:label="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_RocheMember" xlink:label="nktr_RocheMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:label="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_MirceraMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_FovistaMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_MovantikMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_PegasysMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_PegasysAndMirceraMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_MovantikFixedDoseCombinationProgramMember" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_HemophiliaMember" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_StatementScenarioAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_StatementGeographicalAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="7.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenueArrangementByTypeTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_PotentialDevelopmentMilestones" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_IncreaseDecreaseInRevenue" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_PercentageOfPostApprovalStudyCostsToRepay" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_ConsiderationReceivedForProductDelivered" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_PaymentForReimbursementOfCosts" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_UpFrontPaymentArrangementMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_RocheMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_AmgenIncMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_OphthotechCorporationMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_AstraZenecaAbMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_BayerHealthcareLlcMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_BaxaltaMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="nktr_OtherPartnerMember" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfReportingCategoryDomain" xlink:to="nktr_PerformanceMilestonePaymentsMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis" xlink:to="us-gaap_NameOfReportingCategoryDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis" xlink:to="us-gaap_NameOfReportingCategoryDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_EuropeanUnionMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_US" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureNetLossPerShareAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>nktr-20150630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 4 -->
<!-- Creation date: 2015-08-05T06:53:07Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_6185658_1646304_1_1">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_6185658_1646304_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_6185658_1649249_1_1">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_6185658_1649249_2_1">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_AccruedClinicalTrialExpenses" xlink:label="nktr_AccruedClinicalTrialExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_AccruedClinicalTrialExpenses_lbl" xml:lang="en-US" id="id_6185658_1719676_3_1">Accrued clinical trial expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_AccruedClinicalTrialExpenses_lbl" xml:lang="en-US" id="id_6185658_1719676_1_1">Accrued Clinical Trial Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_AccruedClinicalTrialExpenses_lbl" xml:lang="en-US" id="id_6185658_1719676_2_1">Accrued clinical trial expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_AccruedClinicalTrialExpenses" xlink:to="nktr_AccruedClinicalTrialExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_6185658_1647633_1_1">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_6185658_1647633_2_1">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" id="id_6185658_1644587_1_1">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" id="id_6185658_1644587_2_1">Capital in excess of par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_6185658_1634242_1_1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_6185658_1634242_2_1">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_6185658_1650010_1_1">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_6185658_1650010_2_1">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_6185658_1633423_1_1">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_6185658_1633423_2_1">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_AmgenIncMember" xlink:label="nktr_AmgenIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_AmgenIncMember_lbl" xml:lang="en-US" id="id_6185658_1760274_3_1">Amgen Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_AmgenIncMember_lbl" xml:lang="en-US" id="id_6185658_1760274_1_1">Amgen Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_AmgenIncMember_lbl" xml:lang="en-US" id="id_6185658_1760274_2_1">Amgen, Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_AmgenIncMember" xlink:to="nktr_AmgenIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_6185658_1634668_1_1">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_6185658_1634668_2_1">Weighted average diluted securities excluded from diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_6185658_1636654_1_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_6185658_1636654_2_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_6185658_1632222_1_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_6185658_1632222_2_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" id="id_6185658_1651152_1_1">Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" id="id_6185658_1651152_2_1">Asset impairment charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_6185658_1648873_1_1">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_6185658_1648873_6_1">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_6185658_1636242_1_1">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_6185658_1636242_2_1">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_6185658_1650014_1_1">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_6185658_1650014_6_1">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_6185658_1643954_1_1">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_6185658_1643954_2_1">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_AstraZenecaAbMember" xlink:label="nktr_AstraZenecaAbMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_AstraZenecaAbMember_lbl" xml:lang="en-US" id="id_6185658_1814659_3_1">AstraZeneca AB.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_AstraZenecaAbMember_lbl" xml:lang="en-US" id="id_6185658_1814659_1_1">Astra Zeneca Ab [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_AstraZenecaAbMember_lbl" xml:lang="en-US" id="id_6185658_1814659_2_1">AstraZeneca AB [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_AstraZenecaAbMember" xlink:to="nktr_AstraZenecaAbMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_6185658_1648368_1_1">Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_6185658_1648368_2_1">Available-for-sale investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent_lbl" xml:lang="en-US" id="id_6185658_1649628_1_1">Available-for-sale Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent_lbl" xml:lang="en-US" id="id_6185658_1649628_2_1">Short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds_lbl" xml:lang="en-US" id="id_6185658_1647175_1_1">Available-for-sale Securities, Gross Realized Gains (Losses), Sale Proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds_lbl" xml:lang="en-US" id="id_6185658_1647175_2_1">Available-for-sale securities, sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_6185658_1642755_1_1">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_6185658_1642755_2_1">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" id="id_6185658_1638287_1_1">Balance Sheet Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" id="id_6185658_1638287_2_1">Balance Sheet Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" id="id_6185658_1637883_1_1">Balance Sheet Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" id="id_6185658_1637883_2_1">Balance Sheet Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_BaxaltaMember" xlink:label="nktr_BaxaltaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_BaxaltaMember_lbl" xml:lang="en-US" id="id_6185658_1977273_3_1">Baxalta [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_BaxaltaMember_lbl" xml:lang="en-US" id="id_6185658_1977273_1_1">Baxalta [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_BaxaltaMember_lbl" xml:lang="en-US" id="id_6185658_1977273_2_1">Baxalta [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_BaxaltaMember" xlink:to="nktr_BaxaltaMember_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_BayerHealthcareLlcMember" xlink:label="nktr_BayerHealthcareLlcMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_BayerHealthcareLlcMember_lbl" xml:lang="en-US" id="id_6185658_1834994_3_1">Bayer Healthcare LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_BayerHealthcareLlcMember_lbl" xml:lang="en-US" id="id_6185658_1834994_1_1">Bayer Healthcare Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_BayerHealthcareLlcMember_lbl" xml:lang="en-US" id="id_6185658_1834994_2_1">Bayer Healthcare LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_BayerHealthcareLlcMember" xlink:to="nktr_BayerHealthcareLlcMember_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember" xlink:label="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember_lbl" xml:lang="en-US" id="id_6185658_1774465_3_1">BAY41-6551 (Amikacin Inhale).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember_lbl" xml:lang="en-US" id="id_6185658_1774465_1_1">Bay Four One Six Five Five One Amikacin Inhale [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember_lbl" xml:lang="en-US" id="id_6185658_1774465_2_1">BAY41-6551 (Amikacin Inhale) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember" xlink:to="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="us-gaap_CapitalLeaseObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligations_lbl" xml:lang="en-US" id="id_6185658_1645131_1_1">Capital Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeaseObligations_lbl" xml:lang="en-US" id="id_6185658_1645131_2_1">Capital lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligations" xlink:to="us-gaap_CapitalLeaseObligations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US" id="id_6185658_1647847_1_1">Capital Lease Obligations, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US" id="id_6185658_1647847_2_1">Capital lease obligations, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xml:lang="en-US" id="id_6185658_1647848_1_1">Capital Lease Obligations, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xml:lang="en-US" id="id_6185658_1647848_2_1">Capital lease obligations, less current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" id="id_6185658_1643967_1_1">Cash and Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" id="id_6185658_1643967_2_1">Cash and Cash Equivalents [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_6185658_1651160_1_1">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_6185658_1651160_4_1">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_6185658_1651160_5_1">Cash and cash equivalents at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_6185658_1651160_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_6185658_1648882_1_1">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_6185658_1648882_6_1">Net increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_lbl" xml:lang="en-US" id="id_6185658_1749159_3_1">Cash and Investments in Marketable Securities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_lbl" xml:lang="en-US" id="id_6185658_1749159_1_1">Cash and Investments in Marketable Securities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_lbl" xml:lang="en-US" id="id_6185658_1749159_2_1">Cash and Investments in Marketable Securities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesTable_lbl" xml:lang="en-US" id="id_6185658_1908775_3_1">Cash and Investments in Marketable Securities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesTable_lbl" xml:lang="en-US" id="id_6185658_1908775_1_1">Cash and Investments in Marketable Securities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesTable_lbl" xml:lang="en-US" id="id_6185658_1908775_2_1">Cash and Investments in Marketable Securities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:to="nktr_CashAndInvestmentsInMarketableSecuritiesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_CashAndRestrictedCash" xlink:label="nktr_CashAndRestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_CashAndRestrictedCash_lbl" xml:lang="en-US" id="id_6185658_1839184_3_1">Cash And Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_CashAndRestrictedCash_lbl" xml:lang="en-US" id="id_6185658_1839184_1_1">Cash And Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_CashAndRestrictedCash_lbl" xml:lang="en-US" id="id_6185658_1839184_2_1">Cash, including restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_CashAndRestrictedCash" xlink:to="nktr_CashAndRestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_lbl" xml:lang="en-US" id="id_6185658_1919004_3_1">Cash, Restricted Cash, Cash Equivalents, And Available For Sale Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_lbl" xml:lang="en-US" id="id_6185658_1919004_1_1">Cash, Restricted Cash, Cash Equivalents, And Available For Sale Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_lbl" xml:lang="en-US" id="id_6185658_1919004_2_1">Cash and investments in marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_lbl" xml:lang="en-US" id="id_6185658_1919004_6_1">Total cash and investments in marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xml:lang="en-US" id="id_6185658_1640681_1_1">Certificates of Deposit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xml:lang="en-US" id="id_6185658_1640681_2_1">Certificates of Deposit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6185658_1636286_1_1">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6185658_1636286_2_1">License and Collaboration Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_6185658_1646952_1_1">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_6185658_1646952_2_1">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_6185658_1640697_1_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_6185658_1640697_2_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6185658_1641131_1_1">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6185658_1641131_2_1">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_6185658_1637092_1_1">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_6185658_1637092_2_1">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_6185658_1633455_1_1">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_6185658_1633455_2_1">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_6185658_1641977_1_1">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_6185658_1641977_2_1">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6185658_1635113_1_1">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6185658_1635113_2_1">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_6185658_1646846_1_1">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_6185658_1646846_2_1">Common stock, $0.0001 par value, 300,000 authorized; 132,185 shares and 131,216 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="id_6185658_1646845_1_1">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="id_6185658_1646845_2_1">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_ConsiderationReceivedForProductDelivered" xlink:label="nktr_ConsiderationReceivedForProductDelivered"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_ConsiderationReceivedForProductDelivered_lbl" xml:lang="en-US" id="id_6185658_1748115_3_1">Consideration received for product delivered.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_ConsiderationReceivedForProductDelivered_lbl" xml:lang="en-US" id="id_6185658_1748115_1_1">Consideration Received for Product Delivered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_ConsiderationReceivedForProductDelivered_lbl" xml:lang="en-US" id="id_6185658_1748115_2_1">Consideration received for product delivered in 2013</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ConsiderationReceivedForProductDelivered" xlink:to="nktr_ConsiderationReceivedForProductDelivered_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" id="id_6185658_1638320_1_1">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" id="id_6185658_1638320_2_1">Basis of Presentation and Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xml:lang="en-US" id="id_6185658_1636295_1_1">Contingent Consideration by Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xml:lang="en-US" id="id_6185658_1636295_2_1">Contingent Consideration by Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xml:lang="en-US" id="id_6185658_1637095_1_1">Contingent Consideration Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xml:lang="en-US" id="id_6185658_1637095_2_1">Contingent Consideration Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents" xlink:label="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents_lbl" xml:lang="en-US" id="id_6185658_1844591_3_1">Contingent payments receivable based on development events.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents_lbl" xml:lang="en-US" id="id_6185658_1844591_1_1">Contingent Payments Receivable Based On Development Events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents_lbl" xml:lang="en-US" id="id_6185658_1844591_2_1">Contingent payments receivable based on development events regulatory to be pursued and completed solely by others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents" xlink:to="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_CorporateCommercialPaperMember" xlink:label="nktr_CorporateCommercialPaperMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_CorporateCommercialPaperMember_lbl" xml:lang="en-US" id="id_6185658_1671183_3_1">Corporate Commercial Paper [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_CorporateCommercialPaperMember_lbl" xml:lang="en-US" id="id_6185658_1671183_1_1">Corporate Commercial Paper [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_CorporateCommercialPaperMember_lbl" xml:lang="en-US" id="id_6185658_1671183_2_1">Corporate Commercial Paper [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_CorporateCommercialPaperMember" xlink:to="nktr_CorporateCommercialPaperMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" id="id_6185658_1633464_1_1">Corporate Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" id="id_6185658_1633464_2_1">Corporate Notes and Bonds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US" id="id_6185658_1650908_1_1">Cost of Goods Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US" id="id_6185658_1650908_2_1">Cost of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" id="id_6185658_1638321_1_1">Cost of Sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" id="id_6185658_1638321_2_1">Cost of Goods Sold [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" id="id_6185658_1649274_1_1">Costs and Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" id="id_6185658_1649274_6_1">Total operating costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" id="id_6185658_1639495_1_1">Costs and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" id="id_6185658_1639495_2_1">Operating costs and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_6185658_1638733_1_1">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_6185658_1638733_2_1">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" id="id_6185658_1639882_1_1">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" id="id_6185658_1639882_2_1">Senior secured notes, interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" id="id_6185658_1635899_1_1">Debt Instrument, Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" id="id_6185658_1635899_2_1">Senior secured notes, maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_DebtInvestmentMaturityDateDescription" xlink:label="nktr_DebtInvestmentMaturityDateDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_DebtInvestmentMaturityDateDescription_lbl" xml:lang="en-US" id="id_6185658_1778253_3_1">Debt investment maturity date description.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_DebtInvestmentMaturityDateDescription_lbl" xml:lang="en-US" id="id_6185658_1778253_1_1">Debt Investment Maturity Date Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_DebtInvestmentMaturityDateDescription_lbl" xml:lang="en-US" id="id_6185658_1778253_2_1">Weighted average maturity term for debt securities investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_DebtInvestmentMaturityDateDescription" xlink:to="nktr_DebtInvestmentMaturityDateDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_DebtInvestmentMaximumMaturityPeriod" xlink:label="nktr_DebtInvestmentMaximumMaturityPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_DebtInvestmentMaximumMaturityPeriod_lbl" xml:lang="en-US" id="id_6185658_1853043_3_1">Debt investment maximum maturity period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_DebtInvestmentMaximumMaturityPeriod_lbl" xml:lang="en-US" id="id_6185658_1853043_1_1">Debt Investment Maximum Maturity Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_DebtInvestmentMaximumMaturityPeriod_lbl" xml:lang="en-US" id="id_6185658_1853043_2_1">Maximum maturity term for debt securities investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_DebtInvestmentMaximumMaturityPeriod" xlink:to="nktr_DebtInvestmentMaximumMaturityPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_6185658_1645505_1_1">Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_6185658_1645505_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueArrangementByTypeTable_lbl" xml:lang="en-US" id="id_6185658_1637935_1_1">Deferred Revenue Arrangement, by Type [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueArrangementByTypeTable_lbl" xml:lang="en-US" id="id_6185658_1637935_2_1">Deferred Revenue Arrangement, by Type [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_DeferredRevenueArrangementByTypeTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="us-gaap_DeferredRevenueArrangementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueArrangementLineItems_lbl" xml:lang="en-US" id="id_6185658_1639887_1_1">Deferred Revenue Arrangement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueArrangementLineItems_lbl" xml:lang="en-US" id="id_6185658_1639887_2_1">Deferred Revenue Arrangement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenueArrangementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xml:lang="en-US" id="id_6185658_1643986_1_1">Deferred Revenue Arrangement Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xml:lang="en-US" id="id_6185658_1643986_2_1">Deferred Revenue Arrangement Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xml:lang="en-US" id="id_6185658_1640271_1_1">Deferred Revenue [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xml:lang="en-US" id="id_6185658_1640271_2_1">Deferred Revenue [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_6185658_1646286_1_1">Deferred Revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_6185658_1646286_2_1">Deferred revenue, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_6185658_1646837_1_1">Deferred Revenue, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_6185658_1646837_2_1">Deferred revenue, less current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" id="id_6185658_1651177_1_1">Depreciation, Depletion and Amortization, Nonproduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" id="id_6185658_1651177_2_1">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_6185658_1640297_1_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_6185658_1640297_2_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_6185658_1642836_1_1">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_6185658_1642836_2_1">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_DocumentAndEntityInformationAbstract" xlink:label="nktr_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_6185658_1666892_3_1">Document and entity information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_6185658_1666892_1_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_6185658_1666892_2_1">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="nktr_DocumentAndEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_6185658_1631516_1_1">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_6185658_1631516_2_1">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_6185658_1633130_1_1">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_6185658_1633130_2_1">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_6185658_1642039_1_1">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_6185658_1642039_2_1">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_6185658_1634742_1_1">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_6185658_1634742_2_1">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_6185658_1633917_1_1">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_6185658_1633917_2_1">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_6185658_1634329_1_1">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_6185658_1634329_2_1">Basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_6185658_1644008_1_1">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_6185658_1644008_2_1">Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" id="id_6185658_1644010_1_1">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" id="id_6185658_1644010_2_1">Effective income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US" id="id_6185658_1650530_1_1">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US" id="id_6185658_1650530_2_1">Effect of exchange rates on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6185658_1644907_1_1">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6185658_1644907_2_1">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_6185658_1639519_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_6185658_1639519_2_1">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_6185658_1633925_1_1">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_6185658_1633925_2_1">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_6185658_1634753_1_1">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_6185658_1634753_2_1">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6185658_1635556_1_1">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6185658_1635556_2_1">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_6185658_1640311_1_1">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_6185658_1640311_2_1">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_6185658_1635557_1_1">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_6185658_1635557_2_1">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_6185658_1639155_1_1">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_6185658_1639155_2_1">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_EstimatedAnnualInterestRateOnRoyaltyLiability" xlink:label="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability_lbl" xml:lang="en-US" id="id_6185658_1782743_3_1">Estimated Annual Interest Rate On Royalty Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability_lbl" xml:lang="en-US" id="id_6185658_1782743_1_1">Estimated Annual Interest Rate On Royalty Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability_lbl" xml:lang="en-US" id="id_6185658_1782743_2_1">Annual interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability" xlink:to="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="us-gaap_EuropeanUnionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EuropeanUnionMember_lbl" xml:lang="en-US" id="id_6185658_1632305_1_1">European Union [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EuropeanUnionMember_lbl" xml:lang="en-US" id="id_6185658_1632305_2_1">European Union [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EuropeanUnionMember" xlink:to="us-gaap_EuropeanUnionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_6185658_1633150_1_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_6185658_1633150_2_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_6185658_1636361_1_1">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_6185658_1636361_2_1">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" id="id_6185658_1645487_1_1">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" id="id_6185658_1645487_2_1">Level 1 to level 2 transfers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" id="id_6185658_1645488_1_1">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" id="id_6185658_1645488_2_1">Level 2 to level 1 transfers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" id="id_6185658_1631919_1_1">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" id="id_6185658_1631919_2_1">Portfolio of Cash and Investments in Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_6185658_1634760_1_1">Fair Value, Hierarchy [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_6185658_1634760_2_1">Fair Value, Hierarchy [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_6185658_1642853_1_1">Fair Value Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_6185658_1642853_2_1">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" id="id_6185658_1637542_1_1">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" id="id_6185658_1637542_2_1">Cash and Investments in Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_6185658_1643241_1_1">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_6185658_1643241_2_1">Fair Value Hierarchy Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_6185658_1637150_1_1">Fair Value, Inputs, Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_6185658_1637150_2_1">Fair Value Hierarchy Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_6185658_1634767_1_1">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_6185658_1634767_2_1">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_6185658_1637995_1_1">Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_6185658_1637995_2_1">Fair Value Hierarchy [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xml:lang="en-US" id="id_6185658_1640338_1_1">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xml:lang="en-US" id="id_6185658_1640338_2_1">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_FovistaMember" xlink:label="nktr_FovistaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_FovistaMember_lbl" xml:lang="en-US" id="id_6185658_1656106_3_1">Fovista.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_FovistaMember_lbl" xml:lang="en-US" id="id_6185658_1656106_1_1">Fovista [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_FovistaMember_lbl" xml:lang="en-US" id="id_6185658_1656106_2_1">Fovista [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_FovistaMember" xlink:to="nktr_FovistaMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_6185658_1650296_1_1">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_6185658_1650296_2_1">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_6185658_1639948_1_1">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_6185658_1639948_2_1">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" id="id_6185658_1650936_1_1">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" id="id_6185658_1650936_2_1">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_HemophiliaMember" xlink:label="nktr_HemophiliaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_HemophiliaMember_lbl" xml:lang="en-US" id="id_6185658_1715959_3_1">Hemophilia.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_HemophiliaMember_lbl" xml:lang="en-US" id="id_6185658_1715959_1_1">Hemophilia [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_HemophiliaMember_lbl" xml:lang="en-US" id="id_6185658_1715959_2_1">BAX 855 (Hemophilia) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_HemophiliaMember" xlink:to="nktr_HemophiliaMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="id_6185658_1647034_1_1">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="id_6185658_1647034_6_1">Loss before provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_6185658_1631567_1_1">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_6185658_1631567_2_1">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_6185658_1634394_1_1">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_6185658_1634394_2_1">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_6185658_1635998_1_1">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_6185658_1635998_2_1">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6185658_1648041_1_1">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_6185658_1648041_2_1">Provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_6185658_1644088_1_1">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_6185658_1644088_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_6185658_1651075_1_1">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_6185658_1651075_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_6185658_1645919_1_1">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_6185658_1645919_14_1">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses" xlink:label="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses_lbl" xml:lang="en-US" id="id_6185658_1713037_3_1">Accrued clinical trial expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses_lbl" xml:lang="en-US" id="id_6185658_1713037_1_1">Increase Decrease In Accrued Clinical Trial Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses_lbl" xml:lang="en-US" id="id_6185658_1713037_2_1">Accrued clinical trial expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses" xlink:to="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_6185658_1648681_1_1">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_6185658_1648681_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US" id="id_6185658_1649667_1_1">Increase (Decrease) in Employee Related Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US" id="id_6185658_1649667_2_1">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" id="id_6185658_1645450_1_1">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" id="id_6185658_1645450_14_1">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_6185658_1631969_1_1">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_6185658_1631969_2_1">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US" id="id_6185658_1648801_1_1">Increase (Decrease) in Other Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US" id="id_6185658_1648801_2_1">Other accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" id="id_6185658_1645451_1_1">Increase (Decrease) in Other Operating Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" id="id_6185658_1645451_14_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" id="id_6185658_1649797_1_1">Increase (Decrease) in Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" id="id_6185658_1649797_2_1">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_IncreaseDecreaseInRevenue" xlink:label="nktr_IncreaseDecreaseInRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_IncreaseDecreaseInRevenue_lbl" xml:lang="en-US" id="id_6185658_1871431_3_1">Increase Decrease In Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_IncreaseDecreaseInRevenue_lbl" xml:lang="en-US" id="id_6185658_1871431_1_1">Increase Decrease In Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_IncreaseDecreaseInRevenue_lbl" xml:lang="en-US" id="id_6185658_1871431_2_1">Reduction of revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_IncreaseDecreaseInRevenue" xlink:to="nktr_IncreaseDecreaseInRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="us-gaap_IndemnificationGuaranteeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndemnificationGuaranteeMember_lbl" xml:lang="en-US" id="id_6185658_1634809_1_1">Indemnification Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndemnificationGuaranteeMember_lbl" xml:lang="en-US" id="id_6185658_1634809_2_1">Indemnification Obligation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndemnificationGuaranteeMember" xlink:to="us-gaap_IndemnificationGuaranteeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="id_6185658_1649043_1_1">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="id_6185658_1649043_14_1">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" id="id_6185658_1644975_1_1">Interest Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" id="id_6185658_1644975_2_1">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" id="id_6185658_1647684_1_1">Interest Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" id="id_6185658_1647684_2_1">Interest payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US" id="id_6185658_1640385_1_1">Inventory Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US" id="id_6185658_1640385_2_1">Inventory Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6185658_1639585_1_1">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" id="id_6185658_1639585_2_1">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US" id="id_6185658_1649935_1_1">Inventory, Finished Goods, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US" id="id_6185658_1649935_2_1">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" id="id_6185658_1649181_1_1">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" id="id_6185658_1649181_2_1">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" id="id_6185658_1649181_6_1">Total inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US" id="id_6185658_1651473_1_1">Inventory, Raw Materials, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US" id="id_6185658_1651473_2_1">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US" id="id_6185658_1648064_1_1">Inventory, Work in Process, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US" id="id_6185658_1648064_2_1">Work-in-process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" id="id_6185658_1651716_1_1">Investments, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" id="id_6185658_1651716_2_1">Investments in marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" id="id_6185658_1643713_1_1">Investment Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" id="id_6185658_1643713_2_1">Investment Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" id="id_6185658_1635220_1_1">Investments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" id="id_6185658_1635220_2_1">Investments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_6185658_1633579_1_1">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_6185658_1633579_2_1">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_6185658_1646694_1_1">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_6185658_1646694_6_1">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_6185658_1646695_1_1">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_6185658_1646695_6_1">Total liabilities and stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6185658_1636826_1_1">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6185658_1636826_2_1">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6185658_1647463_1_1">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6185658_1647463_6_1">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_6185658_1639229_1_1">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_6185658_1639229_2_1">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments" xlink:label="nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments_lbl" xml:lang="en-US" id="id_6185658_1803909_3_1">Liability to AZ for DTC advertising payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments_lbl" xml:lang="en-US" id="id_6185658_1803909_1_1">Liabilities To Partners For Direct Consumer Advertising Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments_lbl" xml:lang="en-US" id="id_6185658_1803909_2_1">Liability to AZ for DTC advertising payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments" xlink:to="nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_lbl" xml:lang="en-US" id="id_6185658_1758808_3_1">Liability Related to Sale of Future Royalties [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_lbl" xml:lang="en-US" id="id_6185658_1758808_1_1">Liability Related to Sale of Future Royalties [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_lbl" xml:lang="en-US" id="id_6185658_1758808_2_1">Liability Related to Sale of Future Royalties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_lbl" xml:lang="en-US" id="id_6185658_1978832_3_1">Liability related to sale of future royalties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_lbl" xml:lang="en-US" id="id_6185658_1978832_1_1">Liability Related To Sale Of Future Royalties [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_lbl" xml:lang="en-US" id="id_6185658_1978832_2_1">Liability Related to Sale of Future Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" xlink:to="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_lbl" xml:lang="en-US" id="id_6185658_1868363_3_1">Liability Related to Sale of Future Royalties [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_lbl" xml:lang="en-US" id="id_6185658_1868363_1_1">Liability Related to Sale of Future Royalties [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_lbl" xml:lang="en-US" id="id_6185658_1868363_2_1">Liability Related to Sale of Future Royalties [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:to="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_lbl" xml:lang="en-US" id="id_6185658_1695216_3_1">Liability Related To Sale Of Potential Future Royalties Non Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_lbl" xml:lang="en-US" id="id_6185658_1695216_1_1">Liability Related To Sale Of Potential Future Royalties Non Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_lbl" xml:lang="en-US" id="id_6185658_1695216_2_1">Liability related to sale of future royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:to="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_lbl" xml:lang="en-US" id="id_6185658_1742692_3_1">Liability related to sale of potential future royalties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_lbl" xml:lang="en-US" id="id_6185658_1742692_1_1">Liability Related To Sale Of Potential Future Royalties [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_lbl" xml:lang="en-US" id="id_6185658_1742692_2_1">Liability Related to Sale of Future Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:to="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LicenseAndCollaborationAgreementsAbstract" xlink:label="nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_LicenseAndCollaborationAgreementsAbstract_lbl" xml:lang="en-US" id="id_6185658_1957517_3_1">License and collaboration agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_LicenseAndCollaborationAgreementsAbstract_lbl" xml:lang="en-US" id="id_6185658_1957517_1_1">License And Collaboration Agreements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_LicenseAndCollaborationAgreementsAbstract_lbl" xml:lang="en-US" id="id_6185658_1957517_2_1">License And Collaboration Agreements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LicenseAndCollaborationAgreementsAbstract" xlink:to="nktr_LicenseAndCollaborationAgreementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LicenseAndCollaborationAgreementsLineItems" xlink:label="nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_LicenseAndCollaborationAgreementsLineItems_lbl" xml:lang="en-US" id="id_6185658_1877782_3_1">License and collaboration agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_LicenseAndCollaborationAgreementsLineItems_lbl" xml:lang="en-US" id="id_6185658_1877782_1_1">License And Collaboration Agreements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_LicenseAndCollaborationAgreementsLineItems_lbl" xml:lang="en-US" id="id_6185658_1877782_2_1">License And Collaboration Agreements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LicenseAndCollaborationAgreementsLineItems" xlink:to="nktr_LicenseAndCollaborationAgreementsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LicenseAndCollaborationAgreementsTable" xlink:label="nktr_LicenseAndCollaborationAgreementsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_LicenseAndCollaborationAgreementsTable_lbl" xml:lang="en-US" id="id_6185658_1808433_3_1">License and collaboration agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_LicenseAndCollaborationAgreementsTable_lbl" xml:lang="en-US" id="id_6185658_1808433_1_1">License And Collaboration Agreements [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_LicenseAndCollaborationAgreementsTable_lbl" xml:lang="en-US" id="id_6185658_1808433_2_1">License And Collaboration Agreements [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LicenseAndCollaborationAgreementsTable" xlink:to="nktr_LicenseAndCollaborationAgreementsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LicenseCollaborationOtherRevenue" xlink:label="nktr_LicenseCollaborationOtherRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_LicenseCollaborationOtherRevenue_lbl" xml:lang="en-US" id="id_6185658_1938095_3_1">Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_LicenseCollaborationOtherRevenue_lbl" xml:lang="en-US" id="id_6185658_1938095_1_1">License Collaboration Other Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_LicenseCollaborationOtherRevenue_lbl" xml:lang="en-US" id="id_6185658_1938095_2_1">License, collaboration and other revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_LicenseCollaborationOtherRevenue" xlink:to="nktr_LicenseCollaborationOtherRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" id="id_6185658_1645693_1_1">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" id="id_6185658_1645693_2_1">Long-term debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" id="id_6185658_1643325_1_1">Long-term Debt, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" id="id_6185658_1643325_2_1">Long-term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" id="id_6185658_1640415_1_1">Long-term Debt, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" id="id_6185658_1640415_2_1">Long-term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xml:lang="en-US" id="id_6185658_1640416_1_1">Loss Contingency Nature [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xml:lang="en-US" id="id_6185658_1640416_2_1">Loss Contingency Nature [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" id="id_6185658_1637626_1_1">Loss Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" id="id_6185658_1637626_2_1">Loss Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" id="id_6185658_1643738_1_1">Loss Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" id="id_6185658_1643738_2_1">Loss Contingencies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xml:lang="en-US" id="id_6185658_1647672_1_1">Loss Contingency Accrual</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xml:lang="en-US" id="id_6185658_1647672_2_1">Indemnification obligations, liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xml:lang="en-US" id="id_6185658_1642550_1_1">Loss Contingency, Nature [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xml:lang="en-US" id="id_6185658_1642550_2_1">Loss Contingency, Nature [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_LossContingencyNatureDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_MilestoneScenarioOneMember" xlink:label="nktr_MilestoneScenarioOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_MilestoneScenarioOneMember_lbl" xml:lang="en-US" id="id_6185658_1787206_3_1">Milestone Scenario One.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_MilestoneScenarioOneMember_lbl" xml:lang="en-US" id="id_6185658_1787206_1_1">Milestone Scenario One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_MilestoneScenarioOneMember_lbl" xml:lang="en-US" id="id_6185658_1787206_2_1">Milestone Scenario One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_MilestoneScenarioOneMember" xlink:to="nktr_MilestoneScenarioOneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_MilestoneScenarioTwoMember" xlink:label="nktr_MilestoneScenarioTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_MilestoneScenarioTwoMember_lbl" xml:lang="en-US" id="id_6185658_1698241_3_1">Milestone Scenario Two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_MilestoneScenarioTwoMember_lbl" xml:lang="en-US" id="id_6185658_1698241_1_1">Milestone Scenario Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_MilestoneScenarioTwoMember_lbl" xml:lang="en-US" id="id_6185658_1698241_2_1">Milestone Scenario Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_MilestoneScenarioTwoMember" xlink:to="nktr_MilestoneScenarioTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_MirceraMember" xlink:label="nktr_MirceraMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_MirceraMember_lbl" xml:lang="en-US" id="id_6185658_1950545_3_1">Mircera.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_MirceraMember_lbl" xml:lang="en-US" id="id_6185658_1950545_1_1">Mircera [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_MirceraMember_lbl" xml:lang="en-US" id="id_6185658_1950545_2_1">MIRCERA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_MirceraMember" xlink:to="nktr_MirceraMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" id="id_6185658_1637231_1_1">Money Market Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" id="id_6185658_1637231_2_1">Money Market Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" xlink:label="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember_lbl" xml:lang="en-US" id="id_6185658_1710542_3_1">Movantik And Movantik Fixed Dose Combination Program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember_lbl" xml:lang="en-US" id="id_6185658_1710542_1_1">Movantik And Movantik Fixed Dose Combination Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember_lbl" xml:lang="en-US" id="id_6185658_1710542_2_1">MOVANTIKTM (NKTR-118) and MOVANTIKTM fixed-dose combination program (NKTR-119) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" xlink:to="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_MovantikFixedDoseCombinationProgramMember" xlink:label="nktr_MovantikFixedDoseCombinationProgramMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_MovantikFixedDoseCombinationProgramMember_lbl" xml:lang="en-US" id="id_6185658_1722353_3_1">Movantik Fixed Dose Combination Program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_MovantikFixedDoseCombinationProgramMember_lbl" xml:lang="en-US" id="id_6185658_1722353_1_1">Movantik Fixed Dose Combination Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_MovantikFixedDoseCombinationProgramMember_lbl" xml:lang="en-US" id="id_6185658_1722353_2_1">Movantik Fixed-dose Combination Program [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_MovantikFixedDoseCombinationProgramMember" xlink:to="nktr_MovantikFixedDoseCombinationProgramMember_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_MovantikMember" xlink:label="nktr_MovantikMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_MovantikMember_lbl" xml:lang="en-US" id="id_6185658_1689625_3_1">Movantik.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_MovantikMember_lbl" xml:lang="en-US" id="id_6185658_1689625_1_1">Movantik [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_MovantikMember_lbl" xml:lang="en-US" id="id_6185658_1689625_2_1">MOVANTIK [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_MovantikMember" xlink:to="nktr_MovantikMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfReportingCategoryDomain" xlink:label="us-gaap_NameOfReportingCategoryDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NameOfReportingCategoryDomain_lbl" xml:lang="en-US" id="id_6185658_1635263_1_1">Name of Reporting Category [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NameOfReportingCategoryDomain_lbl" xml:lang="en-US" id="id_6185658_1635263_2_1">Name of Reporting Category [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NameOfReportingCategoryDomain" xlink:to="us-gaap_NameOfReportingCategoryDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6185658_1649336_1_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6185658_1649336_6_1">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6185658_1633620_1_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6185658_1633620_2_1">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6185658_1649062_1_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6185658_1649062_6_1">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6185658_1638471_1_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_6185658_1638471_2_1">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_6185658_1638472_1_1">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_6185658_1638472_2_1">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6185658_1631616_1_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_6185658_1631616_6_1">Net cash provided by (used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_6185658_1644530_1_1">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_6185658_1644530_2_1">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_6185658_1644530_6_1">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_NeulastaMember" xlink:label="nktr_NeulastaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_NeulastaMember_lbl" xml:lang="en-US" id="id_6185658_1746553_3_1">Neulasta.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_NeulastaMember_lbl" xml:lang="en-US" id="id_6185658_1746553_1_1">Neulasta [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_NeulastaMember_lbl" xml:lang="en-US" id="id_6185658_1746553_2_1">Neulasta [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_NeulastaMember" xlink:to="nktr_NeulastaMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_6185658_1642952_1_1">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_6185658_1642952_2_1">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:label="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_lbl" xml:lang="en-US" id="id_6185658_1661738_3_1">Non-cash interest expense related to sale of royalties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_lbl" xml:lang="en-US" id="id_6185658_1661738_1_1">Non Cash Interest Expense Related to Sale of Royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_lbl" xml:lang="en-US" id="id_6185658_1661738_2_1">Non-cash interest expense on liability related to sale of future royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_lbl" xml:lang="en-US" id="id_6185658_1661738_14_1">Non-cash interest expense on liability related to sale of future royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:to="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_lbl" xml:lang="en-US" id="id_6185658_1860667_3_1">Non cash royalty revenue related to sale future royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_lbl" xml:lang="en-US" id="id_6185658_1860667_1_1">Non Cash Royalty Revenue Related To Sale Of Future Royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_lbl" xml:lang="en-US" id="id_6185658_1860667_2_1">Non-cash royalty revenue related to sale of future royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_lbl" xml:lang="en-US" id="id_6185658_1860667_14_1">Non-cash royalty revenue related to sale of future royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:to="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_6185658_1645682_1_1">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_6185658_1645682_6_1">Total non-operating expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="id_6185658_1631622_1_1">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="id_6185658_1631622_2_1">Non-operating income (expense):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="id_6185658_1632417_1_1">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="id_6185658_1632417_2_1">Number of business segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_6185658_1645424_1_1">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_6185658_1645424_6_1">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_OphthotechCorporationMember" xlink:label="nktr_OphthotechCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_OphthotechCorporationMember_lbl" xml:lang="en-US" id="id_6185658_1738293_3_1">Ophthotech Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_OphthotechCorporationMember_lbl" xml:lang="en-US" id="id_6185658_1738293_1_1">Ophthotech Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_OphthotechCorporationMember_lbl" xml:lang="en-US" id="id_6185658_1738293_2_1">Ophthotech Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_OphthotechCorporationMember" xlink:to="nktr_OphthotechCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_6185658_1641734_1_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_6185658_1641734_2_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_6185658_1639641_1_1">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_6185658_1639641_2_1">Organization and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_OrganizationPolicyTextBlock" xlink:label="nktr_OrganizationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_OrganizationPolicyTextBlock_lbl" xml:lang="en-US" id="id_6185658_1755066_3_1">Organization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_OrganizationPolicyTextBlock_lbl" xml:lang="en-US" id="id_6185658_1755066_1_1">Organization Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_OrganizationPolicyTextBlock_lbl" xml:lang="en-US" id="id_6185658_1755066_2_1">Organization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_OrganizationPolicyTextBlock" xlink:to="nktr_OrganizationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6185658_1644757_1_1">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6185658_1644757_2_1">Other accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" id="id_6185658_1650088_1_1">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" id="id_6185658_1650088_2_1">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="id_6185658_1648447_1_1">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="id_6185658_1648447_2_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_lbl" xml:lang="en-US" id="id_6185658_1638889_1_1">Other Current Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_lbl" xml:lang="en-US" id="id_6185658_1638889_2_1">Other Current Liabilities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesMember" xlink:to="us-gaap_OtherCurrentLiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6185658_1645991_1_1">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_6185658_1645991_2_1">Other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US" id="id_6185658_1638486_1_1">Other Liabilities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US" id="id_6185658_1638486_2_1">Other Liabilities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_6185658_1645291_1_1">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_6185658_1645291_2_1">Other long-term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" id="id_6185658_1647909_1_1">Other Noncash Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" id="id_6185658_1647909_14_1">Other non-cash transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xml:lang="en-US" id="id_6185658_1635282_1_1">Other Noncurrent Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xml:lang="en-US" id="id_6185658_1635282_2_1">Other Long-Term Liabilities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_6185658_1645664_1_1">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_6185658_1645664_2_1">Interest income and other income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_OtherPartnerMember" xlink:label="nktr_OtherPartnerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_OtherPartnerMember_lbl" xml:lang="en-US" id="id_6185658_1888068_3_1">Other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_OtherPartnerMember_lbl" xml:lang="en-US" id="id_6185658_1888068_1_1">Other Partner [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_OtherPartnerMember_lbl" xml:lang="en-US" id="id_6185658_1888068_2_1">Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_OtherPartnerMember" xlink:to="nktr_OtherPartnerMember_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PaymentForReimbursementOfCosts" xlink:label="nktr_PaymentForReimbursementOfCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_PaymentForReimbursementOfCosts_lbl" xml:lang="en-US" id="id_6185658_1735275_3_1">Payment made to Bayer for cost of Phase 3 clinical trial.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_PaymentForReimbursementOfCosts_lbl" xml:lang="en-US" id="id_6185658_1735275_1_1">Payment For Reimbursement Of Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_PaymentForReimbursementOfCosts_lbl" xml:lang="en-US" id="id_6185658_1735275_2_1">Payment made to Bayer for cost of Phase 3 clinical trial</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PaymentForReimbursementOfCosts" xlink:to="nktr_PaymentForReimbursementOfCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearOne_lbl" xml:lang="en-US" id="id_6185658_1857056_3_1">Payment Made For Milestone Not Achieved Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearOne_lbl" xml:lang="en-US" id="id_6185658_1857056_1_1">Payment Made For Milestone Not Achieved Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearOne_lbl" xml:lang="en-US" id="id_6185658_1857056_2_1">Payment made for milestone not achieved year one</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:to="nktr_PaymentMadeForMilestoneNotAchievedYearOne_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearTwo_lbl" xml:lang="en-US" id="id_6185658_1938055_3_1">Payment Made For Milestone Not Achieved Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearTwo_lbl" xml:lang="en-US" id="id_6185658_1938055_1_1">Payment Made For Milestone Not Achieved Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearTwo_lbl" xml:lang="en-US" id="id_6185658_1938055_2_1">Payment made for milestone not achieved year two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:to="nktr_PaymentMadeForMilestoneNotAchievedYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_6185658_1647771_1_1">Payments to Acquire Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_6185658_1647771_14_1">Purchases of investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_6185658_1644389_1_1">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_6185658_1644389_14_1">Purchases of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PegasysAndMirceraMember" xlink:label="nktr_PegasysAndMirceraMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_PegasysAndMirceraMember_lbl" xml:lang="en-US" id="id_6185658_1849413_3_1">Pegasys And Mircera.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_PegasysAndMirceraMember_lbl" xml:lang="en-US" id="id_6185658_1849413_1_1">Pegasys And Mircera [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_PegasysAndMirceraMember_lbl" xml:lang="en-US" id="id_6185658_1849413_2_1">PEGASYS and MIRCERA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PegasysAndMirceraMember" xlink:to="nktr_PegasysAndMirceraMember_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PegasysMember" xlink:label="nktr_PegasysMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_PegasysMember_lbl" xml:lang="en-US" id="id_6185658_1905729_3_1">Pegasys.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_PegasysMember_lbl" xml:lang="en-US" id="id_6185658_1905729_1_1">Pegasys [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_PegasysMember_lbl" xml:lang="en-US" id="id_6185658_1905729_2_1">PEGASYS [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PegasysMember" xlink:to="nktr_PegasysMember_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PercentageOfPostApprovalStudyCostsToRepay" xlink:label="nktr_PercentageOfPostApprovalStudyCostsToRepay"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_PercentageOfPostApprovalStudyCostsToRepay_lbl" xml:lang="en-US" id="id_6185658_1734283_3_1">Percentage of post approval study costs to repay.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_PercentageOfPostApprovalStudyCostsToRepay_lbl" xml:lang="en-US" id="id_6185658_1734283_1_1">Percentage of Post Approval Study Costs to Repay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_PercentageOfPostApprovalStudyCostsToRepay_lbl" xml:lang="en-US" id="id_6185658_1734283_2_1">Percentage of post approval study costs to repay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PercentageOfPostApprovalStudyCostsToRepay" xlink:to="nktr_PercentageOfPostApprovalStudyCostsToRepay_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PerformanceMilestonePaymentsMember" xlink:label="nktr_PerformanceMilestonePaymentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_PerformanceMilestonePaymentsMember_lbl" xml:lang="en-US" id="id_6185658_1836928_3_1">Performance Milestone Payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_PerformanceMilestonePaymentsMember_lbl" xml:lang="en-US" id="id_6185658_1836928_1_1">Performance Milestone Payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_PerformanceMilestonePaymentsMember_lbl" xml:lang="en-US" id="id_6185658_1836928_2_1">Performance-based Milestone Payments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PerformanceMilestonePaymentsMember" xlink:to="nktr_PerformanceMilestonePaymentsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PotentialDevelopmentMilestones" xlink:label="nktr_PotentialDevelopmentMilestones"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_PotentialDevelopmentMilestones_lbl" xml:lang="en-US" id="id_6185658_1885896_3_1">Potential development milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_PotentialDevelopmentMilestones_lbl" xml:lang="en-US" id="id_6185658_1885896_1_1">Potential Development Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_PotentialDevelopmentMilestones_lbl" xml:lang="en-US" id="id_6185658_1885896_2_1">Potential future additional payments for development milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PotentialDevelopmentMilestones" xlink:to="nktr_PotentialDevelopmentMilestones_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies" xlink:label="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies_lbl" xml:lang="en-US" id="id_6185658_1670076_3_1">Potential Reduction In Future Royalty Payments To Repay Post Approval Studies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies_lbl" xml:lang="en-US" id="id_6185658_1670076_1_1">Potential Reduction In Future Royalty Payments To Repay Post Approval Studies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies_lbl" xml:lang="en-US" id="id_6185658_1670076_2_1">Maximum potential reduction in royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies" xlink:to="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired" xlink:label="nktr_PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired_lbl" xml:lang="en-US" id="id_6185658_1979777_3_1">Potential royalty reduction on sales to repay post-approval study if required.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired_lbl" xml:lang="en-US" id="id_6185658_1979777_1_1">Potential Royalty Reduction On Sales To Repay Post Approval Study If Required</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired_lbl" xml:lang="en-US" id="id_6185658_1979777_2_1">Potential reduction in U.S. royalty rate for repayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired" xlink:to="nktr_PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_6185658_1642594_1_1">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_6185658_1642594_2_1">Preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PreferredStockShareDesignated" xlink:label="nktr_PreferredStockShareDesignated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_PreferredStockShareDesignated_lbl" xml:lang="en-US" id="id_6185658_1874170_3_1">Preferred stock, shares designated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_PreferredStockShareDesignated_lbl" xml:lang="en-US" id="id_6185658_1874170_1_1">Preferred Stock Share Designated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_PreferredStockShareDesignated_lbl" xml:lang="en-US" id="id_6185658_1874170_2_1">Preferred stock, shares designated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PreferredStockShareDesignated" xlink:to="nktr_PreferredStockShareDesignated_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_6185658_1639289_1_1">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_6185658_1639289_2_1">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_6185658_1640465_1_1">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_6185658_1640465_2_1">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6185658_1634872_1_1">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_6185658_1634872_2_1">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_6185658_1647540_1_1">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_6185658_1647540_2_1">Preferred stock, $0.0001 par value, 10,000 shares authorized, no shares designated, issued or outstanding at June 30, 2015 or December 31, 2014</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis" xlink:label="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis_lbl" xml:lang="en-US" id="id_6185658_1632061_1_1">Principal Transaction Revenue, Description of Reporting Category [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis_lbl" xml:lang="en-US" id="id_6185658_1632061_2_1">Principal Transaction Revenue, Description of Reporting Category [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis" xlink:to="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US" id="id_6185658_1641315_1_1">Reclassification, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US" id="id_6185658_1641315_2_1">Reclassifications</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_lbl" xml:lang="en-US" id="id_6185658_1939521_3_1">Proceeds From Issuance Of Common Stock Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_lbl" xml:lang="en-US" id="id_6185658_1939521_1_1">Proceeds From Issuance Of Common Stock Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_lbl" xml:lang="en-US" id="id_6185658_1939521_2_1">Issuance of common stock, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:to="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xml:lang="en-US" id="id_6185658_1648222_1_1">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Excluding Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xml:lang="en-US" id="id_6185658_1648222_2_1">Proceeds from shares issued under equity compensation plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_6185658_1650991_1_1">Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_6185658_1650991_2_1">Maturities of investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_6185658_1648095_1_1">Proceeds from Sale of Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_lbl" xml:lang="en-US" id="id_6185658_1648095_2_1">Sale of investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:label="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_lbl" xml:lang="en-US" id="id_6185658_1776806_3_1">Proceeds from sale of potential future royalties gross.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_lbl" xml:lang="en-US" id="id_6185658_1776806_1_1">Proceeds From Sale Of Potential Future Royalties Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_lbl" xml:lang="en-US" id="id_6185658_1776806_2_1">Proceeds from sale of royalty rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:to="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_ProductSalesAndRoyalties" xlink:label="nktr_ProductSalesAndRoyalties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_ProductSalesAndRoyalties_lbl" xml:lang="en-US" id="id_6185658_1741825_3_1">Includes Product sales (aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts) and royalties (Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated Includes Product sales (aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts) and royalties (Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_ProductSalesAndRoyalties_lbl" xml:lang="en-US" id="id_6185658_1741825_1_1">Product Sales And Royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_ProductSalesAndRoyalties_lbl" xml:lang="en-US" id="id_6185658_1741825_2_1">Product sales and royalty revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_ProductSalesAndRoyalties" xlink:to="nktr_ProductSalesAndRoyalties_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_6185658_1649598_1_1">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_6185658_1649598_2_1">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_6185658_1634506_1_1">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_6185658_1634506_2_1">Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PurchaseAndSaleAgreementMember" xlink:label="nktr_PurchaseAndSaleAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_PurchaseAndSaleAgreementMember_lbl" xml:lang="en-US" id="id_6185658_1754234_3_1">Purchase and sale agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_PurchaseAndSaleAgreementMember_lbl" xml:lang="en-US" id="id_6185658_1754234_1_1">Purchase And Sale Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_PurchaseAndSaleAgreementMember_lbl" xml:lang="en-US" id="id_6185658_1754234_2_1">Purchase and Sale Agreement with RPI [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_PurchaseAndSaleAgreementMember" xlink:to="nktr_PurchaseAndSaleAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts" xlink:label="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts_lbl" xml:lang="en-US" id="id_6185658_1733589_3_1">Repayment Of And Proceeds From Sale Of Future Royalties Net Of Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts_lbl" xml:lang="en-US" id="id_6185658_1733589_1_1">Repayment Of And Proceeds From Sale Of Future Royalties Net Of Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts_lbl" xml:lang="en-US" id="id_6185658_1733589_2_1">Repayment of proceeds from sale of future royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts" xlink:to="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US" id="id_6185658_1644374_1_1">Repayments of Long-term Capital Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US" id="id_6185658_1644374_14_1">Payment of capital lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_6185658_1649370_1_1">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_6185658_1649370_2_1">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_6185658_1642216_1_1">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_6185658_1642216_2_1">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_6185658_1635712_1_1">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_6185658_1635712_2_1">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_6185658_1650872_1_1">Restricted Cash and Cash Equivalents, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_6185658_1650872_2_1">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_6185658_1646649_1_1">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_6185658_1646649_2_1">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US" id="id_6185658_1646547_1_1">Revenue Recognition, Milestone Method, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US" id="id_6185658_1646547_2_1">Development milestones achieved</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_6185658_1633725_1_1">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_6185658_1633725_2_1">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_6185658_1644847_1_1">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_6185658_1644847_6_1">Total revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_RocheMember" xlink:label="nktr_RocheMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_RocheMember_lbl" xml:lang="en-US" id="id_6185658_1664673_3_1">Roche.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_RocheMember_lbl" xml:lang="en-US" id="id_6185658_1664673_1_1">Roche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_RocheMember_lbl" xml:lang="en-US" id="id_6185658_1664673_2_1">Roche [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_RocheMember" xlink:to="nktr_RocheMember_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_RoyaltyAgreementContingentPaymentDescription" xlink:label="nktr_RoyaltyAgreementContingentPaymentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_RoyaltyAgreementContingentPaymentDescription_lbl" xml:lang="en-US" id="id_6185658_1893942_3_1">Royalty agreement contingent payment description.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_RoyaltyAgreementContingentPaymentDescription_lbl" xml:lang="en-US" id="id_6185658_1893942_1_1">Royalty Agreement Contingent Payment Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_RoyaltyAgreementContingentPaymentDescription_lbl" xml:lang="en-US" id="id_6185658_1893942_2_1">Royalty agreement contingent payment description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_RoyaltyAgreementContingentPaymentDescription" xlink:to="nktr_RoyaltyAgreementContingentPaymentDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="us-gaap_SalesRevenueNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetAbstract_lbl" xml:lang="en-US" id="id_6185658_1636504_1_1">Revenue, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetAbstract_lbl" xml:lang="en-US" id="id_6185658_1636504_2_1">Revenue:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetAbstract" xlink:to="us-gaap_SalesRevenueNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioForecastMember_lbl" xml:lang="en-US" id="id_6185658_1641344_1_1">Scenario, Forecast [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioForecastMember_lbl" xml:lang="en-US" id="id_6185658_1641344_2_1">Scenario, Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioForecastMember" xlink:to="us-gaap_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_6185658_1638535_1_1">Scenario, Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_6185658_1638535_2_1">Scenario, Unspecified [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_6185658_1634103_1_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_6185658_1634103_2_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US" id="id_6185658_1636119_1_1">Cash, Cash Equivalents and Investments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US" id="id_6185658_1636119_2_1">Cash and Investments in Marketable Securities, Including Cash Equivalents and Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xml:lang="en-US" id="id_6185658_1637737_1_1">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xml:lang="en-US" id="id_6185658_1637737_2_1">License, Collaboration and Other Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_6185658_1633292_1_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_6185658_1633292_2_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_6185658_1638543_1_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_6185658_1638543_2_1">Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" id="id_6185658_1638546_1_1">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" id="id_6185658_1638546_2_1">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_6185658_1643015_1_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_6185658_1643015_2_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xml:lang="en-US" id="id_6185658_1642624_1_1">Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xml:lang="en-US" id="id_6185658_1642624_2_1">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_6185658_1634128_1_1">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_6185658_1634128_2_1">Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeniorLongTermNotes_lbl" xml:lang="en-US" id="id_6185658_1644851_1_1">Senior Notes, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeniorLongTermNotes_lbl" xml:lang="en-US" id="id_6185658_1644851_2_1">Senior secured notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeniorLongTermNotes_lbl" xml:lang="en-US" id="id_6185658_1644851_12_1">Senior secured notes, carrying amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorLongTermNotes" xlink:to="us-gaap_SeniorLongTermNotes_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeniorNotesMember_lbl" xml:lang="en-US" id="id_6185658_1636521_1_1">Senior Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeniorNotesMember_lbl" xml:lang="en-US" id="id_6185658_1636521_2_1">12% Senior Secured Notes Due July 2017 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorNotesMember" xlink:to="us-gaap_SeniorNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_6185658_1648110_1_1">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_6185658_1648110_2_1">Total stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_6185658_1637335_1_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_6185658_1637335_2_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_6185658_1644248_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_6185658_1644248_2_1">Granted stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_6185658_1641797_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_6185658_1641797_2_1">Weighted average grant-date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_6185658_1634939_1_1">Equity Award [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_6185658_1634939_2_1">Equity Award [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_SignificantConcentrationsPolicyTextBlock" xlink:label="nktr_SignificantConcentrationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_SignificantConcentrationsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6185658_1793449_3_1">Significant concentrations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_SignificantConcentrationsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6185658_1793449_1_1">Significant Concentrations Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_SignificantConcentrationsPolicyTextBlock_lbl" xml:lang="en-US" id="id_6185658_1793449_2_1">Significant Concentrations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_SignificantConcentrationsPolicyTextBlock" xlink:to="nktr_SignificantConcentrationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US" id="id_6185658_1641811_1_1">Geographical [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US" id="id_6185658_1641811_2_1">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_6185658_1643038_1_1">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_6185658_1643038_2_1">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_6185658_1640591_1_1">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_6185658_1640591_2_1">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" id="id_6185658_1639796_1_1">Statement of Comprehensive Income [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" id="id_6185658_1639796_2_1">Statement of Comprehensive Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_6185658_1640593_1_1">Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_6185658_1640593_2_1">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_6185658_1644941_1_1">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_6185658_1644941_6_1">Total stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6185658_1634143_1_1">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_6185658_1634143_2_1">Stockholders' equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" id="id_6185658_1640611_1_1">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" id="id_6185658_1640611_2_1">Stock issuances under equity compensation plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_6185658_1643862_1_1">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_6185658_1643862_2_1">Supplemental disclosure of cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_6185658_1639366_1_1">Text Block [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_6185658_1639366_2_1">Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_6185658_1643125_1_1">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_6185658_1643125_2_1">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_6185658_1634968_1_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_6185658_1634968_2_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:label="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_lbl" xml:lang="en-US" id="id_6185658_1739036_3_1">Upfront and Milestone Payments Received Under License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_lbl" xml:lang="en-US" id="id_6185658_1739036_1_1">Upfront and Milestone Payments Received Under License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_lbl" xml:lang="en-US" id="id_6185658_1739036_2_1">Received upfront and milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:to="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UpFrontPaymentArrangementMember_lbl" xml:lang="en-US" id="id_6185658_1643540_1_1">Up-front Payment Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UpFrontPaymentArrangementMember_lbl" xml:lang="en-US" id="id_6185658_1643540_2_1">Upfront Payment Arrangement in 2007 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UpFrontPaymentArrangementMember" xlink:to="us-gaap_UpFrontPaymentArrangementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" id="id_6185658_1641076_1_1">UNITED STATES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US" id="id_6185658_1641076_2_1">United States [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_6185658_1642359_1_1">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_6185658_1642359_2_1">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_6185658_1643551_1_1">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_6185658_1643551_2_1">Weighted average shares outstanding used in computing basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>nktr-20150630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.22.4 -->
<!-- Round: 4 -->
<!-- Creation date: 2015-08-05T06:53:07Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DocumentandEntityInformation" roleURI="http://www.nektar.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.nektar.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_StatementOfPartnersCapital" roleURI="http://www.nektar.com/taxonomy/role/StatementOfPartnersCapital"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureInventoryInventory" roleURI="http://www.nektar.com/taxonomy/role/DisclosureInventoryInventory"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureLicenseAndCollaborationAgreementsAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpense" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#DisclosureNetLossPerShareAdditionalInformation" roleURI="http://www.nektar.com/taxonomy/role/DisclosureNetLossPerShareAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="nktr-20150630.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_DocumentAndEntityInformationAbstract" xlink:label="nktr_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassified" xlink:title="104000 - Statement - Statement of Financial Position, Classified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_AccruedClinicalTrialExpenses" xlink:label="nktr_AccruedClinicalTrialExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_SeniorLongTermNotes" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="nktr_AccruedClinicalTrialExpenses" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PreferredStockShareDesignated" xlink:label="nktr_PreferredStockShareDesignated"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="nktr_PreferredStockShareDesignated" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfIncomeAlternative" xlink:title="124100 - Statement - Statement of Income">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LicenseCollaborationOtherRevenue" xlink:label="nktr_LicenseCollaborationOtherRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:label="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_ProductSalesAndRoyalties" xlink:label="nktr_ProductSalesAndRoyalties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="us-gaap_SalesRevenueNetAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SalesRevenueNetAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1.1400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" order="1.1500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueNetAbstract" xlink:to="nktr_ProductSalesAndRoyalties" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueNetAbstract" xlink:to="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueNetAbstract" xlink:to="nktr_LicenseCollaborationOtherRevenue" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalesRevenueNetAbstract" xlink:to="us-gaap_Revenues" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfPartnersCapital" xlink:title="152000 - Statement - Statement of Partners' Capital">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirect" xlink:title="152200 - Statement - Statement of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses" xlink:label="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:label="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts" xlink:label="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="1.1400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.1500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.1600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.1700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1.2800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" order="1.3400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.3600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="us-gaap_CapitalLeaseObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SeniorLongTermNotes" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LongTermDebt" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CapitalLeaseObligations" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:label="nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_DebtInvestmentMaturityDateDescription" xlink:label="nktr_DebtInvestmentMaturityDateDescription"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_DebtInvestmentMaximumMaturityPeriod" xlink:label="nktr_DebtInvestmentMaximumMaturityPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="us-gaap_SeniorLongTermNotes"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="nktr_CashAndInvestmentsInMarketableSecuritiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="nktr_DebtInvestmentMaximumMaturityPeriod" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="nktr_DebtInvestmentMaturityDateDescription" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="us-gaap_SeniorLongTermNotes" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:to="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SeniorNotesMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_CashAndRestrictedCash" xlink:label="nktr_CashAndRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_CorporateCommercialPaperMember" xlink:label="nktr_CorporateCommercialPaperMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="nktr_CashAndRestrictedCash" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="nktr_CorporateCommercialPaperMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureInventoryInventory">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_EstimatedAnnualInterestRateOnRoyaltyLiability" xlink:label="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_MilestoneScenarioOneMember" xlink:label="nktr_MilestoneScenarioOneMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_MilestoneScenarioTwoMember" xlink:label="nktr_MilestoneScenarioTwoMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearOne" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearOne"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PaymentMadeForMilestoneNotAchievedYearTwo" xlink:label="nktr_PaymentMadeForMilestoneNotAchievedYearTwo"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:label="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PurchaseAndSaleAgreementMember" xlink:label="nktr_PurchaseAndSaleAgreementMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_RoyaltyAgreementContingentPaymentDescription" xlink:label="nktr_RoyaltyAgreementContingentPaymentDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_PurchaseAndSaleAgreementMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nktr_MilestoneScenarioOneMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="nktr_MilestoneScenarioTwoMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_EstimatedAnnualInterestRateOnRoyaltyLiability" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_PaymentMadeForMilestoneNotAchievedYearOne" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_PaymentMadeForMilestoneNotAchievedYearTwo" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="nktr_RoyaltyAgreementContingentPaymentDescription" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:to="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="us-gaap_IndemnificationGuaranteeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_IndemnificationGuaranteeMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue">
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_AmgenIncMember" xlink:label="nktr_AmgenIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_AstraZenecaAbMember" xlink:label="nktr_AstraZenecaAbMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_BaxaltaMember" xlink:label="nktr_BaxaltaMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_BayerHealthcareLlcMember" xlink:label="nktr_BayerHealthcareLlcMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember" xlink:label="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_HemophiliaMember" xlink:label="nktr_HemophiliaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LicenseAndCollaborationAgreementsLineItems" xlink:label="nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LicenseAndCollaborationAgreementsTable" xlink:label="nktr_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LicenseCollaborationOtherRevenue" xlink:label="nktr_LicenseCollaborationOtherRevenue"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" xlink:label="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_NeulastaMember" xlink:label="nktr_NeulastaMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_OtherPartnerMember" xlink:label="nktr_OtherPartnerMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PegasysAndMirceraMember" xlink:label="nktr_PegasysAndMirceraMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_RocheMember" xlink:label="nktr_RocheMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_PegasysAndMirceraMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_NeulastaMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_HemophiliaMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_AstraZenecaAbMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_RocheMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_AmgenIncMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_BayerHealthcareLlcMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_BaxaltaMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_OtherPartnerMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LicenseAndCollaborationAgreementsLineItems" xlink:to="nktr_LicenseCollaborationOtherRevenue" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LicenseAndCollaborationAgreementsTable" xlink:to="dei_LegalEntityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LicenseAndCollaborationAgreementsTable" xlink:to="nktr_LicenseAndCollaborationAgreementsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="nktr_LicenseAndCollaborationAgreementsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_AmgenIncMember" xlink:label="nktr_AmgenIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_AstraZenecaAbMember" xlink:label="nktr_AstraZenecaAbMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_BaxaltaMember" xlink:label="nktr_BaxaltaMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_BayerHealthcareLlcMember" xlink:label="nktr_BayerHealthcareLlcMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_ConsiderationReceivedForProductDelivered" xlink:label="nktr_ConsiderationReceivedForProductDelivered"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents" xlink:label="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="us-gaap_DeferredRevenueArrangementByTypeTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="us-gaap_DeferredRevenueArrangementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="us-gaap_EuropeanUnionMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_FovistaMember" xlink:label="nktr_FovistaMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_HemophiliaMember" xlink:label="nktr_HemophiliaMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_IncreaseDecreaseInRevenue" xlink:label="nktr_IncreaseDecreaseInRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments" xlink:label="nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LicenseAndCollaborationAgreementsAbstract" xlink:label="nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_MirceraMember" xlink:label="nktr_MirceraMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" xlink:label="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_MovantikFixedDoseCombinationProgramMember" xlink:label="nktr_MovantikFixedDoseCombinationProgramMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_MovantikMember" xlink:label="nktr_MovantikMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfReportingCategoryDomain" xlink:label="us-gaap_NameOfReportingCategoryDomain"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_OphthotechCorporationMember" xlink:label="nktr_OphthotechCorporationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_OtherPartnerMember" xlink:label="nktr_OtherPartnerMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PaymentForReimbursementOfCosts" xlink:label="nktr_PaymentForReimbursementOfCosts"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PegasysAndMirceraMember" xlink:label="nktr_PegasysAndMirceraMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PegasysMember" xlink:label="nktr_PegasysMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PercentageOfPostApprovalStudyCostsToRepay" xlink:label="nktr_PercentageOfPostApprovalStudyCostsToRepay"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PerformanceMilestonePaymentsMember" xlink:label="nktr_PerformanceMilestonePaymentsMember"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PotentialDevelopmentMilestones" xlink:label="nktr_PotentialDevelopmentMilestones"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies" xlink:label="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired" xlink:label="nktr_PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis" xlink:label="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_RocheMember" xlink:label="nktr_RocheMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:label="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_MirceraMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_FovistaMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_MovantikMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_PegasysMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_PegasysAndMirceraMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_MovantikAndMovantikFixedDoseCombinationProgramMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_MovantikFixedDoseCombinationProgramMember" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nktr_HemophiliaMember" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentLiabilitiesMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="dei_LegalEntityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_StatementScenarioAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_StatementGeographicalAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="16.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementByTypeTable" xlink:to="us-gaap_DeferredRevenueArrangementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_PotentialDevelopmentMilestones" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_IncreaseDecreaseInRevenue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_PercentageOfPostApprovalStudyCostsToRepay" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_ConsiderationReceivedForProductDelivered" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="nktr_PaymentForReimbursementOfCosts" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_UpFrontPaymentArrangementMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_RocheMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_AmgenIncMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_OphthotechCorporationMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_AstraZenecaAbMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_BayerHealthcareLlcMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_BaxaltaMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="nktr_OtherPartnerMember" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nktr_LicenseAndCollaborationAgreementsAbstract" xlink:to="us-gaap_DeferredRevenueArrangementByTypeTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfReportingCategoryDomain" xlink:to="nktr_PerformanceMilestonePaymentsMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis" xlink:to="us-gaap_NameOfReportingCategoryDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_EuropeanUnionMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_US" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/DisclosureNetLossPerShareAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" xlink:label="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_OrganizationPolicyTextBlock" xlink:label="nktr_OrganizationPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_SignificantConcentrationsPolicyTextBlock" xlink:label="nktr_SignificantConcentrationsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="nktr_OrganizationPolicyTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="nktr_SignificantConcentrationsPolicyTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock">
    <loc xlink:type="locator" xlink:href="nktr-20150630.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:label="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0````(`!HS!D=V;+^IJ@$``/`4```3````6T-O;G1E;G1?5'EP97-=
M+GAM;,V8RV[",!!%?P5E6Q%CT]*'@$WIMD5J?\!-)L0B?L@V`?Z^=H"JC6@%
M+9%FDP=W//<FXYP%X[>M`=?;R$JY25)Z;QX(<5D)DKM4&U!!*;25W(=;NR"&
M9TN^`,(&@Q')M/*@?-_''LET_%*#M2*'WN-.B+TG"3>F$AGW0BM2J[S5M:^+
M0F20ZVPEPY+4!VNX"GK2FW/KG[D,+<BF(HVP.](TZN0RALY8X+DK`;RL4N>W
M%;AC_COEX#R#@J\J?Y;Q_MVE%JJFQI7"[*V>-J&+"[]-DJ"ZDQS:"W]+)F0<
MFE&+;ROB_1^?I?42:UG-+%^+ED'=V9CB.95<J&.C6FN[?-=Z><EM`O&I<LC[
MQH9"Z\6171**YT%U)+3^E_=AIV3:PDF&L;##CZ+D%O)7;\-\CW\;7PNZRQ'G
MVES_-/1&=*0Y=0B)LW(P)#F&2')<(\EQ@R3'"$F.6R0Y[I#DN$>2@PZP!,%"
M5(H%J10+4RD6J%(L5*58L$JQ<)5B`2O%0E:&A:P,"UD9%K(R+&1E6,C*L)"5
M82$KPT)6AH6L#`M9AUC(.OPD*VG^Z)Q^`%!+`P04````"``:,P9'2'4%[L4`
M```K`@``"P```%]R96QS+RYR96QSK9++;L)`#$5_)9I]<4HE%A%AQ88=0OR`
M.^,\E,QXY#$B_?N.V(#"0ZW$TJ][CZZ\#JFL#C2B]AQ2U\=43'X,J<K]VG2J
ML0)(MB./:<&10IXV+!XUE])"1#M@2[`LRQ7(K8[9K.?:Q<[51G;NTQ1'E):T
M-M,(9Y;AFWE89.D\^(GT%V-NFM[2ENW)4]`'_K,-`\]YEE<>QW8OG*\M"_V/
MZ'D4X$G1H>)%]2-F`Q+M*;V"^GH`A3&^.R6:E((C-Z."N[_8_`)02P,$%```
M``@`&C,&1V2&T#=T`0``RA,``!H```!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<\782VK#,!#&\:L$'Z#RC/(FR:J;;-M>0#@3VR1^(*FTN7U=+XK[T-!%
MX-O8V(+1'PP_A'=MR+=/<G6Q[MI0U7V8O3?7-FR']_NLBK'?&A.*2AH7'KI>
MVF'UW/G&Q>'1EZ9WQ<658CC/E\9/YV2'W<_9L^-IG_GCB;+9B_.EQ'WVUOE+
MJ$1B,..-'H8-AN5;+__9OCN?ZT(>N^*UD3;^46&^-LA,.HC300P)LND@"PF:
MIX/FD*!%.F@!"5JF@Y:0H%4Z:`4)6J>#UI"@33IH`PFB7)$QQR1I6&.T)H5K
MPGA-"MB$$9L4L@EC-BEH$T9M4M@FC-NDP$T8N4FAFS!VDX(W8?1F16_&Z,V*
MW@PZ:VN';8S>K.C-&+U9T9LQ>K.B-V/T9D5OQNC-BMZ,T9L5O1FC-RMZ,T9O
MJ^AM,7I;16^+T=M.]`Z5\W)ZCKYNRW#OFF_#U:()WB'>KG+_E'&JVC#1.@X[
MB1FO=_]$X]3/$//KM]WA`U!+`P04````"``:,P9'KK[+%H4"``!P"0``$```
M`&1O8U!R;W!S+V%P<"YX;6R]5E%OVC`0_BM6GK8'&DBW;D(T4DL[K5*[HH5U
MSX=S`0O'CFR#RG[]S@FDH0W5DH?QPOG\?3[?=V<[$V6'XYG1!1HGT++G7"H[
M)N=EL'*N&(>AY2O,P9X11-%LIDT.CH9F&>HL$QQO--_DJ%P8#8<7(3X[5"FF
M@Z)>-(@G/LI544C!P0FMX@?!C;8Z<^SVF:.<A*\!)8-63I!OC'"[>%AAFJX2
MDW"0.*58<0;28H5Z<9:8J<X+4+NP&MT+M;:_BKF^`8=-UO%$M?H*#*84]&CU
MVEEBON\H3^FYTQ6H):9-[-O)@Q9/:*S/=!2=#>E72W#P5VLCI$(M9R",C2=;
M-]XB=]KLR[1U?:N4:NZ+;I_FM#\;L`58].9EL`4C0+F`6?&'AE%0A:V\I2T+
MZTS\6YNU72$Z.PEK9VDVL4U;?(K/1R6"K&-D6&<6[V4[RMM[YL))M(_9#(S[
M3U*4.1V$.!\%C>P/2S!0*;M5CMJ1W:DJ%!6O*4EM336="V4Q9619+45*;9:R
M:Y"@.+(>G/,NG,31'^VY!^=S#\Y%*^?1+$&)/Z5(I7;))L_![)C.6"*6[7'`
MKDKLG=JB=5YVRX1B#V#6Z*"5XZ&*NF/7.GLO8"&DK]E/E.6FG68)71E^&]\V
M)[+-<[$/[C=#.3OJ4%2<;K@34;B79X^6$A;:5(E?+0UB*R=QFJ\'UU"IFE,'
MV],-]0,=N]?6LAD:5EY*W34?G:CM>YJ/VFM;:\X^S&%!A_5C=UE&7SO)LH_4
M/>UHV#WM:-2#$_7@M!_K%WD'K"'U#1T!(4])_4Z?1Z=.]3M]S@;=2QI]Z<'I
MV`8#YJ>Z<J[25/SCP=JC/1'DFP>O^7*]>J?"X^^K^"]02P,$%`````@`&C,&
M1\2T]X4_`0``:0,``!$```!D;V-0<F]P<R]C;W)E+GAM;,V334_#,`R&_PKJ
MO4NZL0E%70^`.#$)B2$0MY!X6UCSH<13UW]/EG4M`RZ[<:MKOX]?QTDI'!/6
MPY.W#CPJ"%=[79O`A)MG&T3'"`EB`YJ'4:PP,;FR7G.,H5\3Q\66KX&,*9T1
M#<@E1TX.P-SUQ*PJI6#"`T?K.[P4/=[M?)U@4A"H08/!0(I10;+JQ6R-;4Q)
M!GU51L<U#[BP4JT4R-MV*/N=BIT1O`Y'.<B^??K[IX>4(5E7N0^JKVJ:9M1,
M4ET<N"!OB\?G=#:Y,@&Y$1!503%L'<RS4^?7R=W]\B&KQK28YO0FI[,EG;'Q
M-9O2]\-D9_X&P[H;XM\Z/AE,VT6%-5RXVZ21:;GI,X$D!.&50V7-1;B$^29.
ML+#[^`2!EX,Z8;IL6V@;ZV6HTOT:HL/+B2M;6]\>4S^BLU=5?0%02P,$%```
M``@`&C,&1YE<G",0!@``G"<``!,```!X;"]T:&5M92]T:&5M93$N>&UL[5I;
M<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M3A^%$5B-;'EDD81_OT<V$,N6
M#>V23;J;/`0LZ?O.14?GZ#AY\^XN8NB&B)3R>&#9+]O6N[<OWN!7,B0103`9
MIZ_PP`JE3%ZU6FD`PSA]R1,2P]R"BPA+>!3+UES@6QHO(];JM-O=5H1I;*$8
M1V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I
M.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R
M#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2BW`<!.!1NY["G?1LOZ1!";2C
M:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K=]W3CHG&K=!X#;[Q3X?#KHG&
MJ]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5`TR``6'!VULS2`Y9>*?IUE!K9';O=
M05SP6.XYB1'^QL4$UFG2&98T1G*=D`4.`#?$T4Q0?*]!MHK@PI+27)#6SRFU
M4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4?VFK`:?MNYO/D_QSZ.2?IY/7
M34+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/
MY)Z,<B.[W?98??9/1VXCUZG`LR+7E$8D19_(+;KD$3BU20TR$S\(G8:8:E`<
M`J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]5Z%82=J$^!!&&N*<<^9ST6S[
M!Z5&T?95O-RCEU@5`9<8WS2J-2S%UGB5P/&MG#P=$Q+-E`L&08:7)"82J3E^
M34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH,QK!1J\;=8=HTCQZ_@7YG#4*
M')$;'0)G&[-&(81IN_`>KR2.FJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2
MM!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)
MP>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*
M!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+`.7\N?<^E[[GT/:'2MS<C?6?!
MTXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8.9_`[/UH/I[Q[?K9)(2OFEDM
M(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;
MY.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X2O2QS'!.'LL,.V<\DAVV=Z`=
M-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y"M-2D&_#^>G%>!KB.=D$N7V8
M5VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&
MMV"XU_$L%.!D8"V@!X.O40+R4E5@,5O&`RN0HGQ,C$7H<.>77%_CT9+CVZ9E
MM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+
M$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE
M,6>F\M\M#`DL6XA9$N)-7>W5YYN<KGHB=OJ7=\%@\OUPR4</Y3OG7_1=0ZY^
M]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#NDI`&$P'-E,E$\`*"9*8<@)CZ
M"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP#`4A%W+C[^^3:G>,U_HL@6V$5#)D
MU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;S
MHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->YA,L0Z1^P7V*BH`1JV*^NJ]/
M^26<.[1[\8$@F_S6VZ3VW>`,?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::Q
MK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!U4#E/]O4#6CV#30<D05>,9FV
M-J/D3@H\W/[O#;#"Q([A[8N_`5!+`P04````"``:,P9'U@#H=5@"``"V"@``
M#0```'AL+W-T>6QE<RYX;6S-5EMKVS`4_BM"*:.%$=O9FG:K;1B%P&`K@^9A
M;T6V94>@BR?+F=-?/UU\20Q9VC0M]8N./IWSG4]'LH_#2FTHOE]AK$##**\B
MN%*J_.IY5;K"#%5346*N5W(A&5)Z*@NO*B5&666"&/5FOC_W&"(<QB&OV8*I
M"J2BYBJ"GWL(N/A;D>$(/IQ_^%,+=7,&W#CY.)GX#Q<W8_S<+EQ`X#B^9Q$,
MYI?0>SKIU-?/7F:[.J*?/Y/^?^0CZJL]U*V[9NHB1X'7)M!K:QN'N>!#B6?0
M`7%8/8(UHMH_,.ZIH$("I<]09[`(1PP[CUM$22*)`7/$"-TX>&8`>^RM'R-<
M2)O;91CGF?I#)EDD$?3;Y^GIDH'=#F9[A-+=[6D@#DND%)9\H2>@M9>;4F^.
M"XZ=2.MWP+N0:!/,+K<"[*#S)D)F6/:9`]A!<4AQKG2`),7*C$J41KI02C!M
M9`05@B-J*+N(UM"T*:;TWKQDO_,=[B8'SL><L0^!4=&9NA"M.5P#6U1OF\UQ
M;],>QPN:O$^@HU%9TLTW2@K.L!/KH(5H9X?H@SWT<8@Z5K`2DCQJ?W,14@U@
M"<$:2T72;>2O1.42-ZJ]P5Z3[U-X[)9?4]/IJS:HT5?PK<MS='(+W=4LP7)A
M/WO/E_3IZO"1V;<3CF2^[:TY0L()BF-ZXKN5-G^_TE[G3IU$VO4+I7EM9]AJ
M/SO-IT=!4A.J".\T(/.[<&=TTYV^,#0>S9DU0\^QJPHE^B=R)XLFRW".:JI^
MD;50=C&"@_W#R`_FO=>RIXC@8/_$&:G9%ZM@^%.-_P%02P,$%`````@`&C,&
M1Q\)K_Q3`P``00L```\```!X;"]W;W)K8F]O:RYX;6R5EMM.XS`00'_%RM/N
M`]O:O0`51>*ZB\1-%+'/;N*V(QR[LAU8^/H=)RU,M]Z(/M5.XA-[YF0Z1W[T
M:MWSU-IG]J?4QH_<.%N$L!QU.CY?J%+Z'W:I#-Z;65?*@%,W[]C9#')U;O.J
M5"9T1+<[[#BE90!K_`*6/EO1_%=H?NF4+/Q"J5#J!E9*,-GQD1_-0*LGY3R"
MF5PN;V6IQMD?G3$M?;@H(*ABG/5Q:E_5Q@57+4\KT'$RZ`ZR3H2MCWKO6&X+
MU<`>%^!_KVYDK%`S6>GPB)M=OW><<=$78M@PXF-/H%X]!<8+3.8!7M2CG(ZS
M;L9D%>PEZ*#<N0SJI[/5$LP<61F;@?-A$H];/UF"@1+>X[YQYA?V]9=U\&Y-
MD'J2.ZMUO2K>J!?A&_S'%=QC@'SCP2"G#S$3XVS81>`+>)B"AO`VSNJQ5O$D
MG7^.4H?_<\1,'9QUBIDT!;LP`2GLRC3)P]#$/>##5T7]8C<"'+BK@C>AHJ`S
M:PIEO"H8CKS54&!4"G8JM32Y8@0D"$CL"NH14(^`>E\&30+^X)$)J$]`_5U!
M`P(:$-!@5]"0@(8$--P&W;FY-/!>IZC.W*0J2^G>F)VQ"<P):)^`]A,[DGY1
M`Z[,"WY>T03/P+`;Z9Y5D`1T0$`'VZ"XW@3KWLB20[+D<'O)-<A&6_80*PL&
M(E@VD5K%4UQ65+TN=:^;"FQ9PFKW\308WH`?HS(Y*$]!&Q(G++[&JH<)6D&T
MEE/KFBB?S)U2%$4UY@F/)\'FSWNGLDEWB571;WU2U&">4/@61]?6>W:O')LL
MI-O8`=66)[QMM813;SD5EZ?,;?.$4W,Y59<GW/TPA7W#0J>5_TY74U]Y0MC6
M!/$#BJ+&\H2R_TO0:E\414WF"95;(RVZM/A1E45*Y;9("TY15&:1*LFM*$%1
M&S4Y591;4;0H"^JT2#C]F?\]1EPXQW(#FKH@J-\BX7=K`1'4;T']%LG*W%)`
MV!Y%4;]%PN]60\4^15'9Q:ZR"RJ[H+*+763?8_$615'914+V%M1)40#]@Z:R
M]Q*R;]>W%23RI*8H*GN/KQJ<SYX&VSHPJH@=GZ]?@RU3'MM`_&G*=7\0/^,X
MO\'6<)S%_@U;M4KK,[QV9ZZMK+N<AKQN_([_`E!+`P04````"``:,P9'1QJ$
M/%4"``#T!P``&````'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;(65VVZC,!"&
M7P7Q`,4VIR0B2$U65?=BI:H7N]<.<0(J8-9V0O?MUZ=0J`S<!-OY__EF#&-G
M/64?O"1$>)]-W?*]7PK1[8*`%R5I,'^B'6GE/Q?*&BSDE%T#WC&"S]K4U`$"
M(`D:7+5^GNFU-Y9G]";JJB5OS..WIL'LWX'4M-_[T'\LO%?74JB%(,^"P7>N
M&M+RBK8>(Y>]_PQW1Q@IB5;\KDC/1V-/)7^B]$--?I[W/E`YD)H40H7`\G$G
M1U+7*I(D_[5!OYC*.!X_HK_H<F7Z)\S)D=9_JK,H9;;`]\[D@F^U>*?]*[$U
MQ"I@06NN?[WBQ@5M'A;?:_"G>5:M?O;FGRBT-K<!60,:#"A:-(36$`X&LW6!
MR4S7]0,+G&>,]AXS+Z/#ZIW#72AWKO"X7I0E<5\)Y$[EV3T'67!78:P"C10'
MHX"#(I"Q!P!R`29VI.UH'G`TBM`-"%V`<%Q!J.V1VQZY[-'8'FE[/,UOK#@8
M1>(&Q*N`6-O3!8!1;-R`9!60:/MV`6`4$+@)Z2HA-7XX1<1:TAJ$D2``8S=D
MLPK9&,BW+R49UV$E,Y_*=A6Q-?YH8:NL9*8*=3JL,"`P$9(%R$.3SE"<;3NE
MV*[<++P2J]F")`7;&9*S?Z<DTYYPZ?NR&C3S@4%G$T\IIHL17*)8#9JAK/<Z
M-*V,POE=.UH-#%&80@"^EQ2,#MF&L*N^?+A7T%NK[[K1ZG#!/2-]2'_)\ZS#
M5_(+LVO5<N]$A3SJ];E\H500F05XDCF5\@H>)C6Y"#5,Y9B92\E,!.T>=^QP
MT>?_`5!+`P04````"``:,P9'C4!V0&`$``!5%@``&````'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;(V878^C-A2&_TJ4^UU\_,TH$ZFAJMJ+2JN]:*^9Q)E$
M"R$%9K+]]S7XD`VS^+@W$V`>F]=?#X;-K6F_=2?G^M7WNKITS^M3WU^?LJS;
MGUQ==I^;J[OX_QR;MBY[?]J^9MVU=>5A+%17&6=,9W5YOJRWF_':EW:[:=[Z
MZGQQ7]I5]U;79?OOSE7-[7D-Z^G"U_/KJ1\N9-M-=B]W.-?NTIV;RZIUQ^?U
M+_!4"#L@(_'7V=VZA^/5$/ZE:;X-)W\<GM=LR.`JM^^'*DK_\^X*5U5#3?[.
M_V"E/^XY%'P\GFK_;6RNC_]2=JYHJK_/A_[DT[+UZN".Y5O5?VUNOSML@QHJ
MW#=5-_Y=[=^ZOJFG(NM577X/O^?+^'L+_[$,BRT7X%B`WPN`)`L(+"`^%,A"
MLK%=OY9]N=VTS6W5AL&XEL.8PY/P/;=?=>-%WZ1N/0"^I[:;]RV7F^Q]J`<1
M_H#L$(D3!1+JCF3^_O<0?"F$>`S!0WF]7%XLE9>/Y44H;^81S8A<0B,08=:H
M.%4$"KC0D;;(9!89;F3G=U&/61!1C+$X52Q1LRPJF46%*G(B"R)"&*N(,(AQ
M)56^G$8GT^BQ#D&T>8>(ME3'3!`SRTE,,HD)-0"1)"#`X./2F$5!BN>*+V>Q
MR2PV9.%$EH!88PFH0,A"I%?R9)(\)!%$$D08YU(367)<`Y;'YNZ@V40<8.%F
M1/_OD#$<%+'@B@EC?F9%\BR:<IXG6$X0RV2'C-&*$9.K6,3F>1:E.<_#<1U0
M>0*CC*:F#E):Q68QI!4,09W"4&D"(Y76FN"*B9.@>:Q_%D4\>ZA`$*B(C7A:
MGQ"L)RA_(L,MM6Z*B?(S,)(FK4\(WI.4/Y$!9DEM(::,C,@<T@Z%X#Y)2109
MFY.V0,H8%ANJM$4AZ$]2&D4F-T`.5:"TA%B:M$DA"%!2*D5&YT`NA05JOKE*
MBY0S7$Y$&F24IC(74TT*(J+@:8URP#JH-+BAY+FE.F?"I#219<73&N5!?M0,
MW2$#@@.UK!!32L<&*^U1CNZC/(J,!6;([A$XDYF,Y4EO9WFPJ*3VL\A`:D>[
MS,T3I:W,@TLE964^6=D25#'5!"*B09ZV,D>54E9&!CAX]U!Y)LX/6.2YQ]-B
MYD&GBA(S,D;DFESOB'G]Q/*DU<R#4!6E9F3`;PRH?=R$21/;%_"TG'E0JOK0
M\-G;(C+2[RL_!IJ]+TX<4]Q&YI!("UJ@?&6DAD6ISO8Z`M`\D1K2&A3H+DWT
M"C*,Z)"?D'F.__$J+W!K0LP69,C'^,_,/$G:?"+8BGJQV"$#5H*A7FR+.\@E
MY+%12KM/!&,IRGW(?`*94VOICD6?5B)M/Q&,I2G[(?,)+%-`;@3OI+%:L-AZ
M2AM0!&UIRH#(",5RZA$Q85J(R)9'I`TH<$O)J;5EH^]&\P5FX^]&V<,'P&OY
MZOXLV]?SI5N]-'W?U..'OV/3],[7PS[[9IY<>;B?5.[8#X?&'[?AJV<XZ9OK
M]!'W_B5Y^Q]02P,$%`````@`&C,&1Z<[+_$R`@``(P@``!@```!X;"]W;W)K
M<VAE971S+W-H965T,RYX;6R-ELN.FS`81E\%\0"Q#>&2B"!UJ*IV46DTBW;M
M)$Y`8S"UG3!]^_I"*$1@)HM@.^?[?0S(3M8Q_BY*0J3W4=-&'/Q2RG8/@#B5
MI,9BPUK2J%\NC-=8JBZ_`M%R@L\F5%,00!B#&E>-GV=F[)7G&;M)6C7DE7OB
M5M>8_WTAE'4''_F/@;?J6DH]`/(,#+ES59-&5*SQ.+D<_"]H7R"#&.)713HQ
M:GM:_LC8N^[\.!]\J!T()2>I2V!UN9."4*HKJ9G_]$7_SZF#X_:C^C>S7*5_
MQ((4C/ZNSK)4MM#WSN2";U2^L>X[Z=<0Z8(G1H7Y]DXW(5G]B/A>C3_LM6K,
MM;._)+L^-A\(^D`P!-#6&0C[0/@4`-;,K.LKECC/..L\;A]&B_4S1_M0W;F3
M)\R@6I+P-:#N5)[=\SC,P%W7Z9%@A+Q8)%@FBIZ(!@2H^0>)8$XB'$L$5F([
MGP_G\MMQ/K3Y:*J8&J2QB[`(W$`(T3)6S&(3F^VJS=;:Q--IHK&-11"TGV6P
M6``G1M&J462-$H>115PJS\3$(5YUB*U#ZG"(5QV>B8E#LNJ06(>=PR%9=7@F
M)@[IJD-JX@ETO*OIY][566QBLUNUV5D;Y+@C%@GA^LNZ1$Z<]`:[(H6@M0H<
M5CV#P@"ED5MK0%&`XF6OV;URZF7WN21T>:'/>R&G%QAMYRV^DI^87ZM&>$<F
MU<E@MO$+8Y*H4G"C"I?JQ!XZE%RD;B:JS>T99CN2M8\C>?A?D/\#4$L#!!0`
M```(`!HS!D=[F'0^@`0``)84```8````>&PO=V]R:W-H965T<R]S:&5E=#0N
M>&ULC9A-CZ,X$(;_"LH]C6UL8T?I2!-@M'M8:32'G3.=N#O10,@`Z<S^^S78
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MK((R_VU^SY?^]V[^(Y`UFS<@UH`,!D,_\P:1-8@>!A0TH-:`_M\>F#5@DQY"
MH[T?N31O\]VVKNY!;:;[FG>K"F^8GIM#T/2->M":50?HN=AM/W<QW8:?G1^+
MD"=D;Q'F1U*#X($(=?]#$&0NB%$/I#<G_@X20\0<B&'12?8?)Z,PH[DPH^>Q
MBHQ]/&]/Y^SILSTU]F(<8MPC%S,2!L$XQI&?2@S%A,1^*+6NI,#$3V6N0X'$
MO"RV*(L967+<"WN691`:4^2'$@N)*/9#J8%$C(@?R@R$$<=H7A1?%,5-/T"\
M>X-P@@0@RD`XC@4#5%D*$4D!9YG!"!/<LX;C15VQT84!708AA'.`2BPEV'2E
MCH09"D>8<FC"8COU1-!Y86)Q<PHCC,S;R\6!D<8>$+.7=I981(&!,13#T+)(
MK2LAIZ?!:%@L%2',YF5U^7!!%T9&&!#RWC*4T>E9,5)FL8B#NR^UF"24`*.9
M62QFB'IV*9Y-7V-U)O-`FVMO&8PP-`B)Q23'P$F66HH@*H!C*G-]2D8]Z0+/
MIL6Q.).P!(?$&4;OU0@Z6RW&,"6@.N+VJQ#0PG0<BCGR[#@\FT_'^B)[F$/Z
M#+.F$>5`Y(GC")$8&*]T\$<`*G,4DWHD//IF\_WH2,(FN0J?A^74BFVZ@W*K
M9=848R@1#1B%9C9UF#Z*@4XSATE$/%4?7LZQV.0S"259RZP99N#1-&#0V9PZ
M3&=:L(!X<,RK;SG78I/6IE7:6)_-HQ18CHES!"YLFT,9>"Q9R%?LX=D\.Q8E
M[.D.B1+#Z@!/7(<Q:#.F#M,U*C2YV<#)YT4PUK=<!V"3="54"%AFS0B%N,1Q
M$:$4S)C2*:0<V`R9XV)!F>?8)<L5`;'Y&:H(+(,Y-'\.DE!I:Z$HAM:E@X2G
MKB7+E0"QZ7L2R^CKRC)ZWOATFXR^KQP7$3[]&!E]8CE.9TN(RQP7:\ZS\\AR
M.4#(["D@1PH-LT8OU$\E#VJZ\>1(WH!AP%OVP'CD$;=<"Q"3<254"UA&5R><
M0MO.<21&T`=G^O#'P&PP^&.Z$I\H#)\N74I5?_3774UPJ&Z7MBL'GEJ'*[4O
MI+NTF;3O\2;!,^TIWF3FPNSA?K>]YA_JK[S^.%^:X*UJVZKL[W7>JZI5.F3T
MH@6<5'X<7@KUWG:/L7ZNS;69>6FKJ[L%'*XB=_\"4$L#!!0````(`!HS!D<B
M+'CA!`(``'4%```8````>&PO=V]R:W-H965T<R]S:&5E=#4N>&ULC53+CML@
M%/T5Y'T'/V,G<BQ-'E6[J#2:16=-'/S0@'&!Q-._+Z\X3NI,NS%P?<ZYAPO<
M?&#\73082_!!22?67B-EOX)0E`VF2#RQ'G?J3\4X15(M>0U%SS$Z&A(E,/3]
M!:2H[;PB-[$77N3L)$G;X1<.Q(E2Q']O,&'#V@N\2^"UK1NI`[#(X<@[MA1W
MHF4=X+A:>\_!:A]KA`'\;/$@)G.@O1\8>]>+[\>UYVL+F.!2:@6DAC/>8D*T
MD$K\RVE>4VKB='Y1_VIVJ]P?D,!;1M[:HVR46=\#1URA$Y&O;/B&W182+5@R
M(LP7E"<A&;U0/$#1AQW;SHR#_9/YCC9/"!TA'`ECGGE"Y`C1E1!_2H@=(?[?
M#(DC)'<9H-V[J=P.253DG`V`V]/ND;Y4P2I19U,"88*J:,+3`'4617XNEED.
MSUK'0<()9&,A:?(8LK.08$1`E7\T$<Z9N,D0&GKX.,'6(M+%)Q[^*;+_2^3&
M9C1G,YK6*K*U6L[SXSE^/.7'MDJ^?^LQ-9C.EL)BOB1AEBX?P[8.%H5)%C^&
M[1PLR-)%]ABV=[`T2^+X;G-P<JDHYK5YS@*4[-1)79Y)=.P8SZ&^E'?Q3;#:
M!C/QG>HPMB%<Y8N\1S7^@7C==@(<F%1/P=S;BC&)E6/_23V!1O7`<4%P)?4T
M57-NVX)=2-9?FMS8:8L_4$L#!!0````(`!HS!D<S[,=,C@0``%46```8````
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&ULA9C;CJ,X$(9?!>6>"2[C`ZUTI`FK
MT>S%2J.YV+VF$^>@@9`%NC/[]@NX3(<(EV\2(+_+?_GP4?'F7C>_VK,Q7?2[
M*J_MZ^K<=;>7];K=GTU5M%_JF[GVOQSKIBJZ_K8YK=M;8XK#V*@JUY`D<ET5
ME^MJNQF?_6BVF_J]*R]7\Z.)VO>J*IK_=J:L[Z\KMG(/?EY.YVYXL-YNUE.[
MPZ4RU_927Z/&'%]77]E+SK-!,BK^OIA[^W`=#>;?ZOK7<//GX765#!Y,:?;=
M$*+HOSY,;LIRB-3W_"\&_>QS:/AX[:)_&]/M[;\5K<GK\I_+H3OW;I-5=##'
MXKWL?M;W[P9S$$/`?5VVXV>T?V^[NG)-5E%5_+;?E^OX?;>_Z`2;+3<`;`!3
M@ZF?Y08<&_#/!NF8J74VYO5'T17;35/?H\9.QJT8YIR]\'[D]E$[/NQ3:E>#
MH!^I[>9CRQ*V67\,@5`##YH=:B;%NH\^=0%+7<R:P]@<_!WD5J'D<@]\J0?^
MF`3')&`Y0+H4('T,D(X!,C'WJ$;)U69A)3'3FBN_+$>9ZF5ZV8T(IB,P';X<
M0`;3D78\L[E/\9B.E<1:)>!7Y:ABB63)LAD5-*/LV":$&>7FCS3C5`(\2U$'
MO6@,D1)FK"93S],\\V)%6H!8MI(%K60N&\**U0C-.6'%BJ1@V;*5@6@!+RQ!
M,Y(P@Z)8`B/<H$I+S\"P123-EC]S3%*>$(O(F2=DB<*I18>:6%&#ZT2:>78S
M6Z33W(S%$R>&;8<:T*`I-QRG0/CF.HPZ9@G%R:FV&D9MVAQ%RL<YM@BZN1=+
M.DZ!"C4Q([TXD7^>PM1DEG8IN6BL1B2*V+<YJF+0TF<GS$UF>9>2RP:9")Q<
M-E85<YGYME08G<PB+R4(O4,-TX*8T1Q5,6>IQTV8GLSAD\A[AZ(X33D!_!QE
M2G)/`0)A@H(C*+64G8@I1;WGP(%6",]TP2)$YX80HM2VV3F13`3ULD-9K!A7
M'JS#(I-G6`=`1[Y",DQ2P$*/48MP$K'DN:J=9^5T6BG?.(=Q"HA*1KQ%=N"*
M1TA32>W422AEFOE68YBK@!4DH^H<%/75%(4R5'FJ/PA3%21ZH0H=%,6IT-1.
M=;*^UO&4^A#F*B`S&?4&1%$_8YIZ4^9.)R#SKNM%MLZWAG9@\(0(`Q$RMYJI
MK!"(D-+#G+E5*#SSSL-$Y`YV%!%11+W:41*K)/&9"=.0(^B`HB&*2#..JE(F
MGNGFX>J4(PFI0GJ'(J4R"AA.E4F?G3!5.8(0**JB2'"**;D+Q43&/#N4AYG*
M4U?54(80E4#1"T6^@X4P23F2%"B2HD@+LD9%5=P#Q5,4\C!-.=*4RGHWB;@D
M!T=B]9U(#W=XF*;<5:`435$$B2;+9I3Q1&:>_S<\S%*.+`5?3F&6<F3I\W^Q
MV7D0BC1_9LKL.,BI)#QOA_7#:5UEFM-XBME&^_K]V@W'8P]/IY/2KS"<]CT]
MW[&7W)YW?H;9;F[%R?Q5-*?+M8W>ZJZKJ_'@[UC7G>F-)5_ZD3^;XC#=E.;8
M#9>JOV[LJ:>]Z>J;.\2=3I*W_P-02P,$%`````@`&C,&1\=:^.JA`0``L0,`
M`!@```!X;"]W;W)K<VAE971S+W-H965T-RYX;6QM4]MNI#`,_94H']`P8;J7
M$8/4Z6K5/JQ4]6'W.0,&HB8QFX2A_?LF@:&TXH78YIQC.W:*$>V+ZP`\>=7*
MN"/MO.\/C+FJ`RW<#?9@PI\&K18^N+9EKK<@ZD32BO$L^\:TD(:618H]V;+`
MP2MIX,D2-V@M[-L)%(Y'NJ/7P+-L.Q\#K"S8PJNE!N,D&F*A.=*[W>&TCX@$
M^"MA="N;Q-K/B"_1>:R/-(LE@(+*1P41C@O<@U)1*"3^/VM^I(S$M7U5_YVZ
M#=6?A8-[5/]D[;M0;$9)#8T8E'_&\0'F%FZC8(7*I2^I!N=17RF4:/$ZG=*D
M<YS^_,AFVC:!SP3^A<"F1*G,7\*+LK`X$CM=;2_B!'<''BZB(BX%0X6.1D!H
MO"PNY8[_+-@E"LT8OL*<9LR"8$%]2<&W4GRB\T3GV_1\BYZO*\RG['FV+;#?
M$MBO!?;;+:XQIQF3?VV2K>Y4@VW3ZCA2X6#2HJZBRW;>\323#WA9]**%/\*V
MTCAR1A\FF\;0('H(Z;.;6TJZ\'X61T'CH_D]V'9:J<GQV%\?R/)*RW=02P,$
M%`````@`&C,&1S2D;Q&B`0``L0,``!@```!X;"]W;W)K<VAE971S+W-H965T
M."YX;6QM4\MNI#`0_!7+'Q`SAF17(P8IDRA*#I&B'';/'FC`BDT3VPS9OU_;
M/,*NN.#NIJJZVH]\1/-A6P!'OK3J[(FVSO5'QFS9@A;V!GOH_)\:C1;.IZ9A
MMC<@JDC2BO$DN6-:R(X6>:R]F2+'P2G9P9LA=M!:F#]G4#B>Z($NA7?9M"X4
M6)&SE5=)#9V5V!$#]8G>'X[G+"`BX)>$T6YB$KQ?$#]"\E*=:!(L@(+2!07A
MERL\@%)!R#?^G#6_6P;B-E[4G^*TWOU%6'A`]5M6KO5F$THJJ,6@W#N.SS"/
M<!L$2U0V?DDY6(=ZH5"BQ=>TRBZNX_0GNYMI^P0^$_A*^)E$XU.C:/-1.%'D
M!D=BIJWM13C!PY'[C2B)C47OT-(`\(,7^;4XI#QGUR`T8_@&<YXQ*X)Y];4%
MWVOQ#YU'.M^GIWOT=.LPG1VF^P+9GD"V%<CV1]QBS@LF^Z\)V^RI!M/$JV-)
MB4,7+^JFNM[.>Q[/Y!M>Y+UHX%681G:67-#YDXW'4",Z\.V3FUM*6O]^UD1!
M[4+XP\=FNE)3XK!?'LCZ2HN_4$L#!!0````(`!HS!D>8&A67HP$``*\#```8
M````>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL;5/-;J,P$'X5RP]0$R!M%1&D
MIM5J][!2U</NV8$!K-H>:IO0OGUM0PB[XH)GAN]GQC_%B.;==@".?"JI[9%V
MSO4'QFS5@>+V#GO0_D^#1G'G4],RVQO@=20IR=(DN6>*"TW+(M9>35G@X*30
M\&J('93BYNL$$L<CW=%KX4VTG0L%5A9LX=5"@;8"-3'0'.G3[G#*`R("_@@8
M[2HFH?<SXGM(?M5'FH060$+E@@+WRP6>0<H@Y(T_9LV;92"NXZOZCSBM[_[,
M+3RC_"MJU_EF$TIJ:/@@W1N./V$>81\$*Y0V?DDU6(?J2J%$\<]I%3JNX_0G
M2V?:-B&=">E">$QBXY-1;/.%.UX6!D=BIJWM>3C!W2'U&U$1&XN^0TL#P`]>
M%I<RVQ7L$G1F2+J"G";(#<&\^.*0;CG\0T\C/=VF9UOT;-U@-KEG^VV!?$L@
M7PODFQ.N(:=\]KC_SX.M=E2!:>/%L:3"0<=KNJHN=_,I'B&[P<NBYRW\YJ85
MVI(S.G^N\1`:1`?>/KG;4]+YU[,D$AH7P@<?F^E"38G#_OH\EC=:?@-02P,$
M%`````@`&C,&1TOI$`*C`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T
M,3`N>&UL;5/+;J0P$/P5RQ\0,Q[RV!&#E$D4)8>5HAQVSQYHP(I-$]L,V;]?
MVSQ"(BZXNZFJKO8C&]"\VP;`D4^M6GNDC7/=@3%;-*"%O<(.6O^G0J.%\ZFI
MF>T,B#*2M&(\26Z8%K*E>19KKR;/L'=*MO!JB.VU%N;?"10.1[JC<^%-UHT+
M!99G;.&54D-K);;$0'6D][O#*0V("/@C8;"KF`3O9\3WD+R41YH$"Z"@<$%!
M^.4"#Z!4$/*-/R;-KY:!N(YG]:<XK7=_%A8>4/V5I6N\V822$BK1*_>&PS-,
M(UP'P0*5C5]2]-:AGBF4:/$YKK*-ZS#^26\FVC:!3P2^$.Z2:'QL%&T^"B?R
MS.!`S+BUG0@GN#MPOQ$%L;'H'5H:`'[P/+ODN_UMQBY!:,+P%>8T818$\^I+
M"[[5XAN=1SK?IN^WZ/NUP_WD\&Y;(-T22-<"Z?:(:\QIQOSZT82M]E2#J>/5
ML:3`OHT7=55=;N<]CV?R!<^S3M3P6YA:MI:<T?F3C<=0(3KP[9.K:TH:_WZ6
M1$'E0GCK8S->J3%QV,T/9'FE^7]02P,$%`````@`&C,&1PHEMBFB`0``L0,`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,3$N>&UL=5/+CMP@$/P5Q`<L'L:3
M1"./I9V-HN00:;6'Y,S8;1LMT`[@\>;O`_BQ3N1<3'>[JKJ:1S&B?74=@"=O
M6AEWH9WW_9DQ5W6@A7O`'DSXTZ#5PH?4MLSU%D2=2%HQGF4?F!;2T+)(M6=;
M%CAX)0T\6^(&K87]?06%XX4>Z%)XD6WG8X&5!5MYM=1@G$1#+#07^G@X7_.(
M2(`?$D:WB4GT?D-\C<FW^D*S:`$45#XJB+#<X0F4BD*A\:]9\[UE)&[C1?U+
MFC:XOPD'3ZA^RMIWP6Q&20V-&)1_P?$KS".<HF"%RJ4OJ0;G42\42K1XFU9I
MTCI.?TY\INT3^$S@*^%3EHQ/C9+-S\*+LK`X$CMM;2_B"1[./&Q$15PJ!H>.
M1D`8O"SNY2'/"G:/0C.&;S#7&;,B6%!?6_"]%G_1>:+S??IQCW[<.CS.#O_3
M/]\3R+<"^?Z(6\QUP?SKDFWV5(-MT]5QI,+!I(NZJ:ZW\S$=(GN'ET4O6O@N
M;"N-(S?TX633,32('D+[[.%$21?>SYHH:'P,/X;83E=J2CSVRP-97VGY!U!+
M`P04````"``:,P9';]0L#:$!``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE
M970Q,BYX;6QM4]MNI#`,_94H']`P0+NK$8/4Z:IJ'RI5?=A]SH"!J$E,DS!T
M_WZ3<"E;\4)L<\ZQ'3O%B.;==@".?"JI[8EVSO5'QFS5@>+V!GO0_D^#1G'G
M7=,RVQO@=20IR=(DN6.*"TW+(L9>35G@X*30\&J('93BYN\9)(XG>J!+X$VT
MG0L!5A9LY=5"@;8"-3'0G.C]X7C.`R("?@L8[<8FH?8+XGMPGNL334()(*%R
M08'[XPH/(&40\HD_9LVOE(&XM1?UQ]BMK_["+3R@_"-JU_EB$TIJ:/@@W1N.
M3S"W<!L$*Y0V?DDU6(=JH5"B^.=T"AW/<?KS,YEI^X1T)J3?"&Q*%,O\Q1TO
M"X,C,=/5]CQ,\'!,_454Q,:@K]#2`/"-E\6U/.19P:Y!:,:D&\QYQJP(YM77
M%.E>BO_H::2G^_1LCYYM*\RF[%FR+Y#O">1;@7R_Q2WFO&#R;TG8YDX5F#:N
MCB45#CHNZB:Z;N=]&F?R!2^+GK?PPDTKM"47='ZR<0P-H@.?/KFYI:3S[V=U
M)#0NF#^\;::5FAR'_?)`UE=:_@-02P,$%`````@`&C,&1Z0JN<2C`0``L0,`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,3,N>&UL;5/;;J,P$/T5RQ]0$T*:
M*B)(3:O5[L-*51]VGQT8P*KM86T3NG]?VUQ**U[PS'#.F3.^Y`.:-]L"./*N
MI+9GVCK7G1BS90N*VSOL0/L_-1K%G4]-PVQG@%>1I"1+D^2>*2XT+?)8>S%%
MCKV30L.+(;97BIO_%Y`XG.F.SH57T;0N%%B1LX57"07:"M3$0'VFC[O3)0N(
M"/@C8+"KF`3O5\2WD/RJSC0)%D!"Z8("]\L-GD#*(.0;_YLT/UL&XCJ>U7_$
M:;W[*[?PA/*OJ%SKS2:45%#S7KI7''["-,(A")8H;?R2LK<.U4RA1/'W<14Z
MKL/XYYA-M&U".A'2A?"01.-CHVCSF3M>Y`8'8L:M[7@XP=TI]1M1$AN+WJ&E
M`>`'+_);L<L..;L%H0F3KC"7";,@F%=?6J1;+;[0TTA/M^G[+?I^[7`_.;S?
M%LBV!+*U0+8]XAISF3'';TW8:D\5F"9>'4M*['6\J*OJ<CL?TW@FG_`B[W@#
MO[EIA+;DBLZ?;#R&&M&!;Y_<'2AI_?M9$@FU"^'1QV:\4F/BL)L?R/)*BP]0
M2P,$%`````@`&C,&1]5*X>&D`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL;5/!;MLP#/T501]0.8JS=8%CH.E0;(<!10_;6;%I6Z@DNI(<
M=W\_279<=_#%(NGW'DF1*D:TKZX#\.1=*^-.M/.^/S+FJ@ZT<'?8@PE_&K1:
M^.#:EKG>@J@322O&L^P+TT(:6A8I]FS+`@>OI(%G2]R@M;!_SZ!P/-$=O05>
M9-OY&&!EP19>+348)]$0"\V)/NR.YSPB$N"WA-&M;!)KOR"^1N=G?:)9+`$4
M5#XJB'!<X1&4BD(A\=NL^9$R$M?V3?TI=1NJOP@'CZC^R-IWH=B,DAH:,2C_
M@N,/F%LX1,$*E4M?4@W.H[Y1*-'B?3JE2><X_=EG,VV;P&<"7PCWB<"F1*G,
M[\*+LK`X$CM=;2_B!'=''BZB(BX%0X6.1D!HO"RNY2Z_+]@U"LT8OL*<9\R"
M8$%]2<&W4GRB\T3GV_3]%GV_KG`_5_AM6R#?$LC7`OEVBVO,><8<LO^2L-6=
M:K!M6AU'*AQ,6M15=-G.!YYF\@$OBUZT\$O85AI'+NC#9-,8&D0/(7UV=Z"D
M"^]G<10T/II?@VVGE9H<C_WM@2ROM/P'4$L#!!0````(`!HS!D?2G25D0P(`
M`!L(```9````>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;(56P8Z;,!#]%8L/
M6#`DD$0$:;-5U1XJK?;0GAWB!+0VIK83MG]?VQ@65L9<@FW>O#?#S'B2=XR_
MBPIC"3XH:<0QJ*1L#V$HR@I3))Y8BQOUYLHX15)M^2T4+<?H8HPH">,H2D.*
MZB8H<G/VRHN<W26I&_S*@;A3BOB_$R:L.P8P&`[>ZELE]4%8Y.%H=ZDI;D3-
M&L#Q]1@\P\,);C7$('[7N!.3-=#.GQE[UYN?EV,0:1\PP:74%$@]'O@%$Z*9
ME/)?2_JIJ0VGZX']NPE7N7]&`K\P\J>^R$IY&P7@@J_H3N0;ZWY@&X/QL&1$
MF%]0WH5D=#`)`$4?_;-NS+/KW^PB:^8VB*U!_,4@[(6,F]^01$7.60=X_VU;
MI%,(#['Z$"40YE!Y*`(-4($7^:.`6YB'#TUD,?$$<[*8$1$J]E$B=DG,S&-C
M'KO-$Y=Y,O4PZ=63R$VP<1%LI@0;&V(\#W&*.0V8Q"VR71796H*-1V3`;-TB
MZ:I(:@E2C\B`R=PBV:I(9@EV'I$!LW>+[%9%=CU!&GE$!LQ"X>U71?:6P)?X
M`;.0>-W=*RHPLA2^U(^@A=Q#9Z?.=6P;IK[LCZ"%]$-GN\YU8DOA*X`1M%`!
MT-G7<QW;V)FO!D;00A'`]?:'MK<S7QF,H*4Z6+\!H&WO)//I6%"V^:(33BYO
MBOG-S"@!2G9OS$B<G(YS\#DVE_\GO,A;=,._$+_5C0!G)M4(,??]E3&)E7[T
MI.*HU*0>-P1?I5YF:LW[V=5O)&N'43S^'RC^`U!+`P04````"``:,P9'_=78
MI[,!```6!```&0```'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6R%5%M/Y"`4
M_BN$'R`=.N.XDTX31V/T81/CP^XSTYZV1"X5Z-3]]POT8C6-OA0X?)=S@-.L
MU^;5-@`.O4NA[!$WSK4'0FS1@&3V2K>@_$ZEC63.+TU-;&N`E9$D!:%)<DTD
MXPKG68P]FSS3G1-<P;-!MI.2F7\G$+H_X@V>`B^\;EP(D#PC,Z_D$I3E6B$#
MU1'?;@ZG74!$P!\.O5W,4<C]K/5K6#R51YR$%$!`X8("\\,%[D"((.2-WT;-
M#\M`7,XG]8=8K<_^S"S<:?&7EZ[QR288E5"Q3K@7W3_"6$+,L-#"QB\J.NNT
MG"@82?8^C%S%L1]V;I*1MDZ@(X%^(9#!**9YSQS+,Z-[9(:C;5FXP<V!^H,H
MD(U!GZ'%`>`+S[-+OMGO,G()0B.&+C"G$3,CB%>?+>B:Q2<ZC72Z3D_7Z.DR
MPW1P3]-U@>V:P'8IL!U+O/Y<XA)SFC#[=9/=CR:[4>#F&Y,)\^N+"5E<G`13
MQ_=I4:$[%;MA$9U;X);&B_^`YUG+:OC-3,V516?M_/.)=UUI[<#;)U>^BL8W
MZ;P04+DPW?NY&=[ML'"ZG;IP_A7D_P%02P,$%`````@`&C,&1P$1',BF`0``
ML`,``!D```!X;"]W;W)K<VAE971S+W-H965T,3<N>&UL;5/;;IPP$/T5RQ\0
M<]LV6K%(V511^E`IRD/[[(4!K-@>:ILE_?O:AB4DX@7/#.><N=GEA.;-]@".
MO"NI[8GVS@U'QFS=@^+V#@?0_D^+1G'G7=,Q.QC@320IR;(D^<84%YI698R]
MF*K$T4FAX<40.RK%S;\S2)Q.-*6WP*OH>A<"K"K9RFN$`FT%:F*@/=&']'@N
M`B("?@N8[,8FH?8+XEMP?C8GFH020$+M@@+WQQ4>0<H@Y!/_730_4@;BUKZI
M/\5N??47;N$1Y1_1N-X7FU#20,M'Z5YQ>H:EA4,0K%':^"7U:!VJ&X42Q=_G
M4^AX3O.?/%MH^X1L(60KX3Z)A<^)8ID_N.-5:7`B9A[MP,,&TV/F!U$3&X.^
M0DL#P#=>E=<JO4]*=@U""R;;8,X+9D4PK[ZFR/92?*)GD9[MT_,]>KZM,)^S
MYX=]@6)/H-@*%%$@3S]WN(6<BV4*7WMDFY$J,%V\.9;4..IX3S?1]7(^Q!VR
M#WA5#KR#7]QT0EMR0><7&[?0(CKPZ9.[`R6]?SZK(Z%UP?SN;3/?J-EQ.-S>
MQ_I(J_]02P,$%`````@`&C,&1]^GP$>D`0``L0,``!D```!X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL;5/;;N0@#/T5Q`>4#$EWJU$F4J>KU>[#2E4?VF<F
M<2XJX"R02?OW!7)I6N4EV,XYQS8V^8CFU;8`CKPIJ>V)ML[U1\9LV8(2]@9[
MT/Y/C48)YUW3,-L;$%4D*<EXDOQ@2G2:%GF,/9HBQ\')3L.C(7902ICW,T@<
M3_1`E\!3U[0N!%B1LY57=0JT[5`3`_6)WA^.YRP@(N"Y@]%N;!)JOR"^!N=O
M=:))*`$DE"XH"']<X0&D#$(^\?]9\S-E(&[M1?UW[-97?Q$6'E"^=)5K?;$)
M)1748I#N"<<_,+=P&P1+E#9^23E8AVJA4*+$VW1V.I[C].<NF6G[!#X3^#<"
MFQ+%,G\))XK<X$C,=+6]"!,\'+F_B)+8&/056AH`OO$BOQ:'.YZS:Q":,7R#
M.<^8%<&\^IJ"[Z7X0N>1SO?IZ1X]W5:83MG39%\@VQ/(M@+9W&+ZM<4MYKQ@
MLF])V.9.%9@FKHXE)0XZ+NHFNF[G/8\S^807>2\:^"=,TVE++NC\9.,8:D0'
M/GUR<TM)Z]_/ZDBH73!_>MM,*S4Y#OOE@:ROM/@`4$L#!!0````(`!HS!D<.
MD^%6J`$``+$#```9````>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;&U3VV[;
M,`S]%4$?4#F.DQ2!8Z#I,&P/`XH^;,^*3=M")=&3Y+C[^TGRI6[A%XNDSSDD
M12H?T+S9%L"1=R6UO=#6N>[,F"U;4-P^8`?:_ZG1*.Z\:QIF.P.\BB0E69HD
M1Z:XT+3(8^S%%#GV3@H-+X;87BEN_EU!XG"A.SH'7D73NA!@1<X67B44:"M0
M$P/UA3[MSM<L("+@MX#!KFP2:K\AO@7G9W6A22@!))0N*'!_W.$9I`Q"/O'?
M2?,C92"N[5G]>^S65W_C%IY1_A&5:WVQ"245U+R7[A6''S"U<`B")4H;OZ3L
MK4,U4RA1_'T\A8[G,/XY91-MFY!.A'0A/":Q\#%1+/,;=[S(#0[$C%?;\3#!
MW3GU%U$2&X.^0DL#P#=>Y/=B]WC(V3T(39ATA;E.F`7!O/J2(MU*\8F>1GJZ
M3=]OT??K"O=C]NRX+9!M"61K@6QJ\?BYQ37F.F-.7Y*PU9TJ,$U<'4M*['5<
MU%5TV<ZG-,[D`U[D'6_@%S>-T);<T/G)QC'4B`Y\^N3A0$GKW\_B2*A=,$_>
M-N-*C8[#;GX@RRLM_@-02P,$%`````@`&C,&1]O1H+^M`@``9PH``!D```!X
M;"]W;W)K<VAE971S+W-H965T,C`N>&ULC9;9DJ(P&(5?A>(!&A)V"ZEJUYF+
MJ>KJBYGKJ%&I!N(DL>UY^\DF@LWFA4#\SOE/%DG2&Z$?[(PQM[[*HF)S^\SY
M9>8X;'_&)6(OY((K\<N1T!)Q\4A/#KM0C`Y*5!8.=-W0*5%>V5FJVMYHEI(K
M+_(*OU&+7<L2T7\+7)#;W`;VO>$]/YVY;'"RU*EUA[S$%<M)95%\G-NO8+8%
M"E'$[QS?6./>DN%WA'S(AY^'N>W*#+C`>RXMD+A\XB4N"NDD*O\UIH^:4MB\
MO[MO5'=%_!UB>$F*/_F!GT5:U[8.^(BN!7\GMQ_8]"&0AGM2,/5M[:^,D_(N
ML:T2?>EK7JGK3?\2NT;6+8!&`&L!!(,"SPB\J0+?"/Q:`/Q!06`$P:-"/"@(
MC2"<6B$R@NBI#XX>734W*\11EE)RLZA>4!<DURV816+V]Q93C6):F"T!,=M9
M^IF!.$Z=3VED&-A@%IJ)@GYD;6QJPA$!ZA2P*T6K`C0IDOX22\,D;C^STDP4
M#B2]VX!^9C-NL[W;P.XN>UU=]IH#[VD#S^TV\+L,_*:!;Q)X[9218BH]KIJ!
M41*&KOCTD^O)Y-:0(8RAWR1;\8/1^(&R\9_67=!,KQ$``]?]GJE)KB>3VSZR
ME3X<31^:P?<'XAO&\X*Q^'UD*U0T&BHRH8*!4)J)1R-U<ZU`\6B@6,^Q/[!"
M-1*$OC>\/B=R6U,R`+`W=S*:.S$#&0X,4#+TQI,[X4@-X)HB47]OE@8:&IAO
M2#M(YP[0#F+>W<G37[$)+6HHZ8=64Z#U%&C3`>EN.8T]KL3TI,XOS-J3:\7E
M"[;16I^17J'<(Y_:%V"V`AWM:S#;Z#WU89^E%W3"OQ`]Y16S=H2+G5EMHT="
M.!9YW1>Q-,[BU%<_%/C(Y6TD[JD^!^D'3B[W8UU]MLS^`U!+`P04````"``:
M,P9'TY'@[1,"``!0!@``&0```'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6R-
ME=]NFS`8Q5\%\0"U,=B$BB"M2:;M8E+5B^W:29R`:C"SG="]_6SL4!(1TIOX
M#[]S.!\?.'DGY+LJ&=/!1\T;M0Q+K=MG`-2N9#553Z)EC;ER$+*FVBSE$:A6
M,KKO134'"$(":EHU89'W>Z^RR,5)\ZIAKS)0I[JF\M\+XZ);AE%XV7BKCJ6V
M&Z#(P:#;5S5K5"6:0++#,OP6/6^()7K@=\4Z-9H'-OM6B'>[^+E?AM!&8)SM
MM'6@9CBS%>/<&ID;__6>G[>TPO'\XOZ]K]:DWU+%5H+_J?:Z-&%A&.S9@9ZX
M?A/=#^9+P-9P)[CJ?X/=26E17R1A4-,/-U9-/W;NR@)ZV;0`>0$:!%$R*XB]
M(/ZJ(/&"Y*L"[`7X1@!<[?V36U--BUR*+I"NVRVU+U7TC$UO=H'J-\U#4Z$%
M3"^*_%R85R@'9VOD&31B7CQSGUAY`M]'U@Y)R7UD<\D2#0PP=0S%H*EBXG$Q
MR!N@:8-XRB`9&\3.(+T.F?9(XQZ&1^`BQ?>IE:,B%),9:NVH&)(LNT]M/)5!
MDD[7E3RL*W&A%]=WP>.Z/(+A[:LPIE93U%46_#`+=A;93!:/Q'&ZP#-A/(9P
M@K/I-.1A&N+;&<^TW#-I1@B<Z;G'"%J@Y"8.&'V:+3VR7U0>JT8%6Z'-5]Y_
MD@<A-#,V\,G46)KC?5AP=M!VFIJY=">>6VC17L[OX4^D^`]02P,$%`````@`
M&C,&1V5U%I(*`P``O@T``!D```!X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
MC5==DYHP%/TK##^@$.1+!YE91:=]Z,S./K3/68W*+!!+XKK]]TU(0$)#H@\"
MX=QSS[T)!Y+=<?M!+@A1YZNN&K)V+Y1>5YY'#A=40_(-7U'#[IQP6T/*+MNS
M1ZXM@L<NJ*Z\P/=CKX9EX^99-_;:YAF^T:ILT&OKD%M=P_;O!E7XOG:!VP^\
ME><+Y0->GGE#W+&L44-*W#@M.JW=%[#:!SZ'=(A?);J3T;G#Q;]C_,$O?AS7
MKL\UH`H=**>`[/")MJBJ.!/+_$>2/G+RP/%YS[[ORF7RWR%!6US]+H_TPM3Z
MKG-$)WBKZ!N^?T>RAH@3'G!%NG_G<",4UWV(Z]3P2QS+ICO>Q9W4EV'Z@$`&
M!$/`D$<?L)`!BT=`:`P(94#X"$B-`9$,B)[-$,N`>!+@B69UK2X@A7G6XKO3
MBO5QA7P9@E7,)O/@D&Z0=9FX',`F+\\^\\`/,^^3$TE,,,)L!":)YB&%@(`!
MX3$!@XI`IT+)$`@5\PFV`I'$!@U6DIV=9"])(GTE"UTEBW$_%[*?,P2ACB`<
M$X228")RC"EZ3*)/$EF31)(@-23I,4M]DMB:)!8$P%>3)!VF$1,O,`;$UHHH
M!")BQLE^\[C=E$DI)[&6DXAR)BV+QM5(2.1KI(R!A0DXUKR?`2K24ZOT5,X$
M,&A/=7T>([961&%%[*8(I9"EM9"E+"0P%+*T+BDM0BG$RK&;(I1"^'O-4@GP
M92D+0RD2!)Y846:HLJ9FH6H-VG>'6H-\>8!PAD)K_(I=@L#LET#KN*J*A?;!
M5&RFQUB;4\PA555V&P?2HT$T;[&;`60R>PU(%6.W>R"]'"2F/#THG<EC=WS0
M6_[,.P-H759=$(EE0=C=#J3/M#Y]IO7_@U0Q=L<"RV=:OS2W/K#[23#C)\IC
M$#QM$L4L5`CS1M^:-6K/W;:`.`=\:RB?T='HL/5X"?BWZF1\`U9;H!DOP&HG
M-A8/^CR[PC/Z"=MSV1#G'5/VA=Q]SIXPIHBI]K^Q9^'"-E/#185.E)\F[+P5
MVPMQ0?&UWRT-6[;\'U!+`P04````"``:,P9'L\!TW7,"```A"0``&0```'AL
M+W=O<FMS:&5E=',O<VAE970R,RYX;6R-5L&.FS`4_!7$!RRV`0,106JHJO90
M:;6']NPD3D`+F-I.V/Y];3`I1`;V`K:9-\P;GI]).\;?14&I=#[JJA%[MY"R
MW7F>.!6T)N*%M;113RZ,UT2J*;]ZHN64G/N@NO(0`-BK2=FX6=JOO?(L93=9
ME0U]Y8ZXU37A?P^T8MW>A>ZX\%9>"ZD7O"SU'G'GLJ:-*%GC<'K9NU_@+H>1
MAO2(7R7MQ&3L:/%'QM[UY,=Y[P*M@5;T)#4%4;<[S6E5:2;UYC^&]/\[=>!T
M/+)_Z]-5\H]$T)Q5O\NS+)1:X#IG>B&W2KZQ[CLU.82:\,0JT5^=TTU(5H\A
MKE.3C^%>-OV]&Y[$P(39`Y`)0(\`&*P&^";`?PKP!F5]7E^))%G*6>?PX6.T
M1']SN/.5<R='](LJ)>%J@'(J2^\90B#U[IK(8-`$<S"8941N$.$#XBD!#Q7(
MIL*?JD!&!;03^#:"8$K@&X(GD5&/:88T#,8'<8B78?E(%09A8I<3;,H)#(<_
M?T\XE6,PB8]74+E!8>ACNYAP4TPX4(`U,083)1B#%34&AE&,`KL<O"D'&V\6
M"*+-8HG6BR7>5!#;BV5FR("!<9C`:,60$::J92&?9%-.,A:<G4!WI`U'(%BW
M!%K[P$P$A)\PQ8""(/&3%5-&&$K@4D[6EC`7-/:$A;J'UJ8PM\7?L&5[(\-Q
M)Z\4P<&`(`[ABGOY"(,(+306N+V9H=F"*%Z@L&[`N2UXPQ;K%IRKB.RVS/KM
M"$I0LM)N#0H\:?$FAUE+KO0GX=>R$<Z1274N]H?8A3%)%05X4;85ZG_E,:GH
M1>IAI,9\.,&'B63M^$/R^"O*_@%02P,$%`````@`&C,&1WY'&_?F`0``5`4`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,C0N>&ULA93=;ILP',5?!?$`-3:8
M+!%!:IFJ[F)2U8OMV@$34`UFMA.ZMY^_PF@%Y`9_<,[Q[X^QLY&+=]E0JH*/
MCO7R&#9*#0<`9-G0CL@'/M!>OZFYZ(C20W$&<A"45-;4,8"B*`4=:?LPS^S<
MJ\@S?E&L[>FK".2EZXCX^T09'X\A#&\3;^VY468"Y!F8?%7;T5ZVO`\$K8_A
M(SP4J5%8P:^6CG+6#PS[B?-W,_A1'</((%!&2V42B&ZNM*",F2"]\!^?^7])
M8YSW;^G/MEI-?R*2%IS];BO5:-@H#"I:DPM3;WQ\H;X$;`)+SJ1]!N5%*M[=
M+&'0D0_7MKUM1_<&I]ZV;$#>@"8#3#8-L3?$7PS`D=FZOA-%\DSP,1!N+P9B
MMAP>8OWERD#:25V2#(U`?ZD\N^8([3-P-4%>@V::)Z]95Q1>@2<)T``3!5JB
MB.<4R/IAO!(0+P4D\X#8`<319\B=U?2NC)MFC]9%A1?I/WX9);F+DOAEX.=5
M\!S%:5((=^NBPHDP_+9;1L%W4;!'01LH3@-3B#=0G`CC=&6#TKLHJ4>)-S;(
M:6`$4;*Q0UZ%]AA]@0&S`S"0,_U)Q+GM97#B2I\E^^/7G"NJ4Z('75^CK[AI
MP&BM3'>G^\*=>C=0?+C=8=-%FO\#4$L#!!0````(`!HS!D<9&+9B;`(``#()
M```9````>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;(U6T9*:,!3]%88/6!((
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M=U=G?^:"E3W%=4KRJ>]YU=U;_20&AC9.\`W!OQ)T):R$P!""9PG($-"SA-`0
MPF<)D2%$SQ*P(>!GJQ0;0GP7P=/;T6WFB@B2)@UKG4:?P)JH@PY?8WE<]@[O
M%N4^<E<!Y/%(DTOJ!RCQ+DK(8/P!9M%C0CMFV6,B.V;58[`=\]U@[(BU1N`'
M@3:3(MLO(IZLV+5L_EC9@F'9?&,E'A<(Q@304"#0"<QN<\0=I-*ET!"$$;"#
MU@84WQ=U"-IH4(R!;P=M-0B""()Q4VC2%#)5N7,UQ&P,!EF"A)-!0B,`'P3I
M,?YXD&@R2&0$@G$!/'E`\.,#$D]F$)L,D'W+5AH3`&`IYFPRRLQ$"<<%U"=@
MPB@$CYW"T7?031+0]"N*[%Z7!H2M9N%HU]X&,FV+L$5BM&]O[083=J>[!/8M
M$-OM+@P(RD;Y8M@;O.AK<J(_27/**^[LF)#?C.X%?V1,4*D#7F1#9?('YCHI
MZ%&H(9;C1G_2]42PNO]#N?XFI?\`4$L#!!0````(`!HS!D=MM/C9GP$``.P#
M```9````>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;(53RV[;,!#\%8(?$.KE
M&C5D`8V*H#T4"')HS[2TLHCPH9"TE?Y]^;(J&$I[$7>7,\-9KEC/2K^:$<"B
M=\&E.>+1VNE`B.E&$-0\J`FDVQF4%M2Z5)^)F330/I`$)T66?2*",HF;.M2>
M=5.KB^5,PK-&YB($U;\?@:OYB'-\*[RP\VA]@30U67@]$R`-4Q)I&([X2WYH
M*X\(@)\,9K.*D?=^4NK5)]_[(\Z\!>#06:]`W7*%%CCW0N[@MZ3Y]TA/7,<W
M]:?0K7-_H@9:Q7^QWH[.;(91#P.]</NBYF^06MAYP4YQ$[ZHNQBKQ(V"D:#O
M<64RK'/<V5>)MDTH$J%8"/F_"64BE'<$$IV%OKY22YM:JQGI.(N)^I'GA]+=
M7(=,*+J6#/8`=U--?6V*ZG--KEXH88H5YC%A/D:T";%;(,096%P46RZJM8LB
M\;-M@7)+H%P+E$D@WQ:H_NN@2@)W7>X#1L9[B)CL8T1[CX@FR&HP$SW##ZK/
M3!IT4M;-.`QD4,J"4\@>=AB-[NDM"8?!^G#O8AW_QIA8-=W>UO+`FS]02P,$
M%`````@`&C,&1V##+^$D`P``F@T``!D```!X;"]W;W)K<VAE971S+W-H965T
M,C<N>&ULC5?-CILP&'P5Q`,4;/XC@K1+4K6'2JL]M&<V<1*T@%/L;+9O7QL;
M@K/&3@X!G/G&X\$9?<ZON'\G)X2H\]DV'5F[)TK/*\\CNQ-J*_(-GU''?CG@
MOJTH>^R/'CGWJ-H/16WC0=^/O;:J.[?(A[&7OLCQA39UAUYZAUS:MNK_/:,&
M7]<N<,>!U_IXHGS`*W)OJMO7+>I(C3NG1X>U^P166P@Y9$#\KM&5S.X=+OX-
MXW?^\'._=GVN`35H1SE%Q2X?J$1-PYG8S'\EZ6U.7CB_']F_#\ME\M\J@DK<
M_*GW],34^JZS1X?JTM!7?/V!Y!HB3KC##1F^G=V%4-R.):[35I_B6G?#]2I^
M27U9IB^`L@!.!=,\^H)`%@2W@M!8$,J"\-$9(ED0W<W@B;4/SFTJ6A5YCZ].
M+U[WN>*["JPB]FYV#AD&F6G$Y0#V+HK\HX!1D'L?G$ABX`SS+#!)M`S9"`B8
M$!X3,*F`.A7*#%"H6)Z@%(@D-FBPDFR_D"@R`YW,8&Y6(,T*]02ACB"<$X0#
M0>JK&I,!T@DK!"2&?KH,*@4()$D:+:,V$N7#+#20;4.YJC1>,":RKBN2%)&>
M(+8Z&YN=3:P*$JVST=Q9`3$@2BMB(Q"9SS[+J.T]C[*6U+J65)JQ\#HRJYN9
MV4V>HA8)P+?[*3$!R!*#IR,*@LS@JT3%X?VV5WR=4&!AHP%MX*DK&Q,O6:#0
MII5B+X`6?[5)HJH('O!78`",3'OV(=0&C-%EW+<ZE+HR>\2!*4X6*+1IHOH;
M6?S5YHFJ(G[`7X$)LLADKTRF(`M,]L;R)?@&KNTX(0@7_MG`GG,@D=YD"Q3:
M>%'M32WV:@-&59$]8*_$&/[0I<3$L3$;!,@8,]L1Q)KAA2;$'GI0Q`N,%W8_
MU*:+XBT$9F^A-EU4%=#>)$@,@(FI2QA1_ES.US9!PF`<F+J$VY39_=;S9HUG
MB_KCT/(39X<O'>7^S$:G8\73<*JX&W\&JQ)HQC?L&"(.#3?Z(C]71_2KZH]U
M1YPW3%F[//2V!XPI8HK];VR#G-A!:7IHT('RVX3=]^+H(!XH/H\GH>DX5OP'
M4$L#!!0````(`!HS!D=&,)2)8P4``/\B```9````>&PO=V]R:W-H965T<R]S
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M&62H@2`#@1I(,I"H@2(#A1IH,M"H@2$#@QKD9)"C!GW.A\REL,DQV0PVL>EF
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MIKEJ_\I^'#3,J,!0)CZ4H:&,VT,>7]@\O+!]!8E-@J7D(_<'?&=%/`U$S-R'
MZG@T@L?X?`#TL`@^#."'94C4@T@&@P8`8D2081X?`$(LPA`#(&((123BH;W-
M`(X8@20]QP9S`S(.VD2"=B,RGD>.!#V(,A$(F@,P<>+$<(\/-R+CXL#"07,W
M(N-Y\/CV_D0BVMZ^J`&8>`8L,8FZBXK0:`!-W-+DJ[\`33Q"$P=HXLI=@\=1
M#Z)<AH(&:.(ZGM#W)&*YEH'1@,+$#9)0$AD>B@T@E%,5,[[+(3=XHX1F:3BA
M&5";,EN;`A=5]R1B06@R`-&,$#7*O\;W)/HK,AQRP4CX&>WQX29OO,@BLLAN
M\L;SD.Y%'FTM$@4+;P8@FA&BQG.%E;G)&P>M(T$#/&4&"=H`00,X91:GW.U#
M`#B)"$X"P$D`.'TCT7G0;X0/'N%X5@!V@K#+?3[<+(U7)XNL#M)4698"!_HU
MB;+H\MR24I^?$V\/,%+:$\6W#`#*0@)5@D2^80"(!4&<G_7MIZ*KH\ASX26`
M&BN(]#SS+]\5B=ZD9#P:<"8(.A-RWR8"VC\1Z?\D<,DJ"?4\=#:12`3WC`0.
M!4F'0NZ[F0#T?S+2_TF@'$I".->!3744><J'!#B7Q'GN.8TE<OLD<K4J`8JD
MBI\WGTG$>'!W2X`E29AX?0#=GXQT?Q(HAC)'=O<@TL&H%<"22BEJ3Z.O@/9/
M1=H_!10Y90D)1:V0]D\!+"FD_2,1#X\&`*6H)J;<OY$_J'&1\XP&U#@E:31/
MLZG<Z(TSJB(9!7A2GOYOO,9'Z$)1`[5)&7+DFS%0FU2D-FF`)PW<F_RJD=JD
M@=JDB3SI.:HU4)MTI#9I@"?MN;D_RK5&>-(`3UH`])+(-PP`DK8@!;J!&Q*9
M8$Q`L=.*!O-<96B@[].1OD\#'&F#9-+>;`E&#=0Z3<0IWS<20.-G(HV?`3@R
M#(B:1)*90-0&J'6&N_?OZ*LP*W+OK.3D^^%=\5)^*>J7U;:9/%9M6VT.7PL_
M5U5;=I[2=UT4R[)8'%^LR^>V?]I#4`^_SQA>M-7NDGYN<OS-R_Q_4$L#!!0`
M```(`!HS!D=L#LN#G0(``($)```9````>&PO=V]R:W-H965T<R]S:&5E=#(Y
M+GAM;(V6VW*;,!"&7X7A`8(D$`</9B8^=-J+SF1RT5XKMFPS`>0B.4[?OCJ!
M<2K`-P:);U?__N"5\BMKW_F)4N%]UE7#E_Y)B/,B"/CN1&O"G]B9-O+)@;4U
M$7+8'@-^;BG9ZZ"Z"A``<5"3LO&+7,^]M$7.+J(J&_K2>OQ2UZ3]NZ(5NRY]
MZ'<3K^7Q)-1$4.1!'[<O:]KPDC5>2P]+_QDNMC!4B"9^E?3*!_>>$O_&V+L:
M_-@O?:`TT(KNA$I!Y.6#KFE5J4QRY3\VZ6U-%3B\[[)_T^5*^6^$TS6K?I=[
M<9)J@>_MZ8%<*O'*KM^IK0&KA#M6<?WK[2Y<L+H+\;V:?)IKV>CKU3Q)@0US
M!R`;@/J`?AUW0&@#PEM`-!D0V8#HT16P#<!?5@A,[=JY#1&DR%MV]5KSNL]$
M?55P@>6[V7E<3TK3N*\`^2Z*_*,(09(''RJ19="`61DFP>/(QB"P)P(IH%>!
M7"KN5D`Z'(TOL#9$$D]HF$VR_2_)G<S0)3,<FA5:LU)W@LB5(!HFB&R"[%YD
MHIG&>&&8",=@'%I;",;1.+0Q4):$R3BT-5"*$787A6>+PJ8H"-P)XEE;XVE;
MDUD%B=M6/+35,"B<8-:62<$XLS$,CL-Q9FN9+',7E,X6E%I+1_Y0V:REV;2E
MJH_.2(#@`5,MA"#"$[9:"J8AFC#64A&.D@EK.UDI&/E>H;/GW9=FFQY$(RF<
M#>O.7XAF#'8VDWL5X0/-P$((9O%$-^@H@-%$.[!4%*.I?M!1$'W]^(+!_E+3
M]JAW=N[MV*41RI[!;']Z>$9J?_HROX*+-73,;]1I0^]GM_1%?B9'^I.TQ[+A
MWAL3<E?46]B!,4&E8/`DOX^3/`_U@XH>A+I-Y'UK3@AF(-BY._#TIZ[B'U!+
M`P04````"``:,P9'75!TJ64"``"L!P``&0```'AL+W=O<FMS:&5E=',O<VAE
M970S,"YX;6R-5=N.FS`0_17$!X2K,8D(T@92M0^55OO0/CO$"6@!4]M9MG]?
MWT)(%DA?8GLXY\R9<>1)>D+?68DQMSZ;NF5;N^2\VS@.*TK<(+8B'6[%EQ.A
M#>+B2,\.ZRA&1T5J:L=WW<AI4-7:::)BKS1-R(7758M?J<4N38/HWQVN2;^U
M/?L:>*O.)9<!)TV<@7>L&MRRBK06Q:>M_>)M]K%$*,"O"O=LM+>D]P,A[_+P
MX[BU76D!U[C@4@&)Y0-GN*ZED$C\QVC>4DKB>']5_Z:J%>X/B.&,U+^K(R^%
M6=>VCOB$+C5_(_UW;$H`4K`@-5._5G%AG#17BFTUZ%.O5:O67G^!:T.;)OB&
MX`^$(<\T(3"$X$8(%PFA(83_FP$8`GC(X.C:5>=RQ%&:4-);5-]VA^2?RML`
M<3>%Q510-(W9$B#N(DT^TL`+$N=#"AF,/\+L-`:">4BN(=Z`<(2!P84_Y>(N
M@Z_H_GR"3"-@M.#AJ<C^B\B=S6#*9C!N5F":%4X+A%,"X5@@-`(/K00*T^I>
M:`P,@C7PYV&9D0(N>+R[,2S7L'6T]H$[#]MKF.=Z,([A='7@:77`5#?3W^AI
M?Z/E_L*G#J`1@`O]U9@H%L_F0GL-*O3C:`&6:U@(UZZWU%[C"\+(#=WIXN*G
MQ<6FN/@^T7I<G,:$J]B;!V4:!%9^.`_*-2A:!0M*^ZM2_'ACSN@M:C`]JRG`
MK()<6BXO?10=!LV++]^RA_C.VV3>1#P7@TG/D9M\FG3HC'\B>JY:9AT(%R^H
M>NY.A'`L_+HK<2NE&)W#H<8G+K=0[*F>)OK`27>=C<.`3O\!4$L#!!0````(
M`!HS!D?8XB7!!0(``+0%```9````>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM
M;(U479.;(!3]*XP_("AJTLT89S8F.^U#9W;VH7TFAJBS("Z0N/WWY2O&I";;
M%X'K.><>+G"SGHMW61.BP">CK5P%M5+=$D)9UH1A.>,=:?6?`Q<,*[T4%92=
M('AO28Q"%(9SR'#3!GEF8Z\BS_A1T:8EKP+((V-8_%D3ROM5$`7GP%M3U<H$
M8)[!@;=O&&EEPUL@R&$5/$?+;6H0%O"K(;T<S8'QON/\W2Q^[%=!:"P02DIE
M%+`>3J0@E!HAG?C#:UY2&N)X?E9_L;O5[G=8DH+3W\U>U=IL&(`].>`C56^\
M_T[\%JS#DE-IOZ`\2L79F1(`AC_=V+1V[-V?;Z&G31.0)Z"!,.29)L2>$%\(
MR4-"X@G)_V9(/2&]R0#=WFWE-ECA/!.\!\*==H?-I8J6J3Z;$D@;U$63@0'H
ML\BS4QY'3QD\&2&/02/,VF$6Z7W(QD&B`0&U@<$%FG)QE0%9.KJ?H'"(Q?R!
MAR]%MO^(7-F,IVPFXV+%OEAW!)(I@7@LD#@!%$X+I%\Z2+U`=+U+\RXTJ'75
M="`4S>8/4(5'H5GZ`+49M!8/4-L!]72S,3BZDXR(RG8#"4I^;)6IS2@Z-)QG
M9.[T37P=+8MH(K[1#<KUDXM\GG6X(C^QJ)I6@AU7^B79:W_@7!'M-YSI2M>Z
MA0X+2@[*3!=Z+EQ7<0O%NW./'!IU_A=02P,$%`````@`&C,&1\3:D;8550``
MEBX!`!0```!X;"]S:&%R9613=')I;F=S+GAM;.V]ZV[<6)8N^+OW4Q`-%T8&
MJ$@I=+&47:<`6;:SW)6^E&5WGN[&_&!$4!(S(\@HDF$Y"N?'>8CY,R\Q#S&/
M<I[DK.O>:_,2"J5K!@.<`0I9MH/DOJV][NM;?VR:-OFV6I;-?_GG^[9=__C#
M#\W\/E]ES:1:YR7\<EO5JZR%O]9W/S3K.L\6S7V>MZOE#].CH_,?5EE1_G.R
M*8N_;?+K:E.V_^6?3Z;3?_[3'YOB3W]L__2JFF]6>=DF6;E(7I=MT6Z3MR5_
MLZC*Y#!I[K,Z;_[X0_NG/_Z`[_![Y\F[JFSO&WAGD2^ZO_[KIIPD)T=I,CTZ
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M@`O9)`=?RFRS*."7YW"OOMR\2@Z>/4^>)469?+ZO-@U\NT\`^1PHZ9@NR^G8
MYF5-`]__L?=SUMS3O9[C'_*_;8JOV1*>[PWR*8?#+N8X97RT^_/-?56WAVU>
MKV"J7^'9U=!'8&^1O31)G<]S&&FVS-.DS-ON<V_A$V4[<$0?VGLXP'FTIAY%
M5RU0R>YG/M;`&>MVFR;K92:<#1>_QFD/3NFGJEH\%,O>#>$9[9K)\&]Z+LLB
MFQ7+HBWR_N'X[5IG6]RK@=_K#1Y(M0(^WQ#W&WUF690%7A\X1?AO_@W?Z/-L
M68Z\-/;4VQ).&@YY;&+7V;K`I2_SK,F3:K8L[FAR3>K/90WT,C#=5_EM#@\L
M@$*`!#;YHR_$%&%V<S=9['CP)B^+JDZ:')Z%B915VW]FQP*7>=,\-NF?9?0M
M+'-);*"MD@8N7E+=)K>;%@9.ZFJ;+8?FU]^B?8;D?5I6Y1W?TD=W:L<#R/H*
MON',.T#,`\?+R_G0=B*#O*^6B[QN_C>Z9.VV1^D?:UU4P_STV='DZ.CH&`BL
M3H`CX2J/CU+X)]$UDFS3`LLI_IXOX+I6^J^+O"GN2MS1-"F:!FD8CK(*7#G)
MV@0D;^Z5"_P=&&B^FL'VC#)1YO7C<SLYXLF%6?U+<GPR38\OSOR$8:..88#I
M\;G^D\P0?]DY17R@-\<4SK]9Y_.V^)HO^S)3"!3D1OYMCO0!E.4G/,`D-JL-
M4V+%%PI82IW?P^V'SP/9-$.\W+^SR&^+>='CF4Q(S0`!/$IRM.9]WGRZ6#WX
MF.%%N<];Y(<H9I\E/XRHL#<M?(V4*]B^-T4)WT3N^;%JBD=4S1Y%CVY^[\D>
MA>_[1J#^?=]@"MSWZ6J7=F-OR.A:X\<>7>C@X\-S'GQTYX0'Z<8?.%V8#VM4
M!)&OCRAF.B6CG:6/:&LG>UM%/3;TB1G^`/>L%IMY2Q*$;PX+CZV*B)YR7I6'
MI/!UGOL]XNCG8H[["(*Z6BZS6<4;QDR-6,G('/C*C_PH&P_,<%XU(F54&>GK
ML/`(SO0.5+0F@;/L[2HHKV`TS%G37<"0RXHTO9Z2EY<YFB+X6+98@<:$MQLY
M[/#LJQW3[.T3\-#DMJY6^A90U="YA&\6)7#A/#F0+S[O+=RK8?+$Z#$7G0<3
M.*#E]^@@?F298SCM[J0'E6G>O3):K;PP^#SMW2P'$S]/UG7UM6B0Q."O.ER;
M?>M/\N/>3[[/VT$9]S)KBCD33;'<X!Z5\F0"\^;;WWWGE[RXN\='LZ^P-#`H
M^[PHV2#?`2:!4G9#JY_]CI'V8F'7D2"GC?P]-F8D".-OON6-'1>%UX_J$ONM
M!"GYS;)Z^'TKH-=OZ75["U'?0AUJQ`);_+H16Q:O!YBM%6@`<$?\Z<"_XI_I
MFA%I`E-/9MOD0,[X^7X#D99\"%3PB#GW*H>M!!W$\]ALA?K^WP<?9IV_5"Z`
MSIH&YS#`>:[O,U#@29*9^9+E2L/L,E.[!LF(Z3%N3[Q_^@8^=KKLA'ADT]]E
MP.58W03ZVN&W^+@!X0%G\]AS-\(^]_W4>I<;8G27E'L,K?&Q?;EE'7;WOGS,
MMGK5YV.&;E_$KL-;L*YYGB]DS+V%"BAVI+3CN)$ZAS<,MU4?(&D[P.[MH)&)
MM0'^4HL%$=TOVOC]"')HZWJ^P=M;L,APKF!UT95*T)/8H,"=[^MJP]%!6M6T
MY0>+G/_TG`3&OM\8]>NA=3G+[XJRQ)7@69&[^$GOYRCMQ]Z\V:S72^+:0#:+
MHID#F\1C)V(28H2E>'?]L$MRG14+$=NL:?282GV7E<+W:*(WF]4JJ[<XS@U8
M0058I'BEQ(>&B_T(@F7(0V$_E1H)I%\&<ZC!Y=`_1':@$5#CXN]]U>;)<?(_
M_OO_D>PY:3<P:6??=;^`R@5[FB6SHEH#I:^R>;XA>Y:H.RNWR7V>+?ZVR6K<
M/F(7-UF9O*EQYLV\2MUUMBQ@@\LBHYF@>E2O*_9[P].O0"E\@#$FB8PE:C/1
MOUL7ZWQ9E'2JBWH#^B]J-@LB]?8>2`0FLP2+#K2>.OGX^J?MTJ_998NO>(D7
MR;I:`L=`7T/YZP;8"BAG^?R^K);5W1;O98LTTB0/10NRZQZYSZ_L[G`@=(L5
MWLV<?IB!VGY;L):`LVF(<M8P)![-Q'W8H!4R;`*8RYS<@\H&#P*QD^UK#J0J
M[RI6R96QH^#'];(0AOU!_74N:C0[Q,">(IV!ON?,Y\QG)LD57"F<W6;9ILF#
M?J?[%3B>3>V:S0QUR!9I#[4/L?;*_(Z,E'#!>I8&'BELE6,>3(=*JV6FAFX?
MV"/S^+HN@#"+Y1;>JJO-W3U]V]V1@82KI.\OR?:#C1FR_E99N;F%W0416]ZY
M[*[.\^`R#,S4:B6P&QW?%VZ)N\]@B]=PWM]@4FT.DWHV?7$Y>9&LBN42A[.<
MT<A>^+.#5?R6M^BD9H\NG32,LVRJ%!0<))G>@+`U"_?L^.1D<F:'",[313Z#
MPX(S66Y(GW]V/#V;'/EGJUO7##B1:7K/+LQ'=PG8U,&O#_<%D.RSL\EYF(AW
M]4X<VB>TA(A%,<^"V17K)>D9+N)I=!WF5L^^]0RM"0R-5\<7S#_@UN+Y2H5D
M:71#-UYD,!7BCS#:PSU0Q_:P>BCS!1%QL2B`ND#U2-[GO[59#6H[?&)-/`S4
M^[?`3++GN(BO>,5^+E:HZR<'_+"3GW&LH=>__$7?P'->L@@1MN@RC:G@VY;V
M^#[,\KQ,@+6![2^<T,WMYDV0]8(*OLYJN30CMLN0D'"WL`W5`U']O><TWL#!
M?[OQ-,K1=M$B'+G<&S)F#VY>7S\/LK%8P8?(Z5_>$3>!PX#%MU[K:>^K)G?U
M!F@!KBFHFUF!%G'5,E&B?YP4]$`%1CHS-X?%NA+_"4XQ,$C0B;Y,;B8),P7\
M"38W7Y/M&P38VE.B._CIZNHC3STKRPV,Q"I$@^(#MAZI4O829\6KF("!2:P+
M98]<&F`M8%ESK`Y^:O+=)`QSD^FS<PSWN"9!9LT[7.@#S0'($^VF'/WF*)UQ
MPL0\LZ+&PX^T`:2!,+K>#_:(J.'BY+*P*'H"Q8CD+2M#C[3G"V2W-3(RV.D:
MF=`2K(AYL.(Z^N<L;Q^0M'$9P$J!<1-+1(\*R"7A*/,MWPJ@0S-(@F'/)&/-
M%M^G6[/T&Y!GP*+T0_YR;__'?_\_&[,QL@,.:+:R7Q=9O0'=0XPB3\VTM991
MN=[G)LEG,YD[H&PQ5T4XPNX)$=#697O$.4121L$'6(L3XZ')Y[IP?&JO\`/,
MLG+X0PK[`YLEDR")K1MO-]62)7$EN*F..)-5(F`?NQLT0(@38?>]91*=-ZWG
MT<'?M-PT3-5\IFYPCOV]+I'A@*F">M\BP9W#,Z3GG'D.U_<U*Y9(?X<PQ"&9
MAT$VH[57T-EX^?>0=_2G!>D4=`"@GN2LA#7%MV3%KO4<7>M>KCL?1$.G.O&3
M;+$0,88CY30"A1&-S@=L8ID!R\6_LH2H-F3:[45%;>68BJP+RPC*O9;@^G%`
M6H(#>4<\EF0:?N>)/,5MU($V0=FY%QFCNINQRN1ZT<CD(</X$PALU0UQ93+&
MV"4VF\,'W;FO1(57+"D^$5<`ZG%O@),GQT>'?U&^G&PQ(XC/O#^QVV()_XY&
M!!T("$\DP3?YK-X@;Y^>\^;R/EC)9R?2WA>-^RM;4\MMF$RBD_EKTMQ7F^4"
MI1CFU[%W%^R:DMF%'_]QQ4M9<'2^+*N)J*I'Q-WHSM%DW=X[-W&?-,%`8QJI
MN`33KD^0!/A7W$^A:Q0*3LQ/Y94X&&^SZHZL@\'XRG6;7)4:]U0I"3OD13;8
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M.!C!2V+SP@M<E/Z3^N2QD8PSNQ)U[CF-2[+78E,/1R?QAS%G<NJ:D1`*,ROU
MX"`EW^F_@ZR]8Q$>SI%\(S,RQF&X<+QP'"`$8`MI33AA,&!1./+7A5M8*J3+
M::[S#,X:Z)W)$WVZ54F'I&8:7*:B!M4"73QSG,AG8HAA"GC4[/`BNQ\9%_`'
M7-6OF\4=FYA`/!N^I?.LKDEV$!'L8@4/][EP7R?/*D-%489.(#`9*&E&#HB6
MVL#^T#31@X7>&:!JU''MO40?)6I]>"9D)S#MLK*X7NC!UOGM$EF8.#:<%<-T
MZ\IM9-OX`8@L@_TY`SN7/Z5B.]<1;XL:P]4@4EK0Z$#O`>G6T>_<M1C'H+.L
MT`66?RVJ34,FK[`N^!%SKO"=(6;GYMFZZTP(:J3W#?(Y5GQ*FK9'TW36NIPD
M-V@M]/70146'8_@57MAYZX:F[+,$0Q@-%=34*_QPY3$<[U2T6\I`%U9L!TD0
M9>)N<J(XFWF/OA$>)2<=!'37V:8I2DP_:^1Q5O1N,3E=C`&P1K=B[;E!!W#'
MVVMX'IF?#7KWBN:>,^G`T/^:+[M.:;K4G:GIC&;Y/-OP=7=^NA5*!)B5G&13
MK`HTA3'^"[;XO`D9#PX($_W^\'B#[B?K%R2.G+4B7]><IM,,>$<I8-80=VRW
M:[ZLL$-MM8)=3S&,`DQTMJ$+L<I!PBPDSR>_0T,$^+K+RZ]%797L5!:??627
M`%$P,UJ0$C]P.&ZV99?6?9&#HO,-;#+2GS[<`NTA<X,1@0=&*DJ>K8`6C&T&
MVMJ<,OKY3I'UJ2NA2077<B=R@9^?%56@`<<*<*%!!7Q[6<TS<[O)DT">L@W&
M4EDF9_TT<V"92PD=EBV9KD#C2TF^W)3R%YCU`EF(OB5N]/5(?A6+.^!".0K'
M!EVT0(VPLVSP`I/*Y:SYHC8)2R<<C6B+OFY$/H4?.$[A>G$*KPO`\2+#MCP7
M'5<2JQ3WFLO0U4A+QG]85)M9"QINXO=FMJ6QZJ](J/B(,C9D*"XPROZK1%Z!
MZ0HWTC@'+:>E-"HOS3T!T*MR@2GL@>1+*6)%_B">".>?1G:C4661O4$-JS`+
M`D5]G8.1F<#M^PV_[M1A8D1T%,O1%\0=X>>HJS/'+YFY=?+87J+QBSX:.PS&
M2=F/L3/?V+&IY8-L:[3&2C+72-W!:&I!5T<2K9'7&.Z!/X%9J(=?9P^!W%*)
MA@DIB<YI"2<!$XVT+.2<H&EYK8OH%\P/M/N-O]!/H,-\K"N;'"SJ9YYGQ-0>
M2"'>XJHP7(0.']8><#ZTQBTJHLB44*G!/*\YNH.0+?CE3,@2A)%(JT^5!:!\
M:XE!.-DM=9LNLRV[DDG/K#=K-?=0GV`%+.7SE57#1LJ5HP7RO6=%L!OEI+1R
M^R;O5451.ER/C>4D<_4-&`H1L8VN]%3$(CW&%)SY=2?9`BP$5`0EN8`I0YEW
M:A01])^37\OQ^0Q$:+Q5GX#^4\%D?$A(;;&BX\BA9=8U:E_BJT&C->;=KL>[
M.Y8,J(]MJ62\RK8R.1F!CMW1L8NM[B,E/X*>"`])<@P''.'G'*E*>`-IPLZ3
MYEBD-PW\V;^9ND@.LQ..C\\_$C-\DC!6!W'VG%F59[>L67Y#2U8#T4=-B5J0
M-I>HLE(\Q"<$C<XK*C;A:SL2V39/TIVL:K(S*N5;/JZQ@I/`",UASHD;T7'3
MY15QL&7SW]BLSCN=D"KD1IK7V;)'JP*Y#5-Y]'Z=B\H+2@AY4M`>DEA^B"*!
MD5%FR^W?5:DR(U`R@$XO,J>]2P7?V+#W1@TE/E7R4IEWZ)AFR/?-YE&DGY])
M2%[.2>R#Q+F[;Y%NE2CA.1P%7B95.F4_DO<B!:75?WJ2R&5T!2DK>!__3GX"
MWHHEQY[(<C(2&3<HWA^G)IPDDH9\;G_'B:$B0R'F"$KDC^+[+AIT(S2;C)S7
M.8H1G"5K7&5TF/DWC!BDNAU;4(X;5\W)AEFPZX!<&\A#;HMOS'P7.<;,BY*K
M_5B,$<%S--MY2WA+UG.-MMD5F[!`7/DZBC.5H";L(M=$25J9YZI:>,N)]JSD
M52`E[?I0ZAXH<$CJ)O[!!P;Y4ZPE^"!K]U,NXIAXY^`+`X0M&F%5BKN+PT(N
M<A2)QI]:0U??(DE`F=UB$W/R@7W[X/7-Q^?L=_49-.3(O/F(YT34S2>4AQ-T
M6>N#+\D#22\-E@/IDQ.FN)7'63FN_.U`=<AA&CZ9=PEE/1]F2[(XT'%!2F`8
M$^>A/EC9/<K<Z''16`K-MOY$[%DFR#2K6AD3Y::`X40:X5+R"-HJY50CGS"U
M!)IHM^K3'+ZL$J$A0U`>]M,E8Q[#[/*JIPNUR*.Y@V&/E(U;2]9O%'92#H7J
M#;Q4?)62,-P>V"IB^MN@'$B4EUW^QO7"9Q:K&\91+)1M(IGL!(B)7'P4[!\E
M!K`,P:PL[/D`T4]<5)7B.C4JD1T8J1O,-YATF5DT[2'&),=%M<DM(MVD1SE.
MU8^0^-2U$'!3K?I>YS!.&>R#8)6`!A57S;B?]%Z2K*1D,*P17XIS2U4'8P\-
M3B[F!>B>X<WB`RIJ5MQQHUBM]ZD9G.,DQBQ=/'%Q>%T:N4TMKCX*=U)\5LM_
M'(DRWAPOA7JU05[$<$E)$U@@R$#_H[[%3GZ)M?@GX2TF4;6N@BA@$=@3!<DO
M>*)2ZJ@$6<;U2P7I$8\6L6!]'`C!&6Y4FU!:)E51JMKKC`2F]?BIINSJ>2BP
M/L7HR>8%#EHXXW&$,V`.ZCE[;@NS*"AG=E%L`!>8/`E6GX^@P;3LMF5OL;7+
M(@^%(P&?+?*)V[<XBP/*?&2P<ZIRHYIM'O;ZMC]/8,(;8M:J`^F9CC!M[\91
MR8H')@&$C81Y!EAO(XD36=/7BP?,K53L/RE+P#F%735G!C-$6G/55U':?4S0
M3D..4U+(L[FG1A34EN/A]:%XW9!0MKYH&D^EJPL)G[>;Y2TZM*O-F,+8J*5H
M[`GK-"49?<MQB(+C"*DQB'RJ:^JC,VXX%S;M.REMIBQRLNA-S1+E$/<*^"0:
MI)KJ7$6JPB3Y";:.<Y%\:$ZK,#@(/$Y"Z8BP].K^HJ_1P-V,YV&L-Q.0P"!_
M.+*BD>-BCQA\_E#M&%!0KT.L=$0O#$D0\WL,^V@T+0M9O""&@DD:LQ.*0C0D
M1T`2;>-@AHM82_0)&<Q[%!YR#3M1XBCG_*"H]EG5,AMVIG<I+]BS7T%4HQYC
M+KH;"U:"M1;/"NO#2_8[H_Z-#AMW4#QG=H"I`U6Y9,-+IB^BD-99+7/VX9`3
M09QJ3J0D"5K.-8MN3*UB5*P361]LOH9OJDU+=6OLB"`GJ)[8\$=3F'+!V8M^
M\\E\2NR!!H+>VG"YZ]K%!1VNY.:36).GV9U%@2VS(2EY6&`"NFNLWXD7I0@9
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M83J)3L=G`6;F+F3+Z"Z#0L@!_G++^Q<V5.ZB95]RERD"1,5@%$KS$@@,Q>`$
MW$4'G61%+`]1&>1T1NR2&SII=DFS^KF27?->(-"[9N&>H],I<(&H*D7E0H8>
M.+C6J<V2)BL]?'UD'BQ&T`4BW]I'BHCM8)D3/$[Y)2'C.=*?@NV2-5Y-%RN@
MK[MRF2`<I3,S)4%4W$J0B=6]00'[U+NL`9'@"%\V(6R#=&O2KSKWFX6A,"^]
M[*X3!Y<,-U%,=9P))OU)UK%)[^(,+!>5&X7=(TU#IV"VDHTBE@5TI*YCAJ@/
M7K4/V*^@>-/$(W83+6&V'5E"&JHP65]XU'OX'5RV=RI[LEI1*_"8R`3[6BTW
M*Q-N\U8[60F^QH"U73O&S"<;..\[V)K3@.6@1P[5@W!@=+XTL.0_Z?..YMN=
MJW\ZD6D^?8LC1(U7YM:_YDRN^`'+%@0I0RKF*,$S:[B^38TU-6Q@CE0EE(8*
MOV",=K$W5*@AS@+*R>"J#U%!O-3>\$0K#(LD^7T;F1X/J=Q*V(\#J'E+&:^=
MR"#R-&.21?95R?%'90:@)-0+(KY"N>0.I?K-GH/C,Q3Q1&5P9";PC;LZ6TET
MA_+_N`3PH72W&TS(Q;N!J61U7JQFF[IA\B&FF9F);REVC:18+SCU#U4"[\_U
MJ7Y\2,+^8S7#&<,R^$^)'YCM80]VB'6B@1<LQJB^L":I\:OPM3*_J]I"4OXH
M1UG2+B1>*`X(']8VT4DXHDV)S,^G(7!9FRB0\,.B0H?@1[V>/I7/?[Z1F#[:
M(^*:3HS^Y3IW4RF#K`!V>V!B$&8;Y&4-I.%+[*6ZE0V#CA:GP?<X`S-L<YS!
MX3AC4V]F2*T(-B+06GNX64O8W^?D*I`!9[9W=$?QKK"W(R:&CD'N=GZ_DVXR
M,ME@T+;`K[A$E]X?4FLC1RL[OF-*]4[Q[K<PH+'.?7&Q9&(R5_99K&*I^X?H
MBSNV0YYS9C3V2OAYZI<,#8AYT4IJQ-LRF+91&FEPG46<!S13GRO;<)0W^#_'
M<G>3#6NL$I$2GQ,7SKD@U$B*D>-9LC%-$GZ+I95WG&[>M('Q3]P5UX5'47W!
M=`JQ):W3$_-XP[6"#FL(2(G%=]3ONT?%-WK/I0*7W"Y9PQG]A4E'EY)!]<R@
M5BCG+%=8?;L\5TD]0<.0XY_6_>M700$0Y77$0H=3CBFDRT!+)B56ZZ?$SG!X
MFI/DS]4#K!+T)>,+L*]Q<)OQFOP72*UQP:E(J4ZHZ6CQ0<8GB45/%)T/#K)2
M=MIIB017:J)GXRN%V!]\0-T:_"HK(FB=<9'KS\&/YQ/@?=`AH^P)M\37.+Y*
M)ZS+;20*HD4`E%:KKH6&8]3R%T<Y^`T[J0/3,6824_=@-C(*7Z7,*`]YK\6)
M3D^A`Y.F_#,FW/],%LL59>A2KA@E50_DZO?3\VV^I6:7N`&X&7:3:ZI_5$O4
M>A@AR<_63^,!(,F)N,*=-!OCTTLC?J2%.7EP>?E,=5.U0L?*Z>I(0QBNFW&-
MSI;XE/A=)!>26)Q.`BF5B"]X@8VM7.>4M4"YV5EIMZ\HI5YBQA@QF2]#H8F0
M/U"G*MXH$CJHEU)IL("!8I0"B&E3JQ:#5DA;S(LU"2K0$1"!`Q::+P)VE*^7
M]^-IX3/ET-DZ#!?FC'E"&/M+/!.3VK7(\!(=FSQL/#'T8X4IPTBW8WNA*1]^
M6F@1/-18FETF"U`7*3V[;8PXBSY<)N^(\CV80U:6U89"KO[\F4*W6(BVK@JC
M9K]\?77]X7WRD63O28A9-.UFP:DQ"%!^>'PT)=>RY!8>9G<<DD!,`'[L`;B`
M%.%Y^!&081EF[H/`G.'E)T\TICF#+DWTIIY)>JCA/+<0?)CG?>R.H+W&NZFN
M$TI4(_]'_YJ&K'$]YRBWF!5_VB?7?3NYJRM0GKS-#?>VT.":WZ%)\E*T"4<\
MNNO.D?NNA\*>[;**EM$Z/DPI$:1DUBB[=>($#>XSPNQAJ28+_<>+=.,*5Z^.
MU`O93(_>UP$`Q'T1$`B"A8C`*(!3E9(V23Y<>+N6<%R,)W)R^@>V+RB?_#9'
MSS>&QB2"B"\*,^H@H&CE=%Q<(5@RS&2(9TFN-09FZ%!#5*;E?6Y91BV+W\A#
M#5R4,HK]'1$+.`GRA546JF/).T!'=<5WC'T`=`>WLJ_XK5!#:5ZZP32=K`:Q
M^K*"_TL.WES=O'PN`%KN;@,&)N?/+]C/`1QB\.UKFW!U<'5S_=R='YVG/M/-
MI)T2)I*FH])V7GNKB3CKM2\<&'@[Q85=P9U8"G.AI<&D%?3+SQES`H",EY+`
MZ+H0#@CGT@$78Z<V*BWLUC0/.'Z`]0#YE,2V\.9MV&_B8R5`P^C3JACY$;_D
M?)HUTARR:ITHJDZ>6I6Z%>6#"Z&PI%<5+@/D]:]92>7,?#'/)\D7<OPLJK4O
M<\?<N7".*]A:<EF3;P0UW+:N`IZTIJSI2'Z=I*M*RK_2,,D&&8I%F%T442SG
M-(>T/"Y8T@RV1XM()Z/X9&\CN!\4-@KW$Z!4NB^_00'U;R3>7OD*V$<AO*;)
MR*!N<%!W/8Q(E`PB$EG^3TA+$>0:)W/;_@NIU-9)HG23')`&*=B7SR?NM1?'
M9K7`$#V_C8H0QN'>G@$]I1<OSN`/Q]/TY/S,=3I!)-,S@C[G_W/#C2"2Z<E)
M^N+B+)G"8Z=GET[0^)^R13B5%Y?I^?D1_NE\FEY,3Y$8Q7N%`$T%3!PX['UQ
M=^\K&^CN6NBG#W2G_'B.8DS1,UT/DH?/)>'!E2:?P3P";60%/)B\'Z#)<R'U
M@H.4F#DK>?O-?7';,F"C^8YUO>$<S/#$^U81.&7[4%%M.NG8A/?/KJJ"JIG@
M9CUT86?E?<I3Q-B%5K;CRZ2Y&.0KMPMFWH1M[#$A1E8\Q]XH[J<:H3`,*D@/
M-42`-]IDL'3&/0[5/TE>=9`TW"/ZQ6Z%)!KRE,T(T0<;4L7*K0^(]6!,G*4S
M,Z_=6@\-@FE[;B<P"CNJ"&[L;#)5/#".L=[A1KOQ;29/`I:EL]M_:-=)_W'J
M_#+#<D)AQVGF?4UJJK+`=^P8FO28!'SR6821]I#%&3OH,1)J9N4B<[X@0.L5
M4-=8PMXM5<Z=&8>K]P?CT1Q/_S`,P8:WDSX`;[\0\:NL%:<%UYAF!$N)Q@D@
M!GY=XB;/R=6$R:*\D`TY+"D'3\SE#F96EJ#U6F:T()W]T&0=N6#DAI.,O;NK
M<P)*U&I&62[>L'B_E9='<@2>IC1H=AT`AXJ/1!-0R@4GRF^1ZY!;3PM!;[D#
MDZ0BDFO1,TGO=-8:)$&[0F<N"*FB\@B@^S)\K2WI"K<?G1%I?RZ`W8%-LDU^
M)N_/$^6>8EX:A+Y9A><Z18%W<99>'K^@/TW3L]-3\[Q)(UAGZ.R=)J>GZ>7)
M97(ZA9?.W%7_+L<"$<3JV;D7B.^`>V[5FF?2.DZ.S].SXVER?)Q.IY=4GLXW
MC7$W<\)X2M[_<)7`D/``J-,DR:TRT24,>OH2!/D)0M\<GYS_PT0Q[S\#G?YU
M4[6:Q=UP_@6GN]'7V+7+G&/N*\]);(3:\XE\<$H??%NN-_B(>'&`=G4XGP5=
MS=#"XG1=J;Q<P)V;X_VC_#']6_"(_\U.DS)KM-![<$K_$K\0MH>]TDY1$WBQ
M_Q*@]0J>O<]^#5,EEQF!WSDT%*J9(+!B)79X2,B"`)AHEB%)9<D.)C0R'6E=
ML>]L>$]/:$^_E&:([A0Q:,H``K,M&"QMRW,M*YV,][$R:]378H`RFAK<0^>!
M2';,[6I8T2!.FE'+-G7`Z]G#%X1(T*S&^,O2RP^2">PDGU5?&?*4RK/\`M`#
M@/D=,$^9WJ;V1&=FP)X!P<J)_%L=<!(7W1V5F,'_ZJM\9&?#AQHMX&![ZQ!Y
M\*RN?I,.`MX.2@U0EI?'LAZE8H[08KYFSMH?4#X8>V`<-F*D,R%)R%]J,D,T
M,%3DQ=0^<#WZ%[NJ78"^B,M(!\F9C@4FJ'7/,#YL"%F"DAQA-TG"3SYX(1^B
M>5I(!A/UZ.N'N_U0KN.':B-\.,VO#H"*2HKXAM".)@D:.KE7*85A+@W.("<:
M1*#U)YLEQE5,XIS0L[T[D?=#[[1<X<#[@R6MGW'!\K#&>P>_MN./MTJ5-$>[
M$3WE?5^I&LK_5`\YLX&>,>_;_1ES_#%K_$3$@KSIPC<LL&%K2XE[:L2P3O#)
MEM"C?$M/+J?T_U.P;W^IZM\.B_)0$#L2D*&PYK/T^.*%>X,-8^Y])/`X/0=2
M.DO/P&AF(>M1F%"E.$J/IZ=L5E^>3<T"(N>]J?1?</81);"MZ51N"V#X:^DH
MX*B^=ZS**`DE4&8D5;!8-#J+'$#_DM`'AHH!?/:,UFAA7,`'7(1Z"70'=BN5
M/V$^B90`1LLELL"L23*EX;08-(Z-D=HS;`J>J7L,ZV*YLUEA/M4+30P"8OD+
M-HCHY"K*L?F5PW=`+7=]D@T=_#X%$:#M']YPF/+36*.#S_FW-GFYK.:_/4;E
MIT3E>PSF_&#N@T4W/"6>,N7449MOGB7:B8+V%;_FKC2')CG`<^@]D/@'GO.]
M_O3QK3B3\^1S#4+&'<`_/4_)^W%["W,6754KYCX2:D"*-(O.5-(1?*$"&IJ<
MSH+?5;)>,$0#5UMS^#@GH)1N:AS.V9?FO>8"/)XKB,(F2O!_J.KEX@%3_'R5
M72JI30A03Q56L4<5=A"6<9`]3Z[?OON/MU?)__U_#?[/<65GP7PX%^^K#>M'
M]9;)0&<FN@.ZC@^A_)3C3&(<V["&8"E[,+7A$,?QBS]HCELH:C%Q9!^_<[V=
MA5W'$Z$-^G+]DNCA4S6_SQ4FA!U@Q.\IH3:D*V(4';-:<N\58NV=E;R"TJQ]
M`#W5ZNV0)$*:NO\<80]YT*M0ENH_"7?Y#N@QI/.PK",7]#KR;W/Z`:NCIH6.
M9B3U]W_B/AJB?>1^I.*+YL#G*9&5_^L)SXD=!\$#`JND;7[VPMKD\.EG)Y,C
MY]T]MNMCRE&'D*<]0-B8GO7N[:?KUY^0:%T7_';7*N#H,MQVG!4IKG@'G;F#
M:O.S1FNS,VW>"==0H`I6)2-W-%%T&W)<:6FBC=-(=@554T@%FWA1-,=_D:]*
M4^IO4#F\B<@UO`KIG5G\=Q^W8+PN<O`B1?U65@_+?'&7<_`Z\NI(!R_@<ASG
MX`2TQO0H\TJ([K(;HI5[3=PI;CUEH$NLIO1SHFO;%X#BM1YK-B:@1;;*[G)_
M9;U=%I>_<YFJ'CS76C_8,EUQ\N$\S1[UHS"=1K#7NQK![GSX"9K?&<G$G5\#
M*^X.&,N[K$4WE7M#?!]K,9`"X?]]G3:H#M525KS,'II-08`O]:Q0`+/4S<&F
M7%&`AMHMW05RU#Y'B.65JMXIC,O"NK@`ZQ+<1FF2`^E46T_^3/4KGG,P]`JN
M?J*J(RQ[R$C%Q81<'$9S;$+QJ:&]V]C"YB)M#CC/JI:Z&\TX"8S(Q(!N`EVP
M"1?E95.^JC<)6%5K/'B_21/WLD1RK<R<\!HRW!>7R2PI\^)O'EJ9HIS$FS5;
MC*$A-=6)NBLYL#Z5<YCT7MBU7\'R(8N'OV-;.";UAE#74DP!*=AYNB0Z0=.H
MR9?I"/]B"!N*%:V9X0DSRS@W>4X89IBE,P%532D$=SE@T+I-N4;<L7G+64MO
MV<&Z*6^SKQ5CS_#T_.VG-":6]=N0VLG26\U23L[A'!HXB4).C\$9.O!1+H1<
MQ9'MP:'BUB]TM%EKH3HY3.M,HA*#,6&XC<`@W\;<ESP#<"/+/*!?TXV5.C#/
M^QJ'#2NPK%,SP_<OU1#?B]8V+K74/89\"N:318S0^C.V!)R$H6UBO<^;U\*!
M3J8]L1"30HTSY<KCVQRKE%0>,443V@+JOJ0!1<L(:B=%;5J;6Q^#+XL6*RCT
M'!!0&1+@3CP60+C-!P\=#`7&N],L6.JD@CX3-.Q\)OH@+E5'V4.&,/P<92'1
M.7B4@"S@=WF'63!*/TL()]2`[Y+H8.@%$QE&7.<T/,4L"'615/ANV5W8+T+0
MYQ2G\)VR8A$IPTG%=84KI7OD.9^FO?IJSQ&!3/S8QWCZ2[+089.^E/(V&UML
M@KJ+W"R_PV:AX7*(/]LM"A)1[48;C@^W61HVOY@S=V8_H(0E00FCO]("6WP8
M<0@%V['BI@BPJU'UF]?9?'(CESL77?>!=F-A'0B]7_(%7^FV2SGDX54]1"@,
MCU1!-,+[9<"U]00=R;NH"+1+AO9*LMN2+F5I#)=4E$@6*(%N_-"L4@`1<@\Q
MZ3DEJ#1>Y/H\(^8I7D'A='@4@**;6#?THW=GDKP4P%L2YSZD&$\SD/WXIR1Q
MS67LH-:5LEE!";I+1&\$"W2S&MH%,RD0+:6D^`ZK$>^K:.,C>&5*$G12<A0W
MT1*W^GYM6MR>D)V<=S#2!UN442O%@K0;U&?/Q<?S^.M.P8LB3XXB,XR*3B\:
M`DI+W(QM&(&V@T&8NFXE6Q_GHRNO96KN,:#?Q`/]3I(O@5^.UL(-XRR)41IA
M1#J%L@EPC@,HD!;/EXUF6RX?5?9K9=NX8M'1))QI?QC<RO#*#U1<'Q7757&?
MPA%L%NYJ]IC"A.S<%#`@G7/01$">O0*BA7XV=&<:O@$376*F(K<1$K^ZL'F)
MJV!>B2UL"6J1+2-XK`@B)7_NFJ%<92C,EX[1EWW7HV%TT4X#&4EG<:$U/%?4
M4PEYL-IW;61<&;4(>N8CD$J=Y#QG`P^?*0X5Q9]NNGE('WE-[A7JG<B!\/^O
M5?]DQD2^)?\GT*5!RO\';/X\2ZY>)N\^_-O5^\]O_Y)\?H?_>X;Y`?K?Y/*(
MLO;HKXZ=>4"H5S?_?B.^S)/T^/(%_'=Z?)F<IZ='%_A?S&M8P?&FV/4;N'(.
MI@\P?WS^.)V>'<E_I^G9D?S7O<RVL"E_SH&*[N=X/C__?)V\O/KWT^/#\[.S
MX^3@:E7\EH&.`I^\AR-^GIQ<GE'0Y02_=G2&,SD]A^]\@T]D\.I_32[.SI*#
M/^>K:GV//N;GR07,[OPRP1D?P[K.'?><AO=?7&"D97H&^Y2>GUQ@M.7%Y>4(
M,%8Z<(S/8-U36/VSY/@%I3!BZ&::7I[B/TW/THOS<W<U%,5[U)P)P&^>9(/8
M[<(6$+)%N#06L\#GA75Z9!Y/+R8G(4\L6`A:_A_@?3M\6_8Z3>CP>%<^K.^!
MA)%G!QPU-X/Y//1!*L98LQ;&,@Q!4*`#,!M]L*//=`A95/>@`E!.0@2'.,(F
MPC*=>K@>2<P3CI0UO35W+]N/W5GZ%KULR4E*J'>MTCYWOG%@_O[<L>'@U7/R
MQ5(16'@G"PY?FNMRTQ@)Z`)Z$U8>E1T'[8AY)T26"JH@'SZE/G;X"?\/;K[^
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M?O"`0WK].06("&X=G/4OIW!E7#ZO'I^CO[IWD2T46A*WU5TN^H(6BU7(A^BM
MY\:<<1:P8F330DC(1F.RY-G940@!>BP*D6&W<)/:^\0TV\.C88T;TY*UD,CY
MW?)IZ=YFT5L;4=)^E@PLE];:K2FPW;2_YJ&63O6J7H#ZV?3<M/0.G$+*%<W>
MZ!T<QBYB(,I`IM.CU$4!;LUP[@36O*?.CC89UE]_'-1@G6BPT04^&N3.\^HP
M\E/'@%B87;2J8IU%-;.!V1S0OSXWTAM],A@R0",,\X^U76E!$T2:YAG[3D%>
M]'%3X)ZM/]Z.X%9JRV8;K#VHI=%(9/GA`U[+]R"@MGKO1%1-R0F@R^"Z9;\"
M1N&!+Q0L@YW5FYDP'F`2.:J!DN*`_L5B:7$V1,G]J<Y6AR4ZOPALJLPWH`D6
M&=*Q&Z5C<RO+I.-;0.;[[/3(1.\/A%015@(Q)1A#"A:`9,%<R.OQSJ1;:)W'
MB?E81\N&C]`,54(X\G("JSBV$]"9P<"\O^J^B!T/F&A1K:@J'%42;^93Y'KP
M%"9N7YT_DTP7@A7&'V)FUK%K(M2X`>PJ850N[G,AJ/9Q-Z:N(X>^U\7;D=P9
M\2UD]9WVQPNHT2$;DXLOAW,LDHX9.\P.G9+1/NS0'N3WLD.C!DTOOI,?LAW^
M8Q(,\&%C)^B'@QITS/0>!W>/3%,4SUJ+L7`'\J_/)>3#;"?8(G#=S@QW#.B0
M8"T4=R4'$4V/.;`1"LEX#HM,K@(#V6C[%J.V&M`O*2R*WV7$K9!S*8X,?X"(
M[##3G.;`.*DB/10*S6K<FQ+TA^3JU;^_!X/A\VNA;#$DC,YA0;)BHLGZ]7^#
MMUBN;$2+,;*HV^_&)B,WU@0N8]:%2<7T/=X0H@J&%E6,"S8+<'\>O_<]%&9S
M[]U>]WXLM\K34@](.+HW2:34GZ9*R`8/@UNV$];L^G")L"4:I*</(F=69KPN
MOG*[AE@TPL+4/2:(/OD.A(V6V_>V=;64;!8*QLD1@R:0<_L,X"`MS@95P7L@
M]F^,>,6U"IPW0!4`OBD@XR:JK+VO.*?A>!HJ6*F=)/I0HNPUVK(1J8]0IF0C
MM(W'P=#5L(+%N)0CLB3(U`M#8R!(+).0YO`^UA,=5-(!+BE::2V>N5E!B0+S
MP-`8$C/D/A`TP:LKVADY(1$0KJ]G2'6]-)XT7>\[,L-%;K*82QMOG=:LX61^
M3-Y@)@X;<_MXJ(:_XP["OS]/$PZFA9WDU2#H@S6:PRO.F#;[^A-8/KD1CX&%
MP`\NK'Z0!EB$"SL0S.V=FHSPP,O)F2$<8W\'S8U9!O&;L%K&$0]I!!$C<B&%
M,J`9EXL>$_.*.@*4VMFYP+!@U$@C,4=-[O!XH8.5)ZJ>9$FYH:/$&8X&1@+K
M'HFBB(/;?;E^V7,L#>^RT1:?G1U/+G3'W2B<];Y"QSU%31P6%VXO-3$Z`^ND
MRA=>6*2,,;PUH&UW`0A;6P(K?&&TBMM.6HJ7/S;19&<P2V+M/B%=/%<S31="
MT>`3L#UPMH1D+4GN,OB'-%S7#5!<#&JX&L8GMTK<*B=:R3YZ+YG_).GV5G>K
M*$#>B_/?4)MQQE*Z-FW&N\^9A%88S#[IJSBN&7GQYA[N@H`Q>B311Y)@7U#2
MP-A<I-QHK".Z+S;@(GS;=`)Y[$BRQ(VO0L0%?3`P2]\7Z!R*9%X+#$&(VV*P
M[>02_WN!1<=GYR?XW\O+<:!A7>0T/9Z>)<?IQ<DT.4W/3C&H>7%TIEV;AC)%
MS:N7Y_#?HS-\]7SZ`OY[/#U^;'N?X3A4&PV/GV.-UV7ZX@3KR"_2L^F9ZU4D
M[HN(I<[X\PNL1:/?SD^GZ06,19-)&(.GZ54)M$,((?2U0XHFFU)%Y+RGDXMC
M0C!M[C,1G8@Y<>K\O\4C3-S>8!?1@C2ZX$Y?7*;HM,0?3](7+\[3H],]UI3H
MFMSC:SJ?G`RLZ>(4_\T-K8E2$KT8C"?CPR(+OVZW<]VGW%P@:L>&,#42N2*#
M_+$1'BM:U4;F#]S]24#[R7;A5/,\'H.'\*8`>I*&&A\5<1#EE(.(_6^[\6_S
M>\/?5FU;&B%W3`+^ID)OV<@:]Z&/+Q["6H))N?B]]TN`PUZ<G&!))E/CV5%Z
M!AN#@AQ&($+ITV(9-0![R@V0(2_/+S%S@J**QW`57J07%R]V#=J32^]![?@9
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MW`/7_W=DY^A@J.9.CR?G407?=!ILQW\4[PC`!'W)OFMV"<SNA9T=3O=R>'8]
M)O.AOLM*G^V)I6R;%3F6X+LWQE5AP2CAHE&%UX'^Z?FNK^[Z+7@L9D75R2F5
M>YY@3;J$0L4+#!3]IL9LQF9>(=+=L@`I5&(?9$H-"6YDED;+[($H6\:R[8?<
MNECGY)B3^A';>8&<0C`9-/0ZGF$N[U#<V76U!!V?0`]_W5#JM?%>@`1K44@V
MP6_D[=:.DSHTQ?#5+-;Q-I&F[H^#H$M<2S+_;7N]JKRK.#"ON";D7LDX&.^;
M>,S%;I,^CCF;8O0]9QU8X3-]Z-Q@Q-FO4"Z\L^GXANWYV)VI2^*4MF";B).8
ML^E"]U?.;\T7W=JG@-6B!B2A;G1`7WWOIJ$DT"B0$;6E&*W'@-UH^V:TNT=T
MA4Y,Z,6EN;R8X#H,V^0&89LP<;BI=KE^%N[9\<E)[.@BM&$JS4&81.OUZ<"&
M4%W>`.8:J=H7YJ,$!$9XU53^%S>X1`\'2R50SP,;1<6"_2(]IO22>C!@\H_%
M=<51/\(9S+%#<<,VN$K]`3ZSYT=<]!'W81_P4@WY<+9&R*PF=[^P7%^+9\QJ
MA>/TT.!(K-@/<;D]K!XP:H47HU@4U"3G1X5!_DSQ*^*+P'0)%/DY+N(K7EN?
MM\(/._D9QQIZ_<M?]`U..B>,`6&U3F#Y1`>Q]44A-S/'BJI2N*N;V\TC)%GJ
MME#+11Q1T`)<<5#57$!UZ6@_/G!]8_`\88*OOW%NJ*/*8>IBEQS<O+[FCHX*
MLNN;CW">'I8CM80"$IQ#KMX07H3Z&&^KJF5"]WA?@0IL':DO0R_QGY8=6$"*
M\T5M3M"?OK"]XM>>$MW!3U=7'WGJ8H:IJB75N'._ES@K7H4673F49W(10]@F
M%;_;3A+&'H@\?4E=PDM)PM&V<Y#B+=\1I,P1J$7K[HDAHW'>Q6%&&@BCZ_U@
M>U/QM9U<%A9O3Z`8D>9E9>B1]GR!+!Q+$*]L8SG;X$$HAV%;/?(3E4^%WF>P
M,E##2N%2\ZW7S,T@G#48VK`[NC5+OP%4[Z\?\I>;.Y&&C9$=<)1*9)?`\G\#
M^@RWY3&M=+HHRZ[WN4GRV4RFAR#:J:S`R[_1K"+UU()NDM^C9/PJE>&:96W,
M)%B+$].]R0WR0KY?C1;B,CBNF>-*.IX$:0&Z\793+5EJA1W#LG>0ZG;`4"LA
M3H3=]Y9I$:<4$)X-I>6&JWWE3-W@'/M[3565'LT5=XZR'?$Y9YZKR@$,V@A4
MNI1Z-B]3R5Z(@HK?@8[624EJ(Z@TJT<"FUAB1^I0'RY%S'M1D>!5-)&=;@3E
M7DL8,3XGW/G<N`F>RE/<ILQ`'2+V^GE/,F8`/E+#7*^RD#R%$70>>3)XC+%+
M;#8G(`1&35R`"J]84GSBWO.@OKS!4MWCH\._>$<=X3?SF?<GQO%N*ETA`?OZ
M&DDP.`?/I0D$[8.5?'$R8-&XOWJ\!S^91"?S5[#M0S5U)G5<8"N5`4S`227)
M(XJ7LN#H?%E6$U%5CXB[T9VCR;J]=P[QD"D(EOJ./ZEO_,%U\:&V%04XM:D3
MND:AX$QVKP[&VZRZ(^M@.>+&,M>E*F!2:L8<7Z-2$J.#*K(+JN*C1&S3Q4M'
M9>!F;P/J7E`UA4*!HZK(=UO[1'5U[R\<YE3HWEZ9;/=WNK.L.7K1N8\6C@]1
MV6*[Y<Q^5*)4"6ML!HN6OT>]G:C[Y8H=*=R8(TCRX.TS/8P$);-[P%39&44'
M;6O6D7="*W&%J-J?_`?FYGR58FE:G1E.:KKPT:E-C$_'C6Z+L!U%/0D=E/%U
M*@51Y84!$QC"RX)Z"</#FSDZ"A6CFDD$^PI?,X'D$//%S`]1H>=LR$7-NXDV
MQD+FIE&?Z-AQZ]K@*.X!#5)JLJ`3\F.AG8Z3'T4]Z?ZLX4]6&4GH=WL&N;D%
M/4JE->)BK'N?78D'B]-0IZ\%#+`AG6*=1@`'M;V>+YEV8X%0*:<4)]+20^.D
M2(BHE%)6BC]'<L\,M\$;Q&F4KPMSL51(E]-<9\$Z;235W7=W]RD3+FI11IPU
M(D#"M""?6R9MG)`_X*I^W2SNV"(%XMET^ID);.TX*]`.=F!5RK/*?U'RH1\*
M+(R,LD'X@&BI#>S/7!(PR$$$5(TJL;V7M3:)PX0'-"L,G,]FO="#57@E[>S6
MQ3U"E^I@KSLBRV"NSC`;S72\HYP2'I&@/VU+NRY[_]35#A]]@*#0J<H,6!V%
M?;XBS@!9U,+JL*.&@B8-,$?L^MCU500MU;LS^=RK."V'EA4U$1*8J[Z:*ZE\
MAK\Q"I,;FG*M.D+<3"KU]D0JO4I5<["4A%ZWV,R2"&D_@24G@@7=W1_U'H^@
MLX;G19T?$3[!]_=KY''6/&^K^4:M$\S@%O/3#7JY.R[M3D]S+(R:+1E3%Z5F
M62'2<<?S3FRC,S6=D8;$<7P_W0IE#@5")<62,:US..]JA5XO7R7K@/0Q.@J/
M8_^W*.6->#[!O!`@@F9A]5W`@A2,_+?=KB4M3!M;(=`N`O3/&*>(VV=HQQ_-
M"'1Y^;6HJY(]YQ*8B`PE!@H&=D?PZ$.'XP3VX?J^R$&5^J8M'3[<`K4B^T24
MJB)6@O)LU:<>8SN"-HFMQ^KA6SO^)-O1OK<7]4(-32H?P0IQ'BO$.]02;>EM
M4^;)Y[?!PE-6%[RWDI-/&0I#C#*//`G7:9D+DRSE+S#K1>["6Q)DB&$IHES`
M*+\P),R1Z<[P5$0D6D''@A-'(Z*4[M1#D"RN%\4Q[<&I$:85!]21T+2RSTI'
MW5UIR51W4VUF+;:6]GLSTT9UE,:./$5X**-Y>![>?[73I5D8GT:!:#DMI5L%
M>&HE`-MZG8)"=P2HQRB!FOCKGT;.IF5-HA8$#5$[5\\1:Z^55DV_Y,Z#*P7M
M(8ITZ0OB6`G`"+(Z<_PA_>61O40S'KU-@YV-=B,,22Z,#T$*.+ZV2Y.&]K6B
M]TCS<I/M7).!JX=?6T3S5&*%0DJB#EO"\:VSD.6"$N@50J+?BE+Q$^/YC+JG
M&ZYEG?+D*O(H8%DC`'IUSFT1N'&G*C:4^$/5/Z@C(S=#?8M:^*)C"]F"7\Z$
M;%H8B0R.5%D`PXI15P[9+=^9.=NR4YQ4X'JS5L,551W6#1F[0U<-&ZEU0UPE
MP873^$@W!BP=^\*;O%<5Q3"Y7-(DG'K,N#@MC$T`Q+UF><K`9)*6W45U-.D9
M.+)R_=3H/+XACY-BXWZL:4`E8^O0M%O<XQ&)./._%QTG%FT,`K3=6:21F-N[
M'K<?!?HA#KK53#$>@0C%$:%4'>S_'WVQ9A9@"!DB*L)8<9Z8QR+G@P!2X^5K
M`6,J$A&,IV34'==/1>[ETW,K9+5V?11:6H\,X"T,@#\D?4),Y:*/9`I$V'%P
MBZG-`.7J2ULNC>FLL/QIO<P/<P5U-L?-R6XL0+AEC37`0[DP4H4F;X77V4V!
M)A+R)[X7T?NA:8GO&K8I)3<B1-#`8L+6&7_W?9W#")1<H=.+?`/>/X1O;-@5
MI58?GRIYZ,P[VO4\B]#R#':#HF6E*.X(V!XHSQ2]4)^:DHW&E'UHWH,6].,`
M3>[;HQ91/K=NQ9+C;F0&&AF.&Q3OC_,=U6>4J:9WN38]6Y$%(PLB=@KZZH_B
M]R\(';?99.2XSU'P4.]5TM'*Z#"UI[1L!\$-.\*[);8G!6O<#_6V^,;L6L$A
MN<%3)K!U$D(JJ/F=X@:B*Z#&5J57@ANL2/P^QE:"8K&+7!6(WK/;E>UJ2P4A
M`=]BUX>HXA<U!>K:A;F*&A3E3_E**+[RW4^YB&-*3]8!PHZ;\S'@^E=L1VB\
M7F)<I-9JU[=(=E`;@M"EH//VP>N;C\_9Y^PSDL@K>_,1SXFH6]NM^Q-$2,4`
MF4+R3A,%$.B#FJ+=:@$*J=.5OQVH0#E*_4=+DIL7'69+,FZXA\@OML4[SD/]
MS[)[E`DS``-E]W2V]2=BSS)!IEG532A/34&XMAT<]913MWP"VA)HHE5,!#=\
M624Z13:G/.RG2YX&3#$(C<29+M1=$,U]DG"SB0<N.-Q&(3?E4%2J5H,<)O[/
M]P&VBIC^MHN;I14@QLU#9Q8K*,;K+91MHKCLH8B)7!PHH5^#7S`C5>N>#Q#]
MQ'VT=E;\MX[E&*D;S#>8=)E9-.TAQF/WJ#1O1NK9#%SQ+P:PU=H4!&YJ%'Z&
M8`D61;!C)KX/@I9S_J3W<AA/P5>:#3?X"6AR$2^(JM'@'XHZ0&NQ(>#34GSE
M.>T)=?TL8^T;N4TM?DL*]3*PM30,<23*>'-")58=K]*[/#FWJ6@""P09Z'_4
MMP0VEN-,H3]!(XQ*[;$@"E@$]D1!\DL'`IOVIBH/:19^;VU)[9B_VT*,M0FW
MZ4F-VFO!(FD]?JJ"5?90-+E]P8ILDPD<2B28@WK.GB_,IE)`TNRB6`T&^I,$
MJ\_%T$`B(V33'0Z67.33H&876$@R&4%+#'XR3\(43/=(OZIRHYIM'O;ZMC]/
M!6=V!A%B%]/VCA^5K%0)*XFC$K,:8+U-Z/PX"HH6Z\6UJ6/$.85=-6<&,T1:
M<PAYS*$+C8<.5+PP/R<E)&1:1QS/=W(8$LK6L4[CJ71U(8'V=K.\1>]\M1E3
M&'WUI+$GK']6V]SA]2DX*)(:@\BG#J<^U#0"53O4.<QD'B,GB][4K%L.[P_@
MNQE589+\I"6SSL<9?;_LH3+8R!P9%I9Q4^)8HX&[&<_#6&\FND*E^/[(BB;N
MN%2#;B=V#"BHUR'P.Z(7A@203D5RR(I&\`5ODA;=BD[4%5&.U-@-,HK,N(BU
M1)^0P1:FRE;[!4;M_9S/4I?9A)[$EO*"/:M@U3'>U7#D%:RU>%9P%0D<'IL>
ME>SB<0?%<V8'F#91E4LVO&3Z(@IIG14W,"W8B:`-QD5*DJ#E/+OHQM0J1L4Z
MD?5EH2%'M6F!4#4C(NHR-OS1%*9<<.:FWWPNG+('&@AZ:V/_KFL7%TV,+$9;
M$1Q@%*4S&\)@UC`!W376[\2+$J$:!#8]R[D2*]=6&[RPWO'8^8M6'Q&U$XB.
M,9+N46&WC:0T2/7'8Z^J?*OS$;$'@,75E&@.(H8#\QK3BTBO<X8=*DY%^I)1
M@C:U@EAB`YOH.<K'-VI(L,C$A-,J?I:'D;>!7(R^L<2@,X3S$'>(REU=4\0G
M[+A4)#1XVPCPP<"Y#.,NI$YEJ3!KT.!],DZ4@$!^4>,7!CJ1!&R4#X):)+&'
M`(+!6#]!B`1QX)897(_[/!2^&%&`E@SH@A*PYD24)"!!J+2O9MK'QXZI4*SD
MT$??;A36*\J`AN!,_V^=CL^`S)JH@X2]RZ`0<K8"-O7!_3/`$P_J#_;L2^XR
MQ8S03NST,P%#,3@!=]%!'Z'9RR"G,V*7W"#"!CFQ6?U<R:YY+Q#H7;-PS]'I
M%+A`5.6C<D&;UZ8V0YRL]/#U,:0/$B-9`+_?1XJ([6"94X8->C*;[1WI3\%V
M(7@$5M.[>-RQ@*:NAV:F)(@(XH.D%:E[@P+VJ7=90RC!$;YL0J#GEOJ>>)6B
M<[]9&`KSTLON.B%WR>X3Q53'X5);SK@VN6J"(SZ*P6'VRVPE&T4L"^A(7<<,
M41^\:A]1EQZ:>,1NHB7,MB-+2)7U"7[3X][#[^"RO5/9D]6*6I$+`)#[6BTW
M*Q.@\U8[60F^OH*U73O&S.<U..\[,!T]<3D*8AP.C,Z7!I9D+GW>#6'BA*<3
MF>:3M[@?4S(QB%>&";SF++6G/C\.#L(0EUK`2+FQ61-WNU.[")9(!59I*+@,
MMFQ(U>$OJDS$"EP4L\'3'\*0R!.\W>K[*-/[-A0^'I$10-\(/KL;BD26:"RZ
M+IXK<0KA):'A6*%,=H=._F;/P;G#*P@)U"5'9B*8B!(<HEQ(KLA\*-WM!G.9
MM3E)IU$*][@WG=(H6,Z]@#@-$C4*[P[V:8\>V93<9Y&6XHQ=&MROQ$[,]K`#
M/`17+:@S=O>,^J^@T/E5V*)I4YAR>K?D>4BX4?P7/HYN@IMP1)L2>:?/>^"*
M0-$_X8=%A?Y$CQT4T"+UD]JJ"LT9\6PG1GWKHJ(J97#70_*:8`H3IC?D90VD
MH0]JL7&J</A6"=1H?YR-:OO8_!*UT*/L5;V9(9<CF)A`:^WA9BUY!CX_&6&R
M*">75MQ1/<4YP\Z2F!@Z]KS;^?U.?LO(9(,]'.")/8Q7=VJ1GY;]YC&E>I]Z
M]UL8#UGGOM9;LE*9J?N,7C'T_4/TQ1W;(<\Y,QH[-?P\]4N&!CP8,^=BO"V#
M91REU`;/6\1Y0+'U><--M]?.6!ZSH*]F$M`2EQ77'+H@$TD(DM]:,E--_4+`
M-^,35,8_<5=<IA\W7F$8JA":TA)'L:XW7&;IL/R"=&!\1]W&>Q3@4VMB+H@F
MKTW6<'5#85+SI=I2'3NH5,HYRQ56US#/57)=T*[D\*GU'D?-FCRO(Q8ZG'Y-
M$6%DSE%ZL`=$R:28$4[3`-H95X)]C6/CY#.)(%4VV)]6?9*46X6*DA9B9'R2
M6"]&P?W@7RM].T:I+N$B5W2,?,T%&U3B\=9?H++"EJU6XR+7GX,?SQ<#^)A%
MQLU^E_@:AV?IA'6YC011M"""4H;5,]%PB%O^XK1U5=1-RUI93-V#F=DH?)4R
MHYSLO1;7>J2=72G;/V,MPL]D_UQ1,O*C#U`R6^@V']<Y]$L;;$*H)K,XA'>2
M5!`XR*#,^#*)J&R+]#,*\4ANNWX:#PQ)5,0;-8L,&^D39R/^I350>?"P^2Q_
M4_%#9,"I_DASTM(0RZ&VQ-?$S2/)FL02=1)(V0S_ZIW.QC2GAD<-5ZYFI=V^
MHI1:DYFTT?,E/#01<C_J5,7Y14(*]=@`D48IJRL@ODVM6@\:/6TQ+]8DV$"G
M0`"53:FH13$T@1_/-_:<B]33PW%ASJE@.B>>Z4F98&3GB4Y.#CV>&+K-PI2E
MB?+@7FB&B9\6&B`/-5;!E\D"U$M*/&\;(_ZB#Y?).[HI'HNC`_XK"0Y]3&5D
MG2]?7UU_>-\#,@;]8K/@3)SW?_G\Z?#X:$J>;$E^/,SN.`*"\`O\V`-P#:EW
M].@Q(/.P&0L<#/5&;5IN[0?,HR"\#>\(I8<:3JL+L8YYWH=>"=INO)OJJ:&\
M.'*W]*]IR(?7<XZ2G]E08+3F[MO)75V!LN5-_-#N!<Y&=VB2O!3M0W#O.]XC
MN>]Z*.Q(+ZMH&:WCPY1J3,JVC=)O>^P-P>5!/GW.OO6+$>UO6$#+^L3CI=,#
M<'/:NY3VG3_;9M]"MW1/40+-06`=$40(MJ&2%%#R+L/;M00*8^28D],_L.E"
MN?&W.?KDEZ$I"[XH?*N#=:/U['%-BJ`&,3\B]B9YXQ@RHO,/\:)6^L2R^%L6
MOY'O'-MU87:TOTYB7"=!=+$V-%0NE'<@INJ*;R?)\:<^[^BV;TVSLE`8:UZZ
MP?RCK`:!_[*"_TL.WES=O'PN^'WN;E,LI)1@P0X<X$6#;U_;3+*#JYOKY^X<
MH;(UA<_DTQ+ZGN;9TFE<>WN.6ZK[&HJ!MU-G.ZR<R=)@THHYZ.>,R0YP89:2
MF>FZN!R(^^,Q&$5CGBEZ"?MKS0/.]RV>Y0:1CU@=$/N&'4(^"`17@)O/+/1+
MSF><2Q\%/U%4ZCRQZ^50Z!8N5R.<9E7-9OE=49)'^5^SDKNET3T\GR1?R*.U
M8%PTK>!\".>X0J3^F;@EJ3BKK:N`C*:Y>'U00E1TI/I!KP!)(1G*X]S[D8C@
M.;T[Y!MRF9BFYCU6ZMLE^5_R..AL%*\@\'I.05C2IX]O.2C_Y?HE;:BT?2M]
M+T;I_$ZJ2W`GHIJ*9F-.%=_8Y-[1#>?S*2@,XC745.V18(7%GRL:9RKF0MJ8
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M/X7;]$M5_W98E(=2O9K`LN%0S]+CBQ?N#6*EWWM?TW%Z#IKM67H&5Y3WQ6,>
M4+/D]'AZRI?X\FS:<Q3LT?=^=#-\7N)U+R^1&T"+6M3?Q">W`#?.-[?<,QWR
M_V\!_K],"_!]NT2,DO+H"R.AS_\/=WCP[*9+T!T8L?^5>C[\(X&4#Y.KX%HW
M$`W)P2L0.L6R1UNP[1/O@OAR\RHY>-9[YAT"2JF'9.29H>\(5$2O^TD^]Y\[
M'?G<D]3400>S1Z7M?WH$7K8'<^\QZ+N`"4WRWY*1Q5VQ1S&XF!`FXJX_Q]?>
M5C7>'52$N@^>G$Z.CO[P?9;'X=.TSJ?:&)ZX8"`Y3Z!M^/IG90:[2."D^V-P
ML;PM89R-R%GC>1$'8XR;]Q.Z#`DE8;QSP>]0S;YWYQ^YCV'+OF^@__P9HP)O
M$?.FM^IWV;=BM5FA1K>ANC*Z&]Q===9:-31L2&_G'JK0H@^-^+Y?H0,T_SVC
M?2ASCQ$W--B`+6"M5A00/:9`ULPQ^BHX"C?UI0Q]!J(/Z+/'X\_>#,!:I]T`
M4/>EX^D?$GGQ1EY\3_;2*U`I_G6S)(_CB^0_WY%*WCO0X3$5MVN0C1Q/A]C(
M\(?\R2T&/@2SFR38KO:?_@GG^)TK`T;*FWTRNMBG7KC?;VT_G8\%DS@5KD2#
M_6S`E]YIX(R:>WE(Y!+WI0P8R8PQONL6[[9_AW9MA]G:>]S;X>^]W?Z2['9S
M4CN\!-/QX_-?O@X6_D>R\+_WTVSB\U$F;S;[S_9X])-O?X]$"&X$4HY?B1]A
MUQAL`1\FQJA_*NU%-GJ/&\<F^H"(-5;ZL)3TAGK?LE80DT^A(O)&*B+?<`+$
M)U\1^00)^-AERV>39'I*2D//5V!UU)[KQ/[84S>>MIR=-Y218'?SX1=#?%C+
M?4.'U7ZJMM26KH<`5SJY]"-MR-^]_73]^M,56..:_7@\'6K&TP.I/='8Y%3Q
M!^?WY!.67"TTEE#!P%!G@V6_?=28=S[#_09,:ZST2E#(C]T1R5?D9F4$J>C?
M-X'LA2@)96^;!X9##>8?,ES[4/7>WP!WR<151;1S%??*Q>#)Z.!X1_.%%&]K
M:;$OXZ7"Z3Y77:V*-B1L7UNTS^_1.M\"`:S*$(4,T8_1^5/_KW@"NVY)=X2H
M]-3`%OXN;^!ALJ_?[^G\1R=PM6L"._E#[(`SLDI]<9_?)0><WG!\P9TWS"\$
M6W"XJ*AX=37#5@6$>R3-X_7%R^>C)\6./#.N^O1H).8.HR];SY[YA'?RC;TW
MZ.$S']CI[!O_*+O[HN\,>/[&WF=2&*7H_4CM=U^RFWP]P5C$H+#Z@.7+8Y*,
MWM2^D?V^?%_]CSTQ9QTT?9.;1.OEXZ*UYZRREOS1CA^/+G?]V#,CR,J0S_8<
MJ/;'@0E)WHK>\RM3$KOK=G[T;9,EB7.HWI7-V*$*M$?OVF/WZWJDR+NJ/?9"
MR-J%*S)TCH\.BG<^5$2)LS((R]!B>(R#>$PB`YG6!SW[/?/Z(E]466S/C99[
M-&X0CS*VIS"SWD4<[&\?F1C217UTE%&&_Z4LO%=]?+>#:@HJZ=5_$"V\^GS-
M`']M0:GNHUONTVFHV<M@K.NI\X,?F'%>"]ZQ-73_49O@!R$W[F=T'GW?,*H!
MIEB?!#\W[=-/XG'1/:[>@<V+&5-W#`9,J=M:3,QIGSXI"A/[>^;6R<F0Q:`^
MO=#LO?8'COG<:K!\QT+@WQ@D-RMQEW9H@-<#=:41E*X4B43AF*_RF"^QEJRP
M34T9:*9H*%2F(E`QTL9W+FN_,_\XO+64)>FU<W1LW%(-NZR\^Y5!O]O_ZYK@
M=_+7'?,%.H9-^BUY$^9T;>;T4>;TN[3#G68:D`N_S)7-'"#L)E9S>=!35=+O
M$I&/??Q[SN'5H.KA[=/OU9+WOAJC$>G#Y+%@]=/M+FHK+><0?='N''`&^YS?
MW(>L7J3Q:Q1,WJ4)[@[G]ID?D]Y/%)N^P=CTN/:TNR9Y]$4;F[Z*8]./O;KC
MJ!ZW7YXE/T@WY7_XH>P\@9O!UNZC;=V'7_\@71Q&-Q7;T*-LL5V0'PUK4?/Z
M0TJR"64A/4NLUQ9]K^V6QM7R?QBFX`ZG?7$'+-=WPS8!C-??I.A!,L)7ZTU(
MU1[J\;[C#'HKU[[D)H*71^.--RX/W_ZA:=H__4]02P$"%`,4````"``:,P9'
M=FR_J:H!``#P%```$P``````````````@`$`````6T-O;G1E;G1?5'EP97-=
M+GAM;%!+`0(4`Q0````(`!HS!D=(=07NQ0```"L"```+``````````````"`
M`=L!``!?<F5L<R\N<F5L<U!+`0(4`Q0````(`!HS!D=DAM`W=`$``,H3```:
M``````````````"``<D"``!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M`0(4`Q0````(`!HS!D>NOLL6A0(``'`)```0``````````````"``74$``!D
M;V-0<F]P<R]A<'`N>&UL4$L!`A0#%`````@`&C,&1\2T]X4_`0``:0,``!$`
M`````````````(`!*`<``&1O8U!R;W!S+V-O<F4N>&UL4$L!`A0#%`````@`
M&C,&1YE<G",0!@``G"<``!,``````````````(`!E@@``'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"%`,4````"``:,P9'U@#H=5@"``"V"@``#0``````````
M````@`'7#@``>&PO<W1Y;&5S+GAM;%!+`0(4`Q0````(`!HS!D<?":_\4P,`
M`$$+```/``````````````"``5H1``!X;"]W;W)K8F]O:RYX;6Q02P$"%`,4
M````"``:,P9'1QJ$/%4"``#T!P``&```````````````@`':%```>&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L!`A0#%`````@`&C,&1XU`=D!@!```518`
M`!@``````````````(`!91<``'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+
M`0(4`Q0````(`!HS!D>G.R_Q,@(``",(```8``````````````"``?L;``!X
M;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"%`,4````"``:,P9'>YAT/H`$
M``"6%```&```````````````@`%C'@``>&PO=V]R:W-H965T<R]S:&5E=#0N
M>&UL4$L!`A0#%`````@`&C,&1R(L>.$$`@``=04``!@``````````````(`!
M&2,``'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+`0(4`Q0````(`!HS!D<S
M[,=,C@0``%46```8``````````````"``5,E``!X;"]W;W)K<VAE971S+W-H
M965T-BYX;6Q02P$"%`,4````"``:,P9'QUKXZJ$!``"Q`P``&```````````
M````@`$7*@``>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!`A0#%`````@`
M&C,&1S2D;Q&B`0``L0,``!@``````````````(`![BL``'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+`0(4`Q0````(`!HS!D>8&A67HP$``*\#```8````
M``````````"``<8M``!X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"%`,4
M````"``:,P9'2^D0`J,!``"Q`P``&0``````````````@`&?+P``>&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+`0(4`Q0````(`!HS!D<*);8IH@$``+$#
M```9``````````````"``7DQ``!X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L!`A0#%`````@`&C,&1V_4+`VA`0``L0,``!D``````````````(`!4C,`
M`'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"%`,4````"``:,P9'I"JY
MQ*,!``"Q`P``&0``````````````@`$J-0``>&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+`0(4`Q0````(`!HS!D?52N'AI`$``+$#```9````````````
M``"``00W``!X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L!`A0#%`````@`
M&C,&1]*=)61#`@``&P@``!D``````````````(`!WS@``'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"%`,4````"``:,P9'_=78I[,!```6!```&0``
M````````````@`%9.P``>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+`0(4
M`Q0````(`!HS!D<!$1S(I@$``+`#```9``````````````"``4,]``!X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L!`A0#%`````@`&C,&1]^GP$>D`0``
ML0,``!D``````````````(`!(#\``'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"%`,4````"``:,P9'#I/A5J@!``"Q`P``&0``````````````@`'[
M0```>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+`0(4`Q0````(`!HS!D?;
MT:"_K0(``&<*```9``````````````"``=I"``!X;"]W;W)K<VAE971S+W-H
M965T,C`N>&UL4$L!`A0#%`````@`&C,&1].1X.T3`@``4`8``!D`````````
M`````(`!OD4``'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"%`,4````
M"``:,P9'9746D@H#``"^#0``&0``````````````@`$(2```>&PO=V]R:W-H
M965T<R]S:&5E=#(R+GAM;%!+`0(4`Q0````(`!HS!D>SP'3=<P(``"$)```9
M``````````````"``4E+``!X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L!
M`A0#%`````@`&C,&1WY'&_?F`0``5`4``!D``````````````(`!\TT``'AL
M+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"%`,4````"``:,P9'&1BV8FP"
M```R"0``&0``````````````@`$04```>&PO=V]R:W-H965T<R]S:&5E=#(U
M+GAM;%!+`0(4`Q0````(`!HS!D=MM/C9GP$``.P#```9``````````````"`
M`;-2``!X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L!`A0#%`````@`&C,&
M1V##+^$D`P``F@T``!D``````````````(`!B50``'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"%`,4````"``:,P9'1C"4B6,%``#_(@``&0``````
M````````@`'D5P``>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+`0(4`Q0`
M```(`!HS!D=L#LN#G0(``($)```9``````````````"``7Y=``!X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L!`A0#%`````@`&C,&1UU0=*EE`@``K`<`
M`!D``````````````(`!4F```'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"%`,4````"``:,P9'V.(EP04"``"T!0``&0``````````````@`'N8@``
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+`0(4`Q0````(`!HS!D?$VI&V
M%54``)8N`0`4``````````````"``2IE``!X;"]S:&%R9613=')I;F=S+GAM
7;%!+!08`````*``H`,H*``!QN@``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295535555296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 24, 2012</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Mar. 31, 2013</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue related to sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,740<span></span>
</td>
<td class="nump">$ 4,837<span></span>
</td>
<td class="nump">$ 8,702<span></span>
</td>
<td class="nump">$ 10,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EstimatedAnnualInterestRateOnRoyaltyLiability', window );">Annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RoyaltyAgreementContingentPaymentDescription', window );">Royalty agreement contingent payment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As a result of worldwide net sales of MIRCERA&#174; for the 12 month periods ended December 31, 2013 and 2012 not reaching certain minimum thresholds.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=nktr_MilestoneScenarioOneMember', window );">Milestone Scenario One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PaymentMadeForMilestoneNotAchievedYearOne', window );">Payment made for milestone not achieved year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=nktr_MilestoneScenarioTwoMember', window );">Milestone Scenario Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PaymentMadeForMilestoneNotAchievedYearTwo', window );">Payment made for milestone not achieved year two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember', window );">Purchase and Sale Agreement with RPI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross', window );">Proceeds from sale of royalty rights</a></td>
<td class="nump">$ 124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EstimatedAnnualInterestRateOnRoyaltyLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Annual Interest Rate On Royalty Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EstimatedAnnualInterestRateOnRoyaltyLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability Related to Sale of Future Royalties [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentMadeForMilestoneNotAchievedYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Made For Milestone Not Achieved Year One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PaymentMadeForMilestoneNotAchievedYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentMadeForMilestoneNotAchievedYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Made For Milestone Not Achieved Year Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PaymentMadeForMilestoneNotAchievedYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of potential future royalties gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RoyaltyAgreementContingentPaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty agreement contingent payment description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RoyaltyAgreementContingentPaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=nktr_MilestoneScenarioOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=nktr_MilestoneScenarioOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=nktr_MilestoneScenarioTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=nktr_MilestoneScenarioTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295541515248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Note 3 &#x2014; Inventory</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Inventory consists of the following (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Raw materials</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,392</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Work-in-process</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,117</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,187</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Finished goods</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,615</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,565</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total inventory</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,124</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,952</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Inventory is generally manufactured upon receipt of firm purchase
 orders from our collaboration partners. Inventory includes direct
 materials, direct labor, and manufacturing overhead and cost is
 determined on a first-in, first-out basis. Inventory is valued at
 the lower of cost or market and defective or excess inventory is
 written down to net realizable value based on historical experience
 or projected usage.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph a, b, c<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295547649840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">$ 4,560<span></span>
</td>
<td class="nump">$ 4,164<span></span>
</td>
<td class="nump">$ 9,737<span></span>
</td>
<td class="nump">$ 8,525<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Goods Sold [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="nump">563<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">2,125<span></span>
</td>
<td class="nump">1,832<span></span>
</td>
<td class="nump">4,547<span></span>
</td>
<td class="nump">3,805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">$ 2,196<span></span>
</td>
<td class="nump">$ 2,052<span></span>
</td>
<td class="nump">$ 4,627<span></span>
</td>
<td class="nump">$ 4,121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295466625776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 16, 2014</div></th>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Nov. 30, 2013</div></th>
<th class="th"><div>Jun. 30, 2013</div></th>
<th class="th"><div>Feb. 29, 2012</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Dec. 31, 2009</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2007</div></th>
<th class="th"><div>Jul. 31, 2016</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_RocheMember', window );">Roche [Member] | MIRCERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ConsiderationReceivedForProductDelivered', window );">Consideration received for product delivered in 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_RocheMember', window );">Roche [Member] | MIRCERA [Member] | Performance-based Milestone Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_RocheMember', window );">Roche [Member] | MIRCERA [Member] | Upfront Payment Arrangement in 2007 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_RocheMember', window );">Roche [Member] | PEGASYS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_RocheMember', window );">Roche [Member] | PEGASYS and MIRCERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AmgenIncMember', window );">Amgen, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OphthotechCorporationMember', window );">Ophthotech Corporation [Member] | Fovista [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">AstraZeneca AB [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments', window );">Liability to AZ for DTC advertising payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncreaseDecreaseInRevenue', window );">Reduction of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">AstraZeneca AB [Member] | United States [Member] | Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments', window );">Liability to AZ for DTC advertising payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">AstraZeneca AB [Member] | United States [Member] | Other Long-Term Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments', window );">Liability to AZ for DTC advertising payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">AstraZeneca AB [Member] | Scenario, Forecast [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments', window );">Liability to AZ for DTC advertising payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">AstraZeneca AB [Member] | MOVANTIK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfPostApprovalStudyCostsToRepay', window );">Percentage of post approval study costs to repay</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies', window );">Maximum potential reduction in royalties</a></td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">AstraZeneca AB [Member] | MOVANTIK [Member] | European Union [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents', window );">Contingent payments receivable based on development events regulatory to be pursued and completed solely by others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">AstraZeneca AB [Member] | MOVANTIK [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired', window );">Potential reduction in U.S. royalty rate for repayment</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">AstraZeneca AB [Member] | MOVANTIKTM (NKTR-118) and MOVANTIKTM fixed-dose combination program (NKTR-119) [Member] | Upfront Payment Arrangement in 2007 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">AstraZeneca AB [Member] | Movantik Fixed-dose Combination Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents', window );">Contingent payments receivable based on development events regulatory to be pursued and completed solely by others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember', window );">Bayer Healthcare LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PaymentForReimbursementOfCosts', window );">Payment made to Bayer for cost of Phase 3 clinical trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember', window );">Bayer Healthcare LLC [Member] | Performance-based Milestone Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember', window );">Bayer Healthcare LLC [Member] | Upfront Payment Arrangement in 2007 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BaxaltaMember', window );">Baxalta [Member] | BAX 855 (Hemophilia) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Development milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BaxaltaMember', window );">Baxalta [Member] | BAX 855 (Hemophilia) [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OtherPartnerMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ConsiderationReceivedForProductDelivered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration received for product delivered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ConsiderationReceivedForProductDelivered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent payments receivable based on development events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ContingentPaymentsReceivableBasedOnDevelopmentEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_IncreaseDecreaseInRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_IncreaseDecreaseInRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability to AZ for DTC advertising payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilitiesToPartnersForDirectConsumerAdvertisingPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentForReimbursementOfCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment made to Bayer for cost of Phase 3 clinical trial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PaymentForReimbursementOfCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfPostApprovalStudyCostsToRepay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of post approval study costs to repay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfPostApprovalStudyCostsToRepay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Reduction In Future Royalty Payments To Repay Post Approval Studies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialReductionInFutureRoyaltyPaymentsToRepayPostApprovalStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential royalty reduction on sales to repay post-approval study if required.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialRoyaltyReductionOnSalesToRepayPostApprovalStudyIfRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and Milestone Payments Received Under License Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 28<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51671726&amp;loc=SL6892177-166501<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_MirceraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_MirceraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis=nktr_PerformanceMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrincipleTransactionRevenueDescriptionOfReportingCategoryAxis=nktr_PerformanceMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PegasysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PegasysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PegasysAndMirceraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PegasysAndMirceraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OphthotechCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OphthotechCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_FovistaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_FovistaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AstraZenecaAbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_MovantikMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_MovantikMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_MovantikAndMovantikFixedDoseCombinationProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_MovantikAndMovantikFixedDoseCombinationProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_MovantikFixedDoseCombinationProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_MovantikFixedDoseCombinationProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BaxaltaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BaxaltaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OtherPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OtherPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295535583328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock issuances under equity compensation plans</a></td>
<td class="nump">733,952<span></span>
</td>
<td class="nump">350,513<span></span>
</td>
<td class="nump">969,250<span></span>
</td>
<td class="nump">1,017,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted stock options</a></td>
<td class="nump">68,200<span></span>
</td>
<td class="nump">642,860<span></span>
</td>
<td class="nump">479,010<span></span>
</td>
<td class="nump">3,776,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value</a></td>
<td class="nump">$ 4.81<span></span>
</td>
<td class="nump">$ 5.24<span></span>
</td>
<td class="nump">$ 6.31<span></span>
</td>
<td class="nump">$ 5.84<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (d)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295676990832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Additional Information (Detail) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average diluted securities excluded from diluted net loss per share</a></td>
<td class="nump">21.6<span></span>
</td>
<td class="nump">22.5<span></span>
</td>
<td class="nump">21.7<span></span>
</td>
<td class="nump">21.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Antidilution<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Diluted Earnings Per Share<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Contingent Stock Agreement<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295541523024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Cash and Investments in Marketable Securities</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Note 2&#xA0;</b>&#x2014;<b>&#xA0;Cash and Investments in
 Marketable Securities</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Cash and investments in marketable securities, including cash
 equivalents and restricted cash, are as follows (in thousands).</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Estimated Fair Value at</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>June 30,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">20,875</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,365</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">25,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">25,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Short-term investments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">233,785</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">225,459</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total cash and investments in marketable securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">279,660</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">262,824</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 We invest in liquid, high quality debt securities. Our investments
 in debt securities are subject to interest rate risk. To minimize
 the exposure due to an adverse shift in interest rates, we invest
 in securities with maturities of two years or less and maintain a
 weighted average maturity of one year or less. As of June&#xA0;30,
 2015 and December&#xA0;31, 2014, all of our investments had
 maturities of one year or less.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Gross unrealized gains and losses were not significant at either
 June&#xA0;30, 2015 or December&#xA0;31, 2014. During the three
 months ended June&#xA0;30, 2015 and the three and six months ended
 June&#xA0;30, 2014, we did not sell any of our available-for-sale
 securities. During the six months ended June&#xA0;30, 2015, we sold
 available-for-sale securities totaling $5.2 million, and gross
 realized gains and losses on those sales were not significant. The
 cost of securities sold is based on the specific identification
 method.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Restricted cash of $25.0 million was required to be maintained in a
 separate account until July&#xA0;1, 2015 under the terms of our 12%
 senior secured notes due July 2017. This restriction expired on
 July&#xA0;1, 2015 and the restricted funds were returned to us. We
 are currently required by a covenant under the senior secured notes
 to maintain the aggregate balance of our unrestricted cash and cash
 equivalents of not less than $25.0 million at the end of any two
 consecutive fiscal quarters, subject to certain conditions.</p>
 <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Our portfolio of cash and investments in marketable securities
 includes (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" rowspan="2" align="center"><b>Fair&#xA0;Value</b><br />
 <b>Hierarchy</b><br />
 <b>Level</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Estimated Fair Value at</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Corporate notes and bonds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">2</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">185,917</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">182,544</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Corporate commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">2</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">44,939</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">42,915</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Available-for-sale investments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">230,856</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">225,459</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">1</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16,512</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,229</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Certificate of deposit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">N/A</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,929</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Cash, including restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">N/A</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">29,363</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,136</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total cash and investments in marketable securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">279,660</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">262,824</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 2pt; WHITE-SPACE: normal; BORDER-BOTTOM: rgb(0,0,0) 1px solid; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium/8pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; WIDTH: 156px; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 6pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="7%"></td>
 <td valign="bottom" width="1%"></td>
 <td width="92%"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <i>Level&#xA0;1&#xA0;&#x2014;</i></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">Quoted prices in active markets for identical
 assets or liabilities.</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <i>Level&#xA0;2&#xA0;&#x2014;</i></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">Inputs other than Level&#xA0;1 that are
 observable, either directly or indirectly, such as quoted prices
 for similar assets or liabilities; quoted prices in markets that
 are not active; or other inputs that are observable or can be
 corroborated by observable market data for substantially the full
 term of the assets or liabilities.</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 <i>Level&#xA0;3&#xA0;&#x2014;</i></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">Unobservable inputs that are supported by
 little or no market activity and that are significant to the fair
 value of the assets or liabilities.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 All of our investments are categorized as Level 1 or Level 2, as
 explained in the table above. We use a market approach to value our
 Level 2 investments. The disclosed fair value related to our
 investments is based primarily on the reported fair values in our
 period-end brokerage statements, which are based on market prices
 from a variety of industry standard data providers and generally
 represent quoted prices for similar assets in active markets or
 have been derived from observable market data. We independently
 validate these fair values using available market quotes and other
 information. During the three and six months ended June&#xA0;30,
 2015 and 2014, there were no transfers between Level 1 and Level 2
 of the fair value hierarchy.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Additionally, as of June&#xA0;30, 2015, based on a discounted cash
 flow analysis using Level 3 inputs including financial discount
 rates, we believe the $125.0 million carrying amount of our 12%
 Senior Secured Notes due July 2017 is consistent with its fair
 value.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 30<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 21<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13504-108611<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295535533616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 20,875<span></span>
</td>
<td class="nump">$ 12,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">233,785<span></span>
</td>
<td class="nump">225,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">3,680<span></span>
</td>
<td class="nump">3,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">10,124<span></span>
</td>
<td class="nump">12,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">8,782<span></span>
</td>
<td class="nump">8,817<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">302,246<span></span>
</td>
<td class="nump">288,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">72,158<span></span>
</td>
<td class="nump">70,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">76,501<span></span>
</td>
<td class="nump">76,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">5,762<span></span>
</td>
<td class="nump">6,552<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">456,667<span></span>
</td>
<td class="nump">441,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,833<span></span>
</td>
<td class="nump">2,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">10,824<span></span>
</td>
<td class="nump">5,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AccruedClinicalTrialExpenses', window );">Accrued clinical trial expenses</a></td>
<td class="nump">8,946<span></span>
</td>
<td class="nump">7,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">9,713<span></span>
</td>
<td class="nump">6,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">6,917<span></span>
</td>
<td class="nump">6,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital lease obligations, current portion</a></td>
<td class="nump">5,643<span></span>
</td>
<td class="nump">4,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">22,987<span></span>
</td>
<td class="nump">24,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">13,214<span></span>
</td>
<td class="nump">5,567<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">81,077<span></span>
</td>
<td class="nump">64,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Senior secured notes</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Capital lease obligations, less current portion</a></td>
<td class="nump">2,889<span></span>
</td>
<td class="nump">4,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent', window );">Liability related to sale of future royalties</a></td>
<td class="nump">121,971<span></span>
</td>
<td class="nump">120,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, less current portion</a></td>
<td class="nump">73,963<span></span>
</td>
<td class="nump">76,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">16,668<span></span>
</td>
<td class="nump">14,721<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 421,568<span></span>
</td>
<td class="nump">$ 405,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 10,000 shares authorized, no shares designated, issued or outstanding at June 30, 2015 or December 31, 2014</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 300,000 authorized; 132,185 shares and 131,216 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Capital in excess of par value</a></td>
<td class="nump">1,841,730<span></span>
</td>
<td class="nump">1,824,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,498)<span></span>
</td>
<td class="num">(1,567)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,805,146)<span></span>
</td>
<td class="num">(1,786,309)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">35,099<span></span>
</td>
<td class="nump">36,332<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 456,667<span></span>
</td>
<td class="nump">$ 441,621<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccruedClinicalTrialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AccruedClinicalTrialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability Related To Sale Of Potential Future Royalties Non Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26626-111562<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorLongTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295533328144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,837)<span></span>
</td>
<td class="num">$ (78,838)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue related to sale of future royalties</a></td>
<td class="num">(8,702)<span></span>
</td>
<td class="num">(10,610)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liability related to sale of future royalties</a></td>
<td class="nump">10,202<span></span>
</td>
<td class="nump">10,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">9,737<span></span>
</td>
<td class="nump">8,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,833<span></span>
</td>
<td class="nump">6,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash transactions</a></td>
<td class="num">(621)<span></span>
</td>
<td class="nump">865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(73)<span></span>
</td>
<td class="num">(818)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">2,828<span></span>
</td>
<td class="num">(659)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(1,818)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">5,075<span></span>
</td>
<td class="num">(2,868)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses', window );">Accrued clinical trial expenses</a></td>
<td class="nump">1,238<span></span>
</td>
<td class="num">(3,697)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued expenses</a></td>
<td class="nump">1,859<span></span>
</td>
<td class="num">(314)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(4,434)<span></span>
</td>
<td class="nump">7,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">11,772<span></span>
</td>
<td class="num">(6,557)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">16,057<span></span>
</td>
<td class="num">(71,375)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
<td class="nump">111,001<span></span>
</td>
<td class="nump">118,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of investments</a></td>
<td class="num">(124,468)<span></span>
</td>
<td class="num">(166,496)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities', window );">Sale of investments</a></td>
<td class="nump">5,215<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(4,584)<span></span>
</td>
<td class="num">(5,192)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(12,836)<span></span>
</td>
<td class="num">(52,911)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Payment of capital lease obligations</a></td>
<td class="num">(2,484)<span></span>
</td>
<td class="num">(1,650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts', window );">Repayment of proceeds from sale of future royalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">116,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from shares issued under equity compensation plans</a></td>
<td class="nump">7,798<span></span>
</td>
<td class="nump">7,961<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">5,314<span></span>
</td>
<td class="nump">115,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rates on cash and cash equivalents</a></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">8,510<span></span>
</td>
<td class="num">(8,368)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">12,365<span></span>
</td>
<td class="nump">39,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">20,875<span></span>
</td>
<td class="nump">30,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="nump">$ 8,320<span></span>
</td>
<td class="nump">$ 8,622<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_IncreaseDecreaseInAccruedClinicalTrialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock Net Of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment Of And Proceeds From Sale Of Future Royalties Net Of Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RepaymentOfAndProceedsFromSaleOfFutureRoyaltiesNetOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current liabilities, other noncurrent liabilities, or a combination of other current and noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other income (expense) included in net income that results in no cash inflows or outflows in the period. Includes noncash adjustments to reconcile net income (loss) to cash provided by (used in) operating activities that are not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards other than stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with maturities (principal being due), prepayments and calls (requests of early payments) on securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0001193125-15-279400-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-15-279400-xbrl.zip
M4$L#!!0````(`$DP!D=RW4#/`J8``,JT!0`1`!P`;FMT<BTR,#$U,#8S,"YX
M;6Q55`D``ZHPPU6J,,-5=7@+``$$)0X```0Y`0``U%U;3^1(EGY?:?]#+@^K
M76D#'/<PZNJ1KRVDZH:%ZIG6OB!7I@&KC<W8AH+Y]1OAO&`[';8S<9+N>9AJ
M\(7X3IQ[G'/\T]]>'^/92YCE49I\.8&GQLDL3.;I(DKNOYS\?@.L&^?BXF26
M%T&R".(T";^<O(7YR>QO/__[O_WT'P#,KJ]G;IHD81R';[,_YF$<9D$1SBX2
M]<@\E!?GSX]A4OS/['N0AXM9FLS^L*^_SM`IG,T>BN+I_.SLQX\?IUFV6+_F
M=)X^GLT`6/^)OR^7=SZ;L5.$3DGETG7ZG"S.9]5?.5D8%/+VV4*NXWR&#$B!
M(8!!OQGLG.)S@_]?]>[TZ2V+[A^*V7_-_UO>;%`@G\"SZ]/KTPJP_YS=I$DN
M[WY\"I*WF17'LVOU5#Z[#O,P>PD7IZN7OG[/XIDD:I)_.:G`4[\^3;/[,_DG
M\%FTHL[)\L[SN8119&^;)\J[\W!^>I^^G*TNGJEU`0,"##>//6>9W"W=<ZNK
MZD%2?W`11NW/R`LMMX>O\X?V^]65LR6)JP]$R4N8%^V/+*^UH(GRE"#(N\BV
MO&/]0!)$\[S]CY27U-^`];^1A/>2*Q;:OV&>96D<GJUNVSSU9Y'5'DG"/XL@
M*_E4@3<8-C;W2IYY?FS_`XLB.RO>GN3[TP3(N\(LFF^>ZW^H_D`>S=NQRPLM
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MU^):00K3^/;*@P;''```*33`_QIR7V]OOKFWQFT)EF,H_Q,RC"DW7Z&`A%%3
M_DP,:N)7^2_$A*B?Y258_FQP=C);A//H,8@E_P)Z,HNDFH@6MPP*RJBX)0:S
MF8D8<(6@@!`D@`V9!1!R/6YB*ESDR)L,^=Z3V7,2+5>[4EFWO]^X)S]3H_S?
M3V<?(\<12,J.2E+Z2225UN_<2XJH>).&_C%-;HIT_N?-0Y"%^>5S4?I`\ID]
MN-&X-:JDN/C-WZ(%0XYOR_<`UV8"$$X-8''/`P@CW^&6D`3U;M$MK1`B+U=V
M\C/$"'-84F$8@B7:E1X_]X,H^WL0/X=6GH=%_C5\"6/X+2W_1=^R(,GO)!6M
M1^6&[(B=*+73C]WDMF]`DP&?.Q([=!U@,<,`MD-,ZGB"^XYD`:F"U*O:^4!B
MWP=//R70ZDDX,4IH):*'$CH\=4HX0?Y@)0OUC_?/Y^@EB)646(439-F;Y*#R
MK1\G`<!;%'"$C7S/$P!RQ`'!!`/+<PCP;6P0AU+;]DQ%`72+J8X$V&"F6<K#
M3G@J>O4J+>0-41!?AXOGN0HG+A+_N7C.PNOT+8B+M[7B^)9>AT_!VU6:%];3
M4Y;*-]\4SPNI@':FC@E9JX;%Q&1":E1A,D1[-*IK.]`R?1N8V/6!I#@#EF]8
M0&"3^IZ\B@2_Q=(!N45:XM55Z@B4.(H+@'7VZ@#V">JE$1IC&J@-.S>5N_5<
M/*19]"\98.]*J$%Z29*/4NP+X)FFY"N?2TK8Q`:8^)ZCY)7XSBV\);#%/&%C
M0X,!ZZ\#O9)>;"C#V,5(IGB(!AJ(%8L6K!6,/4OOV=")@"2XW=^0;^G>T"%(
M)?]?9C>%BK1+_7L59N7#QV5AC8MQ^Q1FMYMM/I5+@*WP=:#Z^7HB,HQ;7<PM
M$>Y&T(_V(L^?QT#Z`0'FNPOP<M4]LGM\:`3M*;9M^.ITF*308K*'T`[#5:>%
MM5A$R@<*XJL@6EPD3O`4%4%<H>-1MUU#!KGW@D".ZQ+<CZ6._;)XD*[)?)Y)
M#JGX,4Z99MXU'AH5-S1UN$T.<0UT-X@ZX)LPB=+L:YK<?PNSQ]^D([R[&SHB
M2J2-=R"B3?7<LO8Z.._Q*4[?PO`ZC!7/3VQ#F=Z?%HC4D/8":6RJ8NR'-%Y(
MQUN%@L7;4266=X1AC1AV>^7-F+V4WZ]AD(>7W^/HOCP&&X-EMR,CDQ/7%A@"
M'_H,$->'P$8>`:[/A,"^"RGE2B_KT`G:C`C:%]^B@2H;_%N:S(_/K$BK?2!C
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M=B7Q2*$-D_D'Q'%//#K'9O::1^=)%'\Y*61`O2[V:&'4"1@&I$V."+D&K8BU
M6H5ZZNCX_*9U7+3IS!9VJUB#TKM1Q8Y9^!`F>?027B3S]#'\FN;Y;V%Q>?<M
M>#VJOM0:>0")*9I6?A=8=9I<2(A9F!?3\6^0UA@R$]:YN'WQ@Y(&4P"JK_EA
MI*%&.T$,`CP1NZCUYY`0S8J&'AQ-1I;6LTBSMW^DV9\7R566SL,5TZ\JF`_C
MXCD,$I<1$S",/4"XZP'+$1[@)K,QL0T/>]YM1^3,X!93]P)IJ+67((H5__MI
M=A/$X4TH"70XGQ8SRW>Y90%N0P<0SW2!S:$%7.KZGF4C$UE>5Q"-L"%?5-=@
M6@1M"?HRK3`-=H9Z$>8,M>3E&VMO;&1Y]:AXM+O6XJ8OEZN10LFOQP32D5Z'
MC?1Z=<GML?]U.`^C%\6?\I8)&`Y]65@9*K8D`-H0-!V^]"G,BK>K.$@*Z8RK
M2.M)>>9'WDAMH,%E9%SW@[H@#-68$]A=K1>/,.:-X^U>(!KI]*,DRA_"Q2]I
MNIB.C=3G71FD[3*K!]*F6B>PN]J\`#80:F2S:HO66L()@-*>\0DNM%90DXW,
MBRR:RU#F$`6ZX\:D6CG=.JO>$56=)(JU?T1Q?%2_0!N3<48-6`.[7N_AZZW'
MC4RTVVD(WB@JVGT3-PKK.OCQJXS4LT@N=S**5[N[")NH7?%J<;340K^M*A>^
MI<I&7=YM*JZK9=;+L^()*#.DU68007/5AO)!?!4BK4IUG%A:LGD0?U,4]5Z?
MPB0_[ID$U%HJ8:[L5._Z*S!7,E/7A,>,3_6G:"9>)>CU"Z\V4FP74;IA'MTG
MBB..:I^J,5"E^K-_U8UMJT-O:KUDT71"+\K^Y_V:&H;@'WB*KU=J4OLQH[[#
M'\#8>1JU'P'>NSH8(XSC]QX904P"<5^9@\D]7\BW&Q:W)8.8%A#(-@#!S(78
MM(F%R"WJK.?`I.'"-'!]*FC3H%S5('6"]CR,$1,6\%P72K&G/A`$6\`ACBD<
MSR?$9SWE/(A-"30U*.GKAK)<TQ>F+56!$&I_70/8@G!I[AFS*:8"";\'M(!'
M!,VQD.JVT@)&&33ZFI8@9":6,(%G.U+!$]L%DJ>EEF<65.U?AFE8RP8Z?=-2
M&98<#34S$"<]*)&''5>X`@AL<T!,;@!A<08L6_B6%`G.#:>7G_D14?:W][75
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M34M&LS:VI#>+H`]LR_*!*:!%+&*ZU+6V.>#I.0M5PQ]$53(,17J@+K!=2-$B
M"\,IH3\HVJ-/;.SRB2H5I#08)14X5".$,":,C)*^ZM$(M%DI-;3"XA.)P:'4
M>V,0H]L($&)B<R]:5'(\FYX6-\KG<9H_[]L.7*$'P8C`*G-PA.$8]"BGG^@[
M/1B%VSE]/<YFBTZ>O]?IOI7)WR`>Y1BG'+5%("NUAS!Z;0@EPC)-^5:?0`*(
MXUC`$MP!U'.%!3F6#GU?[J/6QS,`V*=;EITL"3<\2J%C`)4Y`L1W2]7)@<M,
MR_"E.T6%N=W&-:8E^933VQVMRG"JZ/,HXQ[H'DBOK/6(#"+$*'JDG/NCKT8Q
MD;FW&CD$>V"(,!QG^E9I470C%TY^EO:D40JW!Q>,-^&(;`/?>]($FOJ$HQ:P
M^QZ1H<E..!H5I&;"$420=6_H)TXX&IF%_WH3CL8EP)0G'(TKP).:<#2NV+9/
M..H7VT^;<#0RS_YE)QR-N^T=$XYDO&@VZG^/.>%H5-SZ"4<J@]Y20_I9$XY&
M13GM"4?C;JBV!8-R4H\</GO`T;@"JQ]PQ&286M_1GE;VT<;_C,NT^F9OPA'<
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MTT>>C3(J$/UL%&123;OO(6>CC`JN8S:*L>4:?/YLE%&QZF>C&)A-93;*N*[?
M*(KSDV:CC&HCM<J'RK>TR^QGS$89=7>U>0$DMOKU#CD;9510^MDH`K9DE8\V
M&V7<F'3:LU'&]0LF.1MEW,A$[S%@-KW9**,J7GU5:%,E37,VRKB,T#$;Q2!3
MGHTRKLCK,]C<$.]$^,39**/&I_I3-`9Q9?;+9\Y&&=<^_?5FHPS#3Y'E8(-*
MU`P9@!BF`*9`/G`,QW1MSS0<UFV?&5I_?FK\V2AC)V,^J=.JPP9`(>,.,C#L
M.!HQQNRTZAHK@$PX=#SE`3LBMNEQR$ZK#EF"$'V@1>(0G5;OI#E(IU6'H'RL
MT^I`_'&(CIF.',6.C+"R1>D\#!>YGZ6/W0[4+YFDZW!2J#G[TF=#B*Q$9=F]
M30G"?9WYA`@/&9X#.$<4$-.R@<4L3](#NQZT&?'=ODE+RQG,[V9F1YA5`FU:
MT=0S]2^SOSGR%^O/MN](FCV^5H^V*#7H8_7:CCR,U]09BK%*E\U7[9<?L=]\
MW/XR4036?<S^[4(&*]*Z9[OX9[L0K&LBQIX$1+KF>`.M"?AA8M3UD4H42S=(
M<NU+M`@7]MOO>;BX2"Z?PBQ0>LV2+W]9IAI+1?<L?[>ZN-/W*B6AEJ0=-.MS
M4&=;1Z$UD-JP,>GT8T`;U<JKNK-U5;X=Y-%<NH]N%#_O%`[HJ;+-0(ZPB%#?
M,G0QQ(`@1S(0M1G`S#9,)`S;%%*A:8E2:SX`QBG#E:KE;CPM-<O+S@Q7ND#)
MO7PJ2A?+CHWUX]+!3A]5=%B2;PR"M%ESV^&0N]0"GH4@D#)*@.D*!QCJ_Z4W
MX'%3&K&:0+VW$$$N!&\4-.\&JTZ7?X31_8.DEO4BF>8^_.WY\7N87=Z5CU;Z
MSP[`*ZT2-(A94"MI$,6-9-]^V!I"<W<7*AE;U:I\"UY5%_:AM,JV_!#E'7'3
M!K;K($"(AX"E>,?G%J.02L\:.PUFV9@O4I&5P3":*>^GU4"BR[MU(\2'OP)\
M"*W:D1@K$Z2UA/=@3(UCR-5CWU)K7EHE[:'>D6FA]8`I;(R3'@YIRP"_%V\=
M5QOH<X%`ZDHLFO;T?=U-5B\K7(^,1KMU1"!!&GR\7+"N9BXZG)H>Q(98?_+&
M4+/,X7W1C;/$M:<S&7;3QE2`FKC9*;>]^N9NS3.E<]QP^>]%LC[$V"D/=1`_
M55_J2)M9E0X0?7C+0]=W?W;'*J.#`-<FV`!OJ)-A<%I.QW]+D[3.&ZMCB2,S
MMU[]&"T]H%H4#6,Q4;`=9<PFQ'5E.Q#J-D-L5SD=E[NUT:>`?;R]#66K8Z)9
MV[U[N?I.F"'&Q&.F"5QH$ND=<PIL$SEJCB.D/F66A9NA5--#:!X?=(#8VNJ5
M2E=)LS97V@[OTNS=XPYS[[7(@C2304>0O5T4X6-9;2F?S-(X+AEK:0:/+!?Z
MMC8NR%:!XL&H,/2XILQ(7H=!K(9F_!)$2:Z6(\-?>=<ZKWFH6!Y#V[$]1H#`
MA@`$0@JD&!K`D&&;B2EU,?<D29=CP+5YZ=-!1S9#</8$+&.<>1TD8NGX\I@D
M).N.67:JT%:\%N0/GV.'!H'7NLE`-&I[M`#:-).4M=55.TS"NUU:90^B5?1M
M^H*UJ)2MY6^5!#<.+";+V\/:PX;#:20V#Y:[;+.WC+A<QJ%`$,@`H;8`%K&E
M^47$<BSN($Z5NM,B%A35.7I(BK)*&Y7J#))YN,KBY;\GBS"3#*-.%UY"U9#;
M^D*5S3@R&^C;J+G)ZGG+L0#WN:9[3Z(^2-2EU0^<X2T%T8UD4,RY/<#FR`30
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M@@'@\-.>%93F7+.G3*ZPU)E*GSRF61']ZY"IIX&8M=+!**R?6G=`J)3QJK:X
M,MM:"[D:/76;XN@CAY#Z3@B#HDIOX&Z@*M1HY9(1.@0/POWZ8!(SD[]38S=0
M%6IL"LFDQD@6VRG<9H=E>8R8!=+5*&N?R]#MR`JTHW:JUA\P!M1Z5X4J`"]K
MOU7_XD3DI\.:5+M*=:O?5AN;<O<R+=D0L`;-CEQ3JU<=97:ZH3IV`59KNIXK
M(7+26)K7=!E]EV'(H5/0@VC0,31!L$K7;1\*3?O0>RJ_,GBRE)3UE2EH!'WR
M"4H:P)H4[`KM$SA!_SUW04P"^[HPH1"F@X@'?,^A@`B?`_DS`MPS;,<W?<)9
M^='O#F7!R,H+WY57#D^2Y7?/*]UFA%$Z"DF0(HE^JAJMVI))D63K0];255)?
M_O@X2;`B25<_Y@2)47X7N$(,3B1UQB`&4<3X__;>M;EM)$D7_MX1^@\(;\]Y
M[0A"QHT@Z)[N"%Z[?<9M>2WUS)G]XH!(2$(W"'``4C+WU[^961<40("B))(B
M)9ZSNVU)0*$J*RLKKT_6RE<;-F%?^6.YB?`C2=!$$JQH/]%JM_>4!O>W&'XL
M35RD27W#%<-X,%ML)RV"UFZW'6HK;EOWU2JOE29AKI0/S7;16ETG46)[:P:I
M<.\96&?-JZ\)QRP%.I]UT8YEF>XF%FVO5!=LSWAX2DPGGH5C+%<+;Q7GU.#[
M*)J/@S'+Q)Q,YS-V2*[*E9*="7IVGD`C!Q9&_3_M=K$$NZJ/O-LS^D;7TD'W
M[H+B:0QUSVP"M;HFECMZ9LOK+!\&4=9GD=>FX,'?Q-K7X:%.FJ*;&*W>[B)_
MA*<?=N[\='PVI?CAK_#@+/L8LZ2#4MDA_;$/]I$$&M@&X9<K!]VAZUI>S]([
M=AL$L#OLZ7B,]7;'MEW7'%A]J[VRQ7NA]K9YZCGW\>C6"+;-W=K&9E1E"J^_
M'57'P&Z![N[<*R4>2P1&X'$0?N@G(^HY/`RSD1^QOP[A=P\W2YO"+"T;HGV[
MX]J#GN[VVSU0##I]O8W)TZT6Z`5@H)H=,,:Q[^TO_VW]_?W*.3TK*$!S<V:W
MN0(4P'2-4B1WDY@`\HBQ2J7?`Q_Q3\9G\5>4K"FOCLXN@##=Z$&=^>[A@J9M
MMH9==XAMH($+FA9B2A@6T&78LN`&;G4ZK6^(*O'+_XEF/XW#V_]S/?L)IHX_
M3;5LMHB"G]_\WOGZZ\?/>O?LXN+L]P^:,9W]I/WKMX\7`_W\2Z<W^*#%20H[
M\Y-V,?A_%_K%U\[G\^'9U]_Q]W$`CYY][=.3'S__BF]__TGKG7TZ^_I!2Z\O
MWQH-^/_O?M*&9Y\O/F@F#*[]?Q?A),BTS\&=]C69^/'_!V-\[)_]ZQS^_I/&
M9W-Q]H5/Y=/@XF+P-?]"838?/_<'.+#SMY\T_2ZX_"N<Z4A9/9NER5^!?A>.
M9S<TJS=\Z6?S5)LFZ>PJB<)$2ZXT3`/7_'BLA0JH61AK$S_]*YA1_"F3%R0,
M$,9T1V;:6WAH=I/,,W@Y>_<!:?I^^MP$MK9$8/KL>A3^/_YD^M-_?>\8/RV1
MA).3D05GK)]__)\!XPNV!'W8^?WCIW]_J%I$%P@!$X7%?^I\.8?71FC%3+/@
M`913"+&Q=6NC((JRJ8\I4C^_,=C/4W\\%C_3LS^_\9R_O='\*+R.?WZ#J<=!
M^D8#&VP<I/B42J94_6$LWG?=O]%31-;9N/C,+1_X,IG-DHG\9JO^E1T,=3"?
M?E\D>5K!H][]+/IFY6+HR\6S<<_R2V^L?I?/F!\2(6QR$:&9(!HRD'KC-TMD
M3I,[X-^8%.`B@PIR7>(_\)[+9T$W'DWE4CZ5:N^56='O?POATDQ'-XO['_V$
M*7;%Q_:&1"!K&(G<E20:9#-08Q#<!8FE,4O%GSUI42^16Y]]&U=S^O^=QT$^
M"]MHE%@6=;+-[NG^TZ0?C`+$_E'H8E;0Q=DYKZ^C/<!->PWK3."J_:]>;S`8
M#FO8?Y9,U;],'ZVM<#WKTV"(>EDP*2D6.OQ*?*B7I%/TQ0:@@V!K9]1&+Q/0
M*I<4J&V>P8J]MW9Q[G]\R.12='+0:V`"-=IF:ZV7X^0N]:<_OV'_W9VDVN1J
MK4;3<;:[VDV=M7T\6:-D,@G24>A'VM0'._Y5'*W'S3+G.L=IM.WVH1VQ)Z_:
M`L'2?/:CYDQG:ZAHNZ#G#KY1%@I<D2$O14&+^<ZUF(J-?NAIWO8W=Z]"OT8J
MO@8%4:;2ZU=)JF=^%*C>RIU>93L3.D\4XA88;5[3?6UWEV4U&TYSRU?VR],3
M?T_B8,%=_MK5?`],+_,0N,UT&TUS+4WV)9TQTVQ8UH$<L7V^U7I!.@NO0BPD
MQ4#<.)@F63A[[H/W^7WG$)@0;)1M\^"&2;UZ'H\889DH^"H;$AV1VYKJJ[H9
M,4FBP8/>87RMI;*-%D7.CZ=UO=/:;MBN?4C'=2.K=ANFO645_.A(.;H`CE0\
M.E+6N\TNDID?/2SE:Z<WW*ZDQ".C4%:KW7!=X]#NL<>NUK4:GO7\,;?C_;4L
M!6V0@N-D#D=UAZ+W\1_=VQOLA=&Q>)K>DRSGOV#_0[_FB=!Y,OA#$[A+*?.\
M)9;,'3\/KA_8&[D^&[ZJ"F)@-P=]M]G7A[UV5W>ZO:'N&5Y?Q_K0MF'WATZK
M^ZW83)!/Z<TOII("7S?OND*&?P=^^BQE#/:;7W"0JD(&.:=\TAWXZYB>B/SK
M74_5?//+%6Q<P.9:F$IEIR3@L.0:=@GAAD&K&RTV7R7@#KO#7M\U]=[`07C]
MGH>8Z+"&7@>6,?`LV^X?<)6`Z6TEBSWB:6_XCQ#_(2J!E1TC:1+*JU$^__QU
M``\CH;NE0HN4DRS,0**EX6TPUJ[29*(E\#<_K[+*M+MP=J--;WSXXBB8SQ`O
M"(:@/+@PF06CFQ@LBNL%R_@7=<O:U$]G<9"RA+F)OT#GU#R:\6_$@9:D,,HD
M2<F_/+L)M"MX/[D#4?=!FT_AL7A&[T:L*EJ["H*LH0DH,W@:WZ>F&OYHAJ,3
M&"B],L[A0!O:)(S`CL`OBG<;^&$_GE_!B]12DE[*YM-IM,@?HE^F`N+EE!6G
M!.D54CX>!3!&HK0&G"-J.=&N0(:,EL[+4OA2\(/PX`F6J\R"*`I@%ICYQ/O2
M->KGIGR0I@=#U*U;??94^QAK5,N@S1+-9ZAG2$`D.]("]B6<1H$>1+3EA>UO
M:'?`(V-$8[]:T#Z-@RC$.D:XOI6:FS'Q"97=!.H`-+$`])$YAA+N;D*8:VF$
M%''*,GPV"X!M\#F\&S-D##Y;(,2IUHG]:/&_2)/2-V`,6)B<I#H\#$X=-#)Z
M9YX1M_TY'U\SYJ#)^:,;&$%YBS;M$CX1*V3$3_!G8)[I+>PE[H)&-@GC9L&J
M\"1^"5[W46=IP%_AAP1+^5464@8_U;@$0X+BI$F,_2]059`$MA]W#"<K5AK"
MGY%013K!"'<W`=N'2VS\*4]ZF@M';00&-)QZ'\@(RPUF'_#Y%*4!O`]SS.8^
MM@>"G<./P5QG-_Z,5J1L;?`]S)!#.%D6VHV/KR<C5,R"<8/F,$V!*KBHJ_`[
M3!C6,`[@TY,P1E*S+<`S$Q".%IL`HI0E^/<%4A#5O=-#%-U8\;5QV=V9$5GA
MV`54Z(J[3UP1PX16'64M/_`^[7T$XG?,@GQ\'-A?VE,\8ZN&0@D*8L'G4+/X
M#Q3%&?`*%_\I==`B!D6Y4QX,+Q#UCD&Y!&-4''OD860;QM`IXG#!N/!^%E`O
M)<Y?P,(W"7#<-4.`!<:1[Z%0OL2>4P&O_X`/++W_=G#^Y=VI=G&#I_)/UDD6
M)P*_1MZEL\^X-LBY&E<QXS(-R'&7S*.Q-N.@<"`:6#+0%7^!(-5P$[CTT.[H
MM&2(MPK3A,>Q7:_N1WA7X<D%P?VO0/DNSH5+;8W3$5UC>.+*]TZ1NI<+N3OJ
MSFIXR21I+L3ACPWM<C[#5'<09I,0(TFS!,XQWO)X\6.J+KSY/9PM^+7-Q$6%
M2&,7%PP2^2E_7$X:R`G;E2DO2TZ!J^`V3,",45=PJITCOQ//T4V8@75+G$NL
M).0Y^@GAM?"6[DUV3H!H=%DN<JYGX+CX,+N&!5]D?`>5P5$`$:@NNW(8O_/#
M@K^9H<^2Z2$*\]/R8.=">#4E02D6CJR=T[_R,!RFI-N:GD\:/,<CI`.5E13[
M`Z/4-M3Y`GGH1@?Q-(%C%RV*NCV[@IG$8_=N-M.GT3Q;I1'[UVF@F@)+P@9/
M,=?V26+=^+=4+0-W"9SN$-6',9U`Y6"!)(<O@7XL;`X\1'/0TR<XRB%N[):/
M`,>C%,K<\1"4*?6KN/G)8L%#@$KR+*(K+#?D<B.WCH>+&D<<B'/%1'Z8XA64
M)GBFQNG\.N.:<<H4*PQ2$;>/V<6.EPP9N\S4):V&.A_?D;H-,[W!Q]CT%JCZ
MHCG!SI&T`L2?I28O%7R*EC&#@:E;9(?(/XOW?`:'!'2X#/)GX3UV]:')4U3#
MA1FRI(9K_T(1`/;4E"Y%=M$!O^@T$TEETN$),A6?(3T(R'=%L*G*7HR##`R1
M2R383/N<@&KF-!3'!(TB+2%:E9PP&%5HL=R%6:"^HKXP)E&&QB'J7PP+!_:#
MZ6M2FPS&"GD1?4*E9X,]#6/DBB69-Q23Q#'^,P>V`;W%O\+_2UH"2$V0<4C4
MJ2J8Z9I'VW(<'`7<LH#CZ'>-LB(+?,DLYZ/DJR$A&BW\A,,A$[XS])<IU)..
M,WG\P2J8<_M!."Z$$*BQ(X2DDX8?GF[NA6,H/#6V`&C@V1R=5-FRFH$F4)5[
M*T73AS6]HWGE!U`YXC!+%$]H`MUR_QLJ'90"ITZ%GWYF8I"US$48LR55]1LE
M[\3_*ZBT&U510E\4QA^:$=^%3+R:1U<AF+/)O,[?DW'!HKH'45#EWE0R(Z]0
ML&1@"<[P_8;B[9,(2'!>.(@[^;!R!Z#Z"//!%@@O_TH78NG=V4V:S*^9D,R+
M,T7[@Z1@T9YJOP(18VX+SF&>Z<P/8QJ:/4D-9.J8JE%KRTG?W7C9_`;17IQ+
MP3'+-PA7/;N1M]R,[@?V-Z07<9(N7)-'#Y.4)PQ4ZSI@`(I53AW2H>BN&]V$
MP#?,O02V+1WF2V17<J#DOO?BS0QW)SIZ4$$#.V`A[E*V-^2.4&[IPB#\@^)B
M1@7J,HCP5_A7FFXV8S8U&2LX`)_1B`YP^4SFCOM;,)C0\:`(0Y)M!<Z5MM"I
MUBG.#(05<.<891RZT6[9)-Z&[_*8.,G/$7J5XX@YF/EJN,I)RTXB4A=#%D+1
M@A#%-PHX1B-2:A=Y)G7[IZPH8U+Q)'?#\G73UH"`PI,&RYUA!V(>DT%Y('?T
MGO$;M"9U4>B1DIM%'N0""^0"82%<,F,X;EPK4]V3(3%$D!(A2+/DSQ,M83M!
MHBHT:_`@%,QFB<;,C\,C3N@4&H_)[4T%YOP>O`QPW6-RN7,]EJU]:6?5Y7!O
M7N%<H.SWTWC%N5ABXYQ1I4U=<J2ILH^/5AJ&>P)#WMR#W>2W!&K#UU/DW=)F
MEPY"@VO#W"6)\088A1[RX0XL/$GI>8IYD/MEN2,7V96MFBD?A8@,OBUWH3IH
M=)3%:J1VA796X9J19NR4P2?"('A$)<4I.`5:(I<2)4Y5M0#):A0Q%0H<UPFF
M42`N8*&`@,X"6D*&C)D&UW/@B"1=L!MA$H(6P_0Z,I[QL<N%\ICFSV<W2:KH
M*[G>@0JJ#W+DAFD49'4K6@?Z<\%N!=9!;?:&>5R!I_A2<C4SN40YQ`HE\N_R
M^1"1<&BAUV0\"Y53B%F2"E*%F%*#R[T[7Y$4?E00?&"ZTCGPXX6@9$Y<+JW4
MZX`+/M!:2'8'WX/17%%WR'&>!Y-7\07%?H7X(\^(5'B8HX#FQ<*Z53NO38)@
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MW*UXFT3S";L<B[YI<F8(*<M-<?4K*!59A)8IP<(1FG,H+`HCVZA[YTQ,7$\?
MU]D9$L^C`P!G79ZQ?%Y,]:E,=[(B8?C>Y,T2V#I+K/U*OE\XQNSA;>5[6EW#
M-,V>HQNMKJ$[S4Y3;[=;'1U^U^L.3<]MVMZC\CU75^:4CLFR8[<^M9+3!_0(
MDB6;2:U\PFS)@UHZKV+VP.T))4P'(O!R.0<5*<A`->/+8++S"K.2Z89F"05Y
M3I[B@IN"BHAKIJ,23NA@E;U-I)YEZ(0,LQOFJ81!8G@R8MHDF/OC$"U>=AA+
MTQ.SN@Q&/B6GT1SDI!-,(,#>#BRFRL^J!IP=)Y-PI/AW4?VY\?%Z@!>R&?Q-
M+0RF((U/R@O,MZ#@%MR"3""-X-.DURZF3*C(P&Q#&V-/Y?"2::,LZ8:-4]#X
M@_@V3)-8^E/]E-D,:7"#.NLM7KCP8?^:^4NJ-@K)L""1V0-9<J4-F`X,5#B[
MN@*1F])7T;O'!F)^R\"?+-].RR)BK3-?ZA9=ZK*!10<C;#V/C3J"AS=9J"@G
M6.YPL59;/[L66[_0WT(W3DVEP<4]ZUGJI$RYJ5\BT)_A(>PC3=KYML2D8\*J
M^ZZK>]9PJ#NVY>E>RS#UIN4ZGM5O&U;/W+68-%9)R4])?*U_(F.`U:GLLXS$
MK-2,6?(@UOPP%1=UA*N(:!64N4KWM,@DD0G**"60$5CVK&`%%J1)DC$I"S(K
M&`4=V9@4)":')"4\\>%1[PTPD$)./O(=L/0L"K!*H3`*T]%\PKRX+%]MS+!)
MI)-PY*<IB7&N@@O-G7V(XBR8DG*)5EQ$$2/49[A3"H04ZM^DIXB)H/>4K-0\
M\J"8RVG`DUTO@P"#E"HA8>+,#4=Y=_#[5.8LXV2*OE4Q;^F[(U41O>-7"%)-
MOVM0X(P7/@E-'BW943CEECS8#&%&V07P!.8L4#S^*DKNBI0@?P#/'*#+0.P8
M$E4NH2'@ED;^-)SED9^BR9$QZ4U>238YYO?+)PY?NZHCCD@>EE-CFM]=&LYF
M0-)Q<D>)=!0GD,#=A:%C[7<*AJ$<X0:\'\?)G/*-)&,P!E[`G32>)B%/?,=[
MI3OH],X^:U]ND!*V&D;+9O,Q2[?^_(^+K[II6.35U]#;$@6Z?\UB9$"'*7OL
M#F['F'8.YS"^]6D*<#WZ&79I&FF7J-"2[Q]O+E`(B!F%7Y<>RD1E11X/&Q5]
M*,2->;YDD:["L<(+(\@[LGR:<Y5`[#OQUET`1Q8O8K10&+W0PU1Z7[M.D_DT
MMS[A>(<B"BPI=:IU>?H,6;#HY"BY?+A@$!O$0@9Q4E@,B@C:W`*@->TTBH@E
M"'#ZRSHW_[HWV7*9W05H0[LN6#.P1:#^W\7:.IQ(/KT!Q2QZ`?H&HH_Q./C^
MCV"QN?(TJS?LPJMZO^MZNM-J&GJG-1CHEFT->ZV.YSKF`.9IO?D%6YBU#;=E
MM-EL*^=5GO8PC(*T!RQTC:[8'4_:>?/+)S^]#K3.:!1$I):/-9J1NH+"%,M5
M@BP:CUI3[K#D;=09/VUL31VG9?8'@[;>-?H6-IOT]';?:NM6'QAHV+.Q:==^
MV8U?U<HDA3X:)]#>*DA?ZTJJ1M2\FC(+V1+H^@.1.I=)*GDJ1^9CWCN:49=P
M8UZ%,S49)Q%5O7Q,$5M)YK.,A6SR"B-*C@EYW"Q/O$'5Y2;P60XOLRWYU7"R
MHBI,W'VHR\'L9G@QELQ4;L(J=G`AJP0&)*\J][R"A$_'Y-4*A8-^9=!\N/8$
M\"DLD$LQ:ELS&QCE.O4GO$B-`$/H/=`=,.R%6)%T*P-=@2;AY'*>9LQ2)(^]
MKTQ_\4"OYE/.C;5:/4?%%&;ECT;I'`-ELN9#JD&,:W@0I!A^0P4DS^W)M072
M&I6]8K4N5V$,:D9(%$9'AQ)?4KR7R/+9G,IB\*J/01;.0I]%E&YQ!XF:LA93
MYH313Z7Z3^"9.6K\L7`:<B65!YOA#^,DS4YAA"_""<G"/CSL3H.B[@$GD))T
M>1&+&I\D&A0\D()=F7)/V6CHY0!3`/3"%+A5/`CZ="AJ1'D44HUT\F&*)%<(
M3N=0JL@T#]C$0(B.+$N`V#->+,F24^`(S'10JY@3A3LDL-Z6_%-7/`Y0CK'R
MQ#>6A%9DCE)N%.FS*[Y1G'+=A-5\FADHLS-V_FZX%5&>7B&%6A3)%/E7EM"4
M1\-2J"EE+-)6L%(H[HGF,3HJLF2../D8C;F"+/PYI&?^198H)F<KQE)X@B<G
ML'6AT:'FT13,TCS'L2`@01)P+SG1E!LJN3.]Q$M\><#U++;+G6P\*9"26X*3
M'Q2G/GGQ*;D\#:ZBO'*-!Y#)LWG%]U/<57B\.LQ,*514DU60*35J/.=3Y-Z0
MR4?V!9CQ+."+;XF\[KI;1Q%(+$]>FI7L"IT"3_I@$\FU,SZ5Z6(8.^6[+@^X
MR-UF,V;9HI1DPFI,U?1NN1:JC!$2\90)VTN?N5V5*C#.MI3[&>9>;\T72-\\
M/H^L!+M[JOV6W*$/HZ'F&:DOLG)BRKC*QZ`@#\7@11XH7NYW&/F!/U$&JL_V
MU4=7!#H[\CS&F-/\1"0[9MRPQR2J6[+@[V09LYI*).Z6\9]S`:Y%XKIV[^2>
MR&^*+^9E!CY5L*/%B"^R^DW:<;'LC%<_L#-QJIWC01&)2QFK">8_D'.''6;<
MKEPP*4D&C.<5/U&^=TQW$/S*3P1S0ZVU1!D!IF(!66>]CFFYACE0BCR-;H+Q
M/`K.KA#($_\7K=%;/\)M@5'.;T!07\"]_#&'0KM`WMF\O]7K]1VKTQKJAMM&
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M=F7&OD!LEP^.BJ"<*YD[ZCKPY`]N61=_]?1[64K,(31G.#9..#9.V(Y4VAT2
M_]._N)]R_251<$4C`_K%<KG!DP,]Q<!1+T^ON0TZ>=E\/\Q&48*)N%L`JC>'
M7KO?;.KVH&7I3MOJZ=U!LZ]WS5ZGW^^9?=LZ`M77`M43MIE;:("H?5(*!WN%
MA*F.3+TA?CI8Z/JMU%P*@,D"5HC`;JDMP)01P!,%[4K)<"H6;][FR0PE.';,
M"RKGPRTC))4K/_GTX-TBCGXEBOYDZL>42O1'+*LV3^ISZJKA#EEE>A$\_^0'
M"0Z6H]Q7P./G`'T-7K591((H`'B(Y+2<2D$!LOZJG.X'`WP9_+J(1&H$`^6E
M+7A/R!&%-#WZ31ZW+U-?2;SJY+``M5S`LD^4G`+,@&'I&+S83-;GBK1!%;-4
M9LOA1@8QELJRO@`R'X]GE_!ZCRPHYIZHB6%J@<Q]F0D-^`>B?8M:V4SV/R@`
M#(H<NKI&#&E0^"I/PD*"4`X-XE4RN`C"1:#DH&K`UQ+WG11@&J,U<?Q*X?63
M'Y0`^X<'2+OOVY-VH$$\2-A]W\(-LI&<@(I5U&8%/(!R"B4VMNYU<Q),PWA:
M4H+=?GA2@KGB%3'LBNR!1PR[J=\?/[W33S\JMV#=5M.[":;O0^B^T%KUJ4DE
M%S=P:>73F(`>=)/E/V-"ZY@>SH/YE1D0>Y[NL%&:G8??-48H[1GHLXM35.7D
M6N%67>-[\FY=M2-T>5[\]D&SW%.W65%']86I;2L,P+WAI67^N4=I,TM9D6L1
MM9PTN3)1!RN*P'2@__9$9=$AT'+-3*0#2;W:])HWG%EU$&L^[O,S9=`=5O?T
M#IA2_O\$<3#RM4YWNP*NXMW?S_[9^7SQ\1_X1#:O7+&)UM\_!U\O/O8ZG_3.
MIX^_?OZ@"5)=_$Y?@E>+,WG+<`5,[QUW_VSK0]0:1Q\G!%8^N0QC[CUA%:;P
M83&3]KMMT[-*)5DOVE=Z<3GZEWL4R`>]R1D^1QST2*D=1(S;QJ'E_[UDMMC4
M7;8_-]?79'03[/S"^C+XM7/^[_/'7B/B@X.?JJ\3='?__O%K;_"UL^%/[(`V
M3\T<M!MFNW5(`F,SB[;,+2=+[M^BW89C>*]PT>9>5D`<F,4RN0[BAO8Q'E54
M5V^9!3X'\PBQV5Z?;#8;5O.@E+GCHA^;O]]H'I;:?B"+?GD:>-=?!*GV6^!'
MLYL1IHE\^M3;N4CN=O[MF+K;;)K:V\XD_`LS`.!RN/&C8.L>EXWH?^W75R'4
ML-OV:ULTW"7&J]MIL.@<]S#$ZE-5WGMBE8\5OJ7PY4II_!T$L?\,`OC_:5ZS
MJ;W]+9@DTYLP"OV#$+S>ZS-`W5?G:'B%#B6S81@'(G/W1Y4]PQ3CG8O.PV`G
MJ_7J)*5I@.6_Y6+'_5NUU7#MU[?55J/5?GZT@KVI:]W%-\J27:W#+.0$[:BH
M?Q/??#@O'JEXI.*1BH=+Q7WQ/#Q-+[97ZL6?*JOR&LME>2]2=WYDYI/;L`XO
MNOU87+_6(6)</7:QAM5H.Z]E:ZUFPW.?WY-PU(R7[[3=P:)LY*-[JX\<Z?C<
M2SK2\073\1[$H]<*1=,AS(_J9I2-U4@DO%>H!.>0P!S39(9`+GXDNZVH2"L*
M.`B\G<.RL!Y+U#!H.DV3[X2>'RVT'TW+.[7QP8C4_;P1!F^3"Z-0\RZ<;!FU
MA@<B&RP_A-D*9].;V0WAU<!<LE$:7E)OJ$N8U1T##^$M<%;"THA>7C`1MA*Y
M2#DH&U+V\(&7\:5M5?]0NO9N*XNPZ]W)#S7M[-(`>TS-J%-Z(^]/54(>.OE!
M:;LN&A>SYCC3>9K->5-"WL,,.R$E$7+%Y>*D4##VP'XF+_A$7_#.SK<!:^P<
M)Q*A2/8;JD39R<_.R0^B9UA6*IZOE10<W<?/*L[4"]^:QX"IX3^H<6A%S6-%
M0U'ZU8>M'>^WL1\EWX/K)-(2D)?`+>^H0WH:W"+F5X2=#Z^"E/>M@CW.G\?#
M*>H;&\]2WT@3):'36#%C4?E8HO#+Y<H'H=%1JRC60Y3HI0@#=H\6V51[J_S\
M[N0'WMZ2M8&#.Q,V@YJXJV_YVEV21F/X/,,"B^:9@NXFQV``9C.):,<<>]A$
M-<(V:',08E/>_QIGRF\3Y%8&X,NN^`R;@;^<BS9G\=,"3<.,;EGL*H<X6JA=
M^;#P'/>OJ&O5`/TA%G+U0-35=ITQQL$HS.`?3,/;`'&*BCPG$WZ;-;?;UA<>
M1GYJ^#A'/BV#$C),.M!<FZ=&_B6IPLJ#PI7)L;ANKX#]X;3]9PXG$0\#CF(9
M1INU#F5O(>;</"()IW:7!"V^LK</WL\&;Q0I>@JJ^BQ0CY_XO/'CCXYQ:@B-
MF\TB5W5S17<^Y6TFK\(TFREL05A^[#W8*1!''W]][$Z)M=05*;[%[^?7T66*
ME(K]">($GK"^LX,Y"@Q8X1\Q+2?5!G^\0XHC8N3$_Q-_47QDA'9%NL"VLLCR
M*!RC+*DT`QCY?FPU"P13:`$#1/X\AIVK(N&.;(/[;\Y*_?Q^=1R&D`IY01V_
MUXY20"FY6`&]$74/M.R8"T`?A]?AC$-Y+G*BD80O@GJJ]I=<BA_'>%_(>T>+
M`P$S"5NT32GU'/()032SEZYKKZ_5G,7:.5@D)8%HNB00G08=-SCM>/C.9]1W
M=9@DC+O[S*SMC"=A'")/TQWW=MCOO&.^"9386SNJ'(PV[_!,<C29ADDXUL,8
MMIGZ,,?9+)SRF9U][)%`\\?8GEST_V::V^@&+J9PA!H2;*1.<+&H8F$/6Z#1
M\IW1%A0J:&]Q##)Q1`>>$%RW+==OX$HC\U7HDK^3>L?0CSOSV4V2AAE;/K6%
M5\1\#V1OF&5$F0$09I,4O4F897WC(ZN0G>R/`[BO9X'0H*@M<N1_)PSFM]D[
MU!E`^^6]XWE7:^`EOE:@=?LGM+@99_E1`T772M8%:7H7E,2IK_UHPQW$/&IT
M"^%N@Q$$:C6!K,I6]>@J4[:V4=8K3GXH:18"[#94ID4S85H)/9&K,6>C60(/
MG+`V@J5[H&KI<N$;$LJ5[`2B`EAG'F8W>#60ZT-QW26747C-=IZN=J`53?7'
MEJH'"0I.8,=9Z^LE+Q02X#.(!T$B6_.O9KR-^[:6A@*60.(ZTRE84VP9L"O(
M4B-TRO`.YV@:PZ/\M,`N%!BSL;R]'!>Y2MD4+$'-NBNIA,(%U3^T0Y;TT6:-
M<)&BA1&*<XEI63])+2K7E8O"FS$Q6PM[!G>9&'-*I\XGA=Q0IUHZ(8K^RC6V
M)6!QY)6X?E'Y2:H]0?0N.QS-TN$0?Q6#<71W.M[(D062H1RF?C:P-%B6LBIX
M&I>D_7%Z?JJ!V0S;3K+0']^"U0S_!OV*=&/1C9QQ#+((;VZNF@(*4=1V\!29
MS[A9P1JRT_8A.Q1FHQPM'[DM"OW+,`IGBP:[GGXL"BT5W)N9_J-YFN*I$R^&
MK$,ZO2A>._FAXL4HB:]9XS;U5<X8O20>H]\![S/X-^5DD2+>!1444<//;P)0
M%H$;JQV>:!IP04`&*2@*%/!09R4%!NQ(24;\WSD<*1R'B5!XGBFPQ-AI,(%-
MP&TJC*:\YM+GQP&N+HSYN:&;>17]LYMD'HU93WF^83X3`*@Z2DN/,VO12F6/
M\Y,W0Q3:HEMX^4A('E\=88+AQPF<Q!F[5\?":\=G0?-13"18G_1,'75=H>N"
M&.&X_`W._,`0<<$9K_F7<"_QQE>,D%,_!5KZTYM&Z1*[X:I`[A.B$_M(_Q+#
M^L^]>TNM*XA%T/?(^"^<;5,ED#H(K.(_\S`E":`N'H4MZX"`'E&8NSX1FB<0
M]Q*;(?A,-L*+P10$Z"3$MA?4"R.;S<>\_P5VVMC:G8_Q&[;/0J>E0P9:*Q/M
MU2;`L@%04`!(]C!;&X\=JK0@DNAJ9-H.J8Z;MJ$KUR>N>+S"BHX%F)GP8I'<
MPBCK@GMA9G>T=PC(Z5_#Y).0>R_H/K3MOW'M&S?N.\A.=K]EK+7*G,1.\6/R
MW6P.DA"907(F.CYHL[/YY9_!:*;HX%+V^M?`XM=(QY$_!6+'B]+G,$)6_"#L
M#F@8Z$YA8O<VX+-B%T,NJ/DZ<M](R+QY&2D5<8)][@(:CD?)JT8DZ:J,Z5?X
MJ+0Q*"YEHX$S!/7O@-L@F5_?4/Q`,3'F6>G>.TQQO=V>2C*VEP/(U4?_#AKN
M[6!#;NYV[NMA<)G._72AF>UVB]2@0C,H/^]!4^C=Q".LO#-1*4A'3-2H"\;1
M7\EP6!6(PT,KS(#*J%M1(RLU1JINBS3/I.Y(<;IBEZ5EC0$DT59XG>NB)Q6@
M_[DV6JF&DG`L9B59IZYBM]0JJ8H:C9V0V$4AK4-%?`I'')\)RGN@=YB,Y1-R
M('2E"^T%AF/NWUMT<%_ZH[]TH-<2SPB.D;V<\@F?_+`E:A_B:=^6>BZ/.^RN
M577<9TD4Z:5M$SQ$.H\XW^7C3=J0>J:(<^[K5<;.)&@!;$Q4>BF"$&SG"CCE
MW^&+)H.9A[Q6+9PM&Y]*2,E".47G-\@P?S/,;O!QC,"B'IO!J8K'2&1Q#`33
M@Y2"E:%&QKW@N=B[]+-0[5.GH4V=B2YLRY-#,R<_VVQ5*^/`12,>CR+YC=5H
MJV45S7QN?Z"BKK-@UG*'.TR8P/`K)3V.;D*04^*#0GP7B0J&PCB,@RQK4'KN
M6$2.J!,>BQX1@^1M\I1,2R3,.(B`8"GUP\/,OO`JI)W\S]Q'/W3(+(*J"Z!!
M5B/\43!M&B@)?>2I1`\!3)>?$%OP"S$WQ5[1.8(D5CU3BOL*_91HG8**S7-.
MJ8U6)OSME?<2ZS^W'9U'7BZ7P2)A>0O22913K'@=YJ*^0(M\+$84-,_)'$`?
M'!/@S!&$EL:]1PK5>1;PGZ,50ELHI0+<>SY&*="DRM9PW10NR]QW5'%=>J?F
MJD0(>3>JT8?*N]%E=R,P*8T]1@<4/ZX%3[YP.1Q]1K674F=^/0>3%IFLY&[F
M9UT];H5C7GVI9/6WRJ':+D71A1<Q"B].GMPCBD"L2M8.)RD%'EG3^9*L(J>]
M=^H*J5_ES^7=-T$(I\2ZV&I5]@I%&T"Z<\7H*$SSLSQ)QI1?H3@,X)B%&8^A
M'NJ.Y)_0A0[KY^VC,TI'+_@\2UXNY/,H2D9,^\4@G[H12V$1X.$`[E=.0'1;
M*A_CS4Z5;:-\(>YP86DS2B2(BA^X82&35(K"#!,7V?Z`_C8*Y/V%LDSPG"+C
M[A?1,-*Z%HU]ZBR)Z**=P"D@N7"U<;,DOEE(8(4`KQ3?`>=DNF!4ZA^F+-^1
M0ZF,3%WO5E)QI//'-NS^.;!=VI+3A^=&4$HFDT03%CY#.9*B44/B+)9R6CIZ
MR.NS%#G!JY9,*A;3)4.2O8&AF7'(A%PV#V<!'Z*H%5[#C87.(75(2JBLFI=J
M^;QCADS%C%BV.#(?\1X]1S]2,H#:A5S[%$XH@O]VEEP''+^AD+-/[[U3C#.N
MZ4JI6$T^Q?6B9-CZ8(@9A5BSL-'J<F]IFUAO:Y@RBY`S+5/23=A&>:=P87P5
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MT:X:=SD/#!<@[7*ZML=8H%5,[5'2B]@VB$37-`@GE_,TDQ[!+)D$C#*87,%B
MT,(Q5KE9ARF2M^0F6:L<W,_3\7A)2$G;*)6^JX7OY,BM=N*6CK5T@Z-/%4X#
MEKG!?TO%$&Q$RO\LC,GK(=C3H(>`UL5,6)9%@+I*J79"#186,S]*[0WNT5C(
M<;)^:$WE\J<K*DKLQ?*.FLKV-)4<\[U>.<F!V8^*R%J%N'FHJC+MKJR,U%[Z
M2XH)[18::4DZ10@`LO#>\M^_@^\&HSE/I5;SPHVFHK?(NB-TNH77,:L/2;1P
M0E4R>-)2?XJ"!<5?OO=:)[_2YY21C,<OMXG(T!O=Q)A8MSC5+O`4%M]F=6M"
M8<DTCOPO10)+J;T,>%FPDC:..66Y;TDI&.ST__WY[)^=BX$4GSS7JS(\6!9%
M?K7\XVFPE7<'ORBL8K%E/4#*BGNB[I:0.AUI'P7U`0-!-*+,;]1\5E?#TS!D
MQ@:2[/[[9M5M@_NYSGU3<]N<Y`5NW(^+LZ4TLY*`+H8UG(;@<PITBBJ#:9*%
MI#K.DJD.>D_`!^49CJ@C";5H&M[BM8Y:?E&;A06*9A.,XR;!C(?>X5Y!*)-X
M3`F(0BMCGF4X^A$/N5)Q)=]R4.*#,3E%X,J:X8S06W`#I^%[F/&33=D@4_)+
MWR);QS[S@]('"A5*%*,P+6T!X@*3]+0D`O8]I4374B52F-6IZY.`\012@Z\)
M`^]\5<Q*\E/T>M=H-;G2ZQ7"VS!*L<Z$-DT-\>7;5BX-"6&U8<3MC$N>=YM+
M0+4`1F0.8*HO4HCOUEHY0&I&NE*G^@JRTW>D*R@03#U^_<"FW:,Z#)/;\.BG
M?AXMI*0]5.\?Z@_Y7]Z!GD)'HZ*6D9TVPRTF*^;OLBP`X;A=-U]19@'49"3F
M*H4*';*4D(@Q.!A$8;=-)D)5.K,+T&525V`16[%@TN-"YIEF06D8(2=9L:92
M"O-BAJ5(&\S1V%82+`U\2@47"9Q;(8E0V4+4$GBU%^BK6(:V?#=)'(XS+)9;
M*-6QHFRY0)2R(X]!2`O-N+>4>=HII]Q]!OT/B^9P)G"JM,ZO1+6M\@;;DMH3
MMQ36,-NGK69%5(-I''$P4B]$6$J4$T%^0_$Y.1M-DS6]4VNC>;*B1-)J/RB.
M?`]1#_.V?@Z'%S=:VJ=--64Q3Q0Z64+B(..@3E#E6)%%\P&9EXMU!1^P`ODC
MDQ[Q,D;+R0^*H8'EOJK_:BLG6"G00FWUEN6B<@M'&$(1WCO'Y(65ZJ'L@%6A
M#1X:T;84LLH/:8WGH22K?2V>DX'%X9RJD1_5I%\2D<LPD1SO%?T"O>Y2M4FU
MN%"\XS\VS5-/2;<J.CP>X>Z@K,_UW>+5;@K,IUO'+5Z0(6KE"GF^A),"J(@#
M+TZUWY([^%;:T*YA=LP!)0K:IZ3;+/E[>%PFEXO2\R&=5H3^4[=_%"\:H=T\
MDW>CJ`FXY+7WZ!.`OY#?[8H3A*<R$!2?*EP?E@.L:`+"@5;0!:K\^GQ)O-Q?
M79AZ8Z^;;$;I"*+*<UTG?Z+FL%3(YO?C\!9__/O[>:9?^_[T0R^?YVW0R;/2
M^F$VBI(,;(D+.,'=*!G]]0L,HOU=O#CTP_2??C0/\B<S^2BYB."'K\'5SV^"
M)/KV96`:+;NEZ[K9-`W]OPW#:'X[O^A_,SWS&VZ!X=K&-^.-%HY_?A..O[FF
MUW2;WK>>TQ^T3,?5/;O7UAUK:.A>>]C3S8[MVDYGV+';@V\FO/@++H^O[G!D
MZI8OHL]P^#2K!,%UJ=SPJ";_E-];\L&>G]V0Z/@8@S#BA=DA!T+Y*R#0<;"'
M0010:M#Q8BMO@21@6"`@]U$3^3))/O6R&L&+>.+!O+T%^2R2<S$K+`U'*`+P
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MJUN`2S4(E195J5FV3/:T7YO1\%JOIA6?U;#=+2_VY;6Y_UI4S7?.V0][H[(E
M(5CCA\;BA[#JUR#ASV^2=,;@*153]_`.@6T?8L_5)R\;CH'3;#_[,=B;?J3E
MH_,:>FX?J;CYOHPO0;&Y8)`/#_%D'HQ:WVHW7/?@E)['KM:U&I[E'*7\Z^X<
M>Z3C-B3]L0,O7_N_`GY%X.T0A?^9A^.&=@-""#$$*%H_#BYGRF5QJIW-4_5:
M.:%VG:6G*-*E@!.'E`D)7R%@YS3,_CJ%FTK#%C<3D6%'D74*22LP8=0W((.Q
M;L(KFF-A),HXX)-A\U"F0!DD$W\F?L;<AKLDKTN(@BSCI<HP*'4>.,%*093`
MF-L('T8@9SX"%2XC!AZ^+UZO35#@/EG6T*>N,9HC\9V2(DFQP<O)#Z6Y+WU[
MZ4B\5A[^-4TRS*9(`Y8+HUW#9K*MC>`OR`I8DX(Y*6H]A3_3@A#3/D[J<DV1
MU/6[=ZKU69V;[$J`>W9_NUJ-=Q+DG0PHJ[#4Z+9N1JS]SC@<L\50IE&\D#G<
MMWX8H5S#$GX=$X5@'/7D*O-=N[4N?`\T;\)?61I>/6UYP4WSU,K[9>/JKG%_
M3C"IOFY_"(D*TV!8=E/5=F$='BMCREA5>?YIG!\VD2R@6G&0R)$6CC&526"1
MX18%\*WQ\?C4N$(I3<Y284-92QF)^,OJ&IG(9)GY/O$9=G1`J)\1-3"$\S@+
M(VH:HN3)\Q,PKP8\-:V_T4AQ"`>/-C@@3@?BX(T@&I"T>$VF2*_`.<+50=.C
M':[^J#AV2E8&PNMS=F,P.X'$L9?-%_.B`$F#RP7!<MP&L4\+%8NIFOD)E:3*
M*X:`@R0R_R7O]\+7CR*LN!<B"G-23"Z!Y_%XT`U&S3:*&\;@^T3:&4H(N/A.
M&+@<UM5B0<=5B`T/!>`07*3*;2WR'!'1-F10;P\X+=^W=UI`.WS08?F^T]R4
M`Q`@ZZ?K/*#7(<)+)>GL*@'FH\S4AS@?3G[(RZB+^5`?]H/`QWRH_<V'\IRG
MY4.Y*S*,ZI*26@]/2MK@4`?SZ5>>SY,F=^LDL6!"53X+RJRBJ<A\%2691;[T
M6PB6:3JZ6=S_Z"?,[B\^MC<D.F:?[3#0^.SI6DOV98EECRELQQ2V#::P"5@A
M;CZB-GH)ULQN8UT5>V_MXMP_-I/,:S;:9FNMEP\_OF9Z5J/I/']\[<#BR_G)
M4H`=IOZ4E\R^]*/UU-P=QVFT[2VG[NSAJBT0+,^?H[HWH>Q=?&/-B.N+2N<Y
M4G&?DJ+V64'L+`>SGC43]@"$N`5&F]=T7]O=M2_9M@>F)_Z>Q,&"N_Q9G.VY
M]4/S$+C-=!M-<RU-]B6=,=-L6-:!'+%]OM5Z0<I3'3BV"X'-/O?!^_R^<PA,
M"#;*MGEPPZ1>/8]'C+!,%'R5#<E01[8SU5=U,_8("B0'#TF?L13Q@$]KNV&[
M]B$=UXVLVFV8]I95\*,CY>@".%+QZ$AY.?5FN_C&L:;M6-.VGYRYIA1\8?5>
M1SINXPY;NV[.JDW)7950P^_A3>3M3H)Q.)^\]S:7O0OO7/P&KS1=_/`+R1]W
MC]G->YO=;!K&$^$>'Y[=;*YXA3_2MNJ>>7F^&OP0H<"S1%K)J>;212)!>6NZ
M"FXGF_&_YPEUJ$W#44`*MS_B#;I0[V9-5E@!W(A@QOTLPU]C"6G(X+BQ,/`U
M[Z2U)SOY,9[.<6<(AYQJNLHLQYJ0^2DUT[W,@O06I6.#%[%JXS`-1EBFAEL>
MBY^PKFMT@Z##_U%9!89`ULC"21CY:35;_%1\)3?GJ.8,ZZU]7J;)F.XG:O9&
M<PG98L2$E>GB,R-8W"6KY4S3Y)*U?\2B.N4Q'C@<^S.?S71^F<U\PJ2')6)U
MV]6<&B41B!6'K3]R=YF[[3WA[C]B96_+W(&]I9*4\0",`MLV8XP2)X(/B,.P
M")\5<8H7P[R:FR'Y:U=^B/7<MU0E\"2V.$)$\+5WJC$*J#863NXU]NQ$O(2,
M22S-1$JS?UK8$0.&"+Y/(UDM3&6_Q`C^97(;4`>=.;9`D)N-C1M\D%JPIWPC
MJ7\2'U.=!56%@^BC9@98T(LE(NP=I<4#>[W@FA+5XJRY9(AB,^;5P9P7\Z%(
M]/%69=@&<ZQC9>TEDHL0(D`PS8I=(I`VLAJ=KRH7O-CFTX>AL>?9@C6B'\^!
M_`L<*1[[Z9C)/>S_"I=WRM+7KX,8/@?2[P0KZ:?8CQ?8OBBB*V3ZLDZ0X$*H
M;\9E$"!R1TJ]O&A:U1+XE,&$C(,I8@5@+30[8N&8M_?(@@*Y6%-=B1<@AJ*Y
MLL4D''<AC*^0.6?4A[X,IU`)C;`::X-A).#@@4`1T&:I'V=72,;+8':'2Q9\
MBF]PICJ1O4\4%KH1A59'L``I#&2K+=0M5C?_R=OKT@E%5(!`EK-?1<D=;(`?
M+;)0<`S;"UM<$'F(]"J,_9@RS<5`>`@D`,QE$&%3'=J^'\U"*?S(3],%<>.$
M4`D*2`/GK%[_G-?K?UY&&D!!@57S83:3?=NP)ZUZS129@_T/_6JI;<O*[BO%
M1BWGHYM@/(^"LZNZ7B]9)QY_3N)1S9\OD.M]`D?(+O`4;K[-BSVT.NYPX.FF
MT>_JCN5U=,]VAKKE##JM5LMM>_WNH]J\/%934MB^Q-Z"?;%UU0C4SC'!+M3T
MF"HV-,J[_(Q).:'&GXWR*T*FR19$Q38?J*@^JK#]>Y$:^',9XV`-/\HE+#&"
M"^'G-YWI-`IT`E$:W2"OZ'%PAUVHWQ2*1[?D>-F=Z\-N;\7W83^B8'S%L)OZ
M_?'3._WTBZ\6WO37=E`F?H$:8SX-IC+F/Y/NR$6A$'25)<DOJ_YX-<W.2[KU
M;NFSBU-4%45>X9=9XWNK`U@S$<#BP2++/76;Q6`ST>\+:V-9(NC6<B*>PDO+
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MBW8;CN&]PD7O`531X5LLD^L@;F@?X]%R\'S;+/`YF$=^-O-?GVPV&U;SH)2Y
MXZ(?N6BKT3PLM?U`%OWR-/"NOPA2[;?`CV8W(\Q,^_2IMW.1W.W\VS%UM]DT
MM;>=2?@79@#`Y7#C1\'6/2X;T?_:KZ_-;,-NOSJ`!;A+C%>WTV#1.<\/*K$3
ME?>>6.5CA>]2D=P*:?P=!+'_#`+X_VE>LZF]_2V8)-.;,`K]@Q"\WNLS0-U7
MYVAXA0XELV$8!R)S]T>5/<,4VYV+SL-@)ZOUZB2E:8#EOV4TD?U;M=5P[=>W
MU5:CU7Y^A-`C<,P+A^PZ4O%(Q2,57Q(5]\7S\#2]V%ZI%W^JK$IK+)>EO4C=
M^9&93V[#.KSH]F.;7;4:+>_@_)J/7:QA-=K.:]E:J]GPW.?W)"QKQOR9+17#
M-^_M!5Y7^=[M]/[QZ]>S/S[W=65TJ]EL\/]]]QA,KW5EWY$JZQZ1(Z6.5#GR
MSQ,HM:;F_03`TB.)CR3>)(G%TH\'^R@"C^?S2.)72.*C"#R*P./Y/)+X%9/X
M*`*/(O!X/H\DKG5`%Z"93U8`;FX11;,(U]F#OR>$APM/?H%_C1:;Q]MLMII=
MI^^:>F?8MG2G8YAZ>]CW=,]L#NRN[0S:AK4%O,T2XY4`*+T*="O\!Z&+=WT$
M=TVNM"\,KC@'R_R2AO$HG$8!_AG>+1"0-C.')Y=CKH_`^X05N2O@0\\(*U3,
M%$&3)3!M#@+-<6L9'*U\`-ZF9KP4EP5JS*,942:9!BQ:RX"1J9':%<&&<JC:
MNQO@S86>W,4$0(I`^.$X1/#H[`.LX:^9GR((=NI/@_DL'&7:VX\Q_/T=DO@6
M\9D_A9,0Y_J6/7R"**CT`'ZO:H`__B'>.27P;X86FDRF?HS`SPB@.B<$<,1B
M5PZ(`BH=1#!`3"0B\-.1NKT/1%-^"G>NPH+]5Z!-TV#J(_0O$AI8<(Q1]+'"
MC/##4&[QN=SBDQ\XN*O`JTZ#_\S#E.\_!Y(^EPWOB%*#[PQPE9A],@FS#,_"
MV_-![QUKTX%4#B<<@!P&!N)G"#@..X'SF,/LL#-$DN$0*4BUK*&-@G3FAS$,
MD,QB@B^6/1ARUE1`MM4>$NR.B!9B\M2"X8_3\],<:ASW.ICBU_FFXWJG\NC"
M(&]_[72^L`7X<3R'KS&(](QW><"=YU3%F;&UG"(.+TP2WD^F88SS`IK![OE,
MZC8$IOBJT^53^P>V"")PBO0F!'%__.=<(+W3@N\"AN*,%(R#49!E?KJ@2;-9
M$.;W5)51_/#E,Q"'E^54L$,;7^-.L+.\)TQ]]C!&)J1Z>#@IG%9B@C%>B6D&
M7$B`R;!81/QF/$RP\@%G:`;$+<'5&47]Z10N04(1!C('H"YHN#M!/!(]'`+U
M,]I="(+&O[H*1C,^`DF62.Y&@`T!Q%!2""ZX!@&W9ONG3-DNOBLG"#$_2PHK
MHGV?SE/84;I]\A/'L:!SFB%KE(<\U2Z4F5W#Z6/G.THR'`\)REF44Q..SGPR
M9\T(V-%$69H&-[!'B,N/+XJ^"-D,%`80^(CZKRX-AL%#.EM@&TU!$GRA9J^[
M?D0(U^<W04!33F`$_!/O!\-GA)^7VZ(27#U!)-5!N,`()-M+73?*-*LX,WMT
M-BI(S_'=Y84;!S/VAVDTSY@48&R']U@5L99Y($9QG0:@)F-G#-Q/Y"YZ#ADB
M?Q))+=HDZ/`9/?,+K5(;,!O6W@<FQWI+8%L#U`.471AOIG$"B66?`_R7NR@H
MWR.A1WCB]`MV]R=S`M=?B]EGR(V,W:4@*JI":ZWHI`*BMK2B_6`\[%&"%RAI
M4+BN!TIH&&(>^_,Q4\DNUCSVK(F(SQ7L/EQ[D\L@5:AE$K4<[0Z>*70!H:8Y
M['/UXE#9N[SIB2+YZ.1TF$[PE20L<#N,,(0;.Y\$V#__$!>QM@C@)F#,NF*Z
M5V$4C`F[GW,1J%!XD(;!93K/KP1XQ7(9/S":J6J0.L_938BG\K_A7=#`0.F1
MLZ6Y:FBB:=E-,H_&J-#`L:;7@#!_SF,FC)7)W&\>B.NOP!%,>>,'([E']ZDE
M+TT8AG@X5??DI'QE::H-[!B$_)TU>!\;ELNJ]&\B_?(6U3@N*U!!@!'^P[91
MW(^X>+;]PN9B5@O00URZ62!T;V:'/DAWPO9G0J,,J2\.]EX;L:N5ST%\&2Y+
MX!]<V8B8@^\/-C)CFT1*-([!)"?7I"OP<Y8<':O\#W6-10:3:90L@N`\2&_#
M47!^`^OI8LL6,$^0^#06V'\)$_%G5U]E(XPO-+->`K?FYMT<AMWU^H-.7X?_
M;>J.TS%TS^[:>M=M#H:F-W"']F#7;HY53@'6`9TT-YVUO!DI!!2<3%(V;R62
MMY2JX;CSPM5XIG@)-M-8I$0/.I1E$.YJ1_PC&[0NT??I74*P$^F3^J/6=C*M
M2)X5'4">KZ_%\=-;^?2C^A"4N'F-HL#MY9)7HW;_ET'_[_%M(E2/[KK=-7)?
MK=)'0HYRB`TWGDQ&N?JJ;AO/2J\CX[\,?/Z-+O@0FC`<=WB/=OAQ]95E,;+=
MZLHZW7X=S!&T<E`%OTXPJ@'4'R_;8WM:&68?')#08U?J'1P4YB-7VG0/#I+O
ML2O=`[B/-037OHBIKT$68*]B\F^-L9%N,D7W@?`_[%QH/1WFQK0.KF+YR3`W
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M)T>G,NU/R0]\=4E+E64KRT0Y)C8]+&/`O],F/A:^^%'V*)7C.3)]&G;[X&)%
MCUZKM9_=;O<U!^9?2?J7'L;Z-$VP(FOG//W4\)C;,,V#\_H\=='-ANEM>=$O
M79(/,?4![!R6HWIP;&\V7//597HU&V`N/CO;'T/AQU#D`=+OT-26=4*1H7#$
M'(HJ;AH-TWHM`3G3:K2WG:1VC%+MKW_[2,'-RNP'10A6N^Z9PW\<A!_XGX=A
M-O*C?P=^.HC'?81`W)1SW[5ZPRZ\JO>[KJ<[K::A=UJ#@6[9UK#7ZGBN8R(T
MA?WF%QC9TFWS[^]7S2N?^2">A;/%U^":4ICCV6=_LO-9FV]^^3SXQT7GJW;Q
MV^!KY\O@CXN/O7.V@JKY%0,M<H_ZL,HHR>;I%H(K[;YG]WI#3V\.NH;N#&U'
M]\R6I9N=;K_7,JR!Y77W`@'U<P)<9XN8!OHF?\HC+<3NN9ORN4%-CQ&@8P3H
M&`%ZT'5^C``=(T`OP&]XC`#MN=5YC``=(T#[S]S'"-"S\_TQ`G2(;'^,`+W:
M",:1?L<(T#$"=$BZ^#$"]+KC%T<*;E9F+T6`G@5P/G=^AYG2]P@&F5_YH]D<
MVR+-ITF,T-U!."4DP*LPG6`#F=&-3[V8R!.<L=8)K!N*;"8'+T[]=`;#9J?J
MMQB.?Z:-0Q@7&VI(-TR#_TZC(1CL?3X;:E)S&Z0WV(2`^H4A.B'U+Q@',^P5
M%6/CC5CS<9;9#&SA!O\7-NBXQ'YLI\5%`YO,L<$3S@*=_E%RQ^#S:>@DA:^G
M?P4SCBN&#7H(VC[%_C\!=:[)!X,A[E)L\10#"]W%B'B/W518)Q1RX=/7-%9P
M#=.\"3-X-1S![8>0/6D8Q"-&4@U,^#\94/X\\Z^#=5#P5\6@BM&JL_3:CV%*
MN$,%[/Q./%9[U9U=2>3_')`]'QV>/@]E7Y2.[)%%"/QAL`5P_&[':%K]KJ6[
MS4%'=YI-3X<_]/1>>]#O]0VC8W;-1T7`MM2Z$@_K/;TKE\]J73?+1W>2C=2P
MG%D,RZFL0$Q^/I],L*\$'`%E<V&8?'\UL<'$AX\(Y>T'M=VM$AO_04T<50H3
MF9[4VO'02.?\;5W*_2N@EB*^=ADFTQL?QAI11T80CKQ3C(9RGW<X83TDSOU8
M&Z8HH;)1@AV=>B!JKY(T#GUB9KAIDG2*=Q%[OA]$_AU\Y51\C4-%4ML\>'T:
M3H,(+A'D_G$ZO\8V*V-J2<%;Z<&$L*L5771?!K\N(GEPX&U_?(O]A\;:-(D6
M$VK^%/\YO\84C%DPNHF3*+E>:%-X!UOQ9-0WARZ=Y/)/=K'@)91HX02D_RWK
MH'D)E_)5R(+2."/>OPT^B[+X@7UK]H-Y'B#EUN<>[&Z6UH&`8H?.6]8WA]JY
MR9:/Q;9>27R=("?@G<[:O^%NX.XSD+U4:5\#?\!++8SA/H=_\Q%/BIW)\H&H
MFZ7/>^$TL",C&ZD\#C`LM47!%G\S&`)[[BAMU>+@FK>MRQNE,L4K[Y`2BB:$
M5W-4X(C5:=6LIQ)O]ZF\,$W#";7OP69CR?SZAD:'`9A".!-]L4#F8QNS^+I1
MTO&6E#0\"]=IH'1\XOV<L*F9TC(5J#*K:6*&-()A;E#1F\)Q^!ZBC@AS_-%J
MM4];VB2,(M;*BM&"G79![HSU'F2Z&TN>D$WE3O./=:(L:;`>82NF@9.`P7XT
M;?NTJ7XX`H;14>T$9KN$765Z+2[R1]-JGAKR66I!!EI5"$>7)@(D92VO<-H_
M>LJPJ'GZTQ`=(E$`>B+(!K!CV$ZA@).-\'YLGKKY9#+>FV]VF!+!V\U5_&P-
MF?>#S-NXM8\]H4]VWQ-Z/]AI*_?XL2WUL2WUL[6E?L'GZM@9^]@9^]`[8[_P
MXWELSIT;7R?'YMROAO>/_<&/_<%?5G_P%WQ8CRW*UVE1?@C<L2.?VQ\9D7F0
MS<B#FQV=::MO0N;]D.;-.KXU?`B%-Y@!F(*`425T``@70J88\<CB$_\O8'*Q
M'RRTD67SR93T&Q*QZ(Z0-A>W@]#?,&%N+E2FZ-`OG7D6"!O+%`&^!#2B*!!3
M\Q;[#D5:V)$L.,CNNRHJYD=Z($DJ>DH(*U5YRZT[=HQ/E0@WFE5U!.(W.6J@
M\0SN0[CEF+\'!YC-"S;FB*[%<0BT3&62"[S#]0B\R6J_<XI&06$BN1<57TP#
MILK"CHI'0`\-HHB[@T;"EST.(I!U*>KQG%L*P1L9J&DHXPA_$0T`/Y!N``LE
MU;LZJP4V3B;#L,="N+_#%,=F@0LE/E-^0+089>8^&2'QM1Z1TL7O%\82C)-&
M9'^`BI!B\LX(EDQQXAF25[F9\O70_0$_(CW9G_.$)<&)"Y6D^`<R>##CB0)I
M6IHL_(@L'[1Q:EHGL&M01!*1OZ_%[\$^N&87A[JK%)^[I$@/?#+?[+KT(#Z^
MO(-4SJ2#JQSV2]AY.`6,96'#LB2F#1->2SIF80IF$08;1SB9"[IN\VG@QK-`
M-,5.KB@CZB]<VY_S\;7PNP([S=D9'OEI2BH;,<4J47%W$_#;'0;@3XL+&[5(
M#$CZ4_0$PTK89M&",Z`3314CJA@:!%Y'!T;QS&(F`9JQN#_D(F(<S>S?Z5AL
M<QI<12CF>/2,M(-<#Z83&2\*SBWY"6+5W"E[20Y@-IS0G`/Q5<I!TT)07&9@
MEX*9<H@WWJXTAJ]E`_ZH,M23K\=C#6"-3C"4']R&R3RC^`&_%.&/&2BT2,ZJ
M:Q1%@#\M1ZMR)XK,=6"2(&&GG!T7SMYX12AN^E/M'%V)RWZ8<4*'6[D'\0*@
M!-"JB:?"U)".?7+1-*07#"X1K!Q`^<--$%6^8*R]QFO*?:;'4[CB%)X')-VU
MC[D\/)[#E7%+QJ8!>1]B.$?S+(PQ13CCE&1^H*MD-!?NU>DT6O#P`JK=53EB
MI70P116CX$>&V2VL]I&IWC$\&95SUTXKIB=F=1F,_#G3/M"1+R:=H,H*<^-"
M(0LG(89C`A`$R01#XJ2&<&4&[L<4SC&\D&&X7,V$(771GW%3`!8RGH^X,E!.
M&>)5RZBXS193ICL`K6;)!(XO)H8#\</+.=W,DP"4X''&0XS7Z-4%M1-5@/@V
M3).8Y5SQ)+^"FY>EMX.&-";G7\5&(1D6+/A\$P9@NGX/1G-R%YQ=@3!#G0N^
M"LI9P:X*_,E1GJR2)TI0H)?$"'.1'J_WM>)"X@P0,^?9>J4D663*RS#)I0@9
M3.A"#47V*KY/C41R!14#H+F_DU(BYJ!2!\+ZE*DM5`%R2^;#)?>CHSE&\26X
M<Z.`Z]8Q_P%V=\Q48O$>3U7D,H"L*WZ`I6&%1_(N0!,PP]PV$&^P:2(N!8IW
MP`4'KQ;AE13X11)5-+YBWE*J)\L)Y6,4LD*EY0N2`HT1U9K`[`04NZ"S\SP*
M'`&S2VCI^"LL$YI=S:.<1I<+^EYZBY(/'Q&*%RH[:%M(`V#Y99)6N3G!=:4\
MKY26-:..SWFIC>`,>IG?#91FBA(1$V)O0^!;%CRD$"%_OJ`,3?T%T8.;F[DG
M(AF%Q"JC-!B',)<P^PL_1&F9+/2KV*6%9%KQ"@\ER@F+Q1;X@ETE^-=[R(N1
M&!9O5C\%?,WCD#41-QBKTK//8HQ'WWXY`W\<3#$>$E/(A/P@<TS:(`%$-5<H
MN4<SM4HLY<$9<6)2%5JGP1/7^?GCCBGUM&%,@!PP3(=)@]PE0P<_@?L>:[#R
MW!$YB24%0$WZHJBQR,8:^:1:W)'G;(%KPUQF#&DSAP+.B5:Z8-XJ5`W0VY&@
M!H$A;Q2R<E&G%'Z`;Y$3L"'$*9HL,Q*VE)A(=!/)-)&_8`E7Y(Q*YU,18T`7
M`_/.--@YX&LGDG*)10MEHI-YBLKE"9C(57B7T2SAZ>2X+C67F+LF+P/U+'&+
M#-/.&EQ=I<?$B??E^K'6`78=%LS<Q)Q3A"K54"Q-S#6CL#T7P969GH=Y"'?F
M$&&>;-[YZVB*K5,*PD@6EF+W=$32%-UY/#B/T9*B)L7YM*!+U52U<G5DP9F:
M?X,$!XQ"HJ,,)OE!FT_AL7C&':(CYHP.4#;QFYC<K-S=34*NKK"ED2M)\EV\
MUHH5LY2?P@2`?*BH=Y&RI]J6*`$56<'\Q4O%O1DM740E9'D(ESDHY2+TAE+^
M*>J4Z0P$9>W<U$('>1'4%/0HSY*,IQIDE'E<5U"R2">P+Y@7JP<1L]34[:?K
M@&ME"Q:#4H(EM`B>4H!\PF6\,@`++J'S&F\Q)C%+(Z0!]XV!>4F!/72_\X*N
M/'_W5.O$?K3X7V$R*]\X835A8I*%:(Z,\.$[<Q9I%7YYML<\Z*Z\19MVB5J7
M0D8J=&+/:!GK1(B[H!$`!.-FP:KP)'X)7B>O6X,%Q65`/'=/R,%/1=8`$I0L
M"=[`4)(D8GF_Y*A7E&0D5)%.&-_D<0.*2(SD24]SX4C7-5Y3=/%.@MD'GC!&
MF2PPQVSN4\97@,H*SI591W%A:X/OF'G7$&19P!6(KR<C<GZ.602+XFRXJ*OP
M.[O<12$ZDKK!%28Z!JQ.ASB"!V(6%+Q)#S4<L`T5M,.B2'#L@FDAPS>&":TZ
MREI^X(6*,DG&TOE,7!2S/<4SMFHHE*!WE,I.IC+^0R:JL\&8[2+3_\N#X06B
MWC$HEV",BF.?0P&PB#1+O46%38WC<F]70XTVB?=(ZX(K0`:F1+&9^O[;P?F7
M=RS)1I::4E+&^1?D73K['#XAYVI<Q4PF=FIWI"^*XA80#10=#:_X"\RF3Z3T
M0&,-YY%$')`!(XQCW8_(X\:`&/X5*-_%N8B$&TY'7L6W#"I1H.[E0NZ.NK,:
M7C))F@MQ*ER\G,_(;HUX!=`L:3"_JZPSCH!'9HL\#:%:I/&D3W**\L?EI"E&
MP@I"^,N24T28H[""4^T<^9UXCF["8CZKD.=H8L!K(3D7>,8$$(TNRT7.]3SW
MGJ7`%6*B;`>+ZKZ2Y>'+'K-"9Q'1E2+S\Q`02VH@01GE>;)^3O_*PW"8DFYK
M>CYI\%]4AUA)L3\P2FU#G?]2]!<67*`%W9Y=P4SB"7`8'1/E5VG$2ITRF0)+
MP@9/L<2P$:749=<7GD#5)Y4&\*4X=WRIOK?C$5@^`E_)$ED(9>YX",J4^E7<
M_&2Q$!(!]J2(>!:+,.1J4)@4'BYJ'!A)9^>*B?PP96XY/%/,::>4)K)J>N[G
MIXN=AQ*EEPRUFI3G]E!]!M67\.F1<P[-"7:.I!4@_BPU>:G@4^5OF.7J%MDA
M\L_B/9;UQY-WY;/P'KOZA(<Y5\.%&;*DAFO_0A$`]I2`9B`:);%.,Y%49BY*
MD4)4ER4&PBD#0^22T*4TPMYQ&HIC@OG`A25$JY(3;K#0ZEV8!>HKZ@MC$395
MTHQ@/YB^)K7)8*R0E]+@%7IR']_)#XIB2>:-+#L3N=K^U8PEC*D^V$(@AZYY
MM"W'%5A5!W!HMRS@/C'CN0HY@UG.1\FWJCJ(G7`X9,)WAOXRA7K2<2://U@%
M<VX_",>%$`(U=H2,D`K#;\P<\!R>A2<*5]@"&:^=]+-E-:/2]][@`0'0GU,N
M3O,#J!QQF"6*)S2!;KG_3=8FJ%/AIY^9&&0M<Q'&;$E5_4;)2_G?57:C*DKH
MB\+XXUFS3"9>S:,K3'U,YG7^GDP$#Q3W8#&_A<S(*Y:]&K+<TX;B[9-P/0V9
MVYM'0DJ(/E48@0K>#UZ(I7<%R@VK1YJ`3H9Q"H&!EA0LVE/M5R"B*%Z6J=XL
MP>R*%Z?4,U6CUI:3OKOQLOD-HKTXEX)C5DEDQ=JL?`/#C/^-Q9OA`[IP31X]
M3'G"9%Z-4./4R8O\1C>8/BWRT_T3!9<)C(#<]UZ\F2D;,R,%#>R`13$5F-P1
MRBU=&(1_4`;?[@*1PDT(/ZP8F-G4$CN,SXCE@Y7/9.ZXOP6#"1T/BC`42045
MI0"G6J<X,Q!6A*WI9^1&NV63>!N^RR/J)#^QYBN)(^9@YJOA*B<M.XD"%@$E
MA90'[E'`\?`I-5HKUNX79$PJGN1N6+YNVAJ1Y)K,9W"L1547I6*(';UG_`:M
M25T4>J3D9I$'N<`"N4!8J$4L7"M3W9,A,03'K2/-DC_/(L:43*[0K,&#4#";
M)1HS/PZ/.(5Y632&6<0]>!G@NL=SCBB7KWUI9]7E<&]>X5R@[/?3>,6Y6&+C
MG%&E35URI*FRCX]6&H9[`N'V2`D&BVYR5F@B<I`+O%O:[-)!:'!MF+LD,=[`
M:SRF?C8K/DE(8HIYD/MEN2.7I0<0$Y+R48C(4)A>[$)UT.@HB]5([0KMK,(U
M(\U8GFER\@/'0UQ(WRL(.8(LKN!450O(T\NHG(<K<%PGF$:!+,`K%!=1GD4A
MWP3.#X<-0E6$C&?*3%LHCVG^?':3I(J^DNL=J*#Z($=N@ASC4=$ZT)\+=BLO
M/V%%9WCH5>!*$N7))<HA_%G]+I\/2ZC"C)%"!BX*#Z(0LR3S2<DI2:@%/RM@
M$JJ"#TQ75HD4+P0E<^)R::5>!USP43H?^LU9>JU4=\AQG@>35_%%"14"416%
MPL,<!30O%M:MVGF6(L.,Y0FGGHP=DO)_F4M##%?FLK(`Z"BN7A]CN"#Z&BJV
M$8]@Y%^HF0N[JS%0Q$=;[ZKF?@]5C,,+5!R7H_.45/C<]^)GTKW`_1?+IA0)
M5-Q6]`'E\Z5K/KSBR8+,[JC49H[R[G'R3B2NY<DF4:8FV>&95FIK2S*0*5W\
MLA,"L1S/DN7OW%H4WSI%J`2."*14[TY$\F8!OS3G)E)SQ304UF+.+:9%$)L+
M!6DYH4^HO@4\>II^02R7%G*YJ%E(0U!KS#2N8RQ^)[=S!:>N>45S+1Y9E[L5
M;Y-H/E%21J5OFIP9$D&.F>+J5RYEV0I3@H4C-.=06!1&ME'WSIF8N)X^SLM[
MQ?/H`,!9EV<LGQ=3?2U,M[/T1R4+K*]<G@-6R7W,A5P%UU*308?!T4Q"6A.>
MBI\Q^&GAD\P]=\#=A*[:R.'(<]]K7IW)QA2J-)CA&=/0\X2R/",:E0;I9Y4]
M/6@$M9AA51+@%4]Y9FGDP8R@9DI9T4QW4CR/!2=BS/*OQ44+QEHZ)B$6"GUL
MI8]DN/8$\"G*^D8CO68V,,IUZD]X3B)!)3"D[CLT?:_FB(>#DA8K[=,@G%S.
MTXP)(5+0?&7Z!UK9NJ6:!A3MZ9BA1:!I)K.,)#H$8URN=A<-/O3#Y-[D/)^'
M-`Z%75AV59[UCO[<3+5H5$#TE/3U/[G^%`?7"1A5S(8AP"1>Q\2S?V440A8\
M*!G'P+;S&-4L6<;#H)*Y>P/^,$[2[!3S*,2U)]$?Y*`9K_E`YQI/FU(M8J)!
MX<X3)X:<5RS^@:6;6*T3Q"D<&/&@:%0@_%DEVUJ49A0!/'*"%XNB:!X(^2&D
M5UZBE+M#X13.]/F4EQI(B!=L5L3A3&CE):N>AUI8V*/('"5O/,JS5=\HU7'5
M3%CUX,Y`'V#=!FB$*J=#(6@OTK**_"N3MLJC8?+=-)`](SB0!]-]3G(X%.ZB
MEH_1F"O(PI]#>N9?9*$).5LQEL(3W!TVXT4T'V/5<UO`(LFC:@49#=)$PJYD
M+(-;C:37@<%H<^9-X+F4/`S%8(B5%#>N-U(Z`P?S4'#"9@CA?2VZ0^77)1ZO
M#FO^4<CA9_UHE:Q(@7S,O;WS3"0U(-P9N1CP+9%)L$8["Y:9P3L&4/3!SQB$
M5*B@'G$@9A&@0&N=[[H\X");@,V8%RRA6Y-E-:L)!7(ME(LE).(I$[;52#:4
MKHT76@%=1:"+<H\0LA+L[JGV6W('J\7N7[EG6WV1);"3CS\?@\P*\OJ(R".5
M$Z*M(3"O?+:OB`-*>?AYY"SF-)?AM8RC8:/;_I:2Z>]DXKSJO!9WBXIMG:Q2
M6N2>R&]*K"69V.)3S01ZP?!%EC%,.RZ6G?%\&X$[17@;PE6>L2QT_@.+-]%A
MQNW*!9/BUF(\7PERP]07P:\%>)NUEBA]#I2>\BC\F^_;TT^FWQ]F[GS?@KE3
MWV#P`%0V8S<6X"<$`_M$SL@.(;T<3;[55;R$?%4!L;:,JJ;B"8@:+3RQD2^J
MFT#8Y>:2Q&@K8*V2'4AY<A)&2PR/0@V%.5<5438I@D9";Q1N_A.)T1GD<5()
M+*:`$)*P9.AB*)LQ*_>2P74NN$[`XW*\P)\4"C$1O`5(K.?)%TK$(`UXO0_!
M(?FQ2L@P%HT<%PQA06(*TF2*X64Q;QF^)+T/36CJ;T"_(]R#"<CK>2I,"W2Y
MS<)1..7:(BCMV.,,5AZ,*6VSV!9%?EQT<:!R9Q55#XDJE]`0;2VEYL"!?PM>
M5^X4H,`LFQP+?>83AZ]=U1%'U$_)J55WR*14":E5%H:.M=_I@E'Z0?EQG,PI
MY5HR!F/@!6+X3I-0\0MT!YW>V6?M"ZG!MII)E,WF8U9Q]OD?%U]UT[`HL8$7
MA.O^-4L3P@8P[+$[N'0ECK%L\P:JI(\X6J"Y7N)M2^D/B`\#QC\QHPAMTT.9
M*"[-4X)&P7)?L-S$+-)5Q)9X;2@%B)9/<PZ\(_:]@*G!O!5$+U0O2N]KUVD"
M5HUTP,/Q#D4BG*34J=;EZCV94F1*%*->7#"(#6)9$W%26`R*"-K<):QEPFNH
M1G(X3*_&CKRD'V-2B"_\[T>,W564&W)KYB'="(K(_8K)F8[Y.67$G_G?F>N?
MN@@).<0;2E&+J4)S*[HG8PZA0/DE\'[*<S&+7>]LYV_,PT0-2ZX"S,YA.9$\
MB11?Y5=AJ6V?Z!M11-'CK1#%!4=W)@>OP?PSDAEY\MF,'>$9LSNB\"_*H(%[
MG..Q2&',_<.*Q<#,TN/170UXB4)1;;";)NR>(Y/R>)SKJ4E*PH*?2^3`'`A>
MH><Y%I_Z*1C9W03^H[T==LZ[[X"ILSEI5]?S<,PAK<8L^@AJ3.7[/;6H^&WG
MO/<.7G<-MU$TY%3<#@K#Y,7IA?;+`MJ#3FI/NF-)1^Q)M":Y_PWIX/`G!)"/
M*Y:3IY9C*3:>A7G!I)IK3ZKT(/L83X3+Q1/3/*;SRPA]=1):C%Q6H)SZ#"0?
MDP^OPYA275C=R#+Z$NAS)X2^U#K5!IB7*%NS4EJ=+/UF3CL.[^0S(/XT`%Y0
MTML1?H#7>A-HJ/)7)D0Q,04S]\8P+M-8L)A<4(TC6A%.(+->0+3Q-"*AUC.8
M4B4UG$EXTKR!U(P##E/$;2/F`F>R`UIFQ!5W.I5PWOAQR_D5BZ>`M!''WC@I
MPLBRA+W+&;W&#V<F0-;0`\=RJ90'R(^;R>`_'XQG+:,V.V=!>)G("A<XIHP@
M0!$?BU+/.(827KAH$,GC53H+>50OG'"HZ)CY[81'+S\(_]>/B\U7F++KGFI_
M4$K!F/&\@%>_4V72!.0`)=!1[+3$XBR3%;/&Q$?ELKE'EB/)B;N<S+%Q?L1F
MA372O<VPGDX4*`5Q`.)57;UR9/[EH_!^'-[BCW]_/\_T:]^??E#;HA>ZK7;B
ML=J>]>Q*2O2\LT=?-AB`IQ5DR5QDBQ;U%\"IW2@9_?4+S$3[N_CZ.2(#?R1^
M[%/-R!>BWOD-R(&,_B]9.3T%V9VB93#:U^#JYS=!$GW[,C"-EMW2==UL8A<<
MPS":W\XO^M],S_R&K&^XMO'->(/.6-#CHNSG-Q\_#]]HX?CG-^'XFVMZ3;?I
M?>OV6F:KW^SH@XYEZH[;=/1VW^OI!OY?SV@/6FWKFXWC((`$?3VC:;[YI>VV
MK::1T_01JRJ2A7I@,C\V$+:GPNWG))<D?3Q%2B3H6.UFTW([NM/V7-W!?W6[
M7E<WK'['Z`X\I^F8WTQX\1?D)<Y*92$+1BV<-GV63#\PQ8W_XC*9P37Z@83N
M%4Q8ST`A_6#F/U_YDS!:?"C)S"5UC2HXF\7K6Z$728`"Q=91UI1)NUN8<^Y!
M#:[AA/[NSV8%?6)#4Z3K("3,P`]X33QBRD.2R9@2C.G]\%]9Z!S&MTETRU2R
MR+_+YB'A5Z67H0"0I=80D1].R`&"B1,2N8JCYHV"`$4\UI.QV@0>QE,QJEB^
M&D>IRE.A&UH`5U2RD"Y0YNV<,%(V9'>O4!0ID`:#F;?HE`)QE#(_G'!UYB5X
MBAZ!MXF"77["JYR9W064OL&'+UF<B\H4E:85-W[&;+A"\@X/V\O"29P5:RG(
M.L`J.6C2^\8#2<J\6'B1P8BRS.V(_%S_D=W`Z-ZCZ%>QH4)!;:(<H-F,0^TH
M^0Y`OS_GXY"N#S;2)(P1YYF#M\X)U[7!G&XARUB-B)51SF=!U%"VI-RY@3EZ
MV74L<N/QKF0I&R-"2$4OZ:GV2;;I0'KGO5W([SI%*-/1C+F1R=V)/5^N_-N$
MP6FQ2;)FA)AU@7YERJQGZ?`BMLVN9Y%/SYRC3)V$70GY7C($E1+&(O?<LOMW
MIK2KX@DKBDN!-MJ?J36"B0""41S&#'D.=*CQ:A3\;8M4Q7DU#B:QTBH`Z`>R
M-`[R!G(D:V7)1$=FT^RC,,,6T5C>)C**UD^<Y3'V$UFU%8G"\2+L7PZ]6H#0
MX_4C+`/CY`>AL*D):C+[3*3AE3+62.X64FYPOJQ(]2K`RH*0;Q8[_(3P@/B)
M$<'&JXMA>6D40?:IP>A,S5$K=H`"^<F@`Z6TDG1JG"@03A)U(!>`;^]*J`T,
M:5CD2+SC4P#Q@"J1S&&JQ">4Q7+?9SP&<%*#9,@<Y+0GLMQ<0704381.5/@8
M=.!AK"DO'0Z+C%]`7:1P21Z.@:].`YH"2B`&ADWF=;F`)J<<6@`7P@.?CQ0G
M#/^*?Y*7IR:X8A([\M+(DR)D15N0`\>J>1!TH<G$LN6%G10`)=<4.=8.U0TJ
M:4!;CI5G\E9#>!&!#3=2#RW/2D+G:TBZ!M*([3VWA?">X3AIM)'3.2(.,H@2
M6=@KKM82#25<I*+`W%'QH.Q93V2>X<,,<YG#?B>LGRWL;Z%Z!&.@,*M9)B.#
MK.(TY/$X&?T<BW0H"F:-L*6$&$/6B2S-#365?'8T!?XY@@*1,`P,(8DHI_0;
M$]S$#C@A3><E9N6CH8H+EJY(`D/DF+#<K`9O-L'T@IR3Y>>9GOC\#'B1\+;;
M=PJDE-3@I!N#R5RI][)4,M2DI,JK0M'<*U-.M2YO]\'UPVO8C6L".2R0*A<&
M]8/QD`".PDQ_06_FQ*#0>X2(V=_#R7Q2M1?*Q$@_B7D`OUHW_9P46*#0JX@"
M,2<_B-3>+"@*4G8+KM42_>2'QP/*U\#)+_L^'F9F%TWT+Z#9I<RN+S?*ZL@L
MM#Y!#TV?YK8H&>FF:_1<I]G2>[V!I3N=/AKI34=OFJV!:3;A?[WVO49ZE2<4
M'9?Z^<?_&3#O)?_%L//[QT___J"5SL]RA&:GC<2>,%?2-TL>U6,7KVUT\5H^
M<`\]-.S(C8/P0S\9S?&/[.5!/.ZCM-S4F>KU[8YK#WJZVV_W=,?K]/6V;7AZ
MJ]7M#0<#S^QX</"^66]^P4%TP]5MX^_O:^=5E!1_9,'9E>R[N[$Y-YU^;^"Z
M`[W9;;=!#K0\W1L.>_JP.6QY/<=KN6LXZ_8X(G+LB[QW0=Z+FV-?Y&-?Y&-?
MY&-?Y&-?Y%?4%YG]3[5&5U1NBHI/;D.=7:FQSJ^,C7MH7.?14%$7N?FPYK!O
M]3M#R]!;?0.TN[[GZAVO;>MM,*/Z3LMVAV[GJ"G5:4H4;VT5XZT4X-99`K*Z
MLX>M,FTE"><"C:I:<2RE_9U?QBYD3NL:9TF>@H$2[$Q)9LUXBZ-,>\O#H&`(
M@J#(WGW8CSVQ]J"RJ;[8B^*+@BRKO0P5B^@"(6"BL/A/G2_G\!KI,M,L>`#E
M%$)L;-W:"/2N;.JC3_SG-P;[>8IEG?QG>O;G-VWK;V\TT)NNXY_?C,@-_T:[
MI*9.^)1*IE3]82S>;UG,E4)DG8V+S]SR@9D'5W[3KG]E4[\_?GJGGWY?Y(ZT
MXCAY]Y^F-RL70U\N'N-[EE]Z8_6[?,;\/`NYF$LSS00I1N+XS1*9X<S#48-?
MN.6S),A%-^0%%C[DTV"5#_G/5`)!#Z?:>SZY)3]XZ;Y]&`4.D&;GI1*1W=+G
MR-=LCZR5>X2*^,OCRWO7[+S"-1_W>1<R91W5$]2T:UA#`GK:?_5Z@\%P6"-F
M9LE4_<OTT:HN5](_#8:HU`>3DE:JPZ]RJ/=,.M`RZEBS'"K:)"-4O/OC6@H2
M_Y&ZX]!KEMU>Z\4XN4O]Z<]OV'^?/-OG6*EGO)*5-EW[M:RTO67NW93PVA]1
M58O3&"@8E[L47`][H^)<-TRK>6C\_M1%FPW/ME[;HIU&TVF]MD7;#<_8,GN_
M!@V-MS6LJOTX8,'7=E_;<;`:1O,5"C[7>G6"SX%[W7QVP><4TSYKEKH#<I:%
M)7<"4`BIX`'XSCT`%7OP4.FV[6\^G$V.5#Q2\4C%PZ7B(=K3]DK%<G7VP\Z5
MRD<Z4L"T<E^+>PP4"]=Y)6MM-UKVP6F.CURKUVANVQ'T`A5&&T3].)E?1L$.
M[Y?'?W1OK^DC'9][24<ZOF`Z%B7O>TIBK)K8*\N][>?5-`QF]A'PLM=85`]/
MNU[#,@SZJ^M8#<\UF%K+41*SAM+U$%M]8HG2"79HQ!L8JT2PQ.4Z8./I5$J4
M@VQC=/Q'Y]0SJ?4+P8K1EWYLGEK.R0_Y;XM?.4(=5NST8V"$Q2[#2$ZKW3!,
MMM%VH]5R&X:SQE;+C88A[M]J]]2NV&K/P=_!`%5;3<5W\1R+W:G;H3HAR:1Y
M^1B.LA8A'-93.)38?=%"NX&E4`&.+X"T[OO<&A\[^8'1_9(C'U`CEW'`&_8B
M8B-'^`J*GV-?$Y`";!2[T'54M#6)M6%PF2*^(UL852(MCW[RPXKQV9O5HPNP
M`3:'"H2!UWKZ2BV8&74%&JAH=$;E8U0I7JR`P!875+(VWH"TYM"F+=MNM)L6
M.\1-H]$$CD$H.?@<PVQ<.L*QX&;!\(^1(OSK;;?=L)K&"6NU9H(X:34\K[5J
M!NL77#VQJ*I8H04,HT!U%L"N";ASP?[OYDNR7,=H]KM-5[=<9Z@[`[>CMVVW
MK7<&+;?O>I;=[[C'DJPC8OD1L?R(6'Y$+-_'(WE$+#\BEF\<L7QM+>BABDL.
M)'21^KAGYXO)91)M3I^Q>L,NO*KWNZZG.ZVFH7=:@X%NV=:PU^IXKF,.F#Z#
M_9L8=%!A)D6][%_<F.PP2_(SF7UG5Z37G<UGB(:`KX**%XXZ\;@?1G/6?_;)
MR.BZO0R.Y'4<SS4,O6^;MNY8/5?O-+NN;KM=HVUY1K?M>=]L&*\"&=VTX2,6
M?#??NL>MK4B?@9_BX<B^!"F]MWD%M>FV.TW+\72SW3)UIVVV=*_O#O3NP#*L
MCM$U6VUO+U#6J#S?*^H&GX.9]@E!IH$^&A'HL>K?EG#6:',E\ICB"0D1&#M"
M3&CD9[7=LN)+TX6#)7>'%$PK:GG/V:CH$EF6=-2'JE(("H@,?\04%MX\\($%
M^3D@#:Z4G$-*IUPQ;059C2Z+_Z"_@J/#2?0@,<BI)"!9K?SL5Q`3_Y=L65#Y
M@`Y!#H6K(+>(]P(5KXAPF00>4_"=P?I(,$J"(Z;OXGV6!:#]",@4`E4E4"%V
M%<34/E&7#[-K$+<4OHM79F'&I\L>VT)C,+E)9)*?5!1\EHUR9<Y5,S[Y00#1
M(Y^5V8C\%M&"XR%+CBKXPDZ?[F8F)')B[S18]A?7?IEA'UGFJ9N//H%+6`##
M6-9I<^DO6_![,"#U.[&&!TP?)]^JG#Q;6/N>Z:^#.%A[4Y0N%*&>L?9]%_[W
MKW">&2+H'-Y7$#8V<,E:2]>-8[J.T6IW]6Z_9^F.,[#T#O8B&;8Z;M-L.K9E
M]TK-1Z;S-'CSBW%J.\IJUUY&<?GR\6WY>WK]WL`8.*[>M#RX3JU66V_W34LW
M.@XJ3G87%(J]N$ZEM;O9/HY;ND>/313WHXGBLMRI.U'%<_<U$(CN9U?87/LB
M2"<]U@KX$[:-/U/0D[>EW'<M1#C5S9;5TAW;L?7.H.?HPZYM.+UFL]L=()JP
MU5(D3Y@ECF6VOOUQWG_S"^C(3D&_?\":2HC*PE>==$:D@'SA$/]?L`DVF`(#
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MII#3-+@!HD@##^[;LRM0,K>T9-.VG8';;NM]L^V`5=IJZMVVU=.=CFLVATVW
MT['++3'+^]QRB[)LQ2*J3%*4Z=@CJ,J$[09@E.26;I`-OL]27[3\^X@M'("K
MD#)I0JC3XA9\YF/AKB"7XRX)P&U1H4CNCG!+@DEY[D?!N?21_9K"U[]RT^=7
M;!_VB4PN?.H+:^FXF0NEN411V^SVN@/7T3ULQN"89E.'0VCHANDZ;;O9[-NM
MP3?K6Q-I5LN$3=*%%)H^;:GWV"SU@S^ST6+5:KZ6XY0.Z0-657WW8H_#W=Q$
M:RV^5E%V+;/RUEV:?XV[C/^URQT%SRM7:E=IMUH50F5I^N7^1HS?4>[@EI]=
M[2UKV_5'WVP6&?L!BRHUJMY:+^JJ>]=U^BW+`[GGF*[N-+N>WG&Z<`U;3J?7
M:?6L5G,`.UZ[[G:K9)>OTW-:I<U'GA?!P[+9'Q@)`;;!6,HM]?JN'!"]&L_,
M#';M/=!JM;U:9GC*@N_34/O<K2DRMI[7^*J5$J#?E73R>Y>RENW985TP/BFM
M%9Z7`K7Z%XS37L?\7%Y125&'VP/[R<%_T+]W"V(%\U(H=ED>\IE/2ZT(\9IF
M46MZR**J/6;[8936ZD&>Y95WOS#O)0\MDN(+!DC&P;B[^`-$`W/,4%?SCNQ[
MNZT@XA,NS!6&N>7912?;TQ9:MF`SZK0X$.V.GI45:BUUTS8]KVRV%F>^%C,,
M11O:?68&N]8;U[1-9QU66'.9Y7```UK$#*\<9G$O1$3M#=FV'*OHQ%FYBOMN
MQP&O1^*5&_MS0=;KTT:K><\%6;^HASFJ]X<:M?$OTVRUK'7TA:I%E;PO492,
MD%[5:N9>&-&UE\:2M;'>:HH4X`B$<)`Z!?S!O9`(M2Q@&8Y77/L]ZZC*.CJ[
M&GQG';PP6><LKM:TGOF6J%6;=*LH$AZRIF7MX.SJ5P0)/T^B9\YF7F$DM%O+
MNH$R[WJK^G=LB4ZG_TLJDR2(*E&4[;%_I59#,$TP$LQ:H_K1ZUTWYO/%7SQ_
MP*?>HM!+)M2]"RE="AC<_"A;4/9`F%YOAA<^?AXNK=;K>T:_V[=TH]NU=,=H
MVKIG.IB!:`_[K:[7[7D69>C5+%:5_Y43+_4&#*8IS(>U?@9A.<%>I_^[3:?:
MFMM9>_";GEU4_E8L@:TU_FN68F"S1][D@C')U:.+A'DAOXK6G<]L'-=J?J9A
M\3*.1RQ*H4;E$4!G2H_W2+W`JJ&MVX?K'>Q:C<>T;"\GQL/6I!!#9LJ!+(S'
MR[[I(?5UE61D<=+4!S6*JM'()GWFJZ%6,Q+$V<0:%9+!`%B+A^_B3;(OYZ:6
M4=J>J1R;NMDK"Q0FPJ)TF+Z(0H82P3:?JNT8PY[EM8;ZT+;:NM-M-?5VJP-,
M8)BFYYJVW6S:Q]+\E=U2G6(YEMQ3[6O>P/F<-V]F^XE%U6)+CZ7Z9>J>Y<@N
M>2J[Y5`JNT7(&]2KB?713C1?^S)/P?K(6$H\4AI!2D0C<>TM)G<O/9(_\(Y5
MT7_]\I%C`@3:13JGYMQOX9?O&E37='4%>\KSV]G>+;0OH.I,_(8VG:<83Z+R
M*5X4%5#CHP8'!<&QIWP&XP:EM1-4(^OYC/D_HI_W0A.:,\U;,LJ"E;]'?,9^
M&E+%NZQ0ODO2:`RD9,5GV"H\:["_LOH:5F!?4UT,1(55O?7?Y7_H??S]?SYV
MD`FS>25TK(E<],_!UXN/O<XGO?/IXZ^?/V@"<U:,,V`\#4,0*$$.#4/ETR.\
M(1O8(7Q^!?*?E5515<-\.L5VVW(+:8/^Z'4YQ;6W\.]W@KAO+Y5Y__[Q:V_P
M=;\F/L2JL=^2JRMX(=8_^?ELOR8CV+M/,]8(?,4CH'3@(&]GR75`&`>I+)Y(
ML."!GGI'S=LY/\&0US"-:V19S&^@HGF>OH.85*;EG!J:*,(2<$B<V>!AA=U.
M\]ET(FPP?"T9G&HI83C)T9G"TEAH(F]LR:G;X*Q\@DC'K?!`_HDIN]:S!H,+
MR(&0&'LD\76"_%#+'8E2Y9'F-P0[[;P`1M;<!UF0$Y%D'Y6GC)C'G6H\?695
M<M2-TBL:-9JF\*W@#E;Y@UM18@)J("V9A&]8"#N:*VALR1+Y``0DETYYF<<[
M45,CZFA\9BG!-QE*!P%EB-R\";!S,M:2VX`QH&AH/Z:#=A4(+(T5\IN6N,1G
M6+O[4CB-2GO38!+."(8MA$V<454N[#Y<+:=/Q</C%6&\&?F/WFE+4TM+?S2-
M4U>K*2DEILE%36DCY&6$^WB@^_$0O);OV]/+IM\?!M?R?:>-U`]`55V_M_SZ
MJNIY2(`O<$3Q'QR:A:#ON!P3\FM&R/A2[/$V2W!9\$+L93G*+Q:&3%`HM>0`
MAV(P/+V5A9=FZV\D\UD9/;HF4#?!#-=L2=8N:9],M+!3C)H7J;&DBQ!N``,K
M`-J@`,[F(](OQ+LHKD`@("@,HBY%[(-^S(%P0C1LY=?A5I-8C_`;*K^_HB'S
M`>$2$A`S5-D/I$@)KD`,FH#R`;H[EI4JXXK;<EJ`P?''?R)0#H$]J'Y(ME.*
MQIWOQ1&R23#\%\74N>=>QKM!^YW:*PI\3AA`_L)F^Q.D$H&"V`KVG!COQY:B
MF=`M9)\BQF(=LD%1%:LPAQB`PI9O;*%'FU8-A,4RQ)G-;#!;W,@6%2O#Z1G=
MX%D8!>G,!T)B='$RGY"X@'4B?$C&RJI7J4;C)&#%SR">"-7#CU%O2,B&D&@9
M^4%3]%'^086`^8>9Y<7!(+`@@?:2`TBA;!L1@TS\O^B+VM4\95_,I0N>,]CF
M@@(,QUR:3L<CIZ"D^>-QF,-^K=IP0K?-B+2$[8(V&5,4A9]!,!0#FF$P,(P?
MPIA0</GE$W%8NT2K]4/0NVB*8.T$'R0-5&RVC)_Z.S_%B9$-,P)E/Z99$G`@
M'(Q)G$,EJM81F1$^N<M&A'&(6+]7A..GVB0"G"S&`"28.1>$>Z/]%2=W43"^
M#KB*6T3N"V-")@13AL&9P5EEIE,1M4^E-_<WE*7<37('!E8*XNY*2C0$EJ,C
MS&ZG?$T$S(@A3`3-N5P6?6-_XF/8CU^_@@)TL"*X'=E9X4J#<"G!G,,102Q+
MXY^C&>'!56FU"LO@:0YIQ:E]EE[[,;]5MX4P`N]TVCVL%1ITA[K3-3R]VVFV
M]9;5'S0'_99K#MN[1AAQ5P&,J$396X"1?S$4*5^[#),IN=I&P7Q&P%$<%4N[
M"?SQ?^9^*ARP<!QB;9AB2F`V2I"]>SX8[DD:ASX_X*,D!5'C<U6V#XQU1^A/
M_&N\[S)Y25"+#*=!%,:DSX[3.=R`B">$L%M<(,"$L&*+3M:7P:^+B`D.[N<<
MW^*!'L/E%BT0X108[L\YF::S8'03)U%RO4`0ZAG*NDP>?#BC?TJD4#A\X03E
M0*`"@V1B1@S)=`J?Q;OL@1?54Q!LK!5;=X8>N+IVUKY,U61`75+J*$#PBNLJ
MI&Q?`0A&B/8$6YD&_')G\DIU0O$13WY0AU0&.E51PYD/7ZH)ZCC`+>1%R^:7
M""1%VHF"5Q:CEX%N,3^[T:ZBY(X[&A1LFE``R%W-V7T`?$:K9@B4`4.)5UX`
MZ0DW2TBP,"EY-[G#M(1&PQR_0""\PZ+(OTQ2R7I%=Q^Y1/@%P29^);)F56D,
M"EQG5N.@X9?6C3\N674_6JVVXJ#!>PQIP8Z:('?&_#*PK+\":@^BH*`5W+E9
M0KHS<';]-'`2,-B/IFV?-M4/1\`PH+RD$X)$;7`E$Q?YHVDU%?V=5&]0"D(X
M-S011+!+9GQ3?_2481&6C<''@-V(=UOI\D3EGD(L/S9SIQ0!";*K_=X;;L7M
MI-QA?5C01TE.GMJTZ,,6](-LE(;3IZ6NE&ZS-KPWL-M]?3CH]G2G;SMZNV=:
MNC.TS,[0-+R!C7A9YIM?SD`P(GBRL*OYHM::KK*\@3#].^1+$)D=+'N/:WIY
M'',K&&C]IM&V!^T!W."]ONXX;E=O=YH]'=YO=PS+'MK=9BD#26"@F2V^[`<M
M0UG^>2ZC>@F5?7%9L"UUI>-ZK6'7;>E]T^KJ3@?4E<ZPW]:]SJ#G]8?-UK`W
MW"]`-(5$6I%&>ZN]X!4X$ECH=%OEDKVDS:#8`1TG5PG0Q)!`Y5+KYHG-0IM&
M`+.BPWDP1X2G4_PTRGR>W\?5<)*[EW[$,:FYF03,&`4LX#>/^0]`VC'WPO/W
M^+7&(P#<`,=WE&`0`9U%$?X7Y"#P/9BWW#1'3UK`[R7F-\LXO"I^$1$2V?C*
M/49J`=,?^!@%#4)>9W"?W@0QNY2`OC`\W1%35B;"S#.*"41P.]/2\5?8"&MV
M-8]R&ET*S#:*8^/%`/H`<1Q#'(7!X/HGK/:EE^E.9[<S.003[C,1.@@M:T8]
M[B6.G.0,X1-%!9!4DNMYY*/R=!L"S\DXGGP^3^YH_R0\&`)2E6^*GV4)I@8B
M*#/<;2',)<S^XHCQI'L(QPB\0BJ(JB7Q5[B:(R<L%EO@B[S+S3WDQ38_#.!.
M_13P-0?)KPD+)54H_+;)4?@?V@1G6\JNM!RFZ%>+)>`X15A#.OW<,X%M$A3=
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MIC)[KM&U+%.WO0YL=[<YT+LMJZDWV^V>90\LVW-QM=:;7SKKQ(YDY`ANQ.`G
M;76@1]ZAVL.B.VIL1V14/X!VA<1B2E+KJ7X*JD[<-BS%6F=L5>%!VU&2[>];
M1C%7O`+?HT<0[^<(14[)YN(O^Y!-7UN1KB20/W1):^26EZ32MDQ>$V1*R[,Z
MNM<?#'1G@/@V'A#%;3J&US*[0ZO;W;7):ZS6*>]-E%B9)@%CK),HL3)-@N7.
MW9,HL2)-XN2'-1,E*M(DF%:\=J*$DBNZ*E%BS?C2:J94N/J/*=":P)3E52/P
MR[[RX!>A^7#)D4=&'\G7WTS7M@S7_&YZM@LB#'^VFZTV_NRTV\X]=ZYE][L#
MN^6!!+0<W3&,/IP"9ZB[KFMUNJU6SS%:W["LLKZJA-VY4B0^E@`[N!QRVKBN
MX[80_!!HY'I`*Z?M8+G9:APLSX.KV1F`:MIKZ@Z(#U!-+4MO#8QN;]@>.BVW
MA[1:48'C@FQYW.VQ%84L)TC+]JRV0A"WZ9J&>P_S>(8#-TBKK5L6!CD'?0,(
M`OI;U_.`?5S+'/;:C'EJ=;9V\U$:V_8YI.4:5LO)"=)RW&9S(QQB(8?4:O%6
M@2`/X)#MD\0S@09MA22FT72L39#$1I+4\TA1P.S1J5E/Q`ZL5J?5!W6SV01U
MJ^V`SMD9-/4N(AL-NM;`]IQ[3DFS2($].B:,`@I/M!Q@DDWPA(,\4:^(6T9S
M/UG"\PS7NX<ES&$;N`*4;[O9:2+2';"$.P#I:;9Z+<\P!T9S<!]+F-Z^LL0R
M!1[)`DUD@=JR9\NU]_,N;;?@5K15.=EL-]OWL$3+;0];'</5NQT'%#&O:>F=
MH=D$\]0%JQ3L4J=IW,,2UMY*B34H\D@6<9%%ZMMHM%L'Q"$(M`IO@"H/_S5:
M]VE?:W&,M5)U-Q_.,=M!H"52V&T'EFY[-D*\/!V1UERI5#3=(GS&.IBTVULS
MW*'W2LQUUKQ:MW1<Z^%`O%M;M&-9IKN)1=LK32ZGZ3Q\T2R&D,W2>3E?Y4D+
M!Z/B._MO"Y=FVU83?W:;R/&EI0\[+;O=L4V]:W=Z.JQG"`>],]3;GMEQ.DZ[
MW^QWD,<M3+O!#N2ZT8(IJ(`P=6LH`?O`D1?-*'/0HP%KLSEF0/^3Z9PE3)]=
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M^7EA"S$@9UCPCQ5NWK(KLXW+OD^.MJS.L&G:`[WMNC:&@("!'-/6!QW'ZMK]
MOFUW[G/[6M:FW;[/0-)5)"1&:WLNJBIVT[DO>KT62:UUW#R'1%$;30S3-LW5
MKD+7:[OW7NZ&T?:\;J>E=WKP*5#P#-T;.";&(MKM@=T>>H.VT'CJNBIL/!;!
MGQ\F8":&D\MYF@4,/^R!$5I.J,=Y$-<)TEA,HJUIZ:U<U3-PD/.(@(2S;"Z8
M;MON@KDPZ/9`9W:Z?;W==?IZU^V8B")FM(W./4X4L,V;&^.@4N_.KPS$`B]-
M.=KO!#!2?`!1+AY,O_8&G%!&Q^R8;G>@N\X0U.N^.]`[Z*8<>%;'M0:6.\`T
M\)7T\P2?/7[MNV4_TBT<TX!_[$J`K2"??8AW@-M$Z=,RK1(-16S@(=?H6K)N
M=;S(V=8E\+L_1G1@.<SG9-89W6`;[_&_`S_%VI?UB=9B]X$M:.9:;=!I6U[+
MNC?NNE;JF+621G;5=7#_^AY,$TS27)\F;2;*2C1QVY[EF)N@R5K*PX-H`NO;
M+$QRVV"V#M%@(RC)UI-1DG<D1PI+?Z(H!GVB"W:2J_<]#R-LEJ=W3;>C6U9_
MT&K;3:]O]>[3!(R-RY%E;-X'AUCN(])#(@AK$8E,EGM`Q8T5Z,.5S;G*CK2N
MGX4C;%N"OKB':#]M4]$>5_NPULK]!/%0D_98\&#IQJGE*ET&5B^GY'+"S$A,
MB@S&#!>-^4U8I[>G>MMKZ5$E/KJ]EMGJ-SM@HX+@!`9R]';?Z^D&_E_/:`,3
ME,6'(`#H*6#L*CZDAR^J2)62W^[S'-.3>?^[L_D,BZVQ<G?SC/+8+&&@3!5A
M3*ME.$4-^'%+J^K-(9L47_C?L8CT:?V;'G!V'!`H1JO=U;O]'EPTSL#2.\@X
MPU;';9I-Q[;L7HE31#&L[92[<:RSBJ6.5GGKX6?=\_K^.[IMN:7.,X5I5UJ$
MS[N8VKBYY<'AKK+BR@UVBSW2GW]WZGM_6U;;++:2JYA\=?O@IW:SW\9":[>N
M75KDRC643ME^+K6^/6"[:96Z`ZZWT(VTKG_(4M?J7+]"3P?9TO2*W>\.JW/]
M-OBBOG&];8$N6Z#6BVM<_R`];ZW&]3;F4AGUC>N-TRTUK7]R^_)M,%=MUT6S
MO=1S\/[NY5O3ZA^=)U2?64NJWD/S91[=5'<;>U>?_^24^JBN[*G[^/:P6UA4
M;2U>TW2L=NEF6-4<=D.=3K>PQ-HC9[NBLOD1C4XWULEQ"RNNM27:KEG<TP?U
M<7QTY\(M++&^?YEIK-&W<*L]R[8A>^J;U9J\G?W3.I8]O>/4-E9=WZ2N;2H>
M]?O[36T5C6$;+J#:J\:S6TO;_4@PALWEYV^!`O45.JV6][@2G2VM=T?5GRN.
M@VUQL;YW%-EJM>.JM!1+3;;8)XILM=AQ=4AN_VBQS2*_%2+$LMOVGG+')FO<
MK/H:-].PFLY^DF"K-5TK?-.N^V`9NA4S?$LE2RM$@^45XTJ[J-ZI7?(&*Y96
MW`^6T;3V9LV;+%A:H26`N'WXFG=<Q%,FT39J>*H#SY8$2'B--3QKTWTYA#L8
M=EO=;FNH-]TAZ/..TP&R6UW=Z]O=INO!F!UGI?Y:2(!HGEK.*R_A67LOJESR
MZ^]&U2&`;X%IMIL*G@VGZJR%O;V6[6FNG:KC&/N;JE-!CT>GZE27>[6`(9O6
MP:7J;!#0SZQ)U;$Q)?F`4G76.CMKI>I4X]8_>ZK.1O=\1:I.TW*;6T_5V>AB
MZE-U+-<U=Y.JL]G=J4]V<&S'+88_=IRJL]F%UF^=LP>Y.IM=ZXI<'<,JAI5W
MGZNSWE+7RM59D38.PL5KE2.RAY>KLUF^J,_5:5I.NW@'O]!<G345O;5R=<QO
MSD'GZFR6N>IS=4J9+#O,U5E3UJSE%%R1J]-T'^X2?&*NSF;WKCZ`:IH[S-79
MZ*)J<W5`4[,-XYER=3:ZQ-HCYS0=<U]R=3:ZXEICPC3,4FKN+I-U-KK&VEO:
M-)IV.?WX>;)U-BM]5F3K-)=[:3Q?MLYF5UV[RV;+5.*M^Y&NLUDW4*W8:CG&
MTG[O2;K.1BE0R_&N]4AD\BTM=T?9.JMP[1^+'KIUBFPU6V?%*=F;;)W=0I.O
M,/;WDA;;S-99(4'L]GZD^VT7D-I<D:QCM?94A&XU5V>%<]I[,#VV8H5O*55G
M%12W7?0`[BYM9;O@PBLN!\LLE9X^YYHWF:JS"@.1W8@'D*JS7;C=ZL"S9;JO
M/E7G46B[ZR:'K(>VZYQZKQUM=^V]>$JJ3O4A<#WK?@'QM$R=7<$S(>*)T5Y"
M>:M4O1^(^@9RIM/L#SV]-1P:(&@Z`]VSO9YNVP.CW>_V7+/=O`^NR3I`Z#RB
MJ6F4:<H,O'MHUAEX[5;7-O6AW>OKCMD"ONQUN[KI&"UWT!R:0^.^CB&EOD(;
M(%D/>#0<\T"=>&F8I-R9U`\B^$7ZH&P@BR',EDCT*-CC=KLU&'HPO-%IP7TV
M;`/)K"XRG-LW[7;7Z5@567>E[%Q7)=FZZV4DXHNF:6UPT30X#(_-.V8+_A/\
M+%O4IUHVNH&M^OG-S6PV_?#^_=W=W6D6C$ZOD]OWO8__`$,6_E_;<%M&^^_O
M\]?RH;+@6NXT_]7WRS0:AQ^"[]A+/)S]SAK*CL,)QKF3^.<WXR#\\"FX]J,!
MS:OS/01YR)O&PG38"W]_7SG.@SXDA.O%8AJ<72G"5/GD[V$Z@FU:[Z-_?U]<
M[]_?%TC[]VDN?1EU9GY*]Q[BB=LZ,AA<N?EOY8-!/%8>0[T*AQXK#_W]O3+X
MW]]SCGD4^]2)E8-CE\[D.H@_QJ,=;)ZQWN89V]Z\1]^SA[>Y&![[GR`.1G[G
M<O,RH1]<!2D(8.YE4(0#2@LV#_'L'],AWG]"[<H?W;&H2FY!R0O_PGN8_W,8
M?@_&_03=)Y/+,*;;!JZ8Z]2?;/]0&.VU#@4^MKU#L5*#WU.FEV8O*O#+[#:8
M3*-D$024D,WT^QU(N*9N.&M(.'C,U6UC)YM9]-KL^6:R)*+S&=`$Q_B4C)@)
M5]C:E4D/KWN3F3OR)6SR/7D>KWR;R='^$K:9I;I0&L0KW=*50:0]W>)ZA;/K
M?_>CV9J6X*9TNM^"23*]":-P%Q;H_O(0#\4>',]0H/(+$!,D_NO>P.KD@H/;
MT*Z_"-+?`A`$-R,_#3Y%:SH7-B4/X/O#9(XM-<[#[T-0&O!_X:?.)/S+'X7Q
MQ_@&+IS7S6K5.3T'QVI;=G`<DB=AC[FM)J?N\+CM0;[233':YV`>^=FZ2M4+
M9:&:1-6#8Z%GB,Y\@8EDBXPBC[N*T^P;(VV=40Z3.G4`*WMZK/;2Y^NLMYG.
M#C?SZ/-]19M\]/F^CFT^^GQ?S)8>?;Z'Y?/=7QXZ^GP/?0.//M^7Y?/=8U8[
M^GQ?G,]W?[GMZ/,]$)_O_K+0T>=[4#[??6.D_?+Y[@-U'M3>_N".V9;U`NG5
M^#7`VQV,SY$?L<^/L'0V77SXXWS;015SO;"!O;54\7M8B$MJUVN[^QM&V&O5
M<C?!N;WBH_T2U'M`';O-KC%YRERKC<&YMF<Y>^\#9J"RH#3/"O6;W44>L.-%
M@[P,]GP4Q#[0[.(NV8V68NG6.O?P]K:W106HY>UM>2W+V-M[]\G;>Q;OPOUB
MT_;:]Q>(;G%[W286&;:6B@R%J^_`BPIWX>K;867ADZKW6FM=%O#8]JKW;&;S
MF,91)3M<E<Q9KS2:'ML6'QE,Z6@?HY0;XZ!=1RG;ZWD8VMOR,`@>*ON";<]J
M*SSD-EUS?S6=%5'+Z<WL)ID%HYM>DDXYSMYN.6J8W(8[\PN[S^RP8NQD5\=,
M#X]]'JLX/54A7F<;[>UOHVFNCD<>-91]UE!LW5S'+4*/;8F/+'*+6(8%_[@7
MN.GP[:PMA8T.$;1E9S$L"]T']W,Y/6:U=\/EEN&:>.FY;<L[PI6MR4Y?TC`>
MA=,HN`"&ROP1@Y`CCN\'V2@-IPP&]6L`>APZM'JPC==)NB@$4=.K))WX\2A8
MPNP['H"M'0!0#$IX1+9M46V*V]S_%.A/27P]"]))/[BL$*CG01PFZ6>P(7:$
M=[%F*&-KNM_R9AX+C5[0;MI.RS6^L_^V#NVH2B#E[D+^\S<8'0N-%I^PS*BX
M[?*AC_%T/LOH"7OS%\%1@MS'<\?JMM>SR\?RME>RS\?ZMI>SIZM"1X>?:+BU
M4-)&4@PW97/N&E7ML+CXR+5')GH`$QWK-`]^!X^%FB^K4'/O>>WU\-:+W<=C
MQ>V+J[C=8W8[EMP>2,GM/O/0,55O4PRUNU2]/>:G8PWW0=5P[R4G52?`O#8E
M^2%LM1_9+R^+$P^U2G7;Y#EBR#Z=V9WU=G.;N?9+NWD,L[^F73Z&V5_)/A_#
M["]G3X\!RL,*4.XQ$QT#E`>_@\<`Y<L*4.XSKQT#6R\NL+7'['8,;!U(8&N/
M>>@8B#BH0,3><=)^N7_W@3P<+LAT[P=U./R<[T,`E]VT:K*;8][637<MS")\
M[)GY^,BW1S9:Q4:(VN!P?RO35,$LLO<V2+W6Y3]/1S=^%L#MC[[6SG4:[`A<
MD8,,..MA$3A;V56&9R:1/!V[9=IXB1FN=P!>]-L@F^'KRV'.7I#BIT9`KNSL
MJA],DRS<TI:&,6P?/,W@"QD,IOC=%G?*<$R7"M,]8V]]X7G%=Y9)7-U1&&3=
MQ6=_-D_A4.:_7A1W\&,\#B8QVT,8[->Y#Z=W%FS),?4\FRC0!1S;<DSE^-DM
M>&+?-W43Z`+FYF_L55+A]R0.%K_[Z5_!;#B/QUN*JSTO+P$+-551WC)-;V_=
M`)OD)6LWO$1*@\BY14_F)$A'H1]]\:?;BM#L%T/9MN/NO<9W0`R5Q_LY3R$N
MRGDPFJ?A+-Q6[/\96.K9'4R[7+.]?VNVM[UF%=#L:$8\X43*I-9=[-0!X5D]
M,W#4,^W0T=`[_$T\&GHOW-![!EXZ&GHOV=#;`X8Z&GHOR]![#I8ZPJ:^%-C4
M9V*D8PG`WI<`/"MG'//Z]W-;7EGQ^F%MCLS]\2RO145SGO<"<$NWG`O4]2,$
M"SB_"8*:DCTZU+UYFL*:/H7^)<C<]36[ATQE(^ET!\ZS3<NSCCR[&9[]G,2C
M(]MNE6VYXFI9]D%6=CQ_FN7.JX?VBG&6\LQMRS:.^;H/D#`2`66>)M/`C_^(
M=XZ8MMV,X3WDUR-_'KDC+W`\0&YX4$'C86W)$0AS4P=WJT"8S\HDQR:<CY?F
MVRPEW2^F,)HMZP"=\<]7:?P*F.)8?KYOY>?/P![[E/ZZ@S7;(G.^9!(=791[
M[A2TMYO_?JR]/EQ;6994;X\[]DY4.ML7E:U]6S-(@=96U^S"WVJN!Z/9IFH)
MTW:<XW6Q;T@B\H/GHR#V@1E*B5?\M\,DA15GVZ\.<8E3MUK'<^34(Z=N1K-Z
M**?.XY"Q:9@ECF6VOOUQWI>,-0G\;)X&O_"_`?7Z?W\O?LD&P_=+(V4W?AID
M2X.P7Z_QOC*3;S#Q;Z7QQN$M<&J^?GSO\WP"9MPL*6SCO;-GM*E^GX;M!W$R
MP<AG]<!5*\K'7'[Y[^^5N5<N?0K#+!$.?[D&V<X9URR]3B>/_[%FF),?&%/"
M/_]_4$L#!!0````(`$DP!D<&K<,5Z@X``"C3```5`!P`;FMT<BTR,#$U,#8S
M,%]C86PN>&UL550)``.J,,-5JC##575X"P`!!"4.```$.0$``.U=6V\B.19^
M'VG^0RTCK7:E)>0RW3,==6:4ZPHIW2!(S[;V952I,J24HLS8AH3]]7MLZDZY
M+F#B,MTOW0%\.=_QL7UNMC_^_CKSK24BU,/!1>?DZ+ACH<#!KA=,+SI?QMW+
M\76_W_G]MQ]_^/BW;M<:C:P;'`3(]]'*^NH@'Q&;(>O!?L4!GJVL:]MW%K[-
MH#7KW@N>'VV*_F7Q?UT+OOIZ-;JW3H].+.N)L?EYK_?R\G)$B!LU>>3@6<_J
M=J/N_E@3=FZ]/SH]/?HY]<L(+P+WW$I_=4W0NF,72#JW3H]/WG6/?^T>OWLX
M?G_^[NS\^)?_IDOC^8IXTR=F_</Y)Q0^?M>%&F?6Z&ATE,+X=VN,`PJE9W,[
M6%F7OF^->"UJC1!%9(G<H[!1/X1K`4<#>M%)(7Q])/X1)M,>='/6BPIV?OS!
M6A<^?Z5>IL++653\I/?UT_W8>4(SN^L%E-F!DZG(&RNJ>O+APX>>^'5=FGKG
M5+1RCQW!I1H$6M(2_%,W*M;E7W5/3KMG)T>OU.W\QCO\2+"/1FAB"1K.V6J.
M+CK4F\U]U`F_>R)H<M$)GAGAG']W_/[LF-?_Z08[BQD*`*I[&S"/K?K!!).9
MH+IC\7:_C/H9\@/TS&PBA(>%DMCCY7JE3?5V)70$-?\<,Y`VWL=@<N<%,#R>
M[0\Q]7@7U[Y-J3?QD-N0[IJ-OB6"H4U04_8W:)D](>8YMJ\>4Q^6LQFZ]!DB
M`0S\$FT/8K,IY=0",U@`J]ZU/?<8L&-K6O,-*:?TVJ9/=SY^H?W`]0ARV/:T
M;C:U,[4W'G5\3!<$#<C4#KS_B3E_&;CCQ6QFD]5@,O:F`<B?8P?LTG%@.V&P
MYPVQ[SD>HI>N*Z34]G=8?/9!@D+&<*X#-?U@B2CC`P'L_V239\3L1Q^-D;,@
M0`"B=<O![/`77''@%6[_6GA+V^>EH2[LE8QX#D,N_VUK/NJC6`/;U8K@;KUJ
M@#_$A$U@*N#U\E"GRMZ9LPU-"EG'.PL8)JOXCZT1%S2ED-![SW[T?%"W1@AL
M`>0^X#%,+%`"%@Q^'>&5[:N7\)TZ52G@>#;SUB(!`G*-Q:(.-I7Z*=VT(Z4C
M[*"`(M&O[]N/F*PWMRE!8D^G88'LKX$[`#V/C!#(W**I'J:X\[=DAFI!WZH[
MA8#'##O/5]RHYW8Q$"-Z*/[V]I7_N?U@;]/7WJ&J'=`F?2B$]AFQ>TSI$)'Q
M$YA@:C'5:ER-3?(9,T0?<&QAQH8%3>O=L#Y2V+K=:#$8$D2Y9X!_3)FG2>4$
M"U?9RS3U!_3*KGP8PX;<:A'AAS82T1?&CD@,8-\C<V=[Y`_;7Z"$R#T(='DO
M6C$^<(5=G:#4Z6O?>&.E/J%!_9"6=J(3H>(!K='5OM'*3)LAU(#EP_9S-H[Z
MP=Z>@GWSIL0*VJ?T-^QV_UR(+8$ENB3$!F+X#_ME0?T^6X1?\?+0O.=]\R+E
M=YZD#8IPZEYCRJA0RH7),;17HI9Z^=B5CI;S2;$<J:%FWSR[M4D`"UULUZF7
M&GD/(38G23'@&089C%`6!2X/MZZ_Y7TIB!2O.^[E>MXG.34#P(($(`+XD^G8
MYT%^3+*#'?8K(OD3FSZ*</Z"=J>V/>]Q(>@AG]'HF^XZ?^(DC.K_%'[]9VBS
M4)!`+G+7"\*CMU%/L!0B_Z)34;BGD>X1<I"WY-1\1JP>]855FF'8G&C\&]X#
M6<#DAI(\^/U`8)A#)Q;-$55=7A-7%[.%6*&$=Y6O7`0]`4&P&Z[#Y=P-!'P;
M3![L5SFC&[6B!6GLP1K:GML/PK@ZUP-#=Z0,7'5%+7@H12PO9+D?]=%5,3$S
M9;10N;0]GZ\(=YAP2R@5>RZGO+*>#C2A2-XC4"T&C[XW%=M9!92*2BW"\1D'
MSC904O7TH!$AYGQN`KNV"5F!BB2\3%)$=>IJ096L>Z4`\L5TT'J#)@C&WPUC
MAN7S05*X!717RK^\O`[J;\%.P2N$0LLG<CU5KJW5]72@^3?&[HOG^Q*BXY]U
MT-8/&"*(LEJZO*2P'KI#ERQHA%)J4T5TT)@2/PF)Z1*:*>1A*;[4/F'?183R
M+8.MJLDNKJ892[D4[[PJ2"RYI@YR6&.+"=VU-1W<%T9;:)O6'HF*2OIPU#!`
M"@IJIK=RCR\NJXWJ9F+2)OE(T5*/Z<45=-`_)*&B5ZE^%Y740S&>(\)60Y^G
M2P0NWV+FW"\JW_E+J^C`D$TEW]:B:]J*'J3,]@+D1C[\E%\/3`S/\61C5J.B
M#CQC%'B8W.-@^H#(3,0L)`"*2FJAN*X65Z:WI4(:ER1+NDV<J$'X<R.>D3TE
M&);H47[>A;?6]1B:1?4G!,\V/(Y19UCF[+,P`9+%2=5?CH\[U@OBIS'%9_@T
M)S`*@.6B<]JQ%A2(P_.U[[6MZ,H7N`3LKX<`-K&%$V`?#@&81!&+49X<FX8R
MIY2EP=;<Q9(A/CD@\(TW\X0-IP?$AAKQCP3XV2$!+PTC)YA_/B#,67=;@O'=
M`6$L,OT3I._-05K@=TSC++*[DVW*H,VX`F>AZAX#/35H/ZX`6B/FF<`V:">6
MP-[9V9HPPZ#]N$(&2N)]"5R#=N$*N&5NN`2O03MPW4B,9"%/HS9H3]X&=5&I
M&/R9F<M;#6TS'Z!-=NR#@UPC^I^@-W,)+T!?(QLT06WF2EZI?,OCAPET,Q?U
M4MNJ.`4C@6SFBE[J/RK/-DR@FVEVE4"7)90ED`UR:C>8V^63VB#?=CTMI3#.
MFNAH!HEU/;R;.9T)6(,$NA[8.@<!$O@')]N-3WPDO##(NU2/%W7BW8EULHW/
MJ86'SK+7=6JE<O,^3BT)[11(X:%-.@:!D<3;\Z7TI-Y3<5I=<L),6DQ+VC0*
M$+%](./2G8$]1-GZA'5\G50AZ56U]"0K1VOB'2PQZYL"%K!:#.9H?7$7O4(3
M3,*U$Y9,1&]?@6Y8.&`2DE4?I%VXN*`F3`"@;QH9#1(N[+-'?1P$.L-AO()1
MGDASB62E=2;8ETMMOI2BA.3-._"RM^]E:*E71P</09-(!%K"P6P9)?SC,0.;
M/N7&)A=PB",,1=QLV()*JM>MKL)A*[\0LX3T1LUHD0W0"]:+&E^BN`"4SS1Y
M>2WIQ%E22N2[J*2V!.BF3*^HI$3NAP2["X=QR12W-Y<)M[2LIN1@!(8)SR2Z
M@6GF8Y'\5\[0\CIZ4(@50B:^\<]:;3J9^IOU9.24>2.S7>H@K1`\(W-?ZN"N
M-"R,3#!^`R,CX]0MVKF,S.E]8\:5[)U&QO<*E?-L?&N/_#4R+EB3907FKB0F
MV&TYWBIUL2@<6C`KC@\-\U9FIB3SXQ#X4=?(,#+]H\36RVIED2)M9"IY392;
M>IKDH%/+Q3IO]L2S6FZ.&GDJ1HIS*W>3D2=BI"RH]K/N=A!&5VPM_WZ<5F(V
M'XC3<>>;+QI';G(-:^%#)X4ND)J5VW//V!"!9+JPCA.>IW6#UO_+0H9-FM!S
M(]8<Q,9;KQE@^L\P8>%K#A)(936TW(HUF8#<#R:WK\X3OV-Z!,(T"(H9+X'4
MJ`E-@;Z,J/2#7`*T/.174:]=:)+#@XT!I:HJ<9P7]M3H3MJ&+;1C)'*)F+6'
M(5^O'6CD.?.U@94TT0Z,T2'4)J#2==J!0I+I7AN1K'Z+T,4V8.D-PS4KMQ'7
MUN-6V(*FE`J^W8.5NO1`-;]:?0%UM!^$27_`?(=YRW6V=H'#5IZ#L4NC+>+#
M^E%7Q7RHVVB+^)!,1H5\J-OH]U2C[ZE&;4HUBKS2CN!S_:R7S?):[M&+WHO!
MEPX8>03)+W"1X&G20BL02F_6J@M0WH"JE"4'(5?$1?N4+F"77#_]$QTC$4<H
MHE^$RUR2S=2X&4TW.1;0*;QA]$O@(@*3A%_>L!1O9!8ZR?A`2,535?.Z>?/)
M9M%K\P3-0YD4_AG?IX-)\WFKI&W=7%GO`SN!KVQ"R:P>17R%KOC+L/G^\S>3
MB&-2!`3/=L0Q&]DT5]*NGM3`2-`&D^@Z'LD)8&GV8/T6]*:?;>%(SR0'[:B&
M&WEP>D],JVW#&7DYTIZ85ML!8.19YEV9UBP"8^0):#6.H6Q"2X/E7W(W5\NS
M0-0Q3:$&8>2]7XHYN96%9>0%8NKGK3ISS<B[R=1XAF4,W<'&,_*FF#UPLXD_
M2W+3C)G;BB(1K#:HC;P5]@TDK<2O*+E?UDQ!:QC]R9D7Q0>###*QU'%%>:;L
M-R-/NYV0,.G>>?5SL&ZVJI'G#-2SJS1!U,A#P.IY5!("E1P7_F96JF8YGY(C
MQM^YE<WR,_-0T%NPJ3C13G(`^SN_-M/(C7R9Z2TX599*;.2MXXJUT:;Y\D8>
M5GVS):PH$]K4>Q#VSK&-,PNF7G_PQMNC1+JV4>7?]/SCC4<='],%00,RM8/0
M&N'N=LYFLAI,QMXT\":PZ@0LW.$`[A#[GL/?U(CO*>X'$TS6`Z/A&&<"(PR5
MKIUQPJG6#S[9Y!DQOBFGGI"K60X&WE^X`#G_!E_@9I_ITW):M/J%O,)LE^IZ
M[3DC6N_EXGV\5RS)OA(NMLS0;XI&GL$I,2M*O-JUR6_PQ>FWW%94#ONA/W*Z
M+UX=]INH^^+:WI]0;?DN;ZY^,L2$34#+PNN+*>I4:9<&TECU4+<[;^IFDCUW
ML^!W#4'E&=>X_SO;(V)=3B:"1#XJ*GTCJ_,WONF7S62C0J_[DIRJJ;5;P%73
MUA@_`1[_H6-'BSN_XQ?W/B%77-0LLCCY=<9D67(BO[JFKG4X>5J]G'1>1"N-
M(_OED\T0=W`W8[J\HE8\_\'DN1^(K#C:#%!)3<VW&6^*4WYMJAI*HW:WQL#+
MQMPHL[0Q\K(UTTA#4_8*?"Z-KH5V)I[-/!8G?8LPQQ0%[73:A_=;"D)35UQ>
M3@D2ES/2H@LPH73F#LQ6`V@?S\7AE(V4O>)OHQ2L]M';/K["JL<SDH>(B*3(
MMA#X&3-$'W#\YF)\\2E-!_Y@G:#8]]QH@@T)+-\!$Q]3#S8FE1/</&98%BI\
M`-JO?/YRZ;<,/OJB54PH,"%;.EREE#YP^[E=G(T5HX3>=C*VC-`6\E6FE@VA
M!DP\V\_I9^UD>HF.UG9Y2:DY2W1)"#^KSG\X(+I;*/:I;)U)6@L*9X$X79P<
MQ8A/E;5R)';$TL+1B5[HCE2_&GS_V..]/P)"^/!_4$L#!!0````(`$DP!D=_
MKQ(\UQ4``"Q(`0`5`!P`;FMT<BTR,#$U,#8S,%]D968N>&UL550)``.J,,-5
MJC##575X"P`!!"4.```$.0$``.U=;6_C.)+^OL#^!Y\7.-P!ES>G>V8GF.S"
M>>LQD'0".STWMU\:C$3;1,NDEY+3\?SZ*\JR)=D214F423F]P.ZF;;Y4/7RK
M*CXL__K/MYG7><7<)XQ>=L^.3[L=3!WF$CJY['X9'?5'UX-!]Y__^.M??OV/
MHZ/.<-BY891BS\/+SA\.]C!'`>X\HS=&V6S9N<%C0DD`C77N"?WV@GS\/QWQ
MOVX'/OKC:GC?Z1V?=3K3()A?G)Q\__[]F'-WW>*QPV8GG:.C=6^_K^2ZZ/QT
MW.L=?TA\,V0+ZEYTDA]=<XS"CEV0Z*+3.SW[>'3Z]Z/3C\^G/UU\/+\X_?E?
MR=)LON1D,@TZ_^7\-Q0^_7@$-<X[P^/A<4+%_^R,&/6A]&R.Z++3][S.4-3R
M.T/L8_Z*W>.H42]2MP.`4O^RF]#P[85[QXQ/3J";\Y-UP>Y?_])9%;YX\TFJ
MPO?S=?&SDS\>[D?.%,_0$:%^@*B3JB@:RZIZ]LLOOYR$WR9+@QQNL"F>%.OC
MR>K+56F?7/AAG_?,"3%54*>36T+\ZVA=[$A\='36.SH_.W[SW>X_1(>_<N;A
M(1YW0HDO@N4<7W9],IM[N!M]-N5X?-FEWP(NQNGCZ4_GIZ+^WVZ8LYAA"L"X
MMS0@P7)`QXS/0JF['='NE^$@)3[%WP+$PZD61-/V1)0[D39U4E?0(=3\.@I@
M;HH^'L=WA,)@$N0],3]<,-<>\GTR)M@M*;=BH_O4X`EQ7!;^$BT'4QP0!WGZ
M=1K`WC?#?2_`G,+`O^+J2NPVI5U:`".@L$=>HSD)`([*LFXWI%W2:^1/[SSV
MW1]0EW#L!-5EW6VJMK0WQ'<\YB\X?N031,F?X9KO4W>TF,T07SZ.1V1"8?XY
MB`9]QX'#)X`#\HEYQ"'8[[MN.$N15V/S:4($C<`(U$&:`7W%?B`&`N!_0/P;
M#M"+AT?867`0`/NJY6!U>`MA98@*M_]>D%?DB=)0%T[6@!,GP*[XKC*.YB0V
M`+O>*5BO5P/J/S$>C&$IL-7VH%*E<7"JR*01.M$9#1A?;OZHK'%&4QH%O2?H
MA7A@;@VQ!YN\^\Q&L+#`"%@$\.V0+9&G?X;7ZE3G!&>S&5E-"9@@URS<U,$!
MT[^DRW:D=80=3'T<]NMYZ(7QU>$VX3@\T_VH0/I;ZCZ"G<>'&.;<HJP=IKGS
M?8*A>Z)7ZDZCPJ.`.=^N1`A`>-$@3-A#]J>W;^+/ZH-=I:_&5=4[H&7ZT*C:
M9QS<,]]_PGPT!1=,KTY*C>OQ23ZS`/O/;.-A;AP+/VEWP_[HP]'MKC>#)XY]
M$1D0_TRXIW'E6!=ALLLL]6?\%EQY,(8ET;)(\$,;B?4'K1V1C0)-C\P=(OQW
MY"UP+&0#$UK>BU$=GX7!KF^BJ/35M+X;HSZ60?^02CLQJ:'F`57HJFEM\UR;
M)Z@!VP?RMGP<_8-=78*FL9%X04W._I+=-H_"QA-XQ7W.$0@COF@6`O4^+=)?
M\_90ON>FL4C$G<=)AR):NM?,#_S0*`]=CB>T#&OIGQ]UY;`<)\WS2(\T36-V
MBSB%C6[CU^F?-?D]1+HA[JBJEW-_O;X9%Q?7'T.MD>=U.U'#21TVM0@-3EPR
M.XG*G(@*#<H#7<'XP^@?N7B,%EY03KK=ZON1E<T0H95%7=5N4M*PAZ,9GKU@
M7E+,5-4&99Q"$]Q9O."C#3+E),UJ()+7W3!Y!)$G)3,L,DQ=P5-8?2J:TD"Q
M6/5[DNZX06$4>1-VBI7F01B4<9?F8%"8;1Z#05%V:0K[%J812H$Y)<S=Y]NO
MLV2L0$@PB%*2>8+5QWCFH1,>%6/DOX3GQ<(_FB`T/Q%6WPGV`G_]R=&*7GD6
MT?C^%GW\M?^*B"=DNV-<./VQB)\X\_TA1A[Y$[N?X'ST1<@?^Z+4$V<.QJZ_
ME@A:P-YE5U.C)Z5PV+5RQ2=?54<"I@$>P!ZPK4O%1O8J>^@6U)%[U4`YF?7,
MNQO\$@PHK-K0O!A0.(U`U"'LQN&6[(*#X`B[8[*M7X4&S.OW@`*!^/(&)%/2
M)U5!RYQ:M;^>#\GV;[#O<#)?70CNSB6UBHW(^$9FB]FZ1QA0PEP5";.JF9@#
MF\N"/FQQ@7^/7[%W]LS"_^\]<T3],9@^_9DXQW-F1:DF;-&Q%PEX5EW'W":,
MZGBUW/SY&\$<G++I,A2S_T;RSD+%RD;U&M#Y(@+^_"'RG^7*9-0PJL$#1L+\
M2M_1;6"^B4(7<IV4VG@76G[M&='SGM$)'.,SL9\_0V>25959U`:9I8.04[BE
M<AN:)6E?3US/;;F#P37B?`E^8CBU<U0JVXH)34>8$L8%^,\`?AA4S]$FJZ0Y
MB</^I>?(;KF-M+&#WN=IN6&#6C<7A4/5(OE1G3%GL\INW5H05LG!ZC#N8G[9
M/3L]/3Z%_T!S86#X0D0-L'O9!:L?QQ\R<&;>@ELOW*0ONSZ>B#^ZG3E8LL*D
MO>SVNIV%#^JS^2J(T!1\6S'U!H!4,OG7\!V?G@GPW@,..>Y9C$3O`)'0%92*
M43H_8)1*'X0Q+!\.&)8RD:48D8_O!I%T+"I&X*<#1J!<)";&Y.=WADE^Y";&
MY.\'C$FFQ1VK_HL9U3-9`Y4!2%T:))7/=K]C[4\/6GO5(%^$1\\8'AGLH20:
MU8*6F4BHA9N,3Y!=BI)!/+[V;$`D?Z^L%5/,1"4K>+Q!X,R4PZ:V2&011]G6
MV+*Y7T_-MDQI>4AS]YA/A:GB&:NFH-7LDBJ9#*SBGI3FE6CE76SG,\GE5V2F
M$=$@0[K=7;K3-@Z)T<V3MDZ3)B+)UY@'(=,-UNCC^`;/!:%2&E.6U=`S,HS/
MQ4N0,#4#F*2"YHG`-LV42J6&$5S7(HE=,EX_<F2E=2Q@'<#\73]A"^4*+1KW
MD0Z%K)S0"13XS"A?__,*^227^-5,'VU%*8MBIK_]'ZR.9ED=9Z59'6<VK.Z$
M/+W2&O1LT."@>2D)&R'C77R.6@65S.I1P#K)*&A>WFLXF"?@K*Q>"TB7B4+%
M`]/'$$?E@5&\7+E9=POJRLVKG,+[8D0T:E-)+ASJF",'R*?8VS#(O&Z;+\[W
M!E#1L6;S-7KC(,GB)#;?IN\/F%K!&^/7\86W;8TYE]E+L$T7D7N!IHWWE.:O
MY2R8/J8NY7H[5QP6LB@;1>!L%P%3[$FU:\E\AS1_D\QVF\S/>J5=0)?";;FJ
M5/=XD_H7Q.YMIJU54USIVL5F9EJ]\<Z+(A@GI#4WPV6W?JVXHL](O6].F%I)
M\TT0`N($>_[**$;Q)R$E%3E"-GD\K6PK)@*$1C0U%`S=I,\,1&IEXN)51ONK
M94&TO;B>1=H4OJ$LKG=0VI2>:SFDBUL_(#.Q=_4I78@-*G[.`1YTN(,M-]M<
M%@>C7`-:9%;<=G?"2$FQ2[>Q3\ES\\Z4JJ]%X@?BP6B"H31R,.Q^A#U2G$_(
MD91N1IKG[ZR$-'%I+=+`>1`&)%>3//II%/G(9(E9I1DM\D=I4!^0*V*E&[0^
MLZ#O3`G(X?X?1AR&,$MJ]<I[E!4&N+JLHK(>6:.'DG=@L<L3?8?/+3,E+MF$
M'KD7W)FB\+=Q1)^;G\3)7V$%-;1(%:V+3=OQT1@-:T%^I5+U3=@(XE!_'"=L
M38G-EEW6G!M:T<[>!!^*IISYF(M:1%'9!D_'FPJ-0_/!-J7X8C/JMR7:J&SD
M;Z:]S*IJ0[Q-@\8)R\UXO"T[BTE5-V.C<SEK_P`Y-WI@+&U.V7P1IP>22IZ'
M^=NYIF$I&<RPF8VE:>FH>W@VLZ[V"4;H0MK,M-(#1CFORG[:5.7P6M(BS?'$
MC-N@^]%>P8BWB?0D<\>D+G6*K%O6?S4^%]0<LJ8`J.*2F7G*7?;GO8V\RW#Q
M;/5[$T*$3PL$>`<X.[ZN6,E,KE/?3R%\M?PLDF"%O\6U_G@IS3:KW(`5^N7=
M+"E4L$)^V:/3G,+FY5[V'8>#5:^6?U:MK@5:K29Z07K@_!JMUR!YD6TH1TW9
MW2N=TD6"14N,A<80L"*`F_L@KWA;SU?SH,-V.@#*W:V-!^>4GYG(CTWIW)`L
M(./KH?3`9V[P:=ZXW(XM&W@TQ.5T8#+@T%G8_"8Q(+X.D/A1@?2WU'T,IIA'
M$=AR3D3.?7=_!J`/J)-_Z[Y5XMWP*_7P"?I^P-&_,,4.ZK](0,XHIJ7_*_2&
MO`#E]YPNH*G/)>:_86AVZB"8ZYYD=N66U27)'5N(D/.(O-V15RS^"__JS\@W
MY!"8UE/D21AFI>I77QD^=HXG[!4V(B(6Q0?QA]#F0V(MP$=?;\,?;<VT?7>^
MUH+?;WC&YE/B$<D$VBG3/`[W>(*\E;89?GY6"4U\RL)-6\H!5:Z]'VDEO$^E
MFCJE3'64.N3RY<NOHX?]R5[!KB#?`(;UGW?D#;LW3'0]>R$T[/B)LPE',PDO
MM$H[>ABC>.$A7[;Y;Y70TFLX$M$O`>?WG%%*#ZL0%KZ_%.?[`^$.YA+E\XIJ
MXA$Z4\G!DOSZ!PMPORS`:@O;/#=P#_S(O,73!I987>6W=TOC/+$]Z%S./B[[
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MDH(?4<DJJ>5TO6.O1,HE2!=H"_THIV=P]3B&L_X&K_Y_0"5\E/S"!TR%VJ3`
M?V913-D'R^Z&<.R$+SH7,\S[[JM(`>N#-;4VI;+Y/%4;TY3FK8`HT@`]I/WD
M(BUB[UG68H$,1AT^HQE^'`_QG''A?D1)EN6_*B>O<Q!:Z/+B'^?38,H"[$S7
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M5`\8[!TW7>#/G2E0HZ'W0*M?IYN$,QD[R,_.95Q0V*3<7Z@_QPX9$^&522SV
M_/*MEMY0=&^T8E]]PL+QG4^)`\>>5/[<\JV6WA3Z`>S*VQ))=OW\\D:E7T]J
M%<E395O^_*C.:?)E/N8,&A0NRY;YN[ZM_D)=S-?4I#45*>OHJ=R6"?R_S.^$
ML)&`"6RE!U91K?K1;H<M:,"70I'S]3^$#N<)':*/OWX9;8F9^**][T_R'EZ=
M'>[#JZV;I8W*/?N>0>A^@KBKLWUO)#0_+MQ5^3V_I^P=[K*N^<SV_'#?&%:"
MP[X';GMX<GEN:CM42^971!1.DO9EQ%;C#S/4'BCH4=>*-'T*T[J8B9S4M^!^
M+K;C['LX6$-AZ55>?,C9GGNO%#VUQ<^K*NMK^P.KYC7/B;-$FI\?L.8JG.`(
MA@\'#$/-"Z0(H8\'C)`DD!II_],!:Y]O'$7*_VS/F_0*#QC4=H041@?X(KTB
M<$HD")NSLM31NWJ0W>;L+G40J?90S>;T,'70J$$EMSFU3!U()*\/;,Y`H_=8
ML2$Y3<,G00UB5AO2$5;"1IUTV8:DA/6F1PU>8ANR%U8\.Q6?H[<A6V&EZ5%`
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M955M&]@?&;[S,GR/`N9\"R^XK]EL#GB%$8/L3V_?Q)\E?^-6S^,X$4=_'(<W
M<=+G<+OEC*0&G,T]ML1XA/DK$?PC<.]WT.Q[7D1)$D;:.C@.ACYA;GAML!-V
MWTXKJ+D7$TA]PN!9P\E!W;X[@WDN@CP!><715)..M5I=$UH-*"PYO-E&%?*5
MRVI8I('T$;F\SD%H8>@Y_!#[&$ZU*4SU)`E)88VHU#23'F**W84')Z^>74R6
MK+J9OHR@EBEPGMK9A??-9VWH+$R;H8U,I@/FRNYC4'+FJGE*K9J_IW"&)]4M
M.&I:X@SI5-H.'[!X+2@9"4FM,WR1-K"B2^NI9'6T@0%=6G-%K\0XU5GY!4VC
MYI;"CE#M,:9%`1$-OW.FZ1?'OB/N;E.OMG]/+%7&:`!$@/DX3Y)0Y*&,G?)F
MG9.<Y9&(!%XMXS)KJE<(OY)#4K=]>YR0U(.S;)&+XED:&FX5'JMY[G^"@H$_
MH*OM53<VV9VT'Z?_Q60R#;#;?X63>H+#+V_@U+E#A/^.O-Q?WMJW%%8BG;NK
MQ"<'=9\\1`6%0)XXLHFNS.1LA)-GX/L+[-XLN'C1%@YP*+M?+NY2H26C3E^F
M25'LRM>=3\9]PPK6LR9[('6MF$;?."JY@3Q]YWYV[*XVM@<<KVL(>\V6B_G0
MWF$@J6#;M"'@U!#450[J-D2IFK3:4MS!?-^\;$#+2(#FL\CEXOLP["$:]D1F
M:$!<XBU$H'"$'9B;(GW"[9OC+4#C.QAK,:Z+((JKW2).8?;&>LP$ZS$OHJ.E
M;1-V=4W)BV(&VIHW@LV/6-X>8WDUIXI:0$]+)S]B!BV)&;0;LR29:4\^I.[3
M(-N3U+/2#]B=;'(8-)E!YGU)-9K(>PV>61Q:M()X4B&XJ--`L3G"V#9?6"W"
MLD=?^#,+1$*R.T(1=8A(,!71+?Q'/D&4_!FB);(R,8^X*^@`#8Y]D<5K-7LR
M*L<N-I0>D0DE8^(@P-4)'^2)4`NTYXB<@"#[%1A6W[KO5_7U!Q9!L(D/QNI8
M.512.<-MS"94!U0D^Q0/IS?2V@BJ3$SK,%WG%UT.L0>?N<],T"E%=L$HS5XR
MMYZE&PZ<3#,2K)\#;O+'BCW![IERS3SP+MF*TI@X4P]&:NNF>RRCR`@8&S31
M[`\IE3OFC)63OJ8FUHW,CA%=B/FO)Z+S%U`/_O'_4$L#!!0````(`$DP!D>,
M^8]EDTX``/@@!``5`!P`;FMT<BTR,#$U,#8S,%]L86(N>&UL550)``.J,,-5
MJC##575X"P`!!"4.```$.0$``-1=;7/;.)+^OE7['W#>JZM)E62+%/7FF\R6
M8CMSWO7$+MLS.[NIJQ1-0C(O%*D%*<6:7W\`2(H@19"@1`+,5NW$<8#N?IK]
M--Z!'__ZMG+!%J+`\;WW9]KYX`Q`S_)MQUN^/_OUJ3]_NKJ]/?OK3W_^TX__
MT>^#QT=P[7L>=%VX`[];T(7(#"%X-M]\SU_MP)WY`MT`W#G>UQ<S@#U`_FL#
MWP._?WB\`_JY!L!K&*XO+RZ^??MVCI"=2#NW_-4%Z/<33;]%-EV"\;FNGQO,
MOSSZ&\^^!.ROKA`T0UP:V-B:2Z`/M%%_,.T/1L^#\>5H>#F8_(LM[:]WR%F^
MAN`'ZQTN/!CU<8TA>#Q_/&?@_1=X\KT`EUZM36\'YJX+'DFM`#S"`*(MM,]C
MH6X,%V!G>L'[,P;AVPMRSWVTO,!JAA=)P;,__PE$A2_?`B=3X=LP*:Y=_/[+
MW9/U"E=FW_&"T/2L3$4BK*BJ-IO-+NB_1J4#YS*@4NY\BWI)P$#`+4'^UD^*
M]<FO^IK>'VKG;X%]]A-1^"/R7?@(%X#:<!GNUO#]6>"LUBX\BW_WBN"BV`H7
MH0M2_\*#2_PM;:)A1C1H8Z+A+_&O:9R=`5+RU\=;+J!91E94Z2(RTB5_(7&:
M,1.^A="SH9T82JJ7N(M*IYZF0HE8W\H(=(G/?50(G,I:F,$+%;@)^DO37%^0
MX+V`;A@DO^E'X:S%3OY+_.LO<\O"3`B#!W-GOKCP:H,0],)$$\7W_JRB\,7>
M;E(\8SF"@;]!%JSEBNBSU+#@B_M"*JQ<7)RD'.CU?WTZ`X[]_LRQOXRUZ6@\
MFG[1QL9X.#"^:%^TLY\202"6U`.QK!\C_<U""G$>@G<MX](SN-:1I"(X<Y0-
M+Q-9B5GXQPH\<8D+R\>99!WV,U]K@?Q59;@DNGTA^!<*2?$(+>ALB46?8"A&
MC<(J"@A29(=P.,UT8Y:C22JO![#$CM#E=)19TB`&I0<+P<DF3UD,%E&(ZY)Z
M1/*^AHC28X!S2]1HXM\0+6@#[2M<TK%,]QDYIGOSMH9>`(/<MZHNWS`M;-_:
MK#!:VCVI:XQ@U$RTV7@R_C*,HX:(`U8L#X1$(("QQ/-6J%'$_8;!:2RX1!Z@
M`D$B42[M&P:H"WP]%=079ACAO9A/%+6>F]7&)9WE^_`5(C+V0?`5&^5LX2T>
M%Z[@G1\$.#W=+_"8CY_B:TF1V\;6,4VX09J,A\,]^Q(-@*H`&1T@4@)^(&K>
MT089^`LR@%;6'+?G$#WO$)\ZQ,HXQ,7B%;?6Q\1\K@&O[40E]+9MA[2PIOM@
M.O:M=V6NG=!TL;DKWWL*?>LK+TJJ*\HD<:4UPF%JC*:3F+=[H8!(!8X'8KD]
M$$D&5+0BFC8,F3(S%D*@PC<+!@')1&L3@:WI;M0./X4#-4-#,2>I8=[_;8*0
M='&#9Q_W\[$+'-K-3[/#LW]E!J\/R-\Z-K0_['X-(,9POR8SK(ZWG%NAL\7P
M8#!_"4)D6MSA;!NJI+*[>?M%R3$T=$-/\L'>#!#Z8&\(;;$SC3CY9V(/2`P"
M+SOP`[$),^L=V)L%4KO`Y\2R_U653U0[62]P,MH[&8_@:<>`_);\;!'_KEG_
M;A+_^GO_FGN3+M4FK_:XGDUW+7U#)0G2I<*A_?1J(OB!K!J17A3N0M$Y@7AD
MQ(MFL<HRDYB01:*,&0T&VB!.2XE@0"7WH_4U5G8RT%>46%H`3E,%;;]CN!8C
M42G3:P5MAKOB;CJ>C0&TSI?^]L*&#B&B07X@_#,8_N%??9GC'&*3//+1-9>Y
M[WKX[Q)8=*!4N&G!;4LR#D_J`R)`+AE.M%\7L[_M*.>&!@GD8HC-3%2OEM##
M;=@O</4"4<ZU126D3T9GU(M.8(X'^L2(IY^)`-*)E#W1?(+A6L9P\#F2(;G[
M>C(*?8^B1_U?BD/.I'%AM*?3Q(=@E73/O-"Q'7>#^XOP"5H;1'N--V^6N\$=
MRX\8#FF^-A%G[A<W)O)P_S)X@(@V</,56>#B=1D:D2VS<]>$P>*CI?%X&K./
MT0M2Q2#1#$A8`48WF<])M`.L/NHS]D!D@:(.HGSG4=+_`Y*]6]A)YA:/?I80
M4"/PWX/4D3#CR*3`?BR*ATT@($8H[7,VR<1,E[2Q#_,=)J@[QX.W(5SE5\(;
M%__]I*F]S<)D&X]'1J.9"GPF1@!JA:J),B5.U&4Z\3O)7`<4;3!Y93^3DOR%
M$(X+2&?SYI[]R??,]#?/^*>`S&[Z7E`X*CI6BLQL5,\T8;[H^']QTF$T`-.S
M`=;19Y0`5@OX?.VO3,=3E5;:](;>K#>DY8?C*)!)`T>X50G;@P"&MZNUZ2!B
MV17.0<N#77@5A65RM]`"X4E<31LE%"6"0"H)Q*(4D;`!6'H*RTEA67Q8TMA4
M&F(9TO#=H(P;I5R0'_O"06%,IY,A$^LM1;8?FFYE9-<T>DR,?B:2@<DU76KT
M\J-5=716;<'(%I(>K;57Y,?IM@<J0/W^A!-P1"GYZ>GF^4E]")<NX!^"5!?2
M%6=D,F6D!W3-\R%DV=A@X[GE,R]BZ?@H$$Q6MJ+ZG<G.92=:#@`K#VRAE)TO
MJRK0ZR8^8S@;%0=\1S+Y2;BBS:J9Z%>[P:LLKK@T."'/\Q;*B<!_00]:YORE
M9+6\H)CT)?-#&P1C8*H9X]$L7C=/I8#Y!]F+YZ="T/800(+A1>DZ^JF`],-O
MTH'U=#XITD5U#G(EC=36=%QRYO.CCYY,EYF]YB54?@69S177"O%1YW"_L)T(
MZR]\U`^P.&:]0U&SU1`^G8//\;8PWKRKM"FKC+Y,>U;NE&[1IV)`4UFO$V2J
M?3!^K(MP2O4=`,WBC?8'O_HH[&/5J^YSJVSD).2:;C'M9^0'P2,T7></:/]L
M.EY`SA[`@)1Z0+X%H5V_,1,2V@F.BE@J?FY6FXR$"$RU@D0MH'JC`TF0G"LF
MRD&BO6LL;]YCO&8V8#P6^*[=S7Q0AT!BR4+8PTHRR3<3V<]8R_S-X2:&3!F9
M/&<5"P>A/ADEM"7U`1$`/A,1JJ9=CH>A"\.0QIRB@,D0X0"MBKC^8+KDCKZG
M5PC#Y*Z]DA#G%I<8[3P;A%=<IGIR@#X6!:@LD`A32H)FT.E'H9/%C:J@8VE2
MZH^N,";:B53CB\85%+,FLD(XLB;3Z;"<-TKWIS6%L)0['=AS5AV`5?QAO-+(
MI/X'\\UT0Y,_G9\M('LB/Z-=,!9FDXD^&493^'']=N>]N7/X)UBO2;.^?-;^
M!`BZ*`0I$_6%@;Z?HC^$V1"[=A#]#QX7A:\6V??MEIPRY9:5S[EB0T17:X;&
M;&8D],.B0"H+W-U=25Y':P:-5HS&57HRM1EH.N]#=8&SY?1AZ%OBB::8_!%_
MOGL//CEO'YTM)/_'?YNOG*^FY7BWWJOIPE)VB]=7P'AAXT0/0$\,8SR*L\#\
MGX;6'X]&&O@A$0DBF>_D9X.6D"89`A#Y`(L$6`,@XJ/_D-_DP"O.'2TY0J_Z
MY)W(*[7)S.::>IY3,=*-[Z*[@V8`[U]<9TFYSYL:XI66.,;EF"`\E3C2AEK$
MP>2:02H*,++4#&T;`9:Y/]&EP/QR8+)&M!6!Q@YGRSS1(8Z4+^175%+/F+I+
MVI.I,:D@CN+E^R:!EA.IM]_TO/:1ZMN^Q,)3@&"J5_(Y9GW"+CB&:DP]]6Q+
MC:D3A]-*PJ5R.\6Y8^%6T<XEMP%WGWN'(2M`OYS/U#`P>)U[-OGCYM\;9XO[
MIU[EJ;**2E*Y5V9)C<W]XWU+%[S20^KT!T:F\N,+34+53X$JCVDBH9FE6:6+
M.L2Q\,I$:.=XR]_()>?UOGJNKGK&90VJ<7)]/*@@7@^8(4BD@]]X%\*?#'H-
MD>/;-YY]!`E/06]DT-/KI2'#10P>XM^3^_"I@2UB?PI-%$I&/ZI$_P*7CD?N
MR&G9!\<FX%/0ZZ7H.YA\BW.60`XN\%)W4O$#C:I;ST*D@W8-HS]KA0%'A/+$
M7&Q7C?L8IGIE?HYT@$0)^"%1\T[-(>?V/$'/0)-G%YP]5CO!2AXOL;X?*I?'
M?#6C2]S9R*I:K/4V/4%QZ_UBHJ\P)-N,T_W%=YS[$H\4(GM]K;:%HBLNQDQ+
M#JONJ<MH(=&:ZF$O]6O]ID/N"ES+OM`ZZ(ORE;B6':(W[Q`I:W1'IX;]0MUQ
MCI6:UY[)7T\)BDA`5_,9M4YTT]A@.IF,CLIE5$U'T]@1+C@FA;7H@F:RUQ%^
M."9S\?W0J:25X7WMA)7ZLLED]8B5(L<*(>T$EGSK7$%%R2=KA?"6MYDV-9@D
M@P6!5!(=]BC)(Z>@T:2C$4H)IT#:4[]'!F'NQB8S0RA%9G&0R21Y,5_R9"[P
M0F.DS<K.3\9X=OZ\)I-8>-_M%)$J$L$)]HHV1K@Y&C`IHY=G6*]@LH00<:\:
M8-W1`>G;\IL"VLTRTERE?0^NJDYATOR5[><XV7[.*NWGI(?+Y<ZXR?<(>POA
MJ7Z1UB0TD(TSC<>IWE8R\PY1Z"P<\M1@<+^XAFL_<,+2)P3*:LB<5^>;(3QY
M/!A/DRVHC#2RH!7+4[3?NW&,^K$8I4V&5X=A9NZ[PC%*F.2[&*!/'L[=0N:=
M@6LGL%P_V"#X#-_"#R[S-GG^<]>0()-IXF;5N(=Y.HZ9QTH'C'B0R@>?B09`
M5:BB8EM.H-2\<RSRG&NTD)=J\CTP7R((E=]4=41L9^A:TWEJZ+M:.6'R,,B5
M[Y'WKZ%G\>]9+*LAE9Y<,X0;B?$L>8"#D19'(R-/%?4:`J@7`;2J`,KC6&4`
M9CE5[I6.<2BE>M4FUEHRNL&S0\-J=,]F$P'F91I#U3M>VW-$(4./=$0'>,L/
M>D$F<_S966Y7]W!K">D:NVMW\0PM/>0H'-4=Z.NVYXMJAG>>RQ5=W=J^4\5F
MWWL*L0T/)KI'3R$>2MMT$VCRY&5)<%35E,S;"G/$+Z0:S)A>,!Y\4;$]@`4#
M,LM-14=;W=/74]51M%'8.@,[B&"O,>PM;U^_3$8*!FJ>AB+^4<P]:D@PWX2O
M/B(7L59_[8,::KB6-T,XV(9&<@]JEF.10)!*5,ZKTR`6\"F(()JE$!7PBA>$
M'#X5^J43/+H-@HTXA^+2*OD3F2#>@9I-)GSN]$`DKB/$.08;GS0.%YHRPF2C
MK90LC"\Z093[31B$N..-NZ:BGY.MHI(RC!W""7F$1QYEO&%D=H0\1Z/D,\@O
M!ZF,1@6Q6,JEO&L4$ZKTD'"^F!KBU#H`:8RGQKB(+%1*9]J8(S`54.,_!^>#
MP4!+1SH],!P,>OAW3"_MOX$VU'M8V+X#Y]GX5UI/U\;9YHG^"\,S<DSV;QL/
M8J$]0$*)%KB&%EVH!E@$^:W1(_LDU]`BBV/NKB/DY!\D+?H(BDBX1O`5>@'V
MVZUG^2OX"8;WBV?SC1\_W!IRJ<DSHTY$I\.H5!J(Q$7/O+SK`7(FTE\`++D'
MYF&(G)=-M`,K],FLAKK+:IIR@7[H`A=#5TRBJKC,\:G4%<WL/?:Q>!M&>PH>
M<0+"NNR//GI`OKVQPFOHXE^@@[%3O;K2=Q,+&B9\^FZJ:<EQ)E8T3L^1;+#P
M$5A'TH&=B)=\'VH[J+5#U(\LZE@ZV(M7L<6W%>1ZW>]-]K)BA@W5;5VM2>9T
MCVH=!ZIITKW`=QV;&OB`?[)VU2N*)56D-NI\.\1?DQGJ@Y2*>W$]$`D$G^,_
M.[!"V!3:^"[SP*%;4A^PM4G*IYWE!^1XEK-VHQVK&;5JV_CJ0,TV\A7^4L2V
M:'$RS"2&#[O\0UJ''[^BGES>E1M38S?F+&T'8YD@VS"\[-2_V]8P8/U$P!(9
M)Q:L.=H)^*I#W"-VE3YO55U//?=28^HL05=Q+XI#I6]>-8RWG'J5>!4S[S!4
M!9B7<U538]M8U8.YHQMOHJXMF>?`'0MHWWO7<`M=?TW^\6;+/4Q[C!P%8][:
M1HH>Y#:,T4S;CW^3J%S'>N)1$9T]>B&:``Y2.]4%(%4F?S3<LC_R62G1`U)%
M@&H"]QY@=(%(F9IQ<LL^R6>NFC&"BRTW+B'XCDQ$OD"PWJ#]!+KEKW!_G^RT
MPEUFZ.Y()\0/7S%DE2/NHU,,._H^[K,TE"71FAS`@63^'B++,=T'<PT1__VC
MBAKR,U^9.:(M[T33IL,DQ\4"02H14)&*WAYL$J&F$F%5>FH.IGX"3$F90X1V
M3(ZH](V:T4ILUC5\"=-;C<J/B9?6D3I**3&DQJ:^L9%G%1&8N<M*[6'QYG#F
M:/7)#^-E[P^^9Y?CE#<J$0C)[(BDRCUJF!6$]XN??=\.GGR7OW<Q6THJ>S*J
MA>_1'LP&R9LI6`*9O*4R`!&BBA\G(-%9)$N*).`@D<>`PM#)QOPA9'513JX\
MJ6HS\N6D1SJCO,Y"AI:-=2I%>7MP$AZ]F+L=2?Z<>#H,_CQ^5>%/3H/=O*W)
M+0_\=95<,<G!S^H6WH4STR=&&OM1+R$1HNB:^9.@,!=9^6LZ:^DM@;6'!DN@
MR8S^HG#*!_^!$[H0^Y6G_SG%%7*A[E'VX<Q(5S/RG.C`Z?TFT-'6X;Z$()==
M8DCYZ?L2?QS/F`!:YTM_>V%#AY#%(#\0CA@,1_"OOL1//7YT`LMT_PE-=./9
MUWB4DOMZI44E<*-,OWB_8C),9J;BAP,C68`(`S=D;S06)Y<6S0'3CP'6-B-$
M0HRPH=(-*MH.,E*_]3`=Z<SPK8<_(@S"1VQ2=)SW`>(H\$)SR3N`44.`Q/9%
MW"KQG+Q_#XC.2:72>R"1#XB"7G*(/=6AIA5JRP>4A$_0<WP4W3**L7ID^HI<
M2QT[`BGBXO%AS;97-3VGGK>_F"&9:]L5M&H"%93QDK5"_`S>=#;C\#"1IZ"-
M:QI@"<E6"4J[4R0KBD$^J0X\T\@*;*0CN?&7U7$-`PLY:][*IUA%V>NQ0E:)
M;L6?3/51O"Q+B9->'9V-*&"GLB7O-&D!+YLH]G@S>0(PLA4LU;:`F>:.?T!G
M^4JZ(>86CR"7,/W(V)X5/79A$[>D]X0S$:%L+;<6@?=+NN(^;"7+O#FKS2K1
M&CT.*/*EBZJISC`%-HEN6QH-!P8WOU"Y:0A&;]DJSBXG8^7DE@CK/L<\*'BW
MMQV\-*_\DO^6WU,Z*6$J-YGPW*:FU[^`"'<%'\DF/^Z="/E24OOW&=7"ZP*C
MT6"4\"F2`&(1JKKQ)^#0,S@0'X>\CGIAV&1[YX>`.Q#AS$7FT8F2HK<AZ]55
MQX9B@\0/-,R&'(ZP5_KWT@-%*IX_;!&ZW@AT19PK#^02)I9XKEO\O..\1EVG
M9B>X>5?S26$Z+3JI9J;")Y5;`UW)2>7/)A\1N&)LO#OA@>2VN5AQNEB@8B>8
M6/>XK8&#<BQ`1.4'C)N&7$W#CAPQ%@]9,1(J/V1<;EKI.6.AJIWA8;W3M\9`
MGV@<)JH]8-P\RF+R=>%8<9W@%.?;T8>+6V%<O*-"[&LGA=6Q*K9`_`8VG=>B
M]4`LJQ,\.@I7X41)#UCQ!I^UCU1?0E,>;"6<8?W1`99\PE#K$(4IKXXKJ1$U
M+BP<<D9B/9"*ZP1CCD7'(8T+@Z##S#D,P!+RY%RCAC]K!"V'+IR19X57Q*-_
M%*VCB=20RB&N&<+'L31MLF=1*JU'7K-UX?[>,%8T95=\C9_T=?3&H>MYZ!2O
MR<A3RZS*T,QRJ]PK2MBU?Z;I?D$N9X5>$%^8Z)+]=72_.+V*G-YPD=SE4'&N
MX42A,CEZDJ4U1B?)NX?,TV?TBK]4)8AU`JHTOJ^_'UTLLK^&1?5Y"IG^TEOW
ME[0\T0C),JGD]._0Z6SS@36[ZE;44Z5V,=\4FRI,('TZ'#>3<)3?OBK59=%F
M7W+=?S^ZYHK5^%VDD'+F')5#2AS;S"Z^>&\<.9?FA4ZXN_46/EI%_:3BGH9X
M/>G[^`2,$HW)\7@ZT^.-?+'8Z-@A%0R<5++L#7R-@]0R(.?D#&D$DI&LK/?3
M$F;]=,QR]N[5X&>Z>4_47>V?.DU,B<[Z11L'/^+?Y1=ER\M*.G?*-4!X.X`V
MTL8Y/L4'-"-I@(J3?_"T(63Z,<ADG#RM#+/DZ&FY(V3S@9Q]%6-#6E()%_;J
MQ:_WTH:#8B;0H\J=X,&1J`I94(Y*/@<.0JN8`5D7R(O_B'G\*PB*RTF._8QR
M\<',8#C+17Z<(M5=/-``(KTN(IDQ7QA.^8@_!"\OWLF6@9+O0O]9<G03G<*)
MSY@8^8$"J:\NDNM;KPM9+S-JV:#(!^L>GXJYPAL3>8ZW#)(7["O6'+C%)<[N
M\6P0;]IG6KQ.D(@B22Z:F5,^]]\,.OTH=+*FV:J"CIT_*_5'%QA#'IJR\/C[
MVG$W(?>I^*I:"OF3,T4\U0[U&8]&/4"E1H_31G*[0:>3P.X?%HN`V9$,X,&0
MOA!*COE&K_=VB5R<^"SC6)&3ND"UJB4J?GF%]*J_1F(,DGN.BS*X\J6BA@!2
M,I''A,F[PBG`+E&G=&&GW`U*Z+)81"]^1T_^/IMOC_3:?_)&R`:;&M^MZ'N\
M<S(U!,@DE+!5-0)0BZ>L]L*39ZZQ>'JM&7F+!T>,XR:;P>)+L!1QKB4?Z%D?
M.)$/0NP#U3>:U0_F##GK^4L=6^\7-V_6*SEN0`R\]Z[,X!6WO.2/FW]OG*WI
MPL.WQ8X2(9VQ8G:)WYD_&F8X2S9:)`HBQOH>(,)IWXS^P*A12=LV'*%G'0$3
M1Q#:!L035N()^@,L]X1<4M>+^4-:U_"G$F*OUJZ_@S#>X7'GF"^X%2%7Q)2?
MW:FN)Y/"5<:(MS.S03+;$LOLHWA+%"-5\>F>AN%2=LXM"Y$'Z*R.;&X2CLL,
MXX0<HY)F3Q!M'0NF>ZC8759SEUJ`?[I?D`[=TG/^H/>9.GZT]>JNXA:'IK4H
MH'!#IHM?E##2XGDA=J]C9D\D>U+[95>T)Q+,OYG([F6KT:=#U-\JH=2QNC+'
MRLY3#1.[**LU^065YD"RE_:>7OM8^A@2O[R*O)0WHL82AS[*=BD`%08B:8H?
M26H(7[I).H;5C4?R*D.ND&>%KFA_33[:$WF%TQXRW5O/AF]_A[N"I>;B<I)6
MZ0N5UUCP3F[]C;>UQH(`E02P*/DK]PT@TNLBDK&:7QI.R;(^'[RT>/=7*]^C
MG*,M6W"_^?_VOJVY;219\Z_4PVYT.X+N0X+W>9-ENT=G;$DKJ^?L;#],P&21
MPC8)\`"@W)Q?OW7#'044P$)E:6+C3)RV)"!OR"_KEI491['K;SU_+_]:32^9
M14*#).I%Y>?S11$6C"H?)\0MG`CE*(.A1)NVSI7:&D20@H.6X-1F)5/8JJUP
M5/FS4;QTK>$SG4P*R("I3W2=_(ZB_.9\NEI=J%9#4W[ZV3O@\-:-\3X(Y3.>
MXE-&O;;`NDN@6Q:<EY%!"1TH%[Y"&:>3,N;\N=:!BFY=U=J4=S_AO4?3P/SX
MWCW69=O6/F;4OXN\U?=X)O-YP<$S.H@2@O+P:]1QNJECSL?KW:CHY#6*:[F.
M^RF*O2/=4K_Q_3-=*&1-MQ[\I^#B'N)+LMM>#N`]")B^H-M).M5V+RMGF;3<
M2.DCSJ#8DPX]^$@P20^9AAD<ZH+`T`:8V&2`YNN\`UJ!G[%QW<'[\/6'='J5
MM[NI0':<SV%PPJ[_F]^ZUUSSI,E=YBI[Y5'+F2;=.1(JB)&!WEB^5B6GHTK&
M]I3E3E7839;H#X&#SZX7_MT]G/%-%&'6[#EW-/X5N[3@QY;@EK8'"CU_3QZX
M#_PP^9%F6+>>/>OE81![6@7O<&-W+A+$*'_$!!@A+@++A,H)@1(I$*O0(QBS
MI_*2L%L,D05'SH`6=2`L:BKR#`+C?,S2_^'>:K1KZF2DC_X;BW+=V@*1_YN4
M(UR".U8V:M2$/-#^2$#&<@8PUEN*3=*N2WJ_AP4QZ0M^Q8?)<\#^ZSR'KA_M
MB%/>'(.S-..V$PFXR-(HEWJKOEG2M*DZF(\0HXTF*`[$/QV4,AHASLJ*R*'1
M&"PXY!0_",7CA*A%Z%=R[P:`MYO-%@P[0LA)?PQ+20!C6"97%[==M6'8R3`\
ML1G#>HR1P["387AB+X;;W+L-PXUFLP##-7,'/EEHN;O=F0P<EEME4R^UMTY2
MY6L6V/4+:K%^9G,O!'X7?%C+,'`_!F&\"PY>P"HK)[?:LH[5M/$V^NJ&?^"8
MV>1;VI';(N@KHZ(!_FK&!0T!'R[I/__JX9#8Z^7"HE5#<T;%ER'@WBA1AWS6
M1<V^9$H0M#'C$*I6-@Q55#6.2R57K45CNZE`,9@5'&]K(-+X"@3>:N3H4%@^
MR8//;??D"((7]M*G97E32UU+XRAK<,9:;,EL8PNBE&>QM>\`8ZK[+&PY3VI!
MRMS-GAGH]8HR7+V]&6:3>[:!S**YXYU_.B?[5(V))4UO0""L*H9Z,VMG5CG0
M&2%.,-N3A<TZT:9G>=C*IH4JBAJ'E=P?:T$EL8XMD'(Z0\JQ`U).QT2G96T6
M2!%2CH60ZJ5G&Z2:%86$E-,-4HZ%D)IVAM34#DA-.[H:6=77G!P6(36U$%*]
M],P=*#3K!(F>:3?T3&U!3S[]HKJ)4GNWLA\-"(2I"*8>WM?K>67EE=M(`[FS
M:4!E^8@&><WS*D>N1:>RY4#PZOFNO_'H)80H#L]<R.1W_##B@TN^)JV<@W'\
M:QB<3[04;MM^X[5D3:+Z2ED[7&>>)D?Z"7F4XSE"V:^3<W[!&#'.*&4-O\-I
MU&:.`9L9BRN:`%<(-3J^AI:KCI^#5R^*W=KI<LT#IJ\J%K@K5V%=3,8+?A51
MO&^X.>@54D]R4@--VZ]5P5%5P<C%OUH'3R_V5=6$&--_Q3Z97!QN_.W-]NCY
M[$XS+9#]Z4]:\$Z6F-_VEL$1N444]?+)SEI`0%!DN_U%FD@0A1E'M6KJE#5U
M"S0A1SU%E\P/:BJFL1!=C3M%:N_:@[2.NRKK]6REBC?@3:0!%*_`KX?BEN!1
MON>D;C<0;`;!]H=WD'[TY,\F$29XJH?R]309M,2K0`CI);C3)K@Q#R^Y0L&)
M\ZII6??\%1^#TPOM("-?^E2>,;WZ*0N@6H1C,E_/UWP!E)$PO`:Z3O9)47;(
ME=!UBO"V=#?_&ZWF<_1S1NL=_,I(!H%T<52K.<0HP1L%T5YDGXGX=9V"/N!=
M$&8-A7#TZ4\RS@7AUO/=\,(N:-\3<Y`WB6F(?/NDA(LDE@[)T>!8-J`:RAN"
MR_%TQO$LNGC]3.5YAZ@GHDPDE,F$OC.A<EV_:`^2@F"\/,$(%65+ZRP-$R:"
MV#TT#<#66'O!SDEIZSYAR5-(]SEH21GR8ZZ3&&R6G`%8YR<10W\>N,CXC4PA
MV'%5RR&/[&GC$:DB@OK=HWF2[R"B0TH*_(A%BVI.#]7,XE7J;%6LU=O"`IQ\
M$<U#&JX^-;T!AY>\&!WZ(Z]G$LPD]$`O.FG3L1X\"CH"(:C.#1M05#&,14AJ
MS`]J?@<>31V38>;K]:H53Z!)0!KU;,.4!9D_2BZI@"O@S)YTWBFV9C]@'^^\
MYKE<]6GC:*J(H+Q668V3&Q:Y_L[)IOO/@MH[2`1=J1N_(V_QVDOJ;%6TU)L"
M%">/P<';7-JN_4D?AT!*288.#<%7JS)41HA30[^+_X+?]].CIE-4TQ*<2)RM
M%BAUZ@,A)<1NA#]B_M\[_V:SH05IHD?WTE#RL?T]L]AI%D;YO&LR7LY3$#%:
MZ.>$ZCMZCS0AC`1E,!3I5#CI=\PU.\DU,P@I-:\L84O!*':![`EOL/?:"V>Y
M5ZV`6B:/>@FPM'Y2&]HRXGH!M^8:^WC/VF.;57Q6@%V8DADA']>>3\##K^JO
M:@@LV4C+^7PM-]JR_9:\ZVW<PW/HN0<Q(RWOX?6A8/ILOYMXRH?.T_%TR4_^
MTQ;W@AZ**4&$!47#Z0!#JEL,,@D'=,="#+-!P@0Q+LD:LW9B.7`VP9!V<!0^
M.UBV03]`I[D(/>QFQV3@(][A,,3;)_R*_;/Z3*#\'N@TH"2,^B[(8C5IG`,D
MA)&@;,N,^RJ%&0Y3S4*Y9G!#OL0KF\?[.J/8`;*DE_D3/K"I7E8N7?F+-Y``
MA9Y<+F6G7"\6Y4&RB,*$!Q),\KU#;$&D+CL4!\G@2`<,-DFS"Z#M'MV,U19S
MV0%;6L;+)]RZX#3_#B@P<X)T*(N=%,"1(#%'U)ZU<']-9UQ5_CI(T]Q.SM<,
MJ;(9[,"0R%[S][?NR8O=0WL*F"H!4'3)I.I0I'K1O/V4<D""A0T)9(-8@==.
M?"%/8E8N,4@U=[-V88=LA/B+74!M\_!FU#::T!((QR\X%%.2/E-7V?NP`*X7
M2GTEM1HW+QT9@W2'Q\(9JQ8+,.QR55VA*N163F\G;@%I@ZDLPF@:2WB)CFZ>
M4'X9'ITEB;K,[52@F0VPG+X]$UH-VL]RN)1J!XQ&B;LJ0+'.-C;BL/=H64O!
M(D3VVMY8KINW><JPM'7,O-X*N5'ST*RD+1#M-V1*+370&6S](4;+P_`GJ]UV
M\5?+R6PZX8>HM:>*0YY5=#A`[:65_*P4Y`1&IVH,]$]X>]ZPS/1@!WGTH@:@
MAN--^$.6+3[ZWL[CN?&_GMW0]6/<7"ZGY26C`VR3).K7BE;C=!>I0!#=[$,L
M+N>!UL71J:A3I^C#]X.W%Y<]+"B$H^:7Q;&SU4(P`.-WAYN+O)6?,@JA`FOU
M&=AX-DTPPRD,4[*MRPKP&DUF!56P7!5S$*CUG*+/5S6&=/)'U]NV?!SV"(![
M4[[J%Q3660JY<`CZ/E3H[ZM!UDWI1-X5%Y/DI3-,.W;>6^J\.E48UJ59WOGM
M.0RQM`.VY&$0-\]+H%Y/9+&:51S^PA.9!2UHY^^OEU/0RXJK$4V^50^%BOHP
MH!!G_%G_LM:#:/D;1N$A%:-#R?-5.B@(:KE&?!8<*VM2T>FIHCGTM#IA$4+-
M=K$$1^WW6QM>@452]UZ/ZWDSE"RXXJI+2\>BW*AVIVL!C@UW7850GVF1VQ>\
MI35#HWL</^R><(3#UX8CHO8W(7`D%T=]`;N>EN'$&G`PNH@1'B%"FFZ6)L2!
M<:5+ZZ0%"5=U3ZE9@;%V]ZR%6HM90!%'Q&G[JO01"`P1ONIN,\DNJZ1@N:^_
MK&D0$)U5:!]8KI>^O11F7^E9[<IG2A]Y5@V..2^O16BB*2@4G]P?7UWB6YY[
MZ#;VR5^$@*U4&O72![/EM`)F0A:E=&T;^#3IS$]!B:+'A)@5Z&EUS%I,-=L$
M%&G_%81_W/F/8;#!43>H-;P)@36Y.!V*72UF%;!1NC3K2%"V#6ZZU&9XH\3>
M>_[[$R=G!>+:';06<BUV@<)<%!?;<69+SX8/W?"28:3))5&/[LO)(@.9($A6
M<UD_UHPH'+9T*>J4%*61Y.B&?^"8;G>C"&_.H05)?2J.6899BXE@$?9,6#56
M1:X\"(*DA+MRK)XN)],R>A"E`ESY^#J%G&X*F<=%V9WJL5!0'M[_;\F4<Q^$
MWK]8OE!+PEOKBV#XJ)-&O?:OXXPKHPUX56.]ZE7&&#N*&:NZHAQ+4M/TQQ89
M<'_9!Z__L<4>A=6,_H.B:99#$_G5/[_@O7OXY,=>?*D91NJ>,("/&K;*GC*=
M+T4&**.`.`F04>-J-9P.:@SM[PW.0AU;IBO$Z-!^RPCH%E&?^S&+1=(,8O#K
M/VV;Q+W%S^T16W*]I^7ZC@UW6G,RW/C;;W&P^>,E.&Q)L/GTWV<"L?:/5/\:
MC+_7RM+%B^85$+`R")P0.!XTJ%</$J9DE"/]$\)2E0'0T^B:$DC)C64CSEKR
MXI1?MPAWG<N2+%;.H@E_X#ESPVC,YU]W-Q_NOMP]WWWZAF[N/Z)OSP^W?_OK
MPY>/GYZ^_80^_:_?[I[_83,8FU+J.ID-&)S-B=LU#\(`KG-B\VPQK4!KX%SM
M#@-;+W5R0]F&OV_AO*\A65NBOQT`4!^/RB^``J)S!%X[SEH.#)M&G*LTY%=[
MJB@!+>K5[G7-<+EBW)#4-LCQ>`X>W3#VR0?Z'(0?O1!OXMO`C\Y''-YL7W$8
M>Y'G[Q_="]LD+'V^*XF9KHW06U+5J_CCZ7HL6L\GO"XH#M#-_V&WS#X^WR(W
MHT[OW##RAJO1&S)#98;['*"$&_I,S<'XH80ARG%$"4N`@@R&S.-T]1*P0@Y7
M1XNTT,-UIM4:^BZB-O!S\,T]X(?=YW-\#O%3<'$/5+POGH]9R^LF#U&F`17H
M5`54[;0P7ZW&JW)\2\IF$P^F7&B6$^>#4D;H=\J*MZT?9H;1&NR&,<7$0E.H
M1;=A[.'HMX?1$-<U*E0B6R>SF@QHS>TBKZ%D:7#KUX5QO5RMIDXYQ(69'T?"
MCW?<C\.$'=`<;D@C2(+;LP#S0QV8H9MQ&C-.]TAG>W!KZ/%YK55-!KKGFI:#
MW=^W-*@]=^C%MUJLIHMIK]D:8V/G1*V'!?I,T@:T@);8U<,,?>9F<C/8%+F>
MRUT;^UERT"CU&,0$_YY[*+&_#_SZLYAKJ=D2P=I%5=WB7<^=R4(6SW*SDI1C
MU:$)TT$/@SI'-]W6:9^S`5JG7^33;2*G\]S>NOBG'DQ:HZ&B=4%B8Z_5:CLQ
MVR-CUQ7)<N8LUBIKUE,*?4M7KYHM<E4PA*NV8])$_P;+6.7HT3L6#K*8W=#2
MI#?^]C8X$(V#D(6/M*YR)$E,Z/BR^5"G*)GJ9LM\.9\LD]#&:+-$N4V>.G)3
M\L;CV"#J3O+J$N*H0#TKOAV!Y6T,J;VC27M#0:DCCG-!J(OUS`2=EE-/Y;>M
M"SM=C[-6R^5RY;S=N--3WPZ!!_H4<Q@#=(@]=AQ;=@6T>O@9Y*BRA6?#WKW2
MF];%G4[;M./5;#I]NS&GAZX=X@W@AKQ^O3N$&?`=^"Z058\NVG?=&;\",]8C
MK*%G5^L[0-%$*I#J-'JZ&J_G/(Z(-Q%V0Y\LZ[?GD&84$IKHA$,OV/)=(O:[
M@`0:/_*V6#AAB#?8>R4O46\@@2A@#>5.;AA?6)HB)1)Z^Y>8OGJ.\`A]/\>(
M/(:"'_X(;7`8NQYK1$6?Q.PB\T^TDDU,A/=H&1O>.O*7I/<6.KH7*@-_C0RN
MA,DQ"'%"8D?L$OR@LN(#=Z*_H/.)2.?':(=I-CM]F<Z8B>P1T7CS,D)'[X"C
MF%)+TBC)[US_O"./<6.P*X'GT^EP&67[82/1%9HCE%*'B;::?*$09XNQAO<)
MA&M_IE?1?&`=E4=.\D6Y$T-W1E.-5N5PVFPDD`LU@;]_QN'Q(_XNO4*3?\3D
MI9D<7_7VMHMU,BLAK[\GKGM$E`#0K9C>*CA%%;82%8S=@*EQD\*=E[*B4+X<
M"R%:"H'5/FK8M\O\U6MG39UYG8^/X"N"7:^7TT,ODRB0.5@9#;56L`$5O$B4
MXO<3#P,B@TN@WNEE-FG$!F@%,!VZ->##@O)?S<[6A)&<+6!0$D6W9/5!%A38
MWY`%Q(?+O4O/$!]VV:_K:H+U(&`43:I2=?'")$N)$$<Y,HB3!AZ`AE'8Z:>P
M.=QU==\B%CL9S0I\RDZZ%%Z`Q%_78XW%=+EPZO$&>Q=-MX9U`+/A=IFZ`S8B
MZIK#F($05'=6T_(P)'*Z[-+3^L+3E1PU$&<1.A63@@7NL$'-S1HQTO=(80A\
M7&XVF_#L'F[B6S<,+^27K-BYTC>5O0N&'HE`';K-+AW)E$]0M@%*6K04196W
M^.A[.V_#-YZ#[P=OS_X9C:PIW=3%7>6P:S*:!2CDT]"6+0OY&W"(RXNA[('.
M?#ZNQ]DH76H`;V!H4K)V.:6D)!"^ZARQ`545RV@Y)/^:G(5^VV#?#;W@P<>U
M]?W;GC9],"X71379?;5TQN+J6$H,)=00(6?X>%>71A.Y1NAW3A`B9T:7>DY/
M]8R<XK;#*3V_;;'',.A^_A%T0'?V-#BZ4U&4[_6MG-E$BFY"#AK=/362H9N0
MLPK=/=63H;M-/1AT5^`D1W?1'IK033YAZ#8!.O^`>0SGN"M?]QC/9_,$MNQ]
MXSCM+?4D)S4L%GNKP.%W]W3[Z>G&!KS5.'@.8F4U(5:77PG&+U]9'[[/9W\;
M-3;'DCQL<$U9+X'ZOKHS388@2@AQ2HB1`G)YG9HY/30SM7IL=K3\PK'!$GK&
MG>#5)<O2/V[\;?+/S]Z?>/LQH.F(Q^^>S\:$QS#8A^ZQ87CJ0\?X*-9#2-4%
MS83$7'&A+*'-,O_3'Q@G1%FA'"\DF)D>&0>WQ*2O)4!'V\'-PJ/2P]]O[I_O
M_O;\%?U\_[?GI_>3R>H=RU_._65'&;_?4BMM<E8Z"2LE+Z[?63"V7Q%$LBE`
M7]MKC8-7!3][(YXV+W:<Z7Q:"G-61C;-&D\Z:&Q#!-.LOE-5GX>FKNH;C4?]
M@Q!`Y&D/+\`QI-LD?+5>./-BH`"*!'WD+L+=`CSW4:(PU[`'E2W0`]X#N'>/
M^&'WA$]!2$_K1+/A2^,9<_,[!G<$&@7IT#XZ*:I*Z='KF2E%E)`$/FG6J*AS
MA:*F]@N4G#*_;=!N'Q!LX?C6C5[(0/KJ;?'VP^6W"&_O_,]D@/4W1,R;3>R]
M\LY([*S\3'[W<!(7EF69O%<2-8G.JR15SJ!83Z?BX)@P1)0C2EBB[Q?T,^6*
M//\=2AFCC/,(9;Q1QARFLYY)@RT2@VVHP4XY@^U2,[DI/]!@H`5%A6AQO9W?
M7CAIZ0RHB?B;"2^=^_%-%\Y8=Y@![U,(84/>TY#:;W<(?D2\'D==T`%M<J@7
M;/JB#WC378GX=_XKCF+-DQI5HO!11U%2]3%ZO'"4HDW*^(U-:@8Q6'%2<^8V
M(O]+3&3UA*8C@A1"2A<;O[U0TF]"TY7XFPDMG0?CU6PYT1UB;)W0#&K#V@E-
M7="Q<4+3$VSZHH^M$QHA85[\?A&GB1!\=&F0K@L*U"8K*;-<)+$U9&@S3&UX
M"%)+V!T>%%"@$`K:;&DW[*]?QZ@2M3(<7#,MGTX6$[7-V;K0\!;6,8,83+XY
M^_,Y,5A=!'D;`>3*54T7BP,%ECM_$QPQO00I=Z;<,V9AGS%67ES/YM/<WB<G
M@'ZF)-ZAFS@.O>_GF%8KH*5S'UWS_=8T:.<DVAW(JV`1IJ_TBS;I#4:!JO.7
M0%U24DM6T3T^']PH;KA05'K"=%91D;UR4ZO%/$D_3`@8SBJZ1NY)7F[(K*)K
ME'"4E3"2553OZ&E648VF,&/@CYO-)CBS"@!D`/?)/S>\R#GOIRUISEV)B!W)
M&!U)N\FF7A%B/4]7TS]0Q@,5F8R0Z$T/WJ/>C$4<7O]_0\C)C0([]/7S^>+H
MV,.$>@;0P*>3[3N??&8<Q9_^/-$*[:6&@FD'P=H@VXV"\0&XDWBJOKF8T`)D
M?(`._/=LO>8)%@AS'G6M2Z$ZE0YIA8FP`E_F)RR0X%'7B[.Q">?0<X(!+>$T
M^P,QT>':?LW]K;/FUO'QGO(%L<]D-KR!S,S&>D7-;+;6W<8Z@SVG?!%--TIL
M2SUC&URD$QF@L-]%1M7>5XOQ8K%,8S_?J^,N>4E:LE2<=UAH*T;_X8Q1'`($
MG[0A4DW#:I5NS&8&@N&,4AP-VCS$LO@_H*_,AK"+R;#?)WZ68W]G^X(LY\E"
M)-EUY[MW8JB2K02ESYM<H,N$Z-!Z*.DAFZ>5[G\+<N^`=HOUJ,=VCI\I,^03
M*&9:BKG8"/D8M-=2J^\5UL^-1K$*.FW))*WOV0"ESAD1DX6C`BGXI!"]&J=3
M@$QE3Z@L</8.-OM#U4N5P`:?VW&FN]\/N_2H^!O>LTTTV=>6/F\29#(AE%W-
MF4V2*3BC1>=,65Y%0@X(4'JT<XK:?3]'GH^C"$4-RAD#49O7%<#3:`\(T#P4
ML=R0O5#WI$&@U+!7G_/,G!F'R$-E\&'Y##"3N:M56J05Q//IA9)D*5.`:/"H
M/!1DRFO9ZGHXO<0O08PW+[=!>!*]9N59`DV/F]ZZ:I!%]0A[NG+6(G\@HX9R
MY`P?/VA3:2)7"3+10)M^3D_]C&Q_*&`JW>9HLPC(2!?N7=_[%Q/EEL3(X.!M
MV0\W_O:1]EH7H'S8B4N9[N$;^0T_AVU9M^FA;7(TU2&P\F!%_#L9?W-\6:)O
MQIF5!LSSIE.]E#O*V(,O$P&,YQ@RGK%)@DXP%J85VK[-FXM1'[UH<PBB<XC)
MT]^\/6_>Y,>YW!*:1T*;C+5D8!D7XZU$OAZZ*:]TUXND68(6G&>BLG=RPA82
MJ82XZ'?P1#*[/TPE`'.KGH]'-[S0C]!BX#<;;*^(*MKB<M^OJV<MF9.\.8&U
M]7'C:TFY+*H+DSFQAN@YE:=F>@6I2Y%*?$WS:<'BGUX%*W$*;KW8CIMLO=BB
M/LA<+'[!(>L,B;=?LGZ7M^>07G62#6+-+YF<YS1*HG[1:#D7IPN,(!(448XD
MF:)PHD#S!HV*.IFBKE!4G-3!#N!*KE@8;MN-`H>I*,*Q$HX*#QK'3IZ[JAO-
MQ^/5JH`71L4*B/37)P>+#7\?N8P:/"CJ?*D*A(KJP,Y_3]13]?_<LS`0R`10
M#J8K$D[K4)"1`@="7ZWR0X1-&*BZE`0&)<7!D"#@F!N=&CN1-;]C&ADR0=2+
MQ*Q6ZSQ"!,'\O`JX/9E&/9W^>AI%4IM+5A#5:!XP9'5;K5BP3+EBVCY?KR=Y
M'%FV+KE6LYJ9UR$C"0Z8#HL1VU8A.7ERVXLMQ[SM+P)"IRI-AY)EJX4$1?F#
M!/"#5\T:.U=J#(4UN<,VP4YB+1L0J+8>JG\!$'$]UA!SIV&\LF)YI$&_'*X.
M@;]_3Q@?;1VW%-9-<HN`88?*P>X0MU_+DC]O&CEU0B@[UG(]+BR8!+&![V6U
M7YO4K>$L4]%/;DF28.U'M.`?=&IOF^M5H",U""AR>NP\-+T&@:-KU^5S)[GE
MF,')SBT(;=KF9WMT5'JFHY*5^Q`*/EJ+-"MW([I>(VYY"0!L5]^X7<Q*4#-]
MK5@5:#HT93!+ZP")"X\T62I@VI=O0()?-59STCJ\:;MT+,L\HGP>W3#V<=AP
M>:7ZE/$\HXH(JD4A5JOQ0E328D1,YQ5=*7@.U8(*Z#V4*[7)#9#PMTVDOI\E
M#=6KJP5ZC^Z%>OSG('S"WO'[F9B=_ORPNPVBRH5BE3=,0[)9'.5K27-G*?I;
M"X+HZ&Y9Q></[H7XR2X(T890I!FPCR]NA-$4;8@PWL8]D&6+YQX,(UJGWI.\
MWH0B*I"DA8P840"DZ]32N>;K@L4'-8"FL4+!8#KCQE=B1L+KJW<@<Z#`Q_=!
M?+-Y\?`KWOX#N^&#7Y[\=GP9*)JT2Z8ZX,R7X_FB&%@H<8:RE#R9*=-<>LX`
M40Z(L`"))[HUGUBCN5*@T:U^->;04'-,U?>)^FZB_H6J']2K;S+6J(.Z''84
MS6<P`CW_"/I_;OJRG1&(2*;HB.OI:CR?]XA`A(6-$:BSYMTCT%":ZXA`G=7O
M'H'B>O4MBD`Y4'>,0(GY(#8)A831<W"S^>^S%^*;5]<[T,8R1&!:$?$;WIQ#
MKZ8<;1\*!K</.XBE?D:T3-IW)M3I;%W01RF#]\29W[,"FAD/J(.QX<S`CLH>
MB<AT:1+110KOOPE>$ZJ'2^?W%[M:S`K4/H9T.S2^/![HQ4Q_^XG\]G249W1T
M(`")6:E4ZA>+IDFF;QUD$_HCQ#B,V$YYRL0:S.HR0Q6RI]0`)TJ;Z8^;]`<#
M<:N'-V*XV8)ZIO[DPT:7B!#_ZA&?"!OZ8LD>-3ZMKY=#=34Y6\\FHM*5H(0(
M*21HF=YZU*'+1*(+Y+F"%L7XA/O3KS??_O&-@?SKW=/MIZ<;^*.&%MAD4^D&
M,^C$;RMJ8;':Z>.OQ_.ELRX@%`:5?:0N8!$>?WU4**#.%J0UXTL_JD+:/LS=
MXX?=8Q#%-R?:6I>6%SEO+VS[_SEXPB?W4F]ZU9?-HU%1,N73H)FS2L?2A#:;
MH=$3(%>01Q&ESTZ%V#PVI"R,0WH0U2=5U2EUE)!'C#X_\Z.J,Q8@X6`0]9T^
M7QXPE'1$=2[,=#&?KA"T"\*C2U1*=^"2!4+3:-_Z%D#0:1%)=5(X7:R=51IM
M$J*Y_>>$K/G8HE7#2;N&L%,+O>HZ)77??W=IZ_J.2IN*((J@S(<.%6OIB1E!
M3,AZ[N$C?L6'@&T5I$SK,Y":WS`>*QK%4<Y,FZ_62:)`0A!M,XK9D8WQ2*%1
MOTE1OQS%##H@>48:=72*.HJV7NYVZU$/(K\Y):&!GL35?V*X8*&$QBQ0M-M-
M;Y!XPMLSNQ]TY^?;AUVR;4@VI2G/=R0M'G60!0LW_656W<M>CL?+2DQ*V:([
MO]C@\)(->L]BU5"SL##>%M*XP29OPV"*$=&4U5C8_.K^Z1W/1[(@2ZP7IM;S
M?`MZ(VH,1-4@>J6I-4?:I'6CD.G!IR>R,ADN=[LGS,Y_MLW>U)LJ7)SM*[+J
M#N9RO5PNRV$V:QB:^#_Y'\UTR/8DV+;%^]*VA;<C?^3\H>:)A@Q6#K-I.][$
M8`\^:\3;&%POZ&Z'$OZ@8=:,T4J3TT)T_>V7;[]D?N?&/%6,N1K4&;7FD%03
M<J\R.TA""J&%0R+!MSC8_/'HA@\A*R"^_;M[.&.R<O_VXH:R.Z>*+YM,1%&2
M2#G[PIFOQ1W4E#!BE$?TXAHB_LRI(T8>$?J(,8"YCCJ$\DY1^8@K?R+*OU*B
MH)DFG5RWD&6B;B@]LZ`"/T;\(XZ\O4]YUL;QQA>,SUV:I%'=S5C.)LNQF):4
MW2FB)".T38F:GFOH4[`N6/"8@#*2$#,#?2K6AX3*-X0;X%70EHW=K8:!'Y:9
M5-'-.7X)0N]?E9"A^!+8,%R61+V%C)/F@):'7TX3941M&'*O4[015VZCHC!#
MKLPMY4-MK8%LP===%)T[84N\`(PK+H7RK&X\6\R;,<4)VH.G/@HV8LF3*@B)
MHZ+[M6$H9Q1;\/-PCJ/8];>>O^_P=?-O`2,I)XIRY)ZMEDXSG')4[<%4;U4;
M@14TJPJ)KAKG;(-8V4;P.&/+4Z6OS)\$PQ-CKWXM;3ZK7SB-^+[*R*(AJ8=F
M]9#Y'^-?QN/Q)-M*&:')>$1^59WQC9`?5-=7(S&.T5VH'/"0&Z/_//L83<<C
M1+V*_OTCWK`\&S2=L%_.[(%GP:?ED,SL#@-#S]]XIP-^SDJ*/N%7[)_I8G$3
M>B?>A/$)GX*0EC:[)5]H'X27FS\]Z?7;JV@:A?85@BJ/+LYXD5S1Y?S<`\HQ
M1(+C".5XTF3;E"M*V*+?*6.@VIL&C>4,;"QS\4`#N(J1X]IO`!1C@O`1D_^_
M?<*;@QM%K%TK:_:Z_;]G?C\[)[_<`;N1,1M).LFFWNQ].A&+VC+=4=JI5/P7
MO&'SL$9PZHP`>ZN_IU^7$-W=9IJ.;H(-QMOH,]&)SD)I$C,M?W8\!CZ;F-SC
M^&&7_$5>YK`'&?/'/)UE5"X>LYX[D^3PAW-!E`U*J/&J@)23.#(AO.COTK\/
M5S*PX51H8'M,K+1'VSG2P$;A=9`3-<F<9</-()9-/F9E%;WD@8W,#H:.FGI'
MA]P!5#^+PLQ1ZF3EVR6_^5L<WOGTDICWRCK.TU]_H!=9B#*TQC/O4TV<0+XD
MTD3>Z)Q&C\SJ[30=QRF%CETA=!!XB*W',^6/4@%8_0#V)W&_*"\$*Z02C="G
M/S>',]M(X('GX22=09B8*T$8UZD:MW!R(.Q*4[=B>K,S9T1:C`5XMJ47H<59
MF,:O`1V^OKJQ*`;UF.8DTB(5M^[A$#WLNE=3TT(;*'#U%EB](7;:<+((K(PS
M6:EEO%FH8MQI.#-8H*U/9#)D/7&E(>%E4^$VG;B219SKK`P=;JA(5T:55A)`
MP:--+O7!=[R>U\4(2NX-A`&]=F!H3S2W$.>J#BV#LY*UM&_A<*YIOG[^7A3A
M^6L81*W;-RHD(+=N%.13K7"R7*S&B]*V#9\."[_,+M:)>\GIE3JTIXR,Y_$.
M:(::W1H&SP=:[R8Q0^%")C4#8P2\3Z/=%'4+).$1Z84?;_]BR<9,!\S7;LJH
MFD]7L*)WA]BU(3*Y2=E(OG']LP#AIU805:^:35:.*"I/EI"'\Y8`1]`4EQ1_
M=O?[D!5@12$_R4-;,E#X>Q2_8'1B)P/<$>G/B3/N@X#XI^>S7_JT!,F!+-=I
M%Q/ZU^_GR/-Q1!8>[HZ`"6WYK2U",\3D$]/-$#*U#'[092Y?D&R]B+Q.!N%W
M[,<LV/TLCA<1=D,?;YMD.V`WHG^C61NT$],/+Z*_Y+D;<8!<\I07;FE>"($1
M?8.Z77SY*1*8HF^27QQ8PYD-#F.7*)B4@_TEO;B8F,FC.2.A1^NQ,QE<*E%:
MK"I$$;_`Y!ZI8M0LW."G!-WLSAXGM<<^[=Q&GO[_7^DM?*7O7+*\I.<HT3B5
M-Q'JG?G!6D/02$9EYH7\?BXM__K4=+5_^*%7@V).7C'^M3-O3AT'<H!M'*?R
M(ZG<&D"K\OJ*TO=86G2]Z16SJVZI',JKR_5\O4IADR^B7JRA/J)'CF"+:DUJ
M.D4U:TJE@_=157''TAJZV3A688HGW="<&Y9RT_6#EU^W`6LEF=33Y^>Y1603
M[NQ+6!K"$@R:K*'X%S;MN8DB#+Z[U<F)E5!99R,]"T71#8(>M9&Q]89,O%EO
MQH;"J,UO&%\T-HJC.EF:SYSI3&Q1"8(,3VQQX28T34]M-:HV*:A&Y[9LURFE
M"5H&5:.>3N43EO3\X<4OZ.GQSH(2J$K0RV;`[5;2$A&>DE.QAQUA5=W!*FU<
ML;2B7(:T-'=1"UW3T46'T,J%P*?SE6C6D+*EV\(4K/4;QI5M8I'>E\_A!\AX
M-&^TR9LQ6G,D-&\YIV@YWA*J9D.^?#`#%C5UAJ<TMFJS.\2J*14^>MC1F?`S
M#H^W[LF+W<,73`:,A^\';\\3^"53\RX4#*Z=.HC5H1':<E8*%RP%ABTA"#B/
M2'!`C`7*\8!J!S><&6;Y-JPT1UJH?F"J!\VJFUI/]7#O_)*JJ_5@$!QA8I$7
M$GMR):L__4GS'647M9O?,8K2!D'4]]FF2=6KA!Z;O.=KL0N2,+L7&K5T*EKF
MRJW#(DW!#8O8:C.*=6BJW=?H\J8MR.JT.%[,'&>R4,,7T$[`8$I7X=95:2OP
M5]T5Z&HQZ[#(-S7[^(%XTQ8L<G&4-Z[GRXFCAD7[=O&UVT$)GM:BLNC"RJC,
M&0H(E7'H;<BZX]:-7ECR>_1"SQI>R6J7IL/'MVX87CQ_WU0JJ"L5LVCM(IKZ
M!8JT3%?&`5':XJ()^4>.RPC=GL-0,JDS`M7AC."4C+`AM(%1VL>E2XCM;"\8
M]-(L,+S]Y(8^$2:ZV6S.Q_.!;B-\Q#MOX\GR3Q1>-(K1-FF4YWD+LK)*8,F)
MHH0J^CE'%PG"[Z``J5=CAL&\>EM.!1:'JLY9A)Z296#0QC+DGO`FV/NL65K:
M2NPKCE]H)9'\`_*RRCT(&45C5^G4?74^6R;HY+FE.2ZC7'=*SFB$2H^!564>
MVB8,O_G9;M9J#[F;%X_\!;2\;'_7+V*[EQ7MP+I:XEG[>Z!([IM@-5TZ\P;@
MVK<TU:JX(U'<+D0J))6IV040;_)C2?%G\^CI<)*V*HUN`^4-!/3`2KO@"RKX
M,Z4->15`Y@\U7JSQCMQ3L'FI/P^H_-EXVE'&6_5[DCG%<BJRA^C;AG,5>TL\
M226&3$'L+;ZC)KZ9U)BJ0V<9+B4%-2&(W2)*4Q%O`Y]>J:/YROS,75YGM/O[
MYC&H+IQJYZ/U=#US$I#R&UAI<C':I`R29MRT3'?"PCB>A])^DM<^R\O-&"3]
MA_-5AT%"PE`6</I\?\"HTAWDN;#3T8@0TU!VJ5#,+^YQ?/,]BD-W(]M%E3UM
M<)(J$4%Y?;.8CV>%.2N[I8=^3P@!+>"TJ)5?MOT%<C+;XE7YN6V3XB"`V&#?
M#;W@<Q#BC1O57P9J>=@D'&HEZ%#P>B;0D!`:H804<#*,#LV<'IH9PTBCHQ4@
M(K<$)$)^\Z,3WG@[#V\_!D?7DY73ES\/@).*$,H1=C6?SLM0R5%#OW-ZP&BY
M4C^GGWZF,2-UO3K8U)L$!CDO>'MF1=O(5'#K'<ZTTFM6L(T7#L9;>OF"EGP]
M\Q7:PRXY&TSZ*C_3>F]23]#*Q"A&=4JN?I=Z,IXFP.8"L$J).1%R-1)1(@2_
M(I03@[Z4GKRG;<S1[TP8L*@`9U$'P*+FXM`00"X&+^U?#C;BT82B<E(1+7$=
MA#&]EG*7E>=D$K<=.VH@#!+9^DJKOA"<3$0^$&4SJB3FL6R]'!L!)_@C3-,V
M<A(;52SB^>BK&_Z!8V:8#',C4;2--_^J,6LI,=*."'4M\.JCTE7?"#@2!0=B
MN"!T69G],"2^@I-*V/?$LI(_Y^Z\=@Y1VCG"Q"[=:B@#=KF<+JM3M((\*"\0
M0R,1Z?U&]DC^RKN5,1#6UKRTD+?A%S%RPI!9&;7M`ZWHF"2K61+GAH*U)``.
M\H%@(^.GX^D07#"99H:OY-O7]Q^Y.3!91/O')&^-=Y9CQ0#4%J<Z>8%$0XT*
MJ"=G.6NG&@<329`01=J@:(0R>7@OTT0BQ$7BQ3]L6;."6;BR=#5I8?.1<P#8
MU\=,W1_TWR):*L\B=?-[RU&S\ZQF-9_5;/(-A&N;)I*@!N>!E#;!>_^AVB[/
M@@NN@Z-YT$!HT=21+OA]PN4BKGUV7"&WO`X2JIIEZ@*$137RI,33B[(6Q@Z=
M%N!-:1."=F!>S6GK(:Q@&UA$2H)*;J7ZX9(](U+2;GZXX59M`7<M?1!,7RFT
M<O;)E'R=*NBEC6,+>U??+X4'DXQ0)H4M2S.C=JPLQX:UH_DXI`FJ]8%*QZ<"
MB61X3R7Y%0?[T#V]>!OWT)QF)'W>9*21":%>MVGAB(R\/!'H["(]:CF=U#*&
MPS9'*^"JT1*`.'G"IR"D^>7\@J/:Y5VU=\WCIUF@#GDHCNC3(NBBE+!]5W@'
M4-W)JW[G[VAC,.AKO)W<M09Y"O:!0:'O!6%29/4^B*4W>^N>-(JP"OL.UV;G
MDP1/E`IBKX_H2>L&LMK3U3HY.9TBFN]!YHL^)3.(/J\X_!X,K-%$JM((;40I
M)]$+#S8:2&%3Q'Z].>"0SF1HOAM2><XXRG/,.UPD<FHP#GT7Y#IU&!8FSO]$
M0J5O`@]<M8]GC/[S?+@@\L&7=EP-D;E8%1-EFX`@HG:%*?N4]0^;Q$:M!.JM
MY2<34:U;M@T!A!$-:CE928R(G=IPY38MRAG#1:.C%<`A-X8]",GMP<BV8+YX
M/KZ+\5$ZF;R>,#CRNDBKGL4V36]K*6P6MNP54O:(\8<:_PP;SC%C.-BXT0=^
M[3&F\T=Y4_'H@54KB'XE#\;1G<\/HW4[;3V3MQ"G:B577[@YLY6FF#5"0I01
MXL+02PU<'%[O(-C1V]`[[-'F3H;;?=E@9KX530D0T[&Y#@I.X/U^AL&EEJ`E
MM_G;#V#_A;W]"W&$FU<<NGO,_OC1C?%GUPN;JL";EN+-AL!6U=3+.BS72Q,Q
M,I$8"9'Y(X@*C:C4B(G][Q`W-7\;%EA3Z[G">GM*]?V66F]'K?<JL][;C+3*
M`62X4*SV&:V,U=($!)Z%0.2CC2F)\]V[1]R<`S`$*YNB;@_YU8\,UU-Q<YA>
MZJ0%ZO@B#C;S`-PB3B>+6!._K@!5IR#5U_Y:BG!^\_:^M_,V+JNNMR&L^1W%
MJ#G]H=N[IHMOJ@JFVNQX/9W-1&_M'&FT*=`V7&)S&!TG91V+M-.4#[!<CP%U
M=YIU!RNAV16B:?G,3F8"F=<0".-R,MC-GYYTKU[ZO,D9ADP(]5G^:C*I2U"D
M1*`F"7J4JDE/E"IE;)QO<[+"8-UH!U",\(HAGP_!CZBMQFS3*Q!(J9&C0_[Z
M--G23<BQRA6T>@RC"%]X5IN:3G\UC:.IP1UK`24S#C"F/GN^ZV\\]_`81*R[
MB3JVY*_"8$PJC[(3CN?K20W64L(HH6P3YC2I7<5>9[4!,-CJOA(L-AL-&)-W
M_B8XTD4O73"'^(6LF;U7+'ZK#$\E*C!(51%->8MEO5POZ@;(/&G$:=L$6_TV
MJ!D]N]L``,-=W%T"9V5C@B([*2>LLL(K/`N!TKP`74:2:;'"M1VKNO[*.(K*
M&,=-G3/5HJ.B.PP&@LT?+\%A2SX9WPF7?K+*@T:]O\Q=/2=D/4OGCAF1GU"R
M[Q_'H??]S`N"Q@%Z=(>[[-+6[.Y:+1>E'-]45\R(P<)#YF=%;-0:P`Y@M,[P
MI"^``J7SG&4V2>LIJ0/&@AF<'L6=JN(</;!==UJ]L1E&%LRUB$AW473&VX_G
MD-[Q9*D-['PQZG;+I`<ETP#L)I[ZQ&<QR0]EB+-!G$^:W\19C1H*GEF3)3JT
MK3(P(X^P<0G.(G3V"2X$J`OW7]")T(1-$NV/D@K^>]@5)#"<3Z<#FP^[AV0C
M-G>?O6W057S;9`!0$TE]`WZU2`K#YBAG&_#YV__PH_`0RCL5Y;=>M#D$$8E<
M-(YMJ"EVU!1>Q@IVN.[FU`7L=K`@!%[3P_D69%:?,XC!"G/U#;OI0FQ:9IDD
MX*BZ4AVGDSJF,")UI#P:ZC7O[_<1WORR#U[_8XL]ZO(S^@_JZ;.<IY-?_?,Y
M=&DOD&^7X_>@_%6J?S?@V16FZB%TXHCKDN)]Q`F8=>4KY7?4Y!_:=Z6N07VV
M7D60&$T8/.QRF9P-&]OUSYJ,U74"=,CC78@L#$J']2++W1%)>H6XTNX@@)O@
M&A1W!E#<6/QO<M+"&""UDY9$X]].1"Y"U-]^]0XXB@,?BUSGZ`EOL/>*M[_1
M%:-HF9+V_"Y]U>MHF4Y$[BNH:N+J=#V>+GABLF#%7#)EEES7BE#"#C%^2#!$
M*4>SR<MF[#*QU2[-V<UFC",ZG0OMSSDK'5,KG01;L-3G:X-&F@I]E4TAYA:_
MG3Y3@9/K(%E4;JR8U?:6P?E&BRCJ\]+Y;)P@^3UWTO0.:F[4A:VNI559)Q^V
MZG3U?$1DLZ/0EJ*?YB<:*L:Z?NFYH87YP@M%W#3Y@8)MF@.;^/4_Z<<H?-?<
M'PQ`)N.FGFT_7B;CV_W=\Z>/Z-OSS?.G;V:]OZ_<W,%]CUYO9FD:S<7QAG;E
MJA=0;RTI!S(&1+31211[1U=>#+7TD,D(7^"L7L=Z.A?WS`@!UD(H(6%?1>%K
M5'3J5`0-U;7N5(C,574A_+YT$?_^3$.#*,/_<(ZCF,Q2/7__P8V\#9G1?:2M
MO;&LAE)/8@9QU$_"#G.*I.1PI2('9Y7V@XA0CMT(,89L12!8PF#0A'GJ2VY$
MW"A!Q@2=Z2D_F7]M6,-X^IOOJ96VG#/R<8P.012A$[$MHP&)^NO`E(\.5WP(
MCB9AAB^$,/F9_$3^0?,FR`__#U!+`P04````"`!*,`9'IR9GI((F``":MP(`
M%0`<`&YK='(M,C`Q-3`V,S!?<')E+GAM;%54"0`#JS##5:HPPU5U>`L``00E
M#@``!#D!``#M75MSVSBR?C]5^Q]TLE7G4K6.8SN9W4E-=DN^95W'L52RL[>7
M%$U"$C84H`%)Q9I??P!>1%(B0(`$!1K2PTQD"9?&AT:CT>AN_/*7EX4_6`$2
M0(P^O3E[^^[-`"`7>Q#-/KWY^G@R?+RZNWOSES__[C]^^<^3D\%D,KC&"`'?
M!^O!/US@`^*$8/#DO&"$%^O!F(``H-`):7.#>XB^/SL!^,.`_=\;T*_^<3FY
M'YR_/1L,YF&X_'AZ^N/'C[>$>%F;;UV\.!V<G&3]_2VA[./@I[?GYV_?%WZ9
MX`AY'P?%KZX(2#KV*$T?!^?OSCZ<O/O3R;L/3^]^^OCAXN.[/_ZK6!HOUP3.
MYN'@?]S_I87??3BA-2X&D[>3MX5!_M?@$:.`EEXL';0>#'U_,&&U@L&$#I6L
M@/<V;=1/ASN@D*+@TYO""%^>B?\6D]DI[>;B-"OXYG?_,4@*?WP)8*G"CXNL
M^-GI/[[</[ISL'!.(`I"![FEBJRQJJIG/__\\VG\:U(Z@!^#N)5[[,8H21`X
MX)9@?YUDQ4[85R=GYR<79V]?`N_-GUF'OQ#L@PF8#F(:/H;K)?CT)H"+I0_>
MI-_-"9A^>H.^AX0A_^'=3Q?O6/W?7V,W6C`N0MX-"F&XOD-33!8QU6\&K-VO
MD[L2^0A\#QT2,T^8LN(I*W<J;.JT+:$36O/;(^5VP/H836\AHM,#'7^,`\BZ
MN/*=((!3"#Q%NB4;W><(Q@X!JO`KM!S.00A=Q]<_ICLJSQ9@Z(>`(#KQ*]!\
M$+M-::>6@A$B*O6NG"4,*1R-:=UN2#NE5TXPO_7QC^`.>9``-VQ.ZVY3K:F]
MAH'KXR`B8$1F#H*_Q6M^B+S':+%PR'HT?80S1/G/=5`X=%VZG81TTQMC'[H0
M!$//B[G4\5L(GRY(T`@,0YU2<X=6(`C91%#XOSCD.PB=9Q\\`C<BE``0R):C
MJ\./F.;`*MS\&L&5X[/2M"[=*T,"W1!X[+?&.)JCV`#L>EFP7:\&AC_&))S2
MI8`3\2!3I7-PFM"D$3K6&0HQ66\^-!YQ15,:";V'SC/TJ;HU`3X5\MX3?J0+
MBRH!44A_G>"UX^OG\%:=ZF1PO%C`A"4H@USA6*C30Y7^):W:D=89=@$*0-RO
M[SO/F"2;VXR`>$\/T@+E7Y$WHGH>F0#*<Y&J'J:Y\WV"H9O1&W6G<<"/(7:_
M7[)#/3L74V+B'JJ_O7EA'YM/=I.^.A^JW@E5Z4/CT!Y`>(^#8`S(XYP>P?2.
M2:IQ/6>2!QR"X`EO3IB;@T50U+NI?`SHUNUEPJ!HJBH<3_/*^5B8RB[2U)_`
M2WCITSE41*M'A-LV$]D7KW9&-@/H>F9N'4C^YO@1R(GL@*'%O1@=XQ-3V/4Q
MBDQ?78]WH]3G-.B?4F$G)D>H>4(ENNIZM+RCS9C6H.+#\;?../HGNSD%76,C
M.`5UR?V*W7:/PN8DL`)#0AQ*#/NA6PCD^^S1^#6+!_6>N\:B8'>>%@\4Z=*]
MPD$8Q$IY?.08.^NXEG[^:$M'SW'2S$=ZJ.D:LQN'("KH-N<Z_5S#[R$=V[*@
M;3,7@](@:6&`/';?FGS+.M-P51SW3/NF=)2Z\]EE.B9E4-/>XAOS`+AO9WAU
MZ@%X2G%^SSXPP-^?O#M+[\M_3[_Z-J1=>ZS[6]^99<U1N0+\3V]V?S_MG)ZK
MB+!+V5O*E([_3^"0&^1=TRFJ((U;5(W*759DWWS+IF58,2W#YR`D#KMX+!$E
M7Z]['#,R$G0H3T/LW=+O@@H@^67W32>;13DJ\Y+[HS%!AL^0U>7V1]\3;59`
M5OQS]]0D7']%.R3,Z.:!E_\#ZPJRJLOMC3ZJ1J?6W%C:!Z,H9$Y.[%*63ZRH
MTKXHOX4^(%>4LV;Q/1R'U'*I?=$V`3/(1!P*'YQ%%2]6%NN>NB?BL#EZ7"^>
ML5]!5OGW#3W%'7](RK0YQ,T:HA]WMONRVUI:XG09>QR=N'/H;S2%*<$+E;TC
MHP)7K.X!)AX@L3_EV;MW;P9T`%-`=TGO/ADKE\"8NA"0`,0E64V(":7@TYOS
M-X,HH(/#R\2._KK@V=)O<GS.C_@(]K8<IXLC3D(])4?J_1&I&LTSQ^K#$:N*
M?2G'YZ<C/GRM(H?ICT>8!"IWCM.?CCB)C0LY5#\?H>*>-38H4>7RB)+D63('
MK6N5_)?3;1-EIX9+V0"4M#<8LH;/F)KT;G`RV-0N?<;3P::M0=;8'P:%YAJ?
M%:=.\!RC&P4G,\=9L@/CAU/@AT'VS4D2N;4Y.:9??TN])8*QLV;&[E2*;!TC
M:PHW/^.VIWL"7`!7C)H'$,I17UE%BUV5]D`BX%W1DBSLYHG0F4[=Y[:M?O7E
M#:$:+:+X;B3VZV1W)@3,*4%P!9)`'>:`1G$;39^<%S[02JT8&>G&=V[L0.\.
MI1$]!7''&UQ]12/C"0(0;C/9UH_FZ.)<*G`*F:.S1H"4RABG4@K4[;)&J%XY
MT&?R]A83YN%2B"D2XUU;S\1HT@5_#YP`C)Y].(MUCYJAU%3JT3@>,'*;#*50
MS\QHXM"A[9BS\,HA9$UUU=A[D#LBF;I&1L5WB.*-15##U`C2?5$X!=O%3-!Z
MG9Y>TF@6\8KF%.X!W;4KF%_>!/4WBZ6/UP"D/CF94V3M[E!?S\1H/F/L_8#^
M]D7<SL\F:+M#],@-@E#JK,<I;(;NU%F8GABXU!:*F*"QP'X<$HLE#%/(`B:8
MJ)UCWP,D8)M>N'W=+EVMCV.I48VEJQL>FWB%]D3B[9(ACWZ[TPG'"J/J5D_W
MOVJ@V[9F8C9B@TMJ5Y+FI)I*YL8A<2BO*&B8WEK]J[JL,:K5V*1/_%&@10[T
MZ@HFZ!]G5R6U1Z.JDF8HQDM`PO78=Y*+)+I5+ME!DZ^5":N8&$,Y`4U3>X%J
M*V9&&CH0`2_S_"_8Y.GQ#[J0-V<2%4V,YQ$@B,D]1K,G0!9QI`-G`%4EC5`L
MN$*LT9"DJIH9D^2IH2?G!.63@<Q98(^7]V5;?M5-?<W-@*T^L_+`B+<M6WUF
MY?')#5:V^L7*8\%1XFUU@U65+FV=7#&[-GH%2'#,&$5`)-7'#5[G-HL7";R4
M%>\<.9N%D01R$I?G.58VRR<9K(1.83E,=GGH*\-4OD_)8;'+,5\9EBJ38PZ.
M7>[XZDN+ATL3]_O^*P*J%TQ%J$07(K9&P>C`K=+$8VL\C`[`)#RX;`V3:0-?
MZTM"6P-J=/"DP!?)U@@;';")KK/V%V3S^G`KN=WD0#4Y;=NME`@]27/@[#QL
MM])*!*5SW.P\>&M:F1QWLQP].XV)]8Y15;:+;>?,_*1EO;(A@9*$L_`&L`OK
MU0P!8!+QB#E0UNL5TM8?ON-<CI:=IGPUM'BNY#E*UFL24K=$XE"Q'"WK]0<)
MM'CA-SE*=MKM&\@IL8"RWK0H`9,8H2:VQ/XKG"H>9[NV_8ICS86=1L.F.,D?
MAW($[53:U8Z"E;[.^>G/3G&E;IXIA\GF^-AY\:&&CTRZCAPQ6\66$F*JJ5QR
M^(XR2\Y_/C?-V&EI:&LH+2+4Q,2@HG'U,C]8^1%VL]D7*"TC$I/MQ3M,]A0$
MQQ%>IJ;A?!))/KIA%,XI:_R6SR)_)#LU>C&"NR"(Y*E/2_>"<GY>>:DJYN/N
M%!>%9&4M4<SEON*&KT$`9XCUMT6?1`7S6$LNUYI*?1F'<-$**O2%_OJE6U?+
MZIBZ5V25D)5HMH>"Z<%O5TK9'B*FBIO,[F1[*)E.7LMV$MNCS'1B5IV$VK*7
M%]H")W7XL]TA70-XHBW!5MNL)M!V99NMIEE-@'$$6]<667/6L\02/?0IN2A^
M[7<#4YI3__S]F3BG?M*"&>M:0$?``NB#1^SS+3CE4F8L-T'L]\M)1L\MU@=:
M:\YUW.)&<IENO;-[Z030I<1=0S_:-=O(UC*2QQ0@0!R?4C'T%A#%;Q2QY9G"
MS!E)72TSV4.SNZY;*K,3S_>(PCU:`I+X8UV"*2;IG=B3\P*"FQ=*-Y6^5)23
M]1T5-7$\!JU)I1>E;Y9YOW%0Z+)'<PANA&[-@N25-D<Y13AEP$O*GU-NZBM>
M:9.Y>L7K;;N4IOR9+FOLBG*>\XP3CHVOD%/'O"KC<VT=$Q@^@#!?BAP$RV6T
MX,="!9U@OC4W6W&&F\#"*C056]!)==+J.IVVK2ZW8B(%I"LU8X0WJ#J:B&,F
M7!D#B%<:OWROJ*^1S?7UC.3R+),D6*U5)8UE'U5EH9I*FFX-L1>Y(5MG3"D6
M+E5N64.9.0$];[/40-=4:/@XSM$F!E1<Q\PH8GG'8]_-ST;NSM@\9V'9H$Z+
MXY4V0?G?`9S-Z?XQ7-&%,P,/T>(9D-$T/BL5#"9RAZV&C9FT+M6=B,L6I2V;
MA.U1]RK@U`@9VP/M5:"J/?^W"[:W"ZQ=\UJ[B/K^AYK4F`1*?J&\?<=VAP0%
MC/C,9KOW@0)(E<>$=IX&5BTTB4.A[3X&"FAU:A:V/4^N,LX5)EC;/0]45F[9
M4-G.O<`J[JF]4+/=LT`!JZ;'9-O3V4D;2ZL27%2<=U2VSI\3E!"8Q>EJ[,&I
MT4U'LXQ/UF(H:TVV/52Z$6A2>-FY?]98<@M.VKS+`.M#I241:G3I:7V@M"1X
M]7X"U@=(UR.U>S-T"#'18X>$B,Y?FJ9AVZ?S`^,'D4]G5O^_!UD+9L)=MS,F
MY-D2*N^61#4,A\NE?K8L]>L.C?*1<U*M],016V7$6S[9_&G?G\W:W.)E.^*M
MCW\$=_2\2$`!I<WR/1<O7];"(&["Q+H=>O^.@B35\1.>`!<C%\8OP>0VEB?,
M2*3ZT0I2M"[77P/@W:&-@7GHAG"5Y'D2+XU.NC(A*89^W#CP,BL+B)<-700Q
MHXG],"0K&W$F;_',:W\?=^U\5-_.>S2N,:"RDJX9E[`\FM<@^5=I>)PF3(SQ
M&E`)[L)D4T3><(%)"'^+_^0,253#2)##=$HWA='TYL6=.V@&)G3ICU`U\+R(
M!Y4F##F.EUCE#FWEY^:[D-?4Z]=H\I?2E`=4J*K%=;&R)T'ZZA*Y35KHQTQL
M9;V5GH;M>OT8#3\_N_3`!$WT8XS9\WDJ@RK6Z<<H-AIH>L*NC^J1;:`GXZO.
MYRX_/$[]'HTN/T2DS_.J#&V[<A_'U7C>*ELP&<;%LI9RAU`H8BA,JNJ(F@:R
M%X^H55XRO$B3=HV^/ASJ(F_T--XC7-B6%H2:^4.VT=>'0S/^4&V\1[BH6],:
M--3O\;9?#[*-'L-KC^&U?0JOS5Q:W!AG^=C(W?)&$F8ZZ]2F/W1_C2`!PY4#
M?6;JN,6$@?P(W(B(]%*5%GHQ0BIXJ#0)UV/?02&+1*#?QM%1L@/D-Z`KL-4%
MP(N=M5E6*:HU458OY$^*[^BR7^)XBJKUTZ09,RE;J^A,<D1]11X@=)%0;.&*
M77!67[NPB>"RIZ[F36/SQ0G3930F8)GR9&Q#]OU@-%5?MUK:-HU*L@^T&GQM
M$UI6]23#E7:%O-W^MQ_ACN_A"64\JONQ3/N\9:ZE73,!Y!FCC:;W&,V>`%EP
M7I'C3*)*"X9]4C:.!O(.*+M5C(PA6B[]F"+'SRBZ0U-,%HY,)FK)VB;]:+KT
MH=#E?:GB4_B:?,CWB7T#UWT[@W6[!EW15\;Z\/I]X2UTM[#]W?M]@2PX[=L?
M-J5^M;H5'BOAFF%_X)1N%$N7],T"J`X9ONK[Y6:!58>,XX[7F.V15[H!%#D4
MV1Z(U0S+1LYTMD=J=2(?J[R+VD5W'1Z0.^Z/.8!V'GRZW:DYO&CG\4:OPTXY
M6E/!#)O#K+*EOR:M2#_0&JW_.?QV:@$=@=_H0G6#]86=:D)W$D7?A6X^!W9J
M&-W-05M'UQSY)JI)__.*Z'5PY'%_BRO[?`(.2J'1,0$J'DTYS+;:;/?#Z?5N
M&#G2=CY=N4>&%CBPY2C;:O[M#N>VSO\Y]G;FXFKN_"Z3`/3<SC2]>D#KYG8S
MQ_Z@1+(B]BI6K!Q12],7ZA(!K:)*<I3M%+0R?H/-\#R<%PDT8:BL5MC^B($F
M7)5-'.T>/[`/5[7,-+8_AJ"*GEKV)=N?.-"#WDY.KE:O'BSCN:"4D?``P?MV
MWO)IA`2^&]3SP[PJ>-+1"+:_E:`8EE&5[C_)T[&_%Q'VG.7S&@:NCX.(@!&9
M.2AUA&8W3M%BX9#U:/H(9PA.H<N,:(GO&EU^8^Q#EVG*G@<3\@NP&DGQR1P2
M[Q9+!Q(VW5=SA\RX86V<PF82'*J$<O4I;(M#RU5$"#](N*:2EA#".(*(KEP"
MW1#$.\CV+H*\;1-\<H!9@-T$A5J:-)>4<9.Q^,EY8<JO0@(*A09,C"_SPKD&
MSSQN*Q4QDA`C?7%G8V-X!+,J)JLO;R1E0V%'H-,>4)GO9=O#N+`=C:;I.=7Q
M-YI*702GGK:-A'H"1+?PC+4><,C=9JI*FM2&M,[GQFVHM;BUW<:F'78A)]IN
M6>L,S?)^8KLAK3,8ZYUB+36N[1O1C:+=SNYVP,`*M#/;GR+M#%/>.;S="Z8'
M#*C*,6Y_YCQC5JK4+EQ0(._0%X=\!R%3+W-/.MER%%4_\F(GA6VEM:S4&C%J
M<1T%Q5:6^GK]><O#W,LK1_.1:+8V8NH.4<*CF)#-=TGX]Z7CLZ"%QSD`X6>"
MHR5[E[GFW-^Z63,YN(ISUY2'55LQN9WIFOU6]Z%VF@.Z@%:906VW$G0!LL1N
M;+O50">LNHV'3:P*/7X[55WE[<]=+'>A4(8(@@EP?/@;\#X[$`7,)QL$K%06
M)Z.LTTHUVB.%5ZP@U532IN+*<!1E9W!'SZA<I5:MD;W2_E3QA%F#!LP\"/@<
MY@(V<T1AQ_[89."-`6&1P<Z,IVDJ-&!^?&GTY_J:4B8UGE(%+3R5M)_Q0[']
M:Q"X!,8;014OR57LA,87N(BRR-EUXI(I0V%5-2/'2P>26!=-M(9[L`+^V1..
M_SV/4SK0?3P8+IB_$>\HJ=)$7\9XGA)XUGR,W":,CO%RO?GX5P@(U2GGZYC,
MX0OD[>F2E8V.ZPXMHQ3XBR^`71C4#::BAM$1?`$.4R,397T'YFN\H"I3W9BD
MVC#E!12FM[9/M#,!MU46[0/-PBG@%#Y`,]CK\_'9.\5Q_T(IM5O.I#U![H14
MLA8HZ/ZY;<"NW$3MSG`;-*4T2ENML1UAR#DYV&IN;8^B+IN1K997?0BWN".P
MRV%+'Z0JAAI;O;2Z0K-L%K+5'TL?>FH&%5O=L;K%DV^\L3604A^>-<[J#<(J
M5X`\8RN`*]U5;/ND[UHW,M3>'?3!A@N:K$DR@_&PSX<[,#9=\ANNM(XMF]FZ
M*UE2SA9KJ^&BE6FZ$L\JZ[SM#].)3-ZBS>-0N$ML7M_524I&TV:/25KI0C_&
M))QB'^(DZXA,E7YY&RE[$FGU4-D*'^![HFP5/#JQ:_3``B2,<Y?0%3Z:7H,E
M#F`HO!\1U=`S,Y@L,8E#>!8+0)CCY-A9`E))E4P-([AF)#$9FZ\?,;+".CWP
MSZ#\6W@L)U5-O!&:,%H)2\*'O`>,2/;GI1-`KHM<-WV\5I2JG/'TMW_T?^E@
M7+G>4!O:(ZK2%Q^>,V4?GK,^2*@"/>?*(SCOPPBL]D(JZ#D5JX`SK)I*9L=1
MXTM54=`\O5=4N9C10U<2A2U<)A(538SG"T9@G1RL;B/DB14J3N%>&'9T:E1R
M;@+VN@#L#=PZ*6:K0T#G`(O,`K;Z!>P/5$WQ@TT<"_J?M%K[Z:U:8!S`Y>1>
M$#WXN\O]HJQ')AUO/H\WGZI`"LPJNCG5<F_X3B^5SW?N!2WS@^\4O;-=].SR
M?Z^WF_#5I6IKA>VK5-YB4TH=)+YOLM6;M1EH4M>,MCJLMN,SGOUM?\]_O":T
MA+?K!^!(PU!#(2;KS0<3_B^;SG/":B[J1#5,6?%C>FXA@L$<>)\Q]H('$(ZF
M$SJ%9,5UY9&I:71$E)0ZTED1HS1.G!]?Z!(F=(M0`YU?T>AX_H[)]SL4AP8&
M:@,2U#0MG6M6^+::63>QMA]GFD(FXIU#.,0TP4PDM6V_DVN*6;PO'$#NPLQ:
MM9X`GT7$/F%V`S.:WD8A_76"UX[?K]2%A+!G8A?IU=$#)2G_)H[ZHS/+DJT+
M;^956S'CPAD_Y$<)8NGJH9=FD;]<UWA^U-?KT6AJL^O4U]/B]'L3A'#!^'^(
M4,28/(\4'Z%D%:PW2Z7*!UBM`2TT2R[=G;O9(MG*;>R3<FZ&2*7Z6BC^`GTZ
MFQB!1Q=060'Q"`&^0[B@=#?4//W`"M3DI;500Z5G?,N?,/D$T!TT`N*9J2*S
M23-&'MT+YX`4+GFD3_42%;7,Q]A9)_D9/.90L9G]!QP.J:)$<?7^"1Q"6;)J
M%N0K[Y%6RK#-:665]=":YK*YI0IFPHYC3!6PD)[>MO@RSHA32;%B$WKHCH@[
M=P+`W@RF?0YG!,1Z#E]BU-300E6ZSC=MYQM].JTUF5V5ZIN0$TQ%&4T+FJ9`
M9ZLN:_+<U%#/WEQOU#&=[3="TMI[^1:M5DFV_?I1^IRPX321:F;[)9H&M`JJ
MHZV7:*U.2[E$4]W^;37AZH&ST:G!5@NO'D@5C1BVFGXU+7?Y4Y2M81?[!#(^
MXMD::J$'2+43D]4)&9L8$(N*-N=L9FUHA!;0)(XTUD8]M`*PX?*W/VI!WI2J
M"N.!N-0+;4REL%Q5<\[^D#.79@LO%C#,(-E(-[=/U]T"&J7O'=3:,.,9YH$%
M2CQ5*="?(X=R9`BJ;]@D*YEY-R8(2OA>KA]8EFRZ1O.OU\(7<*0;Z,7X>'?+
M$A5Z0;\H[1&GL'FZUT/7)?1\+_>:CUS='HPJ8?2:IY;X-<R:81M(Z7(FT&K&
MM%U_41>8?-2V&.C@H*LT'"A*$%M-UG(;@'!%"CC36K.!!M@.ZCPKL:.5G8W%
M:N_^;CL,NA^[`,5>`E?8I[L]3FQ*&QMGD!8H_XJ\V'*07AJIG<LX[BC#!9VR
M.^3RG6*V2IC0F%Z#\S,/7Z;\_`L@X#K#9P'(%<6T]'_IO#A^Z/![+A?0U.<:
MD+\"VNS<I;+CWA=P%[>L+DIN<<1NJQ[ARRU<`?8?_6NX@-\=%U*VGCN^P*%5
MJ7[SE1$`]^T,KTX]`-FB>,\^L-&\+ZP%^M6W&RIBP^J4E#L_:\'OKV"!EU3N
M0P$#[93I'H=[,'/\9+051H6J$IK<MVN%MM#E7+KV?J@5N)E+U=1)9:FCTB;'
MIX]?1X^S.5Y1K01^IS!D'V_A"_"N,>MZ\0Q1W/&8X!EQ%@(W]";MZ'%0!Y'O
M!"+AOU7"B%LYF3DHC>AG]VO8AUZF[8P+:MAH>DN10BQ?1/R&8;*-UWB>:VE;
MRUS$_#EV2(A$&?4K2NEQA:;B,%@SK><+)"X@`I;@%=7D_.S.!=MM\>>CZ_*^
M79>;"3S;'9I;.X3SEI[M/KIM@=O>O6SUTM6%E]I99W]9<%XGFKLG'UM?;^,=
M+#=05)HP;+68UZ)14F%L]<NNYXDMLZ&M/M6U0/!M7;9Z1TM`4C(YVNK<7(M#
MU9'/5N]D@56.X;&+E:W7U`T-A04_SSI[6*Z'V+7G-#!:9JRUPWG6WDPW!$G2
M__]`5R//<5U^$=M_Q:_53"N/\8'X@QW]V=-O._&ET.#5?O2>L-M[0@_2EXY/
M11]XG`,0WN/$NTEPA<`MWA?:A4[)@@I'SY76E)1"#2?`!7`%O%M,Q@1[D1M>
M`Y]^07+!6:1,NJXN2LOAN$'2)=NY+YV`O0)SS=[<P$OVXPW+,UK]C'N3=DRL
ME.MT"ZWV4."5Z@&E!1&>!*^*PD#DZO9K5#O':NDQW1N-S^'359/S5*)B_\8C
MW%6DJKYF3SL]"-]$!"^!@[XB6/.@<%5)+7+_%J^@T+FH7."U^"-R>J8J/`%T
M%[H&R;]W2."@QB]LL6_D)IK]":=&[X#J'->0`#=.G!`M`!EZ*_8T2T#W^6R3
MKW;P:]K8?CPG.6YGBI4UI<2M\>?JP(OK]7M&:B%[S[36$V3PY/O@+`![7F&)
M"5/BTX>:JC=0N3IZO"Z7\W".0^#.LV?'>-ME;7%C*9>O(D)B#;7PO*9@OQ?7
M,3:*!XS<!@,15;/!+S?9M^C6-@%P\1R1(-XC6*QE4+TUUM2PRELX;;RV=[U]
MTF&@T)G%>2Z#<+A<$BI>_<<P\M8QQD^8BBRG\C$$^<JZ:(W-V<@%F_1RF28D
M`JVVEA[JLBRA!:O-IL-JWA;7T$O5!#!;&)7O=ZB80VF=09'.U/8T<I+XZVA6
M\_BR!*,I/2/$$D;Q^E_?T8WXUPAR+(H:6C6Q\XP)1"Y<^J!P/Y&>Q`HY`RMT
M$(')I5V;)E#8Y)AU\0S%%V&;1?4%4'W'*Q?X;8<%6C1T"%$C649INB<#UPFJ
MWQ>H*6R2[J\H6`(73B$[S0CT=7YY(]2#&1.HGP$[<"WGT*7;AI!Z;GDCU&>^
M$45Z!%*'7]XH]1E+R%!>*OO*H[O:2+.ORRG!M$&F,F^I7]E=W5?DL?R0B2$I
M,QQ5B;[&;9G`_^OREA&;$EC`5B@PZVJUMZBZ.$(A6;.!7&1_L#%<%,:0?OWM
MZ^,6F84?7G.X"R\V[>P8FU8%U];=QP:N<[NB'W1'EN[B95=HA.:8T5VXCB&V
MS4)LSX]BK(.([PL[G7%UH:H$I5VQ''N(PKVP<^NH<R$M.H.+7#9M]YBO=U<M
M(E5SD9:KNW:%*+8`2WA?E^^K=@5_-_*;/+P@M,8P'6H86FO`.`:W#+#S(V!;
M@,EXU&;H71S1VT*OY;U9!NS[(["\=;QK]L]`^W`$34+-+6/VTQ$S:?EW?TA1
MRPJA(KDUJ<9OQ=;,1VTP:WZG96L&I39H-HNHLS4%4QLD6T0EV)J^J0V<@B`8
M6[,\-82+&RMJ:P(H+3MN"Y]%V]/0-L)5WI?9]F2T[=BRA:NP[5EK&^HWDKD-
M;,]2VX@M:V)&;,U3VW(G;N(%;6NJ/?6\`_*VU4.Y@%3)<5!$K]8+,F<ZN\YQ
M#3,KG]FESS7/K'QNEPRJ3Y\KBMW-4;'KN-DR&?NY78=*'=FWS^W2NQMGW[ZP
M2QMLEWW[PKZM]9A]6SK?K^A%<LD;-UL!5,KG430TU0:BYPJ=70)9:ZQQD1-K
MIL!V#JR-3BWY57!"<'.FLTLQD@Z"+8)4F3,N1\C.:RXIA(K1?;GB:.FZJHL\
M+JTK/GK6RQ]1C'.5[*D05+9C=$Q;GWZ[@ZA$VOK'$+O?8W>.*[Q84HTU[JKZ
MVYL7]A&HY:S7$[7-;A5&T_@>5ABGO5O.2.;9#;SL/B0'<`)\NIR]^(KD<4X9
M^YE!G.FH-<\(MVS42'[8Q=+':P`>`5E!YCM)J=OAJJ'OI^Z43,_,KCVH,@]Q
M,JB="Y4M8'3W8@*ISP`!0G=`Y`V]!42035H(5R!=<D*>EZMK8E1WB(H>L-G#
M)!XC$-7HT0B$.5[$=<SD7@H`W4_GE$6*+GL2O"53TTS6H#GP(I^*0CVK7Y2#
MOIN^C*!623!OV-6%C=YV:ME7RVIS)WQDN\K=T<9>FAD.K]KN^"ZQ9Q9AJMF@
M;&=$J?VYB%?%0<)VYW]EC*34!=L=_951DU3A;??H[U0SDY!\!Q+UOC>8M6_U
M^XSWZYE93<,3D'H.`L,?#O&VO2NW]/]RF:,9K0=F-,94HV71`TUL$-LI;_:H
MSI$=!:O\Y3HOD_FFQFPH=3QOVWY_CN0EAX]JDNNLHAH:?E5X)'P>?*8%P^`.
M)7N/;FRJ.WG]./T=P-F<2K_ABJJP,Q#_>$W%X:T#R=\<G_N\Y+ZIZ"727*F2
M[Z#(&_L.8KXTXNS@771E)C4WW7GN@B`"WG5$6$1S/,$Q[8&:%;)!2T9S#59I
M5O5VK;;L9+N=ITO+;VNUQ';PM6MP):>,\H(YH(-[!V#JT";MS\>C3^?6@CU'
M<[7]HN,US(*$7FS[[4%'T]1$0;3]RJ'+DT:E27?7GK2_VPECIMD'EK\O""C#
MQ5CVQR:+0NA!/V)W1H_`I:N")8RZ>7']B([XEG(*XXHH3,WL-PY!=-WDXU@P
M]W&>+5=+VR9.DBTIK[.2:6O>"#:OPHJ_PTQB^SRW^-'RWMSRWI+-Y<SO6CHY
M6OA:6/A,V+LTR^>2:4#/CFC[0>IH<NS&Q[%FWZHV)NJ1M+9CV\W.=#0K=HJH
M-DE_M##N]23?M5UJSR?Y!QRR9*RW$#G(A2S)9>H!&(S(S$'PM[A#EMT1^]!+
M@*=8%H@932LJYP8"6OH1SA"<0M>AL^+&<=G,1$7;<UD.9TK[)55'OYNP$K0:
M8\W12T_;)C3XO<]\!P`V(<.DC-/*B:67O_8^F?L[(1RLK,R^,!,\7AA?3,BZ
M;B4+JY@+1'UR7N3HYQ;7\GA\]J#!.G6_>,(LH(:R2B$O-9UK,:EM6C(Q`P_@
M1X&_"5UE$7*3]9"0)S<SRLV\NOVTAUH&AX^+I$@PJZBXB5D:L]TFN3B=`-=W
M@B"6PS&6WK^C(&20%=)^<29$N1DS8\5+0,(U.Q.Q%WYN?HU@')8FM^JDJ_<N
M/#\AD#,LF9IF1K2=YEQNFNKK&;D?2/)/;9+@J8A[N;I:I%E!$:-RE;VYD:2<
ME-F'I>N:P/]KP,+<@A`NZ#;`N^C<*F35R:A^L[+]CJ.SPZ;X;&"[<U=GL&XO
M6=M=MSH#4EW'LSW`O#.H);=YV]^8ZV;WDE=.;'^;KC/^E5"Z;7^?KD-L)8YH
MMC]?U^$F)WNXM_TAN\X@YMN/;7_=KC-(U0W"MC^*UXWJT/2V87_OYO7F5F\3
MEY3?T)EU5Z@BJ.9^0%C%A/E)#*K\(/IQ;2\S(T4I5S/Z`[PZ%R(2N\\9N>7>
MD#4,`L!>O'$89=Z(O6T;$19C=^D$4)YS99OIRY)\;6(E]]B\<H(Y^X^IO2NZ
MM27/$SS.,0F?`%G<H15([#Q)EK;:*X?V#;\F`:4#1]O-YXV%OK0L.4!W4\9/
M*&2/86U`-:IK5=!3(Q-%-<PX.0D0E1Y"/\28Q&R4S^>BH1^@EB4"Q)R2]?K7
M6+Y=;BB[HB*=?E)4+FJJOZ*U)P_)`:Y#GO5E3&N@D!;=,L,TW`(5/4WK>Z]P
M<FG>F(F%NNF]1L#LEC/Z&!N/ZEISGL24'N#RN\*+!0RS)^NN<&QL!HBYTO=$
M[92BL(:'U=HPL1H5YZ'%,/NQA3::U;)CE1I@![FV-P^#KXIO?/=F8<N3Q^-W
M^1:.80[",`<;;O,:,=91+HCP,7<2?D5KQXQ1GS.)Z<O#+N?GXC/$JM9^[3U:
M*7TZG:(#E%;2J;F+N2[,>B4<'Y91))DS=2V!X+1J5Y[YUA@?18HJ9N:4HJ-@
MV=YC-;U.)ZT$Z>[/+F'4X;P<H)C:29UF4J=YU6EVN4#*$=^/Y:J2,%(P8L,+
MZ9=31BR3*/2/_P=02P,$%`````@`23`&1V<).X'F#0``'HL``!$`'`!N:W1R
M+3(P,34P-C,P+GAS9%54"0`#JC##5:HPPU5U>`L``00E#@``!#D!``#M75]O
MVS@2?U]@OP//#X<N4,=QTG2W0;(+-VYN#:1)8*>+WKX4M$3;1"322U%I?)_^
MAM1?B[)"V6XK`WK8KB3.;SC#&0V'(YJY^./9]]`3$0'E[++3/SKN(,(<[E(V
MO^Q\FG0'DZO1J//'[S__=/&O;A>-QVC(&2.>1U;HLT,\(K`DZ`$_<\;]%9HX
M"^+CUVB*`^(BSM#G]^,;='+41V@AY?*\U_OZ]>N1$&["Y,CA?@]UNTD'?T6B
MG*.W1R<G1V]R+6,>,O<<Y1]="8(E4",7A#A')\?]L^[Q;]WCLX?CM^=GI^?'
MO_Z=I^;+E:#SA42OG%^`^/BL"XA3-#X:'^6T^C>:<!8`M;_$;(4&GH?&"A6@
M,0F(>"+N4<PTT,HB&$$67'9R^GT]/>)BWH,N^KW/'V^B0>G\_!.*:,^?I\*C
M:PCU),&<]B@+)&8.R4$\RAXK$*I9C7F^$P,2B]5_]^Y=3[?FJ,.@.\=XF=+/
M<##5U'%#+QK<?O>TOXZ2JR4)2F&ZI1S''J58$XV11XF%=@8%.'Y[>IPG!^.$
M?KGZKA0]U5,/B+I`101U\M"7<09&T;@RA>5'^JP7->:H'?!+*5;KY`%QCN;\
MJ1<W*J5.C5%P0B'@9=L$C5L5]HV!=0DMAT%#.8(\.XMRB&HIMQ-E3R20Y:BH
MK5PSAJD3E,-TDT+U#51`G7(,-&Q`R*78`(&6(@8\;$[D+?9)L,0.L7)`B'`^
M8?*:"W](9CCT8#3^";%'9Y2X'82E%'0:2K)&$+*,Y'?%Y0(SQJ6.5?I>/5DN
M*9OQ^!8>J!?R7'"//(!7(G7Q:3S:)*.,`VY/T?6&W`F5E)BY'YBD<C4"SL+7
M_740=2\[E12I#(D4+IE11K6T_>,^ZJ($GK\$5BCBA7+,+GI%#D7F(<P,=^QW
M?>U@SPD]#;R!^Q@<4U0!EP)B,9-;(#/)-N/BIXDQ]F*C"0BK7>EN=DT91'>*
MO7L>:$FN/!P$L4<I:XT!\,424&V\4[!8R@BI.9"YA*FY&:X"[E$U<[KH/?;4
M?(,F"T)@HGOUB>'0I=#R2VO/G>QYCR&&RP61%(:FMG$U^@4+O]G5PNC5FI"M
MQ2TL/H(4V2<#3Q+!0(,G4FY:DZS:EF=VMDQ)`L1GZ&ZI<G"J<M;VO:UE1?![
MR6"]<8675&YZ/8M$U19\NXT%U5)#D`70@8N@&QZTEJQIR2L<+*X]_C48,9<*
MXLAR6YIDU=;\=2MK0B=(]]):T<**MUR2X(&GLV`VF'=BCAG]G]8E&V^X&3#W
M/J=G;@K-P$,:.!X/0D&`>D+G#"94!S,Y</22C++Y/?!S*/1-GN5[CSN/.9]I
MD%#5'OJ;RLA3KG"3ET^GZ)/0][%8*<_,]8BR+E'29^NBM5WT&E/Q%_9"DMF@
MIC]5<Z@V_KNB\77H448?Z;5Y%)(H0Q^Q>"023SW(_X@3"F#0FGL+<ZMA99*+
M53;J]:Q=R:#2V/WCHK%37JTA:QORAN(I]:A<C8FGIO`'/L$>@60/$!`4L7<=
M2ACE,5]A3]:>([;G7NT"_:(+I!VAN"<D.5)]J6@?=8+27EHWJ>TFD)C[-`JC
M,&'#=*_F2\+49+EM!*C)LMHA3HP)(..NYX$U_JT#;.$`GH>G7.C%^T`(#&.I
M&K:WOCV_:M.?FK'`44N3V.QI-Y`%#N:"1-VW'E#;`[(QAN4CK--AC+5><<"]
MXH$,)@LLR'OUQ?,>KS2JGE?LVD>UI[PI>LI$`JBK>:%\=ZUWU/:.#U@PB*_!
M/1':0/7LOAE=;=&SHD5OB8S*1L`):5:M+1M?;D@>-++LD`I7[8EO]UA^0*^2
MJ[98MN=*Q(-:^MLYF@V?:I_X=:>J!'H5==+ZP'[+$S5<P()-M0<81<F48VO=
M[[(6J6'L^ERK;6_4)&W6):U;_+`%2@U7V4]/E>YS8E0Y-RU66I=Y<5-89JY<
M4J8RP"@ENYM5IH(#U]5"8\_<3/8M.%?[A5'ZW"71[*),A/S>-?1J"/D(;;?`
M6/B42NK`XKF4;L2RA"[+YVSI1LSQ0K7K7`$^_!/2)^S%1=(Q(`5U5(B!MJ(+
M_CA!JCW6K,W62H-KTK]&J=P1,">Y9I+)'K6WKKYW5[>*F+LQJW8YHR9<U^7:
ML/B]?.6>"SF#^8A'FY)L(-MZTC9=5?N945&NZV>I2.E^*?OR0.N+MKZ8KKK3
MBZ(+E5!46]ZH/&<K^[55?FLD6R-MVBM0V")@-;?LQ*O:\$:AM];6@W9JV<?4
MLGGG@%WF41=?[1%FF;=J[T'K`7N)%;J4IJV7*Z1E=;288+V5N7=R0<280'0.
MB1DS]L"SVE.,<K!523`E>UV@42C=.XJ[;UUHCRYD.=%LQ:7:3;:K'+=Q97>G
MT#5676+-5UC+GWYX5I=&&-F&1:4[G-I7@BN:XJY:9]C5&:S"0AUHM?&-<F^%
M\=OW?U>3WQ*I=@\EVY"L;&V%J3:R42$UMS&UYH7'ZA]UML>8S)`^MN-<G5MQ
MV0FHO_0@$D?/L'`4OOK`C]Y2\"41:DW62]@F#`ST^@DCVF<*XQ=+E7!8"#*[
M[*BS/;K)&0I?`''T['L)B:12]7*5\4&*4?`:8<_K])JK^;H9+10'0(GBPY3-
M@>@-61?Q+%4&VA*5;Q2'`]&V^)I;*`V0$J7S>_+*=+_HY<__@+OU\T$N0'4N
M)&*E9Y5L."P(1><1W7!',ZJ`J+MN@NNJ1]W^2?>T?_0<N+&(=23(1KJ>!`FN
MK@25APQMDD'W7WJJ48]X,DAY=3->]8>C]#`BJU')(V\CH!J6=VI8^F]WD60[
M*;83H?2H)%NO2`"JT[/:CE`\I&H'/U!/ZKK!2Z<^58I3ADMNNAF3+00I.4/*
M3I(\,+WK9FSJRU(XF,I*C`2C+G;JO'C$E57O*4A?[>01YF%95A+D8/'U3NY@
MG+UE)42&BBZ[&8/Z(A2.\K(2(,&HB]TZ+QP*9M=[`M)7&_J/CPG3`EQV!HXC
M0E@%PP2GCM1Y$!1[<2DB_HRK<H@OU611$J2/"CSW.8/ECEB-)/'5"J&#\#20
M`CORLC/#GDYR-"$D/Y2[#QH:3?`R:9I&)P!==AQ!8$G508RJFIK*5J10A>$@
M!)Y4AFHH_B-XN$QZI]#K!D7].6$CYGPD_I2(O&J%ADB9Z!R_<Y?[F+(R72)!
M3%7<4,2KT'T(K7K[FS#BX,'4E+RLM4GBO\?/V)/8$+SPO%DBKXCXDX!X"P=6
M]3>>Z3";21JFR#4/Q1TC$_I\39^(^@_N!CY]Q`X(QA;8(V7*U8`U26';'2.P
MQ"%*R'QXVP*;CWEJOQJ;-UYSO0UY"ZUCW'?6V)7G"T`*)YSJ,:_4O6SC95['
M8OLWF[%<,MW3A*4$71?;W.8Y>,)4]W/-A=K1D#-E80QVXG0(H\590-WX>+DQ
M<0B$+1=TN1?<#1TY)!X\$,FIE=&P6$-VUC]S_F^7X*2;&&3R>X9()\56?XVX
M8T/R1#R^5(T?GHI.LA7\(#Q#+-776+VK!,*).KX2@PC&U/<289,FNR&9RNP5
M_8BE"M6K(0@_)($CZ#+[$*)ULZ2W"_$6;OX-5'RF?N@GDM_K7BL4+*5NE'KQ
MX<2#DF..![$L>?VLR!N4E'P`@*]VVPW@?5'?VB3$TD".X=$=B[;;K=*=>3E%
M:^+BEQ+>2)4J0/<_SJ+7_(D&):N=PO,FA9$_B<^7"QA*4VJSJ4F"PWI=$)B5
MAB3Z_XA9%C+J`K_=U+^_&<[4:6T'W0:]4YJ#R&Z25UXM1WART"TD:T-].*I*
MY=1G@('[I#ZI!>HG?'$6DQN#'7@<0H7+<D]UV?JW/K1!,XVE\/HWE:O"L3=U
MM#<8K`5$F3S_<1.0I1[%,D`]6".K`'6/,;SE[$I_*)(6XV##Y)#C@^5)DEN-
M4:/?EI=V!IM9>`U,HP+DBQOGRZ8$>]`AZ6I&/SM`0^.>^8L'\R<4>3TK2`\B
M#_Q(/5@-@G034`=#WW?,_(A11=2D58PAY\-7_K(R.:)F*0/K;V$N)`O/&R4R
M?X(YES["RY]<7M-GX@ZY>E'\*66ZKWO!YP+[IF9;P9LX`-MH?:"J;M2GB4+?
MDM##936E8D.CA(:\&`>+I'(7UU(*"6.:(>:5J@D\A-I,K%-<N(SGVNJ%ECDB
M]=`',8_?+1=R`8L&9Y%\=@&LX>:55$WR^?P93YL+#95435L?Z>0PKI*9ABEI
M;)(]XLK=-8?TEOK34`3)WU521[_E%'F)\!!B3*S#1^RJK_=IOGC+Y<!94`@:
M[G\)5EMZ3+UM,`<13^ST@=2Y]AAHS&&,`9GC8*5V<VS*Q3=2-.K=C83<)'PS
M1=;?'O%<E\(".5@N!:25WD2&[DI'D@<^)DN\6E/'&M.@CYP@M?[N#+Z;OC#)
M9Y(2B[U,W"@S)E7,W$Z75/"U6>,%PL,(%XD28Z+V.P%PQ/+)Y"H]%S7RPZ*3
MTO(AV87;_LKH>QV?)/V.%;MC*O/>I,AJ-!N3?T*ZOMEL'\R:%`8$F1$!4NE?
MN^L?0`])0.=,K4SR:E?3K15556/PXZPMN$.(&UP+[H^"(%2OFSX\V(\/A[@E
MZL_DQBU&&KD-^B!RRYQBU9]Z@&&P:4BLD`<R'.J]U:^LVE9<LF;?3'(8LT(H
MG`76'T24"NEW$'-R?X&P21.[CJW1ND[_%9*B9Q:_[*J7]4%@%F`=HXMO^W[8
M'8*_C[FS,+^OK#UME)VCR37U16-3<_GNV'HPNR^!WV<>SIT?#D*KG"#^`^N;
MBU#VD*95I#XM9X+K+;#&:B+9OO^)N40DGW03<^:4WYY%$X/W12_Z52A<_A]0
M2P$"'@,4````"`!),`9'<MU`SP*F``#*M`4`$0`8```````!````I($`````
M;FMT<BTR,#$U,#8S,"YX;6Q55`4``ZHPPU5U>`L``00E#@``!#D!``!02P$"
M'@,4````"`!),`9'!JW#%>H.```HTP``%0`8```````!````I(%-I@``;FMT
M<BTR,#$U,#8S,%]C86PN>&UL550%``.J,,-5=7@+``$$)0X```0Y`0``4$L!
M`AX#%`````@`23`&1W^O$CS7%0``+$@!`!4`&````````0```*2!AK4``&YK
M='(M,C`Q-3`V,S!?9&5F+GAM;%54!0`#JC##575X"P`!!"4.```$.0$``%!+
M`0(>`Q0````(`$DP!D>,^8]EDTX``/@@!``5`!@```````$```"D@:S+``!N
M:W1R+3(P,34P-C,P7VQA8BYX;6Q55`4``ZHPPU5U>`L``00E#@``!#D!``!0
M2P$"'@,4````"`!*,`9'IR9GI((F``":MP(`%0`8```````!````I(&.&@$`
M;FMT<BTR,#$U,#8S,%]P<F4N>&UL550%``.K,,-5=7@+``$$)0X```0Y`0``
M4$L!`AX#%`````@`23`&1V<).X'F#0``'HL``!$`&````````0```*2!7T$!
M`&YK='(M,C`Q-3`V,S`N>'-D550%``.J,,-5=7@+``$$)0X```0Y`0``4$L%
3!@`````&``8`&@(``)!/`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295538669840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DebtInvestmentMaximumMaturityPeriod', window );">Maximum maturity term for debt securities investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Two years or less<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DebtInvestmentMaturityDateDescription', window );">Weighted average maturity term for debt securities investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">One year or less<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds', window );">Available-for-sale securities, sold</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Level 1 to level 2 transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Level 2 to level 1 transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Senior secured notes, carrying amount</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">12% Senior Secured Notes Due July 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior secured notes, interest rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Senior secured notes, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 15,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">12% Senior Secured Notes Due July 2017 [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior secured notes, interest rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Senior secured notes, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 15,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Senior secured notes, carrying amount</a></td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Investments in Marketable Securities [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashAndInvestmentsInMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DebtInvestmentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt investment maturity date description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DebtInvestmentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DebtInvestmentMaximumMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt investment maximum maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DebtInvestmentMaximumMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of proceeds received for the sale of securities, categorized neither as held-to-maturity nor trading securities, during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (bb)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (bb)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorLongTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295547676224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Inventory (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 2,392<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">6,117<span></span>
</td>
<td class="nump">5,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,615<span></span>
</td>
<td class="nump">5,565<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 10,124<span></span>
</td>
<td class="nump">$ 12,952<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section BB<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section BB<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section BB<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295547636752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Note 1 &#x2014; Organization and Summary of Significant
 Accounting Policies</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Organization</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 We are a biopharmaceutical company headquartered in San Francisco,
 California and incorporated in Delaware. We are developing a
 pipeline of drug candidates that utilize our PEGylation and
 advanced polymer conjugate technology platforms with the objective
 to improve the benefits of drugs for patients.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Our research and development activities have required significant
 ongoing investment to date and are expected to continue to require
 significant investment. As a result, we expect to continue to incur
 substantial losses and negative cash flows from operations in the
 future. We have financed our operations primarily through cash
 generated from licensing, collaboration and manufacturing
 agreements and financing transactions. At June&#xA0;30, 2015, we
 had approximately $279.7 million in cash and investments in
 marketable securities.&#xA0;Also, as of June&#xA0;30, 2015, we had
 $133.5 million in long-term debt, including $125.0 million of
 senior secured notes and $8.5 million of capital lease obligations,
 of which $5.6 million is current.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Basis of Presentation and Principles of
 Consolidation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Our consolidated financial statements include the financial
 position, results of operations and cash flows of our wholly-owned
 subsidiaries: Nektar Therapeutics (India) Private Limited (Nektar
 India) and Nektar Therapeutics UK Limited. All intercompany
 accounts and transactions have been eliminated in
 consolidation.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 We prepared our Condensed Consolidated Financial Statements
 following the requirements of the Securities and Exchange
 Commission (SEC) for interim reporting. As permitted under those
 rules, certain footnotes or other financial information that are
 normally required by U.S. generally accepted accounting principles
 (GAAP) for annual periods can be condensed or omitted. In the
 opinion of management, these financial statements include all
 normal and recurring adjustments that we consider necessary for the
 fair presentation of our financial position and operating
 results.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Our Condensed Consolidated Financial Statements are denominated in
 U.S. dollars. Accordingly, changes in exchange rates between the
 applicable foreign currency and the U.S. dollar will affect the
 translation of each foreign subsidiary&#x2019;s financial results
 into U.S. dollars for purposes of reporting our consolidated
 financial results. Translation gains and losses are included in
 accumulated other comprehensive loss in the stockholders&#x2019;
 equity section of the Condensed Consolidated Balance Sheets. To
 date, such cumulative currency translation adjustments have not
 been significant to our consolidated financial position.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Our comprehensive loss consists of our net loss plus our foreign
 currency translation gains and losses and unrealized holding gains
 and losses on available-for-sale securities, neither of which were
 significant during the three and six months ended June&#xA0;30,
 2015 and 2014. In addition, there were no significant
 reclassifications out of accumulated other comprehensive loss to
 the statements of operations during the three and six months ended
 June&#xA0;30, 2015 and 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The accompanying Condensed Consolidated Financial Statements are
 unaudited. The Condensed Consolidated Balance Sheet data as of
 December&#xA0;31, 2014 was derived from the audited consolidated
 financial statements which are included in our Annual Report on
 Form&#xA0;10-K for the year ended December&#xA0;31, 2014 filed with
 the SEC on February&#xA0;26, 2015. The information included in this
 Quarterly Report on Form 10-Q should be read in conjunction with
 the consolidated financial statements and the accompanying notes to
 those financial statements included in our Annual Report on Form
 10-K for the year ended December&#xA0;31, 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Revenue, expenses, assets, and liabilities can vary during each
 quarter of the year. The results and trends in these interim
 Condensed Consolidated Financial Statements are not necessarily
 indicative of the results to be expected for the full year or any
 other periods.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Use of Estimates</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The preparation of consolidated financial statements in conformity
 with GAAP requires management to make estimates and assumptions
 that affect the reported amounts of assets and liabilities and
 disclosure of contingent assets and liabilities at the date of the
 consolidated financial statements and the reported amounts of
 revenue and expenses during the reporting period. Accounting
 estimates and assumptions are inherently uncertain. Actual results
 could differ materially from those estimates and assumptions. Our
 estimates include those related to estimated selling prices of
 deliverables in collaboration agreements, estimated periods of
 performance, the net realizable value of inventory, the impairment
 of investments, the impairment of goodwill and long-lived assets,
 contingencies, accrued clinical trial expenses, estimated interest
 expense from our liability related to our sale of future royalties,
 stock-based compensation, and ongoing litigation, among other
 estimates. We base our estimates on historical experience and on
 other assumptions that management believes are reasonable under the
 circumstances. These estimates form the basis for making judgments
 about the carrying values of assets and liabilities when these
 values are not readily apparent from other sources. As appropriate,
 estimates are assessed each period and updated to reflect current
 information and any changes in estimates will generally be
 reflected in the period first identified.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Reclassifications</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Certain items previously reported in specific financial statement
 captions have been reclassified to conform to the current period
 presentation. Such reclassifications do not materially impact
 previously reported revenue, operating loss, net loss, total
 assets, liabilities or stockholders&#x2019; equity.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Segment Information</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 We operate in one business segment which focuses on applying our
 technology platforms to improve the performance of established and
 novel drug candidates. We operate in one segment because our
 business offerings have similar economics and other
 characteristics, including the nature of products and manufacturing
 processes, types of customers, distribution methods and regulatory
 environment. We are comprehensively managed as one business segment
 by our Chief Executive Officer and his management team.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Significant Concentrations</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Our customers are primarily pharmaceutical and biotechnology
 companies that are located in the U.S.&#xA0;and Europe. Our
 accounts receivable balance contains billed and unbilled trade
 receivables from product sales and royalties, as well as milestones
 and time and materials based billings from collaborative research
 and development agreements. When appropriate, we provide for an
 allowance for doubtful accounts by reserving for specifically
 identified doubtful accounts. We generally do not require
 collateral from our customers. We perform a regular review of our
 customers&#x2019; payment histories and associated credit risk. We
 have not experienced significant credit losses from our accounts
 receivable and our allowance for doubtful accounts was not
 significant at either June&#xA0;30, 2015 or December&#xA0;31,
 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 We are dependent on our suppliers and contract manufacturers to
 provide raw materials, drugs and devices of appropriate quality and
 reliability and to meet applicable contract and regulatory
 requirements. In certain cases, we rely on single sources of supply
 of one or more critical materials. Consequently, in the event that
 supplies are delayed or interrupted for any reason, our ability to
 develop and produce our drug candidates or our ability to meet our
 supply obligations could be significantly impaired, which could
 have a material adverse effect on our business, financial condition
 and results of operations.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Revenue Recognition</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Our revenue is derived from our arrangements with pharmaceutical
 and biotechnology collaboration partners and may result from one or
 more of the following: upfront and license fees, payments for
 contract research and development, milestone payments,
 manufacturing and supply payments, and royalties. Our performance
 obligations under our collaborations may include licensing our
 intellectual property, manufacturing and supply obligations, and
 research and development obligations. In order to account for the
 multiple-element arrangements, we identify the deliverables
 included within the arrangement and evaluate which deliverables
 represent separate units of accounting. Analyzing the arrangement
 to identify deliverables requires the use of judgment, and each
 deliverable may be an obligation to deliver services, a right or
 license to use an asset, or another performance obligation. Revenue
 is recognized separately for each identified unit of accounting
 when the basic revenue recognition criteria are met: there is
 persuasive evidence that an arrangement exists, delivery has
 occurred, the price is fixed or determinable, and collection is
 reasonably assured.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 At the inception of each new multiple-element arrangement or the
 material modification of an existing multiple-element arrangement,
 we allocate all consideration received under multiple-element
 arrangements to all units of accounting based on the relative
 selling price method, generally based on our best estimate of
 selling price (ESP). The objective of ESP is to determine the price
 at which we would transact a sale if the product or service was
 sold on a stand-alone basis. We determine ESP for the elements in
 our collaboration arrangements by considering multiple factors
 including, but not limited to, technical complexity of the
 performance obligation and similarity of elements to those
 performed under previous arrangements. Since we apply significant
 judgment in arriving at the ESPs, any material change in our
 estimates would significantly affect the allocation of the total
 consideration to the different elements of a multiple element
 arrangement.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <i>Product sales</i></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Product sales are primarily derived from fixed price and cost-plus
 manufacturing and supply agreements with our collaboration
 partners. We have not experienced any significant returns from our
 customers.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <i>Royalty revenue</i></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Generally, we are entitled to royalties from our collaboration
 partners based on the net sales of their approved drugs that are
 marketed and sold in one or more countries where we hold royalty
 rights. We recognize royalty revenue when the cash is received or
 when the royalty amount to be received is estimable and collection
 is reasonably assured. With respect to the non-cash royalties
 related to sale of future royalties described at Note 4, revenue is
 recognized when estimable, otherwise, revenue is recognized during
 the period in which the related royalty report is received, which
 generally occurs in the quarter after the applicable product sales
 are made.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <i>License, collaboration and other revenue</i></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The amount of upfront fees and other payments received by us in
 license and collaboration arrangements that are allocated to
 continuing performance obligations, such as manufacturing and
 supply obligations, are deferred and generally recognized ratably
 over our expected performance period under each respective
 arrangement. We make our best estimate of the period over which we
 expect to fulfill our performance obligations, which may include
 technology transfer assistance, research activities, clinical
 development activities, and manufacturing activities from
 development through the commercialization of the product. Given the
 uncertainties of these collaboration arrangements, significant
 judgment is required to determine the duration of the performance
 period and this estimate is periodically re-evaluated.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Contingent consideration received from the achievement of a
 substantive milestone is recognized in its entirety in the period
 in which the milestone is achieved, which we believe is consistent
 with the substance of our performance under our various license and
 collaboration agreements. A milestone is defined as an event
 (i)&#xA0;that can only be achieved based in whole or in part either
 on the entity&#x2019;s performance or on the occurrence of a
 specific outcome resulting from the entity&#x2019;s performance,
 (ii)&#xA0;for which there is substantive uncertainty at the date
 the arrangement is entered into that the event will be achieved,
 and (iii)&#xA0;that would result in additional payments being due
 to the entity. A milestone is substantive if the consideration
 earned from the achievement of the milestone is consistent with our
 performance required to achieve the milestone or the increase in
 value to the collaboration resulting from our performance, relates
 solely to our past performance, and is reasonable relative to all
 of the other deliverables and payments within the arrangement.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Our license and collaboration agreements with our partners provide
 for payments to us upon the achievement of development milestones,
 such as the completion of clinical trials or regulatory
 submissions, approvals by regulatory authorities, and commercial
 launches of drugs. Given the challenges inherent in developing and
 obtaining regulatory approval for drug products and in achieving
 commercial launches, there was substantial uncertainty whether any
 such milestones would be achieved at the time of execution of these
 licensing and collaboration agreements. In addition, we evaluated
 whether the development milestones meet the remaining criteria to
 be considered substantive. As a result of our analysis, we consider
 our remaining development milestones under all of our license and
 collaboration agreements to be substantive and, accordingly, we
 expect to recognize as revenue future payments received from such
 milestones only if and as each milestone is achieved.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Our license and collaboration agreements with certain partners also
 provide for contingent payments to us based solely upon the
 performance of the respective partner. For such contingent amounts
 we expect to recognize the payments as revenue when earned under
 the applicable contract, which is generally upon completion of
 performance by the respective partner, provided that collection is
 reasonably assured.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Our license and collaboration agreements with our partners also
 provide for payments to us upon the achievement of specified sales
 volumes of approved drugs. We consider these payments to be similar
 to royalty payments and we will recognize such sales-based payments
 upon achievement of such sales volumes, provided that collection is
 reasonably assured.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Research and Development Expense</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Research and development costs are expensed as incurred and include
 salaries, benefits and other operating costs such as outside
 services, supplies and allocated overhead costs. We perform
 research and development for our proprietary drug candidates and
 technology development and for certain third parties under
 collaboration agreements. For our proprietary drug candidates and
 our internal technology development programs, we invest our own
 funds without reimbursement from a third party.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 We record accruals for the estimated costs of our clinical trial
 activities performed by third parties. The financial terms of these
 agreements are subject to negotiation, vary from contract to
 contract and may result in uneven payment flows to our vendors.
 Payments under the contracts depend on factors such as the
 achievement of certain events, successful enrollment of patients,
 and completion of certain clinical trial activities. We generally
 accrue costs associated with the start-up and reporting phases of
 the clinical trials ratably over the estimated duration of the
 start-up and reporting phases. We generally accrue costs associated
 with the treatment phase of clinical trials based on the total
 estimated cost of the treatment phase on a per patient basis and we
 expense the per patient cost ratably over the estimated patient
 treatment period based on patient enrollment in the trials. In
 specific circumstances, such as for certain time-based costs, we
 recognize clinical trial expenses using a methodology that we
 consider to be more reflective of the timing of costs incurred.
 Advance payments for goods or services that will be used or
 rendered for future research and development activities are
 capitalized as prepaid expenses and recognized as expense as the
 related goods are delivered or the related services are performed.
 We base our estimates on the best information available at the
 time. However, additional information may become available to us
 which may allow us to make a more accurate estimate in future
 periods. In this event, we may be required to record adjustments to
 research and development expenses in future periods when the actual
 level of activity becomes more certain. Such increases or decreases
 in cost are generally considered to be changes in estimates and
 will be reflected in research and development expenses in the
 period identified.</p>
 <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Long-Lived Assets</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 We assess the impairment of long-lived assets, primarily property,
 plant and equipment and goodwill included in other non-current
 assets, whenever events or changes in business circumstances
 indicate that the carrying amounts of the assets may not be fully
 recoverable. When such events occur, we determine whether there has
 been an impairment in value by comparing the asset&#x2019;s carrying
 value with its fair value, as measured by the anticipated
 undiscounted net cash flows of the asset. In the case of goodwill
 impairment, market capitalization is generally used as the measure
 of fair value. If an impairment in value exists, the asset is
 written down to its estimated fair value. In March 2015, we
 announced that the primary endpoint for our BEACON Phase 3 clinical
 study for NKTR-102 as a single-agent therapy for women with
 advanced metastatic breast cancer did not achieve statistical
 significance. As a result, we performed an impairment analysis for
 our long-lived assets, including goodwill, as well as our primary
 long-lived asset group which is dedicated to NKTR-102. Based on
 this analysis, we concluded that there is no impairment at
 March&#xA0;31, 2015 or June&#xA0;30, 2015.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Income Taxes</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 For the three and six months ended June&#xA0;30, 2015 and 2014, we
 recorded an income tax provision for our Nektar India operations at
 an effective tax rate of approximately 34%. The U.S. federal
 deferred tax assets generated from our net operating losses have
 been fully reserved, as we believe it is not more likely than not
 that the benefit will be realized.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Recent Accounting Pronouncements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In May 2014, the Financial Accounting Standards Board (FASB) issued
 guidance codified in Accounting Standards Codification (ASC)
 606,&#xA0;<i>Revenue
 Recognition &#x2014; Revenue from Contracts with Customers</i>,
 which amends the guidance in former ASC 605,&#xA0;<i>Revenue
 Recognition,&#xA0;</i>and is effective for
 public companies for fiscal years beginning after December&#xA0;15,
 2017. Entities have the option of using either a full retrospective
 or a modified retrospective approach to adopt this new guidance. We
 are currently evaluating the impact of the provisions of ASC
 606.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In April 2015, the FASB issued guidance to simplify the
 presentation of debt issuance costs by requiring debt issuance
 costs to be presented as a deduction from the corresponding debt
 liability. This guidance is effective for our interim and annual
 periods beginning January&#xA0;1, 2016. Upon adoption, the new
 guidance must be applied retrospectively to all periods presented.
 We do not believe the adoption of this guidance will have a
 material impact on our consolidated financial statements.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6003-108592<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295538548720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PreferredStockShareDesignated', window );">Preferred stock, shares designated</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">132,185,000<span></span>
</td>
<td class="nump">131,216,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">132,185,000<span></span>
</td>
<td class="nump">131,216,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PreferredStockShareDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock, shares designated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PreferredStockShareDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295660642672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Inventory consists of the following (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Raw materials</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,392</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Work-in-process</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,117</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,187</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Finished goods</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,615</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,565</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total inventory</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,124</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,952</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 2<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph a,b,c<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295533628048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jul. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NKTR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEKTAR THERAPEUTICS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000906709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,371,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295660642672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">License, Collaboration and Other Revenue</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 In accordance with our collaboration agreements, we recognized
 license, collaboration and other revenue as follows (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <br class="Apple-interchange-newline" />
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="39%"></td>
 <td valign="bottom" width="1%"></td>
 <td width="36%"></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Three&#xA0;months&#xA0;ended<br />
 June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Six months ended<br />
 June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom" nowrap="nowrap">
 <p style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 26.65pt">
 <b>Partner</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; MARGIN-TOP: 0pt" align="center"><b>Drug or Drug Candidate</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 AstraZeneca AB</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">MOVANTIK<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">TM</sup>&#xA0;(NKTR-118) and
 MOVANTIK<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">TM</sup>&#xA0;fixed-dose combination program
 (NKTR-119)</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">90,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Roche</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">PEGASYS<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;and MIRCERA<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,219</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,408</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,415</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Amgen, Inc.</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">Neulasta<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,250</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,250</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,500</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,500</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Bayer Healthcare LLC</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">BAY41-6551 (Amikacin Inhale)</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">395</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,393</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,205</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,146</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Baxalta</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">BAX 855 (Hemophilia)</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">88</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">669</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,006</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,278</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,254</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,638</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12,799</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 License, collaboration, and other revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,208</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,785</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">102,948</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">25,866</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"></td>
 <td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">&#xA0;&#xA0;</td>
 <td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom"></td>
 <td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">&#xA0;&#xA0;</td>
 <td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</td>
 <td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">&#xA0;&#xA0;</td>
 <td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</td>
 <td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">&#xA0;&#xA0;</td>
 <td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</td>
 <td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">&#xA0;&#xA0;</td>
 <td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 5px 'Times New Roman'; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 808<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295533063376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNetAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProductSalesAndRoyalties', window );">Product sales and royalty revenue</a></td>
<td class="nump">$ 11,713<span></span>
</td>
<td class="nump">$ 5,891<span></span>
</td>
<td class="nump">$ 19,812<span></span>
</td>
<td class="nump">$ 11,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue related to sale of future royalties</a></td>
<td class="nump">4,740<span></span>
</td>
<td class="nump">4,837<span></span>
</td>
<td class="nump">8,702<span></span>
</td>
<td class="nump">10,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">6,208<span></span>
</td>
<td class="nump">17,785<span></span>
</td>
<td class="nump">102,948<span></span>
</td>
<td class="nump">25,866<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">22,661<span></span>
</td>
<td class="nump">28,513<span></span>
</td>
<td class="nump">131,462<span></span>
</td>
<td class="nump">48,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">10,534<span></span>
</td>
<td class="nump">5,108<span></span>
</td>
<td class="nump">18,978<span></span>
</td>
<td class="nump">13,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">45,412<span></span>
</td>
<td class="nump">36,702<span></span>
</td>
<td class="nump">92,423<span></span>
</td>
<td class="nump">75,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">10,184<span></span>
</td>
<td class="nump">9,619<span></span>
</td>
<td class="nump">20,487<span></span>
</td>
<td class="nump">19,547<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">66,130<span></span>
</td>
<td class="nump">51,429<span></span>
</td>
<td class="nump">131,888<span></span>
</td>
<td class="nump">107,602<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(43,469)<span></span>
</td>
<td class="num">(22,916)<span></span>
</td>
<td class="num">(426)<span></span>
</td>
<td class="num">(59,318)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(4,118)<span></span>
</td>
<td class="num">(4,488)<span></span>
</td>
<td class="num">(8,289)<span></span>
</td>
<td class="num">(9,021)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liability related to sale of future royalties</a></td>
<td class="num">(5,152)<span></span>
</td>
<td class="num">(5,134)<span></span>
</td>
<td class="num">(10,202)<span></span>
</td>
<td class="num">(10,521)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest income and other income (expense), net</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">457<span></span>
</td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating expense, net</a></td>
<td class="num">(9,024)<span></span>
</td>
<td class="num">(9,526)<span></span>
</td>
<td class="num">(18,034)<span></span>
</td>
<td class="num">(19,134)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(52,493)<span></span>
</td>
<td class="num">(32,442)<span></span>
</td>
<td class="num">(18,460)<span></span>
</td>
<td class="num">(78,452)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="nump">377<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (52,657)<span></span>
</td>
<td class="num">$ (32,637)<span></span>
</td>
<td class="num">$ (18,837)<span></span>
</td>
<td class="num">$ (78,838)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding used in computing basic and diluted net loss per share</a></td>
<td class="nump">131,643<span></span>
</td>
<td class="nump">127,040<span></span>
</td>
<td class="nump">131,502<span></span>
</td>
<td class="nump">125,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseCollaborationOtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseCollaborationOtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProductSalesAndRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Includes Product sales (aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts) and royalties (Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated Includes Product sales (aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts) and royalties (Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProductSalesAndRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.2(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 940<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51673353&amp;loc=d3e41242-110953<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 10<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Income Tax Expense (or Benefit)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-04.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295547681024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Note 6 &#x2014; License and Collaboration Agreements</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 We have entered into various collaboration agreements including
 license agreements and collaborative research, manufacturing,
 development and commercialization agreements with various
 pharmaceutical and biotechnology companies. Under these
 collaboration agreements, we are entitled to receive license fees,
 upfront payments, milestone payments, royalties, sales milestones,
 and payments for the manufacture and supply of our proprietary
 PEGylation materials and/or reimbursement for research and
 development activities. All of our collaboration agreements are
 generally cancelable by our partners without significant financial
 penalty. Our costs of performing these services are generally
 included in research and development expense, except that costs for
 product sales to our collaboration partners are included in cost of
 goods sold. In accordance with our collaboration agreements, we
 recognized license, collaboration and other revenue as follows (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="39%"></td>
 <td valign="bottom" width="1%"></td>
 <td width="36%"></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="1%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Three&#xA0;months&#xA0;ended<br />
 June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Six months ended<br />
 June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom" nowrap="nowrap">
 <p style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; WIDTH: 26.65pt">
 <b>Partner</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'; MARGIN-TOP: 0pt" align="center"><b>Drug or Drug Candidate</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 AstraZeneca AB</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">MOVANTIK<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">TM</sup>&#xA0;(NKTR-118) and
 MOVANTIK<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">TM</sup>&#xA0;fixed-dose combination program
 (NKTR-119)</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">90,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Roche</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">PEGASYS<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;and MIRCERA<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,219</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,408</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,415</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Amgen, Inc.</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">Neulasta<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,250</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,250</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,500</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,500</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Bayer Healthcare LLC</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">BAY41-6551 (Amikacin Inhale)</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">395</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,393</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,205</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,146</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Baxalta</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">BAX 855 (Hemophilia)</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">88</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">669</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,006</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,278</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,254</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,638</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12,799</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 License, collaboration, and other revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,208</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,785</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">102,948</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">25,866</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 As of June&#xA0;30, 2015, our collaboration agreements with
 partners included potential future payments for development
 milestones totaling approximately $128.3 million, including amounts
 from our agreements with Baxalta, Bayer, and Ophthotech described
 below. In addition, we are entitled to receive the contingent
 payments described below related to the MOVANTIK<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">TM</sup>&#xA0;and MOVANTIK<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">TM</sup>&#xA0;fixed-dose combination drug
 development programs, respectively, based on development and
 regulatory events to be pursued and completed solely by
 AstraZeneca.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 There have been no material changes to our collaboration agreements
 in the six months ended June&#xA0;30, 2015, except as described
 below.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>AstraZeneca AB</i></b><i>: MOVANTIK<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">TM</sup>&#xA0;(naloxegol oxalate),
 previously referred to as naloxegol and NKTR-118, and
 MOVANTIK<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">TM</sup>&#xA0;fixed-dose combination
 program, previously referred to as NKTR-119</i></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 We are a party to an agreement with AstraZeneca AB (AstraZeneca)
 under which we granted AstraZeneca a worldwide, exclusive license
 under our patents and other intellectual property to develop,
 market, and sell MOVANTIK<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">TM</sup>&#xA0;and MOVANTIK<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">TM</sup>&#xA0;fixed-dose combination
 program. AstraZeneca is responsible for all research, development
 and commercialization and is responsible for all drug development
 and commercialization decisions for MOVANTIK<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">TM&#xA0;</sup>and the
 MOVANTIK<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">TM&#xA0;</sup>fixed-dose combination
 program. AstraZeneca paid us an upfront payment of
 $125.0&#xA0;million, which we received in the fourth quarter of
 2009 and which was fully recognized as of December&#xA0;31, 2010.
 We will be entitled to up to an additional $40.0 million of
 contingent payments upon the first commercial sale of
 MOVENTIG<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;(the naloxegol brand name in
 the European Union or EU) in one major European Union country. We
 are also entitled to receive up to $75.0 million of commercial
 launch contingent payments related to the MOVANTIK<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">TM</sup>&#xA0;fixed-dose combination
 program, based on development events to be pursued and completed
 solely by AstraZeneca. In addition, we are entitled to significant
 and escalating double-digit royalty payments and sales milestone
 payments based on annual worldwide net sales of MOVANTIK<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">TM&#xA0;</sup>and MOVANTIK<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">TM&#xA0;</sup>fixed-dose combination
 products.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 On September&#xA0;16, 2014, the United States Food and Drug
 Administration (FDA) approved MOVANTIK<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">TM</sup>&#xA0;for the treatment of
 opioid-induced constipation (OIC) in adult patients with chronic,
 non-cancer pain. On December&#xA0;9, 2014, AstraZeneca announced
 that MOVENTIG<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;has been granted Marketing
 Authorisation by the European Commission (EC) for the treatment of
 opioid-induced constipation (OIC) in adult patients who have had an
 inadequate response to laxative(s). As a result of the FDA&#x2019;s
 approval, on September&#xA0;16, 2014, we were entitled to a $35.0
 million non-refundable payment from AstraZeneca, which was fully
 recognized as revenue in September 2014 and was received in October
 2014. In addition, the FDA&#x2019;s approval of MOVANTIK<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">TM</sup>&#xA0;extinguished our contingent
 obligation to repay the $70.0 million payment made to us by
 AstraZeneca in November 2013 after the MOVANTIK<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">TM</sup>&#xA0;New Drug Application was
 accepted for review by the FDA. As a result, in September 2014, we
 fully recognized as revenue this $70.0 million payment. On
 March&#xA0;31, 2015, AstraZeneca announced that MOVANTIK&#x2122;
 launched in the United States which resulted in our receipt of a
 $100.0 million non-refundable commercial launch milestone payment
 on March&#xA0;31, 2015, which was recognized as revenue in March
 2015. In addition, in March 2015, we agreed to pay AstraZeneca a
 total of $10.0 million to fund U.S. television advertising in
 consideration for certain additional commercial information rights.
 We recorded this $10.0 million obligation as a liability, with $5.0
 million included in other current liabilities and $5.0 million
 included in other long-term liabilities in our Condensed
 Consolidated Balance Sheet at June&#xA0;30, 2015. We made the
 initial $5.0 million payment to AstraZeneca in July 2015 and will
 pay the remaining $5.0 million in July 2016. We determined that
 this $10.0 million obligation should be recorded as a reduction of
 revenue, which we recorded in the three months ended March&#xA0;31,
 2015. As of June&#xA0;30, 2015, we do not have deferred revenue
 related to this agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In general, other than as described above and in this paragraph,
 AstraZeneca has full responsibility for all research, development
 and commercialization costs under our license agreement. As part of
 its approval of MOVANTIK<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">TM</sup>, the FDA required
 AstraZeneca to perform a post-marketing, observational
 epidemiological study comparing MOVANTIK<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">TM</sup>&#xA0;to other treatments of OIC in
 patients with chronic, non-cancer pain. As a result, the royalty
 rate payable to us from net sales of MOVANTIK<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">TM</sup>&#xA0;in the U.S. by AstraZeneca
 will be reduced by up to two percentage points to fund 33% of the
 external costs incurred by AstraZeneca to fund such post approval
 study subject to a $35.0 million aggregate cap. Any costs incurred
 by AstraZeneca can only be recovered by the reduction of the
 royalty paid to us. In no case can amounts be recovered by the
 reduction of a contingent payment due from AstraZeneca to us or
 through a payment from us to AstraZeneca.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Roche</i></b><i>: PEGASYS<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;and MIRCERA<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup></i></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In February 1997, we entered into a license, manufacturing and
 supply agreement with Roche, under which we granted Roche a
 worldwide, exclusive license to certain intellectual property
 related to our proprietary PEGylation materials used in the
 manufacture and commercialization of PEGASYS<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>. As of
 June&#xA0;30, 2015, we have deferred revenue of approximately $2.6
 million related to this agreement, which we expect to recognize
 through December 2015, the period through which we are required to
 provide back-up manufacturing and supply services related to
 PEGASYS<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In February 2012, we entered into a toll-manufacturing agreement
 with Roche under which we will manufacture the proprietary
 PEGylation material used by Roche to produce MIRCERA<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>. Roche entered
 into the toll-manufacturing agreement with the objective of
 establishing us as a secondary back-up supply source on a
 non-exclusive basis. Under the terms of our toll-manufacturing
 agreement, Roche paid us an upfront payment of $5.0 million and an
 additional $22.0 million in performance-based milestone payments
 upon our achievement of certain manufacturing readiness, validation
 and production milestones, including the delivery of specified
 quantities of PEGylation materials, all of which were completed as
 of January 2013. Roche will also pay us additional consideration
 for any future orders of the PEGylation materials for
 MIRCERA<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;beyond the initial quantities
 manufactured through January 2013.&#xA0;Roche has the right to
 terminate the toll-manufacturing agreement due to an uncured
 material default by us. As of June&#xA0;30, 2015, we have deferred
 revenue of approximately $8.1&#xA0;million, which we expect to
 recognize through December 2016, the estimated end of our
 obligations under this agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In August 2013, we agreed to deliver additional quantities of
 PEGylation materials used by Roche to produce PEGASYS<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;and MIRCERA<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>, all of which
 were delivered in the last quarter of 2013, for total consideration
 of $18.6 million. We determined that these incremental activities
 should be considered a material modification of the existing
 PEGASYS<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;and MIRCERA<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;-related arrangements
 described above. As a result, we allocated the $18.6 million
 consideration to each of these arrangements and determined the
 amounts to be recognized or deferred based on the estimated selling
 prices of the undelivered obligations. As of June&#xA0;30, 2015, we
 have deferred revenue of approximately $3.4&#xA0;million related to
 these activities, which we expect to recognize through December
 2016, the estimated end of our obligations under the modified
 arrangements.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Amgen, Inc.</i></b><i>: Neulasta</i><sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In October 2010, we amended and restated an existing supply and
 license agreement by entering into a supply, dedicated suite and
 manufacturing guarantee agreement (the amended and restated
 agreement) and a license agreement with Amgen Inc. and Amgen
 Manufacturing, Limited (together referred to as Amgen). Under the
 terms of the amended and restated agreement, we received a $50.0
 million payment in the fourth quarter of 2010 in return for our
 guaranteeing the supply of certain quantities of our proprietary
 PEGylation materials to Amgen. As of June&#xA0;30, 2015, we have
 deferred revenue of approximately $26.7&#xA0;million related to
 this agreement, which we expect to recognize through October 2020,
 the estimated end of our obligations under this agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Bayer Healthcare LLC</i></b><i>: BAY41-6551 (Amikacin
 Inhale)</i></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In August 2007, we entered into a co-development, license and
 co-promotion agreement with Bayer Healthcare LLC (Bayer) to develop
 a specially-formulated inhaled Amikacin. We are responsible for
 development and manufacturing and supply of the nebulizer device
 included in the Amikacin product. In April 2013, Bayer initiated a
 Phase 3 clinical trial in the treatment of intubated and
 mechanically ventilated patients with Gram-negative pneumonia. As
 of June&#xA0;30, 2015, we have received an upfront payment of
 $40.0&#xA0;million (which was paid to us in 2007) and milestone
 payments totaling $30.0&#xA0;million. In addition, in June 2013, we
 made a $10.0 million payment to Bayer for the reimbursement of some
 of its costs of the Phase 3 clinical trial.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In addition, we are entitled to receive a total of up to $50.0
 million for development milestones upon achievement of certain
 development objectives, as well as sales milestones upon
 achievement of annual sales targets and royalties based on annual
 worldwide net sales of Amikacin Inhale. As of June&#xA0;30, 2015,
 we have deferred revenue of approximately $20.0 million related to
 this agreement, which we expect to recognize through February 2028,
 the estimated end of our obligations under this agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Baxalta</i></b><i>: Hemophilia</i></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 We are a party to an exclusive research, development, license and
 manufacturing and supply agreement with Baxalta Incorporated
 (Baxalta) executed in September 2005 to develop products designed
 to improve therapies for Hemophilia A patients using our PEGylation
 technology. This Hemophilia A program includes BAX 855, which will
 be marketed in the U.S. under the brand name ADYNOVATE upon
 approval. Under the terms of this agreement, as of June&#xA0;30,
 2015, we are entitled to up to $20.0 million of development
 milestones upon achievement of certain development objectives,
 including $10.0 million due upon marketing authorization in the
 U.S., as well as sales milestones upon achievement of annual sales
 targets and royalties based on annual worldwide net sales of
 products resulting from this agreement. In August 2014, Baxalta
 announced positive top-line results from its Phase 3 pivotal
 clinical trial of BAX 855 which met the primary endpoint for the
 control and prevention of bleeding, routine prophylaxis and
 perioperative management for patients who were 12 years or older.
 As a result of this Phase 3 clinical trial meeting its primary
 endpoint, we earned development milestones totaling $8.0 million in
 September 2014. In December 2014, Baxalta announced that it filed a
 biologic license application with the FDA for BAX 855. As of
 June&#xA0;30, 2015, we do not have significant deferred revenue
 related to this agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Ophthotech Corporation</i></b><i>: Fovista</i><sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 We are a party to an agreement with Ophthotech Corporation
 (Ophthotech), dated September&#xA0;30, 2006, under which Ophthotech
 received a worldwide, exclusive license to certain of our
 proprietary PEGylation technology to develop, manufacture and sell
 Fovista<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>. Under the
 terms of our agreement, we are the exclusive supplier of all of
 Ophthotech&#x2019;s clinical and commercial requirements for our
 proprietary PEGylation reagent used in Fovista<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>, which is
 currently in a Phase 3 clinical program. On May&#xA0;19, 2014,
 Ophthotech entered into a Licensing and Commercialization Agreement
 with Novartis Pharma AG for Fovista<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>. Under our
 agreement with Ophthotech, we received a $19.75 million payment in
 connection with this licensing agreement in June 2014. As of
 June&#xA0;30, 2015, we have deferred revenue of approximately $18.2
 million related to this agreement, which we expect to recognize
 through March 2029, the estimated end of our obligations under our
 agreement with Ophthotech.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In addition, we are entitled to up to $9.5 million in additional
 payments based upon Ophthotech&#x2019;s potential achievement of
 certain regulatory and sales milestones. We are also entitled to
 royalties on net sales of Fovista<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;that vary based on sales
 levels.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Other</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In addition, as of June&#xA0;30, 2015, we have a number of
 collaboration agreements, including with our collaboration partner
 UCB, under which we are entitled to up to a total of $51.8 million
 of development milestones upon achievement of certain development
 objectives, as well as sales milestones upon achievement of annual
 sales targets and royalties based on net sales of commercialized
 products, if any. However, given the current phase of development
 of the potential products under these collaboration agreements, we
 cannot estimate the probability or timing of achieving these
 milestones. As of June&#xA0;30, 2015, we have deferred revenue of
 approximately $18.0 million related to these other collaboration
 agreements, which we expect to recognize through 2020, the
 estimated end of our obligations under those agreements.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 808<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295713089888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>Note 5 &#x2014; Commitments and Contingencies</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Legal Matters</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 From time to time, we are involved in lawsuits, arbitrations,
 claims, investigations and proceedings, consisting of intellectual
 property, commercial, employment and other matters, which arise in
 the ordinary course of business. We make provisions for liabilities
 when it is both probable that a liability has been incurred and the
 amount of the loss can be reasonably estimated. Such provisions are
 reviewed at least quarterly and adjusted to reflect the impact of
 settlement negotiations, judicial and administrative rulings,
 advice of legal counsel, and other information and events
 pertaining to a particular case. Litigation is inherently
 unpredictable. If any unfavorable ruling were to occur in any
 specific period, there exists the possibility of a material adverse
 impact on the results of our operations of that period and on our
 cash flows and liquidity.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b><i>Indemnifications in Connection with Commercial
 Agreements</i></b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 As part of our collaboration agreements with our partners related
 to the license, development, manufacture and supply of drugs based
 on our proprietary technologies and drug candidates, we generally
 agree to defend, indemnify and hold harmless our partners from and
 against third party liabilities arising out of the agreement,
 including product liability (with respect to our activities) and
 infringement of intellectual property to the extent the
 intellectual property is developed by us and licensed to our
 partners. The term of these indemnification obligations is
 generally perpetual any time after execution of the agreement.
 There is generally no limitation on the potential amount of future
 payments we could be required to make under these indemnification
 obligations.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 From time to time we enter into other strategic agreements such as
 divestitures and financing transactions pursuant to which we are
 required to make representations and warranties and undertake to
 perform or comply with certain covenants. In the event it is
 determined that we breached certain of the representations and
 warranties or covenants made by us in any such agreements, we could
 incur substantial indemnification liabilities depending on the
 timing, nature, and amount of any such claims.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">
 To date, we have not incurred costs to defend lawsuits or settle
 claims related to these indemnification obligations. Because the
 aggregate amount of any potential indemnification obligation is not
 a stated amount, the overall maximum amount of any such obligations
 cannot be reasonably estimated. No liabilities have been recorded
 for these obligations in our Condensed Consolidated Balance Sheets
 at either June&#xA0;30, 2015 or December&#xA0;31, 2014.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 460<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 440<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295533311440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">$ 230,856<span></span>
</td>
<td class="nump">$ 225,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndRestrictedCash', window );">Cash, including restricted cash</a></td>
<td class="nump">29,363<span></span>
</td>
<td class="nump">26,136<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">279,660<span></span>
</td>
<td class="nump">262,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Notes and Bonds [Member] | Fair Value Hierarchy Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">185,917<span></span>
</td>
<td class="nump">182,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=nktr_CorporateCommercialPaperMember', window );">Corporate Commercial Paper [Member] | Fair Value Hierarchy Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">44,939<span></span>
</td>
<td class="nump">42,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value Hierarchy Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments in marketable securities</a></td>
<td class="nump">16,512<span></span>
</td>
<td class="nump">11,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments in marketable securities</a></td>
<td class="nump">$ 2,929<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashAndRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Restricted Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashAndRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Restricted Cash, Cash Equivalents, And Available For Sale Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph (aa)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26610-111562<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Trading Securities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6526789<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27723805&amp;loc=d3e24584-111560<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Available-for-Sale Securities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph a, f, g<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=nktr_CorporateCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=nktr_CorporateCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295547664224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Total stock-based compensation expense was recognized in our
 Condensed Consolidated Statements of Operations as follows (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="72%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;months&#xA0;ended</b><br />
 <b>June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Six months ended</b><br />
 <b>June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Cost of goods sold</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">239</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">280</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">563</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">599</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research and development expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,125</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,832</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,547</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,805</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 General and administrative expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,196</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,052</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,627</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,121</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total stock-based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,560</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,164</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,737</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,525</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295535441088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationPolicyTextBlock', window );">Organization</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>Organization</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 We are a biopharmaceutical company headquartered in San Francisco,
 California and incorporated in Delaware. We are developing a
 pipeline of drug candidates that utilize our PEGylation and
 advanced polymer conjugate technology platforms with the objective
 to improve the benefits of drugs for patients.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Our research and development activities have required significant
 ongoing investment to date and are expected to continue to require
 significant investment. As a result, we expect to continue to incur
 substantial losses and negative cash flows from operations in the
 future. We have financed our operations primarily through cash
 generated from licensing, collaboration and manufacturing
 agreements and financing transactions. At June&#xA0;30, 2015, we
 had approximately $279.7 million in cash and investments in
 marketable securities.&#xA0;Also, as of June&#xA0;30, 2015, we had
 $133.5 million in long-term debt, including $125.0 million of
 senior secured notes and $8.5 million of capital lease obligations,
 of which $5.6 million is current.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Basis of Presentation and Principles of
 Consolidation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Our consolidated financial statements include the financial
 position, results of operations and cash flows of our wholly-owned
 subsidiaries: Nektar Therapeutics (India) Private Limited (Nektar
 India) and Nektar Therapeutics UK Limited. All intercompany
 accounts and transactions have been eliminated in
 consolidation.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 We prepared our Condensed Consolidated Financial Statements
 following the requirements of the Securities and Exchange
 Commission (SEC) for interim reporting. As permitted under those
 rules, certain footnotes or other financial information that are
 normally required by U.S. generally accepted accounting principles
 (GAAP) for annual periods can be condensed or omitted. In the
 opinion of management, these financial statements include all
 normal and recurring adjustments that we consider necessary for the
 fair presentation of our financial position and operating
 results.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Our Condensed Consolidated Financial Statements are denominated in
 U.S. dollars. Accordingly, changes in exchange rates between the
 applicable foreign currency and the U.S. dollar will affect the
 translation of each foreign subsidiary&#x2019;s financial results
 into U.S. dollars for purposes of reporting our consolidated
 financial results. Translation gains and losses are included in
 accumulated other comprehensive loss in the stockholders&#x2019;
 equity section of the Condensed Consolidated Balance Sheets. To
 date, such cumulative currency translation adjustments have not
 been significant to our consolidated financial position.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Our comprehensive loss consists of our net loss plus our foreign
 currency translation gains and losses and unrealized holding gains
 and losses on available-for-sale securities, neither of which were
 significant during the three and six months ended June&#xA0;30,
 2015 and 2014. In addition, there were no significant
 reclassifications out of accumulated other comprehensive loss to
 the statements of operations during the three and six months ended
 June&#xA0;30, 2015 and 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 The accompanying Condensed Consolidated Financial Statements are
 unaudited. The Condensed Consolidated Balance Sheet data as of
 December&#xA0;31, 2014 was derived from the audited consolidated
 financial statements which are included in our Annual Report on
 Form&#xA0;10-K for the year ended December&#xA0;31, 2014 filed with
 the SEC on February&#xA0;26, 2015. The information included in this
 Quarterly Report on Form 10-Q should be read in conjunction with
 the consolidated financial statements and the accompanying notes to
 those financial statements included in our Annual Report on Form
 10-K for the year ended December&#xA0;31, 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 Revenue, expenses, assets, and liabilities can vary during each
 quarter of the year. The results and trends in these interim
 Condensed Consolidated Financial Statements are not necessarily
 indicative of the results to be expected for the full year or any
 other periods.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Use of Estimates</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The preparation of consolidated financial statements in conformity
 with GAAP requires management to make estimates and assumptions
 that affect the reported amounts of assets and liabilities and
 disclosure of contingent assets and liabilities at the date of the
 consolidated financial statements and the reported amounts of
 revenue and expenses during the reporting period. Accounting
 estimates and assumptions are inherently uncertain. Actual results
 could differ materially from those estimates and assumptions. Our
 estimates include those related to estimated selling prices of
 deliverables in collaboration agreements, estimated periods of
 performance, the net realizable value of inventory, the impairment
 of investments, the impairment of goodwill and long-lived assets,
 contingencies, accrued clinical trial expenses, estimated interest
 expense from our liability related to our sale of future royalties,
 stock-based compensation, and ongoing litigation, among other
 estimates. We base our estimates on historical experience and on
 other assumptions that management believes are reasonable under the
 circumstances. These estimates form the basis for making judgments
 about the carrying values of assets and liabilities when these
 values are not readily apparent from other sources. As appropriate,
 estimates are assessed each period and updated to reflect current
 information and any changes in estimates will generally be
 reflected in the period first identified.</p>


 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Reclassifications</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Certain items previously reported in specific financial statement
 captions have been reclassified to conform to the current period
 presentation. Such reclassifications do not materially impact
 previously reported revenue, operating loss, net loss, total
 assets, liabilities or stockholders&#x2019; equity.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Segment Information</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 We operate in one business segment which focuses on applying our
 technology platforms to improve the performance of established and
 novel drug candidates. We operate in one segment because our
 business offerings have similar economics and other
 characteristics, including the nature of products and manufacturing
 processes, types of customers, distribution methods and regulatory
 environment. We are comprehensively managed as one business segment
 by our Chief Executive Officer and his management team.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SignificantConcentrationsPolicyTextBlock', window );">Significant Concentrations</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Significant Concentrations</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Our customers are primarily pharmaceutical and biotechnology
 companies that are located in the U.S.&#xA0;and Europe. Our
 accounts receivable balance contains billed and unbilled trade
 receivables from product sales and royalties, as well as milestones
 and time and materials based billings from collaborative research
 and development agreements. When appropriate, we provide for an
 allowance for doubtful accounts by reserving for specifically
 identified doubtful accounts. We generally do not require
 collateral from our customers. We perform a regular review of our
 customers&#x2019; payment histories and associated credit risk. We
 have not experienced significant credit losses from our accounts
 receivable and our allowance for doubtful accounts was not
 significant at either June&#xA0;30, 2015 or December&#xA0;31,
 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 We are dependent on our suppliers and contract manufacturers to
 provide raw materials, drugs and devices of appropriate quality and
 reliability and to meet applicable contract and regulatory
 requirements. In certain cases, we rely on single sources of supply
 of one or more critical materials. Consequently, in the event that
 supplies are delayed or interrupted for any reason, our ability to
 develop and produce our drug candidates or our ability to meet our
 supply obligations could be significantly impaired, which could
 have a material adverse effect on our business, financial condition
 and results of operations.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Revenue Recognition</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Our revenue is derived from our arrangements with pharmaceutical
 and biotechnology collaboration partners and may result from one or
 more of the following: upfront and license fees, payments for
 contract research and development, milestone payments,
 manufacturing and supply payments, and royalties. Our performance
 obligations under our collaborations may include licensing our
 intellectual property, manufacturing and supply obligations, and
 research and development obligations. In order to account for the
 multiple-element arrangements, we identify the deliverables
 included within the arrangement and evaluate which deliverables
 represent separate units of accounting. Analyzing the arrangement
 to identify deliverables requires the use of judgment, and each
 deliverable may be an obligation to deliver services, a right or
 license to use an asset, or another performance obligation. Revenue
 is recognized separately for each identified unit of accounting
 when the basic revenue recognition criteria are met: there is
 persuasive evidence that an arrangement exists, delivery has
 occurred, the price is fixed or determinable, and collection is
 reasonably assured.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 At the inception of each new multiple-element arrangement or the
 material modification of an existing multiple-element arrangement,
 we allocate all consideration received under multiple-element
 arrangements to all units of accounting based on the relative
 selling price method, generally based on our best estimate of
 selling price (ESP). The objective of ESP is to determine the price
 at which we would transact a sale if the product or service was
 sold on a stand-alone basis. We determine ESP for the elements in
 our collaboration arrangements by considering multiple factors
 including, but not limited to, technical complexity of the
 performance obligation and similarity of elements to those
 performed under previous arrangements. Since we apply significant
 judgment in arriving at the ESPs, any material change in our
 estimates would significantly affect the allocation of the total
 consideration to the different elements of a multiple element
 arrangement.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <i>Product sales</i></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Product sales are primarily derived from fixed price and cost-plus
 manufacturing and supply agreements with our collaboration
 partners. We have not experienced any significant returns from our
 customers.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <i>Royalty revenue</i></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Generally, we are entitled to royalties from our collaboration
 partners based on the net sales of their approved drugs that are
 marketed and sold in one or more countries where we hold royalty
 rights. We recognize royalty revenue when the cash is received or
 when the royalty amount to be received is estimable and collection
 is reasonably assured. With respect to the non-cash royalties
 related to sale of future royalties described at Note 4, revenue is
 recognized when estimable, otherwise, revenue is recognized during
 the period in which the related royalty report is received, which
 generally occurs in the quarter after the applicable product sales
 are made.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <i>License, collaboration and other revenue</i></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 The amount of upfront fees and other payments received by us in
 license and collaboration arrangements that are allocated to
 continuing performance obligations, such as manufacturing and
 supply obligations, are deferred and generally recognized ratably
 over our expected performance period under each respective
 arrangement. We make our best estimate of the period over which we
 expect to fulfill our performance obligations, which may include
 technology transfer assistance, research activities, clinical
 development activities, and manufacturing activities from
 development through the commercialization of the product. Given the
 uncertainties of these collaboration arrangements, significant
 judgment is required to determine the duration of the performance
 period and this estimate is periodically re-evaluated.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Contingent consideration received from the achievement of a
 substantive milestone is recognized in its entirety in the period
 in which the milestone is achieved, which we believe is consistent
 with the substance of our performance under our various license and
 collaboration agreements. A milestone is defined as an event
 (i)&#xA0;that can only be achieved based in whole or in part either
 on the entity&#x2019;s performance or on the occurrence of a
 specific outcome resulting from the entity&#x2019;s performance,
 (ii)&#xA0;for which there is substantive uncertainty at the date
 the arrangement is entered into that the event will be achieved,
 and (iii)&#xA0;that would result in additional payments being due
 to the entity. A milestone is substantive if the consideration
 earned from the achievement of the milestone is consistent with our
 performance required to achieve the milestone or the increase in
 value to the collaboration resulting from our performance, relates
 solely to our past performance, and is reasonable relative to all
 of the other deliverables and payments within the arrangement.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Our license and collaboration agreements with our partners provide
 for payments to us upon the achievement of development milestones,
 such as the completion of clinical trials or regulatory
 submissions, approvals by regulatory authorities, and commercial
 launches of drugs. Given the challenges inherent in developing and
 obtaining regulatory approval for drug products and in achieving
 commercial launches, there was substantial uncertainty whether any
 such milestones would be achieved at the time of execution of these
 licensing and collaboration agreements. In addition, we evaluated
 whether the development milestones meet the remaining criteria to
 be considered substantive. As a result of our analysis, we consider
 our remaining development milestones under all of our license and
 collaboration agreements to be substantive and, accordingly, we
 expect to recognize as revenue future payments received from such
 milestones only if and as each milestone is achieved.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Our license and collaboration agreements with certain partners also
 provide for contingent payments to us based solely upon the
 performance of the respective partner. For such contingent amounts
 we expect to recognize the payments as revenue when earned under
 the applicable contract, which is generally upon completion of
 performance by the respective partner, provided that collection is
 reasonably assured.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Our license and collaboration agreements with our partners also
 provide for payments to us upon the achievement of specified sales
 volumes of approved drugs. We consider these payments to be similar
 to royalty payments and we will recognize such sales-based payments
 upon achievement of such sales volumes, provided that collection is
 reasonably assured.</p>


 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Research and Development Expense</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Research and development costs are expensed as incurred and include
 salaries, benefits and other operating costs such as outside
 services, supplies and allocated overhead costs. We perform
 research and development for our proprietary drug candidates and
 technology development and for certain third parties under
 collaboration agreements. For our proprietary drug candidates and
 our internal technology development programs, we invest our own
 funds without reimbursement from a third party.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%">
 We record accruals for the estimated costs of our clinical trial
 activities performed by third parties. The financial terms of these
 agreements are subject to negotiation, vary from contract to
 contract and may result in uneven payment flows to our vendors.
 Payments under the contracts depend on factors such as the
 achievement of certain events, successful enrollment of patients,
 and completion of certain clinical trial activities. We generally
 accrue costs associated with the start-up and reporting phases of
 the clinical trials ratably over the estimated duration of the
 start-up and reporting phases. We generally accrue costs associated
 with the treatment phase of clinical trials based on the total
 estimated cost of the treatment phase on a per patient basis and we
 expense the per patient cost ratably over the estimated patient
 treatment period based on patient enrollment in the trials. In
 specific circumstances, such as for certain time-based costs, we
 recognize clinical trial expenses using a methodology that we
 consider to be more reflective of the timing of costs incurred.
 Advance payments for goods or services that will be used or
 rendered for future research and development activities are
 capitalized as prepaid expenses and recognized as expense as the
 related goods are delivered or the related services are performed.
 We base our estimates on the best information available at the
 time. However, additional information may become available to us
 which may allow us to make a more accurate estimate in future
 periods. In this event, we may be required to record adjustments to
 research and development expenses in future periods when the actual
 level of activity becomes more certain. Such increases or decreases
 in cost are generally considered to be changes in estimates and
 will be reflected in research and development expenses in the
 period identified.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Long-Lived Assets</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 We assess the impairment of long-lived assets, primarily property,
 plant and equipment and goodwill included in other non-current
 assets, whenever events or changes in business circumstances
 indicate that the carrying amounts of the assets may not be fully
 recoverable. When such events occur, we determine whether there has
 been an impairment in value by comparing the asset&#x2019;s carrying
 value with its fair value, as measured by the anticipated
 undiscounted net cash flows of the asset. In the case of goodwill
 impairment, market capitalization is generally used as the measure
 of fair value. If an impairment in value exists, the asset is
 written down to its estimated fair value. In March 2015, we
 announced that the primary endpoint for our BEACON Phase 3 clinical
 study for NKTR-102 as a single-agent therapy for women with
 advanced metastatic breast cancer did not achieve statistical
 significance. As a result, we performed an impairment analysis for
 our long-lived assets, including goodwill, as well as our primary
 long-lived asset group which is dedicated to NKTR-102. Based on
 this analysis, we concluded that there is no impairment at
 March&#xA0;31, 2015 or June&#xA0;30, 2015.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Income Taxes</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 For the three and six months ended June&#xA0;30, 2015 and 2014, we
 recorded an income tax provision for our Nektar India operations at
 an effective tax rate of approximately 34%. The U.S. federal
 deferred tax assets generated from our net operating losses have
 been fully reserved, as we believe it is not more likely than not
 that the benefit will be realized.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b><i>Recent Accounting Pronouncements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In May 2014, the Financial Accounting Standards Board (FASB) issued
 guidance codified in Accounting Standards Codification (ASC)
 606,&#xA0;<i>Revenue
 Recognition &#x2014; Revenue from Contracts with Customers</i>,
 which amends the guidance in former ASC 605,&#xA0;<i>Revenue
 Recognition,&#xA0;</i>and is effective for
 public companies for fiscal years beginning after December&#xA0;15,
 2017. Entities have the option of using either a full retrospective
 or a modified retrospective approach to adopt this new guidance. We
 are currently evaluating the impact of the provisions of ASC
 606.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In April 2015, the FASB issued guidance to simplify the
 presentation of debt issuance costs by requiring debt issuance
 costs to be presented as a deduction from the corresponding debt
 liability. This guidance is effective for our interim and annual
 periods beginning January&#xA0;1, 2016. Upon adoption, the new
 guidance must be applied retrospectively to all periods presented.
 We do not believe the adoption of this guidance will have a
 material impact on our consolidated financial statement</p>


 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock', window );">Liability Related to Sale of Future Royalties</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%">
 We periodically assess the estimated royalty payments to RPI from
 UCB and Roche and to the extent such payments are greater or less
 than our initial estimates, or the timing of such payments is
 materially different than our original estimates, we will
 prospectively adjust the amortization of the Royalty
 Obligation.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OrganizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SignificantConcentrationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant concentrations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SignificantConcentrationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.3A-02)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph k<br><br><br><br> -Article 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02, 03<br><br><br><br> -Article 3A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 19<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 954<br><br><br><br> -SubTopic 740<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 17<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Research and Development<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18823-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section B<br><br><br><br> -Paragraph Question 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295712831696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Note 7 &#x2014; Stock-Based Compensation</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Total stock-based compensation expense was recognized in our
 Condensed Consolidated Statements of Operations as follows (in
 thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="72%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Three&#xA0;months&#xA0;ended<br />
 June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Six months ended<br />
 June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Cost of goods sold</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">239</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">280</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">563</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">599</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Research and development expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,125</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,832</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,547</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,805</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 General and administrative expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,196</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,052</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,627</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,121</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 3em; TEXT-INDENT: -1em">
 Total stock-based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,560</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,164</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,737</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,525</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 During the three months ended June&#xA0;30, 2015 and 2014, we
 granted 68,200 and 642,860 stock options, respectively, at a
 weighted average grant-date fair value of $4.81 per share and $5.24
 per share, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 During the six months ended June&#xA0;30, 2015 and 2014, we granted
 479,010 and 3,776,040 stock options, respectively, at a weighted
 average grant-date fair value of $6.31 per share and $5.84 per
 share, respectively. The number of stock options granted during the
 six months ended June&#xA0;30, 2014 was significantly higher than
 the stock options granted during the six months ended June&#xA0;30,
 2015 because we made our annual employee stock option grant for the
 2013 performance period in February 2014 and our annual employee
 stock option grant for the 2014 performance period in December
 2014.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 As a result of stock issuances under our equity compensation plans,
 during the three months ended June&#xA0;30, 2015 and 2014, we
 issued 733,952 and 350,513 common shares, respectively, and during
 the six months ended June&#xA0;30, 2015 and 2014, we issued 969,250
 and 1,017,887 common shares, respectively.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 40<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295713351216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Note 8 &#x2014; Net Loss Per Share</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Basic net loss per share is calculated based on the
 weighted-average number of common shares outstanding during the
 periods presented. For all periods presented in the accompanying
 Condensed Consolidated Statements of Operations, the net loss
 available to common stockholders is equal to the reported net loss.
 Basic and diluted net loss per share are the same due to our
 historical net losses and the requirement to exclude potentially
 dilutive securities which would have an anti-dilutive effect on net
 loss per share. During the three and six month periods ended
 June&#xA0;30, 2015 and 2014, potentially dilutive securities
 consisted of common shares underlying outstanding stock options.
 During the three months ended June&#xA0;30, 2015 and 2014, there
 were weighted average outstanding stock options of
 21.6&#xA0;million and 22.5&#xA0;million, respectively, and during
 the six months ended June&#xA0;30, 2015 and 2014, there were
 weighted average outstanding stock options of 21.7&#xA0;million and
 21.9&#xA0;million, respectively.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 52<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295668008144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Cash and Investments in Marketable Securities, Including Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Cash and investments in marketable securities, including cash
 equivalents and restricted cash, are as follows (in thousands).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="74%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Estimated Fair Value at</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">20,875</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,365</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">25,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">25,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Short-term investments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">233,785</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">225,459</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 0pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total cash and investments in marketable securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">279,660</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">262,824</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Portfolio of Cash and Investments in Marketable Securities</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Our portfolio of cash and investments in marketable securities
 includes (in thousands):</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" rowspan="2" align="center"><b>Fair&#xA0;Value</b><br />
 <b>Hierarchy</b><br />
 <b>Level</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Estimated Fair Value at</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2014</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Corporate notes and bonds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">2</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">185,917</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">182,544</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Corporate commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">2</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">44,939</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">42,915</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Available-for-sale investments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">230,856</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">225,459</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">1</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16,512</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,229</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Certificate of deposit</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">N/A</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,929</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Cash, including restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">N/A</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">29,363</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,136</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-LEFT: 1em; TEXT-INDENT: -1em">
 Total cash and investments in marketable securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">279,660</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">262,824</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 4pt">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295544131200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents and Restricted Cash (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 20,875<span></span>
</td>
<td class="nump">$ 12,365<span></span>
</td>
<td class="nump">$ 30,699<span></span>
</td>
<td class="nump">$ 39,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">233,785<span></span>
</td>
<td class="nump">225,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">$ 279,660<span></span>
</td>
<td class="nump">$ 262,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Restricted Cash, Cash Equivalents, And Available For Sale Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49167202&amp;loc=d3e26626-111562<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295544337504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember', window );">Indemnification Obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Indemnification obligations, liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295533046624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (52,879)<span></span>
</td>
<td class="num">$ (32,584)<span></span>
</td>
<td class="num">$ (18,768)<span></span>
</td>
<td class="num">$ (78,544)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295670717072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock', window );">Liability Related to Sale of Future Royalties</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 <b>Note 4 &#x2014; Liability Related to Sale of Future
 Royalties</b></p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 On February&#xA0;24, 2012, we entered into a Purchase and Sale
 Agreement (the Purchase and Sale Agreement) with RPI Finance Trust
 (RPI), an affiliate of Royalty Pharma, pursuant to which we sold,
 and RPI purchased, our right to receive royalty payments (the
 Royalty Entitlement) arising from the worldwide net sales, from and
 after January&#xA0;1, 2012, of (a)&#xA0;CIMZIA<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>, under our
 license, manufacturing and supply agreement with UCB Pharma (UCB),
 and (b)&#xA0;MIRCERA<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>, under our
 license, manufacturing and supply agreement with F.
 Hoffmann-La&#xA0;Roche Ltd and Hoffmann-La&#xA0;Roche Inc.
 (together referred to as Roche). We received aggregate cash
 proceeds of $124.0 million for the Royalty
 Entitlement.&#xA0;Although we sold all of our rights to receive
 royalties from the CIMZIA<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;and MIRCERA<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;products, as a result of our
 ongoing manufacturing and supply obligations related to the
 generation of these royalties, we will continue to account for
 these royalties as revenue. We recorded the $124.0 million in
 proceeds from this transaction as a liability (Royalty Obligation)
 that will be amortized using the interest method over the estimated
 life of the Purchase and Sale Agreement as royalties from the
 CIMZIA<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;and MIRCERA<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;products are remitted directly
 to RPI. During the six months ended June&#xA0;30, 2015 and 2014, we
 recognized $8.7 million and $10.6 million, respectively, in
 aggregate royalties from net sales of CIMZIA<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;and MIRCERA<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>.</p>
 <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Since its inception, our estimate of the total interest expense on
 the Royalty Obligation resulted in an effective annual interest
 rate of approximately 17%. We periodically assess the estimated
 royalty payments to RPI from UCB and Roche and to the extent such
 payments are greater or less than our initial estimates, or the
 timing of such payments is materially different than our original
 estimates, we will prospectively adjust the amortization of the
 Royalty Obligation.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 Pursuant to the Purchase and Sale Agreement, in March 2014 and
 March 2013, we were required to pay RPI $7.0 million and $3.0
 million, respectively, as a result of worldwide net sales of
 MIRCERA<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;for the 12 month periods ended
 December&#xA0;31, 2013 and 2012 not reaching certain minimum
 thresholds. The Purchase and Sale Agreement does not include any
 other potential payments related to minimum net sales thresholds
 and, therefore, we do not expect to make any further payments to
 RPI related to this agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px">
 In addition, the Purchase and Sale Agreement grants RPI the right
 to receive certain reports and other information relating to the
 Royalty Entitlement and contains other representations and
 warranties, covenants and indemnification obligations that are
 customary for a transaction of this nature. To our knowledge, we
 are currently in compliance with these provisions of the Purchase
 and Sale Agreement, however, if we were to breach our obligations,
 we could be required to pay damages to RPI that are not limited to
 the purchase price we received in the sale transaction.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295544120272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">$ 6,208<span></span>
</td>
<td class="nump">$ 17,785<span></span>
</td>
<td class="nump">$ 102,948<span></span>
</td>
<td class="nump">$ 25,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">AstraZeneca AB [Member] | MOVANTIKTM (NKTR-118) and MOVANTIKTM fixed-dose combination program (NKTR-119) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_RocheMember', window );">Roche [Member] | PEGASYS and MIRCERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">3,197<span></span>
</td>
<td class="nump">3,219<span></span>
</td>
<td class="nump">6,408<span></span>
</td>
<td class="nump">6,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AmgenIncMember', window );">Amgen, Inc. [Member] | Neulasta [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember', window );">Bayer Healthcare LLC [Member] | BAY41-6551 (Amikacin Inhale) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">2,393<span></span>
</td>
<td class="nump">1,205<span></span>
</td>
<td class="nump">3,146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BaxaltaMember', window );">Baxalta [Member] | BAX 855 (Hemophilia) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">669<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OtherPartnerMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">$ 1,278<span></span>
</td>
<td class="nump">$ 10,254<span></span>
</td>
<td class="nump">$ 2,638<span></span>
</td>
<td class="nump">$ 12,799<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseAndCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseAndCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseCollaborationOtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseCollaborationOtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AstraZenecaAbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_MovantikAndMovantikFixedDoseCombinationProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_MovantikAndMovantikFixedDoseCombinationProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PegasysAndMirceraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PegasysAndMirceraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NeulastaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NeulastaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BayerHealthcareLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_BayFourOneSixFiveFiveOneAmikacinInhaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BaxaltaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BaxaltaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OtherPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OtherPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.2.0.727</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>103</ContextCount>
  <ElementCount>166</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>40</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/StatementOfIncomeAlternative</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/StatementOfPartnersCapital</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Cash and Investments in Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock</Role>
      <ShortName>Cash and Investments in Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Liability Related to Sale of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock</Role>
      <ShortName>Liability Related to Sale of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</ParentRole>
      <Position>15</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Cash and Investments in Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables</Role>
      <ShortName>Cash and Investments in Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock</ParentRole>
      <Position>16</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlockTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock</ParentRole>
      <Position>17</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - License and Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlockTables</Role>
      <ShortName>License and Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock</ParentRole>
      <Position>18</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</ParentRole>
      <Position>19</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformation</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents and Restricted Cash (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsAndRestrictedCash</Role>
      <ShortName>Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents and Restricted Cash (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesAdditionalInformation</Role>
      <ShortName>Cash and Investments in Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureCashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecurities</Role>
      <ShortName>Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Inventory - Inventory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureInventoryInventory</Role>
      <ShortName>Inventory - Inventory (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Liability Related to Sale of Future Royalties - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformation</Role>
      <ShortName>Liability Related to Sale of Future Royalties - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenue</Role>
      <ShortName>License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformation</Role>
      <ShortName>License and Collaboration Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpense</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>131 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>132 - Disclosure - Net Loss Per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/taxonomy/role/DisclosureNetLossPerShareAdditionalInformation</Role>
      <ShortName>Net Loss Per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">In ''Condensed Consolidated Balance Sheets (Unaudited)'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''Condensed Consolidated Statements of Cash Flows (Unaudited)'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression.</Log>
  </Logs>
  <InputFiles>
    <File>nktr-20150630.xml</File>
    <File>nktr-20150630_cal.xml</File>
    <File>nktr-20150630_def.xml</File>
    <File>nktr-20150630_lab.xml</File>
    <File>nktr-20150630_pre.xml</File>
    <File>nktr-20150630.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.2.0.727</span><table class="report" border="0" cellspacing="2" id="idm140295533231072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Cash and investments in marketable securities</a></td>
<td class="nump">$ 279,660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262,824,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Senior secured notes</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">133,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Capital lease obligations</a></td>
<td class="nump">8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital lease obligations, current portion</a></td>
<td class="nump">$ 5,643,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,643,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,512,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Restricted Cash, Cash Equivalents, And Available For Sale Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51824106&amp;loc=d3e2420-110228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 16<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.16)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.16)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20, 22<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorLongTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
